name,description
Cefmenoxime,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefmenoxime.
Cefmetazole,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefmetazole.
Cefpiramide,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefpiramide.
Ceftazidime,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftazidime.
Loracarbef,The therapeutic efficacy of Abciximab can be decreased when used in combination with Loracarbef.
Cefalotin,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefalotin.
Cefotaxime,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefotaxime.
Cefdinir,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefdinir.
Cephalexin,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cephalexin.
Cefixime,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefixime.
Cephaloglycin,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cephaloglycin.
Cefaclor,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefaclor.
Ceforanide,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceforanide.
Cefditoren,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefditoren.
Cefuroxime,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefuroxime.
Cefapirin,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefapirin.
Cefadroxil,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefadroxil.
Cefprozil,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefprozil.
Ceftriaxone,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftriaxone.
Cefamandole,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefamandole.
Cefazolin,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefazolin.
Cefonicid,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefonicid.
Cefoperazone,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefoperazone.
Cefotetan,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefotetan.
Cefoxitin,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefoxitin.
Ceftizoxime,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftizoxime.
Cefradine,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefradine.
Cefepime,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefepime.
Cefacetrile,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefacetrile.
Ceftibuten,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftibuten.
Cefpodoxime,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefpodoxime.
Latamoxef,The therapeutic efficacy of Abciximab can be decreased when used in combination with Latamoxef.
Ceftobiprole,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftobiprole.
Ceftaroline fosamil,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftaroline fosamil.
Cefaloridine,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefaloridine.
Ceftolozane,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftolozane.
Cefminox,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefminox.
Cefroxadine,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefroxadine.
Flomoxef,The therapeutic efficacy of Abciximab can be decreased when used in combination with Flomoxef.
Cefatrizine,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefatrizine.
Cefcapene,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefcapene.
Cefodizime,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefodizime.
Cefsulodin,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefsulodin.
Cefetamet,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefetamet.
Cefbuperazone,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefbuperazone.
Cefozopran,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefozopran.
Cefpirome,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefpirome.
Cefazedone,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefazedone.
Ceftezole,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftezole.
Cefamandole nafate,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefamandole nafate.
Doxycycline,The risk or severity of bleeding can be increased when Doxycycline is combined with Abciximab.
Azithromycin,The risk or severity of adverse effects can be increased when Azithromycin is combined with Abciximab.
Omega-3-acid ethyl esters,The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Abciximab.
Acetylsalicylic acid,Acetylsalicylic acid may increase the antiplatelet activities of Abciximab.
Ibuprofen,The risk or severity of bleeding can be increased when Ibuprofen is combined with Abciximab.
Dexibuprofen,The risk or severity of bleeding can be increased when Dexibuprofen is combined with Abciximab.
Tazobactam,The risk or severity of bleeding can be increased when Tazobactam is combined with Abciximab.
Erythromycin,The risk or severity of bleeding can be increased when Erythromycin is combined with Abciximab.
Trazodone,The risk or severity of bleeding can be increased when Trazodone is combined with Abciximab.
Triamcinolone,The therapeutic efficacy of Abciximab can be decreased when used in combination with Triamcinolone.
Nintedanib,The risk or severity of bleeding can be increased when Abciximab is combined with Nintedanib.
Escitalopram,The risk or severity of bleeding can be increased when Escitalopram is combined with Abciximab.
Sertraline,The risk or severity of bleeding can be increased when Sertraline is combined with Abciximab.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Abciximab."
Methyclothiazide,The therapeutic efficacy of Abciximab can be decreased when used in combination with Methyclothiazide.
Bendroflumethiazide,The therapeutic efficacy of Abciximab can be decreased when used in combination with Bendroflumethiazide.
Benzthiazide,The therapeutic efficacy of Abciximab can be decreased when used in combination with Benzthiazide.
Cyclothiazide,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cyclothiazide.
Hydroflumethiazide,The therapeutic efficacy of Abciximab can be decreased when used in combination with Hydroflumethiazide.
Chlorothiazide,The therapeutic efficacy of Abciximab can be decreased when used in combination with Chlorothiazide.
Hydrochlorothiazide,The therapeutic efficacy of Abciximab can be decreased when used in combination with Hydrochlorothiazide.
Trichlormethiazide,The therapeutic efficacy of Abciximab can be decreased when used in combination with Trichlormethiazide.
Polythiazide,The therapeutic efficacy of Abciximab can be decreased when used in combination with Polythiazide.
Mebutizide,The therapeutic efficacy of Abciximab can be decreased when used in combination with Mebutizide.
Cyclopenthiazide,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cyclopenthiazide.
Apixaban,Apixaban may increase the anticoagulant activities of Drotrecogin alfa.
Dabigatran etexilate,Dabigatran etexilate may increase the anticoagulant activities of Drotrecogin alfa.
Dasatinib,The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Drotrecogin alfa.
Deferasirox,The risk or severity of gastrointestinal bleeding can be increased when Drotrecogin alfa is combined with Deferasirox.
Ursodeoxycholic acid,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Glycochenodeoxycholic Acid.
Cholic Acid,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Cholic Acid.
Glycocholic acid,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Glycocholic acid.
Deoxycholic acid,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Deoxycholic acid.
Taurocholic acid,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Taurocholic acid.
Obeticholic acid,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Obeticholic acid.
Chenodeoxycholic acid,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Tauroursodeoxycholic acid.
Bamet-UD2,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Bamet-UD2.
Dehydrocholic acid,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Dehydrocholic acid.
Hyodeoxycholic Acid,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Hyodeoxycholic Acid.
Edoxaban,The risk or severity of bleeding can be increased when Edoxaban is combined with Drotrecogin alfa.
Ibrutinib,The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Drotrecogin alfa.
Obinutuzumab,The risk or severity of bleeding and hemorrhage can be increased when Drotrecogin alfa is combined with Obinutuzumab.
Rivaroxaban,Drotrecogin alfa may increase the anticoagulant activities of Rivaroxaban.
Sugammadex,The risk or severity of bleeding and hemorrhage can be increased when Drotrecogin alfa is combined with Sugammadex.
Tibolone,Tibolone may increase the anticoagulant activities of Drotrecogin alfa.
Tipranavir,The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Drotrecogin alfa.
Urokinase,Urokinase may increase the anticoagulant activities of Drotrecogin alfa.
Vitamin E,Vitamin E may increase the anticoagulant activities of Drotrecogin alfa.
Vorapaxar,The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Drotrecogin alfa.
Aprotinin,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Aprotinin.
Ginkgo biloba,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Ginkgo biloba.
Ifosfamide,The risk or severity of bleeding can be increased when Ifosfamide is combined with Drotrecogin alfa.
Quinine,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Quinine.
Quinidine,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Quinidine.
Tamoxifen,The risk or severity of bleeding can be increased when Tamoxifen is combined with Drotrecogin alfa.
Toremifene,The risk or severity of bleeding can be increased when Toremifene is combined with Drotrecogin alfa.
Pentoxifylline,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Pentoxifylline.
Pentosan polysulfate,Pentosan polysulfate may increase the anticoagulant activities of Drotrecogin alfa.
Levocarnitine,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Levocarnitine.
Diethylstilbestrol,Diethylstilbestrol may decrease the anticoagulant activities of Drotrecogin alfa.
Chlorotrianisene,Chlorotrianisene may decrease the anticoagulant activities of Drotrecogin alfa.
Conjugated estrogens,Conjugated estrogens may decrease the anticoagulant activities of Drotrecogin alfa.
Estradiol,Estradiol may decrease the anticoagulant activities of Drotrecogin alfa.
Ethinylestradiol,Ethinylestradiol may decrease the anticoagulant activities of Drotrecogin alfa.
Mestranol,Mestranol may decrease the anticoagulant activities of Drotrecogin alfa.
Estriol,Estriol may decrease the anticoagulant activities of Drotrecogin alfa.
Estrone sulfate,Estrone sulfate may decrease the anticoagulant activities of Drotrecogin alfa.
Quinestrol,Quinestrol may decrease the anticoagulant activities of Drotrecogin alfa.
Hexestrol,Hexestrol may decrease the anticoagulant activities of Drotrecogin alfa.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Drotrecogin alfa."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Drotrecogin alfa."
Polyestradiol phosphate,Polyestradiol phosphate may decrease the anticoagulant activities of Drotrecogin alfa.
Esterified estrogens,Esterified estrogens may decrease the anticoagulant activities of Drotrecogin alfa.
Zeranol,Zeranol may decrease the anticoagulant activities of Drotrecogin alfa.
Equol,Equol may decrease the anticoagulant activities of Drotrecogin alfa.
Promestriene,Promestriene may decrease the anticoagulant activities of Drotrecogin alfa.
Methallenestril,Methallenestril may decrease the anticoagulant activities of Drotrecogin alfa.
Epimestrol,Epimestrol may decrease the anticoagulant activities of Drotrecogin alfa.
Moxestrol,Moxestrol may decrease the anticoagulant activities of Drotrecogin alfa.
Estradiol acetate,Estradiol acetate may decrease the anticoagulant activities of Drotrecogin alfa.
Estradiol benzoate,Estradiol benzoate may decrease the anticoagulant activities of Drotrecogin alfa.
Estradiol cypionate,Estradiol cypionate may decrease the anticoagulant activities of Drotrecogin alfa.
Estradiol valerate,Estradiol valerate may decrease the anticoagulant activities of Drotrecogin alfa.
Biochanin A,Biochanin A may decrease the anticoagulant activities of Drotrecogin alfa.
Formononetin,Formononetin may decrease the anticoagulant activities of Drotrecogin alfa.
Icosapent,The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Drotrecogin alfa.
Mesalazine,The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Drotrecogin alfa.
Indomethacin,The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Drotrecogin alfa.
Nabumetone,The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Drotrecogin alfa.
Ketorolac,The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Drotrecogin alfa.
Tenoxicam,The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Drotrecogin alfa.
Celecoxib,The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Drotrecogin alfa.
Tolmetin,The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Drotrecogin alfa.
Rofecoxib,The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Drotrecogin alfa.
Piroxicam,The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Drotrecogin alfa.
Fenoprofen,The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Drotrecogin alfa.
Valdecoxib,The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Drotrecogin alfa.
Diclofenac,The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Drotrecogin alfa.
Sulindac,The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Drotrecogin alfa.
Flurbiprofen,The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Drotrecogin alfa.
Etodolac,The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Drotrecogin alfa.
Mefenamic acid,The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Drotrecogin alfa.
Naproxen,The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Drotrecogin alfa.
Sulfasalazine,The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Drotrecogin alfa.
Phenylbutazone,The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Drotrecogin alfa.
Meloxicam,The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Drotrecogin alfa.
Carprofen,The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Drotrecogin alfa.
Diflunisal,The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Drotrecogin alfa.
Salicylic acid,The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Drotrecogin alfa.
Meclofenamic acid,The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Drotrecogin alfa.
Oxaprozin,The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Drotrecogin alfa.
Ketoprofen,The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Drotrecogin alfa.
Balsalazide,The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Drotrecogin alfa.
Olsalazine,The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Drotrecogin alfa.
Lumiracoxib,The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Drotrecogin alfa.
Magnesium salicylate,The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Drotrecogin alfa.
Salsalate,The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Drotrecogin alfa.
Choline magnesium trisalicylate,The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Drotrecogin alfa.
Antrafenine,The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Drotrecogin alfa.
Aminophenazone,The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Drotrecogin alfa.
Antipyrine,The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Drotrecogin alfa.
Tiaprofenic acid,The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Drotrecogin alfa.
Etoricoxib,The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Drotrecogin alfa.
Taxifolin,The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Drotrecogin alfa.
Oxyphenbutazone,The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Drotrecogin alfa.
Niflumic acid,The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Drotrecogin alfa.
Licofelone,The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Drotrecogin alfa.
Benoxaprofen,The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Drotrecogin alfa.
Metamizole,The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Drotrecogin alfa.
Zomepirac,The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Drotrecogin alfa.
Cimicoxib,The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Drotrecogin alfa.
Lornoxicam,The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Drotrecogin alfa.
Aceclofenac,The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Drotrecogin alfa.
Zaltoprofen,The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Drotrecogin alfa.
Azapropazone,The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Drotrecogin alfa.
Felbinac,The risk or severity of bleeding and hemorrhage can be increased when Felbinac is combined with Drotrecogin alfa.
Parecoxib,The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Drotrecogin alfa.
Salicylamide,The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Drotrecogin alfa.
Kebuzone,The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Drotrecogin alfa.
Isoxicam,The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Drotrecogin alfa.
Indoprofen,The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Drotrecogin alfa.
Ibuproxam,The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Drotrecogin alfa.
Floctafenine,The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Drotrecogin alfa.
Fenbufen,The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Drotrecogin alfa.
Etofenamate,The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Drotrecogin alfa.
Epirizole,The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Drotrecogin alfa.
Benzydamine,The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Drotrecogin alfa.
Loxoprofen,The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Drotrecogin alfa.
Dexketoprofen,The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Drotrecogin alfa.
Droxicam,The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Drotrecogin alfa.
Tolfenamic acid,The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Drotrecogin alfa.
Firocoxib,The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Drotrecogin alfa.
Clonixin,The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Drotrecogin alfa.
Morniflumate,The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Drotrecogin alfa.
Propacetamol,The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Drotrecogin alfa.
Talniflumate,The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Drotrecogin alfa.
Robenacoxib,The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Drotrecogin alfa.
Tepoxalin,The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Drotrecogin alfa.
Flunixin,The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Drotrecogin alfa.
Polmacoxib,The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Drotrecogin alfa.
Betulinic Acid,The risk or severity of bleeding and hemorrhage can be increased when Betulinic Acid is combined with Drotrecogin alfa.
Ebselen,The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Drotrecogin alfa.
Tinoridine,The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Drotrecogin alfa.
Alclofenac,The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Drotrecogin alfa.
Fentiazac,The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Drotrecogin alfa.
Suxibuzone,The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Drotrecogin alfa.
Bumadizone,The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Drotrecogin alfa.
Alminoprofen,The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Drotrecogin alfa.
Flunoxaprofen,The risk or severity of bleeding and hemorrhage can be increased when Flunoxaprofen is combined with Drotrecogin alfa.
Feprazone,The risk or severity of bleeding and hemorrhage can be increased when Feprazone is combined with Drotrecogin alfa.
Difenpiramide,The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Drotrecogin alfa.
Nifenazone,The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Drotrecogin alfa.
Lonazolac,The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Drotrecogin alfa.
Tenidap,The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Drotrecogin alfa.
Bendazac,The risk or severity of bleeding and hemorrhage can be increased when Bendazac is combined with Drotrecogin alfa.
Pranoprofen,The risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Drotrecogin alfa.
Propyphenazone,The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Drotrecogin alfa.
Proglumetacin,The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Drotrecogin alfa.
Guacetisal,The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Drotrecogin alfa.
Ethenzamide,The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Drotrecogin alfa.
Carbaspirin calcium,The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Drotrecogin alfa.
Mofebutazone,The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Drotrecogin alfa.
Proquazone,The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Drotrecogin alfa.
Benorilate,The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Drotrecogin alfa.
Pirprofen,The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Drotrecogin alfa.
Imidazole salicylate,The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Drotrecogin alfa.
SC-236,The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Drotrecogin alfa.
NS-398,The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Drotrecogin alfa.
Flurbiprofen axetil,The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Drotrecogin alfa.
Omacetaxine mepesuccinate,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Omacetaxine mepesuccinate.
Omega-3 fatty acids,Omega-3 fatty acids may increase the anticoagulant activities of Drotrecogin alfa.
Tositumomab,The risk or severity of bleeding and hemorrhage can be increased when Drotrecogin alfa is combined with Tositumomab.
Limaprost,The risk or severity of adverse effects can be increased when Limaprost is combined with Drotrecogin alfa.
Collagenase clostridium histolyticum,The risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Collagenase clostridium histolyticum.
Carbimazole,Carbimazole may increase the anticoagulant activities of Drotrecogin alfa.
Propylthiouracil,Propylthiouracil may increase the anticoagulant activities of Drotrecogin alfa.
Methimazole,Methimazole may increase the anticoagulant activities of Drotrecogin alfa.
"3,5-Diiodotyrosine","3,5-Diiodotyrosine may increase the anticoagulant activities of Drotrecogin alfa."
Potassium Iodide,Potassium Iodide may increase the anticoagulant activities of Drotrecogin alfa.
Dibromotyrosine,Dibromotyrosine may increase the anticoagulant activities of Drotrecogin alfa.
Potassium perchlorate,Potassium perchlorate may increase the anticoagulant activities of Drotrecogin alfa.
Methylthiouracil,Methylthiouracil may increase the anticoagulant activities of Drotrecogin alfa.
Benzylthiouracil,Benzylthiouracil may increase the anticoagulant activities of Drotrecogin alfa.
Mifepristone,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Mifepristone.
p-Coumaric acid,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with p-Coumaric acid.
Octylphenoxy polyethoxyethanol,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Octylphenoxy polyethoxyethanol.
Trestolone,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Trestolone.
Lonidamine,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Lonidamine.
Ulipristal,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ulipristal.
Isosorbide,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Isosorbide.
Cloprostenol,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cloprostenol.
Triptolide,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Triptolide.
Gossypol,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Gossypol.
Ormeloxifene,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ormeloxifene.
Etonogestrel,Etonogestrel may decrease the anticoagulant activities of Drotrecogin alfa.
Desogestrel,Desogestrel may decrease the anticoagulant activities of Drotrecogin alfa.
Megestrol acetate,Megestrol acetate may decrease the anticoagulant activities of Drotrecogin alfa.
Levonorgestrel,Levonorgestrel may decrease the anticoagulant activities of Drotrecogin alfa.
Dydrogesterone,Dydrogesterone may decrease the anticoagulant activities of Drotrecogin alfa.
Progesterone,Progesterone may decrease the anticoagulant activities of Drotrecogin alfa.
Medroxyprogesterone acetate,Medroxyprogesterone acetate may decrease the anticoagulant activities of Drotrecogin alfa.
Norethisterone,Norethisterone may decrease the anticoagulant activities of Drotrecogin alfa.
Ethynodiol diacetate,Ethynodiol diacetate may decrease the anticoagulant activities of Drotrecogin alfa.
Norgestimate,Norgestimate may decrease the anticoagulant activities of Drotrecogin alfa.
Drospirenone,Drospirenone may decrease the anticoagulant activities of Drotrecogin alfa.
Allylestrenol,Allylestrenol may decrease the anticoagulant activities of Drotrecogin alfa.
Cyproterone acetate,Cyproterone acetate may decrease the anticoagulant activities of Drotrecogin alfa.
Norelgestromin,Norelgestromin may decrease the anticoagulant activities of Drotrecogin alfa.
Gestodene,Gestodene may decrease the anticoagulant activities of Drotrecogin alfa.
Hydroxyprogesterone caproate,Hydroxyprogesterone caproate may decrease the anticoagulant activities of Drotrecogin alfa.
Dienogest,Dienogest may decrease the anticoagulant activities of Drotrecogin alfa.
Medrogestone,Medrogestone may decrease the anticoagulant activities of Drotrecogin alfa.
Norethynodrel,Norethynodrel may decrease the anticoagulant activities of Drotrecogin alfa.
Norgestrel,Norgestrel may decrease the anticoagulant activities of Drotrecogin alfa.
Altrenogest,Altrenogest may decrease the anticoagulant activities of Drotrecogin alfa.
Gestrinone,Gestrinone may decrease the anticoagulant activities of Drotrecogin alfa.
Nomegestrol,Nomegestrol may decrease the anticoagulant activities of Drotrecogin alfa.
Lynestrenol,Lynestrenol may decrease the anticoagulant activities of Drotrecogin alfa.
Gestonorone,Gestonorone may decrease the anticoagulant activities of Drotrecogin alfa.
Chlormadinone,Chlormadinone may decrease the anticoagulant activities of Drotrecogin alfa.
Methylestrenolone,Methylestrenolone may decrease the anticoagulant activities of Drotrecogin alfa.
Norgestrienone,Norgestrienone may decrease the anticoagulant activities of Drotrecogin alfa.
Promegestone,Promegestone may decrease the anticoagulant activities of Drotrecogin alfa.
Quingestanol,Quingestanol may decrease the anticoagulant activities of Drotrecogin alfa.
Demegestone,Demegestone may decrease the anticoagulant activities of Drotrecogin alfa.
Etynodiol,Etynodiol may decrease the anticoagulant activities of Drotrecogin alfa.
Nomegestrol acetate,Nomegestrol acetate may decrease the anticoagulant activities of Drotrecogin alfa.
Hydroxyprogesterone,Hydroxyprogesterone may decrease the anticoagulant activities of Drotrecogin alfa.
Norethindrone enanthate,Norethindrone enanthate may decrease the anticoagulant activities of Drotrecogin alfa.
Quingestanol acetate,Quingestanol acetate may decrease the anticoagulant activities of Drotrecogin alfa.
Aminosalicylic acid,The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Drotrecogin alfa.
Bismuth subsalicylate,The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Drotrecogin alfa.
Dersalazine,The risk or severity of bleeding can be increased when Dersalazine is combined with Drotrecogin alfa.
Phenyl aminosalicylate,The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Drotrecogin alfa.
Methyl salicylate,The risk or severity of bleeding can be increased when Methyl salicylate is combined with Drotrecogin alfa.
Trolamine salicylate,The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Drotrecogin alfa.
Aloxiprin,The risk or severity of bleeding can be increased when Aloxiprin is combined with Drotrecogin alfa.
Choline salicylate,The risk or severity of bleeding can be increased when Choline salicylate is combined with Drotrecogin alfa.
Thiosalicylic acid,The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Drotrecogin alfa.
Abciximab,The risk or severity of bleeding can be increased when Abciximab is combined with Drotrecogin alfa.
Eptifibatide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Drotrecogin alfa.
Ticlopidine,The risk or severity of bleeding can be increased when Ticlopidine is combined with Drotrecogin alfa.
Anagrelide,The risk or severity of bleeding can be increased when Anagrelide is combined with Drotrecogin alfa.
Clopidogrel,The risk or severity of bleeding can be increased when Clopidogrel is combined with Drotrecogin alfa.
Tirofiban,The risk or severity of bleeding can be increased when Tirofiban is combined with Drotrecogin alfa.
Dipyridamole,The risk or severity of bleeding can be increased when Dipyridamole is combined with Drotrecogin alfa.
Iloprost,The risk or severity of bleeding can be increased when Iloprost is combined with Drotrecogin alfa.
Sulfinpyrazone,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Drotrecogin alfa.
Cilostazol,The risk or severity of bleeding can be increased when Cilostazol is combined with Drotrecogin alfa.
Ridogrel,The risk or severity of bleeding can be increased when Ridogrel is combined with Drotrecogin alfa.
Sevoflurane,The risk or severity of bleeding can be increased when Sevoflurane is combined with Drotrecogin alfa.
Epoprostenol,The risk or severity of bleeding can be increased when Epoprostenol is combined with Drotrecogin alfa.
Resveratrol,The risk or severity of bleeding can be increased when Resveratrol is combined with Drotrecogin alfa.
Nimesulide,The risk or severity of bleeding can be increased when Nimesulide is combined with Drotrecogin alfa.
Tesmilifene,The risk or severity of bleeding can be increased when Tesmilifene is combined with Drotrecogin alfa.
Defibrotide,The risk or severity of bleeding can be increased when Defibrotide is combined with Drotrecogin alfa.
Beraprost,The risk or severity of bleeding can be increased when Beraprost is combined with Drotrecogin alfa.
Ibudilast,The risk or severity of bleeding can be increased when Ibudilast is combined with Drotrecogin alfa.
Andrographolide,The risk or severity of bleeding can be increased when Andrographolide is combined with Drotrecogin alfa.
Caplacizumab,The risk or severity of bleeding can be increased when Caplacizumab is combined with Drotrecogin alfa.
Prasugrel,The risk or severity of bleeding can be increased when Prasugrel is combined with Drotrecogin alfa.
Cangrelor,The risk or severity of bleeding can be increased when Cangrelor is combined with Drotrecogin alfa.
Tranilast,The risk or severity of bleeding can be increased when Tranilast is combined with Drotrecogin alfa.
Triflusal,The risk or severity of bleeding can be increased when Triflusal is combined with Drotrecogin alfa.
Ticagrelor,The risk or severity of bleeding can be increased when Ticagrelor is combined with Drotrecogin alfa.
Icosapent ethyl,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Drotrecogin alfa.
Trapidil,The risk or severity of bleeding can be increased when Trapidil is combined with Drotrecogin alfa.
Naftopidil,The risk or severity of bleeding can be increased when Naftopidil is combined with Drotrecogin alfa.
Sarpogrelate,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Drotrecogin alfa.
Ifetroban,The risk or severity of bleeding can be increased when Ifetroban is combined with Drotrecogin alfa.
Nitroaspirin,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Drotrecogin alfa.
Ketanserin,The risk or severity of bleeding can be increased when Ketanserin is combined with Drotrecogin alfa.
Indobufen,The risk or severity of bleeding can be increased when Indobufen is combined with Drotrecogin alfa.
Butylphthalide,The risk or severity of bleeding can be increased when Butylphthalide is combined with Drotrecogin alfa.
Hydroxytyrosol,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Drotrecogin alfa.
Ramatroban,The risk or severity of bleeding can be increased when Ramatroban is combined with Drotrecogin alfa.
Picotamide,The risk or severity of bleeding can be increased when Picotamide is combined with Drotrecogin alfa.
Cloricromen,The risk or severity of bleeding can be increased when Cloricromen is combined with Drotrecogin alfa.
Linsidomine,The risk or severity of bleeding can be increased when Linsidomine is combined with Drotrecogin alfa.
Buflomedil,The risk or severity of bleeding can be increased when Buflomedil is combined with Drotrecogin alfa.
Relcovaptan,The risk or severity of bleeding can be increased when Relcovaptan is combined with Drotrecogin alfa.
Treprostinil,The risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Treprostinil.
Hemin,Hemin may increase the anticoagulant activities of Drotrecogin alfa.
Acemetacin,The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Drotrecogin alfa.
Testosterone,Testosterone may increase the anticoagulant activities of Drotrecogin alfa.
Testosterone propionate,Testosterone propionate may increase the anticoagulant activities of Drotrecogin alfa.
1-Testosterone,1-Testosterone may increase the anticoagulant activities of Drotrecogin alfa.
4-Hydroxytestosterone,4-Hydroxytestosterone may increase the anticoagulant activities of Drotrecogin alfa.
Dehydrochloromethyltestosterone,Dehydrochloromethyltestosterone may increase the anticoagulant activities of Drotrecogin alfa.
Boldenone,Boldenone may increase the anticoagulant activities of Drotrecogin alfa.
18-methyl-19-nortestosterone,18-methyl-19-nortestosterone may increase the anticoagulant activities of Drotrecogin alfa.
Calusterone,Calusterone may increase the anticoagulant activities of Drotrecogin alfa.
Formebolone,Formebolone may increase the anticoagulant activities of Drotrecogin alfa.
Methyl-1-testosterone,Methyl-1-testosterone may increase the anticoagulant activities of Drotrecogin alfa.
Stanolone,Stanolone may increase the anticoagulant activities of Drotrecogin alfa.
5beta-dihydrotestosterone,5beta-dihydrotestosterone may increase the anticoagulant activities of Drotrecogin alfa.
Testosterone succinate,Testosterone succinate may increase the anticoagulant activities of Drotrecogin alfa.
Mibolerone,Mibolerone may increase the anticoagulant activities of Drotrecogin alfa.
Testosterone cypionate,Testosterone cypionate may increase the anticoagulant activities of Drotrecogin alfa.
Testosterone enanthate,Testosterone enanthate may increase the anticoagulant activities of Drotrecogin alfa.
Testosterone undecanoate,Testosterone undecanoate may increase the anticoagulant activities of Drotrecogin alfa.
Testosterone enantate benzilic acid hydrazone,Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Drotrecogin alfa.
Stanolone acetate,Stanolone acetate may increase the anticoagulant activities of Drotrecogin alfa.
Trestolone acetate,Trestolone acetate may increase the anticoagulant activities of Drotrecogin alfa.
"(1,2,6,7-3H)Testosterone","(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Drotrecogin alfa."
Drostanolone propionate,Drostanolone propionate may increase the anticoagulant activities of Drotrecogin alfa.
Azficel-T,The risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Azficel-T.
Omega-3-carboxylic acids,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Omega-3-carboxylic acids.
Calcium acetate,The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Drotrecogin alfa.
Calcium chloride,The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Drotrecogin alfa.
Calcium,The therapeutic efficacy of Calcium can be decreased when used in combination with Drotrecogin alfa.
Calcium gluconate,The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Drotrecogin alfa.
Eftrenonacog alfa,The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Drotrecogin alfa.
Albutrepenonacog alfa,The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Drotrecogin alfa.
Emicizumab,The therapeutic efficacy of Emicizumab can be decreased when used in combination with Drotrecogin alfa.
Turoctocog alfa pegol,The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Drotrecogin alfa.
"Antihemophilic factor, human recombinant","The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Drotrecogin alfa."
Coagulation factor VIIa Recombinant Human,The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Drotrecogin alfa.
Coagulation Factor IX (Recombinant),The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Drotrecogin alfa.
Pantothenic acid,The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Drotrecogin alfa.
Formic acid,The therapeutic efficacy of Formic acid can be decreased when used in combination with Drotrecogin alfa.
Platelet Activating Factor,The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Drotrecogin alfa.
Calcium carbonate,The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Drotrecogin alfa.
Turoctocog alfa,The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Drotrecogin alfa.
Fibrinogen human,The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Drotrecogin alfa.
Catridecacog,The therapeutic efficacy of Catridecacog can be decreased when used in combination with Drotrecogin alfa.
"Antihemophilic Factor (Recombinant), PEGylated","The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Drotrecogin alfa."
Calcium citrate,The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Drotrecogin alfa.
Calcium threonate,The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Drotrecogin alfa.
Prothrombin,The therapeutic efficacy of Prothrombin can be decreased when used in combination with Drotrecogin alfa.
Factor IX Complex (Human),The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Drotrecogin alfa.
Calcium Phosphate,The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Drotrecogin alfa.
Susoctocog alfa,The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Drotrecogin alfa.
Rusalatide acetate,The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Drotrecogin alfa.
Vatreptacog alfa,The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Drotrecogin alfa.
Factor XIII (human),The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Drotrecogin alfa.
Von Willebrand Factor Human,The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Drotrecogin alfa.
Coagulation factor X human,The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Drotrecogin alfa.
Coagulation factor VII human,The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Drotrecogin alfa.
Anti-inhibitor coagulant complex,The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Drotrecogin alfa.
Coagulation Factor IX Human,The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Drotrecogin alfa.
Antihemophilic factor human,The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Drotrecogin alfa.
Kallidinogenase,The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Drotrecogin alfa.
Trenonacog alfa,The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Drotrecogin alfa.
Nonacog beta pegol,The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Drotrecogin alfa.
Moroctocog alfa,The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Drotrecogin alfa.
Beroctocog alfa,The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Drotrecogin alfa.
Andexanet alfa,The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Drotrecogin alfa.
Calcium cation,The therapeutic efficacy of Calcium cation can be decreased when used in combination with Drotrecogin alfa.
Damoctocog alfa pegol,The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Drotrecogin alfa.
Fluvoxamine,The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Drotrecogin alfa.
Citalopram,The risk or severity of hemorrhage can be increased when Citalopram is combined with Drotrecogin alfa.
Fluoxetine,The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Drotrecogin alfa.
Paroxetine,The risk or severity of hemorrhage can be increased when Paroxetine is combined with Drotrecogin alfa.
Nefazodone,The risk or severity of hemorrhage can be increased when Nefazodone is combined with Drotrecogin alfa.
Zimelidine,The risk or severity of hemorrhage can be increased when Zimelidine is combined with Drotrecogin alfa.
Dapoxetine,The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Drotrecogin alfa.
Seproxetine,The risk or severity of hemorrhage can be increased when Seproxetine is combined with Drotrecogin alfa.
Indalpine,The risk or severity of hemorrhage can be increased when Indalpine is combined with Drotrecogin alfa.
Ritanserin,The risk or severity of hemorrhage can be increased when Ritanserin is combined with Drotrecogin alfa.
Alaproclate,The risk or severity of hemorrhage can be increased when Alaproclate is combined with Drotrecogin alfa.
Duloxetine,The risk or severity of hemorrhage can be increased when Duloxetine is combined with Drotrecogin alfa.
Sibutramine,The risk or severity of hemorrhage can be increased when Sibutramine is combined with Drotrecogin alfa.
Milnacipran,The risk or severity of hemorrhage can be increased when Milnacipran is combined with Drotrecogin alfa.
Desvenlafaxine,The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Drotrecogin alfa.
Levomilnacipran,The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Drotrecogin alfa.
Venlafaxine,Venlafaxine may increase the antiplatelet activities of Drotrecogin alfa.
Amphetamine,The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Drotrecogin alfa.
Linezolid,The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Drotrecogin alfa.
Furazolidone,The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Drotrecogin alfa.
Procaine,The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Drotrecogin alfa.
Tranylcypromine,The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Drotrecogin alfa.
Phenelzine,The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Drotrecogin alfa.
Minaprine,The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Drotrecogin alfa.
Selegiline,The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Drotrecogin alfa.
Procarbazine,The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Drotrecogin alfa.
Moclobemide,The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Drotrecogin alfa.
Isocarboxazid,The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Drotrecogin alfa.
Rasagiline,The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Drotrecogin alfa.
Pargyline,The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Drotrecogin alfa.
Clorgiline,The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Drotrecogin alfa.
Iproniazid,The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Drotrecogin alfa.
Nialamide,The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Drotrecogin alfa.
Safinamide,The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Drotrecogin alfa.
"7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline","The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Drotrecogin alfa."
Methylene blue,The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Drotrecogin alfa.
Hydracarbazine,The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Drotrecogin alfa.
Pirlindole,The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Drotrecogin alfa.
Toloxatone,The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Drotrecogin alfa.
Benmoxin,The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Drotrecogin alfa.
Mebanazine,The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Drotrecogin alfa.
Octamoxin,The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Drotrecogin alfa.
Pheniprazine,The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Drotrecogin alfa.
Phenoxypropazine,The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Drotrecogin alfa.
Pivhydrazine,The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Drotrecogin alfa.
Safrazine,The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Drotrecogin alfa.
Caroxazone,The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Drotrecogin alfa.
Harmaline,The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Drotrecogin alfa.
Brofaromine,The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Drotrecogin alfa.
Bivalirudin,The risk or severity of bleeding can be increased when Bivalirudin is combined with Drotrecogin alfa.
Dicoumarol,The risk or severity of bleeding can be increased when Dicoumarol is combined with Drotrecogin alfa.
Argatroban,The risk or severity of bleeding can be increased when Argatroban is combined with Drotrecogin alfa.
Ardeparin,The risk or severity of bleeding can be increased when Ardeparin is combined with Drotrecogin alfa.
Phenindione,The risk or severity of bleeding can be increased when Phenindione is combined with Drotrecogin alfa.
Fondaparinux,The risk or severity of bleeding can be increased when Fondaparinux is combined with Drotrecogin alfa.
Warfarin,The risk or severity of bleeding can be increased when Warfarin is combined with Drotrecogin alfa.
Phenprocoumon,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Drotrecogin alfa.
Edetic acid,The risk or severity of bleeding can be increased when Edetic acid is combined with Drotrecogin alfa.
Heparin,The risk or severity of bleeding can be increased when Heparin is combined with Drotrecogin alfa.
Enoxaparin,The risk or severity of bleeding can be increased when Enoxaparin is combined with Drotrecogin alfa.
Acenocoumarol,The risk or severity of bleeding can be increased when Acenocoumarol is combined with Drotrecogin alfa.
Ximelagatran,The risk or severity of bleeding can be increased when Ximelagatran is combined with Drotrecogin alfa.
Ancrod,The risk or severity of bleeding can be increased when Ancrod is combined with Drotrecogin alfa.
Sulodexide,The risk or severity of bleeding can be increased when Sulodexide is combined with Drotrecogin alfa.
Idraparinux,The risk or severity of bleeding can be increased when Idraparinux is combined with Drotrecogin alfa.
Otamixaban,The risk or severity of bleeding can be increased when Otamixaban is combined with Drotrecogin alfa.
Danaparoid,The risk or severity of bleeding can be increased when Danaparoid is combined with Drotrecogin alfa.
Dalteparin,The risk or severity of bleeding can be increased when Dalteparin is combined with Drotrecogin alfa.
Ferulic acid,The risk or severity of bleeding can be increased when Ferulic acid is combined with Drotrecogin alfa.
Ethyl biscoumacetate,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Drotrecogin alfa.
Nadroparin,The risk or severity of bleeding can be increased when Nadroparin is combined with Drotrecogin alfa.
Dextran,The risk or severity of bleeding can be increased when Dextran is combined with Drotrecogin alfa.
Reviparin,The risk or severity of bleeding can be increased when Reviparin is combined with Drotrecogin alfa.
Certoparin,The risk or severity of bleeding can be increased when Certoparin is combined with Drotrecogin alfa.
Desirudin,The risk or severity of bleeding can be increased when Desirudin is combined with Drotrecogin alfa.
Protocatechualdehyde,The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Drotrecogin alfa.
Protein C,The risk or severity of bleeding can be increased when Protein C is combined with Drotrecogin alfa.
Antithrombin III human,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Drotrecogin alfa.
Letaxaban,The risk or severity of bleeding can be increased when Letaxaban is combined with Drotrecogin alfa.
Darexaban,The risk or severity of bleeding can be increased when Darexaban is combined with Drotrecogin alfa.
Nafamostat,The risk or severity of bleeding can be increased when Nafamostat is combined with Drotrecogin alfa.
Gabexate,The risk or severity of bleeding can be increased when Gabexate is combined with Drotrecogin alfa.
Troxerutin,The risk or severity of bleeding can be increased when Troxerutin is combined with Drotrecogin alfa.
Fluindione,The risk or severity of bleeding can be increased when Fluindione is combined with Drotrecogin alfa.
Protein S human,The risk or severity of bleeding can be increased when Protein S human is combined with Drotrecogin alfa.
Melagatran,The risk or severity of bleeding can be increased when Melagatran is combined with Drotrecogin alfa.
Potassium citrate,The risk or severity of bleeding can be increased when Potassium citrate is combined with Drotrecogin alfa.
Sodium citrate,The risk or severity of bleeding can be increased when Sodium citrate is combined with Drotrecogin alfa.
Tenecteplase,The risk or severity of bleeding can be increased when Tenecteplase is combined with Drotrecogin alfa.
Tinzaparin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tinzaparin.
Brinase,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Brinase.
Saruplase,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Saruplase.
Streptokinase,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Streptokinase.
Desmoteplase,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Desmoteplase.
Fibrinolysin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Fibrinolysin.
Astaxanthin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Astaxanthin.
Ditazole,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ditazole.
Bemiparin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bemiparin.
Parnaparin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Parnaparin.
Clorindione,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Clorindione.
Diphenadione,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Diphenadione.
Tioclomarol,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tioclomarol.
Lepirudin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Lepirudin.
Alteplase,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Alteplase.
Reteplase,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Reteplase.
Anistreplase,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Anistreplase.
Tocopherylquinone,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tocopherylquinone.
Amediplase,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Amediplase.
4-hydroxycoumarin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with 4-hydroxycoumarin.
(R)-warfarin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with (R)-warfarin.
(S)-Warfarin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with (S)-Warfarin.
Betrixaban,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Betrixaban.
Edetate calcium disodium anhydrous,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Edetate calcium disodium anhydrous.
Zinc citrate,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Zinc citrate.
Antithrombin Alfa,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Antithrombin Alfa.
Coumarin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Coumarin.
Dabigatran,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dabigatran.
Semuloparin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Semuloparin.
Monteplase,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Monteplase.
Sildenafil,The risk or severity of hemorrhage can be increased when Drotrecogin alfa is combined with Sildenafil.
Peginterferon alfa-2a,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Peginterferon alfa-2a.
Interferon alfa-n1,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-n1.
Interferon alfa-n3,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-n3.
Peginterferon alfa-2b,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Peginterferon alfa-2b.
Interferon gamma-1b,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon gamma-1b.
"Interferon alfa-2a, Recombinant","The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-2a, Recombinant."
Aldesleukin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Aldesleukin.
Gemtuzumab ozogamicin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Gemtuzumab ozogamicin.
Interferon beta-1b,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon beta-1b.
Interferon alfacon-1,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfacon-1.
Rituximab,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Rituximab.
Ibritumomab tiuxetan,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ibritumomab tiuxetan.
Alemtuzumab,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Alemtuzumab.
Interferon alfa-2b,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-2b.
Phenylalanine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Phenylalanine.
Bortezomib,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bortezomib.
Cladribine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cladribine.
Carmustine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Carmustine.
Amsacrine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Amsacrine.
Chlorambucil,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Chlorambucil.
Raltitrexed,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Raltitrexed.
Mitomycin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Mitomycin.
Bexarotene,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bexarotene.
Vindesine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Vindesine.
Floxuridine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Floxuridine.
Tioguanine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tioguanine.
Vinorelbine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Vinorelbine.
Dexrazoxane,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dexrazoxane.
Sorafenib,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Sorafenib.
Streptozocin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Streptozocin.
Gemcitabine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Gemcitabine.
Teniposide,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Teniposide.
Epirubicin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Epirubicin.
Chloramphenicol,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Chloramphenicol.
Lenalidomide,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Lenalidomide.
Altretamine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Altretamine.
Zidovudine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Zidovudine.
Cisplatin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cisplatin.
Oxaliplatin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cyclophosphamide.
Fluorouracil,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Fluorouracil.
Pentostatin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Pentostatin.
Methotrexate,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Methotrexate.
Carbamazepine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Carbamazepine.
Vinblastine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Vinblastine.
Imatinib,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Imatinib.
Clofarabine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Clofarabine.
Pemetrexed,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Pemetrexed.
Daunorubicin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Daunorubicin.
Irinotecan,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Irinotecan.
Etoposide,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Etoposide.
Dacarbazine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dacarbazine.
Temozolomide,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Temozolomide.
Penicillamine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Penicillamine.
Tacrolimus,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tacrolimus.
Sirolimus,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Sirolimus.
Mechlorethamine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Mechlorethamine.
Azacitidine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Azacitidine.
Carboplatin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Carboplatin.
Dactinomycin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dactinomycin.
Cytarabine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cytarabine.
Doxorubicin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Doxorubicin.
Hydroxyurea,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Hydroxyurea.
Busulfan,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Busulfan.
Topotecan,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Topotecan.
Mercaptopurine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Mercaptopurine.
Thalidomide,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Thalidomide.
Melphalan,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Melphalan.
Fludarabine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Fludarabine.
Flucytosine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Flucytosine.
Capecitabine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Capecitabine.
Arsenic trioxide,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Arsenic trioxide.
Idarubicin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Idarubicin.
Mitoxantrone,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Mitoxantrone.
Lomustine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Lomustine.
Paclitaxel,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Paclitaxel.
Docetaxel,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Docetaxel.
Decitabine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Decitabine.
Nelarabine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Nelarabine.
Everolimus,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Everolimus.
Vorinostat,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Vorinostat.
Thiotepa,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Thiotepa.
Ixabepilone,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ixabepilone.
Nilotinib,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Nilotinib.
Belinostat,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Belinostat.
Trabectedin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Trabectedin.
Interferon alfa,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa.
omega interferon,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with omega interferon.
Trastuzumab emtansine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Trastuzumab emtansine.
Temsirolimus,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Temsirolimus.
Bosutinib,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bosutinib.
Bendamustine,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bendamustine.
Cabazitaxel,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cabazitaxel.
Eribulin,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Eribulin.
Ruxolitinib,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ruxolitinib.
Carfilzomib,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Carfilzomib.
Tofacitinib,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tofacitinib.
Ponatinib,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ponatinib.
Pomalidomide,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Pomalidomide.
Tedizolid phosphate,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tedizolid phosphate.
Blinatumomab,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Blinatumomab.
Palbociclib,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Palbociclib.
Olaparib,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Olaparib.
Dinutuximab,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dinutuximab.
Peginterferon beta-1a,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Peginterferon beta-1a.
Cepeginterferon alfa-2B,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cepeginterferon alfa-2B.
Cefotiam,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefotiam.
Cefmenoxime,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefmenoxime.
Cefmetazole,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefmetazole.
Cefpiramide,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefpiramide.
Ceftazidime,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftazidime.
Loracarbef,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Loracarbef.
Cefalotin,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefalotin.
Cefotaxime,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefotaxime.
Cefdinir,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefdinir.
Cephalexin,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cephalexin.
Cefixime,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefixime.
Cephaloglycin,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cephaloglycin.
Cefaclor,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefaclor.
Ceforanide,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceforanide.
Cefditoren,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefditoren.
Cefuroxime,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefuroxime.
Cefapirin,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefapirin.
Cefadroxil,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefadroxil.
Cefprozil,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefprozil.
Ceftriaxone,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftriaxone.
Cefamandole,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefamandole.
Cefazolin,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefazolin.
Cefonicid,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefonicid.
Cefoperazone,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefoperazone.
Cefotetan,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefotetan.
Cefoxitin,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefoxitin.
Ceftizoxime,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftizoxime.
Cefradine,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefradine.
Cefepime,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefepime.
Cefacetrile,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefacetrile.
Ceftibuten,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftibuten.
Cefpodoxime,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefpodoxime.
Latamoxef,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Latamoxef.
Ceftobiprole,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftobiprole.
Ceftaroline fosamil,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftaroline fosamil.
Cefaloridine,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefaloridine.
Ceftolozane,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftolozane.
Cefminox,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefminox.
Cefroxadine,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefroxadine.
Flomoxef,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Flomoxef.
Cefatrizine,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefatrizine.
Cefcapene,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefcapene.
Cefodizime,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefodizime.
Cefsulodin,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefsulodin.
Cefetamet,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefetamet.
Cefbuperazone,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefbuperazone.
Cefozopran,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefozopran.
Cefpirome,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefpirome.
Cefazedone,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefazedone.
Ceftezole,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftezole.
Cefamandole nafate,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefamandole nafate.
Doxycycline,The risk or severity of bleeding can be increased when Doxycycline is combined with Drotrecogin alfa.
Azithromycin,The risk or severity of adverse effects can be increased when Azithromycin is combined with Drotrecogin alfa.
Omega-3-acid ethyl esters,The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Drotrecogin alfa.
Acetylsalicylic acid,Acetylsalicylic acid may increase the anticoagulant activities of Drotrecogin alfa.
Tazobactam,The risk or severity of bleeding can be increased when Tazobactam is combined with Drotrecogin alfa.
Erythromycin,The risk or severity of bleeding can be increased when Erythromycin is combined with Drotrecogin alfa.
Trazodone,The risk or severity of bleeding can be increased when Trazodone is combined with Drotrecogin alfa.
Triamcinolone,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Triamcinolone.
Nintedanib,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Nintedanib.
Escitalopram,The risk or severity of bleeding can be increased when Escitalopram is combined with Drotrecogin alfa.
Sertraline,The risk or severity of bleeding can be increased when Sertraline is combined with Drotrecogin alfa.
Methyclothiazide,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Methyclothiazide.
Bendroflumethiazide,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Bendroflumethiazide.
Benzthiazide,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Benzthiazide.
Cyclothiazide,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cyclothiazide.
Hydroflumethiazide,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Hydroflumethiazide.
Chlorothiazide,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Chlorothiazide.
Hydrochlorothiazide,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Hydrochlorothiazide.
Trichlormethiazide,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Trichlormethiazide.
Polythiazide,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Polythiazide.
Mebutizide,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Mebutizide.
Cyclopenthiazide,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cyclopenthiazide.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Gemtuzumab ozogamicin.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Gemtuzumab ozogamicin.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Gemtuzumab ozogamicin.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Gemtuzumab ozogamicin.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Gemtuzumab ozogamicin.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Gemtuzumab ozogamicin.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Gemtuzumab ozogamicin.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Gemtuzumab ozogamicin.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Gemtuzumab ozogamicin."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Gemtuzumab ozogamicin.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Gemtuzumab ozogamicin.
Pegaspargase,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pegaspargase.
Infliximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Infliximab.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon beta-1b.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfacon-1.
Rituximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rituximab.
Basiliximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Basiliximab.
Muromonab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Muromonab.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibritumomab tiuxetan.
Tositumomab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tositumomab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alemtuzumab.
Alefacept,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alefacept.
Efalizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfa-2b.
Daclizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Beclomethasone dipropionate.
Sorafenib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sorafenib.
Streptozocin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Altretamine.
Zidovudine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zidovudine.
Cisplatin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pentostatin.
Methotrexate,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methotrexate.
Carbamazepine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carbamazepine.
Vinblastine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Linezolid.
Imatinib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Imatinib.
Triamcinolone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Paclitaxel.
Dexamethasone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexamethasone.
Docetaxel,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Decitabine.
Sunitinib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sunitinib.
Nelarabine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nelarabine.
Abatacept,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abatacept.
Corticotropin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with omega interferon.
Apremilast,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Apremilast.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ponatinib.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Certolizumab pegol.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Blinatumomab.
Ibrutinib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibrutinib.
Idelalisib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idelalisib.
Palbociclib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Palbociclib.
Olaparib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olaparib.
Dinutuximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dinutuximab.
Vilanterol,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vilanterol.
Tixocortol,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antilymphocyte immunoglobulin (horse).
Fluprednisolone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Meprednisone.
Tepoxalin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tepoxalin.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Melengestrol.
Ixekizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Peficitinib.
Clobetasol,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clobetasol.
Sarilumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sirukumab.
Baricitinib,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Baricitinib.
Guselkumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Guselkumab.
Deflazacort,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Deflazacort.
Triptolide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Triptolide.
Siponimod,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Siponimod.
Ozanimod,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Prednylidene,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednylidene.
Fluocortin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluclorolone.
Fluticasone,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone.
Tetrandrine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tetrandrine.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Monomethyl fumarate.
Mometasone furoate,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mometasone furoate.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone aceponate.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone acetate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone succinate.
Emapalumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bleselumab.
Natalizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemtuzumab ozogamicin.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Gemtuzumab ozogamicin.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gemtuzumab ozogamicin.
Clozapine,The risk or severity of neutropenia can be increased when Gemtuzumab ozogamicin is combined with Clozapine.
Darbepoetin alfa,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gemtuzumab ozogamicin.
Erythropoietin,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Gemtuzumab ozogamicin.
Peginesatide,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Gemtuzumab ozogamicin.
Methoxy polyethylene glycol-epoetin beta,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gemtuzumab ozogamicin.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Gemtuzumab ozogamicin.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estrone,Estrone may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estradiol,Estradiol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Dienestrol,Dienestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Mestranol,Mestranol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estriol,Estriol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Quinestrol,Quinestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Hexestrol,Hexestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Tibolone,Tibolone may increase the thrombogenic activities of Gemtuzumab ozogamicin.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Gemtuzumab ozogamicin."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Gemtuzumab ozogamicin."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Zeranol,Zeranol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Equol,Equol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Promestriene,Promestriene may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Methallenestril,Methallenestril may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Epimestrol,Epimestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Moxestrol,Moxestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Biochanin A,Biochanin A may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Formononetin,Formononetin may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Leflunomide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Leflunomide.
Tofacitinib,Gemtuzumab ozogamicin may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Gemtuzumab ozogamicin.
Fingolimod,Gemtuzumab ozogamicin may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Gemtuzumab ozogamicin.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Gemtuzumab ozogamicin.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Gemtuzumab ozogamicin.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Gemtuzumab ozogamicin.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Gemtuzumab ozogamicin.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Gemtuzumab ozogamicin.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Gemtuzumab ozogamicin.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Gemtuzumab ozogamicin.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Gemtuzumab ozogamicin.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Gemtuzumab ozogamicin.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Gemtuzumab ozogamicin."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Gemtuzumab ozogamicin.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Gemtuzumab ozogamicin."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Gemtuzumab ozogamicin.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Gemtuzumab ozogamicin.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Gemtuzumab ozogamicin.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Gemtuzumab ozogamicin.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Gemtuzumab ozogamicin.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Gemtuzumab ozogamicin.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Gemtuzumab ozogamicin.
Eptifibatide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Gemtuzumab ozogamicin.
Ticlopidine,The risk or severity of bleeding can be increased when Ticlopidine is combined with Gemtuzumab ozogamicin.
Anagrelide,The risk or severity of bleeding can be increased when Anagrelide is combined with Gemtuzumab ozogamicin.
Clopidogrel,The risk or severity of bleeding can be increased when Clopidogrel is combined with Gemtuzumab ozogamicin.
Tirofiban,The risk or severity of bleeding can be increased when Tirofiban is combined with Gemtuzumab ozogamicin.
Pentoxifylline,The risk or severity of bleeding can be increased when Pentoxifylline is combined with Gemtuzumab ozogamicin.
Acetylsalicylic acid,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Gemtuzumab ozogamicin.
Dipyridamole,The risk or severity of bleeding can be increased when Dipyridamole is combined with Gemtuzumab ozogamicin.
Iloprost,The risk or severity of bleeding can be increased when Iloprost is combined with Gemtuzumab ozogamicin.
Sulfinpyrazone,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Gemtuzumab ozogamicin.
Cilostazol,The risk or severity of bleeding can be increased when Cilostazol is combined with Gemtuzumab ozogamicin.
Ridogrel,The risk or severity of bleeding can be increased when Ridogrel is combined with Gemtuzumab ozogamicin.
Sevoflurane,The risk or severity of bleeding can be increased when Sevoflurane is combined with Gemtuzumab ozogamicin.
Epoprostenol,The risk or severity of bleeding can be increased when Epoprostenol is combined with Gemtuzumab ozogamicin.
Resveratrol,The risk or severity of bleeding can be increased when Resveratrol is combined with Gemtuzumab ozogamicin.
Nimesulide,The risk or severity of bleeding can be increased when Nimesulide is combined with Gemtuzumab ozogamicin.
Tesmilifene,The risk or severity of bleeding can be increased when Tesmilifene is combined with Gemtuzumab ozogamicin.
Defibrotide,The risk or severity of bleeding can be increased when Defibrotide is combined with Gemtuzumab ozogamicin.
Beraprost,The risk or severity of bleeding can be increased when Beraprost is combined with Gemtuzumab ozogamicin.
Ibudilast,The risk or severity of bleeding can be increased when Ibudilast is combined with Gemtuzumab ozogamicin.
Andrographolide,The risk or severity of bleeding can be increased when Andrographolide is combined with Gemtuzumab ozogamicin.
Prasugrel,The risk or severity of bleeding can be increased when Prasugrel is combined with Gemtuzumab ozogamicin.
Cangrelor,The risk or severity of bleeding can be increased when Cangrelor is combined with Gemtuzumab ozogamicin.
Tranilast,The risk or severity of bleeding can be increased when Tranilast is combined with Gemtuzumab ozogamicin.
Triflusal,The risk or severity of bleeding can be increased when Triflusal is combined with Gemtuzumab ozogamicin.
Ticagrelor,The risk or severity of bleeding can be increased when Ticagrelor is combined with Gemtuzumab ozogamicin.
Icosapent ethyl,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Gemtuzumab ozogamicin.
Vorapaxar,The risk or severity of bleeding can be increased when Vorapaxar is combined with Gemtuzumab ozogamicin.
Trapidil,The risk or severity of bleeding can be increased when Trapidil is combined with Gemtuzumab ozogamicin.
Naftopidil,The risk or severity of bleeding can be increased when Naftopidil is combined with Gemtuzumab ozogamicin.
Sarpogrelate,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Gemtuzumab ozogamicin.
Ifetroban,The risk or severity of bleeding can be increased when Ifetroban is combined with Gemtuzumab ozogamicin.
Nitroaspirin,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Gemtuzumab ozogamicin.
Ketanserin,The risk or severity of bleeding can be increased when Ketanserin is combined with Gemtuzumab ozogamicin.
Indobufen,The risk or severity of bleeding can be increased when Indobufen is combined with Gemtuzumab ozogamicin.
Butylphthalide,The risk or severity of bleeding can be increased when Butylphthalide is combined with Gemtuzumab ozogamicin.
Hydroxytyrosol,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Gemtuzumab ozogamicin.
Ramatroban,The risk or severity of bleeding can be increased when Ramatroban is combined with Gemtuzumab ozogamicin.
Picotamide,The risk or severity of bleeding can be increased when Picotamide is combined with Gemtuzumab ozogamicin.
Cloricromen,The risk or severity of bleeding can be increased when Cloricromen is combined with Gemtuzumab ozogamicin.
Linsidomine,The risk or severity of bleeding can be increased when Linsidomine is combined with Gemtuzumab ozogamicin.
Buflomedil,The risk or severity of bleeding can be increased when Buflomedil is combined with Gemtuzumab ozogamicin.
Relcovaptan,The risk or severity of bleeding can be increased when Relcovaptan is combined with Gemtuzumab ozogamicin.
Ocrelizumab,Ocrelizumab may increase the immunosuppressive activities of Gemtuzumab ozogamicin.
Lipegfilgrastim,Gemtuzumab ozogamicin may increase the myelosuppressive activities of Lipegfilgrastim.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Gemtuzumab ozogamicin.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Gemtuzumab ozogamicin.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Gemtuzumab ozogamicin.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Gemtuzumab ozogamicin.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Gemtuzumab ozogamicin.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Gemtuzumab ozogamicin.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Gemtuzumab ozogamicin.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Gemtuzumab ozogamicin.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Gemtuzumab ozogamicin.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Gemtuzumab ozogamicin.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Gemtuzumab ozogamicin.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Gemtuzumab ozogamicin.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Gemtuzumab ozogamicin.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gemtuzumab ozogamicin.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Gemtuzumab ozogamicin.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Gemtuzumab ozogamicin.
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indium In-111 satumomab pendetide.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Digoxin Immune Fab (Ovine).
Capromab pendetide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Capromab pendetide.
Palivizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Palivizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Technetium Tc-99m arcitumomab.
Panitumumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pexelizumab.
Epratuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with NAV 1800.
Otelixizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Veltuzumab.
PRO-542,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lumiliximab.
Ipilimumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clenoliximab.
BIIB015,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Catumaxomab.
Volociximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ofatumumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Raxibacumab.
Nivolumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nivolumab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dulaglutide.
Asfotase alfa,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Evolocumab.
Daratumumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Necitumumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Solanezumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tremelimumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lampalizumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Anifrolumab.
Benralizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Plozalizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Besilesomab.
Burosumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cemiplimab.
Camrelizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Refanezumab.
Bermekimab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nemolizumab.
Gedivumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Naratuximab emtansine.
Tildrakizumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tildrakizumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ustekinumab.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zenocutuzumab.
Palifermin,The therapeutic efficacy of Palifermin can be decreased when used in combination with Gemtuzumab ozogamicin.
Lepirudin,The risk or severity of bleeding can be increased when Lepirudin is combined with Gemtuzumab ozogamicin.
Bivalirudin,The risk or severity of bleeding can be increased when Bivalirudin is combined with Gemtuzumab ozogamicin.
Alteplase,The risk or severity of bleeding can be increased when Alteplase is combined with Gemtuzumab ozogamicin.
Urokinase,The risk or severity of bleeding can be increased when Urokinase is combined with Gemtuzumab ozogamicin.
Reteplase,The risk or severity of bleeding can be increased when Reteplase is combined with Gemtuzumab ozogamicin.
Anistreplase,The risk or severity of bleeding can be increased when Anistreplase is combined with Gemtuzumab ozogamicin.
Tenecteplase,The risk or severity of bleeding can be increased when Tenecteplase is combined with Gemtuzumab ozogamicin.
Drotrecogin alfa,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Gemtuzumab ozogamicin.
Streptokinase,The risk or severity of bleeding can be increased when Streptokinase is combined with Gemtuzumab ozogamicin.
Dicoumarol,The risk or severity of bleeding can be increased when Dicoumarol is combined with Gemtuzumab ozogamicin.
Argatroban,The risk or severity of bleeding can be increased when Argatroban is combined with Gemtuzumab ozogamicin.
Ardeparin,The risk or severity of bleeding can be increased when Ardeparin is combined with Gemtuzumab ozogamicin.
Phenindione,The risk or severity of bleeding can be increased when Phenindione is combined with Gemtuzumab ozogamicin.
Fondaparinux,The risk or severity of bleeding can be increased when Fondaparinux is combined with Gemtuzumab ozogamicin.
Warfarin,The risk or severity of bleeding can be increased when Warfarin is combined with Gemtuzumab ozogamicin.
Pentosan polysulfate,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Gemtuzumab ozogamicin.
Phenprocoumon,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Gemtuzumab ozogamicin.
Heparin,The risk or severity of bleeding can be increased when Heparin is combined with Gemtuzumab ozogamicin.
Enoxaparin,The risk or severity of bleeding can be increased when Enoxaparin is combined with Gemtuzumab ozogamicin.
Acenocoumarol,The risk or severity of bleeding can be increased when Acenocoumarol is combined with Gemtuzumab ozogamicin.
4-hydroxycoumarin,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Gemtuzumab ozogamicin.
Coumarin,The risk or severity of bleeding can be increased when Coumarin is combined with Gemtuzumab ozogamicin.
Ximelagatran,The risk or severity of bleeding can be increased when Ximelagatran is combined with Gemtuzumab ozogamicin.
Desmoteplase,The risk or severity of bleeding can be increased when Desmoteplase is combined with Gemtuzumab ozogamicin.
Ancrod,The risk or severity of bleeding can be increased when Ancrod is combined with Gemtuzumab ozogamicin.
Fibrinolysin,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Gemtuzumab ozogamicin.
Rivaroxaban,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Gemtuzumab ozogamicin.
Sulodexide,The risk or severity of bleeding can be increased when Sulodexide is combined with Gemtuzumab ozogamicin.
Semuloparin,The risk or severity of bleeding can be increased when Semuloparin is combined with Gemtuzumab ozogamicin.
Idraparinux,The risk or severity of bleeding can be increased when Idraparinux is combined with Gemtuzumab ozogamicin.
Astaxanthin,The risk or severity of bleeding can be increased when Astaxanthin is combined with Gemtuzumab ozogamicin.
Apixaban,The risk or severity of bleeding can be increased when Apixaban is combined with Gemtuzumab ozogamicin.
Otamixaban,The risk or severity of bleeding can be increased when Otamixaban is combined with Gemtuzumab ozogamicin.
Amediplase,The risk or severity of bleeding can be increased when Amediplase is combined with Gemtuzumab ozogamicin.
Dabigatran etexilate,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Gemtuzumab ozogamicin.
Danaparoid,The risk or severity of bleeding can be increased when Danaparoid is combined with Gemtuzumab ozogamicin.
Dalteparin,The risk or severity of bleeding can be increased when Dalteparin is combined with Gemtuzumab ozogamicin.
Tinzaparin,The risk or severity of bleeding can be increased when Tinzaparin is combined with Gemtuzumab ozogamicin.
Ferulic acid,The risk or severity of bleeding can be increased when Ferulic acid is combined with Gemtuzumab ozogamicin.
(R)-warfarin,The risk or severity of bleeding can be increased when (R)-warfarin is combined with Gemtuzumab ozogamicin.
Ethyl biscoumacetate,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Gemtuzumab ozogamicin.
Nadroparin,The risk or severity of bleeding can be increased when Nadroparin is combined with Gemtuzumab ozogamicin.
Ditazole,The risk or severity of bleeding can be increased when Ditazole is combined with Gemtuzumab ozogamicin.
Edoxaban,The risk or severity of bleeding can be increased when Edoxaban is combined with Gemtuzumab ozogamicin.
Potassium citrate,The risk or severity of bleeding can be increased when Potassium citrate is combined with Gemtuzumab ozogamicin.
Sodium citrate,The risk or severity of bleeding can be increased when Sodium citrate is combined with Gemtuzumab ozogamicin.
Dextran,The risk or severity of bleeding can be increased when Dextran is combined with Gemtuzumab ozogamicin.
Bemiparin,The risk or severity of bleeding can be increased when Bemiparin is combined with Gemtuzumab ozogamicin.
Reviparin,The risk or severity of bleeding can be increased when Reviparin is combined with Gemtuzumab ozogamicin.
Parnaparin,The risk or severity of bleeding can be increased when Parnaparin is combined with Gemtuzumab ozogamicin.
Certoparin,The risk or severity of bleeding can be increased when Certoparin is combined with Gemtuzumab ozogamicin.
Desirudin,The risk or severity of bleeding can be increased when Desirudin is combined with Gemtuzumab ozogamicin.
Zinc citrate,The risk or severity of bleeding can be increased when Zinc citrate is combined with Gemtuzumab ozogamicin.
Antithrombin Alfa,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Gemtuzumab ozogamicin.
Protein C,The risk or severity of bleeding can be increased when Protein C is combined with Gemtuzumab ozogamicin.
Antithrombin III human,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Gemtuzumab ozogamicin.
Letaxaban,The risk or severity of bleeding can be increased when Letaxaban is combined with Gemtuzumab ozogamicin.
Darexaban,The risk or severity of bleeding can be increased when Darexaban is combined with Gemtuzumab ozogamicin.
Betrixaban,The risk or severity of bleeding can be increased when Betrixaban is combined with Gemtuzumab ozogamicin.
Nafamostat,The risk or severity of bleeding can be increased when Nafamostat is combined with Gemtuzumab ozogamicin.
Monteplase,The risk or severity of bleeding can be increased when Monteplase is combined with Gemtuzumab ozogamicin.
Gabexate,The risk or severity of bleeding can be increased when Gabexate is combined with Gemtuzumab ozogamicin.
Fluindione,The risk or severity of bleeding can be increased when Fluindione is combined with Gemtuzumab ozogamicin.
Protein S human,The risk or severity of bleeding can be increased when Protein S human is combined with Gemtuzumab ozogamicin.
Brinase,The risk or severity of bleeding can be increased when Brinase is combined with Gemtuzumab ozogamicin.
Clorindione,The risk or severity of bleeding can be increased when Clorindione is combined with Gemtuzumab ozogamicin.
Diphenadione,The risk or severity of bleeding can be increased when Diphenadione is combined with Gemtuzumab ozogamicin.
Tioclomarol,The risk or severity of bleeding can be increased when Tioclomarol is combined with Gemtuzumab ozogamicin.
Melagatran,The risk or severity of bleeding can be increased when Melagatran is combined with Gemtuzumab ozogamicin.
Saruplase,The risk or severity of bleeding can be increased when Saruplase is combined with Gemtuzumab ozogamicin.
(S)-Warfarin,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Gemtuzumab ozogamicin.
Tocopherylquinone,The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Gemtuzumab ozogamicin.
Edetate calcium disodium anhydrous,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Gemtuzumab ozogamicin.
Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Gemtuzumab ozogamicin.
Methyclothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Gemtuzumab ozogamicin.
Bendroflumethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Gemtuzumab ozogamicin.
Benzthiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Gemtuzumab ozogamicin.
Cyclothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Gemtuzumab ozogamicin.
Hydroflumethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Gemtuzumab ozogamicin.
Chlorothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Gemtuzumab ozogamicin.
Hydrochlorothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Gemtuzumab ozogamicin.
Trichlormethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Gemtuzumab ozogamicin.
Polythiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Gemtuzumab ozogamicin.
Mebutizide,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Gemtuzumab ozogamicin.
Cyclopenthiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Gemtuzumab ozogamicin.
Tedizolid phosphate,The risk or severity of myelosuppression can be increased when Gemtuzumab ozogamicin is combined with Tedizolid phosphate.
Cyclosporine,Gemtuzumab ozogamicin may increase the immunosuppressive activities of Cyclosporine.
Cyanocobalamin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Gemtuzumab ozogamicin.
Allopurinol,The risk or severity of adverse effects can be increased when Allopurinol is combined with Gemtuzumab ozogamicin.
Pexidartinib,Gemtuzumab ozogamicin may increase the hepatotoxic activities of Pexidartinib.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Gemtuzumab ozogamicin."
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Gemtuzumab ozogamicin.
Lopinavir,The serum concentration of Gemtuzumab ozogamicin can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Gemtuzumab ozogamicin is combined with Inebilizumab.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Estrone,Estrone may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Estradiol,Estradiol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Dienestrol,Dienestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Mestranol,Mestranol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Estriol,Estriol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Quinestrol,Quinestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Hexestrol,Hexestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Tibolone,Tibolone may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Indium In-111 satumomab pendetide."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Indium In-111 satumomab pendetide."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Zeranol,Zeranol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Equol,Equol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Promestriene,Promestriene may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Methallenestril,Methallenestril may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Epimestrol,Epimestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Moxestrol,Moxestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Biochanin A,Biochanin A may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Formononetin,Formononetin may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Indium In-111 satumomab pendetide.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Indium In-111 satumomab pendetide.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Indium In-111 satumomab pendetide.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Indium In-111 satumomab pendetide.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Indium In-111 satumomab pendetide.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indium In-111 satumomab pendetide.
Infliximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Infliximab.
Trastuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Trastuzumab.
Rituximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rituximab.
Basiliximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Basiliximab.
Muromonab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Muromonab.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Digoxin Immune Fab (Ovine).
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ibritumomab tiuxetan.
Tositumomab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tositumomab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Alemtuzumab.
Capromab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Capromab pendetide.
Efalizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Antithymocyte immunoglobulin (rabbit).
Natalizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Natalizumab.
Palivizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Palivizumab.
Daclizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bevacizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Technetium Tc-99m arcitumomab.
Eculizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eculizumab.
Panitumumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pexelizumab.
Afelimomab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Afelimomab.
Epratuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with NAV 1800.
Briakinumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Briakinumab.
Otelixizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Veltuzumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ustekinumab.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Trastuzumab emtansine.
PRO-542,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lumiliximab.
Canakinumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Canakinumab.
Ipilimumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Clenoliximab.
Tocilizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tocilizumab.
BIIB015,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Catumaxomab.
Mepolizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Mepolizumab.
Denosumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Denosumab.
Volociximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ofatumumab.
Golimumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Golimumab.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Brentuximab vedotin.
Belimumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Belimumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Raxibacumab.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Certolizumab pegol.
Obinutuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Obinutuzumab.
Secukinumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vedolizumab.
Nivolumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Nivolumab.
Siltuximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Siltuximab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dulaglutide.
Blinatumomab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Blinatumomab.
Anthrax immune globulin human,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Anthrax immune globulin human.
Dinutuximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dinutuximab.
Asfotase alfa,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Evolocumab.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Antilymphocyte immunoglobulin (horse).
Daratumumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Necitumumab.
Ixekizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ravulizumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Solanezumab.
Sarilumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sarilumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tremelimumab.
Brodalumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sirukumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lampalizumab.
Guselkumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Guselkumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Anifrolumab.
Ocrelizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ocrelizumab.
Benralizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Plozalizumab.
Inebilizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Inebilizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Besilesomab.
Tildrakizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tildrakizumab.
Burosumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Cemiplimab.
Emapalumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Risankizumab.
Camrelizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Refanezumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rozanolixizumab.
Bermekimab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Nemolizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bleselumab.
Gedivumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Naratuximab emtansine.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Zenocutuzumab.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Indium In-111 satumomab pendetide."
Menadione,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Menadione.
Tranexamic acid,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Tranexamic acid.
Aminocaproic acid,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aminocaproic acid.
Aprotinin,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aprotinin.
Hydrogen peroxide,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Hydrogen peroxide.
Aminomethylbenzoic acid,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aminomethylbenzoic acid.
Camostat,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Camostat.
Fibrinogen human,The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Alpha-1-proteinase inhibitor.
Tretinoin,The risk or severity of Thrombosis can be increased when Tretinoin is combined with Alpha-1-proteinase inhibitor.
"Antihemophilic factor, human recombinant","Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic factor, human recombinant."
Coagulation factor VIIa Recombinant Human,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
Coagulation Factor IX (Recombinant),Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).
Calcium acetate,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium acetate.
Calcium chloride,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium chloride.
Calcium,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium.
Pantothenic acid,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Pantothenic acid.
Formic acid,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Formic acid.
Platelet Activating Factor,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Platelet Activating Factor.
Calcium carbonate,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium carbonate.
Turoctocog alfa,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Turoctocog alfa.
Catridecacog,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Catridecacog.
"Antihemophilic Factor (Recombinant), PEGylated","Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic Factor (Recombinant), PEGylated."
Calcium citrate,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium citrate.
Calcium gluconate,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium gluconate.
Calcium threonate,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium threonate.
Prothrombin,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Prothrombin.
Factor IX Complex (Human),Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Factor IX Complex (Human).
Calcium Phosphate,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium Phosphate.
Susoctocog alfa,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Susoctocog alfa.
Eftrenonacog alfa,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Eftrenonacog alfa.
Rusalatide acetate,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Rusalatide acetate.
Vatreptacog alfa,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Vatreptacog alfa.
Factor XIII (human),Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Factor XIII (human).
Von Willebrand Factor Human,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Von Willebrand Factor Human.
Coagulation factor X human,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor X human.
Coagulation factor VII human,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor VII human.
Anti-inhibitor coagulant complex,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Anti-inhibitor coagulant complex.
Coagulation Factor IX Human,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation Factor IX Human.
Antihemophilic factor human,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic factor human.
Kallidinogenase,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Kallidinogenase.
Trenonacog alfa,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Trenonacog alfa.
Albutrepenonacog alfa,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Albutrepenonacog alfa.
Emicizumab,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Emicizumab.
Nonacog beta pegol,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Nonacog beta pegol.
Moroctocog alfa,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Moroctocog alfa.
Beroctocog alfa,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Beroctocog alfa.
Andexanet alfa,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Andexanet alfa.
Calcium cation,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium cation.
Damoctocog alfa pegol,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Damoctocog alfa pegol.
Turoctocog alfa pegol,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Turoctocog alfa pegol.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Pegaspargase.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Pegaspargase.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pegaspargase.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pegaspargase.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Pegaspargase.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Pegaspargase.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Pegaspargase.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Pegaspargase.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Pegaspargase."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pegaspargase.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Pegaspargase.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pegaspargase.
Infliximab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Infliximab.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon beta-1b.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon alfacon-1.
Rituximab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Rituximab.
Basiliximab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Basiliximab.
Muromonab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Muromonab.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ibritumomab tiuxetan.
Tositumomab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tositumomab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Alemtuzumab.
Alefacept,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Alefacept.
Efalizumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Pegaspargase is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon alfa-2b.
Daclizumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Beclomethasone dipropionate.
Sorafenib,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sorafenib.
Streptozocin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Altretamine.
Zidovudine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Zidovudine.
Cisplatin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pentostatin.
Carbamazepine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carbamazepine.
Vinblastine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Linezolid.
Triamcinolone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Paclitaxel.
Docetaxel,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Decitabine.
Sunitinib,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sunitinib.
Nelarabine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Nelarabine.
Abatacept,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Abatacept.
Corticotropin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Pegaspargase is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Pegaspargase is combined with omega interferon.
Apremilast,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Apremilast.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ponatinib.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Certolizumab pegol.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Blinatumomab.
Ibrutinib,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ibrutinib.
Idelalisib,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Idelalisib.
Palbociclib,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Palbociclib.
Olaparib,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Olaparib.
Dinutuximab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dinutuximab.
Vilanterol,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vilanterol.
Tixocortol,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Pegaspargase is combined with Antilymphocyte immunoglobulin (horse).
Fluprednisolone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Meprednisone.
Tepoxalin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tepoxalin.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Melengestrol.
Ixekizumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Peficitinib.
Clobetasol,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Clobetasol.
Sarilumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sirukumab.
Baricitinib,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Baricitinib.
Guselkumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Guselkumab.
Deflazacort,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Deflazacort.
Triptolide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Triptolide.
Siponimod,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Siponimod.
Ozanimod,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Pegaspargase is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Prednylidene,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Prednylidene.
Fluocortin,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluclorolone.
Fluticasone,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluticasone.
Tetrandrine,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tetrandrine.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Monomethyl fumarate.
Mometasone furoate,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mometasone furoate.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydrocortisone aceponate.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydrocortisone acetate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydrocortisone succinate.
Emapalumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bleselumab.
Natalizumab,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pegaspargase.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Pegaspargase.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pegaspargase.
Peginesatide,The risk or severity of Thrombosis can be increased when Pegaspargase is combined with Peginesatide.
Methoxy polyethylene glycol-epoetin beta,The risk or severity of Thrombosis can be increased when Pegaspargase is combined with Methoxy polyethylene glycol-epoetin beta.
Darbepoetin alfa,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pegaspargase.
Erythropoietin,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pegaspargase.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Pegaspargase.
Leflunomide,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Leflunomide.
Tofacitinib,Pegaspargase may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Pegaspargase.
Pegfilgrastim,The therapeutic efficacy of Pegaspargase can be decreased when used in combination with Pegfilgrastim.
Pegademase,The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegaspargase.
Pegvisomant,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegaspargase.
Propylene glycol,The therapeutic efficacy of Propylene glycol can be decreased when used in combination with Pegaspargase.
Heptaethylene glycol,The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegaspargase.
Pegaptanib,The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegaspargase.
Egaptivon pegol,The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Pegaspargase.
PEG-uricase,The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegaspargase.
Peginterferon alfacon-1,The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with Pegaspargase.
GlycoPEG-GCSF,The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Pegaspargase.
Pegnivacogin,The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Pegaspargase.
Pegpleranib,The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Pegaspargase.
Pegsunercept,The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Pegaspargase.
Polidocanol,The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegaspargase.
Pegloticase,The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegaspargase.
Polyethylene glycol,The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegaspargase.
"Antihemophilic Factor (Recombinant), PEGylated","The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Pegaspargase."
Polyethylene glycol 400,The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Pegaspargase.
Insulin peglispro,The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Pegaspargase.
Eptacog alfa pegol (activated),The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Pegaspargase.
Olaptesed Pegol,The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Pegaspargase.
Abicipar Pegol,The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegaspargase.
Lexaptepid Pegol,The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Pegaspargase.
Pegvaliase,The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegaspargase.
Pegamotecan,The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Pegaspargase.
Lipegfilgrastim,The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegaspargase.
Nonacog beta pegol,The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Pegaspargase.
Damoctocog alfa pegol,The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegaspargase.
Elapegademase,The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegaspargase.
Fingolimod,Pegaspargase may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Pegaspargase.
Dexamethasone,The serum concentration of Dexamethasone can be increased when it is combined with Pegaspargase.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Pegaspargase.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Pegaspargase.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Pegaspargase.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Pegaspargase.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Pegaspargase.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Pegaspargase.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Pegaspargase.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Pegaspargase.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Pegaspargase.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Pegaspargase."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Pegaspargase.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Pegaspargase.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pegaspargase."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Pegaspargase.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Pegaspargase.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pegaspargase.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Pegaspargase.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Pegaspargase.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pegaspargase.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Pegaspargase.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Pegaspargase.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Pegaspargase.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Pegaspargase.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Pegaspargase.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Pegaspargase.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Pegaspargase.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Pegaspargase.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Pegaspargase."
Ocrelizumab,Ocrelizumab may increase the immunosuppressive activities of Pegaspargase.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Pegaspargase.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Pegaspargase.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Pegaspargase.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Pegaspargase.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Pegaspargase.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Pegaspargase.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Pegaspargase.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Pegaspargase.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Pegaspargase.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Pegaspargase.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Pegaspargase.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Pegaspargase.
Methotrexate,The therapeutic efficacy of Methotrexate can be decreased when used in combination with Pegaspargase.
Imatinib,The risk or severity of liver damage can be increased when Pegaspargase is combined with Imatinib.
Cyclosporine,Pegaspargase may increase the immunosuppressive activities of Cyclosporine.
Phenytoin,The therapeutic efficacy of Phenytoin can be increased when used in combination with Pegaspargase.
Liothyronine,The therapeutic efficacy of Liothyronine can be increased when used in combination with Pegaspargase.
Levothyroxine,The therapeutic efficacy of Levothyroxine can be increased when used in combination with Pegaspargase.
Mephenytoin,The therapeutic efficacy of Mephenytoin can be increased when used in combination with Pegaspargase.
Furosemide,The therapeutic efficacy of Furosemide can be increased when used in combination with Pegaspargase.
Nitrofurantoin,The therapeutic efficacy of Nitrofurantoin can be increased when used in combination with Pegaspargase.
Ethotoin,The therapeutic efficacy of Ethotoin can be increased when used in combination with Pegaspargase.
Meclofenamic acid,The therapeutic efficacy of Meclofenamic acid can be increased when used in combination with Pegaspargase.
Heparin,The therapeutic efficacy of Heparin can be increased when used in combination with Pegaspargase.
Dantrolene,The therapeutic efficacy of Dantrolene can be increased when used in combination with Pegaspargase.
Fosphenytoin,The therapeutic efficacy of Fosphenytoin can be increased when used in combination with Pegaspargase.
Liotrix,The therapeutic efficacy of Liotrix can be increased when used in combination with Pegaspargase.
Enzalutamide,The therapeutic efficacy of Enzalutamide can be increased when used in combination with Pegaspargase.
Etofenamate,The therapeutic efficacy of Etofenamate can be increased when used in combination with Pegaspargase.
Liothyronine I-131,The therapeutic efficacy of Liothyronine I-131 can be increased when used in combination with Pegaspargase.
Neocitrullamon,The therapeutic efficacy of Neocitrullamon can be increased when used in combination with Pegaspargase.
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Pegaspargase.
Lopinavir,The serum concentration of Pegaspargase can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Pegaspargase is combined with Inebilizumab.
Zolmitriptan,The metabolism of Zolmitriptan can be decreased when combined with Interferon beta-1a.
Caffeine,The metabolism of Caffeine can be decreased when combined with Interferon beta-1a.
Dyphylline,The metabolism of Dyphylline can be decreased when combined with Interferon beta-1a.
Pentoxifylline,The metabolism of Pentoxifylline can be decreased when combined with Interferon beta-1a.
Mercaptopurine,The metabolism of Mercaptopurine can be decreased when combined with Interferon beta-1a.
Oxtriphylline,The metabolism of Oxtriphylline can be decreased when combined with Interferon beta-1a.
Theobromine,The metabolism of Theobromine can be decreased when combined with Interferon beta-1a.
Fenethylline,The metabolism of Fenethylline can be decreased when combined with Interferon beta-1a.
8-azaguanine,The metabolism of 8-azaguanine can be decreased when combined with Interferon beta-1a.
"7,9-Dimethylguanine","The metabolism of 7,9-Dimethylguanine can be decreased when combined with Interferon beta-1a."
Xanthine,The metabolism of Xanthine can be decreased when combined with Interferon beta-1a.
7-Deazaguanine,The metabolism of 7-Deazaguanine can be decreased when combined with Interferon beta-1a.
Guanine,The metabolism of Guanine can be decreased when combined with Interferon beta-1a.
9-Methylguanine,The metabolism of 9-Methylguanine can be decreased when combined with Interferon beta-1a.
Peldesine,The metabolism of Peldesine can be decreased when combined with Interferon beta-1a.
Hypoxanthine,The metabolism of Hypoxanthine can be decreased when combined with Interferon beta-1a.
9-Deazaguanine,The metabolism of 9-Deazaguanine can be decreased when combined with Interferon beta-1a.
Propentofylline,The metabolism of Propentofylline can be decreased when combined with Interferon beta-1a.
Valomaciclovir,The metabolism of Valomaciclovir can be decreased when combined with Interferon beta-1a.
3-isobutyl-1-methyl-7H-xanthine,The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Interferon beta-1a.
Uric acid,The metabolism of Uric acid can be decreased when combined with Interferon beta-1a.
Doxofylline,The metabolism of Doxofylline can be decreased when combined with Interferon beta-1a.
6-O-benzylguanine,The metabolism of 6-O-benzylguanine can be decreased when combined with Interferon beta-1a.
Lisofylline,The metabolism of Lisofylline can be decreased when combined with Interferon beta-1a.
Lobucavir,The metabolism of Lobucavir can be decreased when combined with Interferon beta-1a.
Cafedrine,The metabolism of Cafedrine can be decreased when combined with Interferon beta-1a.
Theodrenaline,The metabolism of Theodrenaline can be decreased when combined with Interferon beta-1a.
Bamifylline,The metabolism of Bamifylline can be decreased when combined with Interferon beta-1a.
Proxyphylline,The metabolism of Proxyphylline can be decreased when combined with Interferon beta-1a.
Acefylline,The metabolism of Acefylline can be decreased when combined with Interferon beta-1a.
Etamiphylline,The metabolism of Etamiphylline can be decreased when combined with Interferon beta-1a.
Pentifylline,The metabolism of Pentifylline can be decreased when combined with Interferon beta-1a.
Bufylline,The metabolism of Bufylline can be decreased when combined with Interferon beta-1a.
Bromotheophylline,The metabolism of Bromotheophylline can be decreased when combined with Interferon beta-1a.
Furafylline,The metabolism of Furafylline can be decreased when combined with Interferon beta-1a.
8-chlorotheophylline,The metabolism of 8-chlorotheophylline can be decreased when combined with Interferon beta-1a.
PCS-499,The metabolism of PCS-499 can be decreased when combined with Interferon beta-1a.
Fluvoxamine,The metabolism of Fluvoxamine can be decreased when combined with Interferon beta-1a.
Nicotine,The metabolism of Nicotine can be decreased when combined with Interferon beta-1a.
Bortezomib,The metabolism of Bortezomib can be decreased when combined with Interferon beta-1a.
Betaxolol,The metabolism of Betaxolol can be decreased when combined with Interferon beta-1a.
Anagrelide,The metabolism of Anagrelide can be decreased when combined with Interferon beta-1a.
Carmustine,The metabolism of Carmustine can be decreased when combined with Interferon beta-1a.
Disopyramide,The metabolism of Disopyramide can be decreased when combined with Interferon beta-1a.
Lidocaine,The metabolism of Lidocaine can be decreased when combined with Interferon beta-1a.
Conjugated estrogens,The metabolism of Conjugated estrogens can be decreased when combined with Interferon beta-1a.
Ropivacaine,The metabolism of Ropivacaine can be decreased when combined with Interferon beta-1a.
Acetaminophen,The metabolism of Acetaminophen can be decreased when combined with Interferon beta-1a.
Olanzapine,The metabolism of Olanzapine can be decreased when combined with Interferon beta-1a.
Chlorzoxazone,The metabolism of Chlorzoxazone can be decreased when combined with Interferon beta-1a.
Clozapine,The metabolism of Clozapine can be decreased when combined with Interferon beta-1a.
Grepafloxacin,The metabolism of Grepafloxacin can be decreased when combined with Interferon beta-1a.
Mirtazapine,The metabolism of Mirtazapine can be decreased when combined with Interferon beta-1a.
Mexiletine,The metabolism of Mexiletine can be decreased when combined with Interferon beta-1a.
Tacrine,The metabolism of Tacrine can be decreased when combined with Interferon beta-1a.
Triamterene,The metabolism of Triamterene can be decreased when combined with Interferon beta-1a.
Promazine,The metabolism of Promazine can be decreased when combined with Interferon beta-1a.
Zolpidem,The metabolism of Zolpidem can be decreased when combined with Interferon beta-1a.
Entecavir,The metabolism of Entecavir can be decreased when combined with Interferon beta-1a.
Nabumetone,The metabolism of Nabumetone can be decreased when combined with Interferon beta-1a.
Quinine,The metabolism of Quinine can be decreased when combined with Interferon beta-1a.
Fluoxetine,The metabolism of Fluoxetine can be decreased when combined with Interferon beta-1a.
Duloxetine,The metabolism of Duloxetine can be decreased when combined with Interferon beta-1a.
Chlorpromazine,The metabolism of Chlorpromazine can be decreased when combined with Interferon beta-1a.
Flutamide,The metabolism of Flutamide can be decreased when combined with Interferon beta-1a.
Haloperidol,The metabolism of Haloperidol can be decreased when combined with Interferon beta-1a.
Albendazole,The metabolism of Albendazole can be decreased when combined with Interferon beta-1a.
Rofecoxib,The metabolism of Rofecoxib can be decreased when combined with Interferon beta-1a.
Fluorouracil,The metabolism of Fluorouracil can be decreased when combined with Interferon beta-1a.
Cinnarizine,The metabolism of Cinnarizine can be decreased when combined with Interferon beta-1a.
Propranolol,The metabolism of Propranolol can be decreased when combined with Interferon beta-1a.
Diclofenac,The metabolism of Diclofenac can be decreased when combined with Interferon beta-1a.
Imatinib,The metabolism of Imatinib can be decreased when combined with Interferon beta-1a.
Guanabenz,The metabolism of Guanabenz can be decreased when combined with Interferon beta-1a.
Pemetrexed,The metabolism of Pemetrexed can be decreased when combined with Interferon beta-1a.
Verapamil,The metabolism of Verapamil can be decreased when combined with Interferon beta-1a.
Paroxetine,The metabolism of Paroxetine can be decreased when combined with Interferon beta-1a.
Thiabendazole,The metabolism of Thiabendazole can be decreased when combined with Interferon beta-1a.
Riluzole,The metabolism of Riluzole can be decreased when combined with Interferon beta-1a.
Zileuton,The metabolism of Zileuton can be decreased when combined with Interferon beta-1a.
Clopidogrel,The metabolism of Clopidogrel can be decreased when combined with Interferon beta-1a.
Estradiol,The metabolism of Estradiol can be decreased when combined with Interferon beta-1a.
Acyclovir,The metabolism of Acyclovir can be decreased when combined with Interferon beta-1a.
Naproxen,The metabolism of Naproxen can be decreased when combined with Interferon beta-1a.
Trifluoperazine,The metabolism of Trifluoperazine can be decreased when combined with Interferon beta-1a.
Perphenazine,The metabolism of Perphenazine can be decreased when combined with Interferon beta-1a.
Terbinafine,The metabolism of Terbinafine can be decreased when combined with Interferon beta-1a.
Ranitidine,The metabolism of Ranitidine can be decreased when combined with Interferon beta-1a.
Ethanol,The metabolism of Ethanol can be decreased when combined with Interferon beta-1a.
Maprotiline,The metabolism of Maprotiline can be decreased when combined with Interferon beta-1a.
Alosetron,The metabolism of Alosetron can be decreased when combined with Interferon beta-1a.
Lomefloxacin,The metabolism of Lomefloxacin can be decreased when combined with Interferon beta-1a.
Ramelteon,The metabolism of Ramelteon can be decreased when combined with Interferon beta-1a.
Azathioprine,The metabolism of Azathioprine can be decreased when combined with Interferon beta-1a.
Frovatriptan,The metabolism of Frovatriptan can be decreased when combined with Interferon beta-1a.
Levobupivacaine,The metabolism of Levobupivacaine can be decreased when combined with Interferon beta-1a.
Cinacalcet,The metabolism of Cinacalcet can be decreased when combined with Interferon beta-1a.
Selegiline,The metabolism of Selegiline can be decreased when combined with Interferon beta-1a.
Tocainide,The metabolism of Tocainide can be decreased when combined with Interferon beta-1a.
Praziquantel,The metabolism of Praziquantel can be decreased when combined with Interferon beta-1a.
Melatonin,The metabolism of Melatonin can be decreased when combined with Interferon beta-1a.
Primaquine,The metabolism of Primaquine can be decreased when combined with Interferon beta-1a.
Hesperetin,The metabolism of Hesperetin can be decreased when combined with Interferon beta-1a.
Leflunomide,The metabolism of Leflunomide can be decreased when combined with Interferon beta-1a.
Nifedipine,The metabolism of Nifedipine can be decreased when combined with Interferon beta-1a.
Carvedilol,The metabolism of Carvedilol can be decreased when combined with Interferon beta-1a.
Cilostazol,The metabolism of Cilostazol can be decreased when combined with Interferon beta-1a.
Propafenone,The metabolism of Propafenone can be decreased when combined with Interferon beta-1a.
Domperidone,The metabolism of Domperidone can be decreased when combined with Interferon beta-1a.
Dexfenfluramine,The metabolism of Dexfenfluramine can be decreased when combined with Interferon beta-1a.
Rasagiline,The metabolism of Rasagiline can be decreased when combined with Interferon beta-1a.
Temafloxacin,The metabolism of Temafloxacin can be decreased when combined with Interferon beta-1a.
Aminophenazone,The metabolism of Aminophenazone can be decreased when combined with Interferon beta-1a.
Antipyrine,The metabolism of Antipyrine can be decreased when combined with Interferon beta-1a.
Bromazepam,The metabolism of Bromazepam can be decreased when combined with Interferon beta-1a.
Thiothixene,The metabolism of Thiothixene can be decreased when combined with Interferon beta-1a.
Etoricoxib,The metabolism of Etoricoxib can be decreased when combined with Interferon beta-1a.
Genistein,The metabolism of Genistein can be decreased when combined with Interferon beta-1a.
Resveratrol,The metabolism of Resveratrol can be decreased when combined with Interferon beta-1a.
Phenacetin,The metabolism of Phenacetin can be decreased when combined with Interferon beta-1a.
Estrone sulfate,The metabolism of Estrone sulfate can be decreased when combined with Interferon beta-1a.
Flunarizine,The metabolism of Flunarizine can be decreased when combined with Interferon beta-1a.
Lorcaserin,The metabolism of Lorcaserin can be decreased when combined with Interferon beta-1a.
Lofexidine,The metabolism of Lofexidine can be decreased when combined with Interferon beta-1a.
Pirfenidone,The metabolism of Pirfenidone can be decreased when combined with Interferon beta-1a.
Apremilast,The metabolism of Apremilast can be decreased when combined with Interferon beta-1a.
Mianserin,The metabolism of Mianserin can be decreased when combined with Interferon beta-1a.
Eltrombopag,The metabolism of Eltrombopag can be decreased when combined with Interferon beta-1a.
Asenapine,The metabolism of Asenapine can be decreased when combined with Interferon beta-1a.
Vadimezan,The metabolism of Vadimezan can be decreased when combined with Interferon beta-1a.
Dapagliflozin,The metabolism of Dapagliflozin can be decreased when combined with Interferon beta-1a.
Pazopanib,The metabolism of Pazopanib can be decreased when combined with Interferon beta-1a.
Agomelatine,The metabolism of Agomelatine can be decreased when combined with Interferon beta-1a.
Axitinib,The metabolism of Axitinib can be decreased when combined with Interferon beta-1a.
Bendamustine,The metabolism of Bendamustine can be decreased when combined with Interferon beta-1a.
Benzyl alcohol,The metabolism of Benzyl alcohol can be decreased when combined with Interferon beta-1a.
Capsaicin,The metabolism of Capsaicin can be decreased when combined with Interferon beta-1a.
(R)-warfarin,The metabolism of (R)-warfarin can be decreased when combined with Interferon beta-1a.
Perampanel,The metabolism of Perampanel can be decreased when combined with Interferon beta-1a.
Tasimelteon,The metabolism of Tasimelteon can be decreased when combined with Interferon beta-1a.
Stiripentol,The metabolism of Stiripentol can be decreased when combined with Interferon beta-1a.
Zotepine,The metabolism of Zotepine can be decreased when combined with Interferon beta-1a.
Propacetamol,The metabolism of Propacetamol can be decreased when combined with Interferon beta-1a.
Ramosetron,The metabolism of Ramosetron can be decreased when combined with Interferon beta-1a.
Binimetinib,The metabolism of Binimetinib can be decreased when combined with Interferon beta-1a.
Voxilaprevir,The metabolism of Voxilaprevir can be decreased when combined with Interferon beta-1a.
Triclabendazole,The metabolism of Triclabendazole can be decreased when combined with Interferon beta-1a.
Rucaparib,The metabolism of Rucaparib can be decreased when combined with Interferon beta-1a.
Dihydralazine,The metabolism of Dihydralazine can be decreased when combined with Interferon beta-1a.
Estradiol acetate,The metabolism of Estradiol acetate can be decreased when combined with Interferon beta-1a.
Estradiol benzoate,The metabolism of Estradiol benzoate can be decreased when combined with Interferon beta-1a.
Estradiol cypionate,The metabolism of Estradiol cypionate can be decreased when combined with Interferon beta-1a.
Estradiol dienanthate,The metabolism of Estradiol dienanthate can be decreased when combined with Interferon beta-1a.
Estradiol valerate,The metabolism of Estradiol valerate can be decreased when combined with Interferon beta-1a.
Istradefylline,The metabolism of Istradefylline can be decreased when combined with Interferon beta-1a.
Azelastine,The metabolism of Azelastine can be decreased when combined with Interferon beta-1a.
Efavirenz,The metabolism of Efavirenz can be decreased when combined with Interferon beta-1a.
Metoclopramide,The metabolism of Metoclopramide can be decreased when combined with Interferon beta-1a.
Bicifadine,The metabolism of Bicifadine can be decreased when combined with Interferon beta-1a.
GTS-21,The metabolism of GTS-21 can be decreased when combined with Interferon beta-1a.
Flecainide,The metabolism of Flecainide can be decreased when combined with Interferon beta-1a.
Ethinylestradiol,The metabolism of Ethinylestradiol can be decreased when combined with Interferon beta-1a.
Amitriptyline,The metabolism of Amitriptyline can be decreased when combined with Interferon beta-1a.
Imipramine,The metabolism of Imipramine can be decreased when combined with Interferon beta-1a.
Doxepin,The metabolism of Doxepin can be decreased when combined with Interferon beta-1a.
Mephenytoin,The metabolism of Mephenytoin can be decreased when combined with Interferon beta-1a.
Nortriptyline,The metabolism of Nortriptyline can be decreased when combined with Interferon beta-1a.
Clonidine,The metabolism of Clonidine can be decreased when combined with Interferon beta-1a.
Cyclobenzaprine,The metabolism of Cyclobenzaprine can be decreased when combined with Interferon beta-1a.
Desipramine,The metabolism of Desipramine can be decreased when combined with Interferon beta-1a.
Clomipramine,The metabolism of Clomipramine can be decreased when combined with Interferon beta-1a.
Selumetinib,The metabolism of Selumetinib can be decreased when combined with Interferon beta-1a.
Theophylline,The metabolism of Theophylline can be decreased when combined with Interferon beta-1a.
Carbamazepine,The metabolism of Carbamazepine can be decreased when combined with Interferon beta-1a.
Warfarin,The metabolism of Warfarin can be decreased when combined with Interferon beta-1a.
Tizanidine,The metabolism of Tizanidine can be decreased when combined with Interferon beta-1a.
Pimozide,The metabolism of Pimozide can be decreased when combined with Interferon beta-1a.
Aminophylline,The metabolism of Aminophylline can be decreased when combined with Interferon beta-1a.
Acenocoumarol,The metabolism of Acenocoumarol can be decreased when combined with Interferon beta-1a.
Sorafenib,The metabolism of Sorafenib can be decreased when combined with Interferon beta-1a.
Erlotinib,The metabolism of Erlotinib can be decreased when combined with Interferon beta-1a.
Etoposide,The metabolism of Etoposide can be decreased when combined with Interferon beta-1a.
Dacarbazine,The metabolism of Dacarbazine can be decreased when combined with Interferon beta-1a.
Dasatinib,The metabolism of Dasatinib can be decreased when combined with Interferon beta-1a.
Pomalidomide,The metabolism of Pomalidomide can be decreased when combined with Interferon beta-1a.
Tegafur,The metabolism of Tegafur can be decreased when combined with Interferon beta-1a.
Enasidenib,The metabolism of Enasidenib can be decreased when combined with Interferon beta-1a.
Tamoxifen,The metabolism of Tamoxifen can be decreased when combined with Interferon beta-1a.
Rubella virus vaccine,The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Interferon beta-1a.
Bacillus calmette-guerin substrain tice live antigen,The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Interferon beta-1a.
Bacillus calmette-guerin substrain connaught live antigen,The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Interferon beta-1a.
Yellow Fever Vaccine,The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Interferon beta-1a.
Anthrax vaccine,The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Interferon beta-1a.
Typhoid Vaccine Live,The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Interferon beta-1a.
Bacillus calmette-guerin substrain danish 1331 live antigen,The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Interferon beta-1a.
BCG vaccine,The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Interferon beta-1a.
Human adenovirus e serotype 4 strain cl-68578 antigen,The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Interferon beta-1a.
Vibrio cholerae CVD 103-HgR strain live antigen,The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Interferon beta-1a.
Adenovirus type 7 vaccine live,The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Interferon beta-1a.
Varicella Zoster Vaccine (Live/attenuated),The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Interferon beta-1a.
Ropinirole,The risk or severity of adverse effects can be increased when Interferon beta-1a is combined with Ropinirole.
Pentostatin,The therapeutic efficacy of Pentostatin can be decreased when used in combination with Pegademase.
Peginterferon alfa-2a,The therapeutic efficacy of Pegademase can be decreased when used in combination with Peginterferon alfa-2a.
Pegfilgrastim,The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegfilgrastim.
Peginterferon alfa-2b,The therapeutic efficacy of Pegademase can be decreased when used in combination with Peginterferon alfa-2b.
Pegaspargase,The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegaspargase.
Pegvisomant,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegademase.
Propylene glycol,The therapeutic efficacy of Propylene glycol can be decreased when used in combination with Pegademase.
Heptaethylene glycol,The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegademase.
Pegaptanib,The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegademase.
Egaptivon pegol,The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Pegademase.
PEG-uricase,The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegademase.
Peginterferon alfacon-1,The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with Pegademase.
GlycoPEG-GCSF,The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Pegademase.
Pegnivacogin,The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Pegademase.
Pegpleranib,The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Pegademase.
Pegsunercept,The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Pegademase.
Polidocanol,The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegademase.
Peginesatide,The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegademase.
Certolizumab pegol,The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegademase.
Methoxy polyethylene glycol-epoetin beta,The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegademase.
Peginterferon beta-1a,The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Pegademase.
Pegloticase,The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegademase.
Polyethylene glycol,The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegademase.
"Antihemophilic Factor (Recombinant), PEGylated","The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Pegademase."
Polyethylene glycol 400,The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Pegademase.
Insulin peglispro,The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Pegademase.
Eptacog alfa pegol (activated),The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Pegademase.
Olaptesed Pegol,The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Pegademase.
Abicipar Pegol,The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegademase.
Lexaptepid Pegol,The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Pegademase.
Cepeginterferon alfa-2B,The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Pegademase.
Pegvaliase,The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegademase.
Pegamotecan,The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Pegademase.
Lipegfilgrastim,The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegademase.
Nonacog beta pegol,The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Pegademase.
Damoctocog alfa pegol,The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegademase.
Elapegademase,The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegademase.
Apixaban,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Apixaban.
Dasatinib,Dasatinib may increase the anticoagulant activities of Eptifibatide.
Ursodeoxycholic acid,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Glycochenodeoxycholic Acid.
Cholic Acid,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Cholic Acid.
Glycocholic acid,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Glycocholic acid.
Deoxycholic acid,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Deoxycholic acid.
Taurocholic acid,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Taurocholic acid.
Obeticholic acid,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Obeticholic acid.
Chenodeoxycholic acid,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tauroursodeoxycholic acid.
Bamet-UD2,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Bamet-UD2.
Dehydrocholic acid,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Dehydrocholic acid.
Hyodeoxycholic Acid,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Hyodeoxycholic Acid.
Glucosamine,Glucosamine may increase the antiplatelet activities of Eptifibatide.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ibritumomab tiuxetan.
Ibrutinib,The risk or severity of adverse effects can be increased when Ibrutinib is combined with Eptifibatide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Obinutuzumab.
Pentoxifylline,Pentoxifylline may increase the antiplatelet activities of Eptifibatide.
Rivaroxaban,Eptifibatide may increase the anticoagulant activities of Rivaroxaban.
Tipranavir,Tipranavir may increase the antiplatelet activities of Eptifibatide.
Urokinase,Eptifibatide may increase the anticoagulant activities of Urokinase.
Vitamin E,Vitamin E may increase the antiplatelet activities of Eptifibatide.
Pentosan polysulfate,The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Eptifibatide.
Limaprost,Limaprost may increase the antiplatelet activities of Eptifibatide.
Omega-3 fatty acids,Omega-3 fatty acids may increase the antiplatelet activities of Eptifibatide.
Tositumomab,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tositumomab.
Lepirudin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Lepirudin.
Bivalirudin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bivalirudin.
Alteplase,The risk or severity of bleeding can be increased when Eptifibatide is combined with Alteplase.
Reteplase,The risk or severity of bleeding can be increased when Eptifibatide is combined with Reteplase.
Anistreplase,The risk or severity of bleeding can be increased when Eptifibatide is combined with Anistreplase.
Tenecteplase,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tenecteplase.
Abciximab,The risk or severity of bleeding can be increased when Eptifibatide is combined with Abciximab.
Drotrecogin alfa,The risk or severity of bleeding can be increased when Eptifibatide is combined with Drotrecogin alfa.
Streptokinase,The risk or severity of bleeding can be increased when Eptifibatide is combined with Streptokinase.
Dicoumarol,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dicoumarol.
Argatroban,The risk or severity of bleeding can be increased when Eptifibatide is combined with Argatroban.
Ardeparin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ardeparin.
Phenindione,The risk or severity of bleeding can be increased when Eptifibatide is combined with Phenindione.
Fondaparinux,The risk or severity of bleeding can be increased when Eptifibatide is combined with Fondaparinux.
Warfarin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Warfarin.
Phenprocoumon,The risk or severity of bleeding can be increased when Eptifibatide is combined with Phenprocoumon.
Dipyridamole,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dipyridamole.
Iloprost,The risk or severity of bleeding can be increased when Eptifibatide is combined with Iloprost.
Heparin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Heparin.
Enoxaparin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Enoxaparin.
Epoprostenol,The risk or severity of bleeding can be increased when Eptifibatide is combined with Epoprostenol.
Acenocoumarol,The risk or severity of bleeding can be increased when Eptifibatide is combined with Acenocoumarol.
4-hydroxycoumarin,The risk or severity of bleeding can be increased when Eptifibatide is combined with 4-hydroxycoumarin.
Coumarin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Coumarin.
Ximelagatran,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ximelagatran.
Desmoteplase,The risk or severity of bleeding can be increased when Eptifibatide is combined with Desmoteplase.
Defibrotide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Defibrotide.
Ancrod,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ancrod.
Beraprost,The risk or severity of bleeding can be increased when Eptifibatide is combined with Beraprost.
Fibrinolysin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Fibrinolysin.
Prasugrel,The risk or severity of bleeding can be increased when Eptifibatide is combined with Prasugrel.
Sulodexide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Sulodexide.
Semuloparin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Semuloparin.
Idraparinux,The risk or severity of bleeding can be increased when Eptifibatide is combined with Idraparinux.
Cangrelor,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cangrelor.
Astaxanthin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Astaxanthin.
Otamixaban,The risk or severity of bleeding can be increased when Eptifibatide is combined with Otamixaban.
Amediplase,The risk or severity of bleeding can be increased when Eptifibatide is combined with Amediplase.
Danaparoid,The risk or severity of bleeding can be increased when Eptifibatide is combined with Danaparoid.
Dalteparin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dalteparin.
Tinzaparin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tinzaparin.
Ferulic acid,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ferulic acid.
(R)-warfarin,The risk or severity of bleeding can be increased when Eptifibatide is combined with (R)-warfarin.
Ethyl biscoumacetate,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ethyl biscoumacetate.
Nadroparin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Nadroparin.
Triflusal,The risk or severity of bleeding can be increased when Eptifibatide is combined with Triflusal.
Ticagrelor,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ticagrelor.
Ditazole,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ditazole.
Vorapaxar,The risk or severity of bleeding can be increased when Eptifibatide is combined with Vorapaxar.
Edoxaban,The risk or severity of bleeding can be increased when Eptifibatide is combined with Edoxaban.
Potassium citrate,The risk or severity of bleeding can be increased when Eptifibatide is combined with Potassium citrate.
Sodium citrate,The risk or severity of bleeding can be increased when Eptifibatide is combined with Sodium citrate.
Dextran,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dextran.
Bemiparin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bemiparin.
Reviparin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Reviparin.
Parnaparin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Parnaparin.
Certoparin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Certoparin.
Desirudin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Desirudin.
Zinc citrate,The risk or severity of bleeding can be increased when Eptifibatide is combined with Zinc citrate.
Antithrombin Alfa,The risk or severity of bleeding can be increased when Eptifibatide is combined with Antithrombin Alfa.
Protein C,The risk or severity of bleeding can be increased when Eptifibatide is combined with Protein C.
Antithrombin III human,The risk or severity of bleeding can be increased when Eptifibatide is combined with Antithrombin III human.
Letaxaban,The risk or severity of bleeding can be increased when Eptifibatide is combined with Letaxaban.
Darexaban,The risk or severity of bleeding can be increased when Eptifibatide is combined with Darexaban.
Betrixaban,The risk or severity of bleeding can be increased when Eptifibatide is combined with Betrixaban.
Nafamostat,The risk or severity of bleeding can be increased when Eptifibatide is combined with Nafamostat.
Monteplase,The risk or severity of bleeding can be increased when Eptifibatide is combined with Monteplase.
Gabexate,The risk or severity of bleeding can be increased when Eptifibatide is combined with Gabexate.
Fluindione,The risk or severity of bleeding can be increased when Eptifibatide is combined with Fluindione.
Protein S human,The risk or severity of bleeding can be increased when Eptifibatide is combined with Protein S human.
Brinase,The risk or severity of bleeding can be increased when Eptifibatide is combined with Brinase.
Clorindione,The risk or severity of bleeding can be increased when Eptifibatide is combined with Clorindione.
Diphenadione,The risk or severity of bleeding can be increased when Eptifibatide is combined with Diphenadione.
Tioclomarol,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tioclomarol.
Melagatran,The risk or severity of bleeding can be increased when Eptifibatide is combined with Melagatran.
Saruplase,The risk or severity of bleeding can be increased when Eptifibatide is combined with Saruplase.
(S)-Warfarin,The risk or severity of bleeding can be increased when Eptifibatide is combined with (S)-Warfarin.
Tocopherylquinone,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tocopherylquinone.
Edetate calcium disodium anhydrous,The risk or severity of bleeding can be increased when Eptifibatide is combined with Edetate calcium disodium anhydrous.
Dabigatran,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dabigatran.
Treprostinil,Treprostinil may increase the antiplatelet activities of Eptifibatide.
Ticlopidine,Eptifibatide may increase the antiplatelet activities of Ticlopidine.
Clopidogrel,Eptifibatide may increase the antiplatelet activities of Clopidogrel.
Tirofiban,Eptifibatide may increase the antiplatelet activities of Tirofiban.
Sulfinpyrazone,Eptifibatide may increase the antiplatelet activities of Sulfinpyrazone.
Cilostazol,Eptifibatide may increase the antiplatelet activities of Cilostazol.
Ridogrel,Eptifibatide may increase the antiplatelet activities of Ridogrel.
Sevoflurane,Eptifibatide may increase the antiplatelet activities of Sevoflurane.
Resveratrol,Eptifibatide may increase the antiplatelet activities of Resveratrol.
Tesmilifene,Eptifibatide may increase the antiplatelet activities of Tesmilifene.
Ibudilast,Eptifibatide may increase the antiplatelet activities of Ibudilast.
Andrographolide,Eptifibatide may increase the antiplatelet activities of Andrographolide.
Caplacizumab,Eptifibatide may increase the antiplatelet activities of Caplacizumab.
Tranilast,Eptifibatide may increase the antiplatelet activities of Tranilast.
Icosapent ethyl,Eptifibatide may increase the antiplatelet activities of Icosapent ethyl.
Trapidil,Eptifibatide may increase the antiplatelet activities of Trapidil.
Naftopidil,Eptifibatide may increase the antiplatelet activities of Naftopidil.
Sarpogrelate,Eptifibatide may increase the antiplatelet activities of Sarpogrelate.
Ifetroban,Eptifibatide may increase the antiplatelet activities of Ifetroban.
Ketanserin,Eptifibatide may increase the antiplatelet activities of Ketanserin.
Butylphthalide,Eptifibatide may increase the antiplatelet activities of Butylphthalide.
Hydroxytyrosol,Eptifibatide may increase the antiplatelet activities of Hydroxytyrosol.
Ramatroban,Eptifibatide may increase the antiplatelet activities of Ramatroban.
Picotamide,Eptifibatide may increase the antiplatelet activities of Picotamide.
Cloricromen,Eptifibatide may increase the antiplatelet activities of Cloricromen.
Linsidomine,Eptifibatide may increase the antiplatelet activities of Linsidomine.
Buflomedil,Eptifibatide may increase the antiplatelet activities of Buflomedil.
Relcovaptan,Eptifibatide may increase the antiplatelet activities of Relcovaptan.
Anagrelide,Eptifibatide may increase the antiplatelet activities of Anagrelide.
Aminosalicylic acid,The risk or severity of bleeding can be increased when Eptifibatide is combined with Aminosalicylic acid.
Bismuth subsalicylate,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bismuth subsalicylate.
Dersalazine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dersalazine.
Phenyl aminosalicylate,The risk or severity of bleeding can be increased when Eptifibatide is combined with Phenyl aminosalicylate.
Methyl salicylate,The risk or severity of bleeding can be increased when Eptifibatide is combined with Methyl salicylate.
Aloxiprin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Aloxiprin.
Choline salicylate,The risk or severity of bleeding can be increased when Eptifibatide is combined with Choline salicylate.
Thiosalicylic acid,The risk or severity of bleeding can be increased when Eptifibatide is combined with Thiosalicylic acid.
Dabigatran etexilate,Eptifibatide may increase the anticoagulant activities of Dabigatran etexilate.
Peginterferon alfa-2a,The risk or severity of bleeding can be increased when Eptifibatide is combined with Peginterferon alfa-2a.
Interferon alfa-n1,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-n1.
Interferon alfa-n3,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-n3.
Peginterferon alfa-2b,The risk or severity of bleeding can be increased when Eptifibatide is combined with Peginterferon alfa-2b.
Interferon gamma-1b,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon gamma-1b.
"Interferon alfa-2a, Recombinant","The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-2a, Recombinant."
Aldesleukin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Aldesleukin.
Gemtuzumab ozogamicin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Gemtuzumab ozogamicin.
Interferon beta-1b,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon beta-1b.
Interferon alfacon-1,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfacon-1.
Rituximab,The risk or severity of bleeding can be increased when Eptifibatide is combined with Rituximab.
Alemtuzumab,The risk or severity of bleeding can be increased when Eptifibatide is combined with Alemtuzumab.
Interferon alfa-2b,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-2b.
Phenylalanine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Phenylalanine.
Bortezomib,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bortezomib.
Cladribine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cladribine.
Carmustine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Carmustine.
Amsacrine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Amsacrine.
Chlorambucil,The risk or severity of bleeding can be increased when Eptifibatide is combined with Chlorambucil.
Raltitrexed,The risk or severity of bleeding can be increased when Eptifibatide is combined with Raltitrexed.
Mitomycin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Mitomycin.
Bexarotene,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bexarotene.
Vindesine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Vindesine.
Floxuridine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Floxuridine.
Tioguanine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tioguanine.
Vinorelbine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Vinorelbine.
Dexrazoxane,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dexrazoxane.
Sorafenib,The risk or severity of bleeding can be increased when Eptifibatide is combined with Sorafenib.
Streptozocin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Streptozocin.
Gemcitabine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Gemcitabine.
Teniposide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Teniposide.
Epirubicin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Epirubicin.
Chloramphenicol,The risk or severity of bleeding can be increased when Eptifibatide is combined with Chloramphenicol.
Lenalidomide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Lenalidomide.
Altretamine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Altretamine.
Zidovudine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Zidovudine.
Cisplatin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cisplatin.
Oxaliplatin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cyclophosphamide.
Fluorouracil,The risk or severity of bleeding can be increased when Eptifibatide is combined with Fluorouracil.
Propylthiouracil,The risk or severity of bleeding can be increased when Eptifibatide is combined with Propylthiouracil.
Pentostatin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Pentostatin.
Methotrexate,The risk or severity of bleeding can be increased when Eptifibatide is combined with Methotrexate.
Carbamazepine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Carbamazepine.
Vinblastine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Vinblastine.
Imatinib,The risk or severity of bleeding can be increased when Eptifibatide is combined with Imatinib.
Clofarabine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Clofarabine.
Pemetrexed,The risk or severity of bleeding can be increased when Eptifibatide is combined with Pemetrexed.
Daunorubicin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Daunorubicin.
Irinotecan,The risk or severity of bleeding can be increased when Eptifibatide is combined with Irinotecan.
Methimazole,The risk or severity of bleeding can be increased when Eptifibatide is combined with Methimazole.
Etoposide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Etoposide.
Dacarbazine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dacarbazine.
Temozolomide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Temozolomide.
Penicillamine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Penicillamine.
Tacrolimus,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tacrolimus.
Sirolimus,The risk or severity of bleeding can be increased when Eptifibatide is combined with Sirolimus.
Mechlorethamine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Mechlorethamine.
Azacitidine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Azacitidine.
Carboplatin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Carboplatin.
Dactinomycin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dactinomycin.
Cytarabine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cytarabine.
Doxorubicin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Doxorubicin.
Hydroxyurea,The risk or severity of bleeding can be increased when Eptifibatide is combined with Hydroxyurea.
Busulfan,The risk or severity of bleeding can be increased when Eptifibatide is combined with Busulfan.
Topotecan,The risk or severity of bleeding can be increased when Eptifibatide is combined with Topotecan.
Mercaptopurine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Mercaptopurine.
Thalidomide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Thalidomide.
Melphalan,The risk or severity of bleeding can be increased when Eptifibatide is combined with Melphalan.
Fludarabine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Fludarabine.
Flucytosine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Flucytosine.
Capecitabine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Capecitabine.
Arsenic trioxide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Arsenic trioxide.
Idarubicin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Idarubicin.
Ifosfamide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ifosfamide.
Mitoxantrone,The risk or severity of bleeding can be increased when Eptifibatide is combined with Mitoxantrone.
Lomustine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Lomustine.
Paclitaxel,The risk or severity of bleeding can be increased when Eptifibatide is combined with Paclitaxel.
Docetaxel,The risk or severity of bleeding can be increased when Eptifibatide is combined with Docetaxel.
Decitabine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Decitabine.
Nelarabine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Nelarabine.
Everolimus,The risk or severity of bleeding can be increased when Eptifibatide is combined with Everolimus.
Vorinostat,The risk or severity of bleeding can be increased when Eptifibatide is combined with Vorinostat.
Thiotepa,The risk or severity of bleeding can be increased when Eptifibatide is combined with Thiotepa.
Ixabepilone,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ixabepilone.
Nilotinib,The risk or severity of bleeding can be increased when Eptifibatide is combined with Nilotinib.
Belinostat,The risk or severity of bleeding can be increased when Eptifibatide is combined with Belinostat.
Trabectedin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Trabectedin.
Interferon alfa,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa.
omega interferon,The risk or severity of bleeding can be increased when Eptifibatide is combined with omega interferon.
Trastuzumab emtansine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Trastuzumab emtansine.
Temsirolimus,The risk or severity of bleeding can be increased when Eptifibatide is combined with Temsirolimus.
Bosutinib,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bosutinib.
Bendamustine,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bendamustine.
Cabazitaxel,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cabazitaxel.
Eribulin,The risk or severity of bleeding can be increased when Eptifibatide is combined with Eribulin.
Ruxolitinib,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ruxolitinib.
Carfilzomib,The risk or severity of bleeding can be increased when Eptifibatide is combined with Carfilzomib.
Tofacitinib,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tofacitinib.
Ponatinib,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ponatinib.
Pomalidomide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Pomalidomide.
Tedizolid phosphate,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tedizolid phosphate.
Blinatumomab,The risk or severity of bleeding can be increased when Eptifibatide is combined with Blinatumomab.
Palbociclib,The risk or severity of bleeding can be increased when Eptifibatide is combined with Palbociclib.
Olaparib,The risk or severity of bleeding can be increased when Eptifibatide is combined with Olaparib.
Dinutuximab,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dinutuximab.
Peginterferon beta-1a,The risk or severity of bleeding can be increased when Eptifibatide is combined with Peginterferon beta-1a.
Cepeginterferon alfa-2B,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cepeginterferon alfa-2B.
Fluvoxamine,The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Eptifibatide.
Citalopram,The risk or severity of hemorrhage can be increased when Citalopram is combined with Eptifibatide.
Fluoxetine,The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Eptifibatide.
Paroxetine,The risk or severity of hemorrhage can be increased when Paroxetine is combined with Eptifibatide.
Nefazodone,The risk or severity of hemorrhage can be increased when Nefazodone is combined with Eptifibatide.
Zimelidine,The risk or severity of hemorrhage can be increased when Zimelidine is combined with Eptifibatide.
Dapoxetine,The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Eptifibatide.
Seproxetine,The risk or severity of hemorrhage can be increased when Seproxetine is combined with Eptifibatide.
Indalpine,The risk or severity of hemorrhage can be increased when Indalpine is combined with Eptifibatide.
Ritanserin,The risk or severity of hemorrhage can be increased when Ritanserin is combined with Eptifibatide.
Alaproclate,The risk or severity of hemorrhage can be increased when Alaproclate is combined with Eptifibatide.
Venlafaxine,Venlafaxine may increase the antiplatelet activities of Eptifibatide.
Duloxetine,Duloxetine may increase the antiplatelet activities of Eptifibatide.
Sibutramine,Sibutramine may increase the antiplatelet activities of Eptifibatide.
Milnacipran,Milnacipran may increase the antiplatelet activities of Eptifibatide.
Desvenlafaxine,Desvenlafaxine may increase the antiplatelet activities of Eptifibatide.
Levomilnacipran,Levomilnacipran may increase the antiplatelet activities of Eptifibatide.
Amphetamine,The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Eptifibatide.
Linezolid,The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Eptifibatide.
Furazolidone,The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Eptifibatide.
Procaine,The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Eptifibatide.
Tranylcypromine,The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Eptifibatide.
Phenelzine,The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Eptifibatide.
Minaprine,The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Eptifibatide.
Selegiline,The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Eptifibatide.
Procarbazine,The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Eptifibatide.
Moclobemide,The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Eptifibatide.
Isocarboxazid,The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Eptifibatide.
Rasagiline,The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Eptifibatide.
Pargyline,The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Eptifibatide.
Clorgiline,The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Eptifibatide.
Iproniazid,The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Eptifibatide.
Nialamide,The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Eptifibatide.
Safinamide,The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Eptifibatide.
"7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline","The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Eptifibatide."
Methylene blue,The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Eptifibatide.
Hydracarbazine,The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Eptifibatide.
Pirlindole,The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Eptifibatide.
Toloxatone,The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Eptifibatide.
Benmoxin,The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Eptifibatide.
Mebanazine,The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Eptifibatide.
Octamoxin,The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Eptifibatide.
Pheniprazine,The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Eptifibatide.
Phenoxypropazine,The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Eptifibatide.
Pivhydrazine,The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Eptifibatide.
Safrazine,The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Eptifibatide.
Caroxazone,The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Eptifibatide.
Harmaline,The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Eptifibatide.
Brofaromine,The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Eptifibatide.
Omega-3-acid ethyl esters,The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Eptifibatide.
Acetylsalicylic acid,Acetylsalicylic acid may increase the antiplatelet activities of Eptifibatide.
Icosapent,The risk or severity of bleeding can be increased when Icosapent is combined with Eptifibatide.
Mesalazine,The risk or severity of bleeding can be increased when Mesalazine is combined with Eptifibatide.
Indomethacin,The risk or severity of bleeding can be increased when Indomethacin is combined with Eptifibatide.
Nabumetone,The risk or severity of bleeding can be increased when Nabumetone is combined with Eptifibatide.
Ketorolac,The risk or severity of bleeding can be increased when Ketorolac is combined with Eptifibatide.
Tenoxicam,The risk or severity of bleeding can be increased when Tenoxicam is combined with Eptifibatide.
Celecoxib,The risk or severity of bleeding can be increased when Celecoxib is combined with Eptifibatide.
Tolmetin,The risk or severity of bleeding can be increased when Tolmetin is combined with Eptifibatide.
Rofecoxib,The risk or severity of bleeding can be increased when Rofecoxib is combined with Eptifibatide.
Piroxicam,The risk or severity of bleeding can be increased when Piroxicam is combined with Eptifibatide.
Fenoprofen,The risk or severity of bleeding can be increased when Fenoprofen is combined with Eptifibatide.
Valdecoxib,The risk or severity of bleeding can be increased when Valdecoxib is combined with Eptifibatide.
Diclofenac,The risk or severity of bleeding can be increased when Diclofenac is combined with Eptifibatide.
Sulindac,The risk or severity of bleeding can be increased when Sulindac is combined with Eptifibatide.
Flurbiprofen,The risk or severity of bleeding can be increased when Flurbiprofen is combined with Eptifibatide.
Etodolac,The risk or severity of bleeding can be increased when Etodolac is combined with Eptifibatide.
Mefenamic acid,The risk or severity of bleeding can be increased when Mefenamic acid is combined with Eptifibatide.
Naproxen,The risk or severity of bleeding can be increased when Naproxen is combined with Eptifibatide.
Sulfasalazine,The risk or severity of bleeding can be increased when Sulfasalazine is combined with Eptifibatide.
Phenylbutazone,The risk or severity of bleeding can be increased when Phenylbutazone is combined with Eptifibatide.
Meloxicam,The risk or severity of bleeding can be increased when Meloxicam is combined with Eptifibatide.
Carprofen,The risk or severity of bleeding can be increased when Carprofen is combined with Eptifibatide.
Diflunisal,The risk or severity of bleeding can be increased when Diflunisal is combined with Eptifibatide.
Salicylic acid,The risk or severity of bleeding can be increased when Salicylic acid is combined with Eptifibatide.
Meclofenamic acid,The risk or severity of bleeding can be increased when Meclofenamic acid is combined with Eptifibatide.
Oxaprozin,The risk or severity of bleeding can be increased when Oxaprozin is combined with Eptifibatide.
Ketoprofen,The risk or severity of bleeding can be increased when Ketoprofen is combined with Eptifibatide.
Balsalazide,The risk or severity of bleeding can be increased when Balsalazide is combined with Eptifibatide.
Ibuprofen,The risk or severity of bleeding can be increased when Ibuprofen is combined with Eptifibatide.
Olsalazine,The risk or severity of bleeding can be increased when Olsalazine is combined with Eptifibatide.
Lumiracoxib,The risk or severity of bleeding can be increased when Lumiracoxib is combined with Eptifibatide.
Magnesium salicylate,The risk or severity of bleeding can be increased when Magnesium salicylate is combined with Eptifibatide.
Salsalate,The risk or severity of bleeding can be increased when Salsalate is combined with Eptifibatide.
Choline magnesium trisalicylate,The risk or severity of bleeding can be increased when Choline magnesium trisalicylate is combined with Eptifibatide.
Antrafenine,The risk or severity of bleeding can be increased when Antrafenine is combined with Eptifibatide.
Aminophenazone,The risk or severity of bleeding can be increased when Aminophenazone is combined with Eptifibatide.
Antipyrine,The risk or severity of bleeding can be increased when Antipyrine is combined with Eptifibatide.
Tiaprofenic acid,The risk or severity of bleeding can be increased when Tiaprofenic acid is combined with Eptifibatide.
Etoricoxib,The risk or severity of bleeding can be increased when Etoricoxib is combined with Eptifibatide.
Taxifolin,The risk or severity of bleeding can be increased when Taxifolin is combined with Eptifibatide.
Oxyphenbutazone,The risk or severity of bleeding can be increased when Oxyphenbutazone is combined with Eptifibatide.
Niflumic acid,The risk or severity of bleeding can be increased when Niflumic acid is combined with Eptifibatide.
Licofelone,The risk or severity of bleeding can be increased when Licofelone is combined with Eptifibatide.
Nimesulide,The risk or severity of bleeding can be increased when Nimesulide is combined with Eptifibatide.
Benoxaprofen,The risk or severity of bleeding can be increased when Benoxaprofen is combined with Eptifibatide.
Metamizole,The risk or severity of bleeding can be increased when Metamizole is combined with Eptifibatide.
Zomepirac,The risk or severity of bleeding can be increased when Zomepirac is combined with Eptifibatide.
Cimicoxib,The risk or severity of bleeding can be increased when Cimicoxib is combined with Eptifibatide.
Lornoxicam,The risk or severity of bleeding can be increased when Lornoxicam is combined with Eptifibatide.
Aceclofenac,The risk or severity of bleeding can be increased when Aceclofenac is combined with Eptifibatide.
Zaltoprofen,The risk or severity of bleeding can be increased when Zaltoprofen is combined with Eptifibatide.
Azapropazone,The risk or severity of bleeding can be increased when Azapropazone is combined with Eptifibatide.
Felbinac,The risk or severity of bleeding can be increased when Felbinac is combined with Eptifibatide.
Parecoxib,The risk or severity of bleeding can be increased when Parecoxib is combined with Eptifibatide.
Salicylamide,The risk or severity of bleeding can be increased when Salicylamide is combined with Eptifibatide.
Kebuzone,The risk or severity of bleeding can be increased when Kebuzone is combined with Eptifibatide.
Isoxicam,The risk or severity of bleeding can be increased when Isoxicam is combined with Eptifibatide.
Indoprofen,The risk or severity of bleeding can be increased when Indoprofen is combined with Eptifibatide.
Ibuproxam,The risk or severity of bleeding can be increased when Ibuproxam is combined with Eptifibatide.
Floctafenine,The risk or severity of bleeding can be increased when Floctafenine is combined with Eptifibatide.
Fenbufen,The risk or severity of bleeding can be increased when Fenbufen is combined with Eptifibatide.
Etofenamate,The risk or severity of bleeding can be increased when Etofenamate is combined with Eptifibatide.
Epirizole,The risk or severity of bleeding can be increased when Epirizole is combined with Eptifibatide.
Benzydamine,The risk or severity of bleeding can be increased when Benzydamine is combined with Eptifibatide.
Loxoprofen,The risk or severity of bleeding can be increased when Loxoprofen is combined with Eptifibatide.
Dexibuprofen,The risk or severity of bleeding can be increased when Dexibuprofen is combined with Eptifibatide.
Dexketoprofen,The risk or severity of bleeding can be increased when Dexketoprofen is combined with Eptifibatide.
Droxicam,The risk or severity of bleeding can be increased when Droxicam is combined with Eptifibatide.
Tolfenamic acid,The risk or severity of bleeding can be increased when Tolfenamic acid is combined with Eptifibatide.
Firocoxib,The risk or severity of bleeding can be increased when Firocoxib is combined with Eptifibatide.
Clonixin,The risk or severity of bleeding can be increased when Clonixin is combined with Eptifibatide.
Morniflumate,The risk or severity of bleeding can be increased when Morniflumate is combined with Eptifibatide.
Propacetamol,The risk or severity of bleeding can be increased when Propacetamol is combined with Eptifibatide.
Talniflumate,The risk or severity of bleeding can be increased when Talniflumate is combined with Eptifibatide.
Robenacoxib,The risk or severity of bleeding can be increased when Robenacoxib is combined with Eptifibatide.
Tepoxalin,The risk or severity of bleeding can be increased when Tepoxalin is combined with Eptifibatide.
Flunixin,The risk or severity of bleeding can be increased when Flunixin is combined with Eptifibatide.
Polmacoxib,The risk or severity of bleeding can be increased when Polmacoxib is combined with Eptifibatide.
Nitroaspirin,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Eptifibatide.
Betulinic Acid,The risk or severity of bleeding can be increased when Betulinic Acid is combined with Eptifibatide.
Indobufen,The risk or severity of bleeding can be increased when Indobufen is combined with Eptifibatide.
Ebselen,The risk or severity of bleeding can be increased when Ebselen is combined with Eptifibatide.
Tinoridine,The risk or severity of bleeding can be increased when Tinoridine is combined with Eptifibatide.
Alclofenac,The risk or severity of bleeding can be increased when Alclofenac is combined with Eptifibatide.
Fentiazac,The risk or severity of bleeding can be increased when Fentiazac is combined with Eptifibatide.
Suxibuzone,The risk or severity of bleeding can be increased when Suxibuzone is combined with Eptifibatide.
Bumadizone,The risk or severity of bleeding can be increased when Bumadizone is combined with Eptifibatide.
Alminoprofen,The risk or severity of bleeding can be increased when Alminoprofen is combined with Eptifibatide.
Flunoxaprofen,The risk or severity of bleeding can be increased when Flunoxaprofen is combined with Eptifibatide.
Feprazone,The risk or severity of bleeding can be increased when Feprazone is combined with Eptifibatide.
Difenpiramide,The risk or severity of bleeding can be increased when Difenpiramide is combined with Eptifibatide.
Nifenazone,The risk or severity of bleeding can be increased when Nifenazone is combined with Eptifibatide.
Lonazolac,The risk or severity of bleeding can be increased when Lonazolac is combined with Eptifibatide.
Tenidap,The risk or severity of bleeding can be increased when Tenidap is combined with Eptifibatide.
Bendazac,The risk or severity of bleeding can be increased when Bendazac is combined with Eptifibatide.
Pranoprofen,The risk or severity of bleeding can be increased when Pranoprofen is combined with Eptifibatide.
Propyphenazone,The risk or severity of bleeding can be increased when Propyphenazone is combined with Eptifibatide.
Proglumetacin,The risk or severity of bleeding can be increased when Proglumetacin is combined with Eptifibatide.
Guacetisal,The risk or severity of bleeding can be increased when Guacetisal is combined with Eptifibatide.
Ethenzamide,The risk or severity of bleeding can be increased when Ethenzamide is combined with Eptifibatide.
Carbaspirin calcium,The risk or severity of bleeding can be increased when Carbaspirin calcium is combined with Eptifibatide.
Mofebutazone,The risk or severity of bleeding can be increased when Mofebutazone is combined with Eptifibatide.
Proquazone,The risk or severity of bleeding can be increased when Proquazone is combined with Eptifibatide.
Benorilate,The risk or severity of bleeding can be increased when Benorilate is combined with Eptifibatide.
Pirprofen,The risk or severity of bleeding can be increased when Pirprofen is combined with Eptifibatide.
Acemetacin,The risk or severity of bleeding can be increased when Acemetacin is combined with Eptifibatide.
Imidazole salicylate,The risk or severity of bleeding can be increased when Imidazole salicylate is combined with Eptifibatide.
SC-236,The risk or severity of bleeding can be increased when SC-236 is combined with Eptifibatide.
NS-398,The risk or severity of bleeding can be increased when NS-398 is combined with Eptifibatide.
Flurbiprofen axetil,The risk or severity of bleeding can be increased when Flurbiprofen axetil is combined with Eptifibatide.
Trazodone,The risk or severity of bleeding can be increased when Trazodone is combined with Eptifibatide.
Escitalopram,The risk or severity of bleeding can be increased when Escitalopram is combined with Eptifibatide.
Sertraline,The risk or severity of bleeding can be increased when Sertraline is combined with Eptifibatide.
Abatacept,The risk or severity of infection can be increased when Infliximab is combined with Abatacept.
Anakinra,The risk or severity of adverse effects can be increased when Infliximab is combined with Anakinra.
Canakinumab,The risk or severity of infection and neutropenia can be increased when Infliximab is combined with Canakinumab.
Certolizumab pegol,The risk or severity of infection can be increased when Infliximab is combined with Certolizumab pegol.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Infliximab.
Etanercept,Etanercept may increase the immunosuppressive activities of Infliximab.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Infliximab.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Infliximab.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Infliximab.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Infliximab.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Infliximab.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Infliximab."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Infliximab.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Infliximab.
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Infliximab.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon beta-1b.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon alfacon-1.
Rituximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Rituximab.
Basiliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Basiliximab.
Muromonab,The risk or severity of adverse effects can be increased when Infliximab is combined with Muromonab.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Infliximab is combined with Ibritumomab tiuxetan.
Tositumomab,The risk or severity of adverse effects can be increased when Infliximab is combined with Tositumomab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Alemtuzumab.
Alefacept,The risk or severity of adverse effects can be increased when Infliximab is combined with Alefacept.
Efalizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Infliximab is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon alfa-2b.
Daclizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Infliximab is combined with Phenylalanine.
Cladribine,The risk or severity of adverse effects can be increased when Infliximab is combined with Cladribine.
Amsacrine,The risk or severity of adverse effects can be increased when Infliximab is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Infliximab is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Infliximab is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Infliximab is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Infliximab is combined with Mitomycin.
Floxuridine,The risk or severity of adverse effects can be increased when Infliximab is combined with Floxuridine.
Tioguanine,The risk or severity of adverse effects can be increased when Infliximab is combined with Tioguanine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Infliximab is combined with Dexrazoxane.
Streptozocin,The risk or severity of adverse effects can be increased when Infliximab is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Infliximab is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Infliximab is combined with Gemcitabine.
Epirubicin,The risk or severity of adverse effects can be increased when Infliximab is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Infliximab is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Infliximab is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Infliximab is combined with Altretamine.
Cisplatin,The risk or severity of adverse effects can be increased when Infliximab is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Infliximab is combined with Oxaliplatin.
Propylthiouracil,The risk or severity of adverse effects can be increased when Infliximab is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Infliximab is combined with Pentostatin.
Linezolid,The risk or severity of adverse effects can be increased when Infliximab is combined with Linezolid.
Clofarabine,The risk or severity of adverse effects can be increased when Infliximab is combined with Clofarabine.
Methimazole,The risk or severity of adverse effects can be increased when Infliximab is combined with Methimazole.
Sulfasalazine,The risk or severity of adverse effects can be increased when Infliximab is combined with Sulfasalazine.
Temozolomide,The risk or severity of adverse effects can be increased when Infliximab is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Infliximab is combined with Penicillamine.
Mechlorethamine,The risk or severity of adverse effects can be increased when Infliximab is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Infliximab is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Infliximab is combined with Carboplatin.
Dactinomycin,The risk or severity of adverse effects can be increased when Infliximab is combined with Dactinomycin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Infliximab is combined with Hydroxyurea.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Infliximab is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Infliximab is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Infliximab is combined with Mercaptopurine.
Melphalan,The risk or severity of adverse effects can be increased when Infliximab is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Infliximab is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Infliximab is combined with Flucytosine.
Procarbazine,The risk or severity of adverse effects can be increased when Infliximab is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Infliximab is combined with Arsenic trioxide.
Mitoxantrone,The risk or severity of adverse effects can be increased when Infliximab is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Infliximab is combined with Lomustine.
Eculizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Infliximab is combined with Decitabine.
Nelarabine,The risk or severity of adverse effects can be increased when Infliximab is combined with Nelarabine.
Stepronin,The risk or severity of adverse effects can be increased when Infliximab is combined with Stepronin.
Castanospermine,The risk or severity of adverse effects can be increased when Infliximab is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Infliximab is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Infliximab is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Infliximab is combined with Brequinar.
Afelimomab,The risk or severity of adverse effects can be increased when Infliximab is combined with Afelimomab.
Interferon alfa,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Infliximab is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Infliximab is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Infliximab is combined with omega interferon.
Mepolizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Mepolizumab.
Abetimus,The risk or severity of adverse effects can be increased when Infliximab is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Infliximab is combined with Belatacept.
Pralatrexate,The risk or severity of adverse effects can be increased when Infliximab is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Infliximab is combined with Wortmannin.
Eribulin,The risk or severity of adverse effects can be increased when Infliximab is combined with Eribulin.
Belimumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Infliximab is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Infliximab is combined with Carfilzomib.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Infliximab is combined with Dimethyl fumarate.
Obinutuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Obinutuzumab.
Secukinumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Secukinumab.
Siltuximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Infliximab is combined with Blinatumomab.
Dinutuximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Dinutuximab.
Tixocortol,The risk or severity of adverse effects can be increased when Infliximab is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Infliximab is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Infliximab is combined with Antilymphocyte immunoglobulin (horse).
Tepoxalin,The risk or severity of adverse effects can be increased when Infliximab is combined with Tepoxalin.
Ixekizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Infliximab is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Infliximab is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Infliximab is combined with Peficitinib.
Sarilumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Sirukumab.
Guselkumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Guselkumab.
Triptolide,The risk or severity of adverse effects can be increased when Infliximab is combined with Triptolide.
Ozanimod,The risk or severity of adverse effects can be increased when Infliximab is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Infliximab is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Infliximab is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Infliximab is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Infliximab is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Infliximab is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Infliximab is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Infliximab is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Infliximab is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Infliximab is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Infliximab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Fluocortin,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Infliximab is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Infliximab is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Infliximab is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Infliximab is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluclorolone.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Infliximab is combined with Monomethyl fumarate.
Emapalumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Bleselumab.
Flunisolide,The risk or severity of adverse effects can be increased when Infliximab is combined with Flunisolide.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Infliximab is combined with Beclomethasone dipropionate.
Betamethasone,The risk or severity of adverse effects can be increased when Infliximab is combined with Betamethasone.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluocinolone acetonide.
Prednisone,The risk or severity of adverse effects can be increased when Infliximab is combined with Prednisone.
Fludrocortisone,The risk or severity of adverse effects can be increased when Infliximab is combined with Fludrocortisone.
Mometasone,The risk or severity of adverse effects can be increased when Infliximab is combined with Mometasone.
Prednisolone,The risk or severity of adverse effects can be increased when Infliximab is combined with Prednisolone.
Methylprednisolone,The risk or severity of adverse effects can be increased when Infliximab is combined with Methylprednisolone.
Estramustine,The risk or severity of adverse effects can be increased when Infliximab is combined with Estramustine.
Corticotropin,The risk or severity of adverse effects can be increased when Infliximab is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Infliximab is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Infliximab is combined with Paramethasone.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Infliximab is combined with Hydroxychloroquine.
Aldosterone,The risk or severity of adverse effects can be increased when Infliximab is combined with Aldosterone.
Fluprednidene,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluocortolone.
Vilanterol,The risk or severity of adverse effects can be increased when Infliximab is combined with Vilanterol.
Fluprednisolone,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Infliximab is combined with Meprednisone.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Infliximab is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Infliximab is combined with Melengestrol.
Clobetasol,The risk or severity of adverse effects can be increased when Infliximab is combined with Clobetasol.
Baricitinib,The risk or severity of adverse effects can be increased when Infliximab is combined with Baricitinib.
Deflazacort,The risk or severity of adverse effects can be increased when Infliximab is combined with Deflazacort.
Prednylidene,The risk or severity of adverse effects can be increased when Infliximab is combined with Prednylidene.
Tetrandrine,The risk or severity of adverse effects can be increased when Infliximab is combined with Tetrandrine.
Mometasone furoate,The risk or severity of adverse effects can be increased when Infliximab is combined with Mometasone furoate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Infliximab is combined with Hydrocortisone succinate.
Budesonide,The risk or severity of adverse effects can be increased when Infliximab is combined with Budesonide.
Colchicine,The risk or severity of adverse effects can be increased when Infliximab is combined with Colchicine.
Natalizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Infliximab.
Rilonacept,The risk or severity of adverse effects can be increased when Infliximab is combined with Rilonacept.
Roflumilast,Infliximab may increase the immunosuppressive activities of Roflumilast.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Infliximab.
Tocilizumab,Tocilizumab may increase the immunosuppressive activities of Infliximab.
Tofacitinib,The risk or severity of adverse effects can be increased when Infliximab is combined with Tofacitinib.
Vedolizumab,The risk or severity of infection can be increased when Infliximab is combined with Vedolizumab.
Adalimumab,Adalimumab may increase the immunosuppressive activities of Infliximab.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Infliximab.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Infliximab.
Estrone,Estrone may increase the thrombogenic activities of Infliximab.
Dienestrol,Dienestrol may increase the thrombogenic activities of Infliximab.
Estriol,Estriol may increase the thrombogenic activities of Infliximab.
Quinestrol,Quinestrol may increase the thrombogenic activities of Infliximab.
Hexestrol,Hexestrol may increase the thrombogenic activities of Infliximab.
Tibolone,Tibolone may increase the thrombogenic activities of Infliximab.
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Infliximab.
Zeranol,Zeranol may increase the thrombogenic activities of Infliximab.
Equol,Equol may increase the thrombogenic activities of Infliximab.
Promestriene,Promestriene may increase the thrombogenic activities of Infliximab.
Methallenestril,Methallenestril may increase the thrombogenic activities of Infliximab.
Epimestrol,Epimestrol may increase the thrombogenic activities of Infliximab.
Moxestrol,Moxestrol may increase the thrombogenic activities of Infliximab.
Biochanin A,Biochanin A may increase the thrombogenic activities of Infliximab.
Formononetin,Formononetin may increase the thrombogenic activities of Infliximab.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Infliximab."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Infliximab."
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Infliximab.
Leflunomide,The risk or severity of adverse effects can be increased when Infliximab is combined with Leflunomide.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Infliximab.
Fingolimod,Infliximab may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Infliximab.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Infliximab.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Infliximab.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Infliximab.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Infliximab.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Infliximab.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Infliximab.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Infliximab.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Infliximab.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Infliximab.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Infliximab."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Infliximab.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Infliximab.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Infliximab."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Infliximab.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Infliximab.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Infliximab.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Infliximab.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Infliximab.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Infliximab.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Infliximab.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Infliximab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Infliximab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Infliximab.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Infliximab.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Infliximab.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Infliximab.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Infliximab.
Ocrelizumab,Ocrelizumab may increase the immunosuppressive activities of Infliximab.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Infliximab.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Infliximab.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Infliximab.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Infliximab.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Infliximab.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Infliximab.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Infliximab.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Infliximab.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Infliximab.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Infliximab.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Infliximab.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Infliximab.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Infliximab.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Infliximab.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Infliximab.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Infliximab.
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Infliximab.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Infliximab is combined with Digoxin Immune Fab (Ovine).
Capromab pendetide,The risk or severity of adverse effects can be increased when Infliximab is combined with Capromab pendetide.
Palivizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Palivizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Infliximab is combined with Technetium Tc-99m arcitumomab.
Panitumumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Pexelizumab.
Epratuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Infliximab is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Infliximab is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Infliximab is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Infliximab is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Infliximab is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Infliximab is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Infliximab is combined with NAV 1800.
Otelixizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Infliximab is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Veltuzumab.
PRO-542,The risk or severity of adverse effects can be increased when Infliximab is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Infliximab is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Infliximab is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Infliximab is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Infliximab is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Infliximab is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Infliximab is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Infliximab is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Infliximab is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Infliximab is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Infliximab is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Lumiliximab.
Ipilimumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Clenoliximab.
BIIB015,The risk or severity of adverse effects can be increased when Infliximab is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Infliximab is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Infliximab is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Infliximab is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Infliximab is combined with Catumaxomab.
Volociximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ofatumumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Raxibacumab.
Nivolumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Nivolumab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Infliximab is combined with Dulaglutide.
Asfotase alfa,The risk or severity of adverse effects can be increased when Infliximab is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Evolocumab.
Daratumumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Necitumumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Infliximab is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Infliximab is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Infliximab is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Infliximab is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Solanezumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Tremelimumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Lampalizumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Infliximab is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Anifrolumab.
Benralizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Infliximab is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Infliximab is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Etaracizumab.
Inclacumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Infliximab is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Infliximab is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Infliximab is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Infliximab is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Infliximab is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Plozalizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Infliximab is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Infliximab is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Infliximab is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Infliximab is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Infliximab is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Infliximab is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Infliximab is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Infliximab is combined with Besilesomab.
Burosumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Infliximab is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Infliximab is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Infliximab is combined with Cemiplimab.
Camrelizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Infliximab is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Infliximab is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Infliximab is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Refanezumab.
Bermekimab,The risk or severity of adverse effects can be increased when Infliximab is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Infliximab is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Infliximab is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Infliximab is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Infliximab is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Infliximab is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Infliximab is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Infliximab is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Infliximab is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Infliximab is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Infliximab is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Nemolizumab.
Gedivumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Infliximab is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Infliximab is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Infliximab is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Infliximab is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Infliximab is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Infliximab is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Infliximab is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Infliximab is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Infliximab is combined with Naratuximab emtansine.
Tildrakizumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Tildrakizumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ustekinumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Infliximab is combined with Polatuzumab vedotin.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Infliximab is combined with Zenocutuzumab.
Somatotropin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Infliximab."
Daptomycin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Daptomycin."
Pravastatin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Pravastatin."
Baclofen,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Baclofen."
Pamidronic acid,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Pamidronic acid."
Carbimazole,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Carbimazole."
Ciprofloxacin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ciprofloxacin."
Nizatidine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Nizatidine."
Niacin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Niacin."
Alendronic acid,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Alendronic acid."
Stavudine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Stavudine."
Nafarelin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Nafarelin."
Amphotericin B,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Amphotericin B."
Naltrexone,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Naltrexone."
Lamivudine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Lamivudine."
Ibandronate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ibandronate."
Eprosartan,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Eprosartan."
Risedronic acid,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Risedronic acid."
Bumetanide,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Bumetanide."
Isoniazid,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Isoniazid."
Methyldopa,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Methyldopa."
Ganciclovir,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ganciclovir."
Minocycline,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Minocycline."
Norfloxacin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Norfloxacin."
Iloprost,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Iloprost."
Ofloxacin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ofloxacin."
Mevastatin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Mevastatin."
Raltegravir,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Raltegravir."
Etofibrate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Etofibrate."
Acipimox,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Acipimox."
Ciprofibrate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ciprofibrate."
Ubidecarenone,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ubidecarenone."
Mebeverine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Mebeverine."
Emetine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Emetine."
Simfibrate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Simfibrate."
Ronifibrate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ronifibrate."
Aluminium clofibrate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Aluminium clofibrate."
Clofibride,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Clofibride."
Fenofibric acid,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Fenofibric acid."
Leuprolide,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Infliximab."
Mefloquine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Mefloquine."
Cimetidine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Cimetidine."
Enalapril,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Enalapril."
Ivermectin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ivermectin."
Clofibrate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Clofibrate."
Isotretinoin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Isotretinoin."
Captopril,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Captopril."
Gemfibrozil,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Gemfibrozil."
Bezafibrate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Bezafibrate."
Caffeine,The metabolism of Caffeine can be increased when combined with Infliximab.
Fluvoxamine,The metabolism of Fluvoxamine can be increased when combined with Infliximab.
Betaxolol,The metabolism of Betaxolol can be increased when combined with Infliximab.
Anagrelide,The metabolism of Anagrelide can be increased when combined with Infliximab.
Carmustine,The metabolism of Carmustine can be increased when combined with Infliximab.
Ropinirole,The metabolism of Ropinirole can be increased when combined with Infliximab.
Disopyramide,The metabolism of Disopyramide can be increased when combined with Infliximab.
Conjugated estrogens,The metabolism of Conjugated estrogens can be increased when combined with Infliximab.
Ropivacaine,The metabolism of Ropivacaine can be increased when combined with Infliximab.
Zolmitriptan,The metabolism of Zolmitriptan can be increased when combined with Infliximab.
Acetaminophen,The metabolism of Acetaminophen can be increased when combined with Infliximab.
Olanzapine,The metabolism of Olanzapine can be increased when combined with Infliximab.
Chlorzoxazone,The metabolism of Chlorzoxazone can be increased when combined with Infliximab.
Grepafloxacin,The metabolism of Grepafloxacin can be increased when combined with Infliximab.
Mirtazapine,The metabolism of Mirtazapine can be increased when combined with Infliximab.
Mexiletine,The metabolism of Mexiletine can be increased when combined with Infliximab.
Tacrine,The metabolism of Tacrine can be increased when combined with Infliximab.
Triamterene,The metabolism of Triamterene can be increased when combined with Infliximab.
Entecavir,The metabolism of Entecavir can be increased when combined with Infliximab.
Chlorpromazine,The metabolism of Chlorpromazine can be increased when combined with Infliximab.
Albendazole,The metabolism of Albendazole can be increased when combined with Infliximab.
Fluorouracil,The metabolism of Fluorouracil can be increased when combined with Infliximab.
Guanabenz,The metabolism of Guanabenz can be increased when combined with Infliximab.
Pemetrexed,The metabolism of Pemetrexed can be increased when combined with Infliximab.
Thiabendazole,The metabolism of Thiabendazole can be increased when combined with Infliximab.
Riluzole,The metabolism of Riluzole can be increased when combined with Infliximab.
Acyclovir,The metabolism of Acyclovir can be increased when combined with Infliximab.
Pentoxifylline,The metabolism of Pentoxifylline can be increased when combined with Infliximab.
Trifluoperazine,The metabolism of Trifluoperazine can be increased when combined with Infliximab.
Ranitidine,The metabolism of Ranitidine can be increased when combined with Infliximab.
Ethanol,The metabolism of Ethanol can be increased when combined with Infliximab.
Maprotiline,The metabolism of Maprotiline can be increased when combined with Infliximab.
Lomefloxacin,The metabolism of Lomefloxacin can be increased when combined with Infliximab.
Azathioprine,The metabolism of Azathioprine can be increased when combined with Infliximab.
Frovatriptan,The metabolism of Frovatriptan can be increased when combined with Infliximab.
Levobupivacaine,The metabolism of Levobupivacaine can be increased when combined with Infliximab.
Cinacalcet,The metabolism of Cinacalcet can be increased when combined with Infliximab.
Tocainide,The metabolism of Tocainide can be increased when combined with Infliximab.
Primaquine,The metabolism of Primaquine can be increased when combined with Infliximab.
Hesperetin,The metabolism of Hesperetin can be increased when combined with Infliximab.
Propafenone,The metabolism of Propafenone can be increased when combined with Infliximab.
Dexfenfluramine,The metabolism of Dexfenfluramine can be increased when combined with Infliximab.
Oxtriphylline,The metabolism of Oxtriphylline can be increased when combined with Infliximab.
Rasagiline,The metabolism of Rasagiline can be increased when combined with Infliximab.
Temafloxacin,The metabolism of Temafloxacin can be increased when combined with Infliximab.
Theobromine,The metabolism of Theobromine can be increased when combined with Infliximab.
Fenethylline,The metabolism of Fenethylline can be increased when combined with Infliximab.
Bromazepam,The metabolism of Bromazepam can be increased when combined with Infliximab.
Thiothixene,The metabolism of Thiothixene can be increased when combined with Infliximab.
Genistein,The metabolism of Genistein can be increased when combined with Infliximab.
8-azaguanine,The metabolism of 8-azaguanine can be increased when combined with Infliximab.
Xanthine,The metabolism of Xanthine can be increased when combined with Infliximab.
9-Methylguanine,The metabolism of 9-Methylguanine can be increased when combined with Infliximab.
Peldesine,The metabolism of Peldesine can be increased when combined with Infliximab.
Resveratrol,The metabolism of Resveratrol can be increased when combined with Infliximab.
Hypoxanthine,The metabolism of Hypoxanthine can be increased when combined with Infliximab.
9-Deazaguanine,The metabolism of 9-Deazaguanine can be increased when combined with Infliximab.
Lorcaserin,The metabolism of Lorcaserin can be increased when combined with Infliximab.
Lofexidine,The metabolism of Lofexidine can be increased when combined with Infliximab.
Pirfenidone,The metabolism of Pirfenidone can be increased when combined with Infliximab.
Mianserin,The metabolism of Mianserin can be increased when combined with Infliximab.
Eltrombopag,The metabolism of Eltrombopag can be increased when combined with Infliximab.
Asenapine,The metabolism of Asenapine can be increased when combined with Infliximab.
Vadimezan,The metabolism of Vadimezan can be increased when combined with Infliximab.
Propentofylline,The metabolism of Propentofylline can be increased when combined with Infliximab.
Agomelatine,The metabolism of Agomelatine can be increased when combined with Infliximab.
Bendamustine,The metabolism of Bendamustine can be increased when combined with Infliximab.
Benzyl alcohol,The metabolism of Benzyl alcohol can be increased when combined with Infliximab.
Capsaicin,The metabolism of Capsaicin can be increased when combined with Infliximab.
(R)-warfarin,The metabolism of (R)-warfarin can be increased when combined with Infliximab.
Tasimelteon,The metabolism of Tasimelteon can be increased when combined with Infliximab.
Stiripentol,The metabolism of Stiripentol can be increased when combined with Infliximab.
Zotepine,The metabolism of Zotepine can be increased when combined with Infliximab.
Doxofylline,The metabolism of Doxofylline can be increased when combined with Infliximab.
Ramosetron,The metabolism of Ramosetron can be increased when combined with Infliximab.
6-O-benzylguanine,The metabolism of 6-O-benzylguanine can be increased when combined with Infliximab.
Binimetinib,The metabolism of Binimetinib can be increased when combined with Infliximab.
Voxilaprevir,The metabolism of Voxilaprevir can be increased when combined with Infliximab.
Triclabendazole,The metabolism of Triclabendazole can be increased when combined with Infliximab.
Rucaparib,The metabolism of Rucaparib can be increased when combined with Infliximab.
Lisofylline,The metabolism of Lisofylline can be increased when combined with Infliximab.
Lobucavir,The metabolism of Lobucavir can be increased when combined with Infliximab.
Cafedrine,The metabolism of Cafedrine can be increased when combined with Infliximab.
Theodrenaline,The metabolism of Theodrenaline can be increased when combined with Infliximab.
Dihydralazine,The metabolism of Dihydralazine can be increased when combined with Infliximab.
Bamifylline,The metabolism of Bamifylline can be increased when combined with Infliximab.
Proxyphylline,The metabolism of Proxyphylline can be increased when combined with Infliximab.
Acefylline,The metabolism of Acefylline can be increased when combined with Infliximab.
Etamiphylline,The metabolism of Etamiphylline can be increased when combined with Infliximab.
Pentifylline,The metabolism of Pentifylline can be increased when combined with Infliximab.
Bufylline,The metabolism of Bufylline can be increased when combined with Infliximab.
Bromotheophylline,The metabolism of Bromotheophylline can be increased when combined with Infliximab.
8-chlorotheophylline,The metabolism of 8-chlorotheophylline can be increased when combined with Infliximab.
Istradefylline,The metabolism of Istradefylline can be increased when combined with Infliximab.
Bicifadine,The metabolism of Bicifadine can be increased when combined with Infliximab.
GTS-21,The metabolism of GTS-21 can be increased when combined with Infliximab.
Ethinylestradiol,The metabolism of Infliximab can be increased when combined with Ethinylestradiol.
Zolpidem,The metabolism of Zolpidem can be increased when combined with Infliximab.
Imipramine,The metabolism of Imipramine can be increased when combined with Infliximab.
Mephenytoin,The metabolism of Mephenytoin can be increased when combined with Infliximab.
Nortriptyline,The metabolism of Nortriptyline can be increased when combined with Infliximab.
Clonidine,The metabolism of Clonidine can be increased when combined with Infliximab.
Cyclobenzaprine,The metabolism of Cyclobenzaprine can be increased when combined with Infliximab.
Clomipramine,The metabolism of Clomipramine can be increased when combined with Infliximab.
Selumetinib,The metabolism of Selumetinib can be increased when combined with Infliximab.
Theophylline,The metabolism of Theophylline can be increased when combined with Infliximab.
Carbamazepine,The metabolism of Carbamazepine can be increased when combined with Infliximab.
Warfarin,The metabolism of Warfarin can be increased when combined with Infliximab.
Tizanidine,The metabolism of Tizanidine can be increased when combined with Infliximab.
Pimozide,The metabolism of Pimozide can be increased when combined with Infliximab.
Aminophylline,The metabolism of Aminophylline can be increased when combined with Infliximab.
Acenocoumarol,The metabolism of Acenocoumarol can be increased when combined with Infliximab.
Tegafur,The metabolism of Tegafur can be increased when combined with Infliximab.
Dacarbazine,The metabolism of Dacarbazine can be increased when combined with Infliximab.
Pomalidomide,The metabolism of Pomalidomide can be increased when combined with Infliximab.
Nevirapine,The metabolism of Nevirapine can be increased when combined with Infliximab.
Flurazepam,The metabolism of Flurazepam can be increased when combined with Infliximab.
Metronidazole,The metabolism of Metronidazole can be increased when combined with Infliximab.
Formoterol,The metabolism of Formoterol can be increased when combined with Infliximab.
Letrozole,The metabolism of Letrozole can be increased when combined with Infliximab.
Methoxyflurane,The metabolism of Methoxyflurane can be increased when combined with Infliximab.
Halothane,The metabolism of Halothane can be increased when combined with Infliximab.
Sevoflurane,The metabolism of Sevoflurane can be increased when combined with Infliximab.
Arformoterol,The metabolism of Arformoterol can be increased when combined with Infliximab.
Flunitrazepam,The metabolism of Flunitrazepam can be increased when combined with Infliximab.
Dapagliflozin,The metabolism of Dapagliflozin can be increased when combined with Infliximab.
Clomethiazole,The metabolism of Clomethiazole can be increased when combined with Infliximab.
Vortioxetine,The metabolism of Vortioxetine can be increased when combined with Infliximab.
Tegafur-uracil,The metabolism of Tegafur-uracil can be increased when combined with Infliximab.
Asunaprevir,The metabolism of Asunaprevir can be increased when combined with Infliximab.
Plitidepsin,The metabolism of Plitidepsin can be increased when combined with Infliximab.
Cenobamate,The metabolism of Cenobamate can be increased when combined with Infliximab.
Tramadol,The metabolism of Tramadol can be increased when combined with Infliximab.
Methadone,The metabolism of Methadone can be increased when combined with Infliximab.
Clobazam,The metabolism of Clobazam can be increased when combined with Infliximab.
Efavirenz,The metabolism of Efavirenz can be increased when combined with Infliximab.
Isoflurane,The metabolism of Isoflurane can be increased when combined with Infliximab.
Brompheniramine,The metabolism of Brompheniramine can be increased when combined with Infliximab.
Loperamide,The metabolism of Loperamide can be increased when combined with Infliximab.
Methylphenobarbital,The metabolism of Methylphenobarbital can be increased when combined with Infliximab.
Benzphetamine,The metabolism of Benzphetamine can be increased when combined with Infliximab.
Promethazine,The metabolism of Promethazine can be increased when combined with Infliximab.
Perhexiline,The metabolism of Perhexiline can be increased when combined with Infliximab.
Ketamine,The metabolism of Ketamine can be increased when combined with Infliximab.
Ethylmorphine,The metabolism of Ethylmorphine can be increased when combined with Infliximab.
Clotiazepam,The metabolism of Clotiazepam can be increased when combined with Infliximab.
Ospemifene,The metabolism of Ospemifene can be increased when combined with Infliximab.
Banoxantrone,The metabolism of Banoxantrone can be increased when combined with Infliximab.
Brivaracetam,The metabolism of Brivaracetam can be increased when combined with Infliximab.
Romidepsin,The metabolism of Romidepsin can be increased when combined with Infliximab.
Prasugrel,The metabolism of Prasugrel can be increased when combined with Infliximab.
Artemether,The metabolism of Artemether can be increased when combined with Infliximab.
Methyltestosterone,The metabolism of Methyltestosterone can be increased when combined with Infliximab.
Ketobemidone,The metabolism of Ketobemidone can be increased when combined with Infliximab.
Seratrodast,The metabolism of Seratrodast can be increased when combined with Infliximab.
Velpatasvir,The metabolism of Velpatasvir can be increased when combined with Infliximab.
Artemisinin,The metabolism of Artemisinin can be increased when combined with Infliximab.
Testosterone cypionate,The metabolism of Testosterone cypionate can be increased when combined with Infliximab.
Testosterone enanthate,The metabolism of Testosterone enanthate can be increased when combined with Infliximab.
Testosterone undecanoate,The metabolism of Testosterone undecanoate can be increased when combined with Infliximab.
Bupropion,The metabolism of Bupropion can be increased when combined with Infliximab.
Hydrocodone,The metabolism of Hydrocodone can be increased when combined with Infliximab.
Voxelotor,The metabolism of Voxelotor can be increased when combined with Infliximab.
Osilodrostat,The metabolism of Osilodrostat can be increased when combined with Infliximab.
Melitracen,The metabolism of Melitracen can be increased when combined with Infliximab.
Lofepramine,The metabolism of Lofepramine can be increased when combined with Infliximab.
Apomorphine,The metabolism of Apomorphine can be increased when combined with Infliximab.
Dosulepin,The metabolism of Dosulepin can be increased when combined with Infliximab.
Pantoprazole,The metabolism of Pantoprazole can be increased when combined with Infliximab.
Citalopram,The metabolism of Citalopram can be increased when combined with Infliximab.
Pentobarbital,The metabolism of Pentobarbital can be increased when combined with Infliximab.
Omeprazole,The metabolism of Omeprazole can be increased when combined with Infliximab.
Trimethadione,The metabolism of Trimethadione can be increased when combined with Infliximab.
Carisoprodol,The metabolism of Carisoprodol can be increased when combined with Infliximab.
Lansoprazole,The metabolism of Lansoprazole can be increased when combined with Infliximab.
Methohexital,The metabolism of Methohexital can be increased when combined with Infliximab.
Voriconazole,The metabolism of Voriconazole can be increased when combined with Infliximab.
Thioridazine,The metabolism of Thioridazine can be increased when combined with Infliximab.
Esomeprazole,The metabolism of Esomeprazole can be increased when combined with Infliximab.
Primidone,The metabolism of Primidone can be increased when combined with Infliximab.
Zonisamide,The metabolism of Zonisamide can be increased when combined with Infliximab.
Rabeprazole,The metabolism of Rabeprazole can be increased when combined with Infliximab.
Proguanil,The metabolism of Proguanil can be increased when combined with Infliximab.
Escitalopram,The metabolism of Escitalopram can be increased when combined with Infliximab.
Lapatinib,The metabolism of Lapatinib can be increased when combined with Infliximab.
St. John's Wort,The metabolism of St. John's Wort can be increased when combined with Infliximab.
Hexobarbital,The metabolism of Hexobarbital can be increased when combined with Infliximab.
Barbital,The metabolism of Barbital can be increased when combined with Infliximab.
Methsuximide,The metabolism of Methsuximide can be increased when combined with Infliximab.
Dexlansoprazole,The metabolism of Dexlansoprazole can be increased when combined with Infliximab.
Lacosamide,The metabolism of Lacosamide can be increased when combined with Infliximab.
Etravirine,The metabolism of Etravirine can be increased when combined with Infliximab.
Apixaban,The metabolism of Apixaban can be increased when combined with Infliximab.
Etizolam,The metabolism of Etizolam can be increased when combined with Infliximab.
Lorlatinib,The metabolism of Lorlatinib can be increased when combined with Infliximab.
Lynestrenol,The metabolism of Lynestrenol can be increased when combined with Infliximab.
Dexrabeprazole,The metabolism of Dexrabeprazole can be increased when combined with Infliximab.
(S)-Warfarin,The metabolism of (S)-Warfarin can be increased when combined with Infliximab.
Paroxetine,The metabolism of Paroxetine can be increased when combined with Infliximab.
Fedratinib,The metabolism of Fedratinib can be increased when combined with Infliximab.
Nebivolol,The metabolism of Nebivolol can be increased when combined with Infliximab.
Vilazodone,The metabolism of Vilazodone can be increased when combined with Infliximab.
Sertraline,The metabolism of Sertraline can be increased when combined with Infliximab.
Esketamine,The metabolism of Esketamine can be increased when combined with Infliximab.
Phenytoin,The metabolism of Phenytoin can be increased when combined with Infliximab.
Thiopental,The metabolism of Thiopental can be increased when combined with Infliximab.
Phenobarbital,The metabolism of Phenobarbital can be increased when combined with Infliximab.
Fosphenytoin,The metabolism of Fosphenytoin can be increased when combined with Infliximab.
Amodiaquine,The metabolism of Amodiaquine can be increased when combined with Infliximab.
Tazarotene,The metabolism of Tazarotene can be increased when combined with Infliximab.
Beraprost,The metabolism of Beraprost can be increased when combined with Infliximab.
Muraglitazar,The metabolism of Muraglitazar can be increased when combined with Infliximab.
Ombitasvir,The metabolism of Ombitasvir can be increased when combined with Infliximab.
Anastrozole,The metabolism of Anastrozole can be increased when combined with Infliximab.
Diethylstilbestrol,The metabolism of Infliximab can be increased when combined with Diethylstilbestrol.
Morphine,The metabolism of Morphine can be increased when combined with Infliximab.
Sulfadiazine,The metabolism of Sulfadiazine can be increased when combined with Infliximab.
Eszopiclone,The metabolism of Eszopiclone can be increased when combined with Infliximab.
Nicardipine,The metabolism of Nicardipine can be increased when combined with Infliximab.
Repaglinide,The metabolism of Repaglinide can be increased when combined with Infliximab.
Sitagliptin,The metabolism of Sitagliptin can be increased when combined with Infliximab.
Odanacatib,The metabolism of Odanacatib can be increased when combined with Infliximab.
Capravirine,The metabolism of Capravirine can be increased when combined with Infliximab.
Riociguat,The metabolism of Riociguat can be increased when combined with Infliximab.
Lobeglitazone,The metabolism of Lobeglitazone can be increased when combined with Infliximab.
Netoglitazone,The metabolism of Netoglitazone can be increased when combined with Infliximab.
Rivoglitazone,The metabolism of Rivoglitazone can be increased when combined with Infliximab.
Ciglitazone,The metabolism of Ciglitazone can be increased when combined with Infliximab.
Selexipag,The metabolism of Selexipag can be increased when combined with Infliximab.
Apalutamide,The metabolism of Apalutamide can be increased when combined with Infliximab.
Glasdegib,The metabolism of Glasdegib can be increased when combined with Infliximab.
Balaglitazone,The metabolism of Balaglitazone can be increased when combined with Infliximab.
Pioglitazone,The metabolism of Pioglitazone can be increased when combined with Infliximab.
Tucatinib,The metabolism of Tucatinib can be increased when combined with Infliximab.
Phenprocoumon,The metabolism of Phenprocoumon can be increased when combined with Infliximab.
Paclitaxel,The metabolism of Paclitaxel can be increased when combined with Infliximab.
Valsartan,The metabolism of Valsartan can be increased when combined with Infliximab.
Nicotine,The metabolism of Nicotine can be increased when combined with Infliximab.
Troglitazone,The metabolism of Troglitazone can be increased when combined with Infliximab.
Torasemide,The metabolism of Torasemide can be increased when combined with Infliximab.
Glimepiride,The metabolism of Glimepiride can be increased when combined with Infliximab.
Venlafaxine,The metabolism of Venlafaxine can be increased when combined with Infliximab.
Desogestrel,The metabolism of Desogestrel can be increased when combined with Infliximab.
Bexarotene,The metabolism of Bexarotene can be increased when combined with Infliximab.
Hydromorphone,The metabolism of Hydromorphone can be increased when combined with Infliximab.
Indomethacin,The metabolism of Indomethacin can be increased when combined with Infliximab.
Diltiazem,The metabolism of Diltiazem can be increased when combined with Infliximab.
Treprostinil,The metabolism of Treprostinil can be increased when combined with Infliximab.
Rosiglitazone,The metabolism of Rosiglitazone can be increased when combined with Infliximab.
Acetohexamide,The metabolism of Acetohexamide can be increased when combined with Infliximab.
Promazine,The metabolism of Promazine can be increased when combined with Infliximab.
Trimethoprim,The metabolism of Trimethoprim can be increased when combined with Infliximab.
Nabumetone,The metabolism of Nabumetone can be increased when combined with Infliximab.
Quinine,The metabolism of Quinine can be increased when combined with Infliximab.
Tenoxicam,The metabolism of Tenoxicam can be increased when combined with Infliximab.
Montelukast,The metabolism of Montelukast can be increased when combined with Infliximab.
Fluoxetine,The metabolism of Fluoxetine can be increased when combined with Infliximab.
Duloxetine,The metabolism of Duloxetine can be increased when combined with Infliximab.
Celecoxib,The metabolism of Celecoxib can be increased when combined with Infliximab.
Zidovudine,The metabolism of Zidovudine can be increased when combined with Infliximab.
Haloperidol,The metabolism of Haloperidol can be increased when combined with Infliximab.
Cyclophosphamide,The metabolism of Cyclophosphamide can be increased when combined with Infliximab.
Rofecoxib,The metabolism of Rofecoxib can be increased when combined with Infliximab.
Zafirlukast,The metabolism of Zafirlukast can be increased when combined with Infliximab.
Piroxicam,The metabolism of Piroxicam can be increased when combined with Infliximab.
Bosentan,The metabolism of Bosentan can be increased when combined with Infliximab.
Cinnarizine,The metabolism of Cinnarizine can be increased when combined with Infliximab.
Valdecoxib,The metabolism of Valdecoxib can be increased when combined with Infliximab.
Diclofenac,The metabolism of Diclofenac can be increased when combined with Infliximab.
Paramethadione,The metabolism of Paramethadione can be increased when combined with Infliximab.
Verapamil,The metabolism of Verapamil can be increased when combined with Infliximab.
Chlorpropamide,The metabolism of Chlorpropamide can be increased when combined with Infliximab.
Losartan,The metabolism of Losartan can be increased when combined with Infliximab.
Amprenavir,The metabolism of Amprenavir can be increased when combined with Infliximab.
Flurbiprofen,The metabolism of Flurbiprofen can be increased when combined with Infliximab.
Nateglinide,The metabolism of Nateglinide can be increased when combined with Infliximab.
Zileuton,The metabolism of Zileuton can be increased when combined with Infliximab.
Etodolac,The metabolism of Etodolac can be increased when combined with Infliximab.
Tretinoin,The metabolism of Tretinoin can be increased when combined with Infliximab.
Clopidogrel,The metabolism of Clopidogrel can be increased when combined with Infliximab.
Estradiol,The metabolism of Estradiol can be increased when combined with Infliximab.
Mefenamic acid,The metabolism of Mefenamic acid can be increased when combined with Infliximab.
Naproxen,The metabolism of Naproxen can be increased when combined with Infliximab.
Candesartan cilexetil,The metabolism of Candesartan cilexetil can be increased when combined with Infliximab.
Phenylbutazone,The metabolism of Phenylbutazone can be increased when combined with Infliximab.
Meloxicam,The metabolism of Meloxicam can be increased when combined with Infliximab.
Propofol,The metabolism of Propofol can be increased when combined with Infliximab.
Tolazamide,The metabolism of Tolazamide can be increased when combined with Infliximab.
Donepezil,The metabolism of Donepezil can be increased when combined with Infliximab.
Terbinafine,The metabolism of Terbinafine can be increased when combined with Infliximab.
Ondansetron,The metabolism of Ondansetron can be increased when combined with Infliximab.
Buprenorphine,The metabolism of Buprenorphine can be increased when combined with Infliximab.
Salicylic acid,The metabolism of Salicylic acid can be increased when combined with Infliximab.
Acetylsalicylic acid,The metabolism of Acetylsalicylic acid can be increased when combined with Infliximab.
Alosetron,The metabolism of Alosetron can be increased when combined with Infliximab.
Azelastine,The metabolism of Azelastine can be increased when combined with Infliximab.
Ramelteon,The metabolism of Ramelteon can be increased when combined with Infliximab.
Glyburide,The metabolism of Glyburide can be increased when combined with Infliximab.
Irbesartan,The metabolism of Irbesartan can be increased when combined with Infliximab.
Tolterodine,The metabolism of Tolterodine can be increased when combined with Infliximab.
Selegiline,The metabolism of Selegiline can be increased when combined with Infliximab.
Thalidomide,The metabolism of Thalidomide can be increased when combined with Infliximab.
Ibuprofen,The metabolism of Ibuprofen can be increased when combined with Infliximab.
Melatonin,The metabolism of Melatonin can be increased when combined with Infliximab.
Glipizide,The metabolism of Glipizide can be increased when combined with Infliximab.
Atazanavir,The metabolism of Atazanavir can be increased when combined with Infliximab.
Diphenhydramine,The metabolism of Diphenhydramine can be increased when combined with Infliximab.
Fluvastatin,The metabolism of Fluvastatin can be increased when combined with Infliximab.
Rosuvastatin,The metabolism of Rosuvastatin can be increased when combined with Infliximab.
Gliclazide,The metabolism of Gliclazide can be increased when combined with Infliximab.
Tolbutamide,The metabolism of Tolbutamide can be increased when combined with Infliximab.
Carvedilol,The metabolism of Carvedilol can be increased when combined with Infliximab.
Thiamylal,The metabolism of Thiamylal can be increased when combined with Infliximab.
Moclobemide,The metabolism of Moclobemide can be increased when combined with Infliximab.
Idarubicin,The metabolism of Idarubicin can be increased when combined with Infliximab.
Zopiclone,The metabolism of Zopiclone can be increased when combined with Infliximab.
Gliquidone,The metabolism of Gliquidone can be increased when combined with Infliximab.
Lumiracoxib,The metabolism of Lumiracoxib can be increased when combined with Infliximab.
Glisoxepide,The metabolism of Glisoxepide can be increased when combined with Infliximab.
Mestranol,The metabolism of Mestranol can be increased when combined with Infliximab.
Aminophenazone,The metabolism of Aminophenazone can be increased when combined with Infliximab.
Antipyrine,The metabolism of Antipyrine can be increased when combined with Infliximab.
Quazepam,The metabolism of Quazepam can be increased when combined with Infliximab.
Etoricoxib,The metabolism of Etoricoxib can be increased when combined with Infliximab.
Doconexent,The metabolism of Doconexent can be increased when combined with Infliximab.
Phenacetin,The metabolism of Phenacetin can be increased when combined with Infliximab.
Arachidonic Acid,The metabolism of Arachidonic Acid can be increased when combined with Infliximab.
Estrone sulfate,The metabolism of Estrone sulfate can be increased when combined with Infliximab.
Coumarin,The metabolism of Coumarin can be increased when combined with Infliximab.
Licofelone,The metabolism of Licofelone can be increased when combined with Infliximab.
Flunarizine,The metabolism of Flunarizine can be increased when combined with Infliximab.
Ximelagatran,The metabolism of Ximelagatran can be increased when combined with Infliximab.
Tapentadol,The metabolism of Tapentadol can be increased when combined with Infliximab.
Sitaxentan,The metabolism of Sitaxentan can be increased when combined with Infliximab.
Indisulam,The metabolism of Indisulam can be increased when combined with Infliximab.
Vicriviroc,The metabolism of Vicriviroc can be increased when combined with Infliximab.
Lornoxicam,The metabolism of Lornoxicam can be increased when combined with Infliximab.
Zaltoprofen,The metabolism of Zaltoprofen can be increased when combined with Infliximab.
Niclosamide,The metabolism of Niclosamide can be increased when combined with Infliximab.
Tranilast,The metabolism of Tranilast can be increased when combined with Infliximab.
Parecoxib,The metabolism of Parecoxib can be increased when combined with Infliximab.
Vismodegib,The metabolism of Vismodegib can be increased when combined with Infliximab.
Pitavastatin,The metabolism of Pitavastatin can be increased when combined with Infliximab.
Cabozantinib,The metabolism of Cabozantinib can be increased when combined with Infliximab.
Enzalutamide,The metabolism of Enzalutamide can be increased when combined with Infliximab.
Glibornuride,The metabolism of Glibornuride can be increased when combined with Infliximab.
Netupitant,The metabolism of Netupitant can be increased when combined with Infliximab.
Cannabidiol,The metabolism of Cannabidiol can be increased when combined with Infliximab.
Olodaterol,The metabolism of Olodaterol can be increased when combined with Infliximab.
Propacetamol,The metabolism of Propacetamol can be increased when combined with Infliximab.
Lesinurad,The metabolism of Lesinurad can be increased when combined with Infliximab.
Rupatadine,The metabolism of Rupatadine can be increased when combined with Infliximab.
Carbutamide,The metabolism of Carbutamide can be increased when combined with Infliximab.
Metahexamide,The metabolism of Metahexamide can be increased when combined with Infliximab.
Candesartan,The metabolism of Candesartan can be increased when combined with Infliximab.
Piperaquine,The metabolism of Piperaquine can be increased when combined with Infliximab.
Estradiol acetate,The metabolism of Estradiol acetate can be increased when combined with Infliximab.
Estradiol benzoate,The metabolism of Estradiol benzoate can be increased when combined with Infliximab.
Estradiol cypionate,The metabolism of Estradiol cypionate can be increased when combined with Infliximab.
Estradiol dienanthate,The metabolism of Estradiol dienanthate can be increased when combined with Infliximab.
Estradiol valerate,The metabolism of Estradiol valerate can be increased when combined with Infliximab.
Medical Cannabis,The metabolism of Medical Cannabis can be increased when combined with Infliximab.
Nabiximols,The metabolism of Nabiximols can be increased when combined with Infliximab.
Diazepam,The metabolism of Diazepam can be increased when combined with Infliximab.
Dextromethorphan,The metabolism of Dextromethorphan can be increased when combined with Infliximab.
Dronabinol,The metabolism of Dronabinol can be increased when combined with Infliximab.
Dexibuprofen,The metabolism of Dexibuprofen can be increased when combined with Infliximab.
Ketorolac,The metabolism of Ketorolac can be increased when combined with Infliximab.
Avapritinib,The metabolism of Avapritinib can be increased when combined with Infliximab.
Amitriptyline,The metabolism of Amitriptyline can be increased when combined with Infliximab.
Doxepin,The metabolism of Doxepin can be increased when combined with Infliximab.
Eletriptan,The metabolism of Eletriptan can be increased when combined with Infliximab.
Alprazolam,The metabolism of Alprazolam can be increased when combined with Infliximab.
Trimipramine,The metabolism of Trimipramine can be increased when combined with Infliximab.
Capecitabine,The metabolism of Capecitabine can be increased when combined with Infliximab.
Dicoumarol,The metabolism of Dicoumarol can be increased when combined with Infliximab.
Valproic acid,The metabolism of Valproic acid can be increased when combined with Infliximab.
Quinidine,The metabolism of Quinidine can be increased when combined with Infliximab.
Fluindione,The metabolism of Fluindione can be increased when combined with Infliximab.
Quetiapine,The metabolism of Quetiapine can be increased when combined with Infliximab.
Amphetamine,The metabolism of Amphetamine can be increased when combined with Infliximab.
Esmolol,The metabolism of Esmolol can be increased when combined with Infliximab.
Benzatropine,The metabolism of Benzatropine can be increased when combined with Infliximab.
Atomoxetine,The metabolism of Atomoxetine can be increased when combined with Infliximab.
Atenolol,The metabolism of Atenolol can be increased when combined with Infliximab.
Timolol,The metabolism of Timolol can be increased when combined with Infliximab.
Remoxipride,The metabolism of Remoxipride can be increased when combined with Infliximab.
Piperazine,The metabolism of Piperazine can be increased when combined with Infliximab.
Nicergoline,The metabolism of Nicergoline can be increased when combined with Infliximab.
Meclizine,The metabolism of Meclizine can be increased when combined with Infliximab.
Minaprine,The metabolism of Minaprine can be increased when combined with Infliximab.
Alprenolol,The metabolism of Alprenolol can be increased when combined with Infliximab.
Phenformin,The metabolism of Phenformin can be increased when combined with Infliximab.
Mesoridazine,The metabolism of Mesoridazine can be increased when combined with Infliximab.
Pindolol,The metabolism of Pindolol can be increased when combined with Infliximab.
Mequitazine,The metabolism of Mequitazine can be increased when combined with Infliximab.
Tegaserod,The metabolism of Tegaserod can be increased when combined with Infliximab.
Acebutolol,The metabolism of Acebutolol can be increased when combined with Infliximab.
Nadolol,The metabolism of Nadolol can be increased when combined with Infliximab.
Encainide,The metabolism of Encainide can be increased when combined with Infliximab.
Metoclopramide,The metabolism of Metoclopramide can be increased when combined with Infliximab.
Lisdexamfetamine,The metabolism of Lisdexamfetamine can be increased when combined with Infliximab.
Bevantolol,The metabolism of Bevantolol can be increased when combined with Infliximab.
Practolol,The metabolism of Practolol can be increased when combined with Infliximab.
Penbutolol,The metabolism of Penbutolol can be increased when combined with Infliximab.
Methotrimeprazine,The metabolism of Methotrimeprazine can be increased when combined with Infliximab.
Aprindine,The metabolism of Aprindine can be increased when combined with Infliximab.
Midomafetamine,The metabolism of Midomafetamine can be increased when combined with Infliximab.
4-Methoxyamphetamine,The metabolism of 4-Methoxyamphetamine can be increased when combined with Infliximab.
Dextroamphetamine,The metabolism of Dextroamphetamine can be increased when combined with Infliximab.
Metamfetamine,The metabolism of Metamfetamine can be increased when combined with Infliximab.
Oxprenolol,The metabolism of Oxprenolol can be increased when combined with Infliximab.
Debrisoquine,The metabolism of Debrisoquine can be increased when combined with Infliximab.
Tetrabenazine,The metabolism of Tetrabenazine can be increased when combined with Infliximab.
Celiprolol,The metabolism of Celiprolol can be increased when combined with Infliximab.
Vernakalant,The metabolism of Vernakalant can be increased when combined with Infliximab.
Repinotan,The metabolism of Repinotan can be increased when combined with Infliximab.
Tafenoquine,The metabolism of Tafenoquine can be increased when combined with Infliximab.
Esmirtazapine,The metabolism of Esmirtazapine can be increased when combined with Infliximab.
Bufuralol,The metabolism of Bufuralol can be increased when combined with Infliximab.
Sparteine,The metabolism of Sparteine can be increased when combined with Infliximab.
Enclomiphene,The metabolism of Enclomiphene can be increased when combined with Infliximab.
Bopindolol,The metabolism of Bopindolol can be increased when combined with Infliximab.
Bupranolol,The metabolism of Bupranolol can be increased when combined with Infliximab.
Indenolol,The metabolism of Indenolol can be increased when combined with Infliximab.
Befunolol,The metabolism of Befunolol can be increased when combined with Infliximab.
Umeclidinium,The metabolism of Umeclidinium can be increased when combined with Infliximab.
Arotinolol,The metabolism of Arotinolol can be increased when combined with Infliximab.
Levobetaxolol,The metabolism of Levobetaxolol can be increased when combined with Infliximab.
Talinolol,The metabolism of Talinolol can be increased when combined with Infliximab.
Anisodamine,The metabolism of Anisodamine can be increased when combined with Infliximab.
Revefenacin,The metabolism of Revefenacin can be increased when combined with Infliximab.
Elagolix,The metabolism of Elagolix can be increased when combined with Infliximab.
Letermovir,The metabolism of Letermovir can be increased when combined with Infliximab.
Landiolol,The metabolism of Landiolol can be increased when combined with Infliximab.
Bucindolol,The metabolism of Bucindolol can be increased when combined with Infliximab.
Esatenolol,The metabolism of Esatenolol can be increased when combined with Infliximab.
Cloranolol,The metabolism of Cloranolol can be increased when combined with Infliximab.
Mepindolol,The metabolism of Mepindolol can be increased when combined with Infliximab.
Dexchlorpheniramine,The metabolism of Dexchlorpheniramine can be increased when combined with Infliximab.
Epanolol,The metabolism of Epanolol can be increased when combined with Infliximab.
Tertatolol,The metabolism of Tertatolol can be increased when combined with Infliximab.
Perphenazine,The metabolism of Perphenazine can be increased when combined with Infliximab.
Butyrfentanyl,The metabolism of Butyrfentanyl can be increased when combined with Infliximab.
Lidocaine,The metabolism of Lidocaine can be increased when combined with Infliximab.
Labetalol,The metabolism of Labetalol can be increased when combined with Infliximab.
"5-methoxy-N,N-dimethyltryptamine","The metabolism of 5-methoxy-N,N-dimethyltryptamine can be increased when combined with Infliximab."
Ciclesonide,The metabolism of Ciclesonide can be increased when combined with Infliximab.
Almotriptan,The metabolism of Almotriptan can be increased when combined with Infliximab.
Levomilnacipran,The metabolism of Levomilnacipran can be increased when combined with Infliximab.
Perospirone,The metabolism of Perospirone can be increased when combined with Infliximab.
Dasabuvir,The metabolism of Dasabuvir can be increased when combined with Infliximab.
Fusidic acid,The metabolism of Fusidic acid can be increased when combined with Infliximab.
Ipecac,The metabolism of Ipecac can be increased when combined with Infliximab.
Cevimeline,The metabolism of Cevimeline can be increased when combined with Infliximab.
Ranolazine,The metabolism of Ranolazine can be increased when combined with Infliximab.
Bupivacaine,The metabolism of Bupivacaine can be increased when combined with Infliximab.
Codeine,The metabolism of Codeine can be increased when combined with Infliximab.
Palonosetron,The metabolism of Palonosetron can be increased when combined with Infliximab.
Lisuride,The metabolism of Lisuride can be increased when combined with Infliximab.
Dextropropoxyphene,The metabolism of Dextropropoxyphene can be increased when combined with Infliximab.
Galantamine,The metabolism of Galantamine can be increased when combined with Infliximab.
Delavirdine,The metabolism of Delavirdine can be increased when combined with Infliximab.
Tamsulosin,The metabolism of Tamsulosin can be increased when combined with Infliximab.
Dolasetron,The metabolism of Dolasetron can be increased when combined with Infliximab.
Nefazodone,The metabolism of Nefazodone can be increased when combined with Infliximab.
Oxymorphone,The metabolism of Oxymorphone can be increased when combined with Infliximab.
Bepridil,The metabolism of Bepridil can be increased when combined with Infliximab.
Yohimbine,The metabolism of Yohimbine can be increased when combined with Infliximab.
Tiotropium,The metabolism of Tiotropium can be increased when combined with Infliximab.
Dihydrocodeine,The metabolism of Dihydrocodeine can be increased when combined with Infliximab.
Solifenacin,The metabolism of Solifenacin can be increased when combined with Infliximab.
Pipotiazine,The metabolism of Pipotiazine can be increased when combined with Infliximab.
Lysergic acid diethylamide,The metabolism of Lysergic acid diethylamide can be increased when combined with Infliximab.
Dapoxetine,The metabolism of Dapoxetine can be increased when combined with Infliximab.
Tesmilifene,The metabolism of Tesmilifene can be increased when combined with Infliximab.
Clevidipine,The metabolism of Clevidipine can be increased when combined with Infliximab.
Rotigotine,The metabolism of Rotigotine can be increased when combined with Infliximab.
Cariprazine,The metabolism of Cariprazine can be increased when combined with Infliximab.
Sertindole,The metabolism of Sertindole can be increased when combined with Infliximab.
Alogliptin,The metabolism of Alogliptin can be increased when combined with Infliximab.
Fesoterodine,The metabolism of Fesoterodine can be increased when combined with Infliximab.
Mirabegron,The metabolism of Mirabegron can be increased when combined with Infliximab.
Brexpiprazole,The metabolism of Brexpiprazole can be increased when combined with Infliximab.
Lorpiprazole,The metabolism of Lorpiprazole can be increased when combined with Infliximab.
Dexchlorpheniramine maleate,The metabolism of Dexchlorpheniramine maleate can be increased when combined with Infliximab.
Opium,The metabolism of Opium can be increased when combined with Infliximab.
Pitolisant,The metabolism of Pitolisant can be increased when combined with Infliximab.
Protriptyline,The metabolism of Protriptyline can be increased when combined with Infliximab.
Darifenacin,The metabolism of Darifenacin can be increased when combined with Infliximab.
Amoxapine,The metabolism of Amoxapine can be increased when combined with Infliximab.
Tipranavir,The metabolism of Tipranavir can be increased when combined with Infliximab.
Eliglustat,The metabolism of Eliglustat can be increased when combined with Infliximab.
Opipramol,The metabolism of Opipramol can be increased when combined with Infliximab.
Sotalol,The metabolism of Sotalol can be increased when combined with Infliximab.
Procainamide,The metabolism of Procainamide can be increased when combined with Infliximab.
Flecainide,The metabolism of Flecainide can be increased when combined with Infliximab.
Enflurane,The metabolism of Enflurane can be increased when combined with Infliximab.
Nilvadipine,The metabolism of Nilvadipine can be increased when combined with Infliximab.
Aniline,The metabolism of Aniline can be increased when combined with Infliximab.
Felbamate,The metabolism of Felbamate can be increased when combined with Infliximab.
Ethosuximide,The metabolism of Ethosuximide can be increased when combined with Infliximab.
Lorazepam,The metabolism of Lorazepam can be increased when combined with Infliximab.
Phentermine,The metabolism of Phentermine can be increased when combined with Infliximab.
Azithromycin,The metabolism of Azithromycin can be increased when combined with Infliximab.
Ticlopidine,The metabolism of Ticlopidine can be increased when combined with Infliximab.
Metoprolol,The metabolism of Metoprolol can be increased when combined with Infliximab.
Famciclovir,The metabolism of Famciclovir can be increased when combined with Infliximab.
Prochlorperazine,The metabolism of Prochlorperazine can be increased when combined with Infliximab.
Cephalexin,The metabolism of Cephalexin can be increased when combined with Infliximab.
Doxazosin,The metabolism of Doxazosin can be increased when combined with Infliximab.
Fenofibrate,The metabolism of Fenofibrate can be increased when combined with Infliximab.
Drospirenone,The metabolism of Drospirenone can be increased when combined with Infliximab.
Pranlukast,The metabolism of Pranlukast can be increased when combined with Infliximab.
Allylestrenol,The metabolism of Allylestrenol can be increased when combined with Infliximab.
Zuclopenthixol,The metabolism of Zuclopenthixol can be increased when combined with Infliximab.
Rufinamide,The metabolism of Rufinamide can be increased when combined with Infliximab.
Prucalopride,The metabolism of Prucalopride can be increased when combined with Infliximab.
Linagliptin,The metabolism of Linagliptin can be increased when combined with Infliximab.
Vorapaxar,The metabolism of Vorapaxar can be increased when combined with Infliximab.
Suvorexant,The metabolism of Suvorexant can be increased when combined with Infliximab.
Nintedanib,The metabolism of Nintedanib can be increased when combined with Infliximab.
Tenofovir alafenamide,The metabolism of Tenofovir alafenamide can be increased when combined with Infliximab.
Osimertinib,The metabolism of Osimertinib can be increased when combined with Infliximab.
Vitamin D,The metabolism of Vitamin D can be increased when combined with Infliximab.
Dihydroergocornine,The metabolism of Dihydroergocornine can be increased when combined with Infliximab.
Ribociclib,The metabolism of Ribociclib can be increased when combined with Infliximab.
Duvelisib,The metabolism of Duvelisib can be increased when combined with Infliximab.
Gilteritinib,The metabolism of Gilteritinib can be increased when combined with Infliximab.
9-aminocamptothecin,The metabolism of 9-aminocamptothecin can be increased when combined with Infliximab.
Methylprednisone,The metabolism of Methylprednisone can be increased when combined with Infliximab.
Dihydroergocristine,The metabolism of Dihydroergocristine can be increased when combined with Infliximab.
Dihydroergocryptine,The metabolism of Dihydroergocryptine can be increased when combined with Infliximab.
Tenofovir,The metabolism of Tenofovir can be increased when combined with Infliximab.
Elexacaftor,The metabolism of Elexacaftor can be increased when combined with Infliximab.
Fosaprepitant,The metabolism of Fosaprepitant can be increased when combined with Infliximab.
Lefamulin,The metabolism of Lefamulin can be increased when combined with Infliximab.
Tazemetostat,The metabolism of Tazemetostat can be increased when combined with Infliximab.
Meperidine,The metabolism of Meperidine can be increased when combined with Infliximab.
Desipramine,The metabolism of Desipramine can be increased when combined with Infliximab.
Siponimod,The metabolism of Siponimod can be increased when combined with Infliximab.
Methysergide,The metabolism of Methysergide can be increased when combined with Infliximab.
Lomitapide,The metabolism of Lomitapide can be increased when combined with Infliximab.
Ebastine,The metabolism of Ebastine can be increased when combined with Infliximab.
Belinostat,The metabolism of Belinostat can be increased when combined with Infliximab.
Amiodarone,The metabolism of Amiodarone can be increased when combined with Infliximab.
Tamoxifen,The metabolism of Tamoxifen can be increased when combined with Infliximab.
Dofetilide,The metabolism of Dofetilide can be increased when combined with Infliximab.
Terfenadine,The metabolism of Terfenadine can be increased when combined with Infliximab.
Levothyroxine,The metabolism of Levothyroxine can be increased when combined with Infliximab.
Cisapride,The metabolism of Cisapride can be increased when combined with Infliximab.
Sirolimus,The metabolism of Sirolimus can be increased when combined with Infliximab.
Busulfan,The metabolism of Busulfan can be increased when combined with Infliximab.
Dasatinib,The metabolism of Dasatinib can be increased when combined with Infliximab.
Digitoxin,The metabolism of Digitoxin can be increased when combined with Infliximab.
Everolimus,The metabolism of Everolimus can be increased when combined with Infliximab.
4-hydroxycoumarin,The metabolism of 4-hydroxycoumarin can be increased when combined with Infliximab.
Dronedarone,The metabolism of Dronedarone can be increased when combined with Infliximab.
Temsirolimus,The metabolism of Temsirolimus can be increased when combined with Infliximab.
Ibrutinib,The metabolism of Ibrutinib can be increased when combined with Infliximab.
Tianeptine,The metabolism of Tianeptine can be increased when combined with Infliximab.
Isavuconazole,The metabolism of Isavuconazole can be increased when combined with Infliximab.
Clorindione,The metabolism of Clorindione can be increased when combined with Infliximab.
Sorafenib,The metabolism of Sorafenib can be increased when combined with Infliximab.
Teniposide,The metabolism of Teniposide can be increased when combined with Infliximab.
Erlotinib,The metabolism of Erlotinib can be increased when combined with Infliximab.
Vincristine,The metabolism of Vincristine can be increased when combined with Infliximab.
Imatinib,The metabolism of Imatinib can be increased when combined with Infliximab.
Etoposide,The metabolism of Etoposide can be increased when combined with Infliximab.
Docetaxel,The metabolism of Docetaxel can be increased when combined with Infliximab.
Sunitinib,The metabolism of Sunitinib can be increased when combined with Infliximab.
Axitinib,The metabolism of Axitinib can be increased when combined with Infliximab.
Crizotinib,The metabolism of Crizotinib can be increased when combined with Infliximab.
Ponatinib,The metabolism of Ponatinib can be increased when combined with Infliximab.
Copanlisib,The metabolism of Copanlisib can be increased when combined with Infliximab.
Bortezomib,The metabolism of Bortezomib can be increased when combined with Infliximab.
Clozapine,The metabolism of Clozapine can be increased when combined with Infliximab.
Ifosfamide,The metabolism of Ifosfamide can be increased when combined with Infliximab.
Trabectedin,The metabolism of Trabectedin can be increased when combined with Infliximab.
Erdafitinib,The metabolism of Erdafitinib can be increased when combined with Infliximab.
Enasidenib,The metabolism of Enasidenib can be increased when combined with Infliximab.
Pazopanib,The metabolism of Pazopanib can be increased when combined with Infliximab.
Cobimetinib,The metabolism of Cobimetinib can be increased when combined with Infliximab.
Ceritinib,The metabolism of Ceritinib can be increased when combined with Infliximab.
Dacomitinib,The metabolism of Dacomitinib can be increased when combined with Infliximab.
Alpelisib,The metabolism of Alpelisib can be increased when combined with Infliximab.
Vindesine,The metabolism of Vindesine can be increased when combined with Infliximab.
Vinorelbine,The metabolism of Vinorelbine can be increased when combined with Infliximab.
Vinblastine,The metabolism of Vinblastine can be increased when combined with Infliximab.
Daunorubicin,The metabolism of Daunorubicin can be increased when combined with Infliximab.
Cytarabine,The metabolism of Cytarabine can be increased when combined with Infliximab.
Doxorubicin,The metabolism of Doxorubicin can be increased when combined with Infliximab.
Trilostane,The metabolism of Trilostane can be increased when combined with Infliximab.
Thiotepa,The metabolism of Thiotepa can be increased when combined with Infliximab.
Ixabepilone,The metabolism of Ixabepilone can be increased when combined with Infliximab.
Nilotinib,The metabolism of Nilotinib can be increased when combined with Infliximab.
Panobinostat,The metabolism of Panobinostat can be increased when combined with Infliximab.
Bosutinib,The metabolism of Bosutinib can be increased when combined with Infliximab.
Brentuximab vedotin,The metabolism of Brentuximab vedotin can be increased when combined with Infliximab.
Ruxolitinib,The metabolism of Ruxolitinib can be increased when combined with Infliximab.
Palbociclib,The metabolism of Palbociclib can be increased when combined with Infliximab.
Dabrafenib,The metabolism of Dabrafenib can be increased when combined with Infliximab.
Brigatinib,The metabolism of Brigatinib can be increased when combined with Infliximab.
Encorafenib,The metabolism of Encorafenib can be increased when combined with Infliximab.
Methotrexate,The metabolism of Methotrexate can be increased when combined with Infliximab.
Vandetanib,The metabolism of Vandetanib can be increased when combined with Infliximab.
Abiraterone,The metabolism of Abiraterone can be increased when combined with Infliximab.
Vemurafenib,The metabolism of Vemurafenib can be increased when combined with Infliximab.
Alectinib,The metabolism of Alectinib can be increased when combined with Infliximab.
Venetoclax,The metabolism of Venetoclax can be increased when combined with Infliximab.
Vinflunine,The metabolism of Vinflunine can be increased when combined with Infliximab.
Acalabrutinib,The metabolism of Acalabrutinib can be increased when combined with Infliximab.
Zanubrutinib,The metabolism of Zanubrutinib can be increased when combined with Infliximab.
Cabergoline,The metabolism of Cabergoline can be increased when combined with Infliximab.
Midostaurin,The metabolism of Midostaurin can be increased when combined with Infliximab.
Sonidegib,The metabolism of Sonidegib can be increased when combined with Infliximab.
Neratinib,The metabolism of Neratinib can be increased when combined with Infliximab.
Entrectinib,The metabolism of Entrectinib can be increased when combined with Infliximab.
Pexidartinib,The metabolism of Pexidartinib can be increased when combined with Infliximab.
Ivosidenib,The metabolism of Ivosidenib can be increased when combined with Infliximab.
Idelalisib,The metabolism of Idelalisib can be increased when combined with Infliximab.
Ixazomib,The metabolism of Ixazomib can be increased when combined with Infliximab.
Erythromycin,The metabolism of Erythromycin can be increased when combined with Infliximab.
Ziprasidone,The metabolism of Ziprasidone can be increased when combined with Infliximab.
Cerivastatin,The metabolism of Cerivastatin can be increased when combined with Infliximab.
Flutamide,The metabolism of Flutamide can be increased when combined with Infliximab.
Ritonavir,The metabolism of Ritonavir can be increased when combined with Infliximab.
Lercanidipine,The metabolism of Lercanidipine can be increased when combined with Infliximab.
Propranolol,The metabolism of Propranolol can be increased when combined with Infliximab.
Fluticasone propionate,The metabolism of Fluticasone propionate can be increased when combined with Infliximab.
Chloroquine,The metabolism of Chloroquine can be increased when combined with Infliximab.
Mycophenolate mofetil,The metabolism of Mycophenolate mofetil can be increased when combined with Infliximab.
Norethisterone,The metabolism of Norethisterone can be increased when combined with Infliximab.
Pentamidine,The metabolism of Pentamidine can be increased when combined with Infliximab.
Hydrocortisone,The metabolism of Hydrocortisone can be increased when combined with Infliximab.
Irinotecan,The metabolism of Irinotecan can be increased when combined with Infliximab.
Disulfiram,The metabolism of Disulfiram can be increased when combined with Infliximab.
Mifepristone,The metabolism of Mifepristone can be increased when combined with Infliximab.
Salmeterol,The metabolism of Salmeterol can be increased when combined with Infliximab.
Zaleplon,The metabolism of Zaleplon can be increased when combined with Infliximab.
Telithromycin,The metabolism of Telithromycin can be increased when combined with Infliximab.
Nitrendipine,The metabolism of Nitrendipine can be increased when combined with Infliximab.
Praziquantel,The metabolism of Praziquantel can be increased when combined with Infliximab.
Oxybutynin,The metabolism of Oxybutynin can be increased when combined with Infliximab.
Atorvastatin,The metabolism of Atorvastatin can be increased when combined with Infliximab.
Quinacrine,The metabolism of Quinacrine can be increased when combined with Infliximab.
Nifedipine,The metabolism of Nifedipine can be increased when combined with Infliximab.
Dutasteride,The metabolism of Dutasteride can be increased when combined with Infliximab.
Cilostazol,The metabolism of Cilostazol can be increased when combined with Infliximab.
Domperidone,The metabolism of Domperidone can be increased when combined with Infliximab.
Clarithromycin,The metabolism of Clarithromycin can be increased when combined with Infliximab.
Finasteride,The metabolism of Finasteride can be increased when combined with Infliximab.
Halofantrine,The metabolism of Halofantrine can be increased when combined with Infliximab.
Telaprevir,The metabolism of Telaprevir can be increased when combined with Infliximab.
Trastuzumab emtansine,The metabolism of Trastuzumab emtansine can be increased when combined with Infliximab.
Udenafil,The metabolism of Udenafil can be increased when combined with Infliximab.
Saxagliptin,The metabolism of Saxagliptin can be increased when combined with Infliximab.
Ambrisentan,The metabolism of Ambrisentan can be increased when combined with Infliximab.
Cethromycin,The metabolism of Cethromycin can be increased when combined with Infliximab.
Cabazitaxel,The metabolism of Cabazitaxel can be increased when combined with Infliximab.
Hydroxyprogesterone caproate,The metabolism of Hydroxyprogesterone caproate can be increased when combined with Infliximab.
Ivacaftor,The metabolism of Ivacaftor can be increased when combined with Infliximab.
Boceprevir,The metabolism of Boceprevir can be increased when combined with Infliximab.
Perampanel,The metabolism of Perampanel can be increased when combined with Infliximab.
Fluticasone furoate,The metabolism of Fluticasone furoate can be increased when combined with Infliximab.
Cobicistat,The metabolism of Cobicistat can be increased when combined with Infliximab.
Olaparib,The metabolism of Olaparib can be increased when combined with Infliximab.
Daclatasvir,The metabolism of Daclatasvir can be increased when combined with Infliximab.
Benidipine,The metabolism of Benidipine can be increased when combined with Infliximab.
Paritaprevir,The metabolism of Paritaprevir can be increased when combined with Infliximab.
Elbasvir,The metabolism of Elbasvir can be increased when combined with Infliximab.
Tezacaftor,The metabolism of Tezacaftor can be increased when combined with Infliximab.
Icotinib,The metabolism of Icotinib can be increased when combined with Infliximab.
Doravirine,The metabolism of Doravirine can be increased when combined with Infliximab.
Fluticasone,The metabolism of Fluticasone can be increased when combined with Infliximab.
Hydrocortisone aceponate,The metabolism of Hydrocortisone aceponate can be increased when combined with Infliximab.
Hydrocortisone acetate,The metabolism of Hydrocortisone acetate can be increased when combined with Infliximab.
Hydrocortisone cypionate,The metabolism of Hydrocortisone cypionate can be increased when combined with Infliximab.
Hydrocortisone phosphate,The metabolism of Hydrocortisone phosphate can be increased when combined with Infliximab.
Progesterone,The metabolism of Progesterone can be increased when combined with Infliximab.
Dexloxiglumide,The metabolism of Dexloxiglumide can be increased when combined with Infliximab.
Azimilide,The metabolism of Azimilide can be increased when combined with Infliximab.
Dapsone,The metabolism of Dapsone can be increased when combined with Infliximab.
Gefitinib,The metabolism of Gefitinib can be increased when combined with Infliximab.
Levonorgestrel,The metabolism of Levonorgestrel can be increased when combined with Infliximab.
Oxycodone,The metabolism of Oxycodone can be increased when combined with Infliximab.
Triamcinolone,The metabolism of Triamcinolone can be increased when combined with Infliximab.
Testosterone,The metabolism of Testosterone can be increased when combined with Infliximab.
Trazodone,The metabolism of Trazodone can be increased when combined with Infliximab.
Risperidone,The metabolism of Risperidone can be increased when combined with Infliximab.
Chlorpheniramine,The metabolism of Chlorpheniramine can be increased when combined with Infliximab.
Aripiprazole,The metabolism of Aripiprazole can be increased when combined with Infliximab.
Paliperidone,The metabolism of Paliperidone can be increased when combined with Infliximab.
Iloperidone,The metabolism of Iloperidone can be increased when combined with Infliximab.
Valbenazine,The metabolism of Valbenazine can be increased when combined with Infliximab.
Deutetrabenazine,The metabolism of Deutetrabenazine can be increased when combined with Infliximab.
Aripiprazole lauroxil,The metabolism of Aripiprazole lauroxil can be increased when combined with Infliximab.
Dexamethasone,The metabolism of Dexamethasone can be increased when combined with Infliximab.
Levamlodipine,The metabolism of Levamlodipine can be increased when combined with Infliximab.
Lemborexant,The metabolism of Lemborexant can be increased when combined with Infliximab.
Hydroxyzine,The metabolism of Hydroxyzine can be increased when combined with Infliximab.
Sildenafil,The metabolism of Sildenafil can be increased when combined with Infliximab.
Lovastatin,The metabolism of Lovastatin can be increased when combined with Infliximab.
Buspirone,The metabolism of Buspirone can be increased when combined with Infliximab.
Simvastatin,The metabolism of Simvastatin can be increased when combined with Infliximab.
Aprepitant,The metabolism of Aprepitant can be increased when combined with Infliximab.
Tadalafil,The metabolism of Tadalafil can be increased when combined with Infliximab.
Vardenafil,The metabolism of Vardenafil can be increased when combined with Infliximab.
Clindamycin,The metabolism of Clindamycin can be increased when combined with Infliximab.
Indinavir,The metabolism of Indinavir can be increased when combined with Infliximab.
Nisoldipine,The metabolism of Nisoldipine can be increased when combined with Infliximab.
Astemizole,The metabolism of Astemizole can be increased when combined with Infliximab.
Midazolam,The metabolism of Midazolam can be increased when combined with Infliximab.
Eplerenone,The metabolism of Eplerenone can be increased when combined with Infliximab.
Alfentanil,The metabolism of Alfentanil can be increased when combined with Infliximab.
Fentanyl,The metabolism of Fentanyl can be increased when combined with Infliximab.
Triazolam,The metabolism of Triazolam can be increased when combined with Infliximab.
Felodipine,The metabolism of Felodipine can be increased when combined with Infliximab.
Levacetylmethadol,The metabolism of Levacetylmethadol can be increased when combined with Infliximab.
Saquinavir,The metabolism of Saquinavir can be increased when combined with Infliximab.
Rivaroxaban,The metabolism of Rivaroxaban can be increased when combined with Infliximab.
Prasterone sulfate,The metabolism of Prasterone sulfate can be increased when combined with Infliximab.
Cyclosporine,Infliximab may increase the immunosuppressive activities of Cyclosporine.
Apremilast,The therapeutic efficacy of Apremilast can be decreased when used in combination with Infliximab.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Infliximab."
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Infliximab.
Lopinavir,The serum concentration of Infliximab can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Infliximab is combined with Inebilizumab.
Fluvoxamine,The therapeutic efficacy of Follitropin can be decreased when used in combination with Fluvoxamine.
Citalopram,The therapeutic efficacy of Follitropin can be decreased when used in combination with Citalopram.
Fluoxetine,The therapeutic efficacy of Follitropin can be decreased when used in combination with Fluoxetine.
Duloxetine,The therapeutic efficacy of Follitropin can be decreased when used in combination with Duloxetine.
Trazodone,The therapeutic efficacy of Follitropin can be decreased when used in combination with Trazodone.
Paroxetine,The therapeutic efficacy of Follitropin can be decreased when used in combination with Paroxetine.
Sertraline,The therapeutic efficacy of Follitropin can be decreased when used in combination with Sertraline.
Sibutramine,The therapeutic efficacy of Follitropin can be decreased when used in combination with Sibutramine.
Nefazodone,The therapeutic efficacy of Follitropin can be decreased when used in combination with Nefazodone.
Escitalopram,The therapeutic efficacy of Follitropin can be decreased when used in combination with Escitalopram.
Zimelidine,The therapeutic efficacy of Follitropin can be decreased when used in combination with Zimelidine.
Dapoxetine,The therapeutic efficacy of Follitropin can be decreased when used in combination with Dapoxetine.
Milnacipran,The therapeutic efficacy of Follitropin can be decreased when used in combination with Milnacipran.
Desvenlafaxine,The therapeutic efficacy of Follitropin can be decreased when used in combination with Desvenlafaxine.
Seproxetine,The therapeutic efficacy of Follitropin can be decreased when used in combination with Seproxetine.
Levomilnacipran,The therapeutic efficacy of Follitropin can be decreased when used in combination with Levomilnacipran.
Indalpine,The therapeutic efficacy of Follitropin can be decreased when used in combination with Indalpine.
Ritanserin,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ritanserin.
Alaproclate,The therapeutic efficacy of Follitropin can be decreased when used in combination with Alaproclate.
Amphetamine,The risk or severity of adverse effects can be increased when Amphetamine is combined with Follitropin.
Phentermine,The risk or severity of adverse effects can be increased when Phentermine is combined with Follitropin.
Midodrine,The risk or severity of adverse effects can be increased when Midodrine is combined with Follitropin.
Norepinephrine,The risk or severity of adverse effects can be increased when Norepinephrine is combined with Follitropin.
Phenylephrine,The risk or severity of adverse effects can be increased when Phenylephrine is combined with Follitropin.
Phenylpropanolamine,The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Follitropin.
Metaraminol,The risk or severity of adverse effects can be increased when Metaraminol is combined with Follitropin.
Epinephrine,The risk or severity of adverse effects can be increased when Epinephrine is combined with Follitropin.
Methoxamine,The risk or severity of adverse effects can be increased when Methoxamine is combined with Follitropin.
Orciprenaline,The risk or severity of adverse effects can be increased when Orciprenaline is combined with Follitropin.
Phenmetrazine,The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Follitropin.
Dobutamine,The risk or severity of adverse effects can be increased when Dobutamine is combined with Follitropin.
Pseudoephedrine,The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Follitropin.
Benzphetamine,The risk or severity of adverse effects can be increased when Benzphetamine is combined with Follitropin.
Ritodrine,The risk or severity of adverse effects can be increased when Ritodrine is combined with Follitropin.
Terbutaline,The risk or severity of adverse effects can be increased when Terbutaline is combined with Follitropin.
Oxymetazoline,The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Follitropin.
Diethylpropion,The risk or severity of adverse effects can be increased when Diethylpropion is combined with Follitropin.
Dopamine,The risk or severity of adverse effects can be increased when Dopamine is combined with Follitropin.
Isoprenaline,The risk or severity of adverse effects can be increased when Isoprenaline is combined with Follitropin.
Lisdexamfetamine,The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Follitropin.
Fenoterol,The risk or severity of adverse effects can be increased when Fenoterol is combined with Follitropin.
Ephedrine,The risk or severity of adverse effects can be increased when Ephedrine is combined with Follitropin.
Mephentermine,The risk or severity of adverse effects can be increased when Mephentermine is combined with Follitropin.
Procaterol,The risk or severity of adverse effects can be increased when Procaterol is combined with Follitropin.
Clenbuterol,The risk or severity of adverse effects can be increased when Clenbuterol is combined with Follitropin.
MMDA,The risk or severity of adverse effects can be increased when MMDA is combined with Follitropin.
Midomafetamine,The risk or severity of adverse effects can be increased when Midomafetamine is combined with Follitropin.
"2,5-Dimethoxy-4-ethylamphetamine","The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Follitropin."
"4-Bromo-2,5-dimethoxyamphetamine","The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Follitropin."
Tenamfetamine,The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Follitropin.
Chlorphentermine,The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Follitropin.
Methylenedioxyethamphetamine,The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Follitropin.
Dextroamphetamine,The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Follitropin.
Metamfetamine,The risk or severity of adverse effects can be increased when Metamfetamine is combined with Follitropin.
Nylidrin,The risk or severity of adverse effects can be increased when Nylidrin is combined with Follitropin.
Tetryzoline,The risk or severity of adverse effects can be increased when Tetryzoline is combined with Follitropin.
Tyramine,The risk or severity of adverse effects can be increased when Tyramine is combined with Follitropin.
Isoxsuprine,The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Follitropin.
Etilefrine,The risk or severity of adverse effects can be increased when Etilefrine is combined with Follitropin.
Synephrine,The risk or severity of adverse effects can be increased when Synephrine is combined with Follitropin.
Iofetamine I-123,The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Follitropin.
Racepinephrine,The risk or severity of adverse effects can be increased when Racepinephrine is combined with Follitropin.
Ritobegron,The risk or severity of adverse effects can be increased when Ritobegron is combined with Follitropin.
Tramazoline,The risk or severity of adverse effects can be increased when Tramazoline is combined with Follitropin.
Mephedrone,The risk or severity of adverse effects can be increased when Mephedrone is combined with Follitropin.
Fenozolone,The risk or severity of adverse effects can be increased when Fenozolone is combined with Follitropin.
Methoxyphenamine,The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Follitropin.
Tretoquinol,The risk or severity of adverse effects can be increased when Tretoquinol is combined with Follitropin.
Gepefrine,The risk or severity of adverse effects can be increased when Gepefrine is combined with Follitropin.
Prenalterol,The risk or severity of adverse effects can be increased when Prenalterol is combined with Follitropin.
Mefenorex,The risk or severity of adverse effects can be increased when Mefenorex is combined with Follitropin.
"2,5-Dimethoxy-4-ethylthioamphetamine","The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Follitropin."
Labetalol,The risk or severity of adverse effects can be increased when Labetalol is combined with Follitropin.
Acebutolol,The risk or severity of adverse effects can be increased when Acebutolol is combined with Follitropin.
Celiprolol,The risk or severity of adverse effects can be increased when Celiprolol is combined with Follitropin.
Bucindolol,The risk or severity of adverse effects can be increased when Bucindolol is combined with Follitropin.
Epanolol,The risk or severity of adverse effects can be increased when Epanolol is combined with Follitropin.
Gefitinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Gefitinib.
Sorafenib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Sorafenib.
Erlotinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Erlotinib.
Imatinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Imatinib.
Dasatinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Dasatinib.
Lapatinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Lapatinib.
Sunitinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Sunitinib.
Genistein,The therapeutic efficacy of Follitropin can be decreased when used in combination with Genistein.
3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone,The therapeutic efficacy of Follitropin can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.
Geldanamycin,The therapeutic efficacy of Follitropin can be decreased when used in combination with Geldanamycin.
PD173955,The therapeutic efficacy of Follitropin can be decreased when used in combination with PD173955.
Radicicol,The therapeutic efficacy of Follitropin can be decreased when used in combination with Radicicol.
Cediranib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Cediranib.
Nilotinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Nilotinib.
Vatalanib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Vatalanib.
Vandetanib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Vandetanib.
Canertinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Canertinib.
Tandutinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Tandutinib.
Motesanib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Motesanib.
Dovitinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Dovitinib.
Glesatinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Glesatinib.
Lestaurtinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Lestaurtinib.
Pazopanib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Pazopanib.
Midostaurin,The therapeutic efficacy of Follitropin can be decreased when used in combination with Midostaurin.
Bosutinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Bosutinib.
Axitinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Axitinib.
Piceatannol,The therapeutic efficacy of Follitropin can be decreased when used in combination with Piceatannol.
Crizotinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Crizotinib.
Cabozantinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Cabozantinib.
Ruxolitinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ruxolitinib.
Vemurafenib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Vemurafenib.
Regorafenib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Regorafenib.
Ponatinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ponatinib.
Afatinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Afatinib.
Ibrutinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ibrutinib.
Ceritinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ceritinib.
Lenvatinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Lenvatinib.
Nintedanib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Nintedanib.
Osimertinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Osimertinib.
Alectinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Alectinib.
Selumetinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Selumetinib.
Pacritinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Pacritinib.
Acalabrutinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Acalabrutinib.
Icotinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Icotinib.
Saracatinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Saracatinib.
Neratinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Neratinib.
Crenolanib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Crenolanib.
Flumatinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Flumatinib.
Dacomitinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Dacomitinib.
Tesevatinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Tesevatinib.
Entrectinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Entrectinib.
Fostamatinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Fostamatinib.
Savolitinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Savolitinib.
Gilteritinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Gilteritinib.
Erdafitinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Erdafitinib.
Brigatinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Brigatinib.
Foretinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Foretinib.
Radotinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Radotinib.
Larotrectinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Larotrectinib.
Pexidartinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Pexidartinib.
Fedratinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Fedratinib.
Tucatinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Tucatinib.
Capmatinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Capmatinib.
Selpercatinib,The therapeutic efficacy of Follitropin can be decreased when used in combination with Selpercatinib.
Interferon alfa,The therapeutic efficacy of Follitropin can be decreased when used in combination with Interferon alfa.
Aldesleukin,The therapeutic efficacy of Follitropin can be decreased when used in combination with Aldesleukin.
Lovastatin,The therapeutic efficacy of Follitropin can be decreased when used in combination with Lovastatin.
Ethionamide,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ethionamide.
Diazepam,The therapeutic efficacy of Follitropin can be decreased when used in combination with Diazepam.
Perphenazine,The therapeutic efficacy of Follitropin can be decreased when used in combination with Perphenazine.
Metoclopramide,The therapeutic efficacy of Follitropin can be decreased when used in combination with Metoclopramide.
Perphenazine enanthate,The therapeutic efficacy of Follitropin can be decreased when used in combination with Perphenazine enanthate.
Aminosalicylic acid,The therapeutic efficacy of Follitropin can be decreased when used in combination with Aminosalicylic acid.
Resorcinol,The therapeutic efficacy of Follitropin can be decreased when used in combination with Resorcinol.
Glimepiride,The therapeutic efficacy of Glimepiride can be decreased when used in combination with Follitropin.
Acetohexamide,The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Follitropin.
Chlorpropamide,The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Follitropin.
Tolazamide,The therapeutic efficacy of Tolazamide can be decreased when used in combination with Follitropin.
Glyburide,The therapeutic efficacy of Glyburide can be decreased when used in combination with Follitropin.
Glipizide,The therapeutic efficacy of Glipizide can be decreased when used in combination with Follitropin.
Gliclazide,The therapeutic efficacy of Gliclazide can be decreased when used in combination with Follitropin.
Tolbutamide,The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Follitropin.
Gliquidone,The therapeutic efficacy of Gliquidone can be decreased when used in combination with Follitropin.
Glisoxepide,The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Follitropin.
Glibornuride,The therapeutic efficacy of Glibornuride can be decreased when used in combination with Follitropin.
Carbutamide,The therapeutic efficacy of Carbutamide can be decreased when used in combination with Follitropin.
Metahexamide,The therapeutic efficacy of Metahexamide can be decreased when used in combination with Follitropin.
Nortriptyline,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Nortriptyline.
Amitriptyline,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Amitriptyline.
Protriptyline,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Protriptyline.
Imipramine,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Imipramine.
Amoxapine,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Amoxapine.
Trimipramine,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Trimipramine.
Doxepin,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Doxepin.
Desipramine,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Desipramine.
Clomipramine,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Clomipramine.
Amineptine,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Amineptine.
Dimetacrine,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Dimetacrine.
Butriptyline,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Butriptyline.
Dosulepin,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Dosulepin.
Tianeptine,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Tianeptine.
Oxaprotiline,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Oxaprotiline.
Opipramol,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Opipramol.
Amitriptylinoxide,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Amitriptylinoxide.
Dibenzepin,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Dibenzepin.
Quinupramine,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Quinupramine.
Melitracen,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Melitracen.
Lofepramine,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Lofepramine.
Iprindole,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Iprindole.
Imipramine oxide,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Imipramine oxide.
Patent Blue,The risk or severity of hypotension can be increased when Patent Blue is combined with Vasopressin.
Carbamazepine,The risk or severity of water intoxication can be increased when Carbamazepine is combined with Vasopressin.
Norepinephrine,The risk or severity of adverse effects can be increased when Norepinephrine is combined with Vasopressin.
Lithium cation,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Lithium cation.
Lithium citrate,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Lithium citrate.
Lithium carbonate,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Lithium carbonate.
Lithium hydroxide,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Lithium hydroxide.
Ardeparin,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Ardeparin.
Heparin,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Heparin.
Enoxaparin,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Enoxaparin.
Sulodexide,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Sulodexide.
Semuloparin,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Semuloparin.
Danaparoid,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Danaparoid.
Dalteparin,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Dalteparin.
Tinzaparin,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Tinzaparin.
Nadroparin,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Nadroparin.
Bemiparin,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Bemiparin.
Reviparin,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Reviparin.
Parnaparin,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Parnaparin.
Certoparin,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Certoparin.
Thyrotropin alfa,Thyrotropin alfa may increase the vasoconstricting activities of Vasopressin.
Liothyronine,Liothyronine may increase the vasoconstricting activities of Vasopressin.
Levothyroxine,Levothyroxine may increase the vasoconstricting activities of Vasopressin.
Liotrix,Liotrix may increase the vasoconstricting activities of Vasopressin.
Tiratricol,Tiratricol may increase the vasoconstricting activities of Vasopressin.
"Thyroid, porcine","Thyroid, porcine may increase the vasoconstricting activities of Vasopressin."
Lidocaine,The risk or severity of hypertension can be increased when Vasopressin is combined with Lidocaine.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon beta-1b.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon beta-1b.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon beta-1b.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon beta-1b.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon beta-1b.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon beta-1b.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon beta-1b.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon beta-1b.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Interferon beta-1b."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Interferon beta-1b.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Interferon beta-1b.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon beta-1b.
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon beta-1b.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon beta-1b.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfacon-1.
Rituximab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Rituximab.
Basiliximab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Basiliximab.
Muromonab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Muromonab.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ibritumomab tiuxetan.
Tositumomab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tositumomab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Alemtuzumab.
Alefacept,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Alefacept.
Efalizumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfa-2b.
Daclizumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Beclomethasone dipropionate.
Sorafenib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sorafenib.
Streptozocin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Altretamine.
Zidovudine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Zidovudine.
Cisplatin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pentostatin.
Methotrexate,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Methotrexate.
Carbamazepine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carbamazepine.
Vinblastine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Linezolid.
Imatinib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Imatinib.
Triamcinolone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Paclitaxel.
Dexamethasone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dexamethasone.
Docetaxel,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Decitabine.
Sunitinib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sunitinib.
Nelarabine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Nelarabine.
Abatacept,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Abatacept.
Corticotropin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with omega interferon.
Apremilast,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Apremilast.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ponatinib.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Certolizumab pegol.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Blinatumomab.
Ibrutinib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ibrutinib.
Idelalisib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Idelalisib.
Palbociclib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Palbociclib.
Olaparib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Olaparib.
Dinutuximab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dinutuximab.
Vilanterol,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vilanterol.
Tixocortol,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Antilymphocyte immunoglobulin (horse).
Fluprednisolone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Meprednisone.
Tepoxalin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tepoxalin.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Melengestrol.
Ixekizumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Peficitinib.
Clobetasol,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Clobetasol.
Sarilumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sirukumab.
Baricitinib,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Baricitinib.
Guselkumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Guselkumab.
Deflazacort,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Deflazacort.
Ocrelizumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ocrelizumab.
Triptolide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Triptolide.
Siponimod,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Siponimod.
Ozanimod,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Prednylidene,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Prednylidene.
Fluocortin,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluclorolone.
Fluticasone,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluticasone.
Tetrandrine,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tetrandrine.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Monomethyl fumarate.
Mometasone furoate,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mometasone furoate.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydrocortisone aceponate.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydrocortisone acetate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydrocortisone succinate.
Emapalumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bleselumab.
Natalizumab,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon beta-1b.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Interferon beta-1b.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Interferon beta-1b.
Clozapine,The risk or severity of neutropenia can be increased when Interferon beta-1b is combined with Clozapine.
Zolmitriptan,The metabolism of Zolmitriptan can be decreased when combined with Interferon beta-1b.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon beta-1b.
Leflunomide,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Leflunomide.
Tofacitinib,Interferon beta-1b may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Interferon beta-1b.
Fingolimod,Interferon beta-1b may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Interferon beta-1b.
Caffeine,The metabolism of Caffeine can be decreased when combined with Interferon beta-1b.
Dyphylline,The metabolism of Dyphylline can be decreased when combined with Interferon beta-1b.
Pentoxifylline,The metabolism of Pentoxifylline can be decreased when combined with Interferon beta-1b.
Oxtriphylline,The metabolism of Oxtriphylline can be decreased when combined with Interferon beta-1b.
Theobromine,The metabolism of Theobromine can be decreased when combined with Interferon beta-1b.
Fenethylline,The metabolism of Fenethylline can be decreased when combined with Interferon beta-1b.
8-azaguanine,The metabolism of 8-azaguanine can be decreased when combined with Interferon beta-1b.
"7,9-Dimethylguanine","The metabolism of 7,9-Dimethylguanine can be decreased when combined with Interferon beta-1b."
Xanthine,The metabolism of Xanthine can be decreased when combined with Interferon beta-1b.
7-Deazaguanine,The metabolism of 7-Deazaguanine can be decreased when combined with Interferon beta-1b.
Guanine,The metabolism of Guanine can be decreased when combined with Interferon beta-1b.
9-Methylguanine,The metabolism of 9-Methylguanine can be decreased when combined with Interferon beta-1b.
Peldesine,The metabolism of Peldesine can be decreased when combined with Interferon beta-1b.
Hypoxanthine,The metabolism of Hypoxanthine can be decreased when combined with Interferon beta-1b.
9-Deazaguanine,The metabolism of 9-Deazaguanine can be decreased when combined with Interferon beta-1b.
Propentofylline,The metabolism of Propentofylline can be decreased when combined with Interferon beta-1b.
Valomaciclovir,The metabolism of Valomaciclovir can be decreased when combined with Interferon beta-1b.
3-isobutyl-1-methyl-7H-xanthine,The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Interferon beta-1b.
Uric acid,The metabolism of Uric acid can be decreased when combined with Interferon beta-1b.
Doxofylline,The metabolism of Doxofylline can be decreased when combined with Interferon beta-1b.
6-O-benzylguanine,The metabolism of 6-O-benzylguanine can be decreased when combined with Interferon beta-1b.
Lisofylline,The metabolism of Lisofylline can be decreased when combined with Interferon beta-1b.
Lobucavir,The metabolism of Lobucavir can be decreased when combined with Interferon beta-1b.
Cafedrine,The metabolism of Cafedrine can be decreased when combined with Interferon beta-1b.
Theodrenaline,The metabolism of Theodrenaline can be decreased when combined with Interferon beta-1b.
Bamifylline,The metabolism of Bamifylline can be decreased when combined with Interferon beta-1b.
Proxyphylline,The metabolism of Proxyphylline can be decreased when combined with Interferon beta-1b.
Acefylline,The metabolism of Acefylline can be decreased when combined with Interferon beta-1b.
Etamiphylline,The metabolism of Etamiphylline can be decreased when combined with Interferon beta-1b.
Pentifylline,The metabolism of Pentifylline can be decreased when combined with Interferon beta-1b.
Bufylline,The metabolism of Bufylline can be decreased when combined with Interferon beta-1b.
Bromotheophylline,The metabolism of Bromotheophylline can be decreased when combined with Interferon beta-1b.
Furafylline,The metabolism of Furafylline can be decreased when combined with Interferon beta-1b.
8-chlorotheophylline,The metabolism of 8-chlorotheophylline can be decreased when combined with Interferon beta-1b.
PCS-499,The metabolism of PCS-499 can be decreased when combined with Interferon beta-1b.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Interferon beta-1b.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Interferon beta-1b.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Interferon beta-1b.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Interferon beta-1b.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Interferon beta-1b.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon beta-1b.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Interferon beta-1b.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Interferon beta-1b.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon beta-1b.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Interferon beta-1b."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon beta-1b.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Interferon beta-1b.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Interferon beta-1b."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Interferon beta-1b.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Interferon beta-1b.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon beta-1b.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon beta-1b.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon beta-1b.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Interferon beta-1b.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Interferon beta-1b.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Interferon beta-1b.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Interferon beta-1b.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Interferon beta-1b.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Interferon beta-1b.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Interferon beta-1b.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Interferon beta-1b.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Interferon beta-1b.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Interferon beta-1b."
Abciximab,The risk or severity of bleeding can be increased when Abciximab is combined with Interferon beta-1b.
Eptifibatide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon beta-1b.
Ticlopidine,The risk or severity of bleeding can be increased when Ticlopidine is combined with Interferon beta-1b.
Tirofiban,The risk or severity of bleeding can be increased when Tirofiban is combined with Interferon beta-1b.
Acetylsalicylic acid,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon beta-1b.
Dipyridamole,The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon beta-1b.
Iloprost,The risk or severity of bleeding can be increased when Iloprost is combined with Interferon beta-1b.
Sulfinpyrazone,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon beta-1b.
Ridogrel,The risk or severity of bleeding can be increased when Ridogrel is combined with Interferon beta-1b.
Sevoflurane,The risk or severity of bleeding can be increased when Sevoflurane is combined with Interferon beta-1b.
Epoprostenol,The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon beta-1b.
Nimesulide,The risk or severity of bleeding can be increased when Nimesulide is combined with Interferon beta-1b.
Tesmilifene,The risk or severity of bleeding can be increased when Tesmilifene is combined with Interferon beta-1b.
Defibrotide,The risk or severity of bleeding can be increased when Defibrotide is combined with Interferon beta-1b.
Beraprost,The risk or severity of bleeding can be increased when Beraprost is combined with Interferon beta-1b.
Ibudilast,The risk or severity of bleeding can be increased when Ibudilast is combined with Interferon beta-1b.
Andrographolide,The risk or severity of bleeding can be increased when Andrographolide is combined with Interferon beta-1b.
Caplacizumab,The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon beta-1b.
Prasugrel,The risk or severity of bleeding can be increased when Prasugrel is combined with Interferon beta-1b.
Cangrelor,The risk or severity of bleeding can be increased when Cangrelor is combined with Interferon beta-1b.
Tranilast,The risk or severity of bleeding can be increased when Tranilast is combined with Interferon beta-1b.
Triflusal,The risk or severity of bleeding can be increased when Triflusal is combined with Interferon beta-1b.
Ticagrelor,The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon beta-1b.
Icosapent ethyl,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Interferon beta-1b.
Vorapaxar,The risk or severity of bleeding can be increased when Vorapaxar is combined with Interferon beta-1b.
Trapidil,The risk or severity of bleeding can be increased when Trapidil is combined with Interferon beta-1b.
Naftopidil,The risk or severity of bleeding can be increased when Naftopidil is combined with Interferon beta-1b.
Sarpogrelate,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Interferon beta-1b.
Ifetroban,The risk or severity of bleeding can be increased when Ifetroban is combined with Interferon beta-1b.
Nitroaspirin,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Interferon beta-1b.
Ketanserin,The risk or severity of bleeding can be increased when Ketanserin is combined with Interferon beta-1b.
Indobufen,The risk or severity of bleeding can be increased when Indobufen is combined with Interferon beta-1b.
Butylphthalide,The risk or severity of bleeding can be increased when Butylphthalide is combined with Interferon beta-1b.
Hydroxytyrosol,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Interferon beta-1b.
Ramatroban,The risk or severity of bleeding can be increased when Ramatroban is combined with Interferon beta-1b.
Picotamide,The risk or severity of bleeding can be increased when Picotamide is combined with Interferon beta-1b.
Cloricromen,The risk or severity of bleeding can be increased when Cloricromen is combined with Interferon beta-1b.
Linsidomine,The risk or severity of bleeding can be increased when Linsidomine is combined with Interferon beta-1b.
Buflomedil,The risk or severity of bleeding can be increased when Buflomedil is combined with Interferon beta-1b.
Relcovaptan,The risk or severity of bleeding can be increased when Relcovaptan is combined with Interferon beta-1b.
Lipegfilgrastim,Interferon beta-1b may increase the myelosuppressive activities of Lipegfilgrastim.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon beta-1b.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Interferon beta-1b.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Interferon beta-1b.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Interferon beta-1b.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Interferon beta-1b.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Interferon beta-1b.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Interferon beta-1b.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Interferon beta-1b.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Interferon beta-1b.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Interferon beta-1b.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Interferon beta-1b.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Interferon beta-1b.
Palifermin,The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon beta-1b.
Fluvoxamine,The metabolism of Fluvoxamine can be decreased when combined with Interferon beta-1b.
Nicotine,The metabolism of Nicotine can be decreased when combined with Interferon beta-1b.
Betaxolol,The metabolism of Betaxolol can be decreased when combined with Interferon beta-1b.
Anagrelide,The metabolism of Anagrelide can be decreased when combined with Interferon beta-1b.
Disopyramide,The metabolism of Disopyramide can be decreased when combined with Interferon beta-1b.
Lidocaine,The metabolism of Lidocaine can be decreased when combined with Interferon beta-1b.
Conjugated estrogens,The metabolism of Conjugated estrogens can be decreased when combined with Interferon beta-1b.
Ropivacaine,The metabolism of Ropivacaine can be decreased when combined with Interferon beta-1b.
Acetaminophen,The metabolism of Acetaminophen can be decreased when combined with Interferon beta-1b.
Olanzapine,The metabolism of Olanzapine can be decreased when combined with Interferon beta-1b.
Chlorzoxazone,The metabolism of Chlorzoxazone can be decreased when combined with Interferon beta-1b.
Grepafloxacin,The metabolism of Grepafloxacin can be decreased when combined with Interferon beta-1b.
Mirtazapine,The metabolism of Mirtazapine can be decreased when combined with Interferon beta-1b.
Mexiletine,The metabolism of Mexiletine can be decreased when combined with Interferon beta-1b.
Tacrine,The metabolism of Tacrine can be decreased when combined with Interferon beta-1b.
Triamterene,The metabolism of Triamterene can be decreased when combined with Interferon beta-1b.
Promazine,The metabolism of Promazine can be decreased when combined with Interferon beta-1b.
Zolpidem,The metabolism of Zolpidem can be decreased when combined with Interferon beta-1b.
Entecavir,The metabolism of Entecavir can be decreased when combined with Interferon beta-1b.
Nabumetone,The metabolism of Nabumetone can be decreased when combined with Interferon beta-1b.
Quinine,The metabolism of Quinine can be decreased when combined with Interferon beta-1b.
Fluoxetine,The metabolism of Fluoxetine can be decreased when combined with Interferon beta-1b.
Duloxetine,The metabolism of Duloxetine can be decreased when combined with Interferon beta-1b.
Chlorpromazine,The metabolism of Chlorpromazine can be decreased when combined with Interferon beta-1b.
Flutamide,The metabolism of Flutamide can be decreased when combined with Interferon beta-1b.
Haloperidol,The metabolism of Haloperidol can be decreased when combined with Interferon beta-1b.
Albendazole,The metabolism of Albendazole can be decreased when combined with Interferon beta-1b.
Rofecoxib,The metabolism of Rofecoxib can be decreased when combined with Interferon beta-1b.
Cinnarizine,The metabolism of Cinnarizine can be decreased when combined with Interferon beta-1b.
Propranolol,The metabolism of Propranolol can be decreased when combined with Interferon beta-1b.
Diclofenac,The metabolism of Diclofenac can be decreased when combined with Interferon beta-1b.
Guanabenz,The metabolism of Guanabenz can be decreased when combined with Interferon beta-1b.
Verapamil,The metabolism of Verapamil can be decreased when combined with Interferon beta-1b.
Paroxetine,The metabolism of Paroxetine can be decreased when combined with Interferon beta-1b.
Thiabendazole,The metabolism of Thiabendazole can be decreased when combined with Interferon beta-1b.
Riluzole,The metabolism of Riluzole can be decreased when combined with Interferon beta-1b.
Zileuton,The metabolism of Zileuton can be decreased when combined with Interferon beta-1b.
Clopidogrel,The metabolism of Clopidogrel can be decreased when combined with Interferon beta-1b.
Estradiol,The metabolism of Estradiol can be decreased when combined with Interferon beta-1b.
Acyclovir,The metabolism of Acyclovir can be decreased when combined with Interferon beta-1b.
Naproxen,The metabolism of Naproxen can be decreased when combined with Interferon beta-1b.
Trifluoperazine,The metabolism of Trifluoperazine can be decreased when combined with Interferon beta-1b.
Perphenazine,The metabolism of Perphenazine can be decreased when combined with Interferon beta-1b.
Terbinafine,The metabolism of Terbinafine can be decreased when combined with Interferon beta-1b.
Ranitidine,The metabolism of Ranitidine can be decreased when combined with Interferon beta-1b.
Ethanol,The metabolism of Ethanol can be decreased when combined with Interferon beta-1b.
Maprotiline,The metabolism of Maprotiline can be decreased when combined with Interferon beta-1b.
Alosetron,The metabolism of Alosetron can be decreased when combined with Interferon beta-1b.
Lomefloxacin,The metabolism of Lomefloxacin can be decreased when combined with Interferon beta-1b.
Ramelteon,The metabolism of Ramelteon can be decreased when combined with Interferon beta-1b.
Frovatriptan,The metabolism of Frovatriptan can be decreased when combined with Interferon beta-1b.
Levobupivacaine,The metabolism of Levobupivacaine can be decreased when combined with Interferon beta-1b.
Cinacalcet,The metabolism of Cinacalcet can be decreased when combined with Interferon beta-1b.
Selegiline,The metabolism of Selegiline can be decreased when combined with Interferon beta-1b.
Tocainide,The metabolism of Tocainide can be decreased when combined with Interferon beta-1b.
Praziquantel,The metabolism of Praziquantel can be decreased when combined with Interferon beta-1b.
Melatonin,The metabolism of Melatonin can be decreased when combined with Interferon beta-1b.
Primaquine,The metabolism of Primaquine can be decreased when combined with Interferon beta-1b.
Hesperetin,The metabolism of Hesperetin can be decreased when combined with Interferon beta-1b.
Nifedipine,The metabolism of Nifedipine can be decreased when combined with Interferon beta-1b.
Carvedilol,The metabolism of Carvedilol can be decreased when combined with Interferon beta-1b.
Cilostazol,The metabolism of Cilostazol can be decreased when combined with Interferon beta-1b.
Propafenone,The metabolism of Propafenone can be decreased when combined with Interferon beta-1b.
Domperidone,The metabolism of Domperidone can be decreased when combined with Interferon beta-1b.
Dexfenfluramine,The metabolism of Dexfenfluramine can be decreased when combined with Interferon beta-1b.
Rasagiline,The metabolism of Rasagiline can be decreased when combined with Interferon beta-1b.
Temafloxacin,The metabolism of Temafloxacin can be decreased when combined with Interferon beta-1b.
Aminophenazone,The metabolism of Aminophenazone can be decreased when combined with Interferon beta-1b.
Antipyrine,The metabolism of Antipyrine can be decreased when combined with Interferon beta-1b.
Bromazepam,The metabolism of Bromazepam can be decreased when combined with Interferon beta-1b.
Thiothixene,The metabolism of Thiothixene can be decreased when combined with Interferon beta-1b.
Etoricoxib,The metabolism of Etoricoxib can be decreased when combined with Interferon beta-1b.
Genistein,The metabolism of Genistein can be decreased when combined with Interferon beta-1b.
Resveratrol,The metabolism of Resveratrol can be decreased when combined with Interferon beta-1b.
Phenacetin,The metabolism of Phenacetin can be decreased when combined with Interferon beta-1b.
Estrone sulfate,The metabolism of Estrone sulfate can be decreased when combined with Interferon beta-1b.
Flunarizine,The metabolism of Flunarizine can be decreased when combined with Interferon beta-1b.
Lorcaserin,The metabolism of Lorcaserin can be decreased when combined with Interferon beta-1b.
Lofexidine,The metabolism of Lofexidine can be decreased when combined with Interferon beta-1b.
Mianserin,The metabolism of Mianserin can be decreased when combined with Interferon beta-1b.
Eltrombopag,The metabolism of Eltrombopag can be decreased when combined with Interferon beta-1b.
Asenapine,The metabolism of Asenapine can be decreased when combined with Interferon beta-1b.
Vadimezan,The metabolism of Vadimezan can be decreased when combined with Interferon beta-1b.
Dapagliflozin,The metabolism of Dapagliflozin can be decreased when combined with Interferon beta-1b.
Agomelatine,The metabolism of Agomelatine can be decreased when combined with Interferon beta-1b.
Axitinib,The metabolism of Axitinib can be decreased when combined with Interferon beta-1b.
Benzyl alcohol,The metabolism of Benzyl alcohol can be decreased when combined with Interferon beta-1b.
Capsaicin,The metabolism of Capsaicin can be decreased when combined with Interferon beta-1b.
(R)-warfarin,The metabolism of (R)-warfarin can be decreased when combined with Interferon beta-1b.
Perampanel,The metabolism of Perampanel can be decreased when combined with Interferon beta-1b.
Tasimelteon,The metabolism of Tasimelteon can be decreased when combined with Interferon beta-1b.
Stiripentol,The metabolism of Stiripentol can be decreased when combined with Interferon beta-1b.
Zotepine,The metabolism of Zotepine can be decreased when combined with Interferon beta-1b.
Propacetamol,The metabolism of Propacetamol can be decreased when combined with Interferon beta-1b.
Ramosetron,The metabolism of Ramosetron can be decreased when combined with Interferon beta-1b.
Binimetinib,The metabolism of Binimetinib can be decreased when combined with Interferon beta-1b.
Voxilaprevir,The metabolism of Voxilaprevir can be decreased when combined with Interferon beta-1b.
Triclabendazole,The metabolism of Triclabendazole can be decreased when combined with Interferon beta-1b.
Rucaparib,The metabolism of Rucaparib can be decreased when combined with Interferon beta-1b.
Dihydralazine,The metabolism of Dihydralazine can be decreased when combined with Interferon beta-1b.
Estradiol acetate,The metabolism of Estradiol acetate can be decreased when combined with Interferon beta-1b.
Estradiol benzoate,The metabolism of Estradiol benzoate can be decreased when combined with Interferon beta-1b.
Estradiol cypionate,The metabolism of Estradiol cypionate can be decreased when combined with Interferon beta-1b.
Estradiol dienanthate,The metabolism of Estradiol dienanthate can be decreased when combined with Interferon beta-1b.
Estradiol valerate,The metabolism of Estradiol valerate can be decreased when combined with Interferon beta-1b.
Istradefylline,The metabolism of Istradefylline can be decreased when combined with Interferon beta-1b.
Azelastine,The metabolism of Azelastine can be decreased when combined with Interferon beta-1b.
Efavirenz,The metabolism of Efavirenz can be decreased when combined with Interferon beta-1b.
Metoclopramide,The metabolism of Metoclopramide can be decreased when combined with Interferon beta-1b.
Bicifadine,The metabolism of Bicifadine can be decreased when combined with Interferon beta-1b.
GTS-21,The metabolism of GTS-21 can be decreased when combined with Interferon beta-1b.
Flecainide,The metabolism of Flecainide can be decreased when combined with Interferon beta-1b.
Ethinylestradiol,The metabolism of Ethinylestradiol can be decreased when combined with Interferon beta-1b.
Amitriptyline,The metabolism of Amitriptyline can be decreased when combined with Interferon beta-1b.
Imipramine,The metabolism of Imipramine can be decreased when combined with Interferon beta-1b.
Doxepin,The metabolism of Doxepin can be decreased when combined with Interferon beta-1b.
Mephenytoin,The metabolism of Mephenytoin can be decreased when combined with Interferon beta-1b.
Nortriptyline,The metabolism of Nortriptyline can be decreased when combined with Interferon beta-1b.
Clonidine,The metabolism of Clonidine can be decreased when combined with Interferon beta-1b.
Cyclobenzaprine,The metabolism of Cyclobenzaprine can be decreased when combined with Interferon beta-1b.
Desipramine,The metabolism of Desipramine can be decreased when combined with Interferon beta-1b.
Clomipramine,The metabolism of Clomipramine can be decreased when combined with Interferon beta-1b.
Selumetinib,The metabolism of Selumetinib can be decreased when combined with Interferon beta-1b.
Theophylline,The metabolism of Theophylline can be decreased when combined with Interferon beta-1b.
Warfarin,The metabolism of Warfarin can be decreased when combined with Interferon beta-1b.
Tizanidine,The metabolism of Tizanidine can be decreased when combined with Interferon beta-1b.
Pimozide,The metabolism of Pimozide can be decreased when combined with Interferon beta-1b.
Aminophylline,The metabolism of Aminophylline can be decreased when combined with Interferon beta-1b.
Acenocoumarol,The metabolism of Acenocoumarol can be decreased when combined with Interferon beta-1b.
Erlotinib,The metabolism of Erlotinib can be decreased when combined with Interferon beta-1b.
Tegafur,The metabolism of Tegafur can be decreased when combined with Interferon beta-1b.
Enasidenib,The metabolism of Enasidenib can be decreased when combined with Interferon beta-1b.
Tamoxifen,The metabolism of Tamoxifen can be decreased when combined with Interferon beta-1b.
Lepirudin,The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon beta-1b.
Bivalirudin,The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon beta-1b.
Alteplase,The risk or severity of bleeding can be increased when Alteplase is combined with Interferon beta-1b.
Urokinase,The risk or severity of bleeding can be increased when Urokinase is combined with Interferon beta-1b.
Reteplase,The risk or severity of bleeding can be increased when Reteplase is combined with Interferon beta-1b.
Anistreplase,The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon beta-1b.
Tenecteplase,The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon beta-1b.
Drotrecogin alfa,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon beta-1b.
Streptokinase,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon beta-1b.
Dicoumarol,The risk or severity of bleeding can be increased when Dicoumarol is combined with Interferon beta-1b.
Argatroban,The risk or severity of bleeding can be increased when Argatroban is combined with Interferon beta-1b.
Ardeparin,The risk or severity of bleeding can be increased when Ardeparin is combined with Interferon beta-1b.
Phenindione,The risk or severity of bleeding can be increased when Phenindione is combined with Interferon beta-1b.
Fondaparinux,The risk or severity of bleeding can be increased when Fondaparinux is combined with Interferon beta-1b.
Pentosan polysulfate,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Interferon beta-1b.
Phenprocoumon,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Interferon beta-1b.
Heparin,The risk or severity of bleeding can be increased when Heparin is combined with Interferon beta-1b.
Enoxaparin,The risk or severity of bleeding can be increased when Enoxaparin is combined with Interferon beta-1b.
4-hydroxycoumarin,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Interferon beta-1b.
Coumarin,The risk or severity of bleeding can be increased when Coumarin is combined with Interferon beta-1b.
Ximelagatran,The risk or severity of bleeding can be increased when Ximelagatran is combined with Interferon beta-1b.
Desmoteplase,The risk or severity of bleeding can be increased when Desmoteplase is combined with Interferon beta-1b.
Ancrod,The risk or severity of bleeding can be increased when Ancrod is combined with Interferon beta-1b.
Fibrinolysin,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Interferon beta-1b.
Rivaroxaban,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Interferon beta-1b.
Sulodexide,The risk or severity of bleeding can be increased when Sulodexide is combined with Interferon beta-1b.
Semuloparin,The risk or severity of bleeding can be increased when Semuloparin is combined with Interferon beta-1b.
Idraparinux,The risk or severity of bleeding can be increased when Idraparinux is combined with Interferon beta-1b.
Astaxanthin,The risk or severity of bleeding can be increased when Astaxanthin is combined with Interferon beta-1b.
Apixaban,The risk or severity of bleeding can be increased when Apixaban is combined with Interferon beta-1b.
Otamixaban,The risk or severity of bleeding can be increased when Otamixaban is combined with Interferon beta-1b.
Amediplase,The risk or severity of bleeding can be increased when Amediplase is combined with Interferon beta-1b.
Dabigatran etexilate,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon beta-1b.
Danaparoid,The risk or severity of bleeding can be increased when Danaparoid is combined with Interferon beta-1b.
Dalteparin,The risk or severity of bleeding can be increased when Dalteparin is combined with Interferon beta-1b.
Tinzaparin,The risk or severity of bleeding can be increased when Tinzaparin is combined with Interferon beta-1b.
Ferulic acid,The risk or severity of bleeding can be increased when Ferulic acid is combined with Interferon beta-1b.
Ethyl biscoumacetate,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Interferon beta-1b.
Nadroparin,The risk or severity of bleeding can be increased when Nadroparin is combined with Interferon beta-1b.
Ditazole,The risk or severity of bleeding can be increased when Ditazole is combined with Interferon beta-1b.
Edoxaban,The risk or severity of bleeding can be increased when Edoxaban is combined with Interferon beta-1b.
Potassium citrate,The risk or severity of bleeding can be increased when Potassium citrate is combined with Interferon beta-1b.
Sodium citrate,The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon beta-1b.
Dextran,The risk or severity of bleeding can be increased when Dextran is combined with Interferon beta-1b.
Bemiparin,The risk or severity of bleeding can be increased when Bemiparin is combined with Interferon beta-1b.
Reviparin,The risk or severity of bleeding can be increased when Reviparin is combined with Interferon beta-1b.
Parnaparin,The risk or severity of bleeding can be increased when Parnaparin is combined with Interferon beta-1b.
Certoparin,The risk or severity of bleeding can be increased when Certoparin is combined with Interferon beta-1b.
Desirudin,The risk or severity of bleeding can be increased when Desirudin is combined with Interferon beta-1b.
Zinc citrate,The risk or severity of bleeding can be increased when Zinc citrate is combined with Interferon beta-1b.
Antithrombin Alfa,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon beta-1b.
Protein C,The risk or severity of bleeding can be increased when Protein C is combined with Interferon beta-1b.
Antithrombin III human,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon beta-1b.
Letaxaban,The risk or severity of bleeding can be increased when Letaxaban is combined with Interferon beta-1b.
Darexaban,The risk or severity of bleeding can be increased when Darexaban is combined with Interferon beta-1b.
Betrixaban,The risk or severity of bleeding can be increased when Betrixaban is combined with Interferon beta-1b.
Nafamostat,The risk or severity of bleeding can be increased when Nafamostat is combined with Interferon beta-1b.
Monteplase,The risk or severity of bleeding can be increased when Monteplase is combined with Interferon beta-1b.
Gabexate,The risk or severity of bleeding can be increased when Gabexate is combined with Interferon beta-1b.
Fluindione,The risk or severity of bleeding can be increased when Fluindione is combined with Interferon beta-1b.
Protein S human,The risk or severity of bleeding can be increased when Protein S human is combined with Interferon beta-1b.
Brinase,The risk or severity of bleeding can be increased when Brinase is combined with Interferon beta-1b.
Clorindione,The risk or severity of bleeding can be increased when Clorindione is combined with Interferon beta-1b.
Diphenadione,The risk or severity of bleeding can be increased when Diphenadione is combined with Interferon beta-1b.
Tioclomarol,The risk or severity of bleeding can be increased when Tioclomarol is combined with Interferon beta-1b.
Melagatran,The risk or severity of bleeding can be increased when Melagatran is combined with Interferon beta-1b.
Saruplase,The risk or severity of bleeding can be increased when Saruplase is combined with Interferon beta-1b.
(S)-Warfarin,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Interferon beta-1b.
Tocopherylquinone,The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Interferon beta-1b.
Edetate calcium disodium anhydrous,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Interferon beta-1b.
Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon beta-1b.
Methyclothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon beta-1b.
Bendroflumethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon beta-1b.
Benzthiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Interferon beta-1b.
Cyclothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Interferon beta-1b.
Hydroflumethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Interferon beta-1b.
Chlorothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Interferon beta-1b.
Hydrochlorothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Interferon beta-1b.
Trichlormethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Interferon beta-1b.
Polythiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Interferon beta-1b.
Mebutizide,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Interferon beta-1b.
Cyclopenthiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Interferon beta-1b.
Tedizolid phosphate,The risk or severity of myelosuppression can be increased when Interferon beta-1b is combined with Tedizolid phosphate.
Cyclosporine,Interferon beta-1b may increase the immunosuppressive activities of Cyclosporine.
Ropinirole,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ropinirole.
Cyanocobalamin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon beta-1b.
Allopurinol,The risk or severity of adverse effects can be increased when Allopurinol is combined with Interferon beta-1b.
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Interferon beta-1b.
Lopinavir,The serum concentration of Interferon beta-1b can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Interferon beta-1b is combined with Inebilizumab.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon alfacon-1.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfacon-1.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfacon-1.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfacon-1.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon alfacon-1.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon alfacon-1.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfacon-1.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon alfacon-1.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Interferon alfacon-1."
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Interferon alfacon-1.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfacon-1.
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon alfacon-1.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon alfacon-1.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfacon-1.
Rituximab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Rituximab.
Basiliximab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Basiliximab.
Muromonab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Muromonab.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ibritumomab tiuxetan.
Tositumomab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tositumomab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Alemtuzumab.
Alefacept,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Alefacept.
Efalizumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Interferon alfa-2b.
Daclizumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Beclomethasone dipropionate.
Sorafenib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sorafenib.
Streptozocin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Altretamine.
Zidovudine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Zidovudine.
Cisplatin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pentostatin.
Methotrexate,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Methotrexate.
Carbamazepine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carbamazepine.
Vinblastine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Linezolid.
Imatinib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Imatinib.
Triamcinolone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Paclitaxel.
Dexamethasone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dexamethasone.
Docetaxel,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Decitabine.
Sunitinib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sunitinib.
Nelarabine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Nelarabine.
Abatacept,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Abatacept.
Corticotropin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with omega interferon.
Apremilast,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Apremilast.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ponatinib.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Certolizumab pegol.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Blinatumomab.
Ibrutinib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ibrutinib.
Idelalisib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Idelalisib.
Palbociclib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Palbociclib.
Olaparib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Olaparib.
Dinutuximab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dinutuximab.
Vilanterol,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vilanterol.
Tixocortol,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Antilymphocyte immunoglobulin (horse).
Fluprednisolone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Meprednisone.
Tepoxalin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tepoxalin.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Melengestrol.
Ixekizumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Peficitinib.
Clobetasol,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Clobetasol.
Sarilumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sirukumab.
Baricitinib,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Baricitinib.
Guselkumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Guselkumab.
Deflazacort,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Deflazacort.
Ocrelizumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ocrelizumab.
Triptolide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Triptolide.
Siponimod,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Siponimod.
Ozanimod,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Prednylidene,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Prednylidene.
Fluocortin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluclorolone.
Fluticasone,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluticasone.
Tetrandrine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tetrandrine.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Monomethyl fumarate.
Mometasone furoate,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mometasone furoate.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydrocortisone aceponate.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydrocortisone acetate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydrocortisone succinate.
Emapalumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bleselumab.
Natalizumab,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon alfacon-1.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Interferon alfacon-1.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Interferon alfacon-1.
Aldesleukin,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Aldesleukin.
Clozapine,The risk or severity of neutropenia can be increased when Interferon alfacon-1 is combined with Clozapine.
Methadone,The serum concentration of Methadone can be increased when it is combined with Interferon alfacon-1.
Ribavirin,The risk or severity of anemia can be increased when Interferon alfacon-1 is combined with Ribavirin.
Zolmitriptan,The metabolism of Zolmitriptan can be decreased when combined with Interferon alfacon-1.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon alfacon-1.
Telbivudine,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Telbivudine.
Leflunomide,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Leflunomide.
Tofacitinib,Interferon alfacon-1 may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Interferon alfacon-1.
Fingolimod,Interferon alfacon-1 may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Interferon alfacon-1.
Caffeine,The metabolism of Caffeine can be decreased when combined with Interferon alfacon-1.
Dyphylline,The metabolism of Dyphylline can be decreased when combined with Interferon alfacon-1.
Pentoxifylline,The metabolism of Pentoxifylline can be decreased when combined with Interferon alfacon-1.
Oxtriphylline,The metabolism of Oxtriphylline can be decreased when combined with Interferon alfacon-1.
Theobromine,The metabolism of Theobromine can be decreased when combined with Interferon alfacon-1.
Fenethylline,The metabolism of Fenethylline can be decreased when combined with Interferon alfacon-1.
8-azaguanine,The metabolism of 8-azaguanine can be decreased when combined with Interferon alfacon-1.
"7,9-Dimethylguanine","The metabolism of 7,9-Dimethylguanine can be decreased when combined with Interferon alfacon-1."
Xanthine,The metabolism of Xanthine can be decreased when combined with Interferon alfacon-1.
7-Deazaguanine,The metabolism of 7-Deazaguanine can be decreased when combined with Interferon alfacon-1.
Guanine,The metabolism of Guanine can be decreased when combined with Interferon alfacon-1.
9-Methylguanine,The metabolism of 9-Methylguanine can be decreased when combined with Interferon alfacon-1.
Peldesine,The metabolism of Peldesine can be decreased when combined with Interferon alfacon-1.
Hypoxanthine,The metabolism of Hypoxanthine can be decreased when combined with Interferon alfacon-1.
9-Deazaguanine,The metabolism of 9-Deazaguanine can be decreased when combined with Interferon alfacon-1.
Propentofylline,The metabolism of Propentofylline can be decreased when combined with Interferon alfacon-1.
Valomaciclovir,The metabolism of Valomaciclovir can be decreased when combined with Interferon alfacon-1.
3-isobutyl-1-methyl-7H-xanthine,The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Interferon alfacon-1.
Uric acid,The metabolism of Uric acid can be decreased when combined with Interferon alfacon-1.
Doxofylline,The metabolism of Doxofylline can be decreased when combined with Interferon alfacon-1.
6-O-benzylguanine,The metabolism of 6-O-benzylguanine can be decreased when combined with Interferon alfacon-1.
Lisofylline,The metabolism of Lisofylline can be decreased when combined with Interferon alfacon-1.
Lobucavir,The metabolism of Lobucavir can be decreased when combined with Interferon alfacon-1.
Cafedrine,The metabolism of Cafedrine can be decreased when combined with Interferon alfacon-1.
Theodrenaline,The metabolism of Theodrenaline can be decreased when combined with Interferon alfacon-1.
Bamifylline,The metabolism of Bamifylline can be decreased when combined with Interferon alfacon-1.
Proxyphylline,The metabolism of Proxyphylline can be decreased when combined with Interferon alfacon-1.
Acefylline,The metabolism of Acefylline can be decreased when combined with Interferon alfacon-1.
Etamiphylline,The metabolism of Etamiphylline can be decreased when combined with Interferon alfacon-1.
Pentifylline,The metabolism of Pentifylline can be decreased when combined with Interferon alfacon-1.
Bufylline,The metabolism of Bufylline can be decreased when combined with Interferon alfacon-1.
Bromotheophylline,The metabolism of Bromotheophylline can be decreased when combined with Interferon alfacon-1.
Furafylline,The metabolism of Furafylline can be decreased when combined with Interferon alfacon-1.
8-chlorotheophylline,The metabolism of 8-chlorotheophylline can be decreased when combined with Interferon alfacon-1.
PCS-499,The metabolism of PCS-499 can be decreased when combined with Interferon alfacon-1.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Interferon alfacon-1.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Interferon alfacon-1.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Interferon alfacon-1.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Interferon alfacon-1.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Interferon alfacon-1.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon alfacon-1.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Interferon alfacon-1.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Interferon alfacon-1.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon alfacon-1.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Interferon alfacon-1."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfacon-1.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Interferon alfacon-1.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Interferon alfacon-1."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Interferon alfacon-1.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Interferon alfacon-1.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfacon-1.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfacon-1.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon alfacon-1.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Interferon alfacon-1.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Interferon alfacon-1.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Interferon alfacon-1.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Interferon alfacon-1.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Interferon alfacon-1.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Interferon alfacon-1.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Interferon alfacon-1.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Interferon alfacon-1.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Interferon alfacon-1.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Interferon alfacon-1."
Abciximab,The risk or severity of bleeding can be increased when Abciximab is combined with Interferon alfacon-1.
Eptifibatide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfacon-1.
Ticlopidine,The risk or severity of bleeding can be increased when Ticlopidine is combined with Interferon alfacon-1.
Tirofiban,The risk or severity of bleeding can be increased when Tirofiban is combined with Interferon alfacon-1.
Acetylsalicylic acid,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon alfacon-1.
Dipyridamole,The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon alfacon-1.
Iloprost,The risk or severity of bleeding can be increased when Iloprost is combined with Interferon alfacon-1.
Sulfinpyrazone,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon alfacon-1.
Ridogrel,The risk or severity of bleeding can be increased when Ridogrel is combined with Interferon alfacon-1.
Sevoflurane,The risk or severity of bleeding can be increased when Sevoflurane is combined with Interferon alfacon-1.
Epoprostenol,The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon alfacon-1.
Nimesulide,The risk or severity of bleeding can be increased when Nimesulide is combined with Interferon alfacon-1.
Tesmilifene,The risk or severity of bleeding can be increased when Tesmilifene is combined with Interferon alfacon-1.
Defibrotide,The risk or severity of bleeding can be increased when Defibrotide is combined with Interferon alfacon-1.
Beraprost,The risk or severity of bleeding can be increased when Beraprost is combined with Interferon alfacon-1.
Ibudilast,The risk or severity of bleeding can be increased when Ibudilast is combined with Interferon alfacon-1.
Andrographolide,The risk or severity of bleeding can be increased when Andrographolide is combined with Interferon alfacon-1.
Caplacizumab,The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfacon-1.
Prasugrel,The risk or severity of bleeding can be increased when Prasugrel is combined with Interferon alfacon-1.
Cangrelor,The risk or severity of bleeding can be increased when Cangrelor is combined with Interferon alfacon-1.
Tranilast,The risk or severity of bleeding can be increased when Tranilast is combined with Interferon alfacon-1.
Triflusal,The risk or severity of bleeding can be increased when Triflusal is combined with Interferon alfacon-1.
Ticagrelor,The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon alfacon-1.
Icosapent ethyl,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Interferon alfacon-1.
Vorapaxar,The risk or severity of bleeding can be increased when Vorapaxar is combined with Interferon alfacon-1.
Trapidil,The risk or severity of bleeding can be increased when Trapidil is combined with Interferon alfacon-1.
Naftopidil,The risk or severity of bleeding can be increased when Naftopidil is combined with Interferon alfacon-1.
Sarpogrelate,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Interferon alfacon-1.
Ifetroban,The risk or severity of bleeding can be increased when Ifetroban is combined with Interferon alfacon-1.
Nitroaspirin,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Interferon alfacon-1.
Ketanserin,The risk or severity of bleeding can be increased when Ketanserin is combined with Interferon alfacon-1.
Indobufen,The risk or severity of bleeding can be increased when Indobufen is combined with Interferon alfacon-1.
Butylphthalide,The risk or severity of bleeding can be increased when Butylphthalide is combined with Interferon alfacon-1.
Hydroxytyrosol,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Interferon alfacon-1.
Ramatroban,The risk or severity of bleeding can be increased when Ramatroban is combined with Interferon alfacon-1.
Picotamide,The risk or severity of bleeding can be increased when Picotamide is combined with Interferon alfacon-1.
Cloricromen,The risk or severity of bleeding can be increased when Cloricromen is combined with Interferon alfacon-1.
Linsidomine,The risk or severity of bleeding can be increased when Linsidomine is combined with Interferon alfacon-1.
Buflomedil,The risk or severity of bleeding can be increased when Buflomedil is combined with Interferon alfacon-1.
Relcovaptan,The risk or severity of bleeding can be increased when Relcovaptan is combined with Interferon alfacon-1.
Lipegfilgrastim,Interferon alfacon-1 may increase the myelosuppressive activities of Lipegfilgrastim.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Interferon alfacon-1 is combined with Varicella Zoster Vaccine (Live/attenuated).
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon alfacon-1.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Interferon alfacon-1.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Interferon alfacon-1.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Interferon alfacon-1.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Interferon alfacon-1.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Interferon alfacon-1.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Interferon alfacon-1.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Interferon alfacon-1.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Interferon alfacon-1.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Interferon alfacon-1.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Interferon alfacon-1.
Palifermin,The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfacon-1.
Fluvoxamine,The metabolism of Fluvoxamine can be decreased when combined with Interferon alfacon-1.
Nicotine,The metabolism of Nicotine can be decreased when combined with Interferon alfacon-1.
Betaxolol,The metabolism of Betaxolol can be decreased when combined with Interferon alfacon-1.
Anagrelide,The metabolism of Anagrelide can be decreased when combined with Interferon alfacon-1.
Disopyramide,The metabolism of Disopyramide can be decreased when combined with Interferon alfacon-1.
Lidocaine,The metabolism of Lidocaine can be decreased when combined with Interferon alfacon-1.
Conjugated estrogens,The metabolism of Conjugated estrogens can be decreased when combined with Interferon alfacon-1.
Ropivacaine,The metabolism of Ropivacaine can be decreased when combined with Interferon alfacon-1.
Acetaminophen,The metabolism of Acetaminophen can be decreased when combined with Interferon alfacon-1.
Olanzapine,The metabolism of Olanzapine can be decreased when combined with Interferon alfacon-1.
Chlorzoxazone,The metabolism of Chlorzoxazone can be decreased when combined with Interferon alfacon-1.
Grepafloxacin,The metabolism of Grepafloxacin can be decreased when combined with Interferon alfacon-1.
Mirtazapine,The metabolism of Mirtazapine can be decreased when combined with Interferon alfacon-1.
Mexiletine,The metabolism of Mexiletine can be decreased when combined with Interferon alfacon-1.
Tacrine,The metabolism of Tacrine can be decreased when combined with Interferon alfacon-1.
Triamterene,The metabolism of Triamterene can be decreased when combined with Interferon alfacon-1.
Promazine,The metabolism of Promazine can be decreased when combined with Interferon alfacon-1.
Zolpidem,The metabolism of Zolpidem can be decreased when combined with Interferon alfacon-1.
Entecavir,The metabolism of Entecavir can be decreased when combined with Interferon alfacon-1.
Nabumetone,The metabolism of Nabumetone can be decreased when combined with Interferon alfacon-1.
Quinine,The metabolism of Quinine can be decreased when combined with Interferon alfacon-1.
Fluoxetine,The metabolism of Fluoxetine can be decreased when combined with Interferon alfacon-1.
Duloxetine,The metabolism of Duloxetine can be decreased when combined with Interferon alfacon-1.
Chlorpromazine,The metabolism of Chlorpromazine can be decreased when combined with Interferon alfacon-1.
Flutamide,The metabolism of Flutamide can be decreased when combined with Interferon alfacon-1.
Haloperidol,The metabolism of Haloperidol can be decreased when combined with Interferon alfacon-1.
Albendazole,The metabolism of Albendazole can be decreased when combined with Interferon alfacon-1.
Rofecoxib,The metabolism of Rofecoxib can be decreased when combined with Interferon alfacon-1.
Cinnarizine,The metabolism of Cinnarizine can be decreased when combined with Interferon alfacon-1.
Propranolol,The metabolism of Propranolol can be decreased when combined with Interferon alfacon-1.
Diclofenac,The metabolism of Diclofenac can be decreased when combined with Interferon alfacon-1.
Guanabenz,The metabolism of Guanabenz can be decreased when combined with Interferon alfacon-1.
Verapamil,The metabolism of Verapamil can be decreased when combined with Interferon alfacon-1.
Paroxetine,The metabolism of Paroxetine can be decreased when combined with Interferon alfacon-1.
Thiabendazole,The metabolism of Thiabendazole can be decreased when combined with Interferon alfacon-1.
Riluzole,The metabolism of Riluzole can be decreased when combined with Interferon alfacon-1.
Zileuton,The metabolism of Zileuton can be decreased when combined with Interferon alfacon-1.
Clopidogrel,The metabolism of Clopidogrel can be decreased when combined with Interferon alfacon-1.
Estradiol,The metabolism of Estradiol can be decreased when combined with Interferon alfacon-1.
Acyclovir,The metabolism of Acyclovir can be decreased when combined with Interferon alfacon-1.
Naproxen,The metabolism of Naproxen can be decreased when combined with Interferon alfacon-1.
Trifluoperazine,The metabolism of Trifluoperazine can be decreased when combined with Interferon alfacon-1.
Perphenazine,The metabolism of Perphenazine can be decreased when combined with Interferon alfacon-1.
Terbinafine,The metabolism of Terbinafine can be decreased when combined with Interferon alfacon-1.
Ranitidine,The metabolism of Ranitidine can be decreased when combined with Interferon alfacon-1.
Ethanol,The metabolism of Ethanol can be decreased when combined with Interferon alfacon-1.
Maprotiline,The metabolism of Maprotiline can be decreased when combined with Interferon alfacon-1.
Alosetron,The metabolism of Alosetron can be decreased when combined with Interferon alfacon-1.
Lomefloxacin,The metabolism of Lomefloxacin can be decreased when combined with Interferon alfacon-1.
Ramelteon,The metabolism of Ramelteon can be decreased when combined with Interferon alfacon-1.
Frovatriptan,The metabolism of Frovatriptan can be decreased when combined with Interferon alfacon-1.
Levobupivacaine,The metabolism of Levobupivacaine can be decreased when combined with Interferon alfacon-1.
Cinacalcet,The metabolism of Cinacalcet can be decreased when combined with Interferon alfacon-1.
Selegiline,The metabolism of Selegiline can be decreased when combined with Interferon alfacon-1.
Tocainide,The metabolism of Tocainide can be decreased when combined with Interferon alfacon-1.
Praziquantel,The metabolism of Praziquantel can be decreased when combined with Interferon alfacon-1.
Melatonin,The metabolism of Melatonin can be decreased when combined with Interferon alfacon-1.
Primaquine,The metabolism of Primaquine can be decreased when combined with Interferon alfacon-1.
Hesperetin,The metabolism of Hesperetin can be decreased when combined with Interferon alfacon-1.
Nifedipine,The metabolism of Nifedipine can be decreased when combined with Interferon alfacon-1.
Carvedilol,The metabolism of Carvedilol can be decreased when combined with Interferon alfacon-1.
Cilostazol,The metabolism of Cilostazol can be decreased when combined with Interferon alfacon-1.
Propafenone,The metabolism of Propafenone can be decreased when combined with Interferon alfacon-1.
Domperidone,The metabolism of Domperidone can be decreased when combined with Interferon alfacon-1.
Dexfenfluramine,The metabolism of Dexfenfluramine can be decreased when combined with Interferon alfacon-1.
Rasagiline,The metabolism of Rasagiline can be decreased when combined with Interferon alfacon-1.
Temafloxacin,The metabolism of Temafloxacin can be decreased when combined with Interferon alfacon-1.
Aminophenazone,The metabolism of Aminophenazone can be decreased when combined with Interferon alfacon-1.
Antipyrine,The metabolism of Antipyrine can be decreased when combined with Interferon alfacon-1.
Bromazepam,The metabolism of Bromazepam can be decreased when combined with Interferon alfacon-1.
Thiothixene,The metabolism of Thiothixene can be decreased when combined with Interferon alfacon-1.
Etoricoxib,The metabolism of Etoricoxib can be decreased when combined with Interferon alfacon-1.
Genistein,The metabolism of Genistein can be decreased when combined with Interferon alfacon-1.
Resveratrol,The metabolism of Resveratrol can be decreased when combined with Interferon alfacon-1.
Phenacetin,The metabolism of Phenacetin can be decreased when combined with Interferon alfacon-1.
Estrone sulfate,The metabolism of Estrone sulfate can be decreased when combined with Interferon alfacon-1.
Flunarizine,The metabolism of Flunarizine can be decreased when combined with Interferon alfacon-1.
Lorcaserin,The metabolism of Lorcaserin can be decreased when combined with Interferon alfacon-1.
Lofexidine,The metabolism of Lofexidine can be decreased when combined with Interferon alfacon-1.
Mianserin,The metabolism of Mianserin can be decreased when combined with Interferon alfacon-1.
Eltrombopag,The metabolism of Eltrombopag can be decreased when combined with Interferon alfacon-1.
Asenapine,The metabolism of Asenapine can be decreased when combined with Interferon alfacon-1.
Vadimezan,The metabolism of Vadimezan can be decreased when combined with Interferon alfacon-1.
Dapagliflozin,The metabolism of Dapagliflozin can be decreased when combined with Interferon alfacon-1.
Agomelatine,The metabolism of Agomelatine can be decreased when combined with Interferon alfacon-1.
Axitinib,The metabolism of Axitinib can be decreased when combined with Interferon alfacon-1.
Benzyl alcohol,The metabolism of Benzyl alcohol can be decreased when combined with Interferon alfacon-1.
Capsaicin,The metabolism of Capsaicin can be decreased when combined with Interferon alfacon-1.
(R)-warfarin,The metabolism of (R)-warfarin can be decreased when combined with Interferon alfacon-1.
Perampanel,The metabolism of Perampanel can be decreased when combined with Interferon alfacon-1.
Tasimelteon,The metabolism of Tasimelteon can be decreased when combined with Interferon alfacon-1.
Stiripentol,The metabolism of Stiripentol can be decreased when combined with Interferon alfacon-1.
Zotepine,The metabolism of Zotepine can be decreased when combined with Interferon alfacon-1.
Propacetamol,The metabolism of Propacetamol can be decreased when combined with Interferon alfacon-1.
Ramosetron,The metabolism of Ramosetron can be decreased when combined with Interferon alfacon-1.
Binimetinib,The metabolism of Binimetinib can be decreased when combined with Interferon alfacon-1.
Voxilaprevir,The metabolism of Voxilaprevir can be decreased when combined with Interferon alfacon-1.
Triclabendazole,The metabolism of Triclabendazole can be decreased when combined with Interferon alfacon-1.
Rucaparib,The metabolism of Rucaparib can be decreased when combined with Interferon alfacon-1.
Dihydralazine,The metabolism of Dihydralazine can be decreased when combined with Interferon alfacon-1.
Estradiol acetate,The metabolism of Estradiol acetate can be decreased when combined with Interferon alfacon-1.
Estradiol benzoate,The metabolism of Estradiol benzoate can be decreased when combined with Interferon alfacon-1.
Estradiol cypionate,The metabolism of Estradiol cypionate can be decreased when combined with Interferon alfacon-1.
Estradiol dienanthate,The metabolism of Estradiol dienanthate can be decreased when combined with Interferon alfacon-1.
Estradiol valerate,The metabolism of Estradiol valerate can be decreased when combined with Interferon alfacon-1.
Istradefylline,The metabolism of Istradefylline can be decreased when combined with Interferon alfacon-1.
Azelastine,The metabolism of Azelastine can be decreased when combined with Interferon alfacon-1.
Efavirenz,The metabolism of Efavirenz can be decreased when combined with Interferon alfacon-1.
Metoclopramide,The metabolism of Metoclopramide can be decreased when combined with Interferon alfacon-1.
Bicifadine,The metabolism of Bicifadine can be decreased when combined with Interferon alfacon-1.
GTS-21,The metabolism of GTS-21 can be decreased when combined with Interferon alfacon-1.
Flecainide,The metabolism of Flecainide can be decreased when combined with Interferon alfacon-1.
Ethinylestradiol,The metabolism of Ethinylestradiol can be decreased when combined with Interferon alfacon-1.
Amitriptyline,The metabolism of Amitriptyline can be decreased when combined with Interferon alfacon-1.
Imipramine,The metabolism of Imipramine can be decreased when combined with Interferon alfacon-1.
Doxepin,The metabolism of Doxepin can be decreased when combined with Interferon alfacon-1.
Mephenytoin,The metabolism of Mephenytoin can be decreased when combined with Interferon alfacon-1.
Nortriptyline,The metabolism of Nortriptyline can be decreased when combined with Interferon alfacon-1.
Clonidine,The metabolism of Clonidine can be decreased when combined with Interferon alfacon-1.
Cyclobenzaprine,The metabolism of Cyclobenzaprine can be decreased when combined with Interferon alfacon-1.
Desipramine,The metabolism of Desipramine can be decreased when combined with Interferon alfacon-1.
Clomipramine,The metabolism of Clomipramine can be decreased when combined with Interferon alfacon-1.
Selumetinib,The metabolism of Selumetinib can be decreased when combined with Interferon alfacon-1.
Theophylline,The metabolism of Theophylline can be decreased when combined with Interferon alfacon-1.
Warfarin,The metabolism of Warfarin can be decreased when combined with Interferon alfacon-1.
Tizanidine,The metabolism of Tizanidine can be decreased when combined with Interferon alfacon-1.
Pimozide,The metabolism of Pimozide can be decreased when combined with Interferon alfacon-1.
Aminophylline,The metabolism of Aminophylline can be decreased when combined with Interferon alfacon-1.
Acenocoumarol,The metabolism of Acenocoumarol can be decreased when combined with Interferon alfacon-1.
Erlotinib,The metabolism of Erlotinib can be decreased when combined with Interferon alfacon-1.
Tegafur,The metabolism of Tegafur can be decreased when combined with Interferon alfacon-1.
Enasidenib,The metabolism of Enasidenib can be decreased when combined with Interferon alfacon-1.
Tamoxifen,The metabolism of Tamoxifen can be decreased when combined with Interferon alfacon-1.
Lepirudin,The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfacon-1.
Bivalirudin,The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon alfacon-1.
Alteplase,The risk or severity of bleeding can be increased when Alteplase is combined with Interferon alfacon-1.
Urokinase,The risk or severity of bleeding can be increased when Urokinase is combined with Interferon alfacon-1.
Reteplase,The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfacon-1.
Anistreplase,The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon alfacon-1.
Tenecteplase,The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon alfacon-1.
Drotrecogin alfa,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfacon-1.
Streptokinase,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfacon-1.
Dicoumarol,The risk or severity of bleeding can be increased when Dicoumarol is combined with Interferon alfacon-1.
Argatroban,The risk or severity of bleeding can be increased when Argatroban is combined with Interferon alfacon-1.
Ardeparin,The risk or severity of bleeding can be increased when Ardeparin is combined with Interferon alfacon-1.
Phenindione,The risk or severity of bleeding can be increased when Phenindione is combined with Interferon alfacon-1.
Fondaparinux,The risk or severity of bleeding can be increased when Fondaparinux is combined with Interferon alfacon-1.
Pentosan polysulfate,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Interferon alfacon-1.
Phenprocoumon,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Interferon alfacon-1.
Heparin,The risk or severity of bleeding can be increased when Heparin is combined with Interferon alfacon-1.
Enoxaparin,The risk or severity of bleeding can be increased when Enoxaparin is combined with Interferon alfacon-1.
4-hydroxycoumarin,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Interferon alfacon-1.
Coumarin,The risk or severity of bleeding can be increased when Coumarin is combined with Interferon alfacon-1.
Ximelagatran,The risk or severity of bleeding can be increased when Ximelagatran is combined with Interferon alfacon-1.
Desmoteplase,The risk or severity of bleeding can be increased when Desmoteplase is combined with Interferon alfacon-1.
Ancrod,The risk or severity of bleeding can be increased when Ancrod is combined with Interferon alfacon-1.
Fibrinolysin,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Interferon alfacon-1.
Rivaroxaban,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Interferon alfacon-1.
Sulodexide,The risk or severity of bleeding can be increased when Sulodexide is combined with Interferon alfacon-1.
Semuloparin,The risk or severity of bleeding can be increased when Semuloparin is combined with Interferon alfacon-1.
Idraparinux,The risk or severity of bleeding can be increased when Idraparinux is combined with Interferon alfacon-1.
Astaxanthin,The risk or severity of bleeding can be increased when Astaxanthin is combined with Interferon alfacon-1.
Apixaban,The risk or severity of bleeding can be increased when Apixaban is combined with Interferon alfacon-1.
Otamixaban,The risk or severity of bleeding can be increased when Otamixaban is combined with Interferon alfacon-1.
Amediplase,The risk or severity of bleeding can be increased when Amediplase is combined with Interferon alfacon-1.
Dabigatran etexilate,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon alfacon-1.
Danaparoid,The risk or severity of bleeding can be increased when Danaparoid is combined with Interferon alfacon-1.
Dalteparin,The risk or severity of bleeding can be increased when Dalteparin is combined with Interferon alfacon-1.
Tinzaparin,The risk or severity of bleeding can be increased when Tinzaparin is combined with Interferon alfacon-1.
Ferulic acid,The risk or severity of bleeding can be increased when Ferulic acid is combined with Interferon alfacon-1.
Ethyl biscoumacetate,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Interferon alfacon-1.
Nadroparin,The risk or severity of bleeding can be increased when Nadroparin is combined with Interferon alfacon-1.
Ditazole,The risk or severity of bleeding can be increased when Ditazole is combined with Interferon alfacon-1.
Edoxaban,The risk or severity of bleeding can be increased when Edoxaban is combined with Interferon alfacon-1.
Potassium citrate,The risk or severity of bleeding can be increased when Potassium citrate is combined with Interferon alfacon-1.
Sodium citrate,The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon alfacon-1.
Dextran,The risk or severity of bleeding can be increased when Dextran is combined with Interferon alfacon-1.
Bemiparin,The risk or severity of bleeding can be increased when Bemiparin is combined with Interferon alfacon-1.
Reviparin,The risk or severity of bleeding can be increased when Reviparin is combined with Interferon alfacon-1.
Parnaparin,The risk or severity of bleeding can be increased when Parnaparin is combined with Interferon alfacon-1.
Certoparin,The risk or severity of bleeding can be increased when Certoparin is combined with Interferon alfacon-1.
Desirudin,The risk or severity of bleeding can be increased when Desirudin is combined with Interferon alfacon-1.
Zinc citrate,The risk or severity of bleeding can be increased when Zinc citrate is combined with Interferon alfacon-1.
Antithrombin Alfa,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon alfacon-1.
Protein C,The risk or severity of bleeding can be increased when Protein C is combined with Interferon alfacon-1.
Antithrombin III human,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon alfacon-1.
Letaxaban,The risk or severity of bleeding can be increased when Letaxaban is combined with Interferon alfacon-1.
Darexaban,The risk or severity of bleeding can be increased when Darexaban is combined with Interferon alfacon-1.
Betrixaban,The risk or severity of bleeding can be increased when Betrixaban is combined with Interferon alfacon-1.
Nafamostat,The risk or severity of bleeding can be increased when Nafamostat is combined with Interferon alfacon-1.
Monteplase,The risk or severity of bleeding can be increased when Monteplase is combined with Interferon alfacon-1.
Gabexate,The risk or severity of bleeding can be increased when Gabexate is combined with Interferon alfacon-1.
Fluindione,The risk or severity of bleeding can be increased when Fluindione is combined with Interferon alfacon-1.
Protein S human,The risk or severity of bleeding can be increased when Protein S human is combined with Interferon alfacon-1.
Brinase,The risk or severity of bleeding can be increased when Brinase is combined with Interferon alfacon-1.
Clorindione,The risk or severity of bleeding can be increased when Clorindione is combined with Interferon alfacon-1.
Diphenadione,The risk or severity of bleeding can be increased when Diphenadione is combined with Interferon alfacon-1.
Tioclomarol,The risk or severity of bleeding can be increased when Tioclomarol is combined with Interferon alfacon-1.
Melagatran,The risk or severity of bleeding can be increased when Melagatran is combined with Interferon alfacon-1.
Saruplase,The risk or severity of bleeding can be increased when Saruplase is combined with Interferon alfacon-1.
(S)-Warfarin,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Interferon alfacon-1.
Tocopherylquinone,The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Interferon alfacon-1.
Edetate calcium disodium anhydrous,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Interferon alfacon-1.
Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon alfacon-1.
Methyclothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon alfacon-1.
Bendroflumethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon alfacon-1.
Benzthiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Interferon alfacon-1.
Cyclothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Interferon alfacon-1.
Hydroflumethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Interferon alfacon-1.
Chlorothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Interferon alfacon-1.
Hydrochlorothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Interferon alfacon-1.
Trichlormethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Interferon alfacon-1.
Polythiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Interferon alfacon-1.
Mebutizide,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Interferon alfacon-1.
Cyclopenthiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Interferon alfacon-1.
Tedizolid phosphate,The risk or severity of myelosuppression can be increased when Interferon alfacon-1 is combined with Tedizolid phosphate.
Cyclosporine,Interferon alfacon-1 may increase the immunosuppressive activities of Cyclosporine.
Ropinirole,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ropinirole.
Cyanocobalamin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfacon-1.
Allopurinol,The risk or severity of adverse effects can be increased when Allopurinol is combined with Interferon alfacon-1.
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Interferon alfacon-1.
Lopinavir,The serum concentration of Interferon alfacon-1 can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Interferon alfacon-1 is combined with Inebilizumab.
Dopamine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Dopamine.
Betamethasone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Betamethasone.
Fluocinolone acetonide,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluocinolone acetonide.
Triamcinolone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Triamcinolone.
Hydrocortisone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hydrocortisone.
Methylprednisolone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methylprednisolone.
Trilostane,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Trilostane.
Dexamethasone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dexamethasone.
Corticotropin,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Corticotropin.
Cortisone acetate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cortisone acetate.
Paramethasone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Paramethasone.
Aldosterone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aldosterone.
Fluprednidene,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluprednidene.
Fluocortolone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluocortolone.
Fluprednisolone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluprednisolone.
Meprednisone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Meprednisone.
Dexamethasone isonicotinate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dexamethasone isonicotinate.
Melengestrol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Melengestrol.
Clobetasol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Clobetasol.
Cortivazol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cortivazol.
Prednylidene,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Prednylidene.
Fluocortin,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluocortin.
Fluperolone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluperolone.
Formocortal,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Formocortal.
Halometasone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Halometasone.
Cloprednol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cloprednol.
Fluclorolone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluclorolone.
Fluticasone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluticasone.
Hydrocortisone aceponate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hydrocortisone aceponate.
Hydrocortisone succinate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hydrocortisone succinate.
Loteprednol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Loteprednol.
Prednisolone hemisuccinate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Prednisolone hemisuccinate.
Fluprednidene acetate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluprednidene acetate.
Methylprednisolone aceponate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methylprednisolone aceponate.
Methylprednisolone hemisuccinate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methylprednisolone hemisuccinate.
Prednisone acetate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Prednisone acetate.
Clocortolone acetate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Clocortolone acetate.
Melengestrol acetate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Melengestrol acetate.
Betamethasone phosphate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Betamethasone phosphate.
Cortisone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cortisone.
Mometasone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mometasone.
Salicylic acid,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Salicylic acid.
Dersalazine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dersalazine.
Phenyl aminosalicylate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Phenyl aminosalicylate.
Nitroaspirin,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Nitroaspirin.
Aloxiprin,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aloxiprin.
Guacetisal,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Guacetisal.
Carbaspirin calcium,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Carbaspirin calcium.
Thiosalicylic acid,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Thiosalicylic acid.
Lidocaine,Hyaluronidase (ovine) can cause an increase in the absorption of Lidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Bupivacaine,Hyaluronidase (ovine) can cause an increase in the absorption of Bupivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Cinchocaine,Hyaluronidase (ovine) can cause an increase in the absorption of Cinchocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Dyclonine,Hyaluronidase (ovine) can cause an increase in the absorption of Dyclonine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Prilocaine,Hyaluronidase (ovine) can cause an increase in the absorption of Prilocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Proparacaine,Hyaluronidase (ovine) can cause an increase in the absorption of Proparacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Oxybuprocaine,Hyaluronidase (ovine) can cause an increase in the absorption of Oxybuprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Mepivacaine,Hyaluronidase (ovine) can cause an increase in the absorption of Mepivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Levobupivacaine,Hyaluronidase (ovine) can cause an increase in the absorption of Levobupivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Benzocaine,Hyaluronidase (ovine) can cause an increase in the absorption of Benzocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Tetrodotoxin,Hyaluronidase (ovine) can cause an increase in the absorption of Tetrodotoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.
Benzyl alcohol,Hyaluronidase (ovine) can cause an increase in the absorption of Benzyl alcohol resulting in an increased serum concentration and potentially a worsening of adverse effects.
Etidocaine,Hyaluronidase (ovine) can cause an increase in the absorption of Etidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Articaine,Hyaluronidase (ovine) can cause an increase in the absorption of Articaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Tetracaine,Hyaluronidase (ovine) can cause an increase in the absorption of Tetracaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Propoxycaine,Hyaluronidase (ovine) can cause an increase in the absorption of Propoxycaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Butamben,Hyaluronidase (ovine) can cause an increase in the absorption of Butamben resulting in an increased serum concentration and potentially a worsening of adverse effects.
Butacaine,Hyaluronidase (ovine) can cause an increase in the absorption of Butacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Butanilicaine,Hyaluronidase (ovine) can cause an increase in the absorption of Butanilicaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Metabutethamine,Hyaluronidase (ovine) can cause an increase in the absorption of Metabutethamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Quinisocaine,Hyaluronidase (ovine) can cause an increase in the absorption of Quinisocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Benzatropine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Benzatropine.
Ziprasidone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Ziprasidone.
Cetirizine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cetirizine.
Buclizine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Buclizine.
Promazine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Promazine.
Imipramine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Imipramine.
Chlorpromazine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorpromazine.
Cimetidine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cimetidine.
Hydroxyzine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hydroxyzine.
Cinnarizine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cinnarizine.
Risperidone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Risperidone.
Benzquinamide,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Benzquinamide.
Propiomazine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Propiomazine.
Brompheniramine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Brompheniramine.
Ranitidine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Ranitidine.
Methdilazine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methdilazine.
Famotidine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Famotidine.
Methantheline,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methantheline.
Azelastine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Azelastine.
Dimenhydrinate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dimenhydrinate.
Promethazine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Promethazine.
Mequitazine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mequitazine.
Diphenhydramine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Diphenhydramine.
Chlorpheniramine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorpheniramine.
Orphenadrine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Orphenadrine.
Cyclizine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cyclizine.
Aripiprazole,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aripiprazole.
Chlorprothixene,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorprothixene.
Methotrimeprazine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methotrimeprazine.
Aceprometazine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aceprometazine.
Phenindamine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Phenindamine.
Zuclopenthixol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Zuclopenthixol.
Phenol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Phenol.
Methapyrilene,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methapyrilene.
Mianserin,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mianserin.
Esmirtazapine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Esmirtazapine.
Chloropyramine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chloropyramine.
Dimetindene,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dimetindene.
Isothipendyl,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Isothipendyl.
Metiamide,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Metiamide.
Roxatidine acetate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Roxatidine acetate.
Dimetotiazine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dimetotiazine.
Chlorphenoxamine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorphenoxamine.
Butriptyline,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Butriptyline.
Dosulepin,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dosulepin.
Ebastine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Ebastine.
Mizolastine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mizolastine.
Lafutidine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Lafutidine.
GSK-1004723,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with GSK-1004723.
Oxatomide,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Oxatomide.
Lavoltidine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Lavoltidine.
Deptropine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Deptropine.
Bamipine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Bamipine.
Tritoqualine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Tritoqualine.
Quifenadine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Quifenadine.
Niperotidine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Niperotidine.
Aripiprazole lauroxil,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aripiprazole lauroxil.
GSK-239512,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with GSK-239512.
ABT-288,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with ABT-288.
Olanzapine,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Olanzapine.
Bethanidine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Bethanidine.
Etomidate,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Etomidate.
Norepinephrine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Norepinephrine.
Phenylephrine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Phenylephrine.
Clonidine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Clonidine.
Metaraminol,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Metaraminol.
Dexmedetomidine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Dexmedetomidine.
Epinephrine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Epinephrine.
Methoxamine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Methoxamine.
Dobutamine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Dobutamine.
Methyldopa,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Methyldopa.
Ergometrine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Ergometrine.
Ephedrine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Ephedrine.
Mephentermine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Mephentermine.
4-Methoxyamphetamine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with 4-Methoxyamphetamine.
"4-Bromo-2,5-dimethoxyphenethylamine","The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with 4-Bromo-2,5-dimethoxyphenethylamine."
Tetryzoline,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Tetryzoline.
Adrafinil,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Adrafinil.
Etilefrine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Etilefrine.
Cirazoline,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Cirazoline.
Synephrine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Synephrine.
Moxonidine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Moxonidine.
Amitraz,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Amitraz.
Medetomidine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Medetomidine.
Xylazine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Xylazine.
Romifidine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Romifidine.
Detomidine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Detomidine.
Rilmenidine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Rilmenidine.
Octopamine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Octopamine.
Norfenefrine,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Norfenefrine.
Diethylstilbestrol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Diethylstilbestrol.
Chlorotrianisene,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorotrianisene.
Conjugated estrogens,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Conjugated estrogens.
Estradiol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol.
Ethinylestradiol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Ethinylestradiol.
Mestranol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mestranol.
Estriol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estriol.
Estrone sulfate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estrone sulfate.
Quinestrol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Quinestrol.
Hexestrol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hexestrol.
Tibolone,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Tibolone.
"Synthetic Conjugated Estrogens, A","The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Synthetic Conjugated Estrogens, A."
"Synthetic Conjugated Estrogens, B","The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Synthetic Conjugated Estrogens, B."
Polyestradiol phosphate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Polyestradiol phosphate.
Esterified estrogens,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Esterified estrogens.
Zeranol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Zeranol.
Equol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Equol.
Promestriene,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Promestriene.
Methallenestril,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methallenestril.
Epimestrol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Epimestrol.
Moxestrol,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Moxestrol.
Estradiol acetate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol acetate.
Estradiol benzoate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol benzoate.
Estradiol cypionate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol cypionate.
Estradiol valerate,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol valerate.
Biochanin A,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Biochanin A.
Formononetin,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Formononetin.
Lorazepam,The therapeutic efficacy of Lorazepam can be decreased when used in combination with Hyaluronidase (ovine).
Adinazolam,The therapeutic efficacy of Adinazolam can be decreased when used in combination with Hyaluronidase (ovine).
Midazolam,The therapeutic efficacy of Midazolam can be decreased when used in combination with Hyaluronidase (ovine).
Halazepam,The therapeutic efficacy of Halazepam can be decreased when used in combination with Hyaluronidase (ovine).
Diazepam,The therapeutic efficacy of Diazepam can be decreased when used in combination with Hyaluronidase (ovine).
Camazepam,The therapeutic efficacy of Camazepam can be decreased when used in combination with Hyaluronidase (ovine).
Delorazepam,The therapeutic efficacy of Delorazepam can be decreased when used in combination with Hyaluronidase (ovine).
Flunitrazepam,The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Hyaluronidase (ovine).
Ethyl loflazepate,The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Hyaluronidase (ovine).
Cloxazolam,The therapeutic efficacy of Cloxazolam can be decreased when used in combination with Hyaluronidase (ovine).
Clotiazepam,The therapeutic efficacy of Clotiazepam can be decreased when used in combination with Hyaluronidase (ovine).
Fludiazepam,The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Hyaluronidase (ovine).
Prazepam,The therapeutic efficacy of Prazepam can be decreased when used in combination with Hyaluronidase (ovine).
Cinolazepam,The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Hyaluronidase (ovine).
Brotizolam,The therapeutic efficacy of Brotizolam can be decreased when used in combination with Hyaluronidase (ovine).
Etizolam,The therapeutic efficacy of Etizolam can be decreased when used in combination with Hyaluronidase (ovine).
Benzodiazepine,The therapeutic efficacy of Benzodiazepine can be decreased when used in combination with Hyaluronidase (ovine).
Pinazepam,The therapeutic efficacy of Pinazepam can be decreased when used in combination with Hyaluronidase (ovine).
Medazepam,The therapeutic efficacy of Medazepam can be decreased when used in combination with Hyaluronidase (ovine).
Loprazolam,The therapeutic efficacy of Loprazolam can be decreased when used in combination with Hyaluronidase (ovine).
Doxefazepam,The therapeutic efficacy of Doxefazepam can be decreased when used in combination with Hyaluronidase (ovine).
Lormetazepam,The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Hyaluronidase (ovine).
Nordazepam,The therapeutic efficacy of Nordazepam can be decreased when used in combination with Hyaluronidase (ovine).
Oxazepam acetate,The therapeutic efficacy of Oxazepam acetate can be decreased when used in combination with Hyaluronidase (ovine).
Cinazepam,The therapeutic efficacy of Cinazepam can be decreased when used in combination with Hyaluronidase (ovine).
Bentazepam,The therapeutic efficacy of Bentazepam can be decreased when used in combination with Hyaluronidase (ovine).
Furosemide,The therapeutic efficacy of Furosemide can be decreased when used in combination with Hyaluronidase (ovine).
Phenytoin,The therapeutic efficacy of Phenytoin can be decreased when used in combination with Hyaluronidase (ovine).
Fosphenytoin,The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Hyaluronidase (ovine).
Liraglutide,Liraglutide may increase the hypoglycemic activities of Insulin pork.
Metreleptin,Metreleptin may increase the hypoglycemic activities of Insulin pork.
Pegvisomant,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin pork.
Pioglitazone,The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin pork.
Pramlintide,Pramlintide may increase the hypoglycemic activities of Insulin pork.
Rosiglitazone,The risk or severity of congestive heart failure can be increased when Insulin pork is combined with Rosiglitazone.
Lipoic acid,The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin pork.
Edetic acid,Edetic acid may increase the hypoglycemic activities of Insulin pork.
Esmolol,Esmolol may increase the hypoglycemic activities of Insulin pork.
Moxifloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Moxifloxacin.
Grepafloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Grepafloxacin.
Enoxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Enoxacin.
Pefloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Pefloxacin.
Ciprofloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Ciprofloxacin.
Trovafloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Trovafloxacin.
Nalidixic acid,The therapeutic efficacy of Insulin pork can be increased when used in combination with Nalidixic acid.
Rosoxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Rosoxacin.
Cinoxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Cinoxacin.
Lomefloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Lomefloxacin.
Gatifloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Gatifloxacin.
Norfloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Norfloxacin.
Levofloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Levofloxacin.
Gemifloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Gemifloxacin.
Ofloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Ofloxacin.
Sparfloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sparfloxacin.
Temafloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Temafloxacin.
Fleroxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Fleroxacin.
Technetium Tc-99m ciprofloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Technetium Tc-99m ciprofloxacin.
Garenoxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Garenoxacin.
Nemonoxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Nemonoxacin.
Flumequine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Flumequine.
Enrofloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Enrofloxacin.
Orbifloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Orbifloxacin.
Sarafloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sarafloxacin.
Difloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Difloxacin.
Pazufloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Pazufloxacin.
Prulifloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Prulifloxacin.
Delafloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Delafloxacin.
Sitafloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sitafloxacin.
Oxolinic acid,The therapeutic efficacy of Insulin pork can be increased when used in combination with Oxolinic acid.
Rufloxacin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Rufloxacin.
Pipemidic acid,The therapeutic efficacy of Insulin pork can be increased when used in combination with Pipemidic acid.
Methyclothiazide,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Methyclothiazide.
Chlorthalidone,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Chlorthalidone.
Bendroflumethiazide,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Bendroflumethiazide.
Metolazone,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Metolazone.
Benzthiazide,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Benzthiazide.
Hydroflumethiazide,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Hydroflumethiazide.
Indapamide,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Indapamide.
Chlorothiazide,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Chlorothiazide.
Hydrochlorothiazide,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Hydrochlorothiazide.
Trichlormethiazide,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Trichlormethiazide.
Polythiazide,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Polythiazide.
Quinethazone,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Quinethazone.
Cyclopenthiazide,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Cyclopenthiazide.
Epitizide,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Epitizide.
Protriptyline,Protriptyline may decrease the hypoglycemic activities of Insulin pork.
Amoxapine,Amoxapine may decrease the hypoglycemic activities of Insulin pork.
Trimipramine,Trimipramine may decrease the hypoglycemic activities of Insulin pork.
Amineptine,Amineptine may decrease the hypoglycemic activities of Insulin pork.
Dimetacrine,Dimetacrine may decrease the hypoglycemic activities of Insulin pork.
Butriptyline,Butriptyline may decrease the hypoglycemic activities of Insulin pork.
Dosulepin,Dosulepin may decrease the hypoglycemic activities of Insulin pork.
Tianeptine,Tianeptine may decrease the hypoglycemic activities of Insulin pork.
Oxaprotiline,Oxaprotiline may decrease the hypoglycemic activities of Insulin pork.
Opipramol,Opipramol may decrease the hypoglycemic activities of Insulin pork.
Amitriptylinoxide,Amitriptylinoxide may decrease the hypoglycemic activities of Insulin pork.
Dibenzepin,Dibenzepin may decrease the hypoglycemic activities of Insulin pork.
Quinupramine,Quinupramine may decrease the hypoglycemic activities of Insulin pork.
Melitracen,Melitracen may decrease the hypoglycemic activities of Insulin pork.
Lofepramine,Lofepramine may decrease the hypoglycemic activities of Insulin pork.
Iprindole,Iprindole may decrease the hypoglycemic activities of Insulin pork.
Imipramine oxide,Imipramine oxide may decrease the hypoglycemic activities of Insulin pork.
Dapagliflozin,Dapagliflozin may increase the hypoglycemic activities of Insulin pork.
Canagliflozin,Canagliflozin may increase the hypoglycemic activities of Insulin pork.
Leuprolide,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Leuprolide.
Goserelin,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Goserelin.
Octreotide,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Octreotide.
Nelfinavir,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Nelfinavir.
Indinavir,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Indinavir.
Ziprasidone,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ziprasidone.
Etonogestrel,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Etonogestrel.
Desogestrel,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Desogestrel.
Olanzapine,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Olanzapine.
Megestrol acetate,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Megestrol acetate.
Clozapine,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Clozapine.
Levonorgestrel,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Levonorgestrel.
Progesterone,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Progesterone.
Chlorpromazine,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Chlorpromazine.
Haloperidol,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Haloperidol.
Ritonavir,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ritonavir.
Piperazine,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Piperazine.
Medroxyprogesterone acetate,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Medroxyprogesterone acetate.
Niacin,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Niacin.
Epinephrine,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Epinephrine.
Norethisterone,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Norethisterone.
Risperidone,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Risperidone.
Pentamidine,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pentamidine.
Ethynodiol diacetate,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ethynodiol diacetate.
Pseudoephedrine,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pseudoephedrine.
Tacrolimus,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Tacrolimus.
Sirolimus,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Sirolimus.
Etacrynic acid,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Etacrynic acid.
Tipranavir,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Tipranavir.
Norgestimate,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Norgestimate.
Ethinylestradiol,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ethinylestradiol.
Atazanavir,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Atazanavir.
Arsenic trioxide,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Arsenic trioxide.
Quetiapine,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Quetiapine.
Saquinavir,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Saquinavir.
Aripiprazole,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Aripiprazole.
Paliperidone,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Paliperidone.
Fosamprenavir,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Fosamprenavir.
St. John's Wort,The therapeutic efficacy of Insulin pork can be decreased when used in combination with St. John's Wort.
Mestranol,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Mestranol.
Ephedra sinica root,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ephedra sinica root.
Drospirenone,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Drospirenone.
Methotrimeprazine,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Methotrimeprazine.
Danazol,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Danazol.
Everolimus,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Everolimus.
Lopinavir,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Lopinavir.
Pipotiazine,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pipotiazine.
Vorinostat,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Vorinostat.
Estrone sulfate,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Estrone sulfate.
Cyproterone acetate,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Cyproterone acetate.
Nilotinib,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Nilotinib.
Iloperidone,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Iloperidone.
Asenapine,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Asenapine.
Temsirolimus,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Temsirolimus.
Pasireotide,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pasireotide.
Buserelin,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Buserelin.
Histrelin,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Histrelin.
Hydroxyprogesterone caproate,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Hydroxyprogesterone caproate.
Lanreotide,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Lanreotide.
Triptorelin,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Triptorelin.
Lurasidone,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Lurasidone.
Dabrafenib,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Dabrafenib.
Articaine,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Articaine.
Ceritinib,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ceritinib.
Dienogest,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Dienogest.
Brexpiprazole,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Brexpiprazole.
Teprotumumab,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Teprotumumab.
Oxandrolone,Oxandrolone may increase the hypoglycemic activities of Insulin pork.
Testosterone,Testosterone may increase the hypoglycemic activities of Insulin pork.
Nandrolone phenpropionate,Nandrolone phenpropionate may increase the hypoglycemic activities of Insulin pork.
Fluoxymesterone,Fluoxymesterone may increase the hypoglycemic activities of Insulin pork.
Testosterone propionate,Testosterone propionate may increase the hypoglycemic activities of Insulin pork.
Stanolone,Stanolone may increase the hypoglycemic activities of Insulin pork.
Oxymetholone,Oxymetholone may increase the hypoglycemic activities of Insulin pork.
Methyltestosterone,Methyltestosterone may increase the hypoglycemic activities of Insulin pork.
Stanozolol,Stanozolol may increase the hypoglycemic activities of Insulin pork.
Nandrolone decanoate,Nandrolone decanoate may increase the hypoglycemic activities of Insulin pork.
GLPG-0492,GLPG-0492 may increase the hypoglycemic activities of Insulin pork.
Nandrolone,Nandrolone may increase the hypoglycemic activities of Insulin pork.
Mesterolone,Mesterolone may increase the hypoglycemic activities of Insulin pork.
Testosterone cypionate,Testosterone cypionate may increase the hypoglycemic activities of Insulin pork.
Testosterone enanthate,Testosterone enanthate may increase the hypoglycemic activities of Insulin pork.
Citalopram,The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin pork.
Pregabalin,The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Insulin pork.
Venlafaxine,The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Insulin pork.
Indomethacin,The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Insulin pork.
Sertraline,The risk or severity of hypoglycemia can be increased when Sertraline is combined with Insulin pork.
Nefazodone,The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Insulin pork.
Escitalopram,The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Insulin pork.
Zimelidine,The risk or severity of hypoglycemia can be increased when Zimelidine is combined with Insulin pork.
Dapoxetine,The risk or severity of hypoglycemia can be increased when Dapoxetine is combined with Insulin pork.
Milnacipran,The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Insulin pork.
Desvenlafaxine,The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Insulin pork.
Levomilnacipran,The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Insulin pork.
Indalpine,The risk or severity of hypoglycemia can be increased when Indalpine is combined with Insulin pork.
Ubidecarenone,The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin pork.
Ritanserin,The risk or severity of hypoglycemia can be increased when Ritanserin is combined with Insulin pork.
Alaproclate,The risk or severity of hypoglycemia can be increased when Alaproclate is combined with Insulin pork.
Cibenzoline,The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Insulin pork.
Clinafloxacin,The risk or severity of hypoglycemia can be increased when Clinafloxacin is combined with Insulin pork.
Aminosalicylic acid,Aminosalicylic acid may increase the hypoglycemic activities of Insulin pork.
Mesalazine,Mesalazine may increase the hypoglycemic activities of Insulin pork.
Sulfasalazine,Sulfasalazine may increase the hypoglycemic activities of Insulin pork.
Diflunisal,Diflunisal may increase the hypoglycemic activities of Insulin pork.
Salicylic acid,Salicylic acid may increase the hypoglycemic activities of Insulin pork.
Balsalazide,Balsalazide may increase the hypoglycemic activities of Insulin pork.
Olsalazine,Olsalazine may increase the hypoglycemic activities of Insulin pork.
Bismuth subsalicylate,Bismuth subsalicylate may increase the hypoglycemic activities of Insulin pork.
Dersalazine,Dersalazine may increase the hypoglycemic activities of Insulin pork.
Phenyl aminosalicylate,Phenyl aminosalicylate may increase the hypoglycemic activities of Insulin pork.
Methyl salicylate,Methyl salicylate may increase the hypoglycemic activities of Insulin pork.
Trolamine salicylate,Trolamine salicylate may increase the hypoglycemic activities of Insulin pork.
Nitroaspirin,Nitroaspirin may increase the hypoglycemic activities of Insulin pork.
Aloxiprin,Aloxiprin may increase the hypoglycemic activities of Insulin pork.
Guacetisal,Guacetisal may increase the hypoglycemic activities of Insulin pork.
Carbaspirin calcium,Carbaspirin calcium may increase the hypoglycemic activities of Insulin pork.
Choline salicylate,Choline salicylate may increase the hypoglycemic activities of Insulin pork.
Thiosalicylic acid,Thiosalicylic acid may increase the hypoglycemic activities of Insulin pork.
Sitagliptin,Sitagliptin may increase the hypoglycemic activities of Insulin pork.
Vildagliptin,Vildagliptin may increase the hypoglycemic activities of Insulin pork.
AMG-222,AMG-222 may increase the hypoglycemic activities of Insulin pork.
Bisegliptin,Bisegliptin may increase the hypoglycemic activities of Insulin pork.
Alogliptin,Alogliptin may increase the hypoglycemic activities of Insulin pork.
Saxagliptin,Saxagliptin may increase the hypoglycemic activities of Insulin pork.
Gosogliptin,Gosogliptin may increase the hypoglycemic activities of Insulin pork.
Linagliptin,Linagliptin may increase the hypoglycemic activities of Insulin pork.
Dutogliptin,Dutogliptin may increase the hypoglycemic activities of Insulin pork.
Teneligliptin,Teneligliptin may increase the hypoglycemic activities of Insulin pork.
Omarigliptin,Omarigliptin may increase the hypoglycemic activities of Insulin pork.
Carmegliptin,Carmegliptin may increase the hypoglycemic activities of Insulin pork.
Gemigliptin,Gemigliptin may increase the hypoglycemic activities of Insulin pork.
Anagliptin,Anagliptin may increase the hypoglycemic activities of Insulin pork.
Evogliptin,Evogliptin may increase the hypoglycemic activities of Insulin pork.
Exenatide,Exenatide may increase the hypoglycemic activities of Insulin pork.
Albiglutide,Albiglutide may increase the hypoglycemic activities of Insulin pork.
Dulaglutide,Dulaglutide may increase the hypoglycemic activities of Insulin pork.
Lixisenatide,Lixisenatide may increase the hypoglycemic activities of Insulin pork.
Semaglutide,Semaglutide may increase the hypoglycemic activities of Insulin pork.
Taspoglutide,Taspoglutide may increase the hypoglycemic activities of Insulin pork.
Tranylcypromine,Tranylcypromine may increase the hypoglycemic activities of Insulin pork.
Phenelzine,Phenelzine may increase the hypoglycemic activities of Insulin pork.
Moclobemide,Moclobemide may increase the hypoglycemic activities of Insulin pork.
Isocarboxazid,Isocarboxazid may increase the hypoglycemic activities of Insulin pork.
Pargyline,Pargyline may increase the hypoglycemic activities of Insulin pork.
Minaprine,Minaprine may increase the hypoglycemic activities of Insulin pork.
Iproniazid,Iproniazid may increase the hypoglycemic activities of Insulin pork.
Nialamide,Nialamide may increase the hypoglycemic activities of Insulin pork.
Pirlindole,Pirlindole may increase the hypoglycemic activities of Insulin pork.
Toloxatone,Toloxatone may increase the hypoglycemic activities of Insulin pork.
Hydracarbazine,Hydracarbazine may increase the hypoglycemic activities of Insulin pork.
Methylene blue,Methylene blue may increase the hypoglycemic activities of Insulin pork.
Benmoxin,Benmoxin may increase the hypoglycemic activities of Insulin pork.
Mebanazine,Mebanazine may increase the hypoglycemic activities of Insulin pork.
Octamoxin,Octamoxin may increase the hypoglycemic activities of Insulin pork.
Pheniprazine,Pheniprazine may increase the hypoglycemic activities of Insulin pork.
Phenoxypropazine,Phenoxypropazine may increase the hypoglycemic activities of Insulin pork.
Pivhydrazine,Pivhydrazine may increase the hypoglycemic activities of Insulin pork.
Safrazine,Safrazine may increase the hypoglycemic activities of Insulin pork.
Caroxazone,Caroxazone may increase the hypoglycemic activities of Insulin pork.
Furazolidone,Furazolidone may increase the hypoglycemic activities of Insulin pork.
"7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline","7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin pork."
Harmaline,Harmaline may increase the hypoglycemic activities of Insulin pork.
Brofaromine,Brofaromine may increase the hypoglycemic activities of Insulin pork.
Procaine,Procaine may increase the hypoglycemic activities of Insulin pork.
Amphetamine,Amphetamine may increase the hypoglycemic activities of Insulin pork.
Procarbazine,Procarbazine may increase the hypoglycemic activities of Insulin pork.
Linezolid,Linezolid may increase the hypoglycemic activities of Insulin pork.
Safinamide,Safinamide may increase the hypoglycemic activities of Insulin pork.
Clorgiline,Clorgiline may increase the hypoglycemic activities of Insulin pork.
Ertugliflozin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Ertugliflozin.
Sildenafil,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sildenafil.
Torasemide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Torasemide.
Sulfisoxazole,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfisoxazole.
Ethoxzolamide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Ethoxzolamide.
Sulfadiazine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfadiazine.
Celecoxib,The therapeutic efficacy of Insulin pork can be increased when used in combination with Celecoxib.
Bosentan,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bosentan.
Sulfamethizole,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamethizole.
Cyclothiazide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Cyclothiazide.
Sulfametopyrazine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfametopyrazine.
Sumatriptan,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sumatriptan.
Furosemide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Furosemide.
Tamsulosin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Tamsulosin.
Acetazolamide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Acetazolamide.
Bumetanide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bumetanide.
Sulfapyridine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfapyridine.
Zonisamide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Zonisamide.
Sulfamethoxazole,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamethoxazole.
Probenecid,The therapeutic efficacy of Insulin pork can be increased when used in combination with Probenecid.
Rosuvastatin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Rosuvastatin.
Diazoxide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Diazoxide.
Diclofenamide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Diclofenamide.
Darunavir,The therapeutic efficacy of Insulin pork can be increased when used in combination with Darunavir.
Sulfacytine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfacytine.
Sulfadoxine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfadoxine.
Glymidine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Glymidine.
Sulfamerazine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamerazine.
Sulfamethazine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamethazine.
Piretanide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Piretanide.
Hydroxyfasudil,The therapeutic efficacy of Insulin pork can be increased when used in combination with Hydroxyfasudil.
Sulfadimethoxine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfadimethoxine.
Simeprevir,The therapeutic efficacy of Insulin pork can be increased when used in combination with Simeprevir.
Sulfaphenazole,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaphenazole.
Sulfameter,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfameter.
5-(2-methylpiperazine-1-sulfonyl)isoquinoline,The therapeutic efficacy of Insulin pork can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.
Fasudil,The therapeutic efficacy of Insulin pork can be increased when used in combination with Fasudil.
Sulfamoxole,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamoxole.
Vemurafenib,The therapeutic efficacy of Insulin pork can be increased when used in combination with Vemurafenib.
Azosemide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Azosemide.
Clorsulon,The therapeutic efficacy of Insulin pork can be increased when used in combination with Clorsulon.
Sulfachlorpyridazine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfachlorpyridazine.
Sulfaethoxypyridazine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaethoxypyridazine.
Sulfanitran,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfanitran.
Sulfaquinoxaline,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaquinoxaline.
Setrobuvir,The therapeutic efficacy of Insulin pork can be increased when used in combination with Setrobuvir.
Chlorsulfaquinoxaline,The therapeutic efficacy of Insulin pork can be increased when used in combination with Chlorsulfaquinoxaline.
Sulfadicramide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfadicramide.
Phthalylsulfathiazole,The therapeutic efficacy of Insulin pork can be increased when used in combination with Phthalylsulfathiazole.
Sulfaisodimidine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaisodimidine.
Meticrane,The therapeutic efficacy of Insulin pork can be increased when used in combination with Meticrane.
Sulfaperin,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaperin.
Mefruside,The therapeutic efficacy of Insulin pork can be increased when used in combination with Mefruside.
Mebutizide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Mebutizide.
Sulfametomidine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfametomidine.
Sulfatolamide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfatolamide.
Sulfamazone,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamazone.
Succinylsulfathiazole,The therapeutic efficacy of Insulin pork can be increased when used in combination with Succinylsulfathiazole.
Clorexolone,The therapeutic efficacy of Insulin pork can be increased when used in combination with Clorexolone.
Clofenamide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Clofenamide.
Sulfathiourea,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfathiourea.
Fenquizone,The therapeutic efficacy of Insulin pork can be increased when used in combination with Fenquizone.
Sulfaguanidine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaguanidine.
Sulfamethoxypyridazine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamethoxypyridazine.
Clopamide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Clopamide.
Xipamide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Xipamide.
Acetyl sulfisoxazole,The therapeutic efficacy of Insulin pork can be increased when used in combination with Acetyl sulfisoxazole.
Tosylchloramide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Tosylchloramide.
Methazolamide,The therapeutic efficacy of Insulin pork can be increased when used in combination with Methazolamide.
Indisulam,The therapeutic efficacy of Insulin pork can be increased when used in combination with Indisulam.
Fluvoxamine,The metabolism of Fluvoxamine can be increased when combined with Insulin pork.
Nicotine,The metabolism of Nicotine can be increased when combined with Insulin pork.
Bortezomib,The metabolism of Bortezomib can be increased when combined with Insulin pork.
Caffeine,The metabolism of Caffeine can be increased when combined with Insulin pork.
Anagrelide,The metabolism of Anagrelide can be increased when combined with Insulin pork.
Carmustine,The metabolism of Carmustine can be increased when combined with Insulin pork.
Lidocaine,The metabolism of Lidocaine can be increased when combined with Insulin pork.
Conjugated estrogens,The metabolism of Conjugated estrogens can be increased when combined with Insulin pork.
Ropivacaine,The metabolism of Ropivacaine can be increased when combined with Insulin pork.
Zolmitriptan,The metabolism of Zolmitriptan can be increased when combined with Insulin pork.
Acetaminophen,The metabolism of Acetaminophen can be increased when combined with Insulin pork.
Chlorzoxazone,The metabolism of Chlorzoxazone can be increased when combined with Insulin pork.
Mirtazapine,The metabolism of Mirtazapine can be increased when combined with Insulin pork.
Mexiletine,The metabolism of Mexiletine can be increased when combined with Insulin pork.
Tacrine,The metabolism of Tacrine can be increased when combined with Insulin pork.
Triamterene,The metabolism of Triamterene can be increased when combined with Insulin pork.
Promazine,The metabolism of Promazine can be increased when combined with Insulin pork.
Zolpidem,The metabolism of Zolpidem can be increased when combined with Insulin pork.
Entecavir,The metabolism of Entecavir can be increased when combined with Insulin pork.
Nabumetone,The metabolism of Nabumetone can be increased when combined with Insulin pork.
Fluoxetine,The metabolism of Fluoxetine can be increased when combined with Insulin pork.
Duloxetine,The metabolism of Duloxetine can be increased when combined with Insulin pork.
Flutamide,The metabolism of Flutamide can be increased when combined with Insulin pork.
Albendazole,The metabolism of Albendazole can be increased when combined with Insulin pork.
Rofecoxib,The metabolism of Rofecoxib can be increased when combined with Insulin pork.
Fluorouracil,The metabolism of Fluorouracil can be increased when combined with Insulin pork.
Cinnarizine,The metabolism of Cinnarizine can be increased when combined with Insulin pork.
Diclofenac,The metabolism of Diclofenac can be increased when combined with Insulin pork.
Imatinib,The metabolism of Imatinib can be increased when combined with Insulin pork.
Guanabenz,The metabolism of Guanabenz can be increased when combined with Insulin pork.
Pemetrexed,The metabolism of Pemetrexed can be increased when combined with Insulin pork.
Verapamil,The metabolism of Verapamil can be increased when combined with Insulin pork.
Paroxetine,The metabolism of Paroxetine can be increased when combined with Insulin pork.
Thiabendazole,The metabolism of Thiabendazole can be increased when combined with Insulin pork.
Riluzole,The metabolism of Riluzole can be increased when combined with Insulin pork.
Zileuton,The metabolism of Zileuton can be increased when combined with Insulin pork.
Clopidogrel,The metabolism of Clopidogrel can be increased when combined with Insulin pork.
Acyclovir,The metabolism of Acyclovir can be increased when combined with Insulin pork.
Naproxen,The metabolism of Naproxen can be increased when combined with Insulin pork.
Pentoxifylline,The metabolism of Pentoxifylline can be increased when combined with Insulin pork.
Trifluoperazine,The metabolism of Trifluoperazine can be increased when combined with Insulin pork.
Perphenazine,The metabolism of Perphenazine can be increased when combined with Insulin pork.
Terbinafine,The metabolism of Terbinafine can be increased when combined with Insulin pork.
Ranitidine,The metabolism of Ranitidine can be increased when combined with Insulin pork.
Ethanol,The metabolism of Ethanol can be increased when combined with Insulin pork.
Maprotiline,The metabolism of Maprotiline can be increased when combined with Insulin pork.
Alosetron,The metabolism of Alosetron can be increased when combined with Insulin pork.
Ramelteon,The metabolism of Ramelteon can be increased when combined with Insulin pork.
Azathioprine,The metabolism of Azathioprine can be increased when combined with Insulin pork.
Frovatriptan,The metabolism of Frovatriptan can be increased when combined with Insulin pork.
Levobupivacaine,The metabolism of Levobupivacaine can be increased when combined with Insulin pork.
Cinacalcet,The metabolism of Cinacalcet can be increased when combined with Insulin pork.
Selegiline,The metabolism of Selegiline can be increased when combined with Insulin pork.
Tocainide,The metabolism of Tocainide can be increased when combined with Insulin pork.
Praziquantel,The metabolism of Praziquantel can be increased when combined with Insulin pork.
Melatonin,The metabolism of Melatonin can be increased when combined with Insulin pork.
Primaquine,The metabolism of Primaquine can be increased when combined with Insulin pork.
Hesperetin,The metabolism of Hesperetin can be increased when combined with Insulin pork.
Leflunomide,The metabolism of Leflunomide can be increased when combined with Insulin pork.
Cilostazol,The metabolism of Cilostazol can be increased when combined with Insulin pork.
Domperidone,The metabolism of Domperidone can be increased when combined with Insulin pork.
Dexfenfluramine,The metabolism of Dexfenfluramine can be increased when combined with Insulin pork.
Oxtriphylline,The metabolism of Oxtriphylline can be increased when combined with Insulin pork.
Rasagiline,The metabolism of Rasagiline can be increased when combined with Insulin pork.
Theobromine,The metabolism of Theobromine can be increased when combined with Insulin pork.
Aminophenazone,The metabolism of Aminophenazone can be increased when combined with Insulin pork.
Antipyrine,The metabolism of Antipyrine can be increased when combined with Insulin pork.
Fenethylline,The metabolism of Fenethylline can be increased when combined with Insulin pork.
Bromazepam,The metabolism of Bromazepam can be increased when combined with Insulin pork.
Thiothixene,The metabolism of Thiothixene can be increased when combined with Insulin pork.
Etoricoxib,The metabolism of Etoricoxib can be increased when combined with Insulin pork.
Genistein,The metabolism of Genistein can be increased when combined with Insulin pork.
8-azaguanine,The metabolism of 8-azaguanine can be increased when combined with Insulin pork.
Xanthine,The metabolism of Xanthine can be increased when combined with Insulin pork.
9-Methylguanine,The metabolism of 9-Methylguanine can be increased when combined with Insulin pork.
Peldesine,The metabolism of Peldesine can be increased when combined with Insulin pork.
Resveratrol,The metabolism of Resveratrol can be increased when combined with Insulin pork.
Phenacetin,The metabolism of Phenacetin can be increased when combined with Insulin pork.
Hypoxanthine,The metabolism of Hypoxanthine can be increased when combined with Insulin pork.
9-Deazaguanine,The metabolism of 9-Deazaguanine can be increased when combined with Insulin pork.
Flunarizine,The metabolism of Flunarizine can be increased when combined with Insulin pork.
Lorcaserin,The metabolism of Lorcaserin can be increased when combined with Insulin pork.
Lofexidine,The metabolism of Lofexidine can be increased when combined with Insulin pork.
Pirfenidone,The metabolism of Pirfenidone can be increased when combined with Insulin pork.
Apremilast,The metabolism of Apremilast can be increased when combined with Insulin pork.
Mianserin,The metabolism of Mianserin can be increased when combined with Insulin pork.
Eltrombopag,The metabolism of Eltrombopag can be increased when combined with Insulin pork.
Vadimezan,The metabolism of Vadimezan can be increased when combined with Insulin pork.
Propentofylline,The metabolism of Propentofylline can be increased when combined with Insulin pork.
Pazopanib,The metabolism of Pazopanib can be increased when combined with Insulin pork.
Agomelatine,The metabolism of Agomelatine can be increased when combined with Insulin pork.
Axitinib,The metabolism of Axitinib can be increased when combined with Insulin pork.
Bendamustine,The metabolism of Bendamustine can be increased when combined with Insulin pork.
Benzyl alcohol,The metabolism of Benzyl alcohol can be increased when combined with Insulin pork.
Capsaicin,The metabolism of Capsaicin can be increased when combined with Insulin pork.
(R)-warfarin,The metabolism of (R)-warfarin can be increased when combined with Insulin pork.
Perampanel,The metabolism of Perampanel can be increased when combined with Insulin pork.
Tasimelteon,The metabolism of Tasimelteon can be increased when combined with Insulin pork.
Stiripentol,The metabolism of Stiripentol can be increased when combined with Insulin pork.
Zotepine,The metabolism of Zotepine can be increased when combined with Insulin pork.
Doxofylline,The metabolism of Doxofylline can be increased when combined with Insulin pork.
Propacetamol,The metabolism of Propacetamol can be increased when combined with Insulin pork.
Ramosetron,The metabolism of Ramosetron can be increased when combined with Insulin pork.
6-O-benzylguanine,The metabolism of 6-O-benzylguanine can be increased when combined with Insulin pork.
Binimetinib,The metabolism of Binimetinib can be increased when combined with Insulin pork.
Voxilaprevir,The metabolism of Voxilaprevir can be increased when combined with Insulin pork.
Triclabendazole,The metabolism of Triclabendazole can be increased when combined with Insulin pork.
Rucaparib,The metabolism of Rucaparib can be increased when combined with Insulin pork.
Lisofylline,The metabolism of Lisofylline can be increased when combined with Insulin pork.
Lobucavir,The metabolism of Lobucavir can be increased when combined with Insulin pork.
Cafedrine,The metabolism of Cafedrine can be increased when combined with Insulin pork.
Theodrenaline,The metabolism of Theodrenaline can be increased when combined with Insulin pork.
Dihydralazine,The metabolism of Dihydralazine can be increased when combined with Insulin pork.
Bamifylline,The metabolism of Bamifylline can be increased when combined with Insulin pork.
Proxyphylline,The metabolism of Proxyphylline can be increased when combined with Insulin pork.
Acefylline,The metabolism of Acefylline can be increased when combined with Insulin pork.
Etamiphylline,The metabolism of Etamiphylline can be increased when combined with Insulin pork.
Pentifylline,The metabolism of Pentifylline can be increased when combined with Insulin pork.
Bufylline,The metabolism of Bufylline can be increased when combined with Insulin pork.
Estradiol acetate,The metabolism of Estradiol acetate can be increased when combined with Insulin pork.
Estradiol benzoate,The metabolism of Estradiol benzoate can be increased when combined with Insulin pork.
Estradiol cypionate,The metabolism of Estradiol cypionate can be increased when combined with Insulin pork.
Estradiol dienanthate,The metabolism of Estradiol dienanthate can be increased when combined with Insulin pork.
Estradiol valerate,The metabolism of Estradiol valerate can be increased when combined with Insulin pork.
Bromotheophylline,The metabolism of Bromotheophylline can be increased when combined with Insulin pork.
8-chlorotheophylline,The metabolism of 8-chlorotheophylline can be increased when combined with Insulin pork.
Nifedipine,The metabolism of Nifedipine can be increased when combined with Insulin pork.
Istradefylline,The metabolism of Istradefylline can be increased when combined with Insulin pork.
Azelastine,The metabolism of Azelastine can be increased when combined with Insulin pork.
Efavirenz,The metabolism of Efavirenz can be increased when combined with Insulin pork.
Bicifadine,The metabolism of Bicifadine can be increased when combined with Insulin pork.
GTS-21,The metabolism of GTS-21 can be increased when combined with Insulin pork.
Flecainide,The metabolism of Flecainide can be increased when combined with Insulin pork.
Estradiol,The metabolism of Estradiol can be increased when combined with Insulin pork.
Amitriptyline,The metabolism of Amitriptyline can be increased when combined with Insulin pork.
Imipramine,The metabolism of Imipramine can be increased when combined with Insulin pork.
Doxepin,The metabolism of Doxepin can be increased when combined with Insulin pork.
Mephenytoin,The metabolism of Mephenytoin can be increased when combined with Insulin pork.
Nortriptyline,The metabolism of Nortriptyline can be increased when combined with Insulin pork.
Clonidine,The metabolism of Clonidine can be increased when combined with Insulin pork.
Cyclobenzaprine,The metabolism of Cyclobenzaprine can be increased when combined with Insulin pork.
Desipramine,The metabolism of Desipramine can be increased when combined with Insulin pork.
Clomipramine,The metabolism of Clomipramine can be increased when combined with Insulin pork.
Selumetinib,The metabolism of Selumetinib can be increased when combined with Insulin pork.
Theophylline,The metabolism of Theophylline can be increased when combined with Insulin pork.
Sorafenib,The metabolism of Sorafenib can be increased when combined with Insulin pork.
Erlotinib,The metabolism of Erlotinib can be increased when combined with Insulin pork.
Carbamazepine,The metabolism of Carbamazepine can be increased when combined with Insulin pork.
Warfarin,The metabolism of Warfarin can be increased when combined with Insulin pork.
Tizanidine,The metabolism of Tizanidine can be increased when combined with Insulin pork.
Etoposide,The metabolism of Etoposide can be increased when combined with Insulin pork.
Dacarbazine,The metabolism of Dacarbazine can be increased when combined with Insulin pork.
Pimozide,The metabolism of Pimozide can be increased when combined with Insulin pork.
Aminophylline,The metabolism of Aminophylline can be increased when combined with Insulin pork.
Dasatinib,The metabolism of Dasatinib can be increased when combined with Insulin pork.
Acenocoumarol,The metabolism of Acenocoumarol can be increased when combined with Insulin pork.
Pomalidomide,The metabolism of Pomalidomide can be increased when combined with Insulin pork.
Tegafur,The metabolism of Tegafur can be increased when combined with Insulin pork.
Enasidenib,The metabolism of Enasidenib can be increased when combined with Insulin pork.
Tamoxifen,The metabolism of Tamoxifen can be increased when combined with Insulin pork.
Insulin human,The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin pork.
Insulin lispro,The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Insulin pork.
Insulin glargine,The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Insulin pork.
Troglitazone,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Troglitazone.
Glimepiride,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glimepiride.
Disopyramide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Disopyramide.
Acarbose,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Acarbose.
Acetohexamide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Acetohexamide.
Quinine,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Quinine.
Miglitol,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Miglitol.
Chlorpropamide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Chlorpropamide.
Nateglinide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Nateglinide.
Mifepristone,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Mifepristone.
Tolazamide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Tolazamide.
Repaglinide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Repaglinide.
Phenformin,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Phenformin.
Glyburide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glyburide.
Glipizide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glipizide.
Gliclazide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Gliclazide.
Tolbutamide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Tolbutamide.
Bromocriptine,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Bromocriptine.
Gliquidone,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Gliquidone.
Mitiglinide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Mitiglinide.
Sunitinib,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Sunitinib.
Mecasermin,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Mecasermin.
Glisoxepide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glisoxepide.
Insulin aspart,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin aspart.
Insulin detemir,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin detemir.
Insulin glulisine,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin glulisine.
AICA ribonucleotide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with AICA ribonucleotide.
Buformin,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Buformin.
Voglibose,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Voglibose.
NN344,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with NN344.
NBI-6024,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with NBI-6024.
Glibornuride,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glibornuride.
Benfluorex,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Benfluorex.
Lobeglitazone,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Lobeglitazone.
Netoglitazone,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Netoglitazone.
Rivoglitazone,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Rivoglitazone.
Ciglitazone,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Ciglitazone.
Insulin beef,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin beef.
Insulin degludec,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin degludec.
Insulin peglispro,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin peglispro.
Insulin tregopil,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin tregopil.
Ipragliflozin,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Ipragliflozin.
Allicin,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Allicin.
Tofogliflozin,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Tofogliflozin.
"2,4-thiazolidinedione","The risk or severity of hypoglycemia can be increased when Insulin pork is combined with 2,4-thiazolidinedione."
Sotagliflozin,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Sotagliflozin.
Balaglitazone,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Balaglitazone.
Remogliflozin etabonate,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Remogliflozin etabonate.
Carbutamide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Carbutamide.
Guar gum,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Guar gum.
Metahexamide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Metahexamide.
Englitazone,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Englitazone.
Tirzepatide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Tirzepatide.
Gastric inhibitory polypeptide,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Gastric inhibitory polypeptide.
Empagliflozin,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Empagliflozin.
Isradipine,The risk or severity of hypoglycemia can be increased when Isradipine is combined with Insulin pork.
Diltiazem,The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Insulin pork.
Trimethadione,The risk or severity of hypoglycemia can be increased when Trimethadione is combined with Insulin pork.
Amlodipine,The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin pork.
Nimodipine,The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Insulin pork.
Nisoldipine,The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Insulin pork.
Lercanidipine,The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Insulin pork.
Lamotrigine,The risk or severity of hypoglycemia can be increased when Lamotrigine is combined with Insulin pork.
Ethosuximide,The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin pork.
Nicardipine,The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Insulin pork.
Magnesium sulfate,The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Insulin pork.
Loperamide,The risk or severity of hypoglycemia can be increased when Loperamide is combined with Insulin pork.
Nitrendipine,The risk or severity of hypoglycemia can be increased when Nitrendipine is combined with Insulin pork.
Perhexiline,The risk or severity of hypoglycemia can be increased when Perhexiline is combined with Insulin pork.
Bepridil,The risk or severity of hypoglycemia can be increased when Bepridil is combined with Insulin pork.
Mibefradil,The risk or severity of hypoglycemia can be increased when Mibefradil is combined with Insulin pork.
Nimesulide,The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Insulin pork.
Prenylamine,The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Insulin pork.
Cyclandelate,The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin pork.
Fluspirilene,The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin pork.
Clevidipine,The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin pork.
Methsuximide,The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin pork.
Seletracetam,The risk or severity of hypoglycemia can be increased when Seletracetam is combined with Insulin pork.
Nylidrin,The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Insulin pork.
Ziconotide,The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Insulin pork.
Dotarizine,The risk or severity of hypoglycemia can be increased when Dotarizine is combined with Insulin pork.
Xylometazoline,The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Insulin pork.
Nilvadipine,The risk or severity of hypoglycemia can be increased when Nilvadipine is combined with Insulin pork.
Tranilast,The risk or severity of hypoglycemia can be increased when Tranilast is combined with Insulin pork.
Agmatine,The risk or severity of hypoglycemia can be increased when Agmatine is combined with Insulin pork.
Fendiline,The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin pork.
Eperisone,The risk or severity of hypoglycemia can be increased when Eperisone is combined with Insulin pork.
Trimebutine,The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin pork.
Pinaverium,The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Insulin pork.
Tolfenamic acid,The risk or severity of hypoglycemia can be increased when Tolfenamic acid is combined with Insulin pork.
Barnidipine,The risk or severity of hypoglycemia can be increased when Barnidipine is combined with Insulin pork.
Aranidipine,The risk or severity of hypoglycemia can be increased when Aranidipine is combined with Insulin pork.
Azelnidipine,The risk or severity of hypoglycemia can be increased when Azelnidipine is combined with Insulin pork.
Benidipine,The risk or severity of hypoglycemia can be increased when Benidipine is combined with Insulin pork.
Cilnidipine,The risk or severity of hypoglycemia can be increased when Cilnidipine is combined with Insulin pork.
Darodipine,The risk or severity of hypoglycemia can be increased when Darodipine is combined with Insulin pork.
Efonidipine,The risk or severity of hypoglycemia can be increased when Efonidipine is combined with Insulin pork.
Lacidipine,The risk or severity of hypoglycemia can be increased when Lacidipine is combined with Insulin pork.
Manidipine,The risk or severity of hypoglycemia can be increased when Manidipine is combined with Insulin pork.
Niguldipine,The risk or severity of hypoglycemia can be increased when Niguldipine is combined with Insulin pork.
Niludipine,The risk or severity of hypoglycemia can be increased when Niludipine is combined with Insulin pork.
Carboxyamidotriazole,The risk or severity of hypoglycemia can be increased when Carboxyamidotriazole is combined with Insulin pork.
Naftopidil,The risk or severity of hypoglycemia can be increased when Naftopidil is combined with Insulin pork.
Tetrahydropalmatine,The risk or severity of hypoglycemia can be increased when Tetrahydropalmatine is combined with Insulin pork.
Vinpocetine,The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Insulin pork.
Gallopamil,The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Insulin pork.
Bencyclane,The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Insulin pork.
Otilonium,The risk or severity of hypoglycemia can be increased when Otilonium is combined with Insulin pork.
Terodiline,The risk or severity of hypoglycemia can be increased when Terodiline is combined with Insulin pork.
Lidoflazine,The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Insulin pork.
Penfluridol,The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Insulin pork.
Caroverine,The risk or severity of hypoglycemia can be increased when Caroverine is combined with Insulin pork.
WIN 55212-2,The risk or severity of hypoglycemia can be increased when WIN 55212-2 is combined with Insulin pork.
Fish oil,The risk or severity of hypoglycemia can be increased when Fish oil is combined with Insulin pork.
Dexverapamil,The risk or severity of hypoglycemia can be increased when Dexverapamil is combined with Insulin pork.
Emopamil,The risk or severity of hypoglycemia can be increased when Emopamil is combined with Insulin pork.
Lomerizine,The risk or severity of hypoglycemia can be increased when Lomerizine is combined with Insulin pork.
Tetrandrine,The risk or severity of hypoglycemia can be increased when Tetrandrine is combined with Insulin pork.
Dexniguldipine,The risk or severity of hypoglycemia can be increased when Dexniguldipine is combined with Insulin pork.
Felodipine,The risk or severity of hypoglycemia can be increased when Felodipine is combined with Insulin pork.
Amiodarone,The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Insulin pork.
Phentermine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Phentermine.
Ropinirole,The metabolism of Ropinirole can be increased when combined with Insulin pork.
Macimorelin,The therapeutic efficacy of Macimorelin can be decreased when used in combination with Insulin pork.
Liothyronine,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Liothyronine.
Metformin,The risk or severity of adverse effects can be increased when Insulin pork is combined with Metformin.
Benazepril,The risk or severity of hypoglycemia can be increased when Benazepril is combined with Insulin pork.
Testosterone undecanoate,The risk or severity of adverse effects can be increased when Testosterone undecanoate is combined with Insulin pork.
Acetylsalicylic acid,The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin pork.
Baclofen,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Baclofen.
Sotalol,The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin pork.
Fluconazole,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Fluconazole.
Glucagon,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Glucagon.
Metoprolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Metoprolol.
Atenolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Atenolol.
Timolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Timolol.
Labetalol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Labetalol.
Bisoprolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bisoprolol.
Alprenolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Alprenolol.
Pindolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Pindolol.
Acebutolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Acebutolol.
Nadolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Nadolol.
Bevantolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bevantolol.
Practolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Practolol.
Penbutolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Penbutolol.
Oxprenolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Oxprenolol.
Dexpropranolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Dexpropranolol.
Celiprolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Celiprolol.
Nebivolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Nebivolol.
Bufuralol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bufuralol.
Bopindolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bopindolol.
Bupranolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bupranolol.
Indenolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Indenolol.
Befunolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Befunolol.
Arotinolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Arotinolol.
Levobetaxolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Levobetaxolol.
Talinolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Talinolol.
Anisodamine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Anisodamine.
Landiolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Landiolol.
Bucindolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bucindolol.
Esatenolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Esatenolol.
Cloranolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Cloranolol.
Mepindolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Mepindolol.
Epanolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Epanolol.
Tertatolol,The therapeutic efficacy of Insulin pork can be increased when used in combination with Tertatolol.
Betaxolol,The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin pork.
Propranolol,The therapeutic efficacy of Propranolol can be increased when used in combination with Insulin pork.
Carvedilol,The therapeutic efficacy of Carvedilol can be increased when used in combination with Insulin pork.
Propafenone,The therapeutic efficacy of Propafenone can be increased when used in combination with Insulin pork.
Hydroxychloroquine,The therapeutic efficacy of Insulin pork can be increased when used in combination with Hydroxychloroquine.
Metoclopramide,The therapeutic efficacy of Metoclopramide can be increased when used in combination with Insulin pork.
Beclomethasone dipropionate,The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Insulin pork.
Betamethasone,The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Insulin pork.
Triamcinolone,The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Insulin pork.
Prednisone,The risk or severity of hyperglycemia can be increased when Prednisone is combined with Insulin pork.
Fludrocortisone,The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Insulin pork.
Hydrocortisone,The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Insulin pork.
Mometasone,The risk or severity of hyperglycemia can be increased when Mometasone is combined with Insulin pork.
Prednisolone,The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Insulin pork.
Methylprednisolone,The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin pork.
Dexamethasone,The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin pork.
Corticotropin,The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Insulin pork.
Cortisone acetate,The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Insulin pork.
Paramethasone,The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Insulin pork.
Ciclesonide,The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Insulin pork.
Fluticasone furoate,The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Insulin pork.
Fluprednidene,The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin pork.
Fluocortolone,The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin pork.
Meprednisone,The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Insulin pork.
Dexamethasone isonicotinate,The risk or severity of hyperglycemia can be increased when Dexamethasone isonicotinate is combined with Insulin pork.
Clobetasol,The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Insulin pork.
Deflazacort,The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Insulin pork.
Cortivazol,The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Insulin pork.
Prednylidene,The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Insulin pork.
Cloprednol,The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Insulin pork.
Fluticasone,The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Insulin pork.
Mometasone furoate,The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Insulin pork.
Flunisolide,The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Insulin pork.
Trilostane,The risk or severity of hyperglycemia can be increased when Trilostane is combined with Insulin pork.
Budesonide,The risk or severity of hyperglycemia can be increased when Budesonide is combined with Insulin pork.
Aldosterone,The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Insulin pork.
Fluprednisolone,The risk or severity of hyperglycemia can be increased when Fluprednisolone is combined with Insulin pork.
Melengestrol,The risk or severity of hyperglycemia can be increased when Melengestrol is combined with Insulin pork.
Cortisone,The risk or severity of hyperglycemia can be increased when Cortisone is combined with Insulin pork.
Diflorasone,The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin pork.
Alclometasone,The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin pork.
Medrysone,The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin pork.
Amcinonide,The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Insulin pork.
Fluorometholone,The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Insulin pork.
Desoximetasone,The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Insulin pork.
Fluticasone propionate,The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Insulin pork.
Fluocinolone acetonide,The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Insulin pork.
Ulobetasol,The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin pork.
Flumethasone,The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Insulin pork.
Clocortolone,The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Insulin pork.
Flurandrenolide,The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Insulin pork.
Loteprednol etabonate,The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin pork.
Rimexolone,The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Insulin pork.
Clobetasol propionate,The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Insulin pork.
Fluocinonide,The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Insulin pork.
Prednicarbate,The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Insulin pork.
Desonide,The risk or severity of hyperglycemia can be increased when Desonide is combined with Insulin pork.
Difluprednate,The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin pork.
Halcinonide,The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin pork.
Tixocortol,The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Insulin pork.
Difluocortolone,The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin pork.
Clobetasone,The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin pork.
Fluocortin,The risk or severity of hyperglycemia can be increased when Fluocortin is combined with Insulin pork.
Fluperolone,The risk or severity of hyperglycemia can be increased when Fluperolone is combined with Insulin pork.
Formocortal,The risk or severity of hyperglycemia can be increased when Formocortal is combined with Insulin pork.
Halometasone,The risk or severity of hyperglycemia can be increased when Halometasone is combined with Insulin pork.
Fluclorolone,The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Insulin pork.
Hydrocortisone aceponate,The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Insulin pork.
Hydrocortisone acetate,The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Insulin pork.
Hydrocortisone butyrate,The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Insulin pork.
Hydrocortisone cypionate,The risk or severity of hyperglycemia can be increased when Hydrocortisone cypionate is combined with Insulin pork.
Hydrocortisone probutate,The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Insulin pork.
Hydrocortisone valerate,The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin pork.
Hydrocortisone succinate,The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Insulin pork.
Loteprednol,The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin pork.
Prednisolone phosphate,The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Insulin pork.
Prednisolone hemisuccinate,The risk or severity of hyperglycemia can be increased when Prednisolone hemisuccinate is combined with Insulin pork.
Fluprednidene acetate,The risk or severity of hyperglycemia can be increased when Fluprednidene acetate is combined with Insulin pork.
Methylprednisolone aceponate,The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin pork.
Methylprednisolone hemisuccinate,The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Insulin pork.
Prednisone acetate,The risk or severity of hyperglycemia can be increased when Prednisone acetate is combined with Insulin pork.
Clocortolone acetate,The risk or severity of hyperglycemia can be increased when Clocortolone acetate is combined with Insulin pork.
Melengestrol acetate,The risk or severity of hyperglycemia can be increased when Melengestrol acetate is combined with Insulin pork.
Betamethasone phosphate,The risk or severity of hyperglycemia can be increased when Betamethasone phosphate is combined with Insulin pork.
Prednisolone acetate,The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Insulin pork.
Levothyroxine,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Levothyroxine.
Thyrotropin alfa,Thyrotropin alfa may decrease the hypoglycemic activities of Insulin pork.
Liotrix,Liotrix may decrease the hypoglycemic activities of Insulin pork.
Tiratricol,Tiratricol may decrease the hypoglycemic activities of Insulin pork.
"Thyroid, porcine","Thyroid, porcine may decrease the hypoglycemic activities of Insulin pork."
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Trastuzumab.
Natalizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trastuzumab.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Trastuzumab.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Trastuzumab.
Darbepoetin alfa,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trastuzumab.
Erythropoietin,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Trastuzumab.
Peginesatide,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Trastuzumab.
Methoxy polyethylene glycol-epoetin beta,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trastuzumab.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Trastuzumab.
Paclitaxel,The serum concentration of Paclitaxel can be decreased when it is combined with Trastuzumab.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Trastuzumab.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Trastuzumab.
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Trastuzumab.
Estrone,Estrone may increase the thrombogenic activities of Trastuzumab.
Estradiol,Estradiol may increase the thrombogenic activities of Trastuzumab.
Dienestrol,Dienestrol may increase the thrombogenic activities of Trastuzumab.
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Trastuzumab.
Mestranol,Mestranol may increase the thrombogenic activities of Trastuzumab.
Estriol,Estriol may increase the thrombogenic activities of Trastuzumab.
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Trastuzumab.
Quinestrol,Quinestrol may increase the thrombogenic activities of Trastuzumab.
Hexestrol,Hexestrol may increase the thrombogenic activities of Trastuzumab.
Tibolone,Tibolone may increase the thrombogenic activities of Trastuzumab.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Trastuzumab."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Trastuzumab."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Trastuzumab.
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Trastuzumab.
Zeranol,Zeranol may increase the thrombogenic activities of Trastuzumab.
Equol,Equol may increase the thrombogenic activities of Trastuzumab.
Promestriene,Promestriene may increase the thrombogenic activities of Trastuzumab.
Methallenestril,Methallenestril may increase the thrombogenic activities of Trastuzumab.
Epimestrol,Epimestrol may increase the thrombogenic activities of Trastuzumab.
Moxestrol,Moxestrol may increase the thrombogenic activities of Trastuzumab.
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Trastuzumab.
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Trastuzumab.
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Trastuzumab.
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Trastuzumab.
Biochanin A,Biochanin A may increase the thrombogenic activities of Trastuzumab.
Formononetin,Formononetin may increase the thrombogenic activities of Trastuzumab.
Leflunomide,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Leflunomide.
Tofacitinib,Trastuzumab may increase the immunosuppressive activities of Tofacitinib.
Etanercept,Trastuzumab may increase the neutropenic activities of Etanercept.
Basiliximab,Trastuzumab may increase the neutropenic activities of Basiliximab.
Muromonab,Trastuzumab may increase the neutropenic activities of Muromonab.
Daclizumab,Trastuzumab may increase the neutropenic activities of Daclizumab.
Cladribine,Trastuzumab may increase the neutropenic activities of Cladribine.
Mycophenolate mofetil,Trastuzumab may increase the neutropenic activities of Mycophenolate mofetil.
Sirolimus,Trastuzumab may increase the neutropenic activities of Sirolimus.
Azathioprine,Trastuzumab may increase the neutropenic activities of Azathioprine.
Mycophenolic acid,Trastuzumab may increase the neutropenic activities of Mycophenolic acid.
Thalidomide,Trastuzumab may increase the neutropenic activities of Thalidomide.
Abatacept,Trastuzumab may increase the neutropenic activities of Abatacept.
Everolimus,Trastuzumab may increase the neutropenic activities of Everolimus.
Belatacept,Trastuzumab may increase the neutropenic activities of Belatacept.
Belimumab,Trastuzumab may increase the neutropenic activities of Belimumab.
Teriflunomide,Trastuzumab may increase the neutropenic activities of Teriflunomide.
Certolizumab pegol,Trastuzumab may increase the neutropenic activities of Certolizumab pegol.
Canakinumab,Trastuzumab may increase the neutropenic activities of Canakinumab.
Vedolizumab,Trastuzumab may increase the neutropenic activities of Vedolizumab.
Siltuximab,Trastuzumab may increase the neutropenic activities of Siltuximab.
Gusperimus,Trastuzumab may increase the neutropenic activities of Gusperimus.
Voclosporin,Trastuzumab may increase the neutropenic activities of Voclosporin.
Antilymphocyte immunoglobulin (horse),Trastuzumab may increase the neutropenic activities of Antilymphocyte immunoglobulin (horse).
Mepolizumab,Trastuzumab may increase the neutropenic activities of Mepolizumab.
Gemcitabine,Trastuzumab may increase the neutropenic activities of Gemcitabine.
Cyclophosphamide,Trastuzumab may increase the neutropenic activities of Cyclophosphamide.
Fluorouracil,Trastuzumab may increase the neutropenic activities of Fluorouracil.
Methotrexate,Trastuzumab may increase the neutropenic activities of Methotrexate.
Triamcinolone,Trastuzumab may increase the neutropenic activities of Triamcinolone.
Cytarabine,Trastuzumab may increase the neutropenic activities of Cytarabine.
Busulfan,Trastuzumab may increase the neutropenic activities of Busulfan.
Mercaptopurine,Trastuzumab may increase the neutropenic activities of Mercaptopurine.
Melphalan,Trastuzumab may increase the neutropenic activities of Melphalan.
Fludarabine,Trastuzumab may increase the neutropenic activities of Fludarabine.
Thiotepa,Trastuzumab may increase the neutropenic activities of Thiotepa.
Glatiramer,Trastuzumab may increase the neutropenic activities of Glatiramer.
Anakinra,Trastuzumab may increase the neutropenic activities of Anakinra.
Adalimumab,Trastuzumab may increase the neutropenic activities of Adalimumab.
Infliximab,Trastuzumab may increase the neutropenic activities of Infliximab.
Alemtuzumab,Trastuzumab may increase the neutropenic activities of Alemtuzumab.
Antithymocyte immunoglobulin (rabbit),Trastuzumab may increase the neutropenic activities of Antithymocyte immunoglobulin (rabbit).
Lenalidomide,Trastuzumab may increase the neutropenic activities of Lenalidomide.
Eculizumab,Trastuzumab may increase the neutropenic activities of Eculizumab.
Tocilizumab,Trastuzumab may increase the neutropenic activities of Tocilizumab.
Rilonacept,Trastuzumab may increase the neutropenic activities of Rilonacept.
Golimumab,Trastuzumab may increase the neutropenic activities of Golimumab.
Pomalidomide,Trastuzumab may increase the neutropenic activities of Pomalidomide.
Secukinumab,Trastuzumab may increase the neutropenic activities of Secukinumab.
Gemtuzumab ozogamicin,Trastuzumab may increase the neutropenic activities of Gemtuzumab ozogamicin.
Pegaspargase,Trastuzumab may increase the neutropenic activities of Pegaspargase.
Rituximab,Trastuzumab may increase the neutropenic activities of Rituximab.
Ibritumomab tiuxetan,Trastuzumab may increase the neutropenic activities of Ibritumomab tiuxetan.
Tositumomab,Trastuzumab may increase the neutropenic activities of Tositumomab.
Phenylalanine,Trastuzumab may increase the neutropenic activities of Phenylalanine.
Carmustine,Trastuzumab may increase the neutropenic activities of Carmustine.
Amsacrine,Trastuzumab may increase the neutropenic activities of Amsacrine.
Bleomycin,Trastuzumab may increase the neutropenic activities of Bleomycin.
Chlorambucil,Trastuzumab may increase the neutropenic activities of Chlorambucil.
Mitomycin,Trastuzumab may increase the neutropenic activities of Mitomycin.
Vindesine,Trastuzumab may increase the neutropenic activities of Vindesine.
Floxuridine,Trastuzumab may increase the neutropenic activities of Floxuridine.
Tioguanine,Trastuzumab may increase the neutropenic activities of Tioguanine.
Vinorelbine,Trastuzumab may increase the neutropenic activities of Vinorelbine.
Sorafenib,Trastuzumab may increase the neutropenic activities of Sorafenib.
Streptozocin,Trastuzumab may increase the neutropenic activities of Streptozocin.
Betamethasone,Trastuzumab may increase the neutropenic activities of Betamethasone.
Teniposide,Trastuzumab may increase the neutropenic activities of Teniposide.
Altretamine,Trastuzumab may increase the neutropenic activities of Altretamine.
Cisplatin,Trastuzumab may increase the neutropenic activities of Cisplatin.
Oxaliplatin,Trastuzumab may increase the neutropenic activities of Oxaliplatin.
Vincristine,Trastuzumab may increase the neutropenic activities of Vincristine.
Pentostatin,Trastuzumab may increase the neutropenic activities of Pentostatin.
Vinblastine,Trastuzumab may increase the neutropenic activities of Vinblastine.
Imatinib,Trastuzumab may increase the neutropenic activities of Imatinib.
Clofarabine,Trastuzumab may increase the neutropenic activities of Clofarabine.
Prednisone,Trastuzumab may increase the neutropenic activities of Prednisone.
Pemetrexed,Trastuzumab may increase the neutropenic activities of Pemetrexed.
Fludrocortisone,Trastuzumab may increase the neutropenic activities of Fludrocortisone.
Imiquimod,Trastuzumab may increase the neutropenic activities of Imiquimod.
Hydrocortisone,Trastuzumab may increase the neutropenic activities of Hydrocortisone.
Tretinoin,Trastuzumab may increase the neutropenic activities of Tretinoin.
Irinotecan,Trastuzumab may increase the neutropenic activities of Irinotecan.
Etoposide,Trastuzumab may increase the neutropenic activities of Etoposide.
Dacarbazine,Trastuzumab may increase the neutropenic activities of Dacarbazine.
Temozolomide,Trastuzumab may increase the neutropenic activities of Temozolomide.
Prednisolone,Trastuzumab may increase the neutropenic activities of Prednisolone.
Mechlorethamine,Trastuzumab may increase the neutropenic activities of Mechlorethamine.
Azacitidine,Trastuzumab may increase the neutropenic activities of Azacitidine.
Carboplatin,Trastuzumab may increase the neutropenic activities of Carboplatin.
Methylprednisolone,Trastuzumab may increase the neutropenic activities of Methylprednisolone.
Dactinomycin,Trastuzumab may increase the neutropenic activities of Dactinomycin.
Hydroxyurea,Trastuzumab may increase the neutropenic activities of Hydroxyurea.
Topotecan,Trastuzumab may increase the neutropenic activities of Topotecan.
Capecitabine,Trastuzumab may increase the neutropenic activities of Capecitabine.
Procarbazine,Trastuzumab may increase the neutropenic activities of Procarbazine.
Ifosfamide,Trastuzumab may increase the neutropenic activities of Ifosfamide.
Estramustine,Trastuzumab may increase the neutropenic activities of Estramustine.
Mitoxantrone,Trastuzumab may increase the neutropenic activities of Mitoxantrone.
Lomustine,Trastuzumab may increase the neutropenic activities of Lomustine.
Budesonide,Trastuzumab may increase the neutropenic activities of Budesonide.
Dexamethasone,Trastuzumab may increase the neutropenic activities of Dexamethasone.
Docetaxel,Trastuzumab may increase the neutropenic activities of Docetaxel.
Dasatinib,Trastuzumab may increase the neutropenic activities of Dasatinib.
Sunitinib,Trastuzumab may increase the neutropenic activities of Sunitinib.
Nelarabine,Trastuzumab may increase the neutropenic activities of Nelarabine.
Corticotropin,Trastuzumab may increase the neutropenic activities of Corticotropin.
Cortisone acetate,Trastuzumab may increase the neutropenic activities of Cortisone acetate.
Nilotinib,Trastuzumab may increase the neutropenic activities of Nilotinib.
Trabectedin,Trastuzumab may increase the neutropenic activities of Trabectedin.
Trastuzumab emtansine,Trastuzumab may increase the neutropenic activities of Trastuzumab emtansine.
Temsirolimus,Trastuzumab may increase the neutropenic activities of Temsirolimus.
Pazopanib,Trastuzumab may increase the neutropenic activities of Pazopanib.
Panobinostat,Trastuzumab may increase the neutropenic activities of Panobinostat.
Cabazitaxel,Trastuzumab may increase the neutropenic activities of Cabazitaxel.
Pralatrexate,Trastuzumab may increase the neutropenic activities of Pralatrexate.
Brentuximab vedotin,Trastuzumab may increase the neutropenic activities of Brentuximab vedotin.
Ruxolitinib,Trastuzumab may increase the neutropenic activities of Ruxolitinib.
Obinutuzumab,Trastuzumab may increase the neutropenic activities of Obinutuzumab.
Blinatumomab,Trastuzumab may increase the neutropenic activities of Blinatumomab.
Ibrutinib,Trastuzumab may increase the neutropenic activities of Ibrutinib.
Idelalisib,Trastuzumab may increase the neutropenic activities of Idelalisib.
Palbociclib,Trastuzumab may increase the neutropenic activities of Palbociclib.
Dinutuximab,Trastuzumab may increase the neutropenic activities of Dinutuximab.
Vilanterol,Trastuzumab may increase the neutropenic activities of Vilanterol.
Stepronin,Trastuzumab may increase the neutropenic activities of Stepronin.
Castanospermine,Trastuzumab may increase the neutropenic activities of Castanospermine.
2-Methoxyethanol,Trastuzumab may increase the neutropenic activities of 2-Methoxyethanol.
Gallium nitrate,Trastuzumab may increase the neutropenic activities of Gallium nitrate.
Dimethyl fumarate,Trastuzumab may increase the neutropenic activities of Dimethyl fumarate.
Deflazacort,Trastuzumab may increase the neutropenic activities of Deflazacort.
Triptolide,Trastuzumab may increase the neutropenic activities of Triptolide.
Mizoribine,Trastuzumab may increase the neutropenic activities of Mizoribine.
Trofosfamide,Trastuzumab may increase the neutropenic activities of Trofosfamide.
Doxifluridine,Trastuzumab may increase the neutropenic activities of Doxifluridine.
Deoxyspergualin,Trastuzumab may increase the neutropenic activities of Deoxyspergualin.
Acteoside,Trastuzumab may increase the neutropenic activities of Acteoside.
Hypericin,Trastuzumab may increase the neutropenic activities of Hypericin.
Alefacept,Trastuzumab may increase the neutropenic activities of Alefacept.
Efalizumab,Trastuzumab may increase the neutropenic activities of Efalizumab.
Pirfenidone,Trastuzumab may increase the neutropenic activities of Pirfenidone.
Afelimomab,Trastuzumab may increase the neutropenic activities of Afelimomab.
Apremilast,Trastuzumab may increase the neutropenic activities of Apremilast.
Abetimus,Trastuzumab may increase the neutropenic activities of Abetimus.
Brodalumab,Trastuzumab may increase the neutropenic activities of Brodalumab.
Begelomab,Trastuzumab may increase the neutropenic activities of Begelomab.
Wortmannin,Trastuzumab may increase the neutropenic activities of Wortmannin.
9-(N-methyl-L-isoleucine)-cyclosporin A,Trastuzumab may increase the neutropenic activities of 9-(N-methyl-L-isoleucine)-cyclosporin A.
Peginterferon alfa-2a,Trastuzumab may increase the neutropenic activities of Peginterferon alfa-2a.
Interferon alfa-n3,Trastuzumab may increase the neutropenic activities of Interferon alfa-n3.
Peginterferon alfa-2b,Trastuzumab may increase the neutropenic activities of Peginterferon alfa-2b.
Aldesleukin,Trastuzumab may increase the neutropenic activities of Aldesleukin.
Interferon alfacon-1,Trastuzumab may increase the neutropenic activities of Interferon alfacon-1.
Bevacizumab,Trastuzumab may increase the neutropenic activities of Bevacizumab.
Bortezomib,Trastuzumab may increase the neutropenic activities of Bortezomib.
Raltitrexed,Trastuzumab may increase the neutropenic activities of Raltitrexed.
Bexarotene,Trastuzumab may increase the neutropenic activities of Bexarotene.
Dexrazoxane,Trastuzumab may increase the neutropenic activities of Dexrazoxane.
Chloramphenicol,Trastuzumab may increase the neutropenic activities of Chloramphenicol.
Zidovudine,Trastuzumab may increase the neutropenic activities of Zidovudine.
Propylthiouracil,Trastuzumab may increase the neutropenic activities of Propylthiouracil.
Carbamazepine,Trastuzumab may increase the neutropenic activities of Carbamazepine.
Linezolid,Trastuzumab may increase the neutropenic activities of Linezolid.
Methimazole,Trastuzumab may increase the neutropenic activities of Methimazole.
Flucytosine,Trastuzumab may increase the neutropenic activities of Flucytosine.
Arsenic trioxide,Trastuzumab may increase the neutropenic activities of Arsenic trioxide.
Decitabine,Trastuzumab may increase the neutropenic activities of Decitabine.
Vorinostat,Trastuzumab may increase the neutropenic activities of Vorinostat.
Ixabepilone,Trastuzumab may increase the neutropenic activities of Ixabepilone.
Belinostat,Trastuzumab may increase the neutropenic activities of Belinostat.
Bosutinib,Trastuzumab may increase the neutropenic activities of Bosutinib.
Bendamustine,Trastuzumab may increase the neutropenic activities of Bendamustine.
Eribulin,Trastuzumab may increase the neutropenic activities of Eribulin.
Carfilzomib,Trastuzumab may increase the neutropenic activities of Carfilzomib.
Ponatinib,Trastuzumab may increase the neutropenic activities of Ponatinib.
Olaparib,Trastuzumab may increase the neutropenic activities of Olaparib.
Sarilumab,Trastuzumab may increase the neutropenic activities of Sarilumab.
Briakinumab,Trastuzumab may increase the neutropenic activities of Briakinumab.
Tepoxalin,Trastuzumab may increase the neutropenic activities of Tepoxalin.
Tetrandrine,Trastuzumab may increase the neutropenic activities of Tetrandrine.
Sulfasalazine,Trastuzumab may increase the neutropenic activities of Sulfasalazine.
Hydroxychloroquine,Trastuzumab may increase the neutropenic activities of Hydroxychloroquine.
Trifluridine,Trastuzumab may increase the neutropenic activities of Trifluridine.
Aldosterone,Trastuzumab may increase the neutropenic activities of Aldosterone.
Trilostane,Trastuzumab may increase the neutropenic activities of Trilostane.
Prednylidene,Trastuzumab may increase the neutropenic activities of Prednylidene.
Paramethasone,Trastuzumab may increase the neutropenic activities of Paramethasone.
Meprednisone,Trastuzumab may increase the neutropenic activities of Meprednisone.
Melengestrol,Trastuzumab may increase the neutropenic activities of Melengestrol.
Fluprednisolone,Trastuzumab may increase the neutropenic activities of Fluprednisolone.
Flunisolide,Trastuzumab may increase the neutropenic activities of Flunisolide.
Cortivazol,Trastuzumab may increase the neutropenic activities of Cortivazol.
Cloprednol,Trastuzumab may increase the neutropenic activities of Cloprednol.
Alclometasone,Trastuzumab may increase the neutropenic activities of Alclometasone.
Amcinonide,Trastuzumab may increase the neutropenic activities of Amcinonide.
Ciclesonide,Trastuzumab may increase the neutropenic activities of Ciclesonide.
Clobetasol,Trastuzumab may increase the neutropenic activities of Clobetasol.
Clobetasol propionate,Trastuzumab may increase the neutropenic activities of Clobetasol propionate.
Clobetasone,Trastuzumab may increase the neutropenic activities of Clobetasone.
Clocortolone,Trastuzumab may increase the neutropenic activities of Clocortolone.
Desonide,Trastuzumab may increase the neutropenic activities of Desonide.
Desoximetasone,Trastuzumab may increase the neutropenic activities of Desoximetasone.
Dexamethasone isonicotinate,Trastuzumab may increase the neutropenic activities of Dexamethasone isonicotinate.
Diflorasone,Trastuzumab may increase the neutropenic activities of Diflorasone.
Difluocortolone,Trastuzumab may increase the neutropenic activities of Difluocortolone.
Difluprednate,Trastuzumab may increase the neutropenic activities of Difluprednate.
Fluclorolone,Trastuzumab may increase the neutropenic activities of Fluclorolone.
Flumethasone,Trastuzumab may increase the neutropenic activities of Flumethasone.
Fluocinolone acetonide,Trastuzumab may increase the neutropenic activities of Fluocinolone acetonide.
Fluocinonide,Trastuzumab may increase the neutropenic activities of Fluocinonide.
Fluocortin,Trastuzumab may increase the neutropenic activities of Fluocortin.
Fluocortolone,Trastuzumab may increase the neutropenic activities of Fluocortolone.
Fluorometholone,Trastuzumab may increase the neutropenic activities of Fluorometholone.
Fluperolone,Trastuzumab may increase the neutropenic activities of Fluperolone.
Fluprednidene,Trastuzumab may increase the neutropenic activities of Fluprednidene.
Flurandrenolide,Trastuzumab may increase the neutropenic activities of Flurandrenolide.
Fluticasone,Trastuzumab may increase the neutropenic activities of Fluticasone.
Fluticasone furoate,Trastuzumab may increase the neutropenic activities of Fluticasone furoate.
Fluticasone propionate,Trastuzumab may increase the neutropenic activities of Fluticasone propionate.
Formocortal,Trastuzumab may increase the neutropenic activities of Formocortal.
Halcinonide,Trastuzumab may increase the neutropenic activities of Halcinonide.
Halometasone,Trastuzumab may increase the neutropenic activities of Halometasone.
Hydrocortisone aceponate,Trastuzumab may increase the neutropenic activities of Hydrocortisone aceponate.
Hydrocortisone acetate,Trastuzumab may increase the neutropenic activities of Hydrocortisone acetate.
Hydrocortisone probutate,Trastuzumab may increase the neutropenic activities of Hydrocortisone probutate.
Hydrocortisone butyrate,Trastuzumab may increase the neutropenic activities of Hydrocortisone butyrate.
Hydrocortisone succinate,Trastuzumab may increase the neutropenic activities of Hydrocortisone succinate.
Hydrocortisone valerate,Trastuzumab may increase the neutropenic activities of Hydrocortisone valerate.
Loteprednol etabonate,Trastuzumab may increase the neutropenic activities of Loteprednol etabonate.
Medrysone,Trastuzumab may increase the neutropenic activities of Medrysone.
Mometasone,Trastuzumab may increase the neutropenic activities of Mometasone.
Mometasone furoate,Trastuzumab may increase the neutropenic activities of Mometasone furoate.
Prednicarbate,Trastuzumab may increase the neutropenic activities of Prednicarbate.
Rimexolone,Trastuzumab may increase the neutropenic activities of Rimexolone.
Tixocortol,Trastuzumab may increase the neutropenic activities of Tixocortol.
Ulobetasol,Trastuzumab may increase the neutropenic activities of Ulobetasol.
Colchicine,Trastuzumab may increase the neutropenic activities of Colchicine.
Monomethyl fumarate,Trastuzumab may increase the neutropenic activities of Monomethyl fumarate.
Penicillamine,Trastuzumab may increase the neutropenic activities of Penicillamine.
Indomethacin,Trastuzumab may increase the neutropenic activities of Indomethacin.
Brequinar,Trastuzumab may increase the neutropenic activities of Brequinar.
Interferon gamma-1b,Trastuzumab may increase the neutropenic activities of Interferon gamma-1b.
omega interferon,Trastuzumab may increase the neutropenic activities of omega interferon.
Interferon alfa-n1,Trastuzumab may increase the neutropenic activities of Interferon alfa-n1.
Peginterferon beta-1a,Trastuzumab may increase the neutropenic activities of Peginterferon beta-1a.
Cepeginterferon alfa-2B,Trastuzumab may increase the neutropenic activities of Cepeginterferon alfa-2B.
Interferon beta-1b,Trastuzumab may increase the neutropenic activities of Interferon beta-1b.
"Interferon alfa-2a, Recombinant","Trastuzumab may increase the neutropenic activities of Interferon alfa-2a, Recombinant."
Interferon alfa,Trastuzumab may increase the neutropenic activities of Interferon alfa.
Interferon alfa-2b,Trastuzumab may increase the neutropenic activities of Interferon alfa-2b.
Ixekizumab,Trastuzumab may increase the neutropenic activities of Ixekizumab.
Sirukumab,Trastuzumab may increase the neutropenic activities of Sirukumab.
Baricitinib,Trastuzumab may increase the neutropenic activities of Baricitinib.
Guselkumab,Trastuzumab may increase the neutropenic activities of Guselkumab.
Ozanimod,Trastuzumab may increase the neutropenic activities of Ozanimod.
Emapalumab,Trastuzumab may increase the neutropenic activities of Emapalumab.
Siponimod,Trastuzumab may increase the neutropenic activities of Siponimod.
Risankizumab,Trastuzumab may increase the neutropenic activities of Risankizumab.
Bleselumab,Trastuzumab may increase the neutropenic activities of Bleselumab.
Beclomethasone dipropionate,Trastuzumab may increase the neutropenic activities of Beclomethasone dipropionate.
Ravulizumab,Trastuzumab may increase the neutropenic activities of Ravulizumab.
Peficitinib,Trastuzumab may increase the neutropenic activities of Peficitinib.
Rozanolixizumab,Trastuzumab may increase the neutropenic activities of Rozanolixizumab.
Fingolimod,Trastuzumab may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Trastuzumab.
Digoxin,Digoxin may decrease the cardiotoxic activities of Trastuzumab.
Acetyldigitoxin,Acetyldigitoxin may decrease the cardiotoxic activities of Trastuzumab.
Deslanoside,Deslanoside may decrease the cardiotoxic activities of Trastuzumab.
Ouabain,Ouabain may decrease the cardiotoxic activities of Trastuzumab.
Digitoxin,Digitoxin may decrease the cardiotoxic activities of Trastuzumab.
Oleandrin,Oleandrin may decrease the cardiotoxic activities of Trastuzumab.
Cymarin,Cymarin may decrease the cardiotoxic activities of Trastuzumab.
Proscillaridin,Proscillaridin may decrease the cardiotoxic activities of Trastuzumab.
Metildigoxin,Metildigoxin may decrease the cardiotoxic activities of Trastuzumab.
Lanatoside C,Lanatoside C may decrease the cardiotoxic activities of Trastuzumab.
Gitoformate,Gitoformate may decrease the cardiotoxic activities of Trastuzumab.
Acetyldigoxin,Acetyldigoxin may decrease the cardiotoxic activities of Trastuzumab.
Peruvoside,Peruvoside may decrease the cardiotoxic activities of Trastuzumab.
Tamoxifen,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Tamoxifen.
Anastrozole,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Anastrozole.
Paclitaxel trevatide,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Paclitaxel trevatide.
Paclitaxel poliglumex,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Paclitaxel poliglumex.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Trastuzumab.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Trastuzumab.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Trastuzumab.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Trastuzumab.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Trastuzumab.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Trastuzumab.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Trastuzumab.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Trastuzumab.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Trastuzumab.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Trastuzumab."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Trastuzumab.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Trastuzumab.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Trastuzumab."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Trastuzumab.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Trastuzumab.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Trastuzumab.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Trastuzumab.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Trastuzumab.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Trastuzumab.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Trastuzumab.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Trastuzumab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Trastuzumab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Trastuzumab.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Trastuzumab.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Trastuzumab.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Trastuzumab.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Trastuzumab.
Ocrelizumab,Ocrelizumab may increase the immunosuppressive activities of Trastuzumab.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Trastuzumab.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Trastuzumab.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Trastuzumab.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Trastuzumab.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Trastuzumab.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Trastuzumab.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Trastuzumab.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Trastuzumab.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Trastuzumab.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Trastuzumab.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Trastuzumab.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Trastuzumab.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Trastuzumab.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Trastuzumab.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Trastuzumab.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Trastuzumab.
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Trastuzumab.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Trastuzumab is combined with Digoxin Immune Fab (Ovine).
Capromab pendetide,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Capromab pendetide.
Palivizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Palivizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Technetium Tc-99m arcitumomab.
Panitumumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pexelizumab.
Epratuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Trastuzumab is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Trastuzumab is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Trastuzumab is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Trastuzumab is combined with NAV 1800.
Otelixizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Trastuzumab is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Veltuzumab.
PRO-542,The risk or severity of adverse effects can be increased when Trastuzumab is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Trastuzumab is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Trastuzumab is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Trastuzumab is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Trastuzumab is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Trastuzumab is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Trastuzumab is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Trastuzumab is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lumiliximab.
Ipilimumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Clenoliximab.
BIIB015,The risk or severity of adverse effects can be increased when Trastuzumab is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Trastuzumab is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Trastuzumab is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Catumaxomab.
Volociximab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ofatumumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Raxibacumab.
Nivolumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Nivolumab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dulaglutide.
Asfotase alfa,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Evolocumab.
Daratumumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Necitumumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Solanezumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tremelimumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lampalizumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Anifrolumab.
Benralizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Trastuzumab is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Plozalizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Besilesomab.
Burosumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Cemiplimab.
Camrelizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Setrusumab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Refanezumab.
Bermekimab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Nemolizumab.
Gedivumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Trastuzumab is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Naratuximab emtansine.
Tildrakizumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tildrakizumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ustekinumab.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Zenocutuzumab.
Cyclosporine,Trastuzumab may increase the immunosuppressive activities of Cyclosporine.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Trastuzumab."
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Trastuzumab.
Lopinavir,The serum concentration of Trastuzumab can be increased when it is combined with Lopinavir.
Epirubicin,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Epirubicin.
Daunorubicin,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Daunorubicin.
Doxorubicin,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Doxorubicin.
Idarubicin,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Idarubicin.
Pirarubicin,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Pirarubicin.
Aldoxorubicin,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Aldoxorubicin.
Gancotamab,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Gancotamab.
Valrubicin,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Valrubicin.
SP1049C,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with SP1049C.
DTS-201,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with DTS-201.
Annamycin,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Annamycin.
Plicamycin,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Plicamycin.
Aclarubicin,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Aclarubicin.
Zorubicin,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Zorubicin.
Sabarubicin,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Sabarubicin.
Zoptarelin doxorubicin,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Zoptarelin doxorubicin.
GPX-150,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with GPX-150.
Inebilizumab,The risk or severity of infection can be increased when Trastuzumab is combined with Inebilizumab.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Rituximab.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Rituximab.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Rituximab.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Rituximab.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Rituximab.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Rituximab.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Rituximab.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Rituximab.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Rituximab."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Rituximab.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Rituximab.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rituximab.
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Rituximab.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Rituximab.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Rituximab.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Rituximab.
Basiliximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Basiliximab.
Muromonab,The risk or severity of adverse effects can be increased when Rituximab is combined with Muromonab.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Rituximab is combined with Ibritumomab tiuxetan.
Tositumomab,The risk or severity of adverse effects can be increased when Rituximab is combined with Tositumomab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Alemtuzumab.
Alefacept,The risk or severity of adverse effects can be increased when Rituximab is combined with Alefacept.
Efalizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Rituximab is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Rituximab is combined with Interferon alfa-2b.
Daclizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Rituximab is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Rituximab is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Rituximab is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Rituximab is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Rituximab is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Rituximab is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Rituximab is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Rituximab is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Rituximab is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Rituximab is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Rituximab is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Rituximab is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Rituximab is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Rituximab is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Rituximab is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Rituximab is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Rituximab is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Rituximab is combined with Beclomethasone dipropionate.
Sorafenib,The risk or severity of adverse effects can be increased when Rituximab is combined with Sorafenib.
Streptozocin,The risk or severity of adverse effects can be increased when Rituximab is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Rituximab is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Rituximab is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Rituximab is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Rituximab is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Rituximab is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Rituximab is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Rituximab is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Rituximab is combined with Altretamine.
Zidovudine,The risk or severity of adverse effects can be increased when Rituximab is combined with Zidovudine.
Oxaliplatin,The risk or severity of adverse effects can be increased when Rituximab is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Rituximab is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Rituximab is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Rituximab is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Rituximab is combined with Pentostatin.
Methotrexate,The risk or severity of adverse effects can be increased when Rituximab is combined with Methotrexate.
Carbamazepine,The risk or severity of adverse effects can be increased when Rituximab is combined with Carbamazepine.
Vinblastine,The risk or severity of adverse effects can be increased when Rituximab is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Rituximab is combined with Linezolid.
Imatinib,The risk or severity of adverse effects can be increased when Rituximab is combined with Imatinib.
Triamcinolone,The risk or severity of adverse effects can be increased when Rituximab is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Rituximab is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Rituximab is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Rituximab is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Rituximab is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Rituximab is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Rituximab is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Rituximab is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Rituximab is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Rituximab is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Rituximab is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Rituximab is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Rituximab is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Rituximab is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Rituximab is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Rituximab is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Rituximab is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Rituximab is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Rituximab is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Rituximab is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Rituximab is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Rituximab is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Rituximab is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Rituximab is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Rituximab is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Rituximab is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Rituximab is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Rituximab is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Rituximab is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Rituximab is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Rituximab is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Rituximab is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Rituximab is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Rituximab is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Rituximab is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Rituximab is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Rituximab is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Rituximab is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Rituximab is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Rituximab is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Rituximab is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Rituximab is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Rituximab is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Rituximab is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Rituximab is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Rituximab is combined with Paclitaxel.
Dexamethasone,The risk or severity of adverse effects can be increased when Rituximab is combined with Dexamethasone.
Docetaxel,The risk or severity of adverse effects can be increased when Rituximab is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Rituximab is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Rituximab is combined with Decitabine.
Sunitinib,The risk or severity of adverse effects can be increased when Rituximab is combined with Sunitinib.
Nelarabine,The risk or severity of adverse effects can be increased when Rituximab is combined with Nelarabine.
Corticotropin,The risk or severity of adverse effects can be increased when Rituximab is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Rituximab is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Rituximab is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Rituximab is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Rituximab is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Rituximab is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Rituximab is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Rituximab is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Rituximab is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Rituximab is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Rituximab is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Rituximab is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Rituximab is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Rituximab is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Rituximab is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Rituximab is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Rituximab is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Rituximab is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Rituximab is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Rituximab is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Rituximab is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Rituximab is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Rituximab is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Rituximab is combined with omega interferon.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Rituximab is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Rituximab is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Rituximab is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Rituximab is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Rituximab is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Rituximab is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Rituximab is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Rituximab is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Rituximab is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Rituximab is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Rituximab is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Rituximab is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Rituximab is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Rituximab is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Rituximab is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Rituximab is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Rituximab is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Rituximab is combined with Ponatinib.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Rituximab is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Rituximab is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Rituximab is combined with Blinatumomab.
Ibrutinib,The risk or severity of adverse effects can be increased when Rituximab is combined with Ibrutinib.
Idelalisib,The risk or severity of adverse effects can be increased when Rituximab is combined with Idelalisib.
Palbociclib,The risk or severity of adverse effects can be increased when Rituximab is combined with Palbociclib.
Olaparib,The risk or severity of adverse effects can be increased when Rituximab is combined with Olaparib.
Dinutuximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Dinutuximab.
Vilanterol,The risk or severity of adverse effects can be increased when Rituximab is combined with Vilanterol.
Tixocortol,The risk or severity of adverse effects can be increased when Rituximab is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Rituximab is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Rituximab is combined with Antilymphocyte immunoglobulin (horse).
Fluprednisolone,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Rituximab is combined with Meprednisone.
Tepoxalin,The risk or severity of adverse effects can be increased when Rituximab is combined with Tepoxalin.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Rituximab is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Rituximab is combined with Melengestrol.
Ixekizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Rituximab is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Rituximab is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Rituximab is combined with Peficitinib.
Clobetasol,The risk or severity of adverse effects can be increased when Rituximab is combined with Clobetasol.
Sarilumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Sirukumab.
Baricitinib,The risk or severity of adverse effects can be increased when Rituximab is combined with Baricitinib.
Guselkumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Guselkumab.
Deflazacort,The risk or severity of adverse effects can be increased when Rituximab is combined with Deflazacort.
Triptolide,The risk or severity of adverse effects can be increased when Rituximab is combined with Triptolide.
Siponimod,The risk or severity of adverse effects can be increased when Rituximab is combined with Siponimod.
Ozanimod,The risk or severity of adverse effects can be increased when Rituximab is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Rituximab is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Rituximab is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Rituximab is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Rituximab is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Rituximab is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Rituximab is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Rituximab is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Rituximab is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Rituximab is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Rituximab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Prednylidene,The risk or severity of adverse effects can be increased when Rituximab is combined with Prednylidene.
Fluocortin,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Rituximab is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Rituximab is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Rituximab is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Rituximab is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluclorolone.
Fluticasone,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluticasone.
Tetrandrine,The risk or severity of adverse effects can be increased when Rituximab is combined with Tetrandrine.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Rituximab is combined with Monomethyl fumarate.
Mometasone furoate,The risk or severity of adverse effects can be increased when Rituximab is combined with Mometasone furoate.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Rituximab is combined with Hydrocortisone aceponate.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Rituximab is combined with Hydrocortisone acetate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Rituximab is combined with Hydrocortisone succinate.
Emapalumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Bleselumab.
Natalizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rituximab.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Rituximab.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Rituximab.
Clozapine,The risk or severity of neutropenia can be increased when Rituximab is combined with Clozapine.
Darbepoetin alfa,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rituximab.
Erythropoietin,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rituximab.
Peginesatide,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Rituximab.
Methoxy polyethylene glycol-epoetin beta,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rituximab.
Abatacept,Rituximab may increase the immunosuppressive activities of Abatacept.
Certolizumab pegol,Rituximab may increase the immunosuppressive activities of Certolizumab pegol.
Tofacitinib,Rituximab may increase the immunosuppressive activities of Tofacitinib.
Valsartan,Valsartan may increase the hypotensive activities of Rituximab.
Ramipril,Ramipril may increase the hypotensive activities of Rituximab.
Esmolol,Esmolol may increase the hypotensive activities of Rituximab.
Betaxolol,Betaxolol may increase the hypotensive activities of Rituximab.
Reserpine,Reserpine may increase the hypotensive activities of Rituximab.
Remikiren,Remikiren may increase the hypotensive activities of Rituximab.
Torasemide,Torasemide may increase the hypotensive activities of Rituximab.
Bethanidine,Bethanidine may increase the hypotensive activities of Rituximab.
Guanadrel,Guanadrel may increase the hypotensive activities of Rituximab.
Metoprolol,Metoprolol may increase the hypotensive activities of Rituximab.
Isradipine,Isradipine may increase the hypotensive activities of Rituximab.
Olmesartan,Olmesartan may increase the hypotensive activities of Rituximab.
Chlorthalidone,Chlorthalidone may increase the hypotensive activities of Rituximab.
Nitroprusside,Nitroprusside may increase the hypotensive activities of Rituximab.
Atenolol,Atenolol may increase the hypotensive activities of Rituximab.
Diltiazem,Diltiazem may increase the hypotensive activities of Rituximab.
Minoxidil,Minoxidil may increase the hypotensive activities of Rituximab.
Timolol,Timolol may increase the hypotensive activities of Rituximab.
Treprostinil,Treprostinil may increase the hypotensive activities of Rituximab.
Amlodipine,Amlodipine may increase the hypotensive activities of Rituximab.
Nimodipine,Nimodipine may increase the hypotensive activities of Rituximab.
Nisoldipine,Nisoldipine may increase the hypotensive activities of Rituximab.
Bendroflumethiazide,Bendroflumethiazide may increase the hypotensive activities of Rituximab.
Prazosin,Prazosin may increase the hypotensive activities of Rituximab.
Fosinopril,Fosinopril may increase the hypotensive activities of Rituximab.
Trandolapril,Trandolapril may increase the hypotensive activities of Rituximab.
Metolazone,Metolazone may increase the hypotensive activities of Rituximab.
Lercanidipine,Lercanidipine may increase the hypotensive activities of Rituximab.
Benazepril,Benazepril may increase the hypotensive activities of Rituximab.
Bosentan,Bosentan may increase the hypotensive activities of Rituximab.
Propranolol,Propranolol may increase the hypotensive activities of Rituximab.
Clonidine,Clonidine may increase the hypotensive activities of Rituximab.
Enalapril,Enalapril may increase the hypotensive activities of Rituximab.
Doxazosin,Doxazosin may increase the hypotensive activities of Rituximab.
Labetalol,Labetalol may increase the hypotensive activities of Rituximab.
Cyclothiazide,Cyclothiazide may increase the hypotensive activities of Rituximab.
Bisoprolol,Bisoprolol may increase the hypotensive activities of Rituximab.
Candoxatril,Candoxatril may increase the hypotensive activities of Rituximab.
Nicardipine,Nicardipine may increase the hypotensive activities of Rituximab.
Guanabenz,Guanabenz may increase the hypotensive activities of Rituximab.
Mecamylamine,Mecamylamine may increase the hypotensive activities of Rituximab.
Losartan,Losartan may increase the hypotensive activities of Rituximab.
Moexipril,Moexipril may increase the hypotensive activities of Rituximab.
Phentolamine,Phentolamine may increase the hypotensive activities of Rituximab.
Eplerenone,Eplerenone may increase the hypotensive activities of Rituximab.
Lisinopril,Lisinopril may increase the hypotensive activities of Rituximab.
Nitroglycerin,Nitroglycerin may increase the hypotensive activities of Rituximab.
Metyrosine,Metyrosine may increase the hypotensive activities of Rituximab.
Hydroflumethiazide,Hydroflumethiazide may increase the hypotensive activities of Rituximab.
Cryptenamine,Cryptenamine may increase the hypotensive activities of Rituximab.
Perindopril,Perindopril may increase the hypotensive activities of Rituximab.
Candesartan cilexetil,Candesartan cilexetil may increase the hypotensive activities of Rituximab.
Tolazoline,Tolazoline may increase the hypotensive activities of Rituximab.
Fenoldopam,Fenoldopam may increase the hypotensive activities of Rituximab.
Indapamide,Indapamide may increase the hypotensive activities of Rituximab.
Tadalafil,Tadalafil may increase the hypotensive activities of Rituximab.
Alprenolol,Alprenolol may increase the hypotensive activities of Rituximab.
Eprosartan,Eprosartan may increase the hypotensive activities of Rituximab.
Chlorothiazide,Chlorothiazide may increase the hypotensive activities of Rituximab.
Quinapril,Quinapril may increase the hypotensive activities of Rituximab.
Omapatrilat,Omapatrilat may increase the hypotensive activities of Rituximab.
Phenoxybenzamine,Phenoxybenzamine may increase the hypotensive activities of Rituximab.
Pindolol,Pindolol may increase the hypotensive activities of Rituximab.
Telmisartan,Telmisartan may increase the hypotensive activities of Rituximab.
Methyldopa,Methyldopa may increase the hypotensive activities of Rituximab.
Hydrochlorothiazide,Hydrochlorothiazide may increase the hypotensive activities of Rituximab.
Guanfacine,Guanfacine may increase the hypotensive activities of Rituximab.
Trichlormethiazide,Trichlormethiazide may increase the hypotensive activities of Rituximab.
Felodipine,Felodipine may increase the hypotensive activities of Rituximab.
Irbesartan,Irbesartan may increase the hypotensive activities of Rituximab.
Nitrendipine,Nitrendipine may increase the hypotensive activities of Rituximab.
Deserpidine,Deserpidine may increase the hypotensive activities of Rituximab.
Pentolinium,Pentolinium may increase the hypotensive activities of Rituximab.
Trimethaphan,Trimethaphan may increase the hypotensive activities of Rituximab.
Diazoxide,Diazoxide may increase the hypotensive activities of Rituximab.
Carvedilol,Carvedilol may increase the hypotensive activities of Rituximab.
Bretylium,Bretylium may increase the hypotensive activities of Rituximab.
Terazosin,Terazosin may increase the hypotensive activities of Rituximab.
Guanethidine,Guanethidine may increase the hypotensive activities of Rituximab.
Rescinnamine,Rescinnamine may increase the hypotensive activities of Rituximab.
Acebutolol,Acebutolol may increase the hypotensive activities of Rituximab.
Captopril,Captopril may increase the hypotensive activities of Rituximab.
Nadolol,Nadolol may increase the hypotensive activities of Rituximab.
Epoprostenol,Epoprostenol may increase the hypotensive activities of Rituximab.
Bepridil,Bepridil may increase the hypotensive activities of Rituximab.
Hydralazine,Hydralazine may increase the hypotensive activities of Rituximab.
Bevantolol,Bevantolol may increase the hypotensive activities of Rituximab.
Practolol,Practolol may increase the hypotensive activities of Rituximab.
Polythiazide,Polythiazide may increase the hypotensive activities of Rituximab.
Cilazapril,Cilazapril may increase the hypotensive activities of Rituximab.
Saprisartan,Saprisartan may increase the hypotensive activities of Rituximab.
Spirapril,Spirapril may increase the hypotensive activities of Rituximab.
Penbutolol,Penbutolol may increase the hypotensive activities of Rituximab.
Mibefradil,Mibefradil may increase the hypotensive activities of Rituximab.
Oxprenolol,Oxprenolol may increase the hypotensive activities of Rituximab.
Pargyline,Pargyline may increase the hypotensive activities of Rituximab.
Dexpropranolol,Dexpropranolol may increase the hypotensive activities of Rituximab.
Tienilic acid,Tienilic acid may increase the hypotensive activities of Rituximab.
Debrisoquine,Debrisoquine may increase the hypotensive activities of Rituximab.
Celiprolol,Celiprolol may increase the hypotensive activities of Rituximab.
Nebivolol,Nebivolol may increase the hypotensive activities of Rituximab.
Lofexidine,Lofexidine may increase the hypotensive activities of Rituximab.
Sitaxentan,Sitaxentan may increase the hypotensive activities of Rituximab.
Ambrisentan,Ambrisentan may increase the hypotensive activities of Rituximab.
Diethylnorspermine,Diethylnorspermine may increase the hypotensive activities of Rituximab.
Nilvadipine,Nilvadipine may increase the hypotensive activities of Rituximab.
Pinacidil,Pinacidil may increase the hypotensive activities of Rituximab.
Ferulic acid,Ferulic acid may increase the hypotensive activities of Rituximab.
Bupranolol,Bupranolol may increase the hypotensive activities of Rituximab.
Temocapril,Temocapril may increase the hypotensive activities of Rituximab.
Riociguat,Riociguat may increase the hypotensive activities of Rituximab.
Macitentan,Macitentan may increase the hypotensive activities of Rituximab.
Indoramin,Indoramin may increase the hypotensive activities of Rituximab.
Indenolol,Indenolol may increase the hypotensive activities of Rituximab.
Hexamethonium,Hexamethonium may increase the hypotensive activities of Rituximab.
Aliskiren,Aliskiren may increase the hypotensive activities of Rituximab.
Trimazosin,Trimazosin may increase the hypotensive activities of Rituximab.
Nicorandil,Nicorandil may increase the hypotensive activities of Rituximab.
Efonidipine,Efonidipine may increase the hypotensive activities of Rituximab.
Lacidipine,Lacidipine may increase the hypotensive activities of Rituximab.
Manidipine,Manidipine may increase the hypotensive activities of Rituximab.
Niguldipine,Niguldipine may increase the hypotensive activities of Rituximab.
Moxonidine,Moxonidine may increase the hypotensive activities of Rituximab.
Rauwolfia serpentina root,Rauwolfia serpentina root may increase the hypotensive activities of Rituximab.
Enalaprilat,Enalaprilat may increase the hypotensive activities of Rituximab.
Selexipag,Selexipag may increase the hypotensive activities of Rituximab.
Angiotensin 1-7,Angiotensin 1-7 may increase the hypotensive activities of Rituximab.
Rilmenidine,Rilmenidine may increase the hypotensive activities of Rituximab.
Talinolol,Talinolol may increase the hypotensive activities of Rituximab.
Imidapril,Imidapril may increase the hypotensive activities of Rituximab.
BQ-123,BQ-123 may increase the hypotensive activities of Rituximab.
Naftopidil,Naftopidil may increase the hypotensive activities of Rituximab.
Tetrahydropalmatine,Tetrahydropalmatine may increase the hypotensive activities of Rituximab.
Landiolol,Landiolol may increase the hypotensive activities of Rituximab.
Ketanserin,Ketanserin may increase the hypotensive activities of Rituximab.
Urapidil,Urapidil may increase the hypotensive activities of Rituximab.
Cicletanine,Cicletanine may increase the hypotensive activities of Rituximab.
Dihydralazine,Dihydralazine may increase the hypotensive activities of Rituximab.
Zofenopril,Zofenopril may increase the hypotensive activities of Rituximab.
Guanoxan,Guanoxan may increase the hypotensive activities of Rituximab.
Delapril,Delapril may increase the hypotensive activities of Rituximab.
Vincamine,Vincamine may increase the hypotensive activities of Rituximab.
Linsidomine,Linsidomine may increase the hypotensive activities of Rituximab.
Guanoxabenz,Guanoxabenz may increase the hypotensive activities of Rituximab.
Tolonidine,Tolonidine may increase the hypotensive activities of Rituximab.
Endralazine,Endralazine may increase the hypotensive activities of Rituximab.
Esatenolol,Esatenolol may increase the hypotensive activities of Rituximab.
Cadralazine,Cadralazine may increase the hypotensive activities of Rituximab.
Cloranolol,Cloranolol may increase the hypotensive activities of Rituximab.
Cyclopenthiazide,Cyclopenthiazide may increase the hypotensive activities of Rituximab.
Bietaserpine,Bietaserpine may increase the hypotensive activities of Rituximab.
Guanazodine,Guanazodine may increase the hypotensive activities of Rituximab.
Methoserpidine,Methoserpidine may increase the hypotensive activities of Rituximab.
Epanolol,Epanolol may increase the hypotensive activities of Rituximab.
Guanoclor,Guanoclor may increase the hypotensive activities of Rituximab.
Muzolimine,Muzolimine may increase the hypotensive activities of Rituximab.
Xipamide,Xipamide may increase the hypotensive activities of Rituximab.
Candesartan,Candesartan may increase the hypotensive activities of Rituximab.
Dexniguldipine,Dexniguldipine may increase the hypotensive activities of Rituximab.
Tocopherylquinone,Tocopherylquinone may increase the hypotensive activities of Rituximab.
Benazeprilat,Benazeprilat may increase the hypotensive activities of Rituximab.
Fosinoprilat,Fosinoprilat may increase the hypotensive activities of Rituximab.
Ramiprilat,Ramiprilat may increase the hypotensive activities of Rituximab.
Perindoprilat,Perindoprilat may increase the hypotensive activities of Rituximab.
Quinaprilat,Quinaprilat may increase the hypotensive activities of Rituximab.
Furosemide,Furosemide may increase the hypotensive activities of Rituximab.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Rituximab.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Rituximab.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Rituximab.
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Rituximab.
Estrone,Estrone may increase the thrombogenic activities of Rituximab.
Estradiol,Estradiol may increase the thrombogenic activities of Rituximab.
Dienestrol,Dienestrol may increase the thrombogenic activities of Rituximab.
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Rituximab.
Mestranol,Mestranol may increase the thrombogenic activities of Rituximab.
Estriol,Estriol may increase the thrombogenic activities of Rituximab.
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Rituximab.
Quinestrol,Quinestrol may increase the thrombogenic activities of Rituximab.
Hexestrol,Hexestrol may increase the thrombogenic activities of Rituximab.
Tibolone,Tibolone may increase the thrombogenic activities of Rituximab.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Rituximab."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Rituximab."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Rituximab.
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Rituximab.
Zeranol,Zeranol may increase the thrombogenic activities of Rituximab.
Equol,Equol may increase the thrombogenic activities of Rituximab.
Promestriene,Promestriene may increase the thrombogenic activities of Rituximab.
Methallenestril,Methallenestril may increase the thrombogenic activities of Rituximab.
Epimestrol,Epimestrol may increase the thrombogenic activities of Rituximab.
Moxestrol,Moxestrol may increase the thrombogenic activities of Rituximab.
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Rituximab.
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Rituximab.
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Rituximab.
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Rituximab.
Biochanin A,Biochanin A may increase the thrombogenic activities of Rituximab.
Formononetin,Formononetin may increase the thrombogenic activities of Rituximab.
Leflunomide,The risk or severity of adverse effects can be increased when Rituximab is combined with Leflunomide.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Rituximab.
Fingolimod,Rituximab may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Rituximab.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Rituximab.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Rituximab.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Rituximab.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Rituximab.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Rituximab.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Rituximab.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Rituximab.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Rituximab.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Rituximab.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Rituximab."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Rituximab.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Rituximab.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Rituximab."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Rituximab.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Rituximab.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Rituximab.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Rituximab.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Rituximab.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Rituximab.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Rituximab.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Rituximab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Rituximab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Rituximab.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Rituximab.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Rituximab.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Rituximab.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Rituximab.
Eptifibatide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Rituximab.
Ticlopidine,The risk or severity of bleeding can be increased when Ticlopidine is combined with Rituximab.
Anagrelide,The risk or severity of bleeding can be increased when Anagrelide is combined with Rituximab.
Clopidogrel,The risk or severity of bleeding can be increased when Clopidogrel is combined with Rituximab.
Tirofiban,The risk or severity of bleeding can be increased when Tirofiban is combined with Rituximab.
Pentoxifylline,The risk or severity of bleeding can be increased when Pentoxifylline is combined with Rituximab.
Acetylsalicylic acid,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Rituximab.
Dipyridamole,The risk or severity of bleeding can be increased when Dipyridamole is combined with Rituximab.
Iloprost,The risk or severity of bleeding can be increased when Iloprost is combined with Rituximab.
Sulfinpyrazone,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Rituximab.
Cilostazol,The risk or severity of bleeding can be increased when Cilostazol is combined with Rituximab.
Ridogrel,The risk or severity of bleeding can be increased when Ridogrel is combined with Rituximab.
Sevoflurane,The risk or severity of bleeding can be increased when Sevoflurane is combined with Rituximab.
Resveratrol,The risk or severity of bleeding can be increased when Resveratrol is combined with Rituximab.
Nimesulide,The risk or severity of bleeding can be increased when Nimesulide is combined with Rituximab.
Tesmilifene,The risk or severity of bleeding can be increased when Tesmilifene is combined with Rituximab.
Defibrotide,The risk or severity of bleeding can be increased when Defibrotide is combined with Rituximab.
Beraprost,The risk or severity of bleeding can be increased when Beraprost is combined with Rituximab.
Ibudilast,The risk or severity of bleeding can be increased when Ibudilast is combined with Rituximab.
Andrographolide,The risk or severity of bleeding can be increased when Andrographolide is combined with Rituximab.
Prasugrel,The risk or severity of bleeding can be increased when Prasugrel is combined with Rituximab.
Cangrelor,The risk or severity of bleeding can be increased when Cangrelor is combined with Rituximab.
Tranilast,The risk or severity of bleeding can be increased when Tranilast is combined with Rituximab.
Triflusal,The risk or severity of bleeding can be increased when Triflusal is combined with Rituximab.
Ticagrelor,The risk or severity of bleeding can be increased when Ticagrelor is combined with Rituximab.
Icosapent ethyl,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Rituximab.
Vorapaxar,The risk or severity of bleeding can be increased when Vorapaxar is combined with Rituximab.
Trapidil,The risk or severity of bleeding can be increased when Trapidil is combined with Rituximab.
Sarpogrelate,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Rituximab.
Ifetroban,The risk or severity of bleeding can be increased when Ifetroban is combined with Rituximab.
Nitroaspirin,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Rituximab.
Indobufen,The risk or severity of bleeding can be increased when Indobufen is combined with Rituximab.
Butylphthalide,The risk or severity of bleeding can be increased when Butylphthalide is combined with Rituximab.
Hydroxytyrosol,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Rituximab.
Ramatroban,The risk or severity of bleeding can be increased when Ramatroban is combined with Rituximab.
Picotamide,The risk or severity of bleeding can be increased when Picotamide is combined with Rituximab.
Cloricromen,The risk or severity of bleeding can be increased when Cloricromen is combined with Rituximab.
Buflomedil,The risk or severity of bleeding can be increased when Buflomedil is combined with Rituximab.
Relcovaptan,The risk or severity of bleeding can be increased when Relcovaptan is combined with Rituximab.
Ocrelizumab,Ocrelizumab may increase the immunosuppressive activities of Rituximab.
Lipegfilgrastim,Rituximab may increase the myelosuppressive activities of Lipegfilgrastim.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Rituximab.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Rituximab.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Rituximab.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Rituximab.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Rituximab.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Rituximab.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Rituximab.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Rituximab.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Rituximab.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Rituximab.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Rituximab.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Rituximab.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Rituximab.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rituximab.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Rituximab.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Rituximab.
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rituximab.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Rituximab is combined with Digoxin Immune Fab (Ovine).
Capromab pendetide,The risk or severity of adverse effects can be increased when Rituximab is combined with Capromab pendetide.
Palivizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Palivizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Rituximab is combined with Technetium Tc-99m arcitumomab.
Panitumumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Pexelizumab.
Epratuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Rituximab is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Rituximab is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Rituximab is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Rituximab is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Rituximab is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Rituximab is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Rituximab is combined with NAV 1800.
Otelixizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Rituximab is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Veltuzumab.
PRO-542,The risk or severity of adverse effects can be increased when Rituximab is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Rituximab is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Rituximab is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Rituximab is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Rituximab is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Rituximab is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Rituximab is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Rituximab is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Rituximab is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Rituximab is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Rituximab is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Lumiliximab.
Ipilimumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Clenoliximab.
BIIB015,The risk or severity of adverse effects can be increased when Rituximab is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Rituximab is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Rituximab is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Rituximab is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Rituximab is combined with Catumaxomab.
Volociximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ofatumumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Raxibacumab.
Nivolumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Nivolumab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Rituximab is combined with Dulaglutide.
Asfotase alfa,The risk or severity of adverse effects can be increased when Rituximab is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Evolocumab.
Daratumumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Necitumumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Rituximab is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Rituximab is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Rituximab is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Rituximab is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Solanezumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Tremelimumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Lampalizumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Rituximab is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Anifrolumab.
Benralizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Rituximab is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Rituximab is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Rituximab is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Rituximab is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Rituximab is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Rituximab is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Rituximab is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Rituximab is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Plozalizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Rituximab is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Rituximab is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Rituximab is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Rituximab is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Rituximab is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Rituximab is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Rituximab is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Rituximab is combined with Besilesomab.
Burosumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Rituximab is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Rituximab is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Rituximab is combined with Cemiplimab.
Camrelizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Rituximab is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Rituximab is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Rituximab is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Refanezumab.
Bermekimab,The risk or severity of adverse effects can be increased when Rituximab is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Rituximab is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Rituximab is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Rituximab is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Rituximab is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Rituximab is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Rituximab is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Rituximab is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Rituximab is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Rituximab is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Rituximab is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Nemolizumab.
Gedivumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Rituximab is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Rituximab is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Rituximab is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Rituximab is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Rituximab is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Rituximab is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Rituximab is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Rituximab is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Rituximab is combined with Naratuximab emtansine.
Tildrakizumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Tildrakizumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ustekinumab.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Rituximab is combined with Zenocutuzumab.
Palifermin,The therapeutic efficacy of Palifermin can be decreased when used in combination with Rituximab.
Lepirudin,The risk or severity of bleeding can be increased when Lepirudin is combined with Rituximab.
Bivalirudin,The risk or severity of bleeding can be increased when Bivalirudin is combined with Rituximab.
Alteplase,The risk or severity of bleeding can be increased when Alteplase is combined with Rituximab.
Urokinase,The risk or severity of bleeding can be increased when Urokinase is combined with Rituximab.
Reteplase,The risk or severity of bleeding can be increased when Reteplase is combined with Rituximab.
Anistreplase,The risk or severity of bleeding can be increased when Anistreplase is combined with Rituximab.
Tenecteplase,The risk or severity of bleeding can be increased when Tenecteplase is combined with Rituximab.
Drotrecogin alfa,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Rituximab.
Streptokinase,The risk or severity of bleeding can be increased when Streptokinase is combined with Rituximab.
Dicoumarol,The risk or severity of bleeding can be increased when Dicoumarol is combined with Rituximab.
Argatroban,The risk or severity of bleeding can be increased when Argatroban is combined with Rituximab.
Ardeparin,The risk or severity of bleeding can be increased when Ardeparin is combined with Rituximab.
Phenindione,The risk or severity of bleeding can be increased when Phenindione is combined with Rituximab.
Fondaparinux,The risk or severity of bleeding can be increased when Fondaparinux is combined with Rituximab.
Warfarin,The risk or severity of bleeding can be increased when Warfarin is combined with Rituximab.
Pentosan polysulfate,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Rituximab.
Phenprocoumon,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Rituximab.
Heparin,The risk or severity of bleeding can be increased when Heparin is combined with Rituximab.
Enoxaparin,The risk or severity of bleeding can be increased when Enoxaparin is combined with Rituximab.
Acenocoumarol,The risk or severity of bleeding can be increased when Acenocoumarol is combined with Rituximab.
4-hydroxycoumarin,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Rituximab.
Coumarin,The risk or severity of bleeding can be increased when Coumarin is combined with Rituximab.
Ximelagatran,The risk or severity of bleeding can be increased when Ximelagatran is combined with Rituximab.
Desmoteplase,The risk or severity of bleeding can be increased when Desmoteplase is combined with Rituximab.
Ancrod,The risk or severity of bleeding can be increased when Ancrod is combined with Rituximab.
Fibrinolysin,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Rituximab.
Rivaroxaban,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Rituximab.
Sulodexide,The risk or severity of bleeding can be increased when Sulodexide is combined with Rituximab.
Semuloparin,The risk or severity of bleeding can be increased when Semuloparin is combined with Rituximab.
Idraparinux,The risk or severity of bleeding can be increased when Idraparinux is combined with Rituximab.
Astaxanthin,The risk or severity of bleeding can be increased when Astaxanthin is combined with Rituximab.
Apixaban,The risk or severity of bleeding can be increased when Apixaban is combined with Rituximab.
Otamixaban,The risk or severity of bleeding can be increased when Otamixaban is combined with Rituximab.
Amediplase,The risk or severity of bleeding can be increased when Amediplase is combined with Rituximab.
Dabigatran etexilate,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Rituximab.
Danaparoid,The risk or severity of bleeding can be increased when Danaparoid is combined with Rituximab.
Dalteparin,The risk or severity of bleeding can be increased when Dalteparin is combined with Rituximab.
Tinzaparin,The risk or severity of bleeding can be increased when Tinzaparin is combined with Rituximab.
(R)-warfarin,The risk or severity of bleeding can be increased when (R)-warfarin is combined with Rituximab.
Ethyl biscoumacetate,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Rituximab.
Nadroparin,The risk or severity of bleeding can be increased when Nadroparin is combined with Rituximab.
Ditazole,The risk or severity of bleeding can be increased when Ditazole is combined with Rituximab.
Edoxaban,The risk or severity of bleeding can be increased when Edoxaban is combined with Rituximab.
Potassium citrate,The risk or severity of bleeding can be increased when Potassium citrate is combined with Rituximab.
Sodium citrate,The risk or severity of bleeding can be increased when Sodium citrate is combined with Rituximab.
Dextran,The risk or severity of bleeding can be increased when Dextran is combined with Rituximab.
Bemiparin,The risk or severity of bleeding can be increased when Bemiparin is combined with Rituximab.
Reviparin,The risk or severity of bleeding can be increased when Reviparin is combined with Rituximab.
Parnaparin,The risk or severity of bleeding can be increased when Parnaparin is combined with Rituximab.
Certoparin,The risk or severity of bleeding can be increased when Certoparin is combined with Rituximab.
Desirudin,The risk or severity of bleeding can be increased when Desirudin is combined with Rituximab.
Zinc citrate,The risk or severity of bleeding can be increased when Zinc citrate is combined with Rituximab.
Antithrombin Alfa,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Rituximab.
Protein C,The risk or severity of bleeding can be increased when Protein C is combined with Rituximab.
Antithrombin III human,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Rituximab.
Letaxaban,The risk or severity of bleeding can be increased when Letaxaban is combined with Rituximab.
Darexaban,The risk or severity of bleeding can be increased when Darexaban is combined with Rituximab.
Betrixaban,The risk or severity of bleeding can be increased when Betrixaban is combined with Rituximab.
Nafamostat,The risk or severity of bleeding can be increased when Nafamostat is combined with Rituximab.
Monteplase,The risk or severity of bleeding can be increased when Monteplase is combined with Rituximab.
Gabexate,The risk or severity of bleeding can be increased when Gabexate is combined with Rituximab.
Fluindione,The risk or severity of bleeding can be increased when Fluindione is combined with Rituximab.
Protein S human,The risk or severity of bleeding can be increased when Protein S human is combined with Rituximab.
Brinase,The risk or severity of bleeding can be increased when Brinase is combined with Rituximab.
Clorindione,The risk or severity of bleeding can be increased when Clorindione is combined with Rituximab.
Diphenadione,The risk or severity of bleeding can be increased when Diphenadione is combined with Rituximab.
Tioclomarol,The risk or severity of bleeding can be increased when Tioclomarol is combined with Rituximab.
Melagatran,The risk or severity of bleeding can be increased when Melagatran is combined with Rituximab.
Saruplase,The risk or severity of bleeding can be increased when Saruplase is combined with Rituximab.
(S)-Warfarin,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Rituximab.
Edetate calcium disodium anhydrous,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Rituximab.
Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Rituximab.
Methyclothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Rituximab.
Benzthiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Rituximab.
Mebutizide,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Rituximab.
Cisplatin,Rituximab may increase the nephrotoxic activities of Cisplatin.
Tedizolid phosphate,The risk or severity of myelosuppression can be increased when Rituximab is combined with Tedizolid phosphate.
Cyclosporine,Rituximab may increase the immunosuppressive activities of Cyclosporine.
Cyanocobalamin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Rituximab.
Allopurinol,The risk or severity of adverse effects can be increased when Allopurinol is combined with Rituximab.
Apremilast,The therapeutic efficacy of Apremilast can be decreased when used in combination with Rituximab.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Rituximab."
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Rituximab.
Lopinavir,The serum concentration of Rituximab can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Rituximab is combined with Inebilizumab.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Basiliximab.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Basiliximab.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Basiliximab.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Basiliximab.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Basiliximab.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Basiliximab.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Basiliximab.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Basiliximab.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Basiliximab."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Basiliximab.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Basiliximab.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Basiliximab.
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Basiliximab.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Basiliximab.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Basiliximab.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Basiliximab.
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Basiliximab.
Muromonab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Muromonab.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibritumomab tiuxetan.
Tositumomab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tositumomab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Alemtuzumab.
Alefacept,The risk or severity of adverse effects can be increased when Basiliximab is combined with Alefacept.
Efalizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Basiliximab is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Basiliximab is combined with Interferon alfa-2b.
Daclizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Basiliximab is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Basiliximab is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Basiliximab is combined with Beclomethasone dipropionate.
Sorafenib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sorafenib.
Streptozocin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Basiliximab is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Altretamine.
Zidovudine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Zidovudine.
Cisplatin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Basiliximab is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pentostatin.
Methotrexate,The risk or severity of adverse effects can be increased when Basiliximab is combined with Methotrexate.
Carbamazepine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carbamazepine.
Vinblastine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Basiliximab is combined with Linezolid.
Imatinib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Imatinib.
Triamcinolone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Basiliximab is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Basiliximab is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Basiliximab is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Basiliximab is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Basiliximab is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Basiliximab is combined with Paclitaxel.
Dexamethasone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dexamethasone.
Docetaxel,The risk or severity of adverse effects can be increased when Basiliximab is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Decitabine.
Sunitinib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sunitinib.
Nelarabine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nelarabine.
Abatacept,The risk or severity of adverse effects can be increased when Basiliximab is combined with Abatacept.
Corticotropin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Basiliximab is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Basiliximab is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Basiliximab is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Basiliximab is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Basiliximab is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Basiliximab is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Basiliximab is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Basiliximab is combined with omega interferon.
Apremilast,The risk or severity of adverse effects can be increased when Basiliximab is combined with Apremilast.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Basiliximab is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Basiliximab is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Basiliximab is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Basiliximab is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ponatinib.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Basiliximab is combined with Certolizumab pegol.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Blinatumomab.
Ibrutinib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibrutinib.
Idelalisib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Idelalisib.
Palbociclib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Palbociclib.
Olaparib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Olaparib.
Dinutuximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dinutuximab.
Vilanterol,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vilanterol.
Tixocortol,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Basiliximab is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Basiliximab is combined with Antilymphocyte immunoglobulin (horse).
Fluprednisolone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Meprednisone.
Tepoxalin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tepoxalin.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Basiliximab is combined with Melengestrol.
Ixekizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Peficitinib.
Clobetasol,The risk or severity of adverse effects can be increased when Basiliximab is combined with Clobetasol.
Sarilumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sirukumab.
Baricitinib,The risk or severity of adverse effects can be increased when Basiliximab is combined with Baricitinib.
Guselkumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Guselkumab.
Deflazacort,The risk or severity of adverse effects can be increased when Basiliximab is combined with Deflazacort.
Triptolide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Triptolide.
Siponimod,The risk or severity of adverse effects can be increased when Basiliximab is combined with Siponimod.
Ozanimod,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Basiliximab is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Basiliximab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Prednylidene,The risk or severity of adverse effects can be increased when Basiliximab is combined with Prednylidene.
Fluocortin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Basiliximab is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluclorolone.
Fluticasone,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluticasone.
Tetrandrine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tetrandrine.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Basiliximab is combined with Monomethyl fumarate.
Mometasone furoate,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mometasone furoate.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydrocortisone aceponate.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydrocortisone acetate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydrocortisone succinate.
Emapalumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bleselumab.
Natalizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Basiliximab.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Basiliximab.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Basiliximab.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Basiliximab.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Basiliximab.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Basiliximab.
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Basiliximab.
Estrone,Estrone may increase the thrombogenic activities of Basiliximab.
Estradiol,Estradiol may increase the thrombogenic activities of Basiliximab.
Dienestrol,Dienestrol may increase the thrombogenic activities of Basiliximab.
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Basiliximab.
Mestranol,Mestranol may increase the thrombogenic activities of Basiliximab.
Estriol,Estriol may increase the thrombogenic activities of Basiliximab.
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Basiliximab.
Quinestrol,Quinestrol may increase the thrombogenic activities of Basiliximab.
Hexestrol,Hexestrol may increase the thrombogenic activities of Basiliximab.
Tibolone,Tibolone may increase the thrombogenic activities of Basiliximab.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Basiliximab."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Basiliximab."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Basiliximab.
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Basiliximab.
Zeranol,Zeranol may increase the thrombogenic activities of Basiliximab.
Equol,Equol may increase the thrombogenic activities of Basiliximab.
Promestriene,Promestriene may increase the thrombogenic activities of Basiliximab.
Methallenestril,Methallenestril may increase the thrombogenic activities of Basiliximab.
Epimestrol,Epimestrol may increase the thrombogenic activities of Basiliximab.
Moxestrol,Moxestrol may increase the thrombogenic activities of Basiliximab.
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Basiliximab.
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Basiliximab.
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Basiliximab.
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Basiliximab.
Biochanin A,Biochanin A may increase the thrombogenic activities of Basiliximab.
Formononetin,Formononetin may increase the thrombogenic activities of Basiliximab.
Leflunomide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Leflunomide.
Tofacitinib,Basiliximab may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Basiliximab.
Fingolimod,Basiliximab may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Basiliximab.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Basiliximab.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Basiliximab.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Basiliximab.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Basiliximab.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Basiliximab.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Basiliximab.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Basiliximab.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Basiliximab.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Basiliximab.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Basiliximab."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Basiliximab.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Basiliximab.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Basiliximab."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Basiliximab.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Basiliximab.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Basiliximab.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Basiliximab.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Basiliximab.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Basiliximab.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Basiliximab.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Basiliximab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Basiliximab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Basiliximab.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Basiliximab.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Basiliximab.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Basiliximab.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Basiliximab.
Ocrelizumab,Ocrelizumab may increase the immunosuppressive activities of Basiliximab.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Basiliximab.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Basiliximab.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Basiliximab.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Basiliximab.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Basiliximab.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Basiliximab.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Basiliximab.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Basiliximab.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Basiliximab.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Basiliximab.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Basiliximab.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Basiliximab.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Basiliximab.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Basiliximab.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Basiliximab.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Basiliximab.
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Basiliximab.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Basiliximab is combined with Digoxin Immune Fab (Ovine).
Capromab pendetide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Capromab pendetide.
Palivizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Palivizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Technetium Tc-99m arcitumomab.
Panitumumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pexelizumab.
Epratuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Basiliximab is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Basiliximab is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Basiliximab is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Basiliximab is combined with NAV 1800.
Otelixizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Basiliximab is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Veltuzumab.
PRO-542,The risk or severity of adverse effects can be increased when Basiliximab is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Basiliximab is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Basiliximab is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Basiliximab is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Basiliximab is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Basiliximab is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Basiliximab is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Basiliximab is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lumiliximab.
Ipilimumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Clenoliximab.
BIIB015,The risk or severity of adverse effects can be increased when Basiliximab is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Basiliximab is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Basiliximab is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Catumaxomab.
Volociximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ofatumumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Raxibacumab.
Nivolumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nivolumab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dulaglutide.
Asfotase alfa,The risk or severity of adverse effects can be increased when Basiliximab is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Evolocumab.
Daratumumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Necitumumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Basiliximab is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Solanezumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tremelimumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lampalizumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Anifrolumab.
Benralizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Basiliximab is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Basiliximab is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Basiliximab is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Plozalizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Basiliximab is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Besilesomab.
Burosumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cemiplimab.
Camrelizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Refanezumab.
Bermekimab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Basiliximab is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nemolizumab.
Gedivumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Basiliximab is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Basiliximab is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Basiliximab is combined with Naratuximab emtansine.
Tildrakizumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tildrakizumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ustekinumab.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Zenocutuzumab.
Cyclosporine,Basiliximab may increase the immunosuppressive activities of Cyclosporine.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Basiliximab."
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Basiliximab.
Lopinavir,The serum concentration of Basiliximab can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Basiliximab is combined with Inebilizumab.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Muromonab.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Muromonab.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Muromonab.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Muromonab.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Muromonab.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Muromonab.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Muromonab.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Muromonab.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Muromonab."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Muromonab.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Muromonab.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Muromonab.
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Muromonab.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Muromonab.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Muromonab.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Muromonab.
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Muromonab.
Basiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Muromonab.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Muromonab is combined with Ibritumomab tiuxetan.
Tositumomab,The risk or severity of adverse effects can be increased when Muromonab is combined with Tositumomab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Alemtuzumab.
Alefacept,The risk or severity of adverse effects can be increased when Muromonab is combined with Alefacept.
Efalizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Muromonab is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Muromonab is combined with Interferon alfa-2b.
Daclizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Muromonab is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Muromonab is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Muromonab is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Muromonab is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Muromonab is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Muromonab is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Muromonab is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Muromonab is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Muromonab is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Muromonab is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Muromonab is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Muromonab is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Muromonab is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Muromonab is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Muromonab is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Muromonab is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Muromonab is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Muromonab is combined with Beclomethasone dipropionate.
Sorafenib,The risk or severity of adverse effects can be increased when Muromonab is combined with Sorafenib.
Streptozocin,The risk or severity of adverse effects can be increased when Muromonab is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Muromonab is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Muromonab is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Muromonab is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Muromonab is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Muromonab is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Muromonab is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Muromonab is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Muromonab is combined with Altretamine.
Zidovudine,The risk or severity of adverse effects can be increased when Muromonab is combined with Zidovudine.
Cisplatin,The risk or severity of adverse effects can be increased when Muromonab is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Muromonab is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Muromonab is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Muromonab is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Muromonab is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Muromonab is combined with Pentostatin.
Methotrexate,The risk or severity of adverse effects can be increased when Muromonab is combined with Methotrexate.
Carbamazepine,The risk or severity of adverse effects can be increased when Muromonab is combined with Carbamazepine.
Vinblastine,The risk or severity of adverse effects can be increased when Muromonab is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Muromonab is combined with Linezolid.
Imatinib,The risk or severity of adverse effects can be increased when Muromonab is combined with Imatinib.
Triamcinolone,The risk or severity of adverse effects can be increased when Muromonab is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Muromonab is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Muromonab is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Muromonab is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Muromonab is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Muromonab is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Muromonab is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Muromonab is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Muromonab is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Muromonab is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Muromonab is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Muromonab is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Muromonab is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Muromonab is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Muromonab is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Muromonab is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Muromonab is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Muromonab is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Muromonab is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Muromonab is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Muromonab is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Muromonab is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Muromonab is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Muromonab is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Muromonab is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Muromonab is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Muromonab is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Muromonab is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Muromonab is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Muromonab is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Muromonab is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Muromonab is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Muromonab is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Muromonab is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Muromonab is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Muromonab is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Muromonab is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Muromonab is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Muromonab is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Muromonab is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Muromonab is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Muromonab is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Muromonab is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Muromonab is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Muromonab is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Muromonab is combined with Paclitaxel.
Dexamethasone,The risk or severity of adverse effects can be increased when Muromonab is combined with Dexamethasone.
Docetaxel,The risk or severity of adverse effects can be increased when Muromonab is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Muromonab is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Muromonab is combined with Decitabine.
Sunitinib,The risk or severity of adverse effects can be increased when Muromonab is combined with Sunitinib.
Nelarabine,The risk or severity of adverse effects can be increased when Muromonab is combined with Nelarabine.
Abatacept,The risk or severity of adverse effects can be increased when Muromonab is combined with Abatacept.
Corticotropin,The risk or severity of adverse effects can be increased when Muromonab is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Muromonab is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Muromonab is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Muromonab is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Muromonab is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Muromonab is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Muromonab is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Muromonab is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Muromonab is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Muromonab is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Muromonab is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Muromonab is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Muromonab is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Muromonab is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Muromonab is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Muromonab is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Muromonab is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Muromonab is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Muromonab is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Muromonab is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Muromonab is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Muromonab is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Muromonab is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Muromonab is combined with omega interferon.
Apremilast,The risk or severity of adverse effects can be increased when Muromonab is combined with Apremilast.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Muromonab is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Muromonab is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Muromonab is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Muromonab is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Muromonab is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Muromonab is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Muromonab is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Muromonab is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Muromonab is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Muromonab is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Muromonab is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Muromonab is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Muromonab is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Muromonab is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Muromonab is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Muromonab is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Muromonab is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Muromonab is combined with Ponatinib.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Muromonab is combined with Certolizumab pegol.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Muromonab is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Muromonab is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Muromonab is combined with Blinatumomab.
Ibrutinib,The risk or severity of adverse effects can be increased when Muromonab is combined with Ibrutinib.
Idelalisib,The risk or severity of adverse effects can be increased when Muromonab is combined with Idelalisib.
Palbociclib,The risk or severity of adverse effects can be increased when Muromonab is combined with Palbociclib.
Olaparib,The risk or severity of adverse effects can be increased when Muromonab is combined with Olaparib.
Dinutuximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Dinutuximab.
Vilanterol,The risk or severity of adverse effects can be increased when Muromonab is combined with Vilanterol.
Tixocortol,The risk or severity of adverse effects can be increased when Muromonab is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Muromonab is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Muromonab is combined with Antilymphocyte immunoglobulin (horse).
Fluprednisolone,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Muromonab is combined with Meprednisone.
Tepoxalin,The risk or severity of adverse effects can be increased when Muromonab is combined with Tepoxalin.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Muromonab is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Muromonab is combined with Melengestrol.
Ixekizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Muromonab is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Muromonab is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Muromonab is combined with Peficitinib.
Clobetasol,The risk or severity of adverse effects can be increased when Muromonab is combined with Clobetasol.
Sarilumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Sirukumab.
Baricitinib,The risk or severity of adverse effects can be increased when Muromonab is combined with Baricitinib.
Guselkumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Guselkumab.
Deflazacort,The risk or severity of adverse effects can be increased when Muromonab is combined with Deflazacort.
Triptolide,The risk or severity of adverse effects can be increased when Muromonab is combined with Triptolide.
Siponimod,The risk or severity of adverse effects can be increased when Muromonab is combined with Siponimod.
Ozanimod,The risk or severity of adverse effects can be increased when Muromonab is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Muromonab is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Muromonab is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Muromonab is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Muromonab is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Muromonab is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Muromonab is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Muromonab is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Muromonab is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Muromonab is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Muromonab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Prednylidene,The risk or severity of adverse effects can be increased when Muromonab is combined with Prednylidene.
Fluocortin,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Muromonab is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Muromonab is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Muromonab is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Muromonab is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluclorolone.
Fluticasone,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluticasone.
Tetrandrine,The risk or severity of adverse effects can be increased when Muromonab is combined with Tetrandrine.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Muromonab is combined with Monomethyl fumarate.
Mometasone furoate,The risk or severity of adverse effects can be increased when Muromonab is combined with Mometasone furoate.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Muromonab is combined with Hydrocortisone aceponate.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Muromonab is combined with Hydrocortisone acetate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Muromonab is combined with Hydrocortisone succinate.
Emapalumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Bleselumab.
Natalizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Muromonab.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Muromonab.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Muromonab.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Muromonab.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Muromonab.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Muromonab.
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Muromonab.
Estrone,Estrone may increase the thrombogenic activities of Muromonab.
Estradiol,Estradiol may increase the thrombogenic activities of Muromonab.
Dienestrol,Dienestrol may increase the thrombogenic activities of Muromonab.
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Muromonab.
Mestranol,Mestranol may increase the thrombogenic activities of Muromonab.
Estriol,Estriol may increase the thrombogenic activities of Muromonab.
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Muromonab.
Quinestrol,Quinestrol may increase the thrombogenic activities of Muromonab.
Hexestrol,Hexestrol may increase the thrombogenic activities of Muromonab.
Tibolone,Tibolone may increase the thrombogenic activities of Muromonab.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Muromonab."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Muromonab."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Muromonab.
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Muromonab.
Zeranol,Zeranol may increase the thrombogenic activities of Muromonab.
Equol,Equol may increase the thrombogenic activities of Muromonab.
Promestriene,Promestriene may increase the thrombogenic activities of Muromonab.
Methallenestril,Methallenestril may increase the thrombogenic activities of Muromonab.
Epimestrol,Epimestrol may increase the thrombogenic activities of Muromonab.
Moxestrol,Moxestrol may increase the thrombogenic activities of Muromonab.
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Muromonab.
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Muromonab.
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Muromonab.
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Muromonab.
Biochanin A,Biochanin A may increase the thrombogenic activities of Muromonab.
Formononetin,Formononetin may increase the thrombogenic activities of Muromonab.
Leflunomide,The risk or severity of adverse effects can be increased when Muromonab is combined with Leflunomide.
Tofacitinib,Muromonab may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Muromonab.
Fingolimod,Muromonab may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Muromonab.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Muromonab.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Muromonab.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Muromonab.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Muromonab.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Muromonab.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Muromonab.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Muromonab.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Muromonab.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Muromonab.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Muromonab."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Muromonab.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Muromonab.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Muromonab."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Muromonab.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Muromonab.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Muromonab.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Muromonab.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Muromonab.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Muromonab.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Muromonab.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Muromonab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Muromonab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Muromonab.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Muromonab.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Muromonab.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Muromonab.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Muromonab.
Ocrelizumab,Ocrelizumab may increase the immunosuppressive activities of Muromonab.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Muromonab.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Muromonab.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Muromonab.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Muromonab.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Muromonab.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Muromonab.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Muromonab.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Muromonab.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Muromonab.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Muromonab.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Muromonab.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Muromonab.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Muromonab.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Muromonab.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Muromonab.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Muromonab.
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Muromonab.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Muromonab is combined with Digoxin Immune Fab (Ovine).
Capromab pendetide,The risk or severity of adverse effects can be increased when Muromonab is combined with Capromab pendetide.
Palivizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Palivizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Muromonab is combined with Technetium Tc-99m arcitumomab.
Panitumumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Pexelizumab.
Epratuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Muromonab is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Muromonab is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Muromonab is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Muromonab is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Muromonab is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Muromonab is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Muromonab is combined with NAV 1800.
Otelixizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Muromonab is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Veltuzumab.
PRO-542,The risk or severity of adverse effects can be increased when Muromonab is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Muromonab is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Muromonab is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Muromonab is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Muromonab is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Muromonab is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Muromonab is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Muromonab is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Muromonab is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Muromonab is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Muromonab is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Lumiliximab.
Ipilimumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Clenoliximab.
BIIB015,The risk or severity of adverse effects can be increased when Muromonab is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Muromonab is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Muromonab is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Muromonab is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Muromonab is combined with Catumaxomab.
Volociximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ofatumumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Raxibacumab.
Nivolumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Nivolumab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Muromonab is combined with Dulaglutide.
Asfotase alfa,The risk or severity of adverse effects can be increased when Muromonab is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Evolocumab.
Daratumumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Necitumumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Muromonab is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Muromonab is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Muromonab is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Muromonab is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Solanezumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Tremelimumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Lampalizumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Muromonab is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Anifrolumab.
Benralizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Muromonab is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Muromonab is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Muromonab is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Muromonab is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Muromonab is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Muromonab is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Muromonab is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Muromonab is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Plozalizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Muromonab is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Muromonab is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Muromonab is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Muromonab is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Muromonab is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Muromonab is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Muromonab is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Muromonab is combined with Besilesomab.
Burosumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Muromonab is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Muromonab is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Muromonab is combined with Cemiplimab.
Camrelizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Muromonab is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Muromonab is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Muromonab is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Refanezumab.
Bermekimab,The risk or severity of adverse effects can be increased when Muromonab is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Muromonab is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Muromonab is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Muromonab is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Muromonab is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Muromonab is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Muromonab is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Muromonab is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Muromonab is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Muromonab is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Muromonab is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Muromonab is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Nemolizumab.
Gedivumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Muromonab is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Muromonab is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Muromonab is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Muromonab is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Muromonab is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Muromonab is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Muromonab is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Muromonab is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Muromonab is combined with Naratuximab emtansine.
Tildrakizumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Tildrakizumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ustekinumab.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Muromonab is combined with Zenocutuzumab.
Cyclosporine,Muromonab may increase the immunosuppressive activities of Cyclosporine.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Muromonab."
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Muromonab.
Lopinavir,The serum concentration of Muromonab can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Muromonab is combined with Inebilizumab.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Estrone,Estrone may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Estradiol,Estradiol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Dienestrol,Dienestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Mestranol,Mestranol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Estriol,Estriol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Quinestrol,Quinestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Hexestrol,Hexestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Tibolone,Tibolone may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Digoxin Immune Fab (Ovine)."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Digoxin Immune Fab (Ovine)."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Zeranol,Zeranol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Equol,Equol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Promestriene,Promestriene may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Methallenestril,Methallenestril may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Epimestrol,Epimestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Moxestrol,Moxestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Biochanin A,Biochanin A may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Formononetin,Formononetin may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Digoxin Immune Fab (Ovine).
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Digoxin Immune Fab (Ovine).
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Digoxin Immune Fab (Ovine).
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Digoxin Immune Fab (Ovine).
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Digoxin Immune Fab (Ovine).
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Digoxin Immune Fab (Ovine).
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Digoxin Immune Fab (Ovine).
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Digoxin Immune Fab (Ovine).
Trastuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Digoxin Immune Fab (Ovine).
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Digoxin Immune Fab (Ovine).
Basiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Digoxin Immune Fab (Ovine).
Muromonab,The risk or severity of adverse effects can be increased when Muromonab is combined with Digoxin Immune Fab (Ovine).
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ibritumomab tiuxetan.
Tositumomab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tositumomab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Alemtuzumab.
Capromab pendetide,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Capromab pendetide.
Efalizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Antithymocyte immunoglobulin (rabbit).
Natalizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Natalizumab.
Palivizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Palivizumab.
Daclizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bevacizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Technetium Tc-99m arcitumomab.
Eculizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eculizumab.
Panitumumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pexelizumab.
Afelimomab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Afelimomab.
Epratuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with NAV 1800.
Briakinumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Briakinumab.
Otelixizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Veltuzumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ustekinumab.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Trastuzumab emtansine.
PRO-542,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lumiliximab.
Canakinumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Canakinumab.
Ipilimumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Clenoliximab.
Tocilizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tocilizumab.
BIIB015,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Catumaxomab.
Mepolizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Mepolizumab.
Denosumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Denosumab.
Volociximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ofatumumab.
Golimumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Golimumab.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Brentuximab vedotin.
Belimumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Belimumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Raxibacumab.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Certolizumab pegol.
Obinutuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Obinutuzumab.
Secukinumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vedolizumab.
Nivolumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Nivolumab.
Siltuximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Siltuximab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dulaglutide.
Blinatumomab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Blinatumomab.
Anthrax immune globulin human,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Anthrax immune globulin human.
Dinutuximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dinutuximab.
Asfotase alfa,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Evolocumab.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Antilymphocyte immunoglobulin (horse).
Daratumumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Necitumumab.
Ixekizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ravulizumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Solanezumab.
Sarilumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sarilumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tremelimumab.
Brodalumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sirukumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lampalizumab.
Guselkumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Guselkumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Anifrolumab.
Ocrelizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ocrelizumab.
Benralizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Plozalizumab.
Inebilizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Inebilizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Besilesomab.
Tildrakizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tildrakizumab.
Burosumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Cemiplimab.
Emapalumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Risankizumab.
Camrelizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Refanezumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rozanolixizumab.
Bermekimab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Nemolizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bleselumab.
Gedivumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Naratuximab emtansine.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Zenocutuzumab.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Digoxin Immune Fab (Ovine)."
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Ibritumomab tiuxetan.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Ibritumomab tiuxetan.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ibritumomab tiuxetan.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ibritumomab tiuxetan.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ibritumomab tiuxetan.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ibritumomab tiuxetan.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Ibritumomab tiuxetan.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ibritumomab tiuxetan.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Ibritumomab tiuxetan."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ibritumomab tiuxetan.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Ibritumomab tiuxetan.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibritumomab tiuxetan.
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ibritumomab tiuxetan.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Ibritumomab tiuxetan.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ibritumomab tiuxetan.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ibritumomab tiuxetan.
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Ibritumomab tiuxetan.
Basiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibritumomab tiuxetan.
Muromonab,The risk or severity of adverse effects can be increased when Muromonab is combined with Ibritumomab tiuxetan.
Tositumomab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tositumomab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alemtuzumab.
Alefacept,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alefacept.
Efalizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Interferon alfa-2b.
Daclizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Beclomethasone dipropionate.
Sorafenib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sorafenib.
Streptozocin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Altretamine.
Zidovudine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zidovudine.
Cisplatin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pentostatin.
Methotrexate,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methotrexate.
Carbamazepine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carbamazepine.
Vinblastine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Linezolid.
Imatinib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Imatinib.
Triamcinolone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Paclitaxel.
Dexamethasone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexamethasone.
Docetaxel,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Decitabine.
Sunitinib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sunitinib.
Nelarabine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nelarabine.
Abatacept,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abatacept.
Corticotropin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with omega interferon.
Apremilast,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Apremilast.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ponatinib.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Certolizumab pegol.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Blinatumomab.
Ibrutinib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ibrutinib.
Idelalisib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Idelalisib.
Palbociclib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Palbociclib.
Olaparib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olaparib.
Dinutuximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dinutuximab.
Vilanterol,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vilanterol.
Tixocortol,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antilymphocyte immunoglobulin (horse).
Fluprednisolone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Meprednisone.
Tepoxalin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tepoxalin.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Melengestrol.
Ixekizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Peficitinib.
Clobetasol,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clobetasol.
Sarilumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sirukumab.
Baricitinib,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Baricitinib.
Guselkumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Guselkumab.
Deflazacort,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Deflazacort.
Triptolide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Triptolide.
Siponimod,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siponimod.
Ozanimod,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Prednylidene,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednylidene.
Fluocortin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluclorolone.
Fluticasone,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone.
Tetrandrine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tetrandrine.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Monomethyl fumarate.
Mometasone furoate,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mometasone furoate.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydrocortisone aceponate.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydrocortisone acetate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydrocortisone succinate.
Emapalumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bleselumab.
Natalizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibritumomab tiuxetan.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Ibritumomab tiuxetan.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ibritumomab tiuxetan.
Clozapine,The risk or severity of neutropenia can be increased when Ibritumomab tiuxetan is combined with Clozapine.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Ibritumomab tiuxetan.
Eptifibatide,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ibritumomab tiuxetan.
Ticlopidine,The risk or severity of adverse effects can be increased when Ticlopidine is combined with Ibritumomab tiuxetan.
Anagrelide,The risk or severity of adverse effects can be increased when Anagrelide is combined with Ibritumomab tiuxetan.
Clopidogrel,The risk or severity of adverse effects can be increased when Clopidogrel is combined with Ibritumomab tiuxetan.
Tirofiban,The risk or severity of adverse effects can be increased when Tirofiban is combined with Ibritumomab tiuxetan.
Pentoxifylline,The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Ibritumomab tiuxetan.
Acetylsalicylic acid,The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibritumomab tiuxetan.
Dipyridamole,The risk or severity of adverse effects can be increased when Dipyridamole is combined with Ibritumomab tiuxetan.
Iloprost,The risk or severity of adverse effects can be increased when Iloprost is combined with Ibritumomab tiuxetan.
Sulfinpyrazone,The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Ibritumomab tiuxetan.
Cilostazol,The risk or severity of adverse effects can be increased when Cilostazol is combined with Ibritumomab tiuxetan.
Ridogrel,The risk or severity of adverse effects can be increased when Ridogrel is combined with Ibritumomab tiuxetan.
Sevoflurane,The risk or severity of adverse effects can be increased when Sevoflurane is combined with Ibritumomab tiuxetan.
Epoprostenol,The risk or severity of adverse effects can be increased when Epoprostenol is combined with Ibritumomab tiuxetan.
Resveratrol,The risk or severity of adverse effects can be increased when Resveratrol is combined with Ibritumomab tiuxetan.
Nimesulide,The risk or severity of adverse effects can be increased when Nimesulide is combined with Ibritumomab tiuxetan.
Tesmilifene,The risk or severity of adverse effects can be increased when Tesmilifene is combined with Ibritumomab tiuxetan.
Defibrotide,The risk or severity of adverse effects can be increased when Defibrotide is combined with Ibritumomab tiuxetan.
Beraprost,The risk or severity of adverse effects can be increased when Beraprost is combined with Ibritumomab tiuxetan.
Ibudilast,The risk or severity of adverse effects can be increased when Ibudilast is combined with Ibritumomab tiuxetan.
Andrographolide,The risk or severity of adverse effects can be increased when Andrographolide is combined with Ibritumomab tiuxetan.
Caplacizumab,The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ibritumomab tiuxetan.
Prasugrel,The risk or severity of adverse effects can be increased when Prasugrel is combined with Ibritumomab tiuxetan.
Cangrelor,The risk or severity of adverse effects can be increased when Cangrelor is combined with Ibritumomab tiuxetan.
Tranilast,The risk or severity of adverse effects can be increased when Tranilast is combined with Ibritumomab tiuxetan.
Triflusal,The risk or severity of adverse effects can be increased when Triflusal is combined with Ibritumomab tiuxetan.
Ticagrelor,The risk or severity of adverse effects can be increased when Ticagrelor is combined with Ibritumomab tiuxetan.
Icosapent ethyl,The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Ibritumomab tiuxetan.
Vorapaxar,The risk or severity of adverse effects can be increased when Vorapaxar is combined with Ibritumomab tiuxetan.
Trapidil,The risk or severity of adverse effects can be increased when Trapidil is combined with Ibritumomab tiuxetan.
Naftopidil,The risk or severity of adverse effects can be increased when Naftopidil is combined with Ibritumomab tiuxetan.
Sarpogrelate,The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Ibritumomab tiuxetan.
Ifetroban,The risk or severity of adverse effects can be increased when Ifetroban is combined with Ibritumomab tiuxetan.
Nitroaspirin,The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ibritumomab tiuxetan.
Ketanserin,The risk or severity of adverse effects can be increased when Ketanserin is combined with Ibritumomab tiuxetan.
Indobufen,The risk or severity of adverse effects can be increased when Indobufen is combined with Ibritumomab tiuxetan.
Butylphthalide,The risk or severity of adverse effects can be increased when Butylphthalide is combined with Ibritumomab tiuxetan.
Hydroxytyrosol,The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Ibritumomab tiuxetan.
Ramatroban,The risk or severity of adverse effects can be increased when Ramatroban is combined with Ibritumomab tiuxetan.
Picotamide,The risk or severity of adverse effects can be increased when Picotamide is combined with Ibritumomab tiuxetan.
Cloricromen,The risk or severity of adverse effects can be increased when Cloricromen is combined with Ibritumomab tiuxetan.
Linsidomine,The risk or severity of adverse effects can be increased when Linsidomine is combined with Ibritumomab tiuxetan.
Buflomedil,The risk or severity of adverse effects can be increased when Buflomedil is combined with Ibritumomab tiuxetan.
Relcovaptan,The risk or severity of adverse effects can be increased when Relcovaptan is combined with Ibritumomab tiuxetan.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ibritumomab tiuxetan.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Ibritumomab tiuxetan.
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Ibritumomab tiuxetan.
Estrone,Estrone may increase the thrombogenic activities of Ibritumomab tiuxetan.
Estradiol,Estradiol may increase the thrombogenic activities of Ibritumomab tiuxetan.
Dienestrol,Dienestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Ibritumomab tiuxetan.
Mestranol,Mestranol may increase the thrombogenic activities of Ibritumomab tiuxetan.
Estriol,Estriol may increase the thrombogenic activities of Ibritumomab tiuxetan.
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Ibritumomab tiuxetan.
Quinestrol,Quinestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.
Hexestrol,Hexestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.
Tibolone,Tibolone may increase the thrombogenic activities of Ibritumomab tiuxetan.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Ibritumomab tiuxetan."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ibritumomab tiuxetan."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Ibritumomab tiuxetan.
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Ibritumomab tiuxetan.
Zeranol,Zeranol may increase the thrombogenic activities of Ibritumomab tiuxetan.
Equol,Equol may increase the thrombogenic activities of Ibritumomab tiuxetan.
Promestriene,Promestriene may increase the thrombogenic activities of Ibritumomab tiuxetan.
Methallenestril,Methallenestril may increase the thrombogenic activities of Ibritumomab tiuxetan.
Epimestrol,Epimestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.
Moxestrol,Moxestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Ibritumomab tiuxetan.
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Ibritumomab tiuxetan.
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Ibritumomab tiuxetan.
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Ibritumomab tiuxetan.
Biochanin A,Biochanin A may increase the thrombogenic activities of Ibritumomab tiuxetan.
Formononetin,Formononetin may increase the thrombogenic activities of Ibritumomab tiuxetan.
Leflunomide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Leflunomide.
Tofacitinib,Ibritumomab tiuxetan may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Ibritumomab tiuxetan.
Fingolimod,Ibritumomab tiuxetan may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Ibritumomab tiuxetan.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Ibritumomab tiuxetan.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Ibritumomab tiuxetan.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Ibritumomab tiuxetan.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ibritumomab tiuxetan.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Ibritumomab tiuxetan.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Ibritumomab tiuxetan.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Ibritumomab tiuxetan.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Ibritumomab tiuxetan.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ibritumomab tiuxetan.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Ibritumomab tiuxetan."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Ibritumomab tiuxetan.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Ibritumomab tiuxetan.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ibritumomab tiuxetan."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Ibritumomab tiuxetan.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Ibritumomab tiuxetan.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ibritumomab tiuxetan.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Ibritumomab tiuxetan.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ibritumomab tiuxetan.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ibritumomab tiuxetan.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Ibritumomab tiuxetan.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Ibritumomab tiuxetan.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Ibritumomab tiuxetan.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Ibritumomab tiuxetan.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Ibritumomab tiuxetan.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Ibritumomab tiuxetan.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Ibritumomab tiuxetan.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Ibritumomab tiuxetan.
Dicoumarol,The risk or severity of adverse effects can be increased when Dicoumarol is combined with Ibritumomab tiuxetan.
Ardeparin,The risk or severity of adverse effects can be increased when Ardeparin is combined with Ibritumomab tiuxetan.
Phenindione,The risk or severity of adverse effects can be increased when Phenindione is combined with Ibritumomab tiuxetan.
Warfarin,The risk or severity of adverse effects can be increased when Warfarin is combined with Ibritumomab tiuxetan.
Pentosan polysulfate,The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Ibritumomab tiuxetan.
Phenprocoumon,The risk or severity of adverse effects can be increased when Phenprocoumon is combined with Ibritumomab tiuxetan.
Acenocoumarol,The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Ibritumomab tiuxetan.
4-hydroxycoumarin,The risk or severity of adverse effects can be increased when 4-hydroxycoumarin is combined with Ibritumomab tiuxetan.
Coumarin,The risk or severity of adverse effects can be increased when Coumarin is combined with Ibritumomab tiuxetan.
Ximelagatran,The risk or severity of adverse effects can be increased when Ximelagatran is combined with Ibritumomab tiuxetan.
Desmoteplase,The risk or severity of adverse effects can be increased when Desmoteplase is combined with Ibritumomab tiuxetan.
Fibrinolysin,The risk or severity of adverse effects can be increased when Fibrinolysin is combined with Ibritumomab tiuxetan.
Rivaroxaban,The risk or severity of adverse effects can be increased when Rivaroxaban is combined with Ibritumomab tiuxetan.
Sulodexide,The risk or severity of adverse effects can be increased when Sulodexide is combined with Ibritumomab tiuxetan.
Semuloparin,The risk or severity of adverse effects can be increased when Semuloparin is combined with Ibritumomab tiuxetan.
Idraparinux,The risk or severity of adverse effects can be increased when Idraparinux is combined with Ibritumomab tiuxetan.
Astaxanthin,The risk or severity of adverse effects can be increased when Astaxanthin is combined with Ibritumomab tiuxetan.
Apixaban,The risk or severity of adverse effects can be increased when Apixaban is combined with Ibritumomab tiuxetan.
Otamixaban,The risk or severity of adverse effects can be increased when Otamixaban is combined with Ibritumomab tiuxetan.
Amediplase,The risk or severity of adverse effects can be increased when Amediplase is combined with Ibritumomab tiuxetan.
Dabigatran etexilate,The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Ibritumomab tiuxetan.
Ferulic acid,The risk or severity of adverse effects can be increased when Ferulic acid is combined with Ibritumomab tiuxetan.
(R)-warfarin,The risk or severity of adverse effects can be increased when (R)-warfarin is combined with Ibritumomab tiuxetan.
Ethyl biscoumacetate,The risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Ibritumomab tiuxetan.
Ditazole,The risk or severity of adverse effects can be increased when Ditazole is combined with Ibritumomab tiuxetan.
Edoxaban,The risk or severity of adverse effects can be increased when Edoxaban is combined with Ibritumomab tiuxetan.
Potassium citrate,The risk or severity of adverse effects can be increased when Potassium citrate is combined with Ibritumomab tiuxetan.
Sodium citrate,The risk or severity of adverse effects can be increased when Sodium citrate is combined with Ibritumomab tiuxetan.
Bemiparin,The risk or severity of adverse effects can be increased when Bemiparin is combined with Ibritumomab tiuxetan.
Reviparin,The risk or severity of adverse effects can be increased when Reviparin is combined with Ibritumomab tiuxetan.
Parnaparin,The risk or severity of adverse effects can be increased when Parnaparin is combined with Ibritumomab tiuxetan.
Certoparin,The risk or severity of adverse effects can be increased when Certoparin is combined with Ibritumomab tiuxetan.
Zinc citrate,The risk or severity of adverse effects can be increased when Zinc citrate is combined with Ibritumomab tiuxetan.
Letaxaban,The risk or severity of adverse effects can be increased when Letaxaban is combined with Ibritumomab tiuxetan.
Darexaban,The risk or severity of adverse effects can be increased when Darexaban is combined with Ibritumomab tiuxetan.
Betrixaban,The risk or severity of adverse effects can be increased when Betrixaban is combined with Ibritumomab tiuxetan.
Nafamostat,The risk or severity of adverse effects can be increased when Nafamostat is combined with Ibritumomab tiuxetan.
Monteplase,The risk or severity of adverse effects can be increased when Monteplase is combined with Ibritumomab tiuxetan.
Gabexate,The risk or severity of adverse effects can be increased when Gabexate is combined with Ibritumomab tiuxetan.
Fluindione,The risk or severity of adverse effects can be increased when Fluindione is combined with Ibritumomab tiuxetan.
Brinase,The risk or severity of adverse effects can be increased when Brinase is combined with Ibritumomab tiuxetan.
Clorindione,The risk or severity of adverse effects can be increased when Clorindione is combined with Ibritumomab tiuxetan.
Diphenadione,The risk or severity of adverse effects can be increased when Diphenadione is combined with Ibritumomab tiuxetan.
Tioclomarol,The risk or severity of adverse effects can be increased when Tioclomarol is combined with Ibritumomab tiuxetan.
Melagatran,The risk or severity of adverse effects can be increased when Melagatran is combined with Ibritumomab tiuxetan.
Saruplase,The risk or severity of adverse effects can be increased when Saruplase is combined with Ibritumomab tiuxetan.
(S)-Warfarin,The risk or severity of adverse effects can be increased when (S)-Warfarin is combined with Ibritumomab tiuxetan.
Tocopherylquinone,The risk or severity of adverse effects can be increased when Tocopherylquinone is combined with Ibritumomab tiuxetan.
Dabigatran,The risk or severity of adverse effects can be increased when Dabigatran is combined with Ibritumomab tiuxetan.
Ocrelizumab,Ocrelizumab may increase the immunosuppressive activities of Ibritumomab tiuxetan.
Lipegfilgrastim,Ibritumomab tiuxetan may increase the myelosuppressive activities of Lipegfilgrastim.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Ibritumomab tiuxetan.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Ibritumomab tiuxetan.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Ibritumomab tiuxetan.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Ibritumomab tiuxetan.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Ibritumomab tiuxetan.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Ibritumomab tiuxetan.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Ibritumomab tiuxetan.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Ibritumomab tiuxetan.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Ibritumomab tiuxetan.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Ibritumomab tiuxetan.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Ibritumomab tiuxetan.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Ibritumomab tiuxetan.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Ibritumomab tiuxetan.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ibritumomab tiuxetan.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Ibritumomab tiuxetan.
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ibritumomab tiuxetan.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ibritumomab tiuxetan.
Capromab pendetide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Capromab pendetide.
Palivizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Palivizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Technetium Tc-99m arcitumomab.
Panitumumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pexelizumab.
Epratuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with NAV 1800.
Otelixizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Veltuzumab.
PRO-542,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with TB-402.
IMC-1C11,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lumiliximab.
Ipilimumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clenoliximab.
BIIB015,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Catumaxomab.
Volociximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ofatumumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Raxibacumab.
Nivolumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nivolumab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dulaglutide.
Asfotase alfa,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Evolocumab.
Daratumumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Necitumumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Solanezumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tremelimumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lampalizumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Anifrolumab.
Benralizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Plozalizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Besilesomab.
Burosumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cemiplimab.
Camrelizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Refanezumab.
Bermekimab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nemolizumab.
Gedivumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Naratuximab emtansine.
Tildrakizumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tildrakizumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ustekinumab.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zenocutuzumab.
Palifermin,The therapeutic efficacy of Palifermin can be decreased when used in combination with Ibritumomab tiuxetan.
Lepirudin,The risk or severity of bleeding can be increased when Lepirudin is combined with Ibritumomab tiuxetan.
Bivalirudin,The risk or severity of bleeding can be increased when Bivalirudin is combined with Ibritumomab tiuxetan.
Alteplase,The risk or severity of bleeding can be increased when Alteplase is combined with Ibritumomab tiuxetan.
Urokinase,The risk or severity of bleeding can be increased when Urokinase is combined with Ibritumomab tiuxetan.
Reteplase,The risk or severity of bleeding can be increased when Reteplase is combined with Ibritumomab tiuxetan.
Anistreplase,The risk or severity of bleeding can be increased when Anistreplase is combined with Ibritumomab tiuxetan.
Tenecteplase,The risk or severity of bleeding can be increased when Tenecteplase is combined with Ibritumomab tiuxetan.
Drotrecogin alfa,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ibritumomab tiuxetan.
Streptokinase,The risk or severity of bleeding can be increased when Streptokinase is combined with Ibritumomab tiuxetan.
Argatroban,The risk or severity of bleeding can be increased when Argatroban is combined with Ibritumomab tiuxetan.
Fondaparinux,The risk or severity of bleeding can be increased when Fondaparinux is combined with Ibritumomab tiuxetan.
Heparin,The risk or severity of bleeding can be increased when Heparin is combined with Ibritumomab tiuxetan.
Enoxaparin,The risk or severity of bleeding can be increased when Enoxaparin is combined with Ibritumomab tiuxetan.
Ancrod,The risk or severity of bleeding can be increased when Ancrod is combined with Ibritumomab tiuxetan.
Danaparoid,The risk or severity of bleeding can be increased when Danaparoid is combined with Ibritumomab tiuxetan.
Dalteparin,The risk or severity of bleeding can be increased when Dalteparin is combined with Ibritumomab tiuxetan.
Tinzaparin,The risk or severity of bleeding can be increased when Tinzaparin is combined with Ibritumomab tiuxetan.
Nadroparin,The risk or severity of bleeding can be increased when Nadroparin is combined with Ibritumomab tiuxetan.
Dextran,The risk or severity of bleeding can be increased when Dextran is combined with Ibritumomab tiuxetan.
Desirudin,The risk or severity of bleeding can be increased when Desirudin is combined with Ibritumomab tiuxetan.
Antithrombin Alfa,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Ibritumomab tiuxetan.
Protein C,The risk or severity of bleeding can be increased when Protein C is combined with Ibritumomab tiuxetan.
Antithrombin III human,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Ibritumomab tiuxetan.
Protein S human,The risk or severity of bleeding can be increased when Protein S human is combined with Ibritumomab tiuxetan.
Edetate calcium disodium anhydrous,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Ibritumomab tiuxetan.
Methyclothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Ibritumomab tiuxetan.
Bendroflumethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Ibritumomab tiuxetan.
Benzthiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Ibritumomab tiuxetan.
Cyclothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Ibritumomab tiuxetan.
Hydroflumethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Ibritumomab tiuxetan.
Chlorothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Ibritumomab tiuxetan.
Hydrochlorothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Ibritumomab tiuxetan.
Trichlormethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Ibritumomab tiuxetan.
Polythiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Ibritumomab tiuxetan.
Mebutizide,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Ibritumomab tiuxetan.
Cyclopenthiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Ibritumomab tiuxetan.
Tedizolid phosphate,The risk or severity of myelosuppression can be increased when Ibritumomab tiuxetan is combined with Tedizolid phosphate.
Cyclosporine,Ibritumomab tiuxetan may increase the immunosuppressive activities of Cyclosporine.
Cyanocobalamin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ibritumomab tiuxetan.
Allopurinol,The risk or severity of adverse effects can be increased when Allopurinol is combined with Ibritumomab tiuxetan.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Ibritumomab tiuxetan."
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Ibritumomab tiuxetan.
Lopinavir,The serum concentration of Ibritumomab tiuxetan can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Ibritumomab tiuxetan is combined with Inebilizumab.
Pravastatin,The risk or severity of myopathy can be increased when Pravastatin is combined with Daptomycin.
Lovastatin,The risk or severity of myopathy can be increased when Lovastatin is combined with Daptomycin.
Cerivastatin,The risk or severity of myopathy can be increased when Cerivastatin is combined with Daptomycin.
Simvastatin,The risk or severity of myopathy can be increased when Simvastatin is combined with Daptomycin.
Atorvastatin,The risk or severity of myopathy can be increased when Atorvastatin is combined with Daptomycin.
Fluvastatin,The risk or severity of myopathy can be increased when Fluvastatin is combined with Daptomycin.
Rosuvastatin,The risk or severity of myopathy can be increased when Rosuvastatin is combined with Daptomycin.
Mevastatin,The risk or severity of myopathy can be increased when Mevastatin is combined with Daptomycin.
Pitavastatin,The risk or severity of myopathy can be increased when Pitavastatin is combined with Daptomycin.
BCG vaccine,The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Daptomycin.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Daptomycin.
Cyclosporine,Cyclosporine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Icosapent,Icosapent may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefotiam,Cefotiam may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Mesalazine,Mesalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefmenoxime,Cefmenoxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefmetazole,Cefmetazole may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Pamidronic acid,Pamidronic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tenofovir disoproxil,Tenofovir disoproxil may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Indomethacin,Indomethacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cidofovir,Cidofovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Triamterene,Triamterene may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefpiramide,Cefpiramide may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ceftazidime,Ceftazidime may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Loracarbef,Loracarbef may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefalotin,Cefalotin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Nabumetone,Nabumetone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ketorolac,Ketorolac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tenoxicam,Tenoxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Celecoxib,Celecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefotaxime,Cefotaxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tolmetin,Tolmetin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Foscarnet,Foscarnet may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Rofecoxib,Rofecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Piroxicam,Piroxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Methotrexate,Methotrexate may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cephalexin,Cephalexin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Fenoprofen,Fenoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Valaciclovir,Valaciclovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Valdecoxib,Valdecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Diclofenac,Diclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Sulindac,Sulindac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Bacitracin,Bacitracin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Amphotericin B,Amphotericin B may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cephaloglycin,Cephaloglycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Flurbiprofen,Flurbiprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Adefovir dipivoxil,Adefovir dipivoxil may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Pentamidine,Pentamidine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Mannitol,Mannitol may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Etodolac,Etodolac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Mefenamic acid,Mefenamic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Acyclovir,Acyclovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Naproxen,Naproxen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Sulfasalazine,Sulfasalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Phenylbutazone,Phenylbutazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Meloxicam,Meloxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Carprofen,Carprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefaclor,Cefaclor may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Diflunisal,Diflunisal may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tacrolimus,Tacrolimus may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Etacrynic acid,Etacrynic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ceforanide,Ceforanide may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Salicylic acid,Salicylic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Meclofenamic acid,Meclofenamic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Acetylsalicylic acid,Acetylsalicylic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Carboplatin,Carboplatin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Oxaprozin,Oxaprozin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Hydrochlorothiazide,Hydrochlorothiazide may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ketoprofen,Ketoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Balsalazide,Balsalazide may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ibuprofen,Ibuprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefditoren,Cefditoren may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Atazanavir,Atazanavir may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Colistimethate,Colistimethate may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefuroxime,Cefuroxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefapirin,Cefapirin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefadroxil,Cefadroxil may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefprozil,Cefprozil may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ceftriaxone,Ceftriaxone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Olsalazine,Olsalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Lumiracoxib,Lumiracoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefamandole,Cefamandole may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefazolin,Cefazolin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefonicid,Cefonicid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefoperazone,Cefoperazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefotetan,Cefotetan may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefoxitin,Cefoxitin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ceftizoxime,Ceftizoxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefradine,Cefradine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Magnesium salicylate,Magnesium salicylate may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Salsalate,Salsalate may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Choline magnesium trisalicylate,Choline magnesium trisalicylate may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefepime,Cefepime may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefacetrile,Cefacetrile may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ceftibuten,Ceftibuten may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefpodoxime,Cefpodoxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Antrafenine,Antrafenine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Aminophenazone,Aminophenazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Antipyrine,Antipyrine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tiaprofenic acid,Tiaprofenic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Lopinavir,Lopinavir may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Etoricoxib,Etoricoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Hydrolyzed Cephalothin,Hydrolyzed Cephalothin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cephalothin Group,Cephalothin Group may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Oxyphenbutazone,Oxyphenbutazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Niflumic acid,Niflumic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Latamoxef,Latamoxef may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Nimesulide,Nimesulide may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Benoxaprofen,Benoxaprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Metamizole,Metamizole may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Zomepirac,Zomepirac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ceftobiprole,Ceftobiprole may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cimicoxib,Cimicoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ceftaroline fosamil,Ceftaroline fosamil may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Lornoxicam,Lornoxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Aceclofenac,Aceclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Zaltoprofen,Zaltoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Azapropazone,Azapropazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Felbinac,Felbinac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Parecoxib,Parecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Salicylamide,Salicylamide may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Kebuzone,Kebuzone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Isoxicam,Isoxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Indoprofen,Indoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ibuproxam,Ibuproxam may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Floctafenine,Floctafenine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Fenbufen,Fenbufen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Etofenamate,Etofenamate may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Epirizole,Epirizole may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefaloridine,Cefaloridine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefminox,Cefminox may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Benzydamine,Benzydamine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Loxoprofen,Loxoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Dexibuprofen,Dexibuprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Dexketoprofen,Dexketoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Droxicam,Droxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tolfenamic acid,Tolfenamic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Firocoxib,Firocoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Clonixin,Clonixin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Morniflumate,Morniflumate may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Propacetamol,Propacetamol may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Talniflumate,Talniflumate may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tenofovir alafenamide,Tenofovir alafenamide may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefroxadine,Cefroxadine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Robenacoxib,Robenacoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tepoxalin,Tepoxalin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Flunixin,Flunixin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Flomoxef,Flomoxef may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Brincidofovir,Brincidofovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Nitroaspirin,Nitroaspirin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Indobufen,Indobufen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tinoridine,Tinoridine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Alclofenac,Alclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Fentiazac,Fentiazac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Suxibuzone,Suxibuzone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefatrizine,Cefatrizine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Bumadizone,Bumadizone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Alminoprofen,Alminoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Flunoxaprofen,Flunoxaprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Feprazone,Feprazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Difenpiramide,Difenpiramide may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Nifenazone,Nifenazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Lonazolac,Lonazolac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefcapene,Cefcapene may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefodizime,Cefodizime may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tenidap,Tenidap may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefsulodin,Cefsulodin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Bendazac,Bendazac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefetamet,Cefetamet may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Pranoprofen,Pranoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Propyphenazone,Propyphenazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Proglumetacin,Proglumetacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Guacetisal,Guacetisal may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ethenzamide,Ethenzamide may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Carbaspirin calcium,Carbaspirin calcium may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Mofebutazone,Mofebutazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefbuperazone,Cefbuperazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Proquazone,Proquazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Benorilate,Benorilate may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefozopran,Cefozopran may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefpirome,Cefpirome may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Pirprofen,Pirprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefazedone,Cefazedone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Acemetacin,Acemetacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ceftezole,Ceftezole may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Imidazole salicylate,Imidazole salicylate may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Adefovir,Adefovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.
SC-236,SC-236 may decrease the excretion rate of Daptomycin which could result in a higher serum level.
NS-398,NS-398 may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tenofovir,Tenofovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Inotersen,Inotersen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Phenazopyridine,Phenazopyridine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Givosiran,Givosiran may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Lithium cation,Lithium cation may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Lithium citrate,Lithium citrate may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Goserelin,Goserelin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Salmon calcitonin,Salmon calcitonin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Desmopressin,Desmopressin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Aldesleukin,Aldesleukin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tositumomab,Daptomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cyanocobalamin,Daptomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Folic acid,Daptomycin may decrease the excretion rate of Folic acid which could result in a higher serum level.
Pyridoxine,Daptomycin may decrease the excretion rate of Pyridoxine which could result in a higher serum level.
Fluvoxamine,Daptomycin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.
Amphetamine,Daptomycin may decrease the excretion rate of Amphetamine which could result in a higher serum level.
Cevimeline,Daptomycin may decrease the excretion rate of Cevimeline which could result in a higher serum level.
Lorazepam,Daptomycin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
Carbidopa,Daptomycin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
Tramadol,Daptomycin may decrease the excretion rate of Tramadol which could result in a higher serum level.
Fluconazole,Daptomycin may decrease the excretion rate of Fluconazole which could result in a higher serum level.
Oseltamivir,Daptomycin may decrease the excretion rate of Oseltamivir which could result in a higher serum level.
Hydroxocobalamin,Daptomycin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.
Reserpine,Daptomycin may decrease the excretion rate of Reserpine which could result in a higher serum level.
Ticlopidine,Daptomycin may decrease the excretion rate of Ticlopidine which could result in a higher serum level.
Pantoprazole,Daptomycin may decrease the excretion rate of Pantoprazole which could result in a higher serum level.
Gadodiamide,Daptomycin may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
Pregabalin,Daptomycin may decrease the excretion rate of Pregabalin which could result in a higher serum level.
Temazepam,Daptomycin may decrease the excretion rate of Temazepam which could result in a higher serum level.
Milrinone,Daptomycin may decrease the excretion rate of Milrinone which could result in a higher serum level.
Butabarbital,Daptomycin may decrease the excretion rate of Butabarbital which could result in a higher serum level.
Ranolazine,Daptomycin may decrease the excretion rate of Ranolazine which could result in a higher serum level.
Benzatropine,Daptomycin may decrease the excretion rate of Benzatropine which could result in a higher serum level.
Doxycycline,Daptomycin may decrease the excretion rate of Doxycycline which could result in a higher serum level.
Carmustine,Daptomycin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Metoprolol,Daptomycin may decrease the excretion rate of Metoprolol which could result in a higher serum level.
Isradipine,Daptomycin may decrease the excretion rate of Isradipine which could result in a higher serum level.
Diatrizoate,Daptomycin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.
Topiramate,Daptomycin may decrease the excretion rate of Topiramate which could result in a higher serum level.
Liothyronine,Daptomycin may decrease the excretion rate of Liothyronine which could result in a higher serum level.
Disopyramide,Daptomycin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Acarbose,Daptomycin may decrease the excretion rate of Acarbose which could result in a higher serum level.
Venlafaxine,Daptomycin may decrease the excretion rate of Venlafaxine which could result in a higher serum level.
Conjugated estrogens,Daptomycin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
Atomoxetine,Daptomycin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.
Bleomycin,Daptomycin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Etomidate,Daptomycin may decrease the excretion rate of Etomidate which could result in a higher serum level.
Etonogestrel,Daptomycin may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
Ropivacaine,Daptomycin may decrease the excretion rate of Ropivacaine which could result in a higher serum level.
Ertapenem,Daptomycin may decrease the excretion rate of Ertapenem which could result in a higher serum level.
Ibutilide,Daptomycin may decrease the excretion rate of Ibutilide which could result in a higher serum level.
Pentobarbital,Daptomycin may decrease the excretion rate of Pentobarbital which could result in a higher serum level.
Acetaminophen,Daptomycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Piperacillin,Daptomycin may decrease the excretion rate of Piperacillin which could result in a higher serum level.
Floxuridine,Daptomycin may decrease the excretion rate of Floxuridine which could result in a higher serum level.
Tolcapone,Daptomycin may decrease the excretion rate of Tolcapone which could result in a higher serum level.
Nitroprusside,Daptomycin may decrease the excretion rate of Nitroprusside which could result in a higher serum level.
Hydromorphone,Daptomycin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.
Ethambutol,Daptomycin may decrease the excretion rate of Ethambutol which could result in a higher serum level.
Metformin,Daptomycin may decrease the excretion rate of Metformin which could result in a higher serum level.
Methadone,Daptomycin may decrease the excretion rate of Methadone which could result in a higher serum level.
Pyrazinamide,Daptomycin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
Cetirizine,Daptomycin may decrease the excretion rate of Cetirizine which could result in a higher serum level.
Clobazam,Daptomycin may decrease the excretion rate of Clobazam which could result in a higher serum level.
Megestrol acetate,Daptomycin may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.
Aztreonam,Daptomycin may decrease the excretion rate of Aztreonam which could result in a higher serum level.
Chlorzoxazone,Daptomycin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.
Sulfadiazine,Daptomycin may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.
Clozapine,Daptomycin may decrease the excretion rate of Clozapine which could result in a higher serum level.
Sucralfate,Daptomycin may decrease the excretion rate of Sucralfate which could result in a higher serum level.
Thiethylperazine,Daptomycin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.
Timolol,Daptomycin may decrease the excretion rate of Timolol which could result in a higher serum level.
Palonosetron,Daptomycin may decrease the excretion rate of Palonosetron which could result in a higher serum level.
Dexrazoxane,Daptomycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Sorafenib,Daptomycin may decrease the excretion rate of Sorafenib which could result in a higher serum level.
Nisoldipine,Daptomycin may decrease the excretion rate of Nisoldipine which could result in a higher serum level.
Eszopiclone,Daptomycin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.
Alprazolam,Daptomycin may decrease the excretion rate of Alprazolam which could result in a higher serum level.
Rosiglitazone,Daptomycin may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.
Pramipexole,Daptomycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.
Ampicillin,Daptomycin may decrease the excretion rate of Ampicillin which could result in a higher serum level.
Secobarbital,Daptomycin may decrease the excretion rate of Secobarbital which could result in a higher serum level.
Methylphenidate,Daptomycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Trifluridine,Daptomycin may decrease the excretion rate of Trifluridine which could result in a higher serum level.
Nitric Oxide,Daptomycin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
Allopurinol,Daptomycin may decrease the excretion rate of Allopurinol which could result in a higher serum level.
Gemcitabine,Daptomycin may decrease the excretion rate of Gemcitabine which could result in a higher serum level.
Duloxetine,Daptomycin may decrease the excretion rate of Duloxetine which could result in a higher serum level.
Chlorpromazine,Daptomycin may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.
Lenalidomide,Daptomycin may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
Buspirone,Daptomycin may decrease the excretion rate of Buspirone which could result in a higher serum level.
Fosinopril,Daptomycin may decrease the excretion rate of Fosinopril which could result in a higher serum level.
Flutamide,Daptomycin may decrease the excretion rate of Flutamide which could result in a higher serum level.
Haloperidol,Daptomycin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cefdinir,Daptomycin may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Azelaic acid,Daptomycin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
Methoxsalen,Daptomycin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
Lamotrigine,Daptomycin may decrease the excretion rate of Lamotrigine which could result in a higher serum level.
Zanamivir,Daptomycin may decrease the excretion rate of Zanamivir which could result in a higher serum level.
Fondaparinux,Daptomycin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Propranolol,Daptomycin may decrease the excretion rate of Propranolol which could result in a higher serum level.
Levocarnitine,Daptomycin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
Fluocinolone acetonide,Daptomycin may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.
Gadoteridol,Daptomycin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
Labetalol,Daptomycin may decrease the excretion rate of Labetalol which could result in a higher serum level.
Medroxyprogesterone acetate,Daptomycin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.
Bisoprolol,Daptomycin may decrease the excretion rate of Bisoprolol which could result in a higher serum level.
Testosterone,Daptomycin may decrease the excretion rate of Testosterone which could result in a higher serum level.
Clorazepic acid,Daptomycin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
Clofarabine,Daptomycin may decrease the excretion rate of Clofarabine which could result in a higher serum level.
Dexmedetomidine,Daptomycin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
Prednisone,Daptomycin may decrease the excretion rate of Prednisone which could result in a higher serum level.
Dyphylline,Daptomycin may decrease the excretion rate of Dyphylline which could result in a higher serum level.
Mecamylamine,Daptomycin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
Metaxalone,Daptomycin may decrease the excretion rate of Metaxalone which could result in a higher serum level.
Verapamil,Daptomycin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Nilutamide,Daptomycin may decrease the excretion rate of Nilutamide which could result in a higher serum level.
Sumatriptan,Daptomycin may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
Chlorpropamide,Daptomycin may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
Midazolam,Daptomycin may decrease the excretion rate of Midazolam which could result in a higher serum level.
Flurazepam,Daptomycin may decrease the excretion rate of Flurazepam which could result in a higher serum level.
Phentolamine,Daptomycin may decrease the excretion rate of Phentolamine which could result in a higher serum level.
Nitrofurantoin,Daptomycin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Tamsulosin,Daptomycin may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
Oxacillin,Daptomycin may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Nedocromil,Daptomycin may decrease the excretion rate of Nedocromil which could result in a higher serum level.
Lisinopril,Daptomycin may decrease the excretion rate of Lisinopril which could result in a higher serum level.
Thiabendazole,Daptomycin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
Nateglinide,Daptomycin may decrease the excretion rate of Nateglinide which could result in a higher serum level.
Pralidoxime,Daptomycin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
Gadobenic acid,Daptomycin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
Tetracycline,Daptomycin may decrease the excretion rate of Tetracycline which could result in a higher serum level.
Meropenem,Daptomycin may decrease the excretion rate of Meropenem which could result in a higher serum level.
Potassium chloride,Daptomycin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
Methimazole,Daptomycin may decrease the excretion rate of Methimazole which could result in a higher serum level.
Tirofiban,Daptomycin may decrease the excretion rate of Tirofiban which could result in a higher serum level.
Phenelzine,Daptomycin may decrease the excretion rate of Phenelzine which could result in a higher serum level.
Propantheline,Daptomycin may decrease the excretion rate of Propantheline which could result in a higher serum level.
Estradiol,Daptomycin may decrease the excretion rate of Estradiol which could result in a higher serum level.
Gadopentetic acid,Daptomycin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
Perindopril,Daptomycin may decrease the excretion rate of Perindopril which could result in a higher serum level.
Fenoldopam,Daptomycin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
Dicyclomine,Daptomycin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Pentoxifylline,Daptomycin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.
Ribavirin,Daptomycin may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Tadalafil,Daptomycin may decrease the excretion rate of Tadalafil which could result in a higher serum level.
Fosfomycin,Daptomycin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Diazepam,Daptomycin may decrease the excretion rate of Diazepam which could result in a higher serum level.
Tolazamide,Daptomycin may decrease the excretion rate of Tolazamide which could result in a higher serum level.
Dobutamine,Daptomycin may decrease the excretion rate of Dobutamine which could result in a higher serum level.
Oxazepam,Daptomycin may decrease the excretion rate of Oxazepam which could result in a higher serum level.
Dacarbazine,Daptomycin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Temozolomide,Daptomycin may decrease the excretion rate of Temozolomide which could result in a higher serum level.
Terbutaline,Daptomycin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Testolactone,Daptomycin may decrease the excretion rate of Testolactone which could result in a higher serum level.
Didanosine,Daptomycin may decrease the excretion rate of Didanosine which could result in a higher serum level.
Tinidazole,Daptomycin may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Amantadine,Daptomycin may decrease the excretion rate of Amantadine which could result in a higher serum level.
Almotriptan,Daptomycin may decrease the excretion rate of Almotriptan which could result in a higher serum level.
Azacitidine,Daptomycin may decrease the excretion rate of Azacitidine which could result in a higher serum level.
Maprotiline,Daptomycin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Rizatriptan,Daptomycin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
Pindolol,Daptomycin may decrease the excretion rate of Pindolol which could result in a higher serum level.
Mepivacaine,Daptomycin may decrease the excretion rate of Mepivacaine which could result in a higher serum level.
Zaleplon,Daptomycin may decrease the excretion rate of Zaleplon which could result in a higher serum level.
Ramelteon,Daptomycin may decrease the excretion rate of Ramelteon which could result in a higher serum level.
Dopamine,Daptomycin may decrease the excretion rate of Dopamine which could result in a higher serum level.
Azathioprine,Daptomycin may decrease the excretion rate of Azathioprine which could result in a higher serum level.
Auranofin,Daptomycin may decrease the excretion rate of Auranofin which could result in a higher serum level.
Salbutamol,Daptomycin may decrease the excretion rate of Salbutamol which could result in a higher serum level.
Levobupivacaine,Daptomycin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.
Edrophonium,Daptomycin may decrease the excretion rate of Edrophonium which could result in a higher serum level.
Metyrapone,Daptomycin may decrease the excretion rate of Metyrapone which could result in a higher serum level.
Guanfacine,Daptomycin may decrease the excretion rate of Guanfacine which could result in a higher serum level.
Isosorbide mononitrate,Daptomycin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
Phylloquinone,Daptomycin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Mycophenolic acid,Daptomycin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
Topotecan,Daptomycin may decrease the excretion rate of Topotecan which could result in a higher serum level.
Probenecid,Daptomycin may decrease the excretion rate of Probenecid which could result in a higher serum level.
Tolterodine,Daptomycin may decrease the excretion rate of Tolterodine which could result in a higher serum level.
Memantine,Daptomycin may decrease the excretion rate of Memantine which could result in a higher serum level.
Lubiprostone,Daptomycin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Abacavir,Daptomycin may decrease the excretion rate of Abacavir which could result in a higher serum level.
Amoxicillin,Daptomycin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Glipizide,Daptomycin may decrease the excretion rate of Glipizide which could result in a higher serum level.
Clonazepam,Daptomycin may decrease the excretion rate of Clonazepam which could result in a higher serum level.
Promethazine,Daptomycin may decrease the excretion rate of Promethazine which could result in a higher serum level.
Dimethyl sulfoxide,Daptomycin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
Flucytosine,Daptomycin may decrease the excretion rate of Flucytosine which could result in a higher serum level.
Capecitabine,Daptomycin may decrease the excretion rate of Capecitabine which could result in a higher serum level.
Sibutramine,Daptomycin may decrease the excretion rate of Sibutramine which could result in a higher serum level.
Nifedipine,Daptomycin may decrease the excretion rate of Nifedipine which could result in a higher serum level.
Tolbutamide,Daptomycin may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
Rabeprazole,Daptomycin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
Tiludronic acid,Daptomycin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
Doxacurium,Daptomycin may decrease the excretion rate of Doxacurium which could result in a higher serum level.
Levofloxacin,Daptomycin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.
Flavoxate,Daptomycin may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Nefazodone,Daptomycin may decrease the excretion rate of Nefazodone which could result in a higher serum level.
Bupropion,Daptomycin may decrease the excretion rate of Bupropion which could result in a higher serum level.
Trimetrexate,Daptomycin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
Cilostazol,Daptomycin may decrease the excretion rate of Cilostazol which could result in a higher serum level.
Arsenic trioxide,Daptomycin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.
Guanethidine,Daptomycin may decrease the excretion rate of Guanethidine which could result in a higher serum level.
Ifosfamide,Daptomycin may decrease the excretion rate of Ifosfamide which could result in a higher serum level.
Naloxone,Daptomycin may decrease the excretion rate of Naloxone which could result in a higher serum level.
Nadolol,Daptomycin may decrease the excretion rate of Nadolol which could result in a higher serum level.
Flumazenil,Daptomycin may decrease the excretion rate of Flumazenil which could result in a higher serum level.
Fomepizole,Daptomycin may decrease the excretion rate of Fomepizole which could result in a higher serum level.
Estazolam,Daptomycin may decrease the excretion rate of Estazolam which could result in a higher serum level.
Ketamine,Daptomycin may decrease the excretion rate of Ketamine which could result in a higher serum level.
Budesonide,Daptomycin may decrease the excretion rate of Budesonide which could result in a higher serum level.
Quetiapine,Daptomycin may decrease the excretion rate of Quetiapine which could result in a higher serum level.
Epoprostenol,Daptomycin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.
Iodixanol,Daptomycin may decrease the excretion rate of Iodixanol which could result in a higher serum level.
Sitagliptin,Daptomycin may decrease the excretion rate of Sitagliptin which could result in a higher serum level.
Paliperidone,Daptomycin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Varenicline,Daptomycin may decrease the excretion rate of Varenicline which could result in a higher serum level.
Arformoterol,Daptomycin may decrease the excretion rate of Arformoterol which could result in a higher serum level.
Hydralazine,Daptomycin may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Penbutolol,Daptomycin may decrease the excretion rate of Penbutolol which could result in a higher serum level.
Rasagiline,Daptomycin may decrease the excretion rate of Rasagiline which could result in a higher serum level.
Tiotropium,Daptomycin may decrease the excretion rate of Tiotropium which could result in a higher serum level.
Testosterone propionate,Daptomycin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.
Amrinone,Daptomycin may decrease the excretion rate of Amrinone which could result in a higher serum level.
Oxybenzone,Daptomycin may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
Allylestrenol,Daptomycin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
Fenproporex,Daptomycin may decrease the excretion rate of Fenproporex which could result in a higher serum level.
Bromazepam,Daptomycin may decrease the excretion rate of Bromazepam which could result in a higher serum level.
Chloral hydrate,Daptomycin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
Metamfetamine,Daptomycin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ketazolam,Daptomycin may decrease the excretion rate of Ketazolam which could result in a higher serum level.
Valganciclovir,Daptomycin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Sorbitol,Daptomycin may decrease the excretion rate of Sorbitol which could result in a higher serum level.
Roflumilast,Daptomycin may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Topiroxostat,Daptomycin may decrease the excretion rate of Topiroxostat which could result in a higher serum level.
Estrone sulfate,Daptomycin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
Lorcaserin,Daptomycin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.
Pegaptanib,Daptomycin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Milnacipran,Daptomycin may decrease the excretion rate of Milnacipran which could result in a higher serum level.
Clevidipine,Daptomycin may decrease the excretion rate of Clevidipine which could result in a higher serum level.
Lofexidine,Daptomycin may decrease the excretion rate of Lofexidine which could result in a higher serum level.
Ezogabine,Daptomycin may decrease the excretion rate of Ezogabine which could result in a higher serum level.
Migalastat,Daptomycin may decrease the excretion rate of Migalastat which could result in a higher serum level.
Brivaracetam,Daptomycin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
Apremilast,Daptomycin may decrease the excretion rate of Apremilast which could result in a higher serum level.
Pentaerythritol tetranitrate,Daptomycin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
Ipilimumab,Daptomycin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Icatibant,Daptomycin may decrease the excretion rate of Icatibant which could result in a higher serum level.
Alogliptin,Daptomycin may decrease the excretion rate of Alogliptin which could result in a higher serum level.
Prasugrel,Daptomycin may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Doripenem,Daptomycin may decrease the excretion rate of Doripenem which could result in a higher serum level.
Rivaroxaban,Daptomycin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Nalmefene,Daptomycin may decrease the excretion rate of Nalmefene which could result in a higher serum level.
Droxidopa,Daptomycin may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Levocetirizine,Daptomycin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.
Saxagliptin,Daptomycin may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
Telavancin,Daptomycin may decrease the excretion rate of Telavancin which could result in a higher serum level.
Prucalopride,Daptomycin may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Flupirtine,Daptomycin may decrease the excretion rate of Flupirtine which could result in a higher serum level.
Dalfampridine,Daptomycin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
Dabigatran etexilate,Daptomycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
Desvenlafaxine,Daptomycin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.
Fesoterodine,Daptomycin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Gadofosveset trisodium,Daptomycin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Methyltestosterone,Daptomycin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
Ammonium chloride,Daptomycin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
Dimercaprol,Daptomycin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
Mangafodipir,Daptomycin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
Methylnaltrexone,Daptomycin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Plerixafor,Daptomycin may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Pralatrexate,Daptomycin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tiopronin,Daptomycin may decrease the excretion rate of Tiopronin which could result in a higher serum level.
Triethylenetetramine,Daptomycin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Ioflupane I-123,Daptomycin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
Deferiprone,Daptomycin may decrease the excretion rate of Deferiprone which could result in a higher serum level.
N-methylnicotinamide,Daptomycin may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.
Gabapentin enacarbil,Daptomycin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
Ruxolitinib,Daptomycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Mirabegron,Daptomycin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Peginesatide,Daptomycin may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Aclidinium,Daptomycin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Enzalutamide,Daptomycin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Teduglutide,Daptomycin may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Certolizumab pegol,Daptomycin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.
Formestane,Daptomycin may decrease the excretion rate of Formestane which could result in a higher serum level.
Glycerol phenylbutyrate,Daptomycin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
Pomalidomide,Daptomycin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Trametinib,Daptomycin may decrease the excretion rate of Trametinib which could result in a higher serum level.
Levomilnacipran,Daptomycin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Macitentan,Daptomycin may decrease the excretion rate of Macitentan which could result in a higher serum level.
Sofosbuvir,Daptomycin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Gemeprost,Daptomycin may decrease the excretion rate of Gemeprost which could result in a higher serum level.
Ledipasvir,Daptomycin may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
Ceftolozane,Daptomycin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Corifollitropin alfa,Daptomycin may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
Vortioxetine,Daptomycin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
Tasimelteon,Daptomycin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
Edoxaban,Daptomycin may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Idebenone,Daptomycin may decrease the excretion rate of Idebenone which could result in a higher serum level.
Vilanterol,Daptomycin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Trimebutine,Daptomycin may decrease the excretion rate of Trimebutine which could result in a higher serum level.
Tixocortol,Daptomycin may decrease the excretion rate of Tixocortol which could result in a higher serum level.
Ancestim,Daptomycin may decrease the excretion rate of Ancestim which could result in a higher serum level.
Magnesium hydroxide,Daptomycin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Hydroxyethyl Starch,Daptomycin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Pentastarch,Daptomycin may decrease the excretion rate of Pentastarch which could result in a higher serum level.
Stiripentol,Daptomycin may decrease the excretion rate of Stiripentol which could result in a higher serum level.
Aurothioglucose,Daptomycin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
Dienogest,Daptomycin may decrease the excretion rate of Dienogest which could result in a higher serum level.
Chromic chloride,Daptomycin may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Gadoteric acid,Daptomycin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Iothalamic acid,Daptomycin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Ioversol,Daptomycin may decrease the excretion rate of Ioversol which could result in a higher serum level.
Ioxilan,Daptomycin may decrease the excretion rate of Ioxilan which could result in a higher serum level.
Isosulfan blue,Daptomycin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Technetium Tc-99m mebrofenin,Daptomycin may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
Technetium Tc-99m oxidronate,Daptomycin may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
Florbetaben (18F),Daptomycin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir (18F),Daptomycin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Iopromide,Daptomycin may decrease the excretion rate of Iopromide which could result in a higher serum level.
Technetium Tc-99m exametazime,Daptomycin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
Technetium Tc-99m pyrophosphate,Daptomycin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Viloxazine,Daptomycin may decrease the excretion rate of Viloxazine which could result in a higher serum level.
Etoperidone,Daptomycin may decrease the excretion rate of Etoperidone which could result in a higher serum level.
Lorpiprazole,Daptomycin may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
Arotinolol,Daptomycin may decrease the excretion rate of Arotinolol which could result in a higher serum level.
Moxisylyte,Daptomycin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
Pholcodine,Daptomycin may decrease the excretion rate of Pholcodine which could result in a higher serum level.
Piracetam,Daptomycin may decrease the excretion rate of Piracetam which could result in a higher serum level.
Bisoxatin,Daptomycin may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
Nicorandil,Daptomycin may decrease the excretion rate of Nicorandil which could result in a higher serum level.
Blonanserin,Daptomycin may decrease the excretion rate of Blonanserin which could result in a higher serum level.
Melperone,Daptomycin may decrease the excretion rate of Melperone which could result in a higher serum level.
Methylene blue,Daptomycin may decrease the excretion rate of Methylene blue which could result in a higher serum level.
Pirlindole,Daptomycin may decrease the excretion rate of Pirlindole which could result in a higher serum level.
Toloxatone,Daptomycin may decrease the excretion rate of Toloxatone which could result in a higher serum level.
Dextran,Daptomycin may decrease the excretion rate of Dextran which could result in a higher serum level.
Tegafur,Daptomycin may decrease the excretion rate of Tegafur which could result in a higher serum level.
Gimeracil,Daptomycin may decrease the excretion rate of Gimeracil which could result in a higher serum level.
Imidafenacin,Daptomycin may decrease the excretion rate of Imidafenacin which could result in a higher serum level.
Idarucizumab,Daptomycin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Lixisenatide,Daptomycin may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Picosulfuric acid,Daptomycin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Sodium aurothiomalate,Daptomycin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
Choline C 11,Daptomycin may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
Magnesium trisilicate,Daptomycin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Sacubitril,Daptomycin may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Chondroitin sulfate,Daptomycin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
"Synthetic Conjugated Estrogens, A","Daptomycin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level."
"Synthetic Conjugated Estrogens, B","Daptomycin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level."
Procaine benzylpenicillin,Daptomycin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Sulbactam,Daptomycin may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sodium fluoride,Daptomycin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
"Antihemophilic Factor (Recombinant), PEGylated","Daptomycin may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level."
Invert sugar,Daptomycin may decrease the excretion rate of Invert sugar which could result in a higher serum level.
Dexpanthenol,Daptomycin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Phosphoric acid,Daptomycin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Sodium acetate,Daptomycin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Magnesium chloride,Daptomycin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Potassium perchlorate,Daptomycin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
Sodium sulfate,Daptomycin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Enalaprilat,Daptomycin may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
Magnesium carbonate,Daptomycin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
Acrivastine,Daptomycin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Octinoxate,Daptomycin may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Fludeoxyglucose (18F),Daptomycin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Iobenguane sulfate I-123,Daptomycin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Ixazomib,Daptomycin may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Polyethylene glycol 400,Daptomycin may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
Potassium nitrate,Daptomycin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium bicarbonate,Daptomycin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
N-acetyltyrosine,Daptomycin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Eucalyptus oil,Daptomycin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Selenious acid,Daptomycin may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Opium,Daptomycin may decrease the excretion rate of Opium which could result in a higher serum level.
Selenium,Daptomycin may decrease the excretion rate of Selenium which could result in a higher serum level.
Chromium,Daptomycin may decrease the excretion rate of Chromium which could result in a higher serum level.
Oxyquinoline,Daptomycin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Pyrantel,Daptomycin may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Bicisate,Daptomycin may decrease the excretion rate of Bicisate which could result in a higher serum level.
Tocopherol,Daptomycin may decrease the excretion rate of Tocopherol which could result in a higher serum level.
DL-Methylephedrine,Daptomycin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
Tetradecyl hydrogen sulfate (ester),Daptomycin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Clove oil,Daptomycin may decrease the excretion rate of Clove oil which could result in a higher serum level.
Evening primrose oil,Daptomycin may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
Pidotimod,Daptomycin may decrease the excretion rate of Pidotimod which could result in a higher serum level.
Lesinurad,Daptomycin may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Indigotindisulfonic acid,Daptomycin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Etafedrine,Daptomycin may decrease the excretion rate of Etafedrine which could result in a higher serum level.
Antithrombin III human,Daptomycin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Pitolisant,Daptomycin may decrease the excretion rate of Pitolisant which could result in a higher serum level.
Naldemedine,Daptomycin may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Tropisetron,Daptomycin may decrease the excretion rate of Tropisetron which could result in a higher serum level.
Baricitinib,Daptomycin may decrease the excretion rate of Baricitinib which could result in a higher serum level.
Apalutamide,Daptomycin may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Valbenazine,Daptomycin may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Delafloxacin,Daptomycin may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
Benznidazole,Daptomycin may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Isoflavone,Daptomycin may decrease the excretion rate of Isoflavone which could result in a higher serum level.
Vaborbactam,Daptomycin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Deutetrabenazine,Daptomycin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Propiverine,Daptomycin may decrease the excretion rate of Propiverine which could result in a higher serum level.
Benserazide,Daptomycin may decrease the excretion rate of Benserazide which could result in a higher serum level.
Tiapride,Daptomycin may decrease the excretion rate of Tiapride which could result in a higher serum level.
Levosalbutamol,Daptomycin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
Inosine pranobex,Daptomycin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
Inositol,Daptomycin may decrease the excretion rate of Inositol which could result in a higher serum level.
Oxabolone cipionate,Daptomycin may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.
Phosphocreatine,Daptomycin may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.
Dichlorobenzyl alcohol,Daptomycin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
Almasilate,Daptomycin may decrease the excretion rate of Almasilate which could result in a higher serum level.
Albutrepenonacog alfa,Daptomycin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Bismuth subgallate,Daptomycin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Testosterone cypionate,Daptomycin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
Testosterone enanthate,Daptomycin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
Testosterone undecanoate,Daptomycin may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
Estradiol acetate,Daptomycin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
Estradiol cypionate,Daptomycin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
Estradiol dienanthate,Daptomycin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.
Estradiol valerate,Daptomycin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
Patent Blue,Daptomycin may decrease the excretion rate of Patent Blue which could result in a higher serum level.
Choline salicylate,Daptomycin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
Pentetic acid,Daptomycin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Potassium acetate,Daptomycin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium sulfate,Daptomycin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
Chromic citrate,Daptomycin may decrease the excretion rate of Chromic citrate which could result in a higher serum level.
Chromic nitrate,Daptomycin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
Chromium gluconate,Daptomycin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
Chromium nicotinate,Daptomycin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Chromous sulfate,Daptomycin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
Solriamfetol,Daptomycin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
Pyrithione,Daptomycin may decrease the excretion rate of Pyrithione which could result in a higher serum level.
Chloroxylenol,Daptomycin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
Resorcinol,Daptomycin may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Golodirsen,Daptomycin may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Amitriptyline,Daptomycin may decrease the excretion rate of Amitriptyline which could result in a higher serum level.
Imipramine,Daptomycin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Doxepin,Daptomycin may decrease the excretion rate of Doxepin which could result in a higher serum level.
Codeine,Daptomycin may decrease the excretion rate of Codeine which could result in a higher serum level.
Meperidine,Daptomycin may decrease the excretion rate of Meperidine which could result in a higher serum level.
Fentanyl,Daptomycin may decrease the excretion rate of Fentanyl which could result in a higher serum level.
Emtricitabine,Daptomycin may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
Desipramine,Daptomycin may decrease the excretion rate of Desipramine which could result in a higher serum level.
Clomipramine,Daptomycin may decrease the excretion rate of Clomipramine which could result in a higher serum level.
Dimetacrine,Daptomycin may decrease the excretion rate of Dimetacrine which could result in a higher serum level.
Lithium hydroxide,Daptomycin may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.
Framycetin,Framycetin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Amikacin,Amikacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tobramycin,Tobramycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Gentamicin,Gentamicin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Netilmicin,Netilmicin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Neomycin,Neomycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Streptomycin,Streptomycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Kanamycin,Kanamycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Paromomycin,Paromomycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ribostamycin,Ribostamycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Geneticin,Geneticin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Apramycin,Apramycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Gentamicin C1a,Gentamicin C1a may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Neamine,Neamine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Arbekacin,Arbekacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Puromycin,Puromycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Dihydrostreptomycin,Dihydrostreptomycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Hygromycin B,Hygromycin B may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Sisomicin,Sisomicin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Dibekacin,Dibekacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Micronomicin,Micronomicin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Isepamicin,Isepamicin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Bekanamycin,Bekanamycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Pentostatin,Daptomycin may decrease the excretion rate of Pentostatin which could result in a higher serum level.
Nedaplatin,Daptomycin may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
Capreomycin,Daptomycin may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Digoxin,Daptomycin may decrease the excretion rate of Digoxin which could result in a higher serum level.
Vancomycin,Daptomycin may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Cisplatin,Daptomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Carbamazepine,Daptomycin may decrease the excretion rate of Carbamazepine which could result in a higher serum level.
Pemetrexed,Daptomycin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Warfarin,Daptomycin may decrease the excretion rate of Warfarin which could result in a higher serum level.
Quinidine,Daptomycin may decrease the excretion rate of Quinidine which could result in a higher serum level.
Isotretinoin,Daptomycin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
Procainamide,Daptomycin may decrease the excretion rate of Procainamide which could result in a higher serum level.
Plazomicin,Daptomycin may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Lithium carbonate,Daptomycin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
Metolazone,Daptomycin may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.
Furosemide,Daptomycin may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.
Indapamide,Daptomycin may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.
Zonisamide,Daptomycin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Canagliflozin,Daptomycin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Mersalyl,Daptomycin may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.
Torasemide,Torasemide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Methyclothiazide,Methyclothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone,Chlorthalidone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Ethoxzolamide,Ethoxzolamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Spironolactone,Spironolactone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Bendroflumethiazide,Bendroflumethiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Benzthiazide,Benzthiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Amiloride,Amiloride may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Cyclothiazide,Cyclothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Eplerenone,Eplerenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Methazolamide,Methazolamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Hydroflumethiazide,Hydroflumethiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Acetazolamide,Acetazolamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Conivaptan,Conivaptan may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Chlorothiazide,Chlorothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Trichlormethiazide,Trichlormethiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Diazoxide,Diazoxide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Diclofenamide,Diclofenamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Polythiazide,Polythiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Quinethazone,Quinethazone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Drospirenone,Drospirenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Theobromine,Theobromine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Piretanide,Piretanide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Tienilic acid,Tienilic acid may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Ularitide,Ularitide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolvaptan,Tolvaptan may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Dapagliflozin,Dapagliflozin may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Indisulam,Indisulam may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Azosemide,Azosemide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Canrenoic acid,Canrenoic acid may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Potassium citrate,Potassium citrate may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Efonidipine,Efonidipine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide,Isosorbide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Ertugliflozin,Ertugliflozin may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Canrenone,Canrenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Rolofylline,Rolofylline may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Spiradoline,Spiradoline may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Cicletanine,Cicletanine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Meticrane,Meticrane may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Ibopamine,Ibopamine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Mefruside,Mefruside may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Mebutizide,Mebutizide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Cyclopenthiazide,Cyclopenthiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Clorexolone,Clorexolone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Clofenamide,Clofenamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Fenquizone,Fenquizone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Clopamide,Clopamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Muzolimine,Muzolimine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Xipamide,Xipamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Epitizide,Epitizide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Bromotheophylline,Bromotheophylline may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Potassium,Potassium may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Dicoumarol,The risk or severity of bleeding can be increased when Daptomycin is combined with Dicoumarol.
Phenindione,The risk or severity of bleeding can be increased when Daptomycin is combined with Phenindione.
Phenprocoumon,The risk or severity of bleeding can be increased when Daptomycin is combined with Phenprocoumon.
Acenocoumarol,The risk or severity of bleeding can be increased when Daptomycin is combined with Acenocoumarol.
4-hydroxycoumarin,The risk or severity of bleeding can be increased when Daptomycin is combined with 4-hydroxycoumarin.
Coumarin,The risk or severity of bleeding can be increased when Daptomycin is combined with Coumarin.
(R)-warfarin,The risk or severity of bleeding can be increased when Daptomycin is combined with (R)-warfarin.
Ethyl biscoumacetate,The risk or severity of bleeding can be increased when Daptomycin is combined with Ethyl biscoumacetate.
Fluindione,The risk or severity of bleeding can be increased when Daptomycin is combined with Fluindione.
Clorindione,The risk or severity of bleeding can be increased when Daptomycin is combined with Clorindione.
Diphenadione,The risk or severity of bleeding can be increased when Daptomycin is combined with Diphenadione.
Tioclomarol,The risk or severity of bleeding can be increased when Daptomycin is combined with Tioclomarol.
(S)-Warfarin,The risk or severity of bleeding can be increased when Daptomycin is combined with (S)-Warfarin.
Leuprolide,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Daptomycin."
Somatotropin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Daptomycin."
Infliximab,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Daptomycin."
Baclofen,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Baclofen."
Sildenafil,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Sildenafil."
Indinavir,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Indinavir."
Cladribine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cladribine."
Phenytoin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Phenytoin."
Mefloquine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Mefloquine."
Tacrine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Tacrine."
Carbimazole,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Carbimazole."
Trimethoprim,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Trimethoprim."
Betamethasone,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Betamethasone."
Montelukast,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Montelukast."
Zidovudine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Zidovudine."
Cimetidine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cimetidine."
Ritonavir,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ritonavir."
Lercanidipine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Lercanidipine."
Ciprofloxacin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ciprofloxacin."
Vincristine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Vincristine."
Propylthiouracil,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Propylthiouracil."
Enalapril,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Enalapril."
Nizatidine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Nizatidine."
Ivermectin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ivermectin."
Chloroquine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Chloroquine."
Triamcinolone,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Triamcinolone."
Niacin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Niacin."
Alendronic acid,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Alendronic acid."
Clofibrate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Clofibrate."
Stavudine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Stavudine."
Nafarelin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Nafarelin."
Mycophenolate mofetil,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Mycophenolate mofetil."
Naltrexone,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Naltrexone."
Lamivudine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Lamivudine."
Ibandronate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ibandronate."
Propofol,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Propofol."
Terbinafine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Terbinafine."
Penicillamine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Penicillamine."
Ranitidine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ranitidine."
Eprosartan,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Eprosartan."
Risedronic acid,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Risedronic acid."
Bumetanide,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Bumetanide."
Triazolam,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Triazolam."
Ethanol,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ethanol."
Salmeterol,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Salmeterol."
Isoniazid,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Isoniazid."
Methyldopa,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Methyldopa."
Cytarabine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cytarabine."
Ganciclovir,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ganciclovir."
Letrozole,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Letrozole."
Sulfamethoxazole,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Sulfamethoxazole."
Minocycline,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Minocycline."
Fenofibrate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Fenofibrate."
Norfloxacin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Norfloxacin."
Iloprost,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Iloprost."
Leflunomide,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Leflunomide."
Amiodarone,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Amiodarone."
Ofloxacin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ofloxacin."
Procarbazine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Procarbazine."
Captopril,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Captopril."
Paclitaxel,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Paclitaxel."
Saquinavir,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Saquinavir."
Metoclopramide,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Metoclopramide."
Dexamethasone,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Dexamethasone."
Gemfibrozil,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Gemfibrozil."
Docetaxel,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Docetaxel."
Bezafibrate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Bezafibrate."
Colchicine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Colchicine."
Fusidic acid,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Fusidic acid."
Trabectedin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Trabectedin."
Raltegravir,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Raltegravir."
Etofibrate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Etofibrate."
Acipimox,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Acipimox."
Ciprofibrate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ciprofibrate."
Ubidecarenone,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ubidecarenone."
Tianeptine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Tianeptine."
Mebeverine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Mebeverine."
Ipecac,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ipecac."
Emetine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Emetine."
Simfibrate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Simfibrate."
Ronifibrate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ronifibrate."
Aluminium clofibrate,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Aluminium clofibrate."
Clofibride,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Clofibride."
Fenofibric acid,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Fenofibric acid."
Vibrio cholerae CVD 103-HgR strain live antigen,The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Daptomycin.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Tositumomab.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Tositumomab.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tositumomab.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Tositumomab.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Tositumomab.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Tositumomab.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Tositumomab.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Tositumomab.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Tositumomab."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tositumomab.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Tositumomab.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tositumomab.
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tositumomab.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Tositumomab.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tositumomab.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tositumomab.
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Tositumomab.
Basiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tositumomab.
Muromonab,The risk or severity of adverse effects can be increased when Muromonab is combined with Tositumomab.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tositumomab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Alemtuzumab.
Alefacept,The risk or severity of adverse effects can be increased when Tositumomab is combined with Alefacept.
Efalizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Tositumomab is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Tositumomab is combined with Interferon alfa-2b.
Daclizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Tositumomab is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Tositumomab is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Tositumomab is combined with Beclomethasone dipropionate.
Sorafenib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sorafenib.
Streptozocin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Tositumomab is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Altretamine.
Zidovudine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Zidovudine.
Cisplatin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Tositumomab is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pentostatin.
Methotrexate,The risk or severity of adverse effects can be increased when Tositumomab is combined with Methotrexate.
Carbamazepine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carbamazepine.
Vinblastine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Tositumomab is combined with Linezolid.
Imatinib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Imatinib.
Triamcinolone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Tositumomab is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Tositumomab is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Tositumomab is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Tositumomab is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Tositumomab is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Tositumomab is combined with Paclitaxel.
Dexamethasone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dexamethasone.
Docetaxel,The risk or severity of adverse effects can be increased when Tositumomab is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Decitabine.
Sunitinib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sunitinib.
Nelarabine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nelarabine.
Abatacept,The risk or severity of adverse effects can be increased when Tositumomab is combined with Abatacept.
Corticotropin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Tositumomab is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Tositumomab is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Tositumomab is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Tositumomab is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Tositumomab is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Tositumomab is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Tositumomab is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Tositumomab is combined with omega interferon.
Apremilast,The risk or severity of adverse effects can be increased when Tositumomab is combined with Apremilast.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Tositumomab is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Tositumomab is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Tositumomab is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Tositumomab is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ponatinib.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Tositumomab is combined with Certolizumab pegol.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Blinatumomab.
Ibrutinib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ibrutinib.
Idelalisib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Idelalisib.
Palbociclib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Palbociclib.
Olaparib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Olaparib.
Dinutuximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dinutuximab.
Vilanterol,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vilanterol.
Tixocortol,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Tositumomab is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Tositumomab is combined with Antilymphocyte immunoglobulin (horse).
Fluprednisolone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Meprednisone.
Tepoxalin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tepoxalin.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Tositumomab is combined with Melengestrol.
Ixekizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Peficitinib.
Clobetasol,The risk or severity of adverse effects can be increased when Tositumomab is combined with Clobetasol.
Sarilumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sirukumab.
Baricitinib,The risk or severity of adverse effects can be increased when Tositumomab is combined with Baricitinib.
Guselkumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Guselkumab.
Deflazacort,The risk or severity of adverse effects can be increased when Tositumomab is combined with Deflazacort.
Triptolide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Triptolide.
Siponimod,The risk or severity of adverse effects can be increased when Tositumomab is combined with Siponimod.
Ozanimod,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Tositumomab is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Tositumomab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Prednylidene,The risk or severity of adverse effects can be increased when Tositumomab is combined with Prednylidene.
Fluocortin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Tositumomab is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluclorolone.
Fluticasone,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluticasone.
Tetrandrine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tetrandrine.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Tositumomab is combined with Monomethyl fumarate.
Mometasone furoate,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mometasone furoate.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydrocortisone aceponate.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydrocortisone acetate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydrocortisone succinate.
Emapalumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bleselumab.
Natalizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tositumomab.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Tositumomab.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tositumomab.
Clozapine,The risk or severity of neutropenia can be increased when Tositumomab is combined with Clozapine.
Peginesatide,The risk or severity of Thrombosis can be increased when Tositumomab is combined with Peginesatide.
Darbepoetin alfa,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tositumomab.
Erythropoietin,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tositumomab.
Methoxy polyethylene glycol-epoetin beta,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tositumomab.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Tositumomab.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Tositumomab.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Tositumomab.
Estrone,Estrone may increase the thrombogenic activities of Tositumomab.
Dienestrol,Dienestrol may increase the thrombogenic activities of Tositumomab.
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Tositumomab.
Mestranol,Mestranol may increase the thrombogenic activities of Tositumomab.
Estriol,Estriol may increase the thrombogenic activities of Tositumomab.
Quinestrol,Quinestrol may increase the thrombogenic activities of Tositumomab.
Hexestrol,Hexestrol may increase the thrombogenic activities of Tositumomab.
Tibolone,Tibolone may increase the thrombogenic activities of Tositumomab.
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Tositumomab.
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Tositumomab.
Zeranol,Zeranol may increase the thrombogenic activities of Tositumomab.
Equol,Equol may increase the thrombogenic activities of Tositumomab.
Promestriene,Promestriene may increase the thrombogenic activities of Tositumomab.
Methallenestril,Methallenestril may increase the thrombogenic activities of Tositumomab.
Epimestrol,Epimestrol may increase the thrombogenic activities of Tositumomab.
Moxestrol,Moxestrol may increase the thrombogenic activities of Tositumomab.
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Tositumomab.
Biochanin A,Biochanin A may increase the thrombogenic activities of Tositumomab.
Formononetin,Formononetin may increase the thrombogenic activities of Tositumomab.
Leflunomide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Leflunomide.
Tofacitinib,Tositumomab may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Tositumomab.
Fingolimod,Tositumomab may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Tositumomab.
Lepirudin,The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Tositumomab.
Bivalirudin,The risk or severity of bleeding and hemorrhage can be increased when Bivalirudin is combined with Tositumomab.
Alteplase,The risk or severity of bleeding and hemorrhage can be increased when Alteplase is combined with Tositumomab.
Urokinase,The risk or severity of bleeding and hemorrhage can be increased when Urokinase is combined with Tositumomab.
Reteplase,The risk or severity of bleeding and hemorrhage can be increased when Reteplase is combined with Tositumomab.
Anistreplase,The risk or severity of bleeding and hemorrhage can be increased when Anistreplase is combined with Tositumomab.
Tenecteplase,The risk or severity of bleeding and hemorrhage can be increased when Tenecteplase is combined with Tositumomab.
Drotrecogin alfa,The risk or severity of bleeding and hemorrhage can be increased when Drotrecogin alfa is combined with Tositumomab.
Streptokinase,The risk or severity of bleeding and hemorrhage can be increased when Streptokinase is combined with Tositumomab.
Dicoumarol,The risk or severity of bleeding and hemorrhage can be increased when Dicoumarol is combined with Tositumomab.
Argatroban,The risk or severity of bleeding and hemorrhage can be increased when Argatroban is combined with Tositumomab.
Ardeparin,The risk or severity of bleeding and hemorrhage can be increased when Ardeparin is combined with Tositumomab.
Phenindione,The risk or severity of bleeding and hemorrhage can be increased when Phenindione is combined with Tositumomab.
Fondaparinux,The risk or severity of bleeding and hemorrhage can be increased when Fondaparinux is combined with Tositumomab.
Warfarin,The risk or severity of bleeding and hemorrhage can be increased when Warfarin is combined with Tositumomab.
Pentosan polysulfate,The risk or severity of bleeding and hemorrhage can be increased when Pentosan polysulfate is combined with Tositumomab.
Phenprocoumon,The risk or severity of bleeding and hemorrhage can be increased when Phenprocoumon is combined with Tositumomab.
Heparin,The risk or severity of bleeding and hemorrhage can be increased when Heparin is combined with Tositumomab.
Enoxaparin,The risk or severity of bleeding and hemorrhage can be increased when Enoxaparin is combined with Tositumomab.
Acenocoumarol,The risk or severity of bleeding and hemorrhage can be increased when Acenocoumarol is combined with Tositumomab.
4-hydroxycoumarin,The risk or severity of bleeding and hemorrhage can be increased when 4-hydroxycoumarin is combined with Tositumomab.
Coumarin,The risk or severity of bleeding and hemorrhage can be increased when Coumarin is combined with Tositumomab.
Ximelagatran,The risk or severity of bleeding and hemorrhage can be increased when Ximelagatran is combined with Tositumomab.
Desmoteplase,The risk or severity of bleeding and hemorrhage can be increased when Desmoteplase is combined with Tositumomab.
Ancrod,The risk or severity of bleeding and hemorrhage can be increased when Ancrod is combined with Tositumomab.
Fibrinolysin,The risk or severity of bleeding and hemorrhage can be increased when Fibrinolysin is combined with Tositumomab.
Rivaroxaban,The risk or severity of bleeding and hemorrhage can be increased when Rivaroxaban is combined with Tositumomab.
Sulodexide,The risk or severity of bleeding and hemorrhage can be increased when Sulodexide is combined with Tositumomab.
Semuloparin,The risk or severity of bleeding and hemorrhage can be increased when Semuloparin is combined with Tositumomab.
Idraparinux,The risk or severity of bleeding and hemorrhage can be increased when Idraparinux is combined with Tositumomab.
Astaxanthin,The risk or severity of bleeding and hemorrhage can be increased when Astaxanthin is combined with Tositumomab.
Apixaban,The risk or severity of bleeding and hemorrhage can be increased when Apixaban is combined with Tositumomab.
Otamixaban,The risk or severity of bleeding and hemorrhage can be increased when Otamixaban is combined with Tositumomab.
Amediplase,The risk or severity of bleeding and hemorrhage can be increased when Amediplase is combined with Tositumomab.
Dabigatran etexilate,The risk or severity of bleeding and hemorrhage can be increased when Dabigatran etexilate is combined with Tositumomab.
Danaparoid,The risk or severity of bleeding and hemorrhage can be increased when Danaparoid is combined with Tositumomab.
Dalteparin,The risk or severity of bleeding and hemorrhage can be increased when Dalteparin is combined with Tositumomab.
Tinzaparin,The risk or severity of bleeding and hemorrhage can be increased when Tinzaparin is combined with Tositumomab.
Ferulic acid,The risk or severity of bleeding and hemorrhage can be increased when Ferulic acid is combined with Tositumomab.
(R)-warfarin,The risk or severity of bleeding and hemorrhage can be increased when (R)-warfarin is combined with Tositumomab.
Ethyl biscoumacetate,The risk or severity of bleeding and hemorrhage can be increased when Ethyl biscoumacetate is combined with Tositumomab.
Nadroparin,The risk or severity of bleeding and hemorrhage can be increased when Nadroparin is combined with Tositumomab.
Ditazole,The risk or severity of bleeding and hemorrhage can be increased when Ditazole is combined with Tositumomab.
Edoxaban,The risk or severity of bleeding and hemorrhage can be increased when Edoxaban is combined with Tositumomab.
Potassium citrate,The risk or severity of bleeding and hemorrhage can be increased when Potassium citrate is combined with Tositumomab.
Sodium citrate,The risk or severity of bleeding and hemorrhage can be increased when Sodium citrate is combined with Tositumomab.
Dextran,The risk or severity of bleeding and hemorrhage can be increased when Dextran is combined with Tositumomab.
Bemiparin,The risk or severity of bleeding and hemorrhage can be increased when Bemiparin is combined with Tositumomab.
Reviparin,The risk or severity of bleeding and hemorrhage can be increased when Reviparin is combined with Tositumomab.
Parnaparin,The risk or severity of bleeding and hemorrhage can be increased when Parnaparin is combined with Tositumomab.
Certoparin,The risk or severity of bleeding and hemorrhage can be increased when Certoparin is combined with Tositumomab.
Desirudin,The risk or severity of bleeding and hemorrhage can be increased when Desirudin is combined with Tositumomab.
Zinc citrate,The risk or severity of bleeding and hemorrhage can be increased when Zinc citrate is combined with Tositumomab.
Antithrombin Alfa,The risk or severity of bleeding and hemorrhage can be increased when Antithrombin Alfa is combined with Tositumomab.
Protein C,The risk or severity of bleeding and hemorrhage can be increased when Protein C is combined with Tositumomab.
Antithrombin III human,The risk or severity of bleeding and hemorrhage can be increased when Antithrombin III human is combined with Tositumomab.
Letaxaban,The risk or severity of bleeding and hemorrhage can be increased when Letaxaban is combined with Tositumomab.
Darexaban,The risk or severity of bleeding and hemorrhage can be increased when Darexaban is combined with Tositumomab.
Betrixaban,The risk or severity of bleeding and hemorrhage can be increased when Betrixaban is combined with Tositumomab.
Nafamostat,The risk or severity of bleeding and hemorrhage can be increased when Nafamostat is combined with Tositumomab.
Monteplase,The risk or severity of bleeding and hemorrhage can be increased when Monteplase is combined with Tositumomab.
Gabexate,The risk or severity of bleeding and hemorrhage can be increased when Gabexate is combined with Tositumomab.
Fluindione,The risk or severity of bleeding and hemorrhage can be increased when Fluindione is combined with Tositumomab.
Protein S human,The risk or severity of bleeding and hemorrhage can be increased when Protein S human is combined with Tositumomab.
Brinase,The risk or severity of bleeding and hemorrhage can be increased when Brinase is combined with Tositumomab.
Clorindione,The risk or severity of bleeding and hemorrhage can be increased when Clorindione is combined with Tositumomab.
Diphenadione,The risk or severity of bleeding and hemorrhage can be increased when Diphenadione is combined with Tositumomab.
Tioclomarol,The risk or severity of bleeding and hemorrhage can be increased when Tioclomarol is combined with Tositumomab.
Melagatran,The risk or severity of bleeding and hemorrhage can be increased when Melagatran is combined with Tositumomab.
Saruplase,The risk or severity of bleeding and hemorrhage can be increased when Saruplase is combined with Tositumomab.
(S)-Warfarin,The risk or severity of bleeding and hemorrhage can be increased when (S)-Warfarin is combined with Tositumomab.
Tocopherylquinone,The risk or severity of bleeding and hemorrhage can be increased when Tocopherylquinone is combined with Tositumomab.
Edetate calcium disodium anhydrous,The risk or severity of bleeding and hemorrhage can be increased when Edetate calcium disodium anhydrous is combined with Tositumomab.
Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Dabigatran is combined with Tositumomab.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Tositumomab.
Eptifibatide,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tositumomab.
Ticlopidine,The risk or severity of adverse effects can be increased when Ticlopidine is combined with Tositumomab.
Anagrelide,The risk or severity of adverse effects can be increased when Anagrelide is combined with Tositumomab.
Clopidogrel,The risk or severity of adverse effects can be increased when Clopidogrel is combined with Tositumomab.
Tirofiban,The risk or severity of adverse effects can be increased when Tirofiban is combined with Tositumomab.
Pentoxifylline,The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Tositumomab.
Acetylsalicylic acid,The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tositumomab.
Dipyridamole,The risk or severity of adverse effects can be increased when Dipyridamole is combined with Tositumomab.
Iloprost,The risk or severity of adverse effects can be increased when Iloprost is combined with Tositumomab.
Sulfinpyrazone,The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Tositumomab.
Cilostazol,The risk or severity of adverse effects can be increased when Cilostazol is combined with Tositumomab.
Ridogrel,The risk or severity of adverse effects can be increased when Ridogrel is combined with Tositumomab.
Sevoflurane,The risk or severity of adverse effects can be increased when Sevoflurane is combined with Tositumomab.
Epoprostenol,The risk or severity of adverse effects can be increased when Epoprostenol is combined with Tositumomab.
Resveratrol,The risk or severity of adverse effects can be increased when Resveratrol is combined with Tositumomab.
Nimesulide,The risk or severity of adverse effects can be increased when Nimesulide is combined with Tositumomab.
Tesmilifene,The risk or severity of adverse effects can be increased when Tesmilifene is combined with Tositumomab.
Defibrotide,The risk or severity of adverse effects can be increased when Defibrotide is combined with Tositumomab.
Beraprost,The risk or severity of adverse effects can be increased when Beraprost is combined with Tositumomab.
Ibudilast,The risk or severity of adverse effects can be increased when Ibudilast is combined with Tositumomab.
Andrographolide,The risk or severity of adverse effects can be increased when Andrographolide is combined with Tositumomab.
Caplacizumab,The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tositumomab.
Prasugrel,The risk or severity of adverse effects can be increased when Prasugrel is combined with Tositumomab.
Cangrelor,The risk or severity of adverse effects can be increased when Cangrelor is combined with Tositumomab.
Tranilast,The risk or severity of adverse effects can be increased when Tranilast is combined with Tositumomab.
Triflusal,The risk or severity of adverse effects can be increased when Triflusal is combined with Tositumomab.
Ticagrelor,The risk or severity of adverse effects can be increased when Ticagrelor is combined with Tositumomab.
Icosapent ethyl,The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Tositumomab.
Vorapaxar,The risk or severity of adverse effects can be increased when Vorapaxar is combined with Tositumomab.
Trapidil,The risk or severity of adverse effects can be increased when Trapidil is combined with Tositumomab.
Naftopidil,The risk or severity of adverse effects can be increased when Naftopidil is combined with Tositumomab.
Sarpogrelate,The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Tositumomab.
Ifetroban,The risk or severity of adverse effects can be increased when Ifetroban is combined with Tositumomab.
Nitroaspirin,The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tositumomab.
Ketanserin,The risk or severity of adverse effects can be increased when Ketanserin is combined with Tositumomab.
Indobufen,The risk or severity of adverse effects can be increased when Indobufen is combined with Tositumomab.
Butylphthalide,The risk or severity of adverse effects can be increased when Butylphthalide is combined with Tositumomab.
Hydroxytyrosol,The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Tositumomab.
Ramatroban,The risk or severity of adverse effects can be increased when Ramatroban is combined with Tositumomab.
Picotamide,The risk or severity of adverse effects can be increased when Picotamide is combined with Tositumomab.
Cloricromen,The risk or severity of adverse effects can be increased when Cloricromen is combined with Tositumomab.
Linsidomine,The risk or severity of adverse effects can be increased when Linsidomine is combined with Tositumomab.
Buflomedil,The risk or severity of adverse effects can be increased when Buflomedil is combined with Tositumomab.
Relcovaptan,The risk or severity of adverse effects can be increased when Relcovaptan is combined with Tositumomab.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Tositumomab.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Tositumomab.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Tositumomab.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Tositumomab.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Tositumomab.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Tositumomab.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Tositumomab.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Tositumomab.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Tositumomab.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Tositumomab."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Tositumomab.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Tositumomab.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tositumomab."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Tositumomab.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Tositumomab.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tositumomab.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Tositumomab.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tositumomab.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tositumomab.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Tositumomab.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Tositumomab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Tositumomab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Tositumomab.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Tositumomab.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Tositumomab.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Tositumomab.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Tositumomab.
Ocrelizumab,Ocrelizumab may increase the immunosuppressive activities of Tositumomab.
Lipegfilgrastim,Tositumomab may increase the myelosuppressive activities of Lipegfilgrastim.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Tositumomab.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Tositumomab.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Tositumomab.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Tositumomab.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Tositumomab.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Tositumomab.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Tositumomab.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Tositumomab.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Tositumomab.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Tositumomab.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Tositumomab.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Tositumomab.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Tositumomab.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tositumomab.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Tositumomab.
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tositumomab.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tositumomab.
Capromab pendetide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Capromab pendetide.
Palivizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Palivizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Technetium Tc-99m arcitumomab.
Panitumumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pexelizumab.
Epratuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Tositumomab is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Tositumomab is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Tositumomab is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Tositumomab is combined with NAV 1800.
Otelixizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Tositumomab is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Veltuzumab.
PRO-542,The risk or severity of adverse effects can be increased when Tositumomab is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Tositumomab is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Tositumomab is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Tositumomab is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Tositumomab is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Tositumomab is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Tositumomab is combined with TB-402.
IMC-1C11,The risk or severity of adverse effects can be increased when Tositumomab is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lumiliximab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Clenoliximab.
BIIB015,The risk or severity of adverse effects can be increased when Tositumomab is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Tositumomab is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Tositumomab is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Catumaxomab.
Volociximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ofatumumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Raxibacumab.
Nivolumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nivolumab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dulaglutide.
Asfotase alfa,The risk or severity of adverse effects can be increased when Tositumomab is combined with Asfotase alfa.
Alirocumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Evolocumab.
Daratumumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Necitumumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Tositumomab is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Solanezumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tremelimumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lampalizumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Anifrolumab.
Benralizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Tositumomab is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Tositumomab is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Tositumomab is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Plozalizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Tositumomab is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Besilesomab.
Burosumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cemiplimab.
Camrelizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Refanezumab.
Bermekimab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Tositumomab is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nemolizumab.
Gedivumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Tositumomab is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Tositumomab is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Tositumomab is combined with Naratuximab emtansine.
Tildrakizumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tildrakizumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ustekinumab.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Zenocutuzumab.
Palifermin,The therapeutic efficacy of Palifermin can be decreased when used in combination with Tositumomab.
Icosapent,Icosapent may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefotiam,Cefotiam may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Mesalazine,Mesalazine may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefmenoxime,Cefmenoxime may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefmetazole,Cefmetazole may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Pamidronic acid,Pamidronic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Tenofovir disoproxil,Tenofovir disoproxil may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cidofovir,Cidofovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Triamterene,Triamterene may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefpiramide,Cefpiramide may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Ceftazidime,Ceftazidime may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Loracarbef,Loracarbef may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefalotin,Cefalotin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Nabumetone,Nabumetone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Ketorolac,Ketorolac may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Tenoxicam,Tenoxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Celecoxib,Celecoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefotaxime,Cefotaxime may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Tolmetin,Tolmetin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Foscarnet,Foscarnet may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Rofecoxib,Rofecoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Piroxicam,Piroxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cephalexin,Cephalexin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Fenoprofen,Fenoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Valaciclovir,Valaciclovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Valdecoxib,Valdecoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Diclofenac,Diclofenac may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Sulindac,Sulindac may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Bacitracin,Bacitracin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Amphotericin B,Amphotericin B may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cephaloglycin,Cephaloglycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Flurbiprofen,Flurbiprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Adefovir dipivoxil,Adefovir dipivoxil may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Pentamidine,Pentamidine may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Mannitol,Mannitol may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Etodolac,Etodolac may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Mefenamic acid,Mefenamic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Acyclovir,Acyclovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Naproxen,Naproxen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Phenylbutazone,Phenylbutazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Meloxicam,Meloxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Carprofen,Carprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefaclor,Cefaclor may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Diflunisal,Diflunisal may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Etacrynic acid,Etacrynic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Ceforanide,Ceforanide may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Salicylic acid,Salicylic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Meclofenamic acid,Meclofenamic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Oxaprozin,Oxaprozin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Hydrochlorothiazide,Hydrochlorothiazide may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Ketoprofen,Ketoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Balsalazide,Balsalazide may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Ibuprofen,Ibuprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefditoren,Cefditoren may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Atazanavir,Atazanavir may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Colistimethate,Colistimethate may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefuroxime,Cefuroxime may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefapirin,Cefapirin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefadroxil,Cefadroxil may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefprozil,Cefprozil may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Ceftriaxone,Ceftriaxone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Olsalazine,Olsalazine may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Lumiracoxib,Lumiracoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefamandole,Cefamandole may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefazolin,Cefazolin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefonicid,Cefonicid may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefoperazone,Cefoperazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefotetan,Cefotetan may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefoxitin,Cefoxitin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Ceftizoxime,Ceftizoxime may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefradine,Cefradine may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Magnesium salicylate,Magnesium salicylate may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Salsalate,Salsalate may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Choline magnesium trisalicylate,Choline magnesium trisalicylate may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefepime,Cefepime may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefacetrile,Cefacetrile may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Ceftibuten,Ceftibuten may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefpodoxime,Cefpodoxime may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Antrafenine,Antrafenine may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Aminophenazone,Aminophenazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Antipyrine,Antipyrine may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Tiaprofenic acid,Tiaprofenic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Etoricoxib,Etoricoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Hydrolyzed Cephalothin,Hydrolyzed Cephalothin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cephalothin Group,Cephalothin Group may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Oxyphenbutazone,Oxyphenbutazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Niflumic acid,Niflumic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Latamoxef,Latamoxef may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Benoxaprofen,Benoxaprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Metamizole,Metamizole may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Zomepirac,Zomepirac may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Ceftobiprole,Ceftobiprole may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cimicoxib,Cimicoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Ceftaroline fosamil,Ceftaroline fosamil may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Lornoxicam,Lornoxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Aceclofenac,Aceclofenac may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Zaltoprofen,Zaltoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Azapropazone,Azapropazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Felbinac,Felbinac may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Parecoxib,Parecoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Salicylamide,Salicylamide may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Kebuzone,Kebuzone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Isoxicam,Isoxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Indoprofen,Indoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Ibuproxam,Ibuproxam may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Floctafenine,Floctafenine may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Fenbufen,Fenbufen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Etofenamate,Etofenamate may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Epirizole,Epirizole may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefaloridine,Cefaloridine may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefminox,Cefminox may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Benzydamine,Benzydamine may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Loxoprofen,Loxoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Dexibuprofen,Dexibuprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Dexketoprofen,Dexketoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Droxicam,Droxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Tolfenamic acid,Tolfenamic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Firocoxib,Firocoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Clonixin,Clonixin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Morniflumate,Morniflumate may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Propacetamol,Propacetamol may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Talniflumate,Talniflumate may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Tenofovir alafenamide,Tenofovir alafenamide may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefroxadine,Cefroxadine may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Robenacoxib,Robenacoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Flunixin,Flunixin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Flomoxef,Flomoxef may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Brincidofovir,Brincidofovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Tinoridine,Tinoridine may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Alclofenac,Alclofenac may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Fentiazac,Fentiazac may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Suxibuzone,Suxibuzone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefatrizine,Cefatrizine may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Bumadizone,Bumadizone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Alminoprofen,Alminoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Flunoxaprofen,Flunoxaprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Feprazone,Feprazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Difenpiramide,Difenpiramide may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Nifenazone,Nifenazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Lonazolac,Lonazolac may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefcapene,Cefcapene may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefodizime,Cefodizime may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Tenidap,Tenidap may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefsulodin,Cefsulodin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Bendazac,Bendazac may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefetamet,Cefetamet may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Pranoprofen,Pranoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Propyphenazone,Propyphenazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Proglumetacin,Proglumetacin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Guacetisal,Guacetisal may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Ethenzamide,Ethenzamide may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Carbaspirin calcium,Carbaspirin calcium may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Mofebutazone,Mofebutazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefbuperazone,Cefbuperazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Proquazone,Proquazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Benorilate,Benorilate may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefozopran,Cefozopran may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefpirome,Cefpirome may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Pirprofen,Pirprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Cefazedone,Cefazedone may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Acemetacin,Acemetacin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Ceftezole,Ceftezole may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Imidazole salicylate,Imidazole salicylate may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Adefovir,Adefovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.
SC-236,SC-236 may decrease the excretion rate of Tositumomab which could result in a higher serum level.
NS-398,NS-398 may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Tenofovir,Tenofovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Inotersen,Inotersen may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Phenazopyridine,Phenazopyridine may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Givosiran,Givosiran may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Lithium cation,Lithium cation may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Lithium citrate,Lithium citrate may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Leuprolide,Leuprolide may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Goserelin,Goserelin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Salmon calcitonin,Salmon calcitonin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Desmopressin,Desmopressin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Daptomycin,Daptomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Folic acid,Tositumomab may decrease the excretion rate of Folic acid which could result in a higher serum level.
Pyridoxine,Tositumomab may decrease the excretion rate of Pyridoxine which could result in a higher serum level.
Fluvoxamine,Tositumomab may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.
Baclofen,Tositumomab may decrease the excretion rate of Baclofen which could result in a higher serum level.
Amphetamine,Tositumomab may decrease the excretion rate of Amphetamine which could result in a higher serum level.
Cevimeline,Tositumomab may decrease the excretion rate of Cevimeline which could result in a higher serum level.
Lorazepam,Tositumomab may decrease the excretion rate of Lorazepam which could result in a higher serum level.
Carbidopa,Tositumomab may decrease the excretion rate of Carbidopa which could result in a higher serum level.
Tramadol,Tositumomab may decrease the excretion rate of Tramadol which could result in a higher serum level.
Fluconazole,Tositumomab may decrease the excretion rate of Fluconazole which could result in a higher serum level.
Oseltamivir,Tositumomab may decrease the excretion rate of Oseltamivir which could result in a higher serum level.
Hydroxocobalamin,Tositumomab may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.
Reserpine,Tositumomab may decrease the excretion rate of Reserpine which could result in a higher serum level.
Pantoprazole,Tositumomab may decrease the excretion rate of Pantoprazole which could result in a higher serum level.
Gadodiamide,Tositumomab may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
Pregabalin,Tositumomab may decrease the excretion rate of Pregabalin which could result in a higher serum level.
Temazepam,Tositumomab may decrease the excretion rate of Temazepam which could result in a higher serum level.
Milrinone,Tositumomab may decrease the excretion rate of Milrinone which could result in a higher serum level.
Butabarbital,Tositumomab may decrease the excretion rate of Butabarbital which could result in a higher serum level.
Ranolazine,Tositumomab may decrease the excretion rate of Ranolazine which could result in a higher serum level.
Benzatropine,Tositumomab may decrease the excretion rate of Benzatropine which could result in a higher serum level.
Doxycycline,Tositumomab may decrease the excretion rate of Doxycycline which could result in a higher serum level.
Metoprolol,Tositumomab may decrease the excretion rate of Metoprolol which could result in a higher serum level.
Isradipine,Tositumomab may decrease the excretion rate of Isradipine which could result in a higher serum level.
Diatrizoate,Tositumomab may decrease the excretion rate of Diatrizoate which could result in a higher serum level.
Topiramate,Tositumomab may decrease the excretion rate of Topiramate which could result in a higher serum level.
Liothyronine,Tositumomab may decrease the excretion rate of Liothyronine which could result in a higher serum level.
Disopyramide,Tositumomab may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Acarbose,Tositumomab may decrease the excretion rate of Acarbose which could result in a higher serum level.
Venlafaxine,Tositumomab may decrease the excretion rate of Venlafaxine which could result in a higher serum level.
Conjugated estrogens,Tositumomab may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
Atomoxetine,Tositumomab may decrease the excretion rate of Atomoxetine which could result in a higher serum level.
Etomidate,Tositumomab may decrease the excretion rate of Etomidate which could result in a higher serum level.
Etonogestrel,Tositumomab may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
Ropivacaine,Tositumomab may decrease the excretion rate of Ropivacaine which could result in a higher serum level.
Ertapenem,Tositumomab may decrease the excretion rate of Ertapenem which could result in a higher serum level.
Ibutilide,Tositumomab may decrease the excretion rate of Ibutilide which could result in a higher serum level.
Pentobarbital,Tositumomab may decrease the excretion rate of Pentobarbital which could result in a higher serum level.
Acetaminophen,Tositumomab may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Piperacillin,Tositumomab may decrease the excretion rate of Piperacillin which could result in a higher serum level.
Tolcapone,Tositumomab may decrease the excretion rate of Tolcapone which could result in a higher serum level.
Nitroprusside,Tositumomab may decrease the excretion rate of Nitroprusside which could result in a higher serum level.
Hydromorphone,Tositumomab may decrease the excretion rate of Hydromorphone which could result in a higher serum level.
Ethambutol,Tositumomab may decrease the excretion rate of Ethambutol which could result in a higher serum level.
Metformin,Tositumomab may decrease the excretion rate of Metformin which could result in a higher serum level.
Methadone,Tositumomab may decrease the excretion rate of Methadone which could result in a higher serum level.
Pyrazinamide,Tositumomab may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
Cetirizine,Tositumomab may decrease the excretion rate of Cetirizine which could result in a higher serum level.
Clobazam,Tositumomab may decrease the excretion rate of Clobazam which could result in a higher serum level.
Megestrol acetate,Tositumomab may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.
Aztreonam,Tositumomab may decrease the excretion rate of Aztreonam which could result in a higher serum level.
Chlorzoxazone,Tositumomab may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.
Sulfadiazine,Tositumomab may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.
Sucralfate,Tositumomab may decrease the excretion rate of Sucralfate which could result in a higher serum level.
Thiethylperazine,Tositumomab may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.
Timolol,Tositumomab may decrease the excretion rate of Timolol which could result in a higher serum level.
Palonosetron,Tositumomab may decrease the excretion rate of Palonosetron which could result in a higher serum level.
Nisoldipine,Tositumomab may decrease the excretion rate of Nisoldipine which could result in a higher serum level.
Eszopiclone,Tositumomab may decrease the excretion rate of Eszopiclone which could result in a higher serum level.
Alprazolam,Tositumomab may decrease the excretion rate of Alprazolam which could result in a higher serum level.
Rosiglitazone,Tositumomab may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.
Pramipexole,Tositumomab may decrease the excretion rate of Pramipexole which could result in a higher serum level.
Ampicillin,Tositumomab may decrease the excretion rate of Ampicillin which could result in a higher serum level.
Secobarbital,Tositumomab may decrease the excretion rate of Secobarbital which could result in a higher serum level.
Methylphenidate,Tositumomab may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Nitric Oxide,Tositumomab may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
Trimethoprim,Tositumomab may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
Duloxetine,Tositumomab may decrease the excretion rate of Duloxetine which could result in a higher serum level.
Chlorpromazine,Tositumomab may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.
Buspirone,Tositumomab may decrease the excretion rate of Buspirone which could result in a higher serum level.
Fosinopril,Tositumomab may decrease the excretion rate of Fosinopril which could result in a higher serum level.
Flutamide,Tositumomab may decrease the excretion rate of Flutamide which could result in a higher serum level.
Haloperidol,Tositumomab may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cefdinir,Tositumomab may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Ciprofloxacin,Tositumomab may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.
Azelaic acid,Tositumomab may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
Methoxsalen,Tositumomab may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
Lamotrigine,Tositumomab may decrease the excretion rate of Lamotrigine which could result in a higher serum level.
Zanamivir,Tositumomab may decrease the excretion rate of Zanamivir which could result in a higher serum level.
Propranolol,Tositumomab may decrease the excretion rate of Propranolol which could result in a higher serum level.
Levocarnitine,Tositumomab may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
Gadoteridol,Tositumomab may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
Labetalol,Tositumomab may decrease the excretion rate of Labetalol which could result in a higher serum level.
Medroxyprogesterone acetate,Tositumomab may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.
Chloroquine,Tositumomab may decrease the excretion rate of Chloroquine which could result in a higher serum level.
Bisoprolol,Tositumomab may decrease the excretion rate of Bisoprolol which could result in a higher serum level.
Testosterone,Tositumomab may decrease the excretion rate of Testosterone which could result in a higher serum level.
Clorazepic acid,Tositumomab may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
Dexmedetomidine,Tositumomab may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
Dyphylline,Tositumomab may decrease the excretion rate of Dyphylline which could result in a higher serum level.
Mecamylamine,Tositumomab may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
Metaxalone,Tositumomab may decrease the excretion rate of Metaxalone which could result in a higher serum level.
Verapamil,Tositumomab may decrease the excretion rate of Verapamil which could result in a higher serum level.
Nilutamide,Tositumomab may decrease the excretion rate of Nilutamide which could result in a higher serum level.
Sumatriptan,Tositumomab may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
Chlorpropamide,Tositumomab may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
Midazolam,Tositumomab may decrease the excretion rate of Midazolam which could result in a higher serum level.
Flurazepam,Tositumomab may decrease the excretion rate of Flurazepam which could result in a higher serum level.
Phentolamine,Tositumomab may decrease the excretion rate of Phentolamine which could result in a higher serum level.
Nitrofurantoin,Tositumomab may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Tamsulosin,Tositumomab may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
Lamivudine,Tositumomab may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Oxacillin,Tositumomab may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Nedocromil,Tositumomab may decrease the excretion rate of Nedocromil which could result in a higher serum level.
Lisinopril,Tositumomab may decrease the excretion rate of Lisinopril which could result in a higher serum level.
Thiabendazole,Tositumomab may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
Nateglinide,Tositumomab may decrease the excretion rate of Nateglinide which could result in a higher serum level.
Pralidoxime,Tositumomab may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
Gadobenic acid,Tositumomab may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
Tetracycline,Tositumomab may decrease the excretion rate of Tetracycline which could result in a higher serum level.
Meropenem,Tositumomab may decrease the excretion rate of Meropenem which could result in a higher serum level.
Potassium chloride,Tositumomab may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
Phenelzine,Tositumomab may decrease the excretion rate of Phenelzine which could result in a higher serum level.
Propantheline,Tositumomab may decrease the excretion rate of Propantheline which could result in a higher serum level.
Estradiol,Tositumomab may decrease the excretion rate of Estradiol which could result in a higher serum level.
Gadopentetic acid,Tositumomab may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
Perindopril,Tositumomab may decrease the excretion rate of Perindopril which could result in a higher serum level.
Fenoldopam,Tositumomab may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
Dicyclomine,Tositumomab may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Ribavirin,Tositumomab may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Tadalafil,Tositumomab may decrease the excretion rate of Tadalafil which could result in a higher serum level.
Fosfomycin,Tositumomab may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Diazepam,Tositumomab may decrease the excretion rate of Diazepam which could result in a higher serum level.
Tolazamide,Tositumomab may decrease the excretion rate of Tolazamide which could result in a higher serum level.
Dobutamine,Tositumomab may decrease the excretion rate of Dobutamine which could result in a higher serum level.
Oxazepam,Tositumomab may decrease the excretion rate of Oxazepam which could result in a higher serum level.
Ranitidine,Tositumomab may decrease the excretion rate of Ranitidine which could result in a higher serum level.
Terbutaline,Tositumomab may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Testolactone,Tositumomab may decrease the excretion rate of Testolactone which could result in a higher serum level.
Triazolam,Tositumomab may decrease the excretion rate of Triazolam which could result in a higher serum level.
Didanosine,Tositumomab may decrease the excretion rate of Didanosine which could result in a higher serum level.
Tinidazole,Tositumomab may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Amantadine,Tositumomab may decrease the excretion rate of Amantadine which could result in a higher serum level.
Almotriptan,Tositumomab may decrease the excretion rate of Almotriptan which could result in a higher serum level.
Maprotiline,Tositumomab may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Isoniazid,Tositumomab may decrease the excretion rate of Isoniazid which could result in a higher serum level.
Rizatriptan,Tositumomab may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
Pindolol,Tositumomab may decrease the excretion rate of Pindolol which could result in a higher serum level.
Mepivacaine,Tositumomab may decrease the excretion rate of Mepivacaine which could result in a higher serum level.
Zaleplon,Tositumomab may decrease the excretion rate of Zaleplon which could result in a higher serum level.
Methyldopa,Tositumomab may decrease the excretion rate of Methyldopa which could result in a higher serum level.
Ramelteon,Tositumomab may decrease the excretion rate of Ramelteon which could result in a higher serum level.
Dopamine,Tositumomab may decrease the excretion rate of Dopamine which could result in a higher serum level.
Auranofin,Tositumomab may decrease the excretion rate of Auranofin which could result in a higher serum level.
Salbutamol,Tositumomab may decrease the excretion rate of Salbutamol which could result in a higher serum level.
Levobupivacaine,Tositumomab may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.
Ganciclovir,Tositumomab may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
Edrophonium,Tositumomab may decrease the excretion rate of Edrophonium which could result in a higher serum level.
Metyrapone,Tositumomab may decrease the excretion rate of Metyrapone which could result in a higher serum level.
Guanfacine,Tositumomab may decrease the excretion rate of Guanfacine which could result in a higher serum level.
Isosorbide mononitrate,Tositumomab may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
Phylloquinone,Tositumomab may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Probenecid,Tositumomab may decrease the excretion rate of Probenecid which could result in a higher serum level.
Tolterodine,Tositumomab may decrease the excretion rate of Tolterodine which could result in a higher serum level.
Fenofibrate,Tositumomab may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Memantine,Tositumomab may decrease the excretion rate of Memantine which could result in a higher serum level.
Lubiprostone,Tositumomab may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Abacavir,Tositumomab may decrease the excretion rate of Abacavir which could result in a higher serum level.
Amoxicillin,Tositumomab may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Glipizide,Tositumomab may decrease the excretion rate of Glipizide which could result in a higher serum level.
Clonazepam,Tositumomab may decrease the excretion rate of Clonazepam which could result in a higher serum level.
Promethazine,Tositumomab may decrease the excretion rate of Promethazine which could result in a higher serum level.
Dimethyl sulfoxide,Tositumomab may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
Sibutramine,Tositumomab may decrease the excretion rate of Sibutramine which could result in a higher serum level.
Nifedipine,Tositumomab may decrease the excretion rate of Nifedipine which could result in a higher serum level.
Tolbutamide,Tositumomab may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
Rabeprazole,Tositumomab may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
Tiludronic acid,Tositumomab may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
Doxacurium,Tositumomab may decrease the excretion rate of Doxacurium which could result in a higher serum level.
Levofloxacin,Tositumomab may decrease the excretion rate of Levofloxacin which could result in a higher serum level.
Flavoxate,Tositumomab may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Nefazodone,Tositumomab may decrease the excretion rate of Nefazodone which could result in a higher serum level.
Bupropion,Tositumomab may decrease the excretion rate of Bupropion which could result in a higher serum level.
Trimetrexate,Tositumomab may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
Guanethidine,Tositumomab may decrease the excretion rate of Guanethidine which could result in a higher serum level.
Naloxone,Tositumomab may decrease the excretion rate of Naloxone which could result in a higher serum level.
Nadolol,Tositumomab may decrease the excretion rate of Nadolol which could result in a higher serum level.
Flumazenil,Tositumomab may decrease the excretion rate of Flumazenil which could result in a higher serum level.
Fomepizole,Tositumomab may decrease the excretion rate of Fomepizole which could result in a higher serum level.
Estazolam,Tositumomab may decrease the excretion rate of Estazolam which could result in a higher serum level.
Ketamine,Tositumomab may decrease the excretion rate of Ketamine which could result in a higher serum level.
Quetiapine,Tositumomab may decrease the excretion rate of Quetiapine which could result in a higher serum level.
Metoclopramide,Tositumomab may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Gemfibrozil,Tositumomab may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.
Iodixanol,Tositumomab may decrease the excretion rate of Iodixanol which could result in a higher serum level.
Sitagliptin,Tositumomab may decrease the excretion rate of Sitagliptin which could result in a higher serum level.
Paliperidone,Tositumomab may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Varenicline,Tositumomab may decrease the excretion rate of Varenicline which could result in a higher serum level.
Arformoterol,Tositumomab may decrease the excretion rate of Arformoterol which could result in a higher serum level.
Hydralazine,Tositumomab may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Penbutolol,Tositumomab may decrease the excretion rate of Penbutolol which could result in a higher serum level.
Rasagiline,Tositumomab may decrease the excretion rate of Rasagiline which could result in a higher serum level.
Tiotropium,Tositumomab may decrease the excretion rate of Tiotropium which could result in a higher serum level.
Testosterone propionate,Tositumomab may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.
Amrinone,Tositumomab may decrease the excretion rate of Amrinone which could result in a higher serum level.
Oxybenzone,Tositumomab may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
Allylestrenol,Tositumomab may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
Fenproporex,Tositumomab may decrease the excretion rate of Fenproporex which could result in a higher serum level.
Bromazepam,Tositumomab may decrease the excretion rate of Bromazepam which could result in a higher serum level.
Chloral hydrate,Tositumomab may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
Metamfetamine,Tositumomab may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ketazolam,Tositumomab may decrease the excretion rate of Ketazolam which could result in a higher serum level.
Valganciclovir,Tositumomab may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Sorbitol,Tositumomab may decrease the excretion rate of Sorbitol which could result in a higher serum level.
Topiroxostat,Tositumomab may decrease the excretion rate of Topiroxostat which could result in a higher serum level.
Estrone sulfate,Tositumomab may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
Lorcaserin,Tositumomab may decrease the excretion rate of Lorcaserin which could result in a higher serum level.
Pegaptanib,Tositumomab may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Milnacipran,Tositumomab may decrease the excretion rate of Milnacipran which could result in a higher serum level.
Clevidipine,Tositumomab may decrease the excretion rate of Clevidipine which could result in a higher serum level.
Lofexidine,Tositumomab may decrease the excretion rate of Lofexidine which could result in a higher serum level.
Ezogabine,Tositumomab may decrease the excretion rate of Ezogabine which could result in a higher serum level.
Migalastat,Tositumomab may decrease the excretion rate of Migalastat which could result in a higher serum level.
Brivaracetam,Tositumomab may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
Pentaerythritol tetranitrate,Tositumomab may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
Ipilimumab,Tositumomab may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Icatibant,Tositumomab may decrease the excretion rate of Icatibant which could result in a higher serum level.
Alogliptin,Tositumomab may decrease the excretion rate of Alogliptin which could result in a higher serum level.
Doripenem,Tositumomab may decrease the excretion rate of Doripenem which could result in a higher serum level.
Nalmefene,Tositumomab may decrease the excretion rate of Nalmefene which could result in a higher serum level.
Droxidopa,Tositumomab may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Levocetirizine,Tositumomab may decrease the excretion rate of Levocetirizine which could result in a higher serum level.
Saxagliptin,Tositumomab may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
Telavancin,Tositumomab may decrease the excretion rate of Telavancin which could result in a higher serum level.
Prucalopride,Tositumomab may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Flupirtine,Tositumomab may decrease the excretion rate of Flupirtine which could result in a higher serum level.
Dalfampridine,Tositumomab may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
Desvenlafaxine,Tositumomab may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.
Fesoterodine,Tositumomab may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Gadofosveset trisodium,Tositumomab may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Methyltestosterone,Tositumomab may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
Ammonium chloride,Tositumomab may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
Dimercaprol,Tositumomab may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
Mangafodipir,Tositumomab may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
Methylnaltrexone,Tositumomab may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Plerixafor,Tositumomab may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Tiopronin,Tositumomab may decrease the excretion rate of Tiopronin which could result in a higher serum level.
Triethylenetetramine,Tositumomab may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Ioflupane I-123,Tositumomab may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
Deferiprone,Tositumomab may decrease the excretion rate of Deferiprone which could result in a higher serum level.
N-methylnicotinamide,Tositumomab may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.
Gabapentin enacarbil,Tositumomab may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
Mirabegron,Tositumomab may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Aclidinium,Tositumomab may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Enzalutamide,Tositumomab may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Teduglutide,Tositumomab may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Formestane,Tositumomab may decrease the excretion rate of Formestane which could result in a higher serum level.
Glycerol phenylbutyrate,Tositumomab may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
Trametinib,Tositumomab may decrease the excretion rate of Trametinib which could result in a higher serum level.
Levomilnacipran,Tositumomab may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Macitentan,Tositumomab may decrease the excretion rate of Macitentan which could result in a higher serum level.
Sofosbuvir,Tositumomab may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Gemeprost,Tositumomab may decrease the excretion rate of Gemeprost which could result in a higher serum level.
Ledipasvir,Tositumomab may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
Ceftolozane,Tositumomab may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Corifollitropin alfa,Tositumomab may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
Vortioxetine,Tositumomab may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
Tasimelteon,Tositumomab may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
Idebenone,Tositumomab may decrease the excretion rate of Idebenone which could result in a higher serum level.
Trimebutine,Tositumomab may decrease the excretion rate of Trimebutine which could result in a higher serum level.
Ancestim,Tositumomab may decrease the excretion rate of Ancestim which could result in a higher serum level.
Magnesium hydroxide,Tositumomab may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Hydroxyethyl Starch,Tositumomab may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Pentastarch,Tositumomab may decrease the excretion rate of Pentastarch which could result in a higher serum level.
Stiripentol,Tositumomab may decrease the excretion rate of Stiripentol which could result in a higher serum level.
Aurothioglucose,Tositumomab may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
Dienogest,Tositumomab may decrease the excretion rate of Dienogest which could result in a higher serum level.
Chromic chloride,Tositumomab may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Gadoteric acid,Tositumomab may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Iothalamic acid,Tositumomab may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Ioversol,Tositumomab may decrease the excretion rate of Ioversol which could result in a higher serum level.
Ioxilan,Tositumomab may decrease the excretion rate of Ioxilan which could result in a higher serum level.
Isosulfan blue,Tositumomab may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Technetium Tc-99m mebrofenin,Tositumomab may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
Technetium Tc-99m oxidronate,Tositumomab may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
Florbetaben (18F),Tositumomab may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir (18F),Tositumomab may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Iopromide,Tositumomab may decrease the excretion rate of Iopromide which could result in a higher serum level.
Technetium Tc-99m exametazime,Tositumomab may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
Technetium Tc-99m pyrophosphate,Tositumomab may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Viloxazine,Tositumomab may decrease the excretion rate of Viloxazine which could result in a higher serum level.
Etoperidone,Tositumomab may decrease the excretion rate of Etoperidone which could result in a higher serum level.
Lorpiprazole,Tositumomab may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
Arotinolol,Tositumomab may decrease the excretion rate of Arotinolol which could result in a higher serum level.
Moxisylyte,Tositumomab may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
Pholcodine,Tositumomab may decrease the excretion rate of Pholcodine which could result in a higher serum level.
Piracetam,Tositumomab may decrease the excretion rate of Piracetam which could result in a higher serum level.
Bisoxatin,Tositumomab may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
Nicorandil,Tositumomab may decrease the excretion rate of Nicorandil which could result in a higher serum level.
Blonanserin,Tositumomab may decrease the excretion rate of Blonanserin which could result in a higher serum level.
Melperone,Tositumomab may decrease the excretion rate of Melperone which could result in a higher serum level.
Methylene blue,Tositumomab may decrease the excretion rate of Methylene blue which could result in a higher serum level.
Pirlindole,Tositumomab may decrease the excretion rate of Pirlindole which could result in a higher serum level.
Toloxatone,Tositumomab may decrease the excretion rate of Toloxatone which could result in a higher serum level.
Tegafur,Tositumomab may decrease the excretion rate of Tegafur which could result in a higher serum level.
Gimeracil,Tositumomab may decrease the excretion rate of Gimeracil which could result in a higher serum level.
Imidafenacin,Tositumomab may decrease the excretion rate of Imidafenacin which could result in a higher serum level.
Idarucizumab,Tositumomab may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Lixisenatide,Tositumomab may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Picosulfuric acid,Tositumomab may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Sodium aurothiomalate,Tositumomab may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
Choline C 11,Tositumomab may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
Magnesium trisilicate,Tositumomab may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Sacubitril,Tositumomab may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Chondroitin sulfate,Tositumomab may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
"Synthetic Conjugated Estrogens, A","Tositumomab may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level."
"Synthetic Conjugated Estrogens, B","Tositumomab may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level."
Procaine benzylpenicillin,Tositumomab may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Sulbactam,Tositumomab may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sodium fluoride,Tositumomab may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
"Antihemophilic Factor (Recombinant), PEGylated","Tositumomab may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level."
Invert sugar,Tositumomab may decrease the excretion rate of Invert sugar which could result in a higher serum level.
Dexpanthenol,Tositumomab may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Phosphoric acid,Tositumomab may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Sodium acetate,Tositumomab may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Magnesium chloride,Tositumomab may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Potassium perchlorate,Tositumomab may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
Sodium sulfate,Tositumomab may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Enalaprilat,Tositumomab may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
Magnesium carbonate,Tositumomab may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
Acrivastine,Tositumomab may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Octinoxate,Tositumomab may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Fludeoxyglucose (18F),Tositumomab may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Iobenguane sulfate I-123,Tositumomab may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Ixazomib,Tositumomab may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Polyethylene glycol 400,Tositumomab may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
Potassium nitrate,Tositumomab may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium bicarbonate,Tositumomab may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
N-acetyltyrosine,Tositumomab may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Eucalyptus oil,Tositumomab may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Selenious acid,Tositumomab may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Opium,Tositumomab may decrease the excretion rate of Opium which could result in a higher serum level.
Selenium,Tositumomab may decrease the excretion rate of Selenium which could result in a higher serum level.
Chromium,Tositumomab may decrease the excretion rate of Chromium which could result in a higher serum level.
Oxyquinoline,Tositumomab may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Pyrantel,Tositumomab may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Bicisate,Tositumomab may decrease the excretion rate of Bicisate which could result in a higher serum level.
Tocopherol,Tositumomab may decrease the excretion rate of Tocopherol which could result in a higher serum level.
DL-Methylephedrine,Tositumomab may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
Tetradecyl hydrogen sulfate (ester),Tositumomab may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Clove oil,Tositumomab may decrease the excretion rate of Clove oil which could result in a higher serum level.
Evening primrose oil,Tositumomab may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
Pidotimod,Tositumomab may decrease the excretion rate of Pidotimod which could result in a higher serum level.
Lesinurad,Tositumomab may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Indigotindisulfonic acid,Tositumomab may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Etafedrine,Tositumomab may decrease the excretion rate of Etafedrine which could result in a higher serum level.
Pitolisant,Tositumomab may decrease the excretion rate of Pitolisant which could result in a higher serum level.
Naldemedine,Tositumomab may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Tropisetron,Tositumomab may decrease the excretion rate of Tropisetron which could result in a higher serum level.
Apalutamide,Tositumomab may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Valbenazine,Tositumomab may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Delafloxacin,Tositumomab may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
Benznidazole,Tositumomab may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Isoflavone,Tositumomab may decrease the excretion rate of Isoflavone which could result in a higher serum level.
Vaborbactam,Tositumomab may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Deutetrabenazine,Tositumomab may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Propiverine,Tositumomab may decrease the excretion rate of Propiverine which could result in a higher serum level.
Benserazide,Tositumomab may decrease the excretion rate of Benserazide which could result in a higher serum level.
Tiapride,Tositumomab may decrease the excretion rate of Tiapride which could result in a higher serum level.
Levosalbutamol,Tositumomab may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
Inosine pranobex,Tositumomab may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
Inositol,Tositumomab may decrease the excretion rate of Inositol which could result in a higher serum level.
Oxabolone cipionate,Tositumomab may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.
Phosphocreatine,Tositumomab may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.
Dichlorobenzyl alcohol,Tositumomab may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
Ipecac,Tositumomab may decrease the excretion rate of Ipecac which could result in a higher serum level.
Almasilate,Tositumomab may decrease the excretion rate of Almasilate which could result in a higher serum level.
Fenofibric acid,Tositumomab may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
Albutrepenonacog alfa,Tositumomab may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Bismuth subgallate,Tositumomab may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Testosterone cypionate,Tositumomab may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
Testosterone enanthate,Tositumomab may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
Testosterone undecanoate,Tositumomab may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
Estradiol acetate,Tositumomab may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
Estradiol cypionate,Tositumomab may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
Estradiol dienanthate,Tositumomab may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.
Estradiol valerate,Tositumomab may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
Patent Blue,Tositumomab may decrease the excretion rate of Patent Blue which could result in a higher serum level.
Choline salicylate,Tositumomab may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
Pentetic acid,Tositumomab may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Potassium acetate,Tositumomab may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium sulfate,Tositumomab may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
Chromic citrate,Tositumomab may decrease the excretion rate of Chromic citrate which could result in a higher serum level.
Chromic nitrate,Tositumomab may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
Chromium gluconate,Tositumomab may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
Chromium nicotinate,Tositumomab may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Chromous sulfate,Tositumomab may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
Solriamfetol,Tositumomab may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
Pyrithione,Tositumomab may decrease the excretion rate of Pyrithione which could result in a higher serum level.
Chloroxylenol,Tositumomab may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
Resorcinol,Tositumomab may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Cimetidine,Tositumomab may decrease the excretion rate of Cimetidine which could result in a higher serum level.
Golodirsen,Tositumomab may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Amitriptyline,Tositumomab may decrease the excretion rate of Amitriptyline which could result in a higher serum level.
Imipramine,Tositumomab may decrease the excretion rate of Imipramine which could result in a higher serum level.
Doxepin,Tositumomab may decrease the excretion rate of Doxepin which could result in a higher serum level.
Codeine,Tositumomab may decrease the excretion rate of Codeine which could result in a higher serum level.
Meperidine,Tositumomab may decrease the excretion rate of Meperidine which could result in a higher serum level.
Fentanyl,Tositumomab may decrease the excretion rate of Fentanyl which could result in a higher serum level.
Emtricitabine,Tositumomab may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
Desipramine,Tositumomab may decrease the excretion rate of Desipramine which could result in a higher serum level.
Clomipramine,Tositumomab may decrease the excretion rate of Clomipramine which could result in a higher serum level.
Dimetacrine,Tositumomab may decrease the excretion rate of Dimetacrine which could result in a higher serum level.
Lithium hydroxide,Tositumomab may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.
Framycetin,Framycetin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Amikacin,Amikacin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Tobramycin,Tobramycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Gentamicin,Gentamicin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Netilmicin,Netilmicin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Neomycin,Neomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Streptomycin,Streptomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Kanamycin,Kanamycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Paromomycin,Paromomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Ribostamycin,Ribostamycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Geneticin,Geneticin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Apramycin,Apramycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Gentamicin C1a,Gentamicin C1a may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Neamine,Neamine may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Arbekacin,Arbekacin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Puromycin,Puromycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Dihydrostreptomycin,Dihydrostreptomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Hygromycin B,Hygromycin B may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Sisomicin,Sisomicin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Dibekacin,Dibekacin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Micronomicin,Micronomicin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Isepamicin,Isepamicin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Bekanamycin,Bekanamycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Nedaplatin,Tositumomab may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
Capreomycin,Tositumomab may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Digoxin,Tositumomab may decrease the excretion rate of Digoxin which could result in a higher serum level.
Vancomycin,Tositumomab may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Quinidine,Tositumomab may decrease the excretion rate of Quinidine which could result in a higher serum level.
Isotretinoin,Tositumomab may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
Procainamide,Tositumomab may decrease the excretion rate of Procainamide which could result in a higher serum level.
Plazomicin,Tositumomab may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Lithium carbonate,Tositumomab may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
Methyclothiazide,Methyclothiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Bendroflumethiazide,Bendroflumethiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Benzthiazide,Benzthiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Cyclothiazide,Cyclothiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Hydroflumethiazide,Hydroflumethiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Chlorothiazide,Chlorothiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Trichlormethiazide,Trichlormethiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Diazoxide,Diazoxide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Polythiazide,Polythiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Mebutizide,Mebutizide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Cyclopenthiazide,Cyclopenthiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Metolazone,Tositumomab may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.
Furosemide,Tositumomab may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.
Indapamide,Tositumomab may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.
Bumetanide,Tositumomab may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.
Zonisamide,Tositumomab may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Canagliflozin,Tositumomab may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Mersalyl,Tositumomab may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.
Torasemide,Torasemide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone,Chlorthalidone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Ethoxzolamide,Ethoxzolamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Spironolactone,Spironolactone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Amiloride,Amiloride may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Eplerenone,Eplerenone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Methazolamide,Methazolamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Acetazolamide,Acetazolamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Conivaptan,Conivaptan may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Diclofenamide,Diclofenamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Quinethazone,Quinethazone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Drospirenone,Drospirenone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Theobromine,Theobromine may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Piretanide,Piretanide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Tienilic acid,Tienilic acid may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Ularitide,Ularitide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Tolvaptan,Tolvaptan may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Dapagliflozin,Dapagliflozin may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Indisulam,Indisulam may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Azosemide,Azosemide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Canrenoic acid,Canrenoic acid may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Efonidipine,Efonidipine may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide,Isosorbide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Ertugliflozin,Ertugliflozin may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Canrenone,Canrenone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Rolofylline,Rolofylline may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Spiradoline,Spiradoline may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Cicletanine,Cicletanine may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Meticrane,Meticrane may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Ibopamine,Ibopamine may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Mefruside,Mefruside may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Clorexolone,Clorexolone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Clofenamide,Clofenamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Fenquizone,Fenquizone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Clopamide,Clopamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Muzolimine,Muzolimine may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Xipamide,Xipamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Epitizide,Epitizide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Bromotheophylline,Bromotheophylline may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Potassium,Potassium may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
Tedizolid phosphate,The risk or severity of myelosuppression can be increased when Tositumomab is combined with Tedizolid phosphate.
Cyclosporine,Tositumomab may increase the immunosuppressive activities of Cyclosporine.
Cyanocobalamin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tositumomab.
Allopurinol,The risk or severity of adverse effects can be increased when Allopurinol is combined with Tositumomab.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Tositumomab."
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Tositumomab.
Lopinavir,The serum concentration of Tositumomab can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Tositumomab is combined with Inebilizumab.
Insulin human,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin human.
Insulin lispro,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin lispro.
Insulin glargine,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin glargine.
Insulin pork,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin pork.
Troglitazone,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Troglitazone.
Glimepiride,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glimepiride.
Sulfisoxazole,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sulfisoxazole.
Disopyramide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Disopyramide.
Acarbose,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Acarbose.
Metformin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Metformin.
Sulfadiazine,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sulfadiazine.
Rosiglitazone,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Rosiglitazone.
Acetohexamide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Acetohexamide.
Quinine,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Quinine.
Miglitol,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Miglitol.
Chlorpropamide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Chlorpropamide.
Nateglinide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Nateglinide.
Pentamidine,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pentamidine.
Mifepristone,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Mifepristone.
Tolazamide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tolazamide.
Repaglinide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Repaglinide.
Phenformin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Phenformin.
Sulfamethoxazole,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sulfamethoxazole.
Glyburide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glyburide.
Glipizide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glipizide.
Gliclazide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gliclazide.
Tolbutamide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tolbutamide.
Pioglitazone,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pioglitazone.
Bromocriptine,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Bromocriptine.
Gliquidone,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gliquidone.
Mitiglinide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Mitiglinide.
Sitagliptin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sitagliptin.
Sunitinib,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sunitinib.
Exenatide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Exenatide.
Mecasermin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Mecasermin.
Pramlintide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pramlintide.
Glisoxepide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glisoxepide.
Insulin aspart,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin aspart.
Insulin detemir,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin detemir.
Insulin glulisine,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin glulisine.
Glymidine,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glymidine.
AICA ribonucleotide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with AICA ribonucleotide.
Buformin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Buformin.
Vildagliptin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Vildagliptin.
Voglibose,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Voglibose.
NN344,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with NN344.
NBI-6024,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with NBI-6024.
AMG-222,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with AMG-222.
Bisegliptin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Bisegliptin.
Alogliptin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Alogliptin.
Dapagliflozin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dapagliflozin.
Saxagliptin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Saxagliptin.
Liraglutide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Liraglutide.
Gosogliptin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gosogliptin.
Linagliptin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Linagliptin.
Canagliflozin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Canagliflozin.
Glibornuride,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glibornuride.
Benfluorex,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Benfluorex.
Empagliflozin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Empagliflozin.
Albiglutide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Albiglutide.
Dulaglutide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dulaglutide.
Lobeglitazone,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Lobeglitazone.
Netoglitazone,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Netoglitazone.
Rivoglitazone,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Rivoglitazone.
Ciglitazone,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ciglitazone.
Lixisenatide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Lixisenatide.
Insulin beef,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin beef.
Insulin degludec,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin degludec.
Insulin peglispro,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin peglispro.
Insulin tregopil,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin tregopil.
Ipragliflozin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ipragliflozin.
Dutogliptin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dutogliptin.
Allicin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Allicin.
Tofogliflozin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tofogliflozin.
Ertugliflozin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ertugliflozin.
"2,4-thiazolidinedione","The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with 2,4-thiazolidinedione."
Teneligliptin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Teneligliptin.
Omarigliptin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Omarigliptin.
Carmegliptin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Carmegliptin.
Gemigliptin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gemigliptin.
Anagliptin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Anagliptin.
Evogliptin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Evogliptin.
Sotagliflozin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sotagliflozin.
Balaglitazone,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Balaglitazone.
Remogliflozin etabonate,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Remogliflozin etabonate.
Carbutamide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Carbutamide.
Guar gum,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Guar gum.
Metahexamide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Metahexamide.
Semaglutide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Semaglutide.
Taspoglutide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Taspoglutide.
Englitazone,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Englitazone.
Tirzepatide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tirzepatide.
Gastric inhibitory polypeptide,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gastric inhibitory polypeptide.
Octreotide,The risk or severity of increased transaminases can be increased when Octreotide is combined with Pegvisomant.
Vapreotide,The risk or severity of increased transaminases can be increased when Vapreotide is combined with Pegvisomant.
Pasireotide,The risk or severity of increased transaminases can be increased when Pasireotide is combined with Pegvisomant.
Lanreotide,The risk or severity of increased transaminases can be increased when Lanreotide is combined with Pegvisomant.
Somatostatin,The risk or severity of increased transaminases can be increased when Somatostatin is combined with Pegvisomant.
Aripiprazole,The metabolism of Aripiprazole can be increased when combined with Pegvisomant.
Aripiprazole lauroxil,The metabolism of Aripiprazole lauroxil can be increased when combined with Pegvisomant.
Morphine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Morphine.
Codeine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Codeine.
Hydromorphone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydromorphone.
Methadone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadone.
Meperidine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Meperidine.
Oxycodone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxycodone.
Butorphanol,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Butorphanol.
Dextropropoxyphene,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextropropoxyphene.
Pentazocine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pentazocine.
Naltrexone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Naltrexone.
Sufentanil,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Sufentanil.
Alfentanil,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alfentanil.
Fentanyl,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fentanyl.
Nalbuphine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Nalbuphine.
Levorphanol,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levorphanol.
Remifentanil,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Remifentanil.
Buprenorphine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Buprenorphine.
Diphenoxylate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Diphenoxylate.
Oxymorphone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxymorphone.
Dezocine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dezocine.
Levacetylmethadol,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levacetylmethadol.
Methadyl acetate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadyl acetate.
Dihydroetorphine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydroetorphine.
Diamorphine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Diamorphine.
Bezitramide,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Bezitramide.
Ethylmorphine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ethylmorphine.
Etorphine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Etorphine.
Dextromoramide,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextromoramide.
Desomorphine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Desomorphine.
Carfentanil,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Carfentanil.
Dihydrocodeine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydrocodeine.
Alphacetylmethadol,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alphacetylmethadol.
Dihydromorphine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydromorphine.
Tapentadol,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tapentadol.
Ketobemidone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ketobemidone.
DPDPE,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with DPDPE.
Lofentanil,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Lofentanil.
Eluxadoline,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Eluxadoline.
Opium,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Opium.
Normethadone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Normethadone.
Piritramide,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Piritramide.
Alphaprodine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alphaprodine.
Nicomorphine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Nicomorphine.
Meptazinol,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Meptazinol.
Phenoperidine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Phenoperidine.
Phenazocine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Phenazocine.
Tilidine,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tilidine.
"Carfentanil, C-11","The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Carfentanil, C-11."
Benzhydrocodone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Benzhydrocodone.
Hydrocodone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocodone.
Dipyridamole,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dipyridamole.
Ephedrine,Pegvisomant may increase the neuromuscular blocking activities of Ephedrine.
Bambuterol,Pegvisomant may increase the neuromuscular blocking activities of Bambuterol.
"Sar9, Met (O2)11-Substance P","Pegvisomant may increase the neuromuscular blocking activities of Sar9, Met (O2)11-Substance P."
Moxisylyte,Pegvisomant may increase the neuromuscular blocking activities of Moxisylyte.
Procaine,Pegvisomant may increase the neuromuscular blocking activities of Procaine.
Cocaine,Pegvisomant may increase the neuromuscular blocking activities of Cocaine.
Trimethaphan,Pegvisomant may increase the neuromuscular blocking activities of Trimethaphan.
Doxacurium,Pegvisomant may increase the neuromuscular blocking activities of Doxacurium.
Chloroprocaine,Pegvisomant may increase the neuromuscular blocking activities of Chloroprocaine.
Tubocurarine,Pegvisomant may increase the neuromuscular blocking activities of Tubocurarine.
Aclidinium,Pegvisomant may increase the neuromuscular blocking activities of Aclidinium.
Propacetamol,Pegvisomant may increase the neuromuscular blocking activities of Propacetamol.
Butyrylthiocholine,Pegvisomant may increase the neuromuscular blocking activities of Butyrylthiocholine.
Irinotecan,Pegvisomant may increase the neuromuscular blocking activities of Irinotecan.
Clevidipine,Pegvisomant may increase the neuromuscular blocking activities of Clevidipine.
Mirabegron,Pegvisomant may increase the neuromuscular blocking activities of Mirabegron.
Ifosfamide,The metabolism of Ifosfamide can be increased when combined with Pegvisomant.
Perampanel,The metabolism of Perampanel can be increased when combined with Pegvisomant.
Warfarin,The metabolism of Warfarin can be increased when combined with Pegvisomant.
Acenocoumarol,The metabolism of Acenocoumarol can be increased when combined with Pegvisomant.
(R)-warfarin,The metabolism of (R)-warfarin can be increased when combined with Pegvisomant.
"R,S-Warfarin alcohol","The metabolism of R,S-Warfarin alcohol can be increased when combined with Pegvisomant."
"S,R-Warfarin alcohol","The metabolism of S,R-Warfarin alcohol can be increased when combined with Pegvisomant."
(S)-Warfarin,The metabolism of (S)-Warfarin can be increased when combined with Pegvisomant.
Succinylcholine,The metabolism of Succinylcholine can be decreased when combined with Pegvisomant.
Peginterferon alfa-2a,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Peginterferon alfa-2a.
Pegfilgrastim,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegfilgrastim.
Peginterferon alfa-2b,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Peginterferon alfa-2b.
Pegaspargase,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegaspargase.
Pegademase,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegademase.
Propylene glycol,The therapeutic efficacy of Propylene glycol can be decreased when used in combination with Pegvisomant.
Heptaethylene glycol,The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegvisomant.
Pegaptanib,The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegvisomant.
Egaptivon pegol,The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Pegvisomant.
PEG-uricase,The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegvisomant.
Peginterferon alfacon-1,The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with Pegvisomant.
GlycoPEG-GCSF,The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Pegvisomant.
Pegnivacogin,The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Pegvisomant.
Pegpleranib,The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Pegvisomant.
Pegsunercept,The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Pegvisomant.
Polidocanol,The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegvisomant.
Peginesatide,The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegvisomant.
Certolizumab pegol,The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegvisomant.
Methoxy polyethylene glycol-epoetin beta,The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegvisomant.
Peginterferon beta-1a,The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Pegvisomant.
Pegloticase,The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegvisomant.
Polyethylene glycol,The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegvisomant.
"Antihemophilic Factor (Recombinant), PEGylated","The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Pegvisomant."
Polyethylene glycol 400,The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Pegvisomant.
Eptacog alfa pegol (activated),The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Pegvisomant.
Olaptesed Pegol,The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Pegvisomant.
Abicipar Pegol,The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegvisomant.
Lexaptepid Pegol,The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Pegvisomant.
Cepeginterferon alfa-2B,The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Pegvisomant.
Pegvaliase,The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegvisomant.
Pegamotecan,The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Pegvisomant.
Lipegfilgrastim,The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegvisomant.
Nonacog beta pegol,The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Pegvisomant.
Damoctocog alfa pegol,The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegvisomant.
Elapegademase,The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegvisomant.
Erlotinib,The serum concentration of Erlotinib can be decreased when it is combined with Pegvisomant.
Trospium,The therapeutic efficacy of Trospium can be decreased when used in combination with Pegvisomant.
Oxyphenonium,The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Pegvisomant.
Butabarbital,The therapeutic efficacy of Butabarbital can be decreased when used in combination with Pegvisomant.
Butalbital,The therapeutic efficacy of Butalbital can be decreased when used in combination with Pegvisomant.
Benzatropine,The therapeutic efficacy of Benzatropine can be decreased when used in combination with Pegvisomant.
Talbutal,The therapeutic efficacy of Talbutal can be decreased when used in combination with Pegvisomant.
Pentobarbital,The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Pegvisomant.
Ipratropium,The therapeutic efficacy of Ipratropium can be decreased when used in combination with Pegvisomant.
Olanzapine,The therapeutic efficacy of Olanzapine can be decreased when used in combination with Pegvisomant.
Metixene,The therapeutic efficacy of Metixene can be decreased when used in combination with Pegvisomant.
Buclizine,The therapeutic efficacy of Buclizine can be decreased when used in combination with Pegvisomant.
Doxylamine,The therapeutic efficacy of Doxylamine can be decreased when used in combination with Pegvisomant.
Trihexyphenidyl,The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Pegvisomant.
Oxyphencyclimine,The therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Pegvisomant.
Procyclidine,The therapeutic efficacy of Procyclidine can be decreased when used in combination with Pegvisomant.
Profenamine,The therapeutic efficacy of Profenamine can be decreased when used in combination with Pegvisomant.
Secobarbital,The therapeutic efficacy of Secobarbital can be decreased when used in combination with Pegvisomant.
Promazine,The therapeutic efficacy of Promazine can be decreased when used in combination with Pegvisomant.
Hyoscyamine,The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Pegvisomant.
Cyproheptadine,The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Pegvisomant.
Methscopolamine bromide,The therapeutic efficacy of Methscopolamine bromide can be decreased when used in combination with Pegvisomant.
Metharbital,The therapeutic efficacy of Metharbital can be decreased when used in combination with Pegvisomant.
Fluoxetine,The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Pegvisomant.
Tridihexethyl,The therapeutic efficacy of Tridihexethyl can be decreased when used in combination with Pegvisomant.
Triflupromazine,The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Pegvisomant.
Dextromethorphan,The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Pegvisomant.
Anisotropine methylbromide,The therapeutic efficacy of Anisotropine methylbromide can be decreased when used in combination with Pegvisomant.
Amoxapine,The therapeutic efficacy of Amoxapine can be decreased when used in combination with Pegvisomant.
Lamotrigine,The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Pegvisomant.
Atropine,The therapeutic efficacy of Atropine can be decreased when used in combination with Pegvisomant.
Thiopental,The therapeutic efficacy of Thiopental can be decreased when used in combination with Pegvisomant.
Nicardipine,The therapeutic efficacy of Nicardipine can be decreased when used in combination with Pegvisomant.
Mecamylamine,The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Pegvisomant.
Pirenzepine,The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Pegvisomant.
Paroxetine,The therapeutic efficacy of Paroxetine can be decreased when used in combination with Pegvisomant.
Homatropine methylbromide,The therapeutic efficacy of Homatropine methylbromide can be decreased when used in combination with Pegvisomant.
Scopolamine,The therapeutic efficacy of Scopolamine can be decreased when used in combination with Pegvisomant.
Isoflurane,The therapeutic efficacy of Isoflurane can be decreased when used in combination with Pegvisomant.
Benzquinamide,The therapeutic efficacy of Benzquinamide can be decreased when used in combination with Pegvisomant.
Clidinium,The therapeutic efficacy of Clidinium can be decreased when used in combination with Pegvisomant.
Propiomazine,The therapeutic efficacy of Propiomazine can be decreased when used in combination with Pegvisomant.
Propantheline,The therapeutic efficacy of Propantheline can be decreased when used in combination with Pegvisomant.
Primidone,The therapeutic efficacy of Primidone can be decreased when used in combination with Pegvisomant.
Dicyclomine,The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Pegvisomant.
Biperiden,The therapeutic efficacy of Biperiden can be decreased when used in combination with Pegvisomant.
Brompheniramine,The therapeutic efficacy of Brompheniramine can be decreased when used in combination with Pegvisomant.
Methylphenobarbital,The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Pegvisomant.
Flupentixol,The therapeutic efficacy of Flupentixol can be decreased when used in combination with Pegvisomant.
Amantadine,The therapeutic efficacy of Amantadine can be decreased when used in combination with Pegvisomant.
Maprotiline,The therapeutic efficacy of Maprotiline can be decreased when used in combination with Pegvisomant.
Methantheline,The therapeutic efficacy of Methantheline can be decreased when used in combination with Pegvisomant.
Hexafluronium,The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Pegvisomant.
Cycrimine,The therapeutic efficacy of Cycrimine can be decreased when used in combination with Pegvisomant.
Desloratadine,The therapeutic efficacy of Desloratadine can be decreased when used in combination with Pegvisomant.
Glycopyrronium,The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Pegvisomant.
Tolterodine,The therapeutic efficacy of Tolterodine can be decreased when used in combination with Pegvisomant.
Oxybutynin,The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Pegvisomant.
Promethazine,The therapeutic efficacy of Promethazine can be decreased when used in combination with Pegvisomant.
Diphenhydramine,The therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Pegvisomant.
Pentolinium,The therapeutic efficacy of Pentolinium can be decreased when used in combination with Pegvisomant.
Flavoxate,The therapeutic efficacy of Flavoxate can be decreased when used in combination with Pegvisomant.
Orphenadrine,The therapeutic efficacy of Orphenadrine can be decreased when used in combination with Pegvisomant.
Escitalopram,The therapeutic efficacy of Escitalopram can be decreased when used in combination with Pegvisomant.
Diphenidol,The therapeutic efficacy of Diphenidol can be decreased when used in combination with Pegvisomant.
Chlorprothixene,The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Pegvisomant.
Fenoterol,The therapeutic efficacy of Fenoterol can be decreased when used in combination with Pegvisomant.
Amobarbital,The therapeutic efficacy of Amobarbital can be decreased when used in combination with Pegvisomant.
Aprobarbital,The therapeutic efficacy of Aprobarbital can be decreased when used in combination with Pegvisomant.
Butobarbital,The therapeutic efficacy of Butobarbital can be decreased when used in combination with Pegvisomant.
Heptabarbital,The therapeutic efficacy of Heptabarbital can be decreased when used in combination with Pegvisomant.
Hexobarbital,The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Pegvisomant.
Methotrimeprazine,The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Pegvisomant.
Tiotropium,The therapeutic efficacy of Tiotropium can be decreased when used in combination with Pegvisomant.
Barbital,The therapeutic efficacy of Barbital can be decreased when used in combination with Pegvisomant.
"Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione","The therapeutic efficacy of Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione can be decreased when used in combination with Pegvisomant."
Solifenacin,The therapeutic efficacy of Solifenacin can be decreased when used in combination with Pegvisomant.
Isopropamide,The therapeutic efficacy of Isopropamide can be decreased when used in combination with Pegvisomant.
Mepenzolate,The therapeutic efficacy of Mepenzolate can be decreased when used in combination with Pegvisomant.
Gantacurium,The therapeutic efficacy of Gantacurium can be decreased when used in combination with Pegvisomant.
Pizotifen,The therapeutic efficacy of Pizotifen can be decreased when used in combination with Pegvisomant.
Fesoterodine,The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Pegvisomant.
Hexocyclium,The therapeutic efficacy of Hexocyclium can be decreased when used in combination with Pegvisomant.
Dimetindene,The therapeutic efficacy of Dimetindene can be decreased when used in combination with Pegvisomant.
Agmatine,The therapeutic efficacy of Agmatine can be decreased when used in combination with Pegvisomant.
Hexamethonium,The therapeutic efficacy of Hexamethonium can be decreased when used in combination with Pegvisomant.
Dexetimide,The therapeutic efficacy of Dexetimide can be decreased when used in combination with Pegvisomant.
Chlorphenoxamine,The therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Pegvisomant.
Benactyzine,The therapeutic efficacy of Benactyzine can be decreased when used in combination with Pegvisomant.
Umeclidinium,The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Pegvisomant.
Trimebutine,The therapeutic efficacy of Trimebutine can be decreased when used in combination with Pegvisomant.
Dosulepin,The therapeutic efficacy of Dosulepin can be decreased when used in combination with Pegvisomant.
Imidafenacin,The therapeutic efficacy of Imidafenacin can be decreased when used in combination with Pegvisomant.
Butylscopolamine,The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Pegvisomant.
Thonzylamine,The therapeutic efficacy of Thonzylamine can be decreased when used in combination with Pegvisomant.
Methscopolamine,The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Pegvisomant.
Revefenacin,The therapeutic efficacy of Revefenacin can be decreased when used in combination with Pegvisomant.
Oxitropium,The therapeutic efficacy of Oxitropium can be decreased when used in combination with Pegvisomant.
Propiverine,The therapeutic efficacy of Propiverine can be decreased when used in combination with Pegvisomant.
Batefenterol,The therapeutic efficacy of Batefenterol can be decreased when used in combination with Pegvisomant.
Mebeverine,The therapeutic efficacy of Mebeverine can be decreased when used in combination with Pegvisomant.
Tropatepine,The therapeutic efficacy of Tropatepine can be decreased when used in combination with Pegvisomant.
Prifinium,The therapeutic efficacy of Prifinium can be decreased when used in combination with Pegvisomant.
Piperidolate,The therapeutic efficacy of Piperidolate can be decreased when used in combination with Pegvisomant.
Benzilone,The therapeutic efficacy of Benzilone can be decreased when used in combination with Pegvisomant.
Difemerine,The therapeutic efficacy of Difemerine can be decreased when used in combination with Pegvisomant.
Phenglutarimide,The therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Pegvisomant.
Mazaticol,The therapeutic efficacy of Mazaticol can be decreased when used in combination with Pegvisomant.
Etybenzatropine,The therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Pegvisomant.
Otilonium,The therapeutic efficacy of Otilonium can be decreased when used in combination with Pegvisomant.
Emepronium,The therapeutic efficacy of Emepronium can be decreased when used in combination with Pegvisomant.
Poldine,The therapeutic efficacy of Poldine can be decreased when used in combination with Pegvisomant.
Bevonium,The therapeutic efficacy of Bevonium can be decreased when used in combination with Pegvisomant.
Rociverine,The therapeutic efficacy of Rociverine can be decreased when used in combination with Pegvisomant.
Bornaprine,The therapeutic efficacy of Bornaprine can be decreased when used in combination with Pegvisomant.
Etanautine,The therapeutic efficacy of Etanautine can be decreased when used in combination with Pegvisomant.
Tiemonium iodide,The therapeutic efficacy of Tiemonium iodide can be decreased when used in combination with Pegvisomant.
Dihexyverine,The therapeutic efficacy of Dihexyverine can be decreased when used in combination with Pegvisomant.
Penthienate,The therapeutic efficacy of Penthienate can be decreased when used in combination with Pegvisomant.
Diphemanil,The therapeutic efficacy of Diphemanil can be decreased when used in combination with Pegvisomant.
Camylofin,The therapeutic efficacy of Camylofin can be decreased when used in combination with Pegvisomant.
Fenpiverinium,The therapeutic efficacy of Fenpiverinium can be decreased when used in combination with Pegvisomant.
Emetonium iodide,The therapeutic efficacy of Emetonium iodide can be decreased when used in combination with Pegvisomant.
Pipenzolate,The therapeutic efficacy of Pipenzolate can be decreased when used in combination with Pegvisomant.
Timepidium,The therapeutic efficacy of Timepidium can be decreased when used in combination with Pegvisomant.
Quetiapine,The therapeutic efficacy of Quetiapine can be decreased when used in combination with Pegvisomant.
Amitriptyline,The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Pegvisomant.
Doxepin,The therapeutic efficacy of Doxepin can be decreased when used in combination with Pegvisomant.
Darifenacin,The therapeutic efficacy of Darifenacin can be decreased when used in combination with Pegvisomant.
Nortriptyline,The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Pegvisomant.
Esmolol,Pegvisomant may increase the bradycardic activities of Esmolol.
Betaxolol,Pegvisomant may increase the bradycardic activities of Betaxolol.
Atenolol,Pegvisomant may increase the bradycardic activities of Atenolol.
Timolol,Pegvisomant may increase the bradycardic activities of Timolol.
Sotalol,Pegvisomant may increase the bradycardic activities of Sotalol.
Labetalol,Pegvisomant may increase the bradycardic activities of Labetalol.
Alprenolol,Pegvisomant may increase the bradycardic activities of Alprenolol.
Pindolol,Pegvisomant may increase the bradycardic activities of Pindolol.
Acebutolol,Pegvisomant may increase the bradycardic activities of Acebutolol.
Nadolol,Pegvisomant may increase the bradycardic activities of Nadolol.
Bevantolol,Pegvisomant may increase the bradycardic activities of Bevantolol.
Practolol,Pegvisomant may increase the bradycardic activities of Practolol.
Penbutolol,Pegvisomant may increase the bradycardic activities of Penbutolol.
Oxprenolol,Pegvisomant may increase the bradycardic activities of Oxprenolol.
Dexpropranolol,Pegvisomant may increase the bradycardic activities of Dexpropranolol.
Celiprolol,Pegvisomant may increase the bradycardic activities of Celiprolol.
Bufuralol,Pegvisomant may increase the bradycardic activities of Bufuralol.
Bopindolol,Pegvisomant may increase the bradycardic activities of Bopindolol.
Bupranolol,Pegvisomant may increase the bradycardic activities of Bupranolol.
Indenolol,Pegvisomant may increase the bradycardic activities of Indenolol.
Befunolol,Pegvisomant may increase the bradycardic activities of Befunolol.
Arotinolol,Pegvisomant may increase the bradycardic activities of Arotinolol.
Levobetaxolol,Pegvisomant may increase the bradycardic activities of Levobetaxolol.
Talinolol,Pegvisomant may increase the bradycardic activities of Talinolol.
Anisodamine,Pegvisomant may increase the bradycardic activities of Anisodamine.
Landiolol,Pegvisomant may increase the bradycardic activities of Landiolol.
Bucindolol,Pegvisomant may increase the bradycardic activities of Bucindolol.
Esatenolol,Pegvisomant may increase the bradycardic activities of Esatenolol.
Cloranolol,Pegvisomant may increase the bradycardic activities of Cloranolol.
Mepindolol,Pegvisomant may increase the bradycardic activities of Mepindolol.
Epanolol,Pegvisomant may increase the bradycardic activities of Epanolol.
Tertatolol,Pegvisomant may increase the bradycardic activities of Tertatolol.
Propranolol,Pegvisomant may increase the bradycardic activities of Propranolol.
Bisoprolol,Pegvisomant may increase the bradycardic activities of Bisoprolol.
Carvedilol,Pegvisomant may increase the bradycardic activities of Carvedilol.
Propafenone,Pegvisomant may increase the bradycardic activities of Propafenone.
Nebivolol,Pegvisomant may increase the bradycardic activities of Nebivolol.
Carbamoylcholine,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Carbamoylcholine.
Bethanechol,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Bethanechol.
Pilocarpine,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Pilocarpine.
Varenicline,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Varenicline.
Acetylcholine,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Acetylcholine.
Arecoline,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Arecoline.
Lobeline,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Lobeline.
NGX267,The risk or severity of adverse effects can be increased when Pegvisomant is combined with NGX267.
GTS-21,The risk or severity of adverse effects can be increased when Pegvisomant is combined with GTS-21.
Methacholine,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Methacholine.
Epibatidine,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Epibatidine.
Xanomeline,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Xanomeline.
Nicotine,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Nicotine.
Cevimeline,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Cevimeline.
Lipoic acid,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Lipoic acid.
Indomethacin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Indomethacin.
Gatifloxacin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gatifloxacin.
Zimelidine,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Zimelidine.
Ubidecarenone,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ubidecarenone.
Ritanserin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ritanserin.
Alaproclate,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Alaproclate.
Cibenzoline,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Cibenzoline.
Clinafloxacin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Clinafloxacin.
Fluvoxamine,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Fluvoxamine.
Citalopram,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Citalopram.
Pregabalin,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pregabalin.
Venlafaxine,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Venlafaxine.
Sertraline,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sertraline.
Nefazodone,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Nefazodone.
Dapoxetine,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dapoxetine.
Desvenlafaxine,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Desvenlafaxine.
Indalpine,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Indalpine.
Tixocortol,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tixocortol.
Cortivazol,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Cortivazol.
Fluocortin,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluocortin.
Fluperolone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluperolone.
Formocortal,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Formocortal.
Halometasone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Halometasone.
Cloprednol,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Cloprednol.
Fluclorolone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluclorolone.
Loteprednol,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Loteprednol.
Prednisolone phosphate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisolone phosphate.
Prednisolone hemisuccinate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisolone hemisuccinate.
Fluprednidene acetate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluprednidene acetate.
Methylprednisolone aceponate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methylprednisolone aceponate.
Methylprednisolone hemisuccinate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methylprednisolone hemisuccinate.
Prednisone acetate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisone acetate.
Clocortolone acetate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Clocortolone acetate.
Melengestrol acetate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Melengestrol acetate.
Betamethasone phosphate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Betamethasone phosphate.
Cortisone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Cortisone.
Flunisolide,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Flunisolide.
Beclomethasone dipropionate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Beclomethasone dipropionate.
Betamethasone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Betamethasone.
Fluticasone propionate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluticasone propionate.
Fluocinolone acetonide,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluocinolone acetonide.
Triamcinolone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Triamcinolone.
Prednisone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisone.
Fludrocortisone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fludrocortisone.
Hydrocortisone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone.
Mometasone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Mometasone.
Prednisolone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisolone.
Methylprednisolone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methylprednisolone.
Trilostane,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Trilostane.
Dexamethasone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dexamethasone.
Corticotropin,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Corticotropin.
Cortisone acetate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Cortisone acetate.
Paramethasone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Paramethasone.
Ciclesonide,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ciclesonide.
Aldosterone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Aldosterone.
Fluticasone furoate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluticasone furoate.
Fluprednidene,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluprednidene.
Fluocortolone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluocortolone.
Fluprednisolone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluprednisolone.
Meprednisone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Meprednisone.
Dexamethasone isonicotinate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dexamethasone isonicotinate.
Melengestrol,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Melengestrol.
Clobetasol,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Clobetasol.
Deflazacort,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Deflazacort.
Prednylidene,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednylidene.
Fluticasone,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluticasone.
Mometasone furoate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Mometasone furoate.
Hydrocortisone aceponate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone aceponate.
Hydrocortisone acetate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone acetate.
Hydrocortisone cypionate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone cypionate.
Hydrocortisone succinate,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone succinate.
Budesonide,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Budesonide.
Metocurine iodide,Pegvisomant may decrease the neuromuscular blocking activities of Metocurine iodide.
Gallamine triethiodide,Pegvisomant may decrease the neuromuscular blocking activities of Gallamine triethiodide.
Cisatracurium,Pegvisomant may decrease the neuromuscular blocking activities of Cisatracurium.
Rocuronium,Pegvisomant may decrease the neuromuscular blocking activities of Rocuronium.
Atracurium besylate,Pegvisomant may decrease the neuromuscular blocking activities of Atracurium besylate.
Mivacurium,Pegvisomant may decrease the neuromuscular blocking activities of Mivacurium.
Metocurine,Pegvisomant may decrease the neuromuscular blocking activities of Metocurine.
Pancuronium,Pegvisomant may decrease the neuromuscular blocking activities of Pancuronium.
Pipecuronium,Pegvisomant may decrease the neuromuscular blocking activities of Pipecuronium.
Vecuronium,Pegvisomant may decrease the neuromuscular blocking activities of Vecuronium.
Rapacuronium,Pegvisomant may decrease the neuromuscular blocking activities of Rapacuronium.
Atracurium,Pegvisomant may decrease the neuromuscular blocking activities of Atracurium.
Gallamine,Pegvisomant may decrease the neuromuscular blocking activities of Gallamine.
Alcuronium,Pegvisomant may decrease the neuromuscular blocking activities of Alcuronium.
Segesterone acetate,The metabolism of Segesterone acetate can be increased when combined with Pegvisomant.
Diethylstilbestrol,The metabolism of Diethylstilbestrol can be increased when combined with Pegvisomant.
Etonogestrel,The metabolism of Etonogestrel can be increased when combined with Pegvisomant.
Desogestrel,The metabolism of Desogestrel can be increased when combined with Pegvisomant.
Megestrol acetate,The metabolism of Megestrol acetate can be increased when combined with Pegvisomant.
Levonorgestrel,The metabolism of Levonorgestrel can be increased when combined with Pegvisomant.
Progesterone,The metabolism of Progesterone can be increased when combined with Pegvisomant.
Medroxyprogesterone acetate,The metabolism of Medroxyprogesterone acetate can be increased when combined with Pegvisomant.
Norethisterone,The metabolism of Norethisterone can be increased when combined with Pegvisomant.
Estradiol,The metabolism of Estradiol can be increased when combined with Pegvisomant.
Ethynodiol diacetate,The metabolism of Ethynodiol diacetate can be increased when combined with Pegvisomant.
Norgestimate,The metabolism of Norgestimate can be increased when combined with Pegvisomant.
Ethinylestradiol,The metabolism of Ethinylestradiol can be increased when combined with Pegvisomant.
Mestranol,The metabolism of Mestranol can be increased when combined with Pegvisomant.
Drospirenone,The metabolism of Drospirenone can be increased when combined with Pegvisomant.
p-Coumaric acid,The metabolism of p-Coumaric acid can be increased when combined with Pegvisomant.
Estrone sulfate,The metabolism of Estrone sulfate can be increased when combined with Pegvisomant.
Octylphenoxy polyethoxyethanol,The metabolism of Octylphenoxy polyethoxyethanol can be increased when combined with Pegvisomant.
Cyproterone acetate,The metabolism of Cyproterone acetate can be increased when combined with Pegvisomant.
Trestolone,The metabolism of Trestolone can be increased when combined with Pegvisomant.
Lonidamine,The metabolism of Lonidamine can be increased when combined with Pegvisomant.
Norelgestromin,The metabolism of Norelgestromin can be increased when combined with Pegvisomant.
Gestodene,The metabolism of Gestodene can be increased when combined with Pegvisomant.
Hydroxyprogesterone caproate,The metabolism of Hydroxyprogesterone caproate can be increased when combined with Pegvisomant.
Dienogest,The metabolism of Dienogest can be increased when combined with Pegvisomant.
Norethynodrel,The metabolism of Norethynodrel can be increased when combined with Pegvisomant.
Norgestrel,The metabolism of Norgestrel can be increased when combined with Pegvisomant.
Isosorbide,The metabolism of Isosorbide can be increased when combined with Pegvisomant.
Cloprostenol,The metabolism of Cloprostenol can be increased when combined with Pegvisomant.
Gestrinone,The metabolism of Gestrinone can be increased when combined with Pegvisomant.
Nomegestrol,The metabolism of Nomegestrol can be increased when combined with Pegvisomant.
Triptolide,The metabolism of Triptolide can be increased when combined with Pegvisomant.
Lynestrenol,The metabolism of Lynestrenol can be increased when combined with Pegvisomant.
Gossypol,The metabolism of Gossypol can be increased when combined with Pegvisomant.
Ormeloxifene,The metabolism of Ormeloxifene can be increased when combined with Pegvisomant.
Chlormadinone,The metabolism of Chlormadinone can be increased when combined with Pegvisomant.
Norgestrienone,The metabolism of Norgestrienone can be increased when combined with Pegvisomant.
Quingestanol,The metabolism of Quingestanol can be increased when combined with Pegvisomant.
Demegestone,The metabolism of Demegestone can be increased when combined with Pegvisomant.
Etynodiol,The metabolism of Etynodiol can be increased when combined with Pegvisomant.
Testosterone enanthate,The metabolism of Testosterone enanthate can be increased when combined with Pegvisomant.
Estradiol benzoate,The metabolism of Estradiol benzoate can be increased when combined with Pegvisomant.
Estradiol cypionate,The metabolism of Estradiol cypionate can be increased when combined with Pegvisomant.
Estradiol valerate,The metabolism of Estradiol valerate can be increased when combined with Pegvisomant.
Nomegestrol acetate,The metabolism of Nomegestrol acetate can be increased when combined with Pegvisomant.
Norethindrone enanthate,The metabolism of Norethindrone enanthate can be increased when combined with Pegvisomant.
Ulipristal,The metabolism of Ulipristal can be increased when combined with Pegvisomant.
Ziprasidone,The metabolism of Ziprasidone can be increased when combined with Pegvisomant.
Chlorpromazine,The metabolism of Chlorpromazine can be increased when combined with Pegvisomant.
Desipramine,The metabolism of Desipramine can be increased when combined with Pegvisomant.
Lorazepam,The metabolism of Lorazepam can be increased when combined with Pegvisomant.
Phentermine,The metabolism of Phentermine can be increased when combined with Pegvisomant.
Azithromycin,The metabolism of Azithromycin can be increased when combined with Pegvisomant.
Ticlopidine,The metabolism of Ticlopidine can be increased when combined with Pegvisomant.
Metoprolol,The metabolism of Metoprolol can be increased when combined with Pegvisomant.
Famciclovir,The metabolism of Famciclovir can be increased when combined with Pegvisomant.
Prochlorperazine,The metabolism of Prochlorperazine can be increased when combined with Pegvisomant.
Duloxetine,The metabolism of Duloxetine can be increased when combined with Pegvisomant.
Albendazole,The metabolism of Albendazole can be increased when combined with Pegvisomant.
Cephalexin,The metabolism of Cephalexin can be increased when combined with Pegvisomant.
Doxazosin,The metabolism of Doxazosin can be increased when combined with Pegvisomant.
Fenofibrate,The metabolism of Fenofibrate can be increased when combined with Pegvisomant.
Atazanavir,The metabolism of Atazanavir can be increased when combined with Pegvisomant.
St. John's Wort,The metabolism of St. John's Wort can be increased when combined with Pegvisomant.
Pranlukast,The metabolism of Pranlukast can be increased when combined with Pegvisomant.
Allylestrenol,The metabolism of Allylestrenol can be increased when combined with Pegvisomant.
Zuclopenthixol,The metabolism of Zuclopenthixol can be increased when combined with Pegvisomant.
Roflumilast,The metabolism of Roflumilast can be increased when combined with Pegvisomant.
Rufinamide,The metabolism of Rufinamide can be increased when combined with Pegvisomant.
Lacosamide,The metabolism of Lacosamide can be increased when combined with Pegvisomant.
Prucalopride,The metabolism of Prucalopride can be increased when combined with Pegvisomant.
Vorapaxar,The metabolism of Vorapaxar can be increased when combined with Pegvisomant.
Suvorexant,The metabolism of Suvorexant can be increased when combined with Pegvisomant.
Netupitant,The metabolism of Netupitant can be increased when combined with Pegvisomant.
Tasimelteon,The metabolism of Tasimelteon can be increased when combined with Pegvisomant.
Nintedanib,The metabolism of Nintedanib can be increased when combined with Pegvisomant.
Tenofovir alafenamide,The metabolism of Tenofovir alafenamide can be increased when combined with Pegvisomant.
Osimertinib,The metabolism of Osimertinib can be increased when combined with Pegvisomant.
Vitamin D,The metabolism of Vitamin D can be increased when combined with Pegvisomant.
Dihydroergocornine,The metabolism of Dihydroergocornine can be increased when combined with Pegvisomant.
Ribociclib,The metabolism of Ribociclib can be increased when combined with Pegvisomant.
Duvelisib,The metabolism of Duvelisib can be increased when combined with Pegvisomant.
Gilteritinib,The metabolism of Gilteritinib can be increased when combined with Pegvisomant.
9-aminocamptothecin,The metabolism of 9-aminocamptothecin can be increased when combined with Pegvisomant.
Methylprednisone,The metabolism of Methylprednisone can be increased when combined with Pegvisomant.
Dihydroergocristine,The metabolism of Dihydroergocristine can be increased when combined with Pegvisomant.
Dihydroergocryptine,The metabolism of Dihydroergocryptine can be increased when combined with Pegvisomant.
Medical Cannabis,The metabolism of Medical Cannabis can be increased when combined with Pegvisomant.
Tenofovir,The metabolism of Tenofovir can be increased when combined with Pegvisomant.
Rosuvastatin,The metabolism of Rosuvastatin can be increased when combined with Pegvisomant.
Zafirlukast,The metabolism of Zafirlukast can be increased when combined with Pegvisomant.
Elexacaftor,The metabolism of Elexacaftor can be increased when combined with Pegvisomant.
Tazemetostat,The metabolism of Tazemetostat can be increased when combined with Pegvisomant.
Fosaprepitant,The metabolism of Fosaprepitant can be increased when combined with Pegvisomant.
Lefamulin,The metabolism of Lefamulin can be increased when combined with Pegvisomant.
Methysergide,The metabolism of Methysergide can be increased when combined with Pegvisomant.
Astemizole,The metabolism of Astemizole can be increased when combined with Pegvisomant.
Lomitapide,The metabolism of Lomitapide can be increased when combined with Pegvisomant.
Ebastine,The metabolism of Ebastine can be increased when combined with Pegvisomant.
Siponimod,The metabolism of Siponimod can be increased when combined with Pegvisomant.
Clozapine,The metabolism of Clozapine can be increased when combined with Pegvisomant.
Cyclosporine,The metabolism of Cyclosporine can be increased when combined with Pegvisomant.
Dofetilide,The metabolism of Dofetilide can be increased when combined with Pegvisomant.
Theophylline,The metabolism of Theophylline can be increased when combined with Pegvisomant.
Terfenadine,The metabolism of Terfenadine can be increased when combined with Pegvisomant.
Levothyroxine,The metabolism of Levothyroxine can be increased when combined with Pegvisomant.
Carbamazepine,The metabolism of Carbamazepine can be increased when combined with Pegvisomant.
Cisapride,The metabolism of Cisapride can be increased when combined with Pegvisomant.
Tacrolimus,The metabolism of Tacrolimus can be increased when combined with Pegvisomant.
Sirolimus,The metabolism of Sirolimus can be increased when combined with Pegvisomant.
Quinidine,The metabolism of Quinidine can be increased when combined with Pegvisomant.
Phenprocoumon,The metabolism of Phenprocoumon can be increased when combined with Pegvisomant.
Busulfan,The metabolism of Busulfan can be increased when combined with Pegvisomant.
Pimozide,The metabolism of Pimozide can be increased when combined with Pegvisomant.
Amiodarone,The metabolism of Amiodarone can be increased when combined with Pegvisomant.
Aminophylline,The metabolism of Aminophylline can be increased when combined with Pegvisomant.
Paclitaxel,The metabolism of Paclitaxel can be increased when combined with Pegvisomant.
Dasatinib,The metabolism of Dasatinib can be increased when combined with Pegvisomant.
Fosphenytoin,The metabolism of Fosphenytoin can be increased when combined with Pegvisomant.
Digitoxin,The metabolism of Digitoxin can be increased when combined with Pegvisomant.
Everolimus,The metabolism of Everolimus can be increased when combined with Pegvisomant.
4-hydroxycoumarin,The metabolism of 4-hydroxycoumarin can be increased when combined with Pegvisomant.
Dronedarone,The metabolism of Dronedarone can be increased when combined with Pegvisomant.
Temsirolimus,The metabolism of Temsirolimus can be increased when combined with Pegvisomant.
Ibrutinib,The metabolism of Ibrutinib can be increased when combined with Pegvisomant.
Tianeptine,The metabolism of Tianeptine can be increased when combined with Pegvisomant.
Isavuconazole,The metabolism of Isavuconazole can be increased when combined with Pegvisomant.
Fluindione,The metabolism of Fluindione can be increased when combined with Pegvisomant.
Clorindione,The metabolism of Clorindione can be increased when combined with Pegvisomant.
Cobimetinib,The metabolism of Cobimetinib can be increased when combined with Pegvisomant.
Idelalisib,The metabolism of Idelalisib can be increased when combined with Pegvisomant.
Ceritinib,The metabolism of Ceritinib can be increased when combined with Pegvisomant.
Dacomitinib,The metabolism of Dacomitinib can be increased when combined with Pegvisomant.
Alpelisib,The metabolism of Alpelisib can be increased when combined with Pegvisomant.
Methotrexate,The metabolism of Methotrexate can be increased when combined with Pegvisomant.
Vinorelbine,The metabolism of Vinorelbine can be increased when combined with Pegvisomant.
Vincristine,The metabolism of Vincristine can be increased when combined with Pegvisomant.
Vinblastine,The metabolism of Vinblastine can be increased when combined with Pegvisomant.
Daunorubicin,The metabolism of Daunorubicin can be increased when combined with Pegvisomant.
Cytarabine,The metabolism of Cytarabine can be increased when combined with Pegvisomant.
Doxorubicin,The metabolism of Doxorubicin can be increased when combined with Pegvisomant.
Docetaxel,The metabolism of Docetaxel can be increased when combined with Pegvisomant.
Thiotepa,The metabolism of Thiotepa can be increased when combined with Pegvisomant.
Trabectedin,The metabolism of Trabectedin can be increased when combined with Pegvisomant.
Vandetanib,The metabolism of Vandetanib can be increased when combined with Pegvisomant.
Abiraterone,The metabolism of Abiraterone can be increased when combined with Pegvisomant.
Vemurafenib,The metabolism of Vemurafenib can be increased when combined with Pegvisomant.
Alectinib,The metabolism of Alectinib can be increased when combined with Pegvisomant.
Venetoclax,The metabolism of Venetoclax can be increased when combined with Pegvisomant.
Vinflunine,The metabolism of Vinflunine can be increased when combined with Pegvisomant.
Acalabrutinib,The metabolism of Acalabrutinib can be increased when combined with Pegvisomant.
Enasidenib,The metabolism of Enasidenib can be increased when combined with Pegvisomant.
Zanubrutinib,The metabolism of Zanubrutinib can be increased when combined with Pegvisomant.
Bortezomib,The metabolism of Bortezomib can be increased when combined with Pegvisomant.
Cabergoline,The metabolism of Cabergoline can be increased when combined with Pegvisomant.
Vindesine,The metabolism of Vindesine can be increased when combined with Pegvisomant.
Sorafenib,The metabolism of Sorafenib can be increased when combined with Pegvisomant.
Teniposide,The metabolism of Teniposide can be increased when combined with Pegvisomant.
Imatinib,The metabolism of Imatinib can be increased when combined with Pegvisomant.
Tamoxifen,The metabolism of Tamoxifen can be increased when combined with Pegvisomant.
Etoposide,The metabolism of Etoposide can be increased when combined with Pegvisomant.
Ixabepilone,The metabolism of Ixabepilone can be increased when combined with Pegvisomant.
Nilotinib,The metabolism of Nilotinib can be increased when combined with Pegvisomant.
Belinostat,The metabolism of Belinostat can be increased when combined with Pegvisomant.
Pazopanib,The metabolism of Pazopanib can be increased when combined with Pegvisomant.
Midostaurin,The metabolism of Midostaurin can be increased when combined with Pegvisomant.
Panobinostat,The metabolism of Panobinostat can be increased when combined with Pegvisomant.
Bosutinib,The metabolism of Bosutinib can be increased when combined with Pegvisomant.
Axitinib,The metabolism of Axitinib can be increased when combined with Pegvisomant.
Crizotinib,The metabolism of Crizotinib can be increased when combined with Pegvisomant.
Brentuximab vedotin,The metabolism of Brentuximab vedotin can be increased when combined with Pegvisomant.
Ruxolitinib,The metabolism of Ruxolitinib can be increased when combined with Pegvisomant.
Ponatinib,The metabolism of Ponatinib can be increased when combined with Pegvisomant.
Dabrafenib,The metabolism of Dabrafenib can be increased when combined with Pegvisomant.
Palbociclib,The metabolism of Palbociclib can be increased when combined with Pegvisomant.
Sonidegib,The metabolism of Sonidegib can be increased when combined with Pegvisomant.
Ixazomib,The metabolism of Ixazomib can be increased when combined with Pegvisomant.
Encorafenib,The metabolism of Encorafenib can be increased when combined with Pegvisomant.
Neratinib,The metabolism of Neratinib can be increased when combined with Pegvisomant.
Erdafitinib,The metabolism of Erdafitinib can be increased when combined with Pegvisomant.
Brigatinib,The metabolism of Brigatinib can be increased when combined with Pegvisomant.
Copanlisib,The metabolism of Copanlisib can be increased when combined with Pegvisomant.
Pexidartinib,The metabolism of Pexidartinib can be increased when combined with Pegvisomant.
Ivosidenib,The metabolism of Ivosidenib can be increased when combined with Pegvisomant.
Milnacipran,The metabolism of Milnacipran can be increased when combined with Pegvisomant.
Levomilnacipran,The metabolism of Levomilnacipran can be increased when combined with Pegvisomant.
Retapamulin,The metabolism of Retapamulin can be increased when combined with Pegvisomant.
Amifampridine,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Amifampridine.
Amlodipine,The metabolism of Amlodipine can be increased when combined with Pegvisomant.
Clonazepam,The metabolism of Clonazepam can be increased when combined with Pegvisomant.
Zolpidem,The metabolism of Zolpidem can be increased when combined with Pegvisomant.
Eszopiclone,The serum concentration of Eszopiclone can be decreased when it is combined with Pegvisomant.
Phenobarbital,The metabolism of Phenobarbital can be decreased when combined with Pegvisomant.
Propofol,The metabolism of Propofol can be decreased when combined with Pegvisomant.
Phenytoin,The metabolism of Phenytoin can be decreased when combined with Pegvisomant.
Lidocaine,The metabolism of Lidocaine can be decreased when combined with Pegvisomant.
Omeprazole,The metabolism of Omeprazole can be decreased when combined with Pegvisomant.
Clobazam,The metabolism of Clobazam can be decreased when combined with Pegvisomant.
Lansoprazole,The metabolism of Lansoprazole can be decreased when combined with Pegvisomant.
Cyclophosphamide,The metabolism of Cyclophosphamide can be decreased when combined with Pegvisomant.
Diclofenac,The metabolism of Diclofenac can be decreased when combined with Pegvisomant.
Tretinoin,The metabolism of Tretinoin can be decreased when combined with Pegvisomant.
Aminophenazone,The metabolism of Aminophenazone can be decreased when combined with Pegvisomant.
Antipyrine,The metabolism of Antipyrine can be decreased when combined with Pegvisomant.
Clotiazepam,The metabolism of Clotiazepam can be decreased when combined with Pegvisomant.
Etizolam,The metabolism of Etizolam can be decreased when combined with Pegvisomant.
Istradefylline,The metabolism of Istradefylline can be decreased when combined with Pegvisomant.
Imipramine,The metabolism of Imipramine can be decreased when combined with Pegvisomant.
Entrectinib,The metabolism of Entrectinib can be increased when combined with Pegvisomant.
Lemborexant,The serum concentration of Lemborexant can be decreased when it is combined with Pegvisomant.
Lumateperone,The serum concentration of Lumateperone can be decreased when it is combined with Pegvisomant.
Ranolazine,The metabolism of Ranolazine can be increased when combined with Pegvisomant.
Tramadol,The metabolism of Pegvisomant can be increased when combined with Tramadol.
Clindamycin,The metabolism of Clindamycin can be increased when combined with Pegvisomant.
Rimegepant,The metabolism of Rimegepant can be increased when combined with Pegvisomant.
Capmatinib,The serum concentration of Capmatinib can be decreased when it is combined with Pegvisomant.
Selpercatinib,The serum concentration of Selpercatinib can be decreased when it is combined with Pegvisomant.
Buprenorphine,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine,Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.
Dronabinol,Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.
Droperidol,Droperidol may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.
Hydrocodone,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine,Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.
Magnesium sulfate,The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Magnesium sulfate.
Metyrosine,Botulinum toxin type A may increase the sedative activities of Metyrosine.
Minocycline,Minocycline may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.
Mirtazapine,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone,Nabilone may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.
Paraldehyde,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel,Perampanel may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.
Pramipexole,Botulinum toxin type A may increase the sedative activities of Pramipexole.
Ropinirole,Botulinum toxin type A may increase the sedative activities of Ropinirole.
Rotigotine,Botulinum toxin type A may increase the sedative activities of Rotigotine.
Rufinamide,The risk or severity of adverse effects can be increased when Rufinamide is combined with Botulinum toxin type A.
Sodium oxybate,Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.
Suvorexant,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol,Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.
Thalidomide,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Succinylcholine,The therapeutic efficacy of Succinylcholine can be increased when used in combination with Botulinum toxin type A.
Decamethonium,The therapeutic efficacy of Decamethonium can be increased when used in combination with Botulinum toxin type A.
Pyrantel,The therapeutic efficacy of Pyrantel can be increased when used in combination with Botulinum toxin type A.
Neosaxitoxin,The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Botulinum toxin type A.
Methadone,The risk or severity of adverse effects can be increased when Methadone is combined with Botulinum toxin type A.
Tramadol,The risk or severity of adverse effects can be increased when Tramadol is combined with Botulinum toxin type A.
Trospium,The risk or severity of adverse effects can be increased when Trospium is combined with Botulinum toxin type A.
Oxyphenonium,The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Botulinum toxin type A.
Butabarbital,The risk or severity of adverse effects can be increased when Butabarbital is combined with Botulinum toxin type A.
Butalbital,The risk or severity of adverse effects can be increased when Butalbital is combined with Botulinum toxin type A.
Benzatropine,The risk or severity of adverse effects can be increased when Benzatropine is combined with Botulinum toxin type A.
Ziprasidone,The risk or severity of adverse effects can be increased when Ziprasidone is combined with Botulinum toxin type A.
Disopyramide,The risk or severity of adverse effects can be increased when Disopyramide is combined with Botulinum toxin type A.
Talbutal,The risk or severity of adverse effects can be increased when Talbutal is combined with Botulinum toxin type A.
Pentobarbital,The risk or severity of adverse effects can be increased when Pentobarbital is combined with Botulinum toxin type A.
Amitriptyline,The risk or severity of adverse effects can be increased when Amitriptyline is combined with Botulinum toxin type A.
Ipratropium,The risk or severity of adverse effects can be increased when Ipratropium is combined with Botulinum toxin type A.
Olanzapine,The risk or severity of adverse effects can be increased when Olanzapine is combined with Botulinum toxin type A.
Metixene,The risk or severity of adverse effects can be increased when Metixene is combined with Botulinum toxin type A.
Terfenadine,The risk or severity of adverse effects can be increased when Terfenadine is combined with Botulinum toxin type A.
Buclizine,The risk or severity of adverse effects can be increased when Buclizine is combined with Botulinum toxin type A.
Clozapine,The risk or severity of adverse effects can be increased when Clozapine is combined with Botulinum toxin type A.
Trihexyphenidyl,The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Botulinum toxin type A.
Oxyphencyclimine,The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Botulinum toxin type A.
Procyclidine,The risk or severity of adverse effects can be increased when Procyclidine is combined with Botulinum toxin type A.
Profenamine,The risk or severity of adverse effects can be increased when Profenamine is combined with Botulinum toxin type A.
Metocurine iodide,The risk or severity of adverse effects can be increased when Metocurine iodide is combined with Botulinum toxin type A.
Secobarbital,The risk or severity of adverse effects can be increased when Secobarbital is combined with Botulinum toxin type A.
Promazine,The risk or severity of adverse effects can be increased when Promazine is combined with Botulinum toxin type A.
Hyoscyamine,The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Botulinum toxin type A.
Cyproheptadine,The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Botulinum toxin type A.
Imipramine,The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum toxin type A.
Methscopolamine bromide,The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Botulinum toxin type A.
Metharbital,The risk or severity of adverse effects can be increased when Metharbital is combined with Botulinum toxin type A.
Fluoxetine,The risk or severity of adverse effects can be increased when Fluoxetine is combined with Botulinum toxin type A.
Chlorpromazine,The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Botulinum toxin type A.
Gallamine triethiodide,The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Botulinum toxin type A.
Darifenacin,The risk or severity of adverse effects can be increased when Darifenacin is combined with Botulinum toxin type A.
Tridihexethyl,The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Botulinum toxin type A.
Triflupromazine,The risk or severity of adverse effects can be increased when Triflupromazine is combined with Botulinum toxin type A.
Dextromethorphan,The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Botulinum toxin type A.
Anisotropine methylbromide,The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Botulinum toxin type A.
Nortriptyline,The risk or severity of adverse effects can be increased when Nortriptyline is combined with Botulinum toxin type A.
Amoxapine,The risk or severity of adverse effects can be increased when Amoxapine is combined with Botulinum toxin type A.
Lamotrigine,The risk or severity of adverse effects can be increased when Lamotrigine is combined with Botulinum toxin type A.
Cisatracurium,The risk or severity of adverse effects can be increased when Cisatracurium is combined with Botulinum toxin type A.
Atropine,The risk or severity of adverse effects can be increased when Atropine is combined with Botulinum toxin type A.
Thiopental,The risk or severity of adverse effects can be increased when Thiopental is combined with Botulinum toxin type A.
Nicardipine,The risk or severity of adverse effects can be increased when Nicardipine is combined with Botulinum toxin type A.
Mecamylamine,The risk or severity of adverse effects can be increased when Mecamylamine is combined with Botulinum toxin type A.
Pirenzepine,The risk or severity of adverse effects can be increased when Pirenzepine is combined with Botulinum toxin type A.
Paroxetine,The risk or severity of adverse effects can be increased when Paroxetine is combined with Botulinum toxin type A.
Procaine,The risk or severity of adverse effects can be increased when Procaine is combined with Botulinum toxin type A.
Homatropine methylbromide,The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Botulinum toxin type A.
Rocuronium,The risk or severity of adverse effects can be increased when Rocuronium is combined with Botulinum toxin type A.
Atracurium besylate,The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Botulinum toxin type A.
Scopolamine,The risk or severity of adverse effects can be increased when Scopolamine is combined with Botulinum toxin type A.
Isoflurane,The risk or severity of adverse effects can be increased when Isoflurane is combined with Botulinum toxin type A.
Benzquinamide,The risk or severity of adverse effects can be increased when Benzquinamide is combined with Botulinum toxin type A.
Clidinium,The risk or severity of adverse effects can be increased when Clidinium is combined with Botulinum toxin type A.
Propiomazine,The risk or severity of adverse effects can be increased when Propiomazine is combined with Botulinum toxin type A.
Propantheline,The risk or severity of adverse effects can be increased when Propantheline is combined with Botulinum toxin type A.
Primidone,The risk or severity of adverse effects can be increased when Primidone is combined with Botulinum toxin type A.
Dicyclomine,The risk or severity of adverse effects can be increased when Dicyclomine is combined with Botulinum toxin type A.
Biperiden,The risk or severity of adverse effects can be increased when Biperiden is combined with Botulinum toxin type A.
Brompheniramine,The risk or severity of adverse effects can be increased when Brompheniramine is combined with Botulinum toxin type A.
Methylphenobarbital,The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Botulinum toxin type A.
Flupentixol,The risk or severity of adverse effects can be increased when Flupentixol is combined with Botulinum toxin type A.
Cocaine,The risk or severity of adverse effects can be increased when Cocaine is combined with Botulinum toxin type A.
Quinidine,The risk or severity of adverse effects can be increased when Quinidine is combined with Botulinum toxin type A.
Amantadine,The risk or severity of adverse effects can be increased when Amantadine is combined with Botulinum toxin type A.
Maprotiline,The risk or severity of adverse effects can be increased when Maprotiline is combined with Botulinum toxin type A.
Methantheline,The risk or severity of adverse effects can be increased when Methantheline is combined with Botulinum toxin type A.
Hexafluronium,The risk or severity of adverse effects can be increased when Hexafluronium is combined with Botulinum toxin type A.
Cycrimine,The risk or severity of adverse effects can be increased when Cycrimine is combined with Botulinum toxin type A.
Desloratadine,The risk or severity of adverse effects can be increased when Desloratadine is combined with Botulinum toxin type A.
Glycopyrronium,The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Botulinum toxin type A.
Tolterodine,The risk or severity of adverse effects can be increased when Tolterodine is combined with Botulinum toxin type A.
Oxybutynin,The risk or severity of adverse effects can be increased when Oxybutynin is combined with Botulinum toxin type A.
Promethazine,The risk or severity of adverse effects can be increased when Promethazine is combined with Botulinum toxin type A.
Diphenhydramine,The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Botulinum toxin type A.
Pentolinium,The risk or severity of adverse effects can be increased when Pentolinium is combined with Botulinum toxin type A.
Trimethaphan,The risk or severity of adverse effects can be increased when Trimethaphan is combined with Botulinum toxin type A.
Doxacurium,The risk or severity of adverse effects can be increased when Doxacurium is combined with Botulinum toxin type A.
Doxepin,The risk or severity of adverse effects can be increased when Doxepin is combined with Botulinum toxin type A.
Flavoxate,The risk or severity of adverse effects can be increased when Flavoxate is combined with Botulinum toxin type A.
Desipramine,The risk or severity of adverse effects can be increased when Desipramine is combined with Botulinum toxin type A.
Chloroprocaine,The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Botulinum toxin type A.
Orphenadrine,The risk or severity of adverse effects can be increased when Orphenadrine is combined with Botulinum toxin type A.
Phenobarbital,The risk or severity of adverse effects can be increased when Phenobarbital is combined with Botulinum toxin type A.
Escitalopram,The risk or severity of adverse effects can be increased when Escitalopram is combined with Botulinum toxin type A.
Tubocurarine,The risk or severity of adverse effects can be increased when Tubocurarine is combined with Botulinum toxin type A.
Quetiapine,The risk or severity of adverse effects can be increased when Quetiapine is combined with Botulinum toxin type A.
Mivacurium,The risk or severity of adverse effects can be increased when Mivacurium is combined with Botulinum toxin type A.
Levacetylmethadol,The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Botulinum toxin type A.
Diphenidol,The risk or severity of adverse effects can be increased when Diphenidol is combined with Botulinum toxin type A.
Aripiprazole,The risk or severity of adverse effects can be increased when Aripiprazole is combined with Botulinum toxin type A.
Chlorprothixene,The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Botulinum toxin type A.
Fenoterol,The risk or severity of adverse effects can be increased when Fenoterol is combined with Botulinum toxin type A.
Metocurine,The risk or severity of adverse effects can be increased when Metocurine is combined with Botulinum toxin type A.
Pancuronium,The risk or severity of adverse effects can be increased when Pancuronium is combined with Botulinum toxin type A.
Pipecuronium,The risk or severity of adverse effects can be increased when Pipecuronium is combined with Botulinum toxin type A.
Vecuronium,The risk or severity of adverse effects can be increased when Vecuronium is combined with Botulinum toxin type A.
Amobarbital,The risk or severity of adverse effects can be increased when Amobarbital is combined with Botulinum toxin type A.
Aprobarbital,The risk or severity of adverse effects can be increased when Aprobarbital is combined with Botulinum toxin type A.
Butobarbital,The risk or severity of adverse effects can be increased when Butobarbital is combined with Botulinum toxin type A.
Heptabarbital,The risk or severity of adverse effects can be increased when Heptabarbital is combined with Botulinum toxin type A.
Hexobarbital,The risk or severity of adverse effects can be increased when Hexobarbital is combined with Botulinum toxin type A.
Methotrimeprazine,The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Botulinum toxin type A.
Tiotropium,The risk or severity of adverse effects can be increased when Tiotropium is combined with Botulinum toxin type A.
Barbital,The risk or severity of adverse effects can be increased when Barbital is combined with Botulinum toxin type A.
"Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione","The risk or severity of adverse effects can be increased when Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione is combined with Botulinum toxin type A."
Solifenacin,The risk or severity of adverse effects can be increased when Solifenacin is combined with Botulinum toxin type A.
Isopropamide,The risk or severity of adverse effects can be increased when Isopropamide is combined with Botulinum toxin type A.
Rapacuronium,The risk or severity of adverse effects can be increased when Rapacuronium is combined with Botulinum toxin type A.
Mepenzolate,The risk or severity of adverse effects can be increased when Mepenzolate is combined with Botulinum toxin type A.
Gantacurium,The risk or severity of adverse effects can be increased when Gantacurium is combined with Botulinum toxin type A.
Pizotifen,The risk or severity of adverse effects can be increased when Pizotifen is combined with Botulinum toxin type A.
Fesoterodine,The risk or severity of adverse effects can be increased when Fesoterodine is combined with Botulinum toxin type A.
Hexocyclium,The risk or severity of adverse effects can be increased when Hexocyclium is combined with Botulinum toxin type A.
Dimetindene,The risk or severity of adverse effects can be increased when Dimetindene is combined with Botulinum toxin type A.
Agmatine,The risk or severity of adverse effects can be increased when Agmatine is combined with Botulinum toxin type A.
Aclidinium,The risk or severity of adverse effects can be increased when Aclidinium is combined with Botulinum toxin type A.
Hexamethonium,The risk or severity of adverse effects can be increased when Hexamethonium is combined with Botulinum toxin type A.
Dexetimide,The risk or severity of adverse effects can be increased when Dexetimide is combined with Botulinum toxin type A.
Chlorphenoxamine,The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Botulinum toxin type A.
Benactyzine,The risk or severity of adverse effects can be increased when Benactyzine is combined with Botulinum toxin type A.
Umeclidinium,The risk or severity of adverse effects can be increased when Umeclidinium is combined with Botulinum toxin type A.
Trimebutine,The risk or severity of adverse effects can be increased when Trimebutine is combined with Botulinum toxin type A.
Dosulepin,The risk or severity of adverse effects can be increased when Dosulepin is combined with Botulinum toxin type A.
Imidafenacin,The risk or severity of adverse effects can be increased when Imidafenacin is combined with Botulinum toxin type A.
Butylscopolamine,The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Botulinum toxin type A.
Thonzylamine,The risk or severity of adverse effects can be increased when Thonzylamine is combined with Botulinum toxin type A.
Methscopolamine,The risk or severity of adverse effects can be increased when Methscopolamine is combined with Botulinum toxin type A.
Revefenacin,The risk or severity of adverse effects can be increased when Revefenacin is combined with Botulinum toxin type A.
Oxitropium,The risk or severity of adverse effects can be increased when Oxitropium is combined with Botulinum toxin type A.
Propiverine,The risk or severity of adverse effects can be increased when Propiverine is combined with Botulinum toxin type A.
Batefenterol,The risk or severity of adverse effects can be increased when Batefenterol is combined with Botulinum toxin type A.
Mebeverine,The risk or severity of adverse effects can be increased when Mebeverine is combined with Botulinum toxin type A.
Tropatepine,The risk or severity of adverse effects can be increased when Tropatepine is combined with Botulinum toxin type A.
Prifinium,The risk or severity of adverse effects can be increased when Prifinium is combined with Botulinum toxin type A.
Atracurium,The risk or severity of adverse effects can be increased when Atracurium is combined with Botulinum toxin type A.
Piperidolate,The risk or severity of adverse effects can be increased when Piperidolate is combined with Botulinum toxin type A.
Benzilone,The risk or severity of adverse effects can be increased when Benzilone is combined with Botulinum toxin type A.
Difemerine,The risk or severity of adverse effects can be increased when Difemerine is combined with Botulinum toxin type A.
Phenglutarimide,The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Botulinum toxin type A.
Mazaticol,The risk or severity of adverse effects can be increased when Mazaticol is combined with Botulinum toxin type A.
Etybenzatropine,The risk or severity of adverse effects can be increased when Etybenzatropine is combined with Botulinum toxin type A.
Otilonium,The risk or severity of adverse effects can be increased when Otilonium is combined with Botulinum toxin type A.
Emepronium,The risk or severity of adverse effects can be increased when Emepronium is combined with Botulinum toxin type A.
Poldine,The risk or severity of adverse effects can be increased when Poldine is combined with Botulinum toxin type A.
Bevonium,The risk or severity of adverse effects can be increased when Bevonium is combined with Botulinum toxin type A.
Rociverine,The risk or severity of adverse effects can be increased when Rociverine is combined with Botulinum toxin type A.
Gallamine,The risk or severity of adverse effects can be increased when Gallamine is combined with Botulinum toxin type A.
Bornaprine,The risk or severity of adverse effects can be increased when Bornaprine is combined with Botulinum toxin type A.
Etanautine,The risk or severity of adverse effects can be increased when Etanautine is combined with Botulinum toxin type A.
Alcuronium,The risk or severity of adverse effects can be increased when Alcuronium is combined with Botulinum toxin type A.
Tiemonium iodide,The risk or severity of adverse effects can be increased when Tiemonium iodide is combined with Botulinum toxin type A.
Dihexyverine,The risk or severity of adverse effects can be increased when Dihexyverine is combined with Botulinum toxin type A.
Penthienate,The risk or severity of adverse effects can be increased when Penthienate is combined with Botulinum toxin type A.
Diphemanil,The risk or severity of adverse effects can be increased when Diphemanil is combined with Botulinum toxin type A.
Camylofin,The risk or severity of adverse effects can be increased when Camylofin is combined with Botulinum toxin type A.
Fenpiverinium,The risk or severity of adverse effects can be increased when Fenpiverinium is combined with Botulinum toxin type A.
Emetonium iodide,The risk or severity of adverse effects can be increased when Emetonium iodide is combined with Botulinum toxin type A.
Pipenzolate,The risk or severity of adverse effects can be increased when Pipenzolate is combined with Botulinum toxin type A.
Timepidium,The risk or severity of adverse effects can be increased when Timepidium is combined with Botulinum toxin type A.
Ethanol,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine,Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.
Fluvoxamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fluvoxamine.
Citalopram,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Citalopram.
Duloxetine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Duloxetine.
Trazodone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trazodone.
Sertraline,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sertraline.
Sibutramine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sibutramine.
Nefazodone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nefazodone.
Zimelidine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zimelidine.
Dapoxetine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dapoxetine.
Milnacipran,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Milnacipran.
Desvenlafaxine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Desvenlafaxine.
Seproxetine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Seproxetine.
Levomilnacipran,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levomilnacipran.
Indalpine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Indalpine.
Ritanserin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ritanserin.
Alaproclate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alaproclate.
Zopiclone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zopiclone.
Tryptophan,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tryptophan.
Baclofen,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Baclofen.
Amphetamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Amphetamine.
Lorazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lorazepam.
Ethchlorvynol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethchlorvynol.
Reserpine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Reserpine.
Eletriptan,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eletriptan.
Enflurane,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Enflurane.
Temazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Temazepam.
Reboxetine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Reboxetine.
Methysergide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methysergide.
Cabergoline,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cabergoline.
Phenytoin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenytoin.
Topiramate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Topiramate.
Clemastine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clemastine.
Venlafaxine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Venlafaxine.
Atomoxetine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Atomoxetine.
Etomidate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etomidate.
Morphine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Morphine.
Valproic acid,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Valproic acid.
Zolmitriptan,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zolmitriptan.
Codeine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Codeine.
Dihydroergotamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dihydroergotamine.
Tolcapone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tolcapone.
Hydromorphone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Hydromorphone.
Cetirizine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cetirizine.
Protriptyline,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Protriptyline.
Trimethadione,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trimethadione.
Clobazam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clobazam.
Chlorzoxazone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlorzoxazone.
Meprobamate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Meprobamate.
Thiethylperazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiethylperazine.
Palonosetron,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Palonosetron.
Sulpiride,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sulpiride.
Alprazolam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alprazolam.
Dexbrompheniramine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dexbrompheniramine.
Loxapine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Loxapine.
Remoxipride,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Remoxipride.
Methocarbamol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methocarbamol.
Triprolidine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Triprolidine.
Prochlorperazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Prochlorperazine.
Meperidine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Meperidine.
Methohexital,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methohexital.
Chlordiazepoxide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlordiazepoxide.
Entacapone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Entacapone.
Oxycodone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxycodone.
Mephenytoin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mephenytoin.
Adinazolam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Adinazolam.
Carbamazepine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carbamazepine.
Fenfluramine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fenfluramine.
Mazindol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mazindol.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fluticasone propionate.
Lisuride,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lisuride.
Ethosuximide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethosuximide.
Linezolid,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Linezolid.
Cisapride,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cisapride.
Butorphanol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Butorphanol.
Furazolidone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Furazolidone.
Paramethadione,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Paramethadione.
Fluphenazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fluphenazine.
Efavirenz,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Efavirenz.
Clorazepic acid,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clorazepic acid.
Dexmedetomidine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dexmedetomidine.
Dyclonine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dyclonine.
Dextropropoxyphene,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dextropropoxyphene.
Pentazocine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pentazocine.
Metaxalone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Metaxalone.
Trimethobenzamide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trimethobenzamide.
Sumatriptan,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sumatriptan.
Thioridazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thioridazine.
Moricizine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Moricizine.
Midazolam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Midazolam.
Flurazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Flurazepam.
Ergotamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ergotamine.
Tizanidine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tizanidine.
Sufentanil,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sufentanil.
Apomorphine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Apomorphine.
Trimipramine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trimipramine.
Risperidone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Risperidone.
Meclizine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Meclizine.
Riluzole,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Riluzole.
Carbinoxamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carbinoxamine.
Tranylcypromine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tranylcypromine.
Ethotoin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethotoin.
Dolasetron,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dolasetron.
Oxcarbazepine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxcarbazepine.
Phenelzine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenelzine.
Halazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Halazepam.
Alfentanil,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alfentanil.
Minaprine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Minaprine.
Fentanyl,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fentanyl.
Propofol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Propofol.
Acetazolamide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Acetazolamide.
Diazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Diazepam.
Trifluoperazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trifluoperazine.
Phensuximide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phensuximide.
Progabide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Progabide.
Oxazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxazepam.
Donepezil,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Donepezil.
Nalbuphine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nalbuphine.
Perphenazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Perphenazine.
Levorphanol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levorphanol.
Benzphetamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benzphetamine.
Alprenolol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alprenolol.
Granisetron,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Granisetron.
Triazolam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Triazolam.
Remifentanil,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Remifentanil.
Ondansetron,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ondansetron.
Tiagabine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tiagabine.
Zonisamide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zonisamide.
Almotriptan,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Almotriptan.
Mesoridazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mesoridazine.
Diethylpropion,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Diethylpropion.
Felbamate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Felbamate.
Naratriptan,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Naratriptan.
Rizatriptan,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Rizatriptan.
Pindolol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pindolol.
Zaleplon,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zaleplon.
Alosetron,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alosetron.
Ramelteon,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ramelteon.
Dimenhydrinate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dimenhydrinate.
Gabapentin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Gabapentin.
Frovatriptan,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Frovatriptan.
Guanfacine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Guanfacine.
Methoxyflurane,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methoxyflurane.
Selegiline,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Selegiline.
Ergoloid mesylate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ergoloid mesylate.
Acetophenazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Acetophenazine.
Melatonin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Melatonin.
Clonazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clonazepam.
Vigabatrin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vigabatrin.
Diphenoxylate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Diphenoxylate.
Pimozide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pimozide.
Methyprylon,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methyprylon.
Chlorpheniramine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlorpheniramine.
Phenacemide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenacemide.
Thiamylal,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiamylal.
Bupropion,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bupropion.
Halothane,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Halothane.
Procarbazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Procarbazine.
Moclobemide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Moclobemide.
Cyclizine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cyclizine.
Chlormezanone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlormezanone.
Pergolide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pergolide.
Desflurane,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Desflurane.
Oxymorphone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxymorphone.
Bromocriptine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bromocriptine.
Levetiracetam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levetiracetam.
Dezocine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dezocine.
Estazolam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Estazolam.
Ketamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ketamine.
Levodopa,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levodopa.
Sevoflurane,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sevoflurane.
Clomipramine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clomipramine.
Alimemazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alimemazine.
Isocarboxazid,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Isocarboxazid.
Ergometrine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ergometrine.
Paliperidone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Paliperidone.
Fosphenytoin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fosphenytoin.
St. John's Wort,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with St. John's Wort.
Lithium cation,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lithium cation.
Penbutolol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Penbutolol.
Rasagiline,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Rasagiline.
Yohimbine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Yohimbine.
Methadyl acetate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methadyl acetate.
Glutethimide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Glutethimide.
gamma-Hydroxybutyric acid,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with gamma-Hydroxybutyric acid.
MMDA,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with MMDA.
Bufotenine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bufotenine.
Dihydroetorphine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dihydroetorphine.
Diamorphine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Diamorphine.
Midomafetamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Midomafetamine.
Fencamfamin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fencamfamin.
Ethylmorphine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethylmorphine.
4-Methoxyamphetamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 4-Methoxyamphetamine.
"4-Bromo-2,5-dimethoxyamphetamine","The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 4-Bromo-2,5-dimethoxyamphetamine."
Dimethyltryptamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dimethyltryptamine.
Camazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Camazepam.
Dichloralphenazone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dichloralphenazone.
Etorphine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etorphine.
Difenoxin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Difenoxin.
Tenamfetamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tenamfetamine.
Delorazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Delorazepam.
Dextromoramide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dextromoramide.
Desomorphine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Desomorphine.
Chlorhexadol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlorhexadol.
Carfentanil,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carfentanil.
Flunitrazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Flunitrazepam.
Ethyl loflazepate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethyl loflazepate.
Drotebanol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Drotebanol.
Dihydrocodeine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dihydrocodeine.
Cloxazolam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cloxazolam.
Alphacetylmethadol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alphacetylmethadol.
Bromazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bromazepam.
Clotiazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clotiazepam.
Cathinone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cathinone.
Chloral hydrate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chloral hydrate.
Dihydromorphine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dihydromorphine.
Fludiazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fludiazepam.
Metamfetamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Metamfetamine.
Oxprenolol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxprenolol.
Ketazolam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ketazolam.
Prazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Prazepam.
Quazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Quazepam.
Cinolazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cinolazepam.
Nitrazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nitrazepam.
Periciazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Periciazine.
Acepromazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Acepromazine.
Aceprometazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Aceprometazine.
Alverine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alverine.
Molindone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Molindone.
Pipotiazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pipotiazine.
Thioproperazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thioproperazine.
Thiothixene,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiothixene.
Zuclopenthixol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zuclopenthixol.
Pargyline,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pargyline.
Rolipram,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Rolipram.
7-Nitroindazole,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 7-Nitroindazole.
S-Ethylisothiourea,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with S-Ethylisothiourea.
Domoic Acid,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Domoic Acid.
Oxitriptan,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxitriptan.
Phencyclidine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phencyclidine.
Clorgiline,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clorgiline.
Valpromide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Valpromide.
Phenethylamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenethylamine.
Aniracetam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Aniracetam.
Iproniazid,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iproniazid.
Methapyrilene,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methapyrilene.
Nialamide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nialamide.
Nomifensine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nomifensine.
Urethane,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Urethane.
Lysergic acid diethylamide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lysergic acid diethylamide.
Methaqualone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methaqualone.
Amineptine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Amineptine.
Flunarizine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Flunarizine.
Fluspirilene,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fluspirilene.
Lorcaserin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lorcaserin.
Osanetant,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Osanetant.
Cilansetron,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cilansetron.
Bifeprunox,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bifeprunox.
Pagoclone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pagoclone.
Flibanserin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Flibanserin.
Renzapride,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Renzapride.
Iloperidone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iloperidone.
Ezogabine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ezogabine.
APD791,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with APD791.
Tetrodotoxin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tetrodotoxin.
Methsuximide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methsuximide.
Pimavanserin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pimavanserin.
Brivaracetam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brivaracetam.
Naronapride,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Naronapride.
Naluzotan,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Naluzotan.
PRX-08066,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with PRX-08066.
BL-1020,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with BL-1020.
Cariprazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cariprazine.
Lumateperone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lumateperone.
YKP-1358,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with YKP-1358.
Sertindole,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sertindole.
Mianserin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mianserin.
Asenapine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Asenapine.
Lacosamide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lacosamide.
Tolperisone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tolperisone.
Levocetirizine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levocetirizine.
Ziconotide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ziconotide.
Amisulpride,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Amisulpride.
Dotarizine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dotarizine.
Remacemide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Remacemide.
Clomethiazole,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clomethiazole.
Deramciclane,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Deramciclane.
Tramiprosate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tramiprosate.
Ocinaplon,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ocinaplon.
Gaboxadol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Gaboxadol.
Adipiplon,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Adipiplon.
Dextofisopam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dextofisopam.
Agomelatine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Agomelatine.
Safinamide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Safinamide.
Saredutant,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Saredutant.
Esmirtazapine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Esmirtazapine.
Vilazodone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vilazodone.
Nitrous oxide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nitrous oxide.
Mepyramine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mepyramine.
Dexmethylphenidate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dexmethylphenidate.
Fospropofol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fospropofol.
Ketobemidone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ketobemidone.
Triclofos,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Triclofos.
Benzyl alcohol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benzyl alcohol.
Mebutamate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mebutamate.
Wortmannin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Wortmannin.
Sulthiame,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sulthiame.
"7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline","The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline."
Cinitapride,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cinitapride.
Tofisopam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tofisopam.
Lurasidone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lurasidone.
Serotonin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Serotonin.
DPDPE,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with DPDPE.
Gabapentin enacarbil,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Gabapentin enacarbil.
Arbaclofen Placarbil,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Arbaclofen Placarbil.
Pomalidomide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pomalidomide.
Perospirone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Perospirone.
Amperozide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Amperozide.
Ifenprodil,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ifenprodil.
Etifoxine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etifoxine.
Eperisone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eperisone.
Dimetacrine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dimetacrine.
Cyamemazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cyamemazine.
Barbexaclone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Barbexaclone.
Beclamide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Beclamide.
Captodiame,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Captodiame.
Butriptyline,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Butriptyline.
Brotizolam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brotizolam.
Benzoctamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benzoctamine.
Vortioxetine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vortioxetine.
Tasimelteon,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tasimelteon.
Stiripentol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Stiripentol.
Eslicarbazepine acetate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eslicarbazepine acetate.
Brexpiprazole,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brexpiprazole.
Etizolam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etizolam.
Lofentanil,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lofentanil.
Edivoxetine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Edivoxetine.
Viloxazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Viloxazine.
Nisoxetine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nisoxetine.
Lortalamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lortalamine.
Talopram,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Talopram.
Etoperidone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etoperidone.
Blonanserin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Blonanserin.
Melperone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Melperone.
Zotepine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zotepine.
Brilaroxazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brilaroxazine.
Methylene blue,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methylene blue.
Hydracarbazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Hydracarbazine.
Pirlindole,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pirlindole.
Toloxatone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Toloxatone.
Benmoxin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benmoxin.
Iproclozide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iproclozide.
Mebanazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mebanazine.
Octamoxin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Octamoxin.
Pheniprazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pheniprazine.
Phenoxypropazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenoxypropazine.
Pivhydrazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pivhydrazine.
Safrazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Safrazine.
Caroxazone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Caroxazone.
Pipamperone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pipamperone.
Tianeptine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tianeptine.
Ramosetron,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ramosetron.
Oxaprotiline,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxaprotiline.
Opium,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Opium.
Alfaxalone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alfaxalone.
Azaperone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Azaperone.
Doramectin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Doramectin.
Medetomidine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Medetomidine.
Xylazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Xylazine.
Propiopromazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Propiopromazine.
Romifidine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Romifidine.
Tiletamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tiletamine.
Tricaine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tricaine.
Zolazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zolazepam.
Detomidine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Detomidine.
Thiocolchicoside,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiocolchicoside.
Normethadone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Normethadone.
Psilocybin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Psilocybin.
Mosapride,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mosapride.
Iferanserin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iferanserin.
Tropisetron,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tropisetron.
Tetrahydrocannabivarin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tetrahydrocannabivarin.
Brexanolone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brexanolone.
Etiracetam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etiracetam.
Lanicemine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lanicemine.
Idalopirdine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Idalopirdine.
Vabicaserin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vabicaserin.
Tetrahydropalmatine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tetrahydropalmatine.
Imagabalin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Imagabalin.
m-Chlorophenylpiperazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with m-Chlorophenylpiperazine.
MK-212,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with MK-212.
Vinpocetine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vinpocetine.
Sarpogrelate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sarpogrelate.
Eplivanserin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eplivanserin.
Gepirone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Gepirone.
Cerlapirdine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cerlapirdine.
Ecopipam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ecopipam.
Eltanolone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eltanolone.
Salvinorin A,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Salvinorin A.
Carisbamate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carisbamate.
Piclozotan,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Piclozotan.
Esreboxetine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Esreboxetine.
Bromperidol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bromperidol.
Orvepitant,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Orvepitant.
Ketanserin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ketanserin.
Piritramide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Piritramide.
Raclopride,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Raclopride.
Benzodiazepine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benzodiazepine.
AZD-3043,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with AZD-3043.
Indiplon,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Indiplon.
Urapidil,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Urapidil.
Perazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Perazine.
TD-8954,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with TD-8954.
Tandospirone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tandospirone.
Benperidol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benperidol.
Eltoprazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eltoprazine.
Opipramol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Opipramol.
Pivagabine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pivagabine.
Prothipendyl,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Prothipendyl.
Hypericin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Hypericin.
Tiapride,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tiapride.
Nefiracetam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nefiracetam.
Valnoctamide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Valnoctamide.
Amitriptylinoxide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Amitriptylinoxide.
Alphaprodine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alphaprodine.
Butaperazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Butaperazine.
Medifoxamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Medifoxamine.
Apronalide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Apronalide.
Dibenzepin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dibenzepin.
Propanidid,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Propanidid.
Quinupramine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Quinupramine.
Proxibarbal,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Proxibarbal.
Clothiapine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clothiapine.
Sultopride,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sultopride.
Febarbamate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Febarbamate.
Trichloroethylene,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trichloroethylene.
Tetrazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tetrazepam.
Pyrithyldione,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pyrithyldione.
Pinazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pinazepam.
Deanol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Deanol.
Phenprobamate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenprobamate.
Styramate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Styramate.
Pheneturide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pheneturide.
Bromisoval,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bromisoval.
Vinbarbital,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vinbarbital.
Chlorproethazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlorproethazine.
Melitracen,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Melitracen.
Neocitrullamon,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Neocitrullamon.
Acetylglycinamide chloral hydrate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Acetylglycinamide chloral hydrate.
Oxypertine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxypertine.
Lofepramine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lofepramine.
Fenyramidol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fenyramidol.
Thiazinam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiazinam.
Medazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Medazepam.
Phenibut,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenibut.
Oxaflozane,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxaflozane.
Meptazinol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Meptazinol.
Iprindole,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iprindole.
Metergoline,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Metergoline.
Mebicar,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mebicar.
Veralipride,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Veralipride.
Gedocarnil,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Gedocarnil.
Iprazochrome,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iprazochrome.
Bifemelane,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bifemelane.
Trifluperidol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trifluperidol.
Moperone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Moperone.
Thiopropazate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiopropazate.
Emylcamate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Emylcamate.
Allobarbital,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Allobarbital.
Naftidrofuryl,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Naftidrofuryl.
Diethyl ether,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Diethyl ether.
Oxiracetam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxiracetam.
Phenoperidine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenoperidine.
Phenazocine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenazocine.
Fabomotizole,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fabomotizole.
Pridinol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pridinol.
Loprazolam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Loprazolam.
Hexapropymate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Hexapropymate.
Fluanisone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fluanisone.
Mosapramine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mosapramine.
Niaprazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Niaprazine.
Vinyl ether,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vinyl ether.
Methylpentynol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methylpentynol.
Cyclobarbital,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cyclobarbital.
Fazadinium bromide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fazadinium bromide.
Mephenoxalone,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mephenoxalone.
Vinylbital,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vinylbital.
Imipramine oxide,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Imipramine oxide.
Dixyrazine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dixyrazine.
Tilidine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tilidine.
Penfluridol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Penfluridol.
Ethadione,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethadione.
Reposal,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Reposal.
Carbromal,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carbromal.
Doxefazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Doxefazepam.
Clopenthixol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clopenthixol.
Lormetazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lormetazepam.
Harmaline,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Harmaline.
Brofaromine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brofaromine.
"2,5-Dimethoxy-4-ethylthioamphetamine","The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 2,5-Dimethoxy-4-ethylthioamphetamine."
"N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine","The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine."
Cyclopropane,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cyclopropane.
MRK-409,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with MRK-409.
"5-methoxy-N,N-dimethyltryptamine","The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 5-methoxy-N,N-dimethyltryptamine."
Nordazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nordazepam.
Cannabidivarin,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cannabidivarin.
Aripiprazole lauroxil,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Aripiprazole lauroxil.
Lithium carbonate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lithium carbonate.
Eslicarbazepine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eslicarbazepine.
Perphenazine enanthate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Perphenazine enanthate.
Oxazepam acetate,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxazepam acetate.
Cinazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cinazepam.
Pyrazolam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pyrazolam.
Bentazepam,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bentazepam.
Solriamfetol,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Solriamfetol.
JNJ-26489112,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with JNJ-26489112.
"Carfentanil, C-11","The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carfentanil, C-11."
Lemborexant,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lemborexant.
Pregabalin,The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Pregabalin.
Lofexidine,The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Lofexidine.
Botulinum Toxin Type B,The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Botulinum toxin type A.
Nicotine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nicotine.
Tetraethylammonium,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tetraethylammonium.
Cyclopentamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cyclopentamine.
Cyclosporine,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Botulinum toxin type A.
Doxycycline,The risk or severity of adverse effects can be increased when Doxycycline is combined with Botulinum toxin type A.
Lymecycline,The risk or severity of adverse effects can be increased when Lymecycline is combined with Botulinum toxin type A.
Capreomycin,The risk or severity of adverse effects can be increased when Capreomycin is combined with Botulinum toxin type A.
Piperacillin,The risk or severity of adverse effects can be increased when Piperacillin is combined with Botulinum toxin type A.
Framycetin,The risk or severity of adverse effects can be increased when Framycetin is combined with Botulinum toxin type A.
Clomocycline,The risk or severity of adverse effects can be increased when Clomocycline is combined with Botulinum toxin type A.
Quinine,The risk or severity of adverse effects can be increased when Quinine is combined with Botulinum toxin type A.
Vancomycin,The risk or severity of adverse effects can be increased when Vancomycin is combined with Botulinum toxin type A.
Tigecycline,The risk or severity of adverse effects can be increased when Tigecycline is combined with Botulinum toxin type A.
Oxytetracycline,The risk or severity of adverse effects can be increased when Oxytetracycline is combined with Botulinum toxin type A.
Chloroquine,The risk or severity of adverse effects can be increased when Chloroquine is combined with Botulinum toxin type A.
Demeclocycline,The risk or severity of adverse effects can be increased when Demeclocycline is combined with Botulinum toxin type A.
Tobramycin,The risk or severity of adverse effects can be increased when Tobramycin is combined with Botulinum toxin type A.
Tetracycline,The risk or severity of adverse effects can be increased when Tetracycline is combined with Botulinum toxin type A.
Gentamicin,The risk or severity of adverse effects can be increased when Gentamicin is combined with Botulinum toxin type A.
Etacrynic acid,The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Botulinum toxin type A.
Metacycline,The risk or severity of adverse effects can be increased when Metacycline is combined with Botulinum toxin type A.
Netilmicin,The risk or severity of adverse effects can be increased when Netilmicin is combined with Botulinum toxin type A.
Neomycin,The risk or severity of adverse effects can be increased when Neomycin is combined with Botulinum toxin type A.
Procainamide,The risk or severity of adverse effects can be increased when Procainamide is combined with Botulinum toxin type A.
Streptomycin,The risk or severity of adverse effects can be increased when Streptomycin is combined with Botulinum toxin type A.
Colistimethate,The risk or severity of adverse effects can be increased when Colistimethate is combined with Botulinum toxin type A.
Kanamycin,The risk or severity of adverse effects can be increased when Kanamycin is combined with Botulinum toxin type A.
Clindamycin,The risk or severity of adverse effects can be increased when Clindamycin is combined with Botulinum toxin type A.
Dantrolene,The risk or severity of adverse effects can be increased when Dantrolene is combined with Botulinum toxin type A.
Rolitetracycline,The risk or severity of adverse effects can be increased when Rolitetracycline is combined with Botulinum toxin type A.
Magnesium oxide,The risk or severity of adverse effects can be increased when Magnesium oxide is combined with Botulinum toxin type A.
Magnesium cation,The risk or severity of adverse effects can be increased when Magnesium cation is combined with Botulinum toxin type A.
Paromomycin,The risk or severity of adverse effects can be increased when Paromomycin is combined with Botulinum toxin type A.
Lincomycin,The risk or severity of adverse effects can be increased when Lincomycin is combined with Botulinum toxin type A.
Ribostamycin,The risk or severity of adverse effects can be increased when Ribostamycin is combined with Botulinum toxin type A.
Geneticin,The risk or severity of adverse effects can be increased when Geneticin is combined with Botulinum toxin type A.
Apramycin,The risk or severity of adverse effects can be increased when Apramycin is combined with Botulinum toxin type A.
Gentamicin C1a,The risk or severity of adverse effects can be increased when Gentamicin C1a is combined with Botulinum toxin type A.
Neamine,The risk or severity of adverse effects can be increased when Neamine is combined with Botulinum toxin type A.
Arbekacin,The risk or severity of adverse effects can be increased when Arbekacin is combined with Botulinum toxin type A.
Viomycin,The risk or severity of adverse effects can be increased when Viomycin is combined with Botulinum toxin type A.
Puromycin,The risk or severity of adverse effects can be increased when Puromycin is combined with Botulinum toxin type A.
Magnesium hydroxide,The risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Botulinum toxin type A.
Magnesium trisilicate,The risk or severity of adverse effects can be increased when Magnesium trisilicate is combined with Botulinum toxin type A.
Magnesium chloride,The risk or severity of adverse effects can be increased when Magnesium chloride is combined with Botulinum toxin type A.
Magnesium acetate tetrahydrate,The risk or severity of adverse effects can be increased when Magnesium acetate tetrahydrate is combined with Botulinum toxin type A.
Magnesium carbonate,The risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Botulinum toxin type A.
Magnesium citrate,The risk or severity of adverse effects can be increased when Magnesium citrate is combined with Botulinum toxin type A.
Magnesium glycinate,The risk or severity of adverse effects can be increased when Magnesium glycinate is combined with Botulinum toxin type A.
Magnesium Aluminum Silicate,The risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Botulinum toxin type A.
Dihydrostreptomycin,The risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Botulinum toxin type A.
Hygromycin B,The risk or severity of adverse effects can be increased when Hygromycin B is combined with Botulinum toxin type A.
Sisomicin,The risk or severity of adverse effects can be increased when Sisomicin is combined with Botulinum toxin type A.
Plazomicin,The risk or severity of adverse effects can be increased when Plazomicin is combined with Botulinum toxin type A.
Magnesium silicate,The risk or severity of adverse effects can be increased when Magnesium silicate is combined with Botulinum toxin type A.
Penimepicycline,The risk or severity of adverse effects can be increased when Penimepicycline is combined with Botulinum toxin type A.
Dibekacin,The risk or severity of adverse effects can be increased when Dibekacin is combined with Botulinum toxin type A.
Micronomicin,The risk or severity of adverse effects can be increased when Micronomicin is combined with Botulinum toxin type A.
Magnesium aspartate,The risk or severity of adverse effects can be increased when Magnesium aspartate is combined with Botulinum toxin type A.
Isepamicin,The risk or severity of adverse effects can be increased when Isepamicin is combined with Botulinum toxin type A.
Bekanamycin,The risk or severity of adverse effects can be increased when Bekanamycin is combined with Botulinum toxin type A.
Magnesium gluconate,The risk or severity of adverse effects can be increased when Magnesium gluconate is combined with Botulinum toxin type A.
Magnesium orotate,The risk or severity of adverse effects can be increased when Magnesium orotate is combined with Botulinum toxin type A.
Magnesium phosphate,The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Botulinum toxin type A.
Magnesium acetate,The risk or severity of adverse effects can be increased when Magnesium acetate is combined with Botulinum toxin type A.
SLV319,The risk or severity of adverse effects can be increased when SLV319 is combined with Botulinum toxin type A.
Rimonabant,The risk or severity of adverse effects can be increased when Rimonabant is combined with Botulinum toxin type A.
Taranabant,The risk or severity of adverse effects can be increased when Taranabant is combined with Botulinum toxin type A.
Cannabidiol,The risk or severity of adverse effects can be increased when Cannabidiol is combined with Botulinum toxin type A.
GW842166,The risk or severity of adverse effects can be increased when GW842166 is combined with Botulinum toxin type A.
Ajulemic acid,The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Botulinum toxin type A.
Ibipinabant,The risk or severity of adverse effects can be increased when Ibipinabant is combined with Botulinum toxin type A.
Surinabant,The risk or severity of adverse effects can be increased when Surinabant is combined with Botulinum toxin type A.
WIN 55212-2,The risk or severity of adverse effects can be increased when WIN 55212-2 is combined with Botulinum toxin type A.
Nabiximols,The risk or severity of adverse effects can be increased when Nabiximols is combined with Botulinum toxin type A.
Palmidrol,The risk or severity of adverse effects can be increased when Palmidrol is combined with Botulinum toxin type A.
Cannabinol,The risk or severity of adverse effects can be increased when Cannabinol is combined with Botulinum toxin type A.
Esketamine,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Esketamine.
Carisoprodol,The risk or severity of adverse effects can be increased when Carisoprodol is combined with Botulinum toxin type A.
Naltrexone,The risk or severity of respiratory depression can be increased when Naltrexone is combined with Botulinum toxin type A.
Bezitramide,The risk or severity of respiratory depression can be increased when Bezitramide is combined with Botulinum toxin type A.
Eluxadoline,The risk or severity of respiratory depression can be increased when Eluxadoline is combined with Botulinum toxin type A.
Nicomorphine,The risk or severity of respiratory depression can be increased when Nicomorphine is combined with Botulinum toxin type A.
Benzhydrocodone,The risk or severity of respiratory depression can be increased when Benzhydrocodone is combined with Botulinum toxin type A.
Eszopiclone,The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Eszopiclone.
Clonidine,The risk or severity of sedation can be increased when Clonidine is combined with Botulinum toxin type A.
Cyclobenzaprine,The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Cyclobenzaprine.
Metoclopramide,The risk or severity of sedation can be increased when Metoclopramide is combined with Botulinum toxin type A.
Lasmiditan,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lasmiditan.
Magnesium,Magnesium can cause a decrease in the absorption of Botulinum toxin type A resulting in a reduced serum concentration and potentially a decrease in efficacy.
Haloperidol,The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Haloperidol.
Nitroprusside,Pancrelipase can cause a decrease in the absorption of Nitroprusside resulting in a reduced serum concentration and potentially a decrease in efficacy.
Prussian blue,Pancrelipase can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron sucrose,Pancrelipase can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric ammonium citrate,Pancrelipase can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferumoxsil,Pancrelipase can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferumoxides,Pancrelipase can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric sulfate,Pancrelipase can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous bisglycinate,Pancrelipase can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gleptoferron,Pancrelipase can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric oxide,Pancrelipase can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron isomaltoside 1000,Pancrelipase can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.
Perflubutane,Pancrelipase can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous sulfate anhydrous,Pancrelipase can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sodium feredetate,Pancrelipase can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric hydroxide,Pancrelipase can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous chloride,Pancrelipase can cause a decrease in the absorption of Ferrous chloride resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric cation,Pancrelipase can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous gluconate,Pancrelipase can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous succinate,Pancrelipase can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous fumarate,Pancrelipase can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tetraferric tricitrate decahydrate,Pancrelipase can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric oxyhydroxide,Pancrelipase can cause a decrease in the absorption of Ferric oxyhydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric maltol,Pancrelipase can cause a decrease in the absorption of Ferric maltol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Apixaban,Apixaban may increase the anticoagulant activities of Streptokinase.
Dabigatran etexilate,Dabigatran etexilate may increase the anticoagulant activities of Streptokinase.
Dasatinib,The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Streptokinase.
Deferasirox,The risk or severity of gastrointestinal bleeding can be increased when Streptokinase is combined with Deferasirox.
Ursodeoxycholic acid,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Glycochenodeoxycholic Acid.
Cholic Acid,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Cholic Acid.
Glycocholic acid,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Glycocholic acid.
Deoxycholic acid,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Deoxycholic acid.
Taurocholic acid,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Taurocholic acid.
Obeticholic acid,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Obeticholic acid.
Chenodeoxycholic acid,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Tauroursodeoxycholic acid.
Bamet-UD2,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Bamet-UD2.
Dehydrocholic acid,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Dehydrocholic acid.
Hyodeoxycholic Acid,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Hyodeoxycholic Acid.
Edoxaban,The risk or severity of bleeding can be increased when Edoxaban is combined with Streptokinase.
Ibrutinib,The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Streptokinase.
Obinutuzumab,The risk or severity of bleeding and hemorrhage can be increased when Streptokinase is combined with Obinutuzumab.
Rivaroxaban,Streptokinase may increase the anticoagulant activities of Rivaroxaban.
Sugammadex,The risk or severity of bleeding and hemorrhage can be increased when Streptokinase is combined with Sugammadex.
Tibolone,Tibolone may increase the anticoagulant activities of Streptokinase.
Tipranavir,The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Streptokinase.
Urokinase,Urokinase may increase the anticoagulant activities of Streptokinase.
Vitamin E,Vitamin E may increase the anticoagulant activities of Streptokinase.
Vorapaxar,The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Streptokinase.
Aprotinin,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Aprotinin.
Duloxetine,The risk or severity of orthostatic hypotension and syncope can be increased when Streptokinase is combined with Duloxetine.
Levodopa,The risk or severity of hypotension and orthostatic hypotension can be increased when Streptokinase is combined with Levodopa.
Risperidone,Streptokinase may increase the hypotensive activities of Risperidone.
Ginkgo biloba,The therapeutic efficacy of Streptokinase can be increased when used in combination with Ginkgo biloba.
Ifosfamide,The risk or severity of bleeding can be increased when Ifosfamide is combined with Streptokinase.
Quinine,The therapeutic efficacy of Streptokinase can be increased when used in combination with Quinine.
Quinidine,The therapeutic efficacy of Streptokinase can be increased when used in combination with Quinidine.
Tamoxifen,The risk or severity of bleeding can be increased when Tamoxifen is combined with Streptokinase.
Toremifene,The risk or severity of bleeding can be increased when Toremifene is combined with Streptokinase.
Ardeparin,Streptokinase may increase the anticoagulant activities of Ardeparin.
Heparin,Streptokinase may increase the anticoagulant activities of Heparin.
Enoxaparin,Streptokinase may increase the anticoagulant activities of Enoxaparin.
Sulodexide,Streptokinase may increase the anticoagulant activities of Sulodexide.
Semuloparin,Streptokinase may increase the anticoagulant activities of Semuloparin.
Danaparoid,Streptokinase may increase the anticoagulant activities of Danaparoid.
Dalteparin,Streptokinase may increase the anticoagulant activities of Dalteparin.
Tinzaparin,Streptokinase may increase the anticoagulant activities of Tinzaparin.
Nadroparin,Streptokinase may increase the anticoagulant activities of Nadroparin.
Bemiparin,Streptokinase may increase the anticoagulant activities of Bemiparin.
Reviparin,Streptokinase may increase the anticoagulant activities of Reviparin.
Parnaparin,Streptokinase may increase the anticoagulant activities of Parnaparin.
Certoparin,Streptokinase may increase the anticoagulant activities of Certoparin.
Pentoxifylline,The therapeutic efficacy of Streptokinase can be increased when used in combination with Pentoxifylline.
Pentosan polysulfate,Pentosan polysulfate may increase the anticoagulant activities of Streptokinase.
Levocarnitine,The therapeutic efficacy of Streptokinase can be increased when used in combination with Levocarnitine.
Aripiprazole,Aripiprazole may increase the hypotensive activities of Streptokinase.
Aripiprazole lauroxil,Aripiprazole lauroxil may increase the hypotensive activities of Streptokinase.
Nicorandil,Nicorandil may increase the hypotensive activities of Streptokinase.
Diethylstilbestrol,Diethylstilbestrol may decrease the anticoagulant activities of Streptokinase.
Chlorotrianisene,Chlorotrianisene may decrease the anticoagulant activities of Streptokinase.
Conjugated estrogens,Conjugated estrogens may decrease the anticoagulant activities of Streptokinase.
Estradiol,Estradiol may decrease the anticoagulant activities of Streptokinase.
Ethinylestradiol,Ethinylestradiol may decrease the anticoagulant activities of Streptokinase.
Mestranol,Mestranol may decrease the anticoagulant activities of Streptokinase.
Estriol,Estriol may decrease the anticoagulant activities of Streptokinase.
Estrone sulfate,Estrone sulfate may decrease the anticoagulant activities of Streptokinase.
Quinestrol,Quinestrol may decrease the anticoagulant activities of Streptokinase.
Hexestrol,Hexestrol may decrease the anticoagulant activities of Streptokinase.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Streptokinase."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Streptokinase."
Polyestradiol phosphate,Polyestradiol phosphate may decrease the anticoagulant activities of Streptokinase.
Esterified estrogens,Esterified estrogens may decrease the anticoagulant activities of Streptokinase.
Zeranol,Zeranol may decrease the anticoagulant activities of Streptokinase.
Equol,Equol may decrease the anticoagulant activities of Streptokinase.
Promestriene,Promestriene may decrease the anticoagulant activities of Streptokinase.
Methallenestril,Methallenestril may decrease the anticoagulant activities of Streptokinase.
Epimestrol,Epimestrol may decrease the anticoagulant activities of Streptokinase.
Moxestrol,Moxestrol may decrease the anticoagulant activities of Streptokinase.
Estradiol acetate,Estradiol acetate may decrease the anticoagulant activities of Streptokinase.
Estradiol benzoate,Estradiol benzoate may decrease the anticoagulant activities of Streptokinase.
Estradiol cypionate,Estradiol cypionate may decrease the anticoagulant activities of Streptokinase.
Estradiol valerate,Estradiol valerate may decrease the anticoagulant activities of Streptokinase.
Biochanin A,Biochanin A may decrease the anticoagulant activities of Streptokinase.
Formononetin,Formononetin may decrease the anticoagulant activities of Streptokinase.
Icosapent,The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Streptokinase.
Mesalazine,The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Streptokinase.
Indomethacin,The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Streptokinase.
Nabumetone,The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Streptokinase.
Ketorolac,The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Streptokinase.
Tenoxicam,The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Streptokinase.
Celecoxib,The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Streptokinase.
Tolmetin,The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Streptokinase.
Rofecoxib,The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Streptokinase.
Piroxicam,The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Streptokinase.
Fenoprofen,The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Streptokinase.
Valdecoxib,The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Streptokinase.
Diclofenac,The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Streptokinase.
Sulindac,The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Streptokinase.
Flurbiprofen,The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Streptokinase.
Etodolac,The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Streptokinase.
Mefenamic acid,The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Streptokinase.
Naproxen,The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Streptokinase.
Sulfasalazine,The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Streptokinase.
Phenylbutazone,The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Streptokinase.
Meloxicam,The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Streptokinase.
Carprofen,The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Streptokinase.
Diflunisal,The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Streptokinase.
Salicylic acid,The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Streptokinase.
Meclofenamic acid,The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Streptokinase.
Oxaprozin,The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Streptokinase.
Ketoprofen,The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Streptokinase.
Balsalazide,The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Streptokinase.
Olsalazine,The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Streptokinase.
Lumiracoxib,The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Streptokinase.
Magnesium salicylate,The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Streptokinase.
Salsalate,The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Streptokinase.
Choline magnesium trisalicylate,The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Streptokinase.
Antrafenine,The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Streptokinase.
Aminophenazone,The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Streptokinase.
Antipyrine,The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Streptokinase.
Tiaprofenic acid,The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Streptokinase.
Etoricoxib,The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Streptokinase.
Taxifolin,The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Streptokinase.
Oxyphenbutazone,The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Streptokinase.
Niflumic acid,The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Streptokinase.
Licofelone,The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Streptokinase.
Benoxaprofen,The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Streptokinase.
Metamizole,The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Streptokinase.
Zomepirac,The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Streptokinase.
Cimicoxib,The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Streptokinase.
Lornoxicam,The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Streptokinase.
Aceclofenac,The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Streptokinase.
Zaltoprofen,The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Streptokinase.
Azapropazone,The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Streptokinase.
Felbinac,The risk or severity of bleeding and hemorrhage can be increased when Felbinac is combined with Streptokinase.
Parecoxib,The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Streptokinase.
Salicylamide,The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Streptokinase.
Kebuzone,The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Streptokinase.
Isoxicam,The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Streptokinase.
Indoprofen,The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Streptokinase.
Ibuproxam,The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Streptokinase.
Floctafenine,The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Streptokinase.
Fenbufen,The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Streptokinase.
Etofenamate,The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Streptokinase.
Epirizole,The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Streptokinase.
Benzydamine,The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Streptokinase.
Loxoprofen,The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Streptokinase.
Dexketoprofen,The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Streptokinase.
Droxicam,The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Streptokinase.
Tolfenamic acid,The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Streptokinase.
Firocoxib,The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Streptokinase.
Clonixin,The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Streptokinase.
Morniflumate,The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Streptokinase.
Propacetamol,The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Streptokinase.
Talniflumate,The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Streptokinase.
Robenacoxib,The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Streptokinase.
Tepoxalin,The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Streptokinase.
Flunixin,The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Streptokinase.
Polmacoxib,The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Streptokinase.
Betulinic Acid,The risk or severity of bleeding and hemorrhage can be increased when Betulinic Acid is combined with Streptokinase.
Ebselen,The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Streptokinase.
Tinoridine,The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Streptokinase.
Alclofenac,The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Streptokinase.
Fentiazac,The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Streptokinase.
Suxibuzone,The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Streptokinase.
Bumadizone,The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Streptokinase.
Alminoprofen,The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Streptokinase.
Flunoxaprofen,The risk or severity of bleeding and hemorrhage can be increased when Flunoxaprofen is combined with Streptokinase.
Feprazone,The risk or severity of bleeding and hemorrhage can be increased when Feprazone is combined with Streptokinase.
Difenpiramide,The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Streptokinase.
Nifenazone,The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Streptokinase.
Lonazolac,The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Streptokinase.
Tenidap,The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Streptokinase.
Bendazac,The risk or severity of bleeding and hemorrhage can be increased when Bendazac is combined with Streptokinase.
Pranoprofen,The risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Streptokinase.
Propyphenazone,The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Streptokinase.
Proglumetacin,The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Streptokinase.
Guacetisal,The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Streptokinase.
Ethenzamide,The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Streptokinase.
Carbaspirin calcium,The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Streptokinase.
Mofebutazone,The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Streptokinase.
Proquazone,The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Streptokinase.
Benorilate,The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Streptokinase.
Pirprofen,The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Streptokinase.
Imidazole salicylate,The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Streptokinase.
SC-236,The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Streptokinase.
NS-398,The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Streptokinase.
Flurbiprofen axetil,The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Streptokinase.
Omacetaxine mepesuccinate,The risk or severity of bleeding can be increased when Streptokinase is combined with Omacetaxine mepesuccinate.
Omega-3 fatty acids,Omega-3 fatty acids may increase the anticoagulant activities of Streptokinase.
Tositumomab,The risk or severity of bleeding and hemorrhage can be increased when Streptokinase is combined with Tositumomab.
Limaprost,The risk or severity of adverse effects can be increased when Limaprost is combined with Streptokinase.
Collagenase clostridium histolyticum,The risk or severity of adverse effects can be increased when Streptokinase is combined with Collagenase clostridium histolyticum.
Carbimazole,Carbimazole may increase the anticoagulant activities of Streptokinase.
Propylthiouracil,Propylthiouracil may increase the anticoagulant activities of Streptokinase.
Methimazole,Methimazole may increase the anticoagulant activities of Streptokinase.
"3,5-Diiodotyrosine","3,5-Diiodotyrosine may increase the anticoagulant activities of Streptokinase."
Potassium Iodide,Potassium Iodide may increase the anticoagulant activities of Streptokinase.
Dibromotyrosine,Dibromotyrosine may increase the anticoagulant activities of Streptokinase.
Potassium perchlorate,Potassium perchlorate may increase the anticoagulant activities of Streptokinase.
Methylthiouracil,Methylthiouracil may increase the anticoagulant activities of Streptokinase.
Benzylthiouracil,Benzylthiouracil may increase the anticoagulant activities of Streptokinase.
Mifepristone,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Mifepristone.
p-Coumaric acid,The therapeutic efficacy of Streptokinase can be decreased when used in combination with p-Coumaric acid.
Octylphenoxy polyethoxyethanol,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Octylphenoxy polyethoxyethanol.
Trestolone,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Trestolone.
Lonidamine,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Lonidamine.
Ulipristal,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ulipristal.
Isosorbide,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Isosorbide.
Cloprostenol,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cloprostenol.
Triptolide,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Triptolide.
Gossypol,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Gossypol.
Ormeloxifene,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ormeloxifene.
Amphetamine,Amphetamine may increase the orthostatic hypotensive activities of Streptokinase.
Linezolid,Linezolid may increase the orthostatic hypotensive activities of Streptokinase.
Furazolidone,Furazolidone may increase the orthostatic hypotensive activities of Streptokinase.
Procaine,Procaine may increase the orthostatic hypotensive activities of Streptokinase.
Tranylcypromine,Tranylcypromine may increase the orthostatic hypotensive activities of Streptokinase.
Phenelzine,Phenelzine may increase the orthostatic hypotensive activities of Streptokinase.
Minaprine,Minaprine may increase the orthostatic hypotensive activities of Streptokinase.
Selegiline,Selegiline may increase the orthostatic hypotensive activities of Streptokinase.
Procarbazine,Procarbazine may increase the orthostatic hypotensive activities of Streptokinase.
Moclobemide,Moclobemide may increase the orthostatic hypotensive activities of Streptokinase.
Isocarboxazid,Isocarboxazid may increase the orthostatic hypotensive activities of Streptokinase.
Rasagiline,Rasagiline may increase the orthostatic hypotensive activities of Streptokinase.
Pargyline,Pargyline may increase the orthostatic hypotensive activities of Streptokinase.
Clorgiline,Clorgiline may increase the orthostatic hypotensive activities of Streptokinase.
Iproniazid,Iproniazid may increase the orthostatic hypotensive activities of Streptokinase.
Nialamide,Nialamide may increase the orthostatic hypotensive activities of Streptokinase.
Safinamide,Safinamide may increase the orthostatic hypotensive activities of Streptokinase.
"7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline","7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the orthostatic hypotensive activities of Streptokinase."
Methylene blue,Methylene blue may increase the orthostatic hypotensive activities of Streptokinase.
Hydracarbazine,Hydracarbazine may increase the orthostatic hypotensive activities of Streptokinase.
Pirlindole,Pirlindole may increase the orthostatic hypotensive activities of Streptokinase.
Toloxatone,Toloxatone may increase the orthostatic hypotensive activities of Streptokinase.
Benmoxin,Benmoxin may increase the orthostatic hypotensive activities of Streptokinase.
Mebanazine,Mebanazine may increase the orthostatic hypotensive activities of Streptokinase.
Octamoxin,Octamoxin may increase the orthostatic hypotensive activities of Streptokinase.
Pheniprazine,Pheniprazine may increase the orthostatic hypotensive activities of Streptokinase.
Phenoxypropazine,Phenoxypropazine may increase the orthostatic hypotensive activities of Streptokinase.
Pivhydrazine,Pivhydrazine may increase the orthostatic hypotensive activities of Streptokinase.
Safrazine,Safrazine may increase the orthostatic hypotensive activities of Streptokinase.
Caroxazone,Caroxazone may increase the orthostatic hypotensive activities of Streptokinase.
Harmaline,Harmaline may increase the orthostatic hypotensive activities of Streptokinase.
Brofaromine,Brofaromine may increase the orthostatic hypotensive activities of Streptokinase.
Etonogestrel,Etonogestrel may decrease the anticoagulant activities of Streptokinase.
Desogestrel,Desogestrel may decrease the anticoagulant activities of Streptokinase.
Megestrol acetate,Megestrol acetate may decrease the anticoagulant activities of Streptokinase.
Levonorgestrel,Levonorgestrel may decrease the anticoagulant activities of Streptokinase.
Dydrogesterone,Dydrogesterone may decrease the anticoagulant activities of Streptokinase.
Progesterone,Progesterone may decrease the anticoagulant activities of Streptokinase.
Medroxyprogesterone acetate,Medroxyprogesterone acetate may decrease the anticoagulant activities of Streptokinase.
Norethisterone,Norethisterone may decrease the anticoagulant activities of Streptokinase.
Ethynodiol diacetate,Ethynodiol diacetate may decrease the anticoagulant activities of Streptokinase.
Norgestimate,Norgestimate may decrease the anticoagulant activities of Streptokinase.
Drospirenone,Drospirenone may decrease the anticoagulant activities of Streptokinase.
Allylestrenol,Allylestrenol may decrease the anticoagulant activities of Streptokinase.
Cyproterone acetate,Cyproterone acetate may decrease the anticoagulant activities of Streptokinase.
Norelgestromin,Norelgestromin may decrease the anticoagulant activities of Streptokinase.
Gestodene,Gestodene may decrease the anticoagulant activities of Streptokinase.
Hydroxyprogesterone caproate,Hydroxyprogesterone caproate may decrease the anticoagulant activities of Streptokinase.
Dienogest,Dienogest may decrease the anticoagulant activities of Streptokinase.
Medrogestone,Medrogestone may decrease the anticoagulant activities of Streptokinase.
Norethynodrel,Norethynodrel may decrease the anticoagulant activities of Streptokinase.
Norgestrel,Norgestrel may decrease the anticoagulant activities of Streptokinase.
Altrenogest,Altrenogest may decrease the anticoagulant activities of Streptokinase.
Gestrinone,Gestrinone may decrease the anticoagulant activities of Streptokinase.
Nomegestrol,Nomegestrol may decrease the anticoagulant activities of Streptokinase.
Lynestrenol,Lynestrenol may decrease the anticoagulant activities of Streptokinase.
Gestonorone,Gestonorone may decrease the anticoagulant activities of Streptokinase.
Chlormadinone,Chlormadinone may decrease the anticoagulant activities of Streptokinase.
Methylestrenolone,Methylestrenolone may decrease the anticoagulant activities of Streptokinase.
Norgestrienone,Norgestrienone may decrease the anticoagulant activities of Streptokinase.
Promegestone,Promegestone may decrease the anticoagulant activities of Streptokinase.
Quingestanol,Quingestanol may decrease the anticoagulant activities of Streptokinase.
Demegestone,Demegestone may decrease the anticoagulant activities of Streptokinase.
Etynodiol,Etynodiol may decrease the anticoagulant activities of Streptokinase.
Nomegestrol acetate,Nomegestrol acetate may decrease the anticoagulant activities of Streptokinase.
Hydroxyprogesterone,Hydroxyprogesterone may decrease the anticoagulant activities of Streptokinase.
Norethindrone enanthate,Norethindrone enanthate may decrease the anticoagulant activities of Streptokinase.
Quingestanol acetate,Quingestanol acetate may decrease the anticoagulant activities of Streptokinase.
Aminosalicylic acid,The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Streptokinase.
Bismuth subsalicylate,The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Streptokinase.
Dersalazine,The risk or severity of bleeding can be increased when Dersalazine is combined with Streptokinase.
Phenyl aminosalicylate,The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Streptokinase.
Methyl salicylate,The risk or severity of bleeding can be increased when Methyl salicylate is combined with Streptokinase.
Trolamine salicylate,The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Streptokinase.
Aloxiprin,The risk or severity of bleeding can be increased when Aloxiprin is combined with Streptokinase.
Choline salicylate,The risk or severity of bleeding can be increased when Choline salicylate is combined with Streptokinase.
Thiosalicylic acid,The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Streptokinase.
Butalbital,Butalbital may increase the hypotensive activities of Streptokinase.
Pentobarbital,Pentobarbital may increase the hypotensive activities of Streptokinase.
Secobarbital,Secobarbital may increase the hypotensive activities of Streptokinase.
Methohexital,Methohexital may increase the hypotensive activities of Streptokinase.
Thiopental,Thiopental may increase the hypotensive activities of Streptokinase.
Primidone,Primidone may increase the hypotensive activities of Streptokinase.
Methylphenobarbital,Methylphenobarbital may increase the hypotensive activities of Streptokinase.
Thiamylal,Thiamylal may increase the hypotensive activities of Streptokinase.
Phenobarbital,Phenobarbital may increase the hypotensive activities of Streptokinase.
Amobarbital,Amobarbital may increase the hypotensive activities of Streptokinase.
Hexobarbital,Hexobarbital may increase the hypotensive activities of Streptokinase.
Barbital,Barbital may increase the hypotensive activities of Streptokinase.
Barbexaclone,Barbexaclone may increase the hypotensive activities of Streptokinase.
Butabarbital,Butabarbital may increase the hypotensive activities of Streptokinase.
Abciximab,The risk or severity of bleeding can be increased when Abciximab is combined with Streptokinase.
Eptifibatide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Streptokinase.
Ticlopidine,The risk or severity of bleeding can be increased when Ticlopidine is combined with Streptokinase.
Anagrelide,The risk or severity of bleeding can be increased when Anagrelide is combined with Streptokinase.
Clopidogrel,The risk or severity of bleeding can be increased when Clopidogrel is combined with Streptokinase.
Tirofiban,The risk or severity of bleeding can be increased when Tirofiban is combined with Streptokinase.
Dipyridamole,The risk or severity of bleeding can be increased when Dipyridamole is combined with Streptokinase.
Iloprost,The risk or severity of bleeding can be increased when Iloprost is combined with Streptokinase.
Sulfinpyrazone,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Streptokinase.
Cilostazol,The risk or severity of bleeding can be increased when Cilostazol is combined with Streptokinase.
Ridogrel,The risk or severity of bleeding can be increased when Ridogrel is combined with Streptokinase.
Sevoflurane,The risk or severity of bleeding can be increased when Sevoflurane is combined with Streptokinase.
Epoprostenol,The risk or severity of bleeding can be increased when Epoprostenol is combined with Streptokinase.
Resveratrol,The risk or severity of bleeding can be increased when Resveratrol is combined with Streptokinase.
Nimesulide,The risk or severity of bleeding can be increased when Nimesulide is combined with Streptokinase.
Tesmilifene,The risk or severity of bleeding can be increased when Tesmilifene is combined with Streptokinase.
Defibrotide,The risk or severity of bleeding can be increased when Defibrotide is combined with Streptokinase.
Beraprost,The risk or severity of bleeding can be increased when Beraprost is combined with Streptokinase.
Ibudilast,The risk or severity of bleeding can be increased when Ibudilast is combined with Streptokinase.
Andrographolide,The risk or severity of bleeding can be increased when Andrographolide is combined with Streptokinase.
Caplacizumab,The risk or severity of bleeding can be increased when Caplacizumab is combined with Streptokinase.
Prasugrel,The risk or severity of bleeding can be increased when Prasugrel is combined with Streptokinase.
Cangrelor,The risk or severity of bleeding can be increased when Cangrelor is combined with Streptokinase.
Tranilast,The risk or severity of bleeding can be increased when Tranilast is combined with Streptokinase.
Triflusal,The risk or severity of bleeding can be increased when Triflusal is combined with Streptokinase.
Ticagrelor,The risk or severity of bleeding can be increased when Ticagrelor is combined with Streptokinase.
Icosapent ethyl,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Streptokinase.
Trapidil,The risk or severity of bleeding can be increased when Trapidil is combined with Streptokinase.
Naftopidil,The risk or severity of bleeding can be increased when Naftopidil is combined with Streptokinase.
Sarpogrelate,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Streptokinase.
Ifetroban,The risk or severity of bleeding can be increased when Ifetroban is combined with Streptokinase.
Nitroaspirin,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Streptokinase.
Ketanserin,The risk or severity of bleeding can be increased when Ketanserin is combined with Streptokinase.
Indobufen,The risk or severity of bleeding can be increased when Indobufen is combined with Streptokinase.
Butylphthalide,The risk or severity of bleeding can be increased when Butylphthalide is combined with Streptokinase.
Hydroxytyrosol,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Streptokinase.
Ramatroban,The risk or severity of bleeding can be increased when Ramatroban is combined with Streptokinase.
Picotamide,The risk or severity of bleeding can be increased when Picotamide is combined with Streptokinase.
Cloricromen,The risk or severity of bleeding can be increased when Cloricromen is combined with Streptokinase.
Linsidomine,The risk or severity of bleeding can be increased when Linsidomine is combined with Streptokinase.
Buflomedil,The risk or severity of bleeding can be increased when Buflomedil is combined with Streptokinase.
Relcovaptan,The risk or severity of bleeding can be increased when Relcovaptan is combined with Streptokinase.
Treprostinil,The risk or severity of adverse effects can be increased when Streptokinase is combined with Treprostinil.
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Streptokinase.
Methyclothiazide,The risk or severity of adverse effects can be increased when Streptokinase is combined with Methyclothiazide.
Ropinirole,The risk or severity of adverse effects can be increased when Streptokinase is combined with Ropinirole.
Morphine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Morphine.
Ropivacaine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Ropivacaine.
Bupivacaine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bupivacaine.
Tolcapone,The risk or severity of adverse effects can be increased when Streptokinase is combined with Tolcapone.
Olanzapine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Olanzapine.
Clozapine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Clozapine.
Triamterene,The risk or severity of adverse effects can be increased when Streptokinase is combined with Triamterene.
Pramipexole,The risk or severity of adverse effects can be increased when Streptokinase is combined with Pramipexole.
Spironolactone,The risk or severity of adverse effects can be increased when Streptokinase is combined with Spironolactone.
Nitric Oxide,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitric Oxide.
Imipramine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Imipramine.
Chlorpromazine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Chlorpromazine.
Nabilone,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nabilone.
Sotalol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Sotalol.
Amiloride,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amiloride.
Clofarabine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Clofarabine.
Dexmedetomidine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Dexmedetomidine.
Verapamil,The risk or severity of adverse effects can be increased when Streptokinase is combined with Verapamil.
Thioridazine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Thioridazine.
Amphotericin B,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amphotericin B.
Furosemide,The risk or severity of adverse effects can be increased when Streptokinase is combined with Furosemide.
Tizanidine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Tizanidine.
Methazolamide,The risk or severity of adverse effects can be increased when Streptokinase is combined with Methazolamide.
Tamsulosin,The risk or severity of adverse effects can be increased when Streptokinase is combined with Tamsulosin.
Sufentanil,The risk or severity of adverse effects can be increased when Streptokinase is combined with Sufentanil.
Apomorphine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Apomorphine.
Mannitol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Mannitol.
Isoflurane,The risk or severity of adverse effects can be increased when Streptokinase is combined with Isoflurane.
Tretinoin,The risk or severity of adverse effects can be increased when Streptokinase is combined with Tretinoin.
Propofol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Propofol.
Conivaptan,The risk or severity of adverse effects can be increased when Streptokinase is combined with Conivaptan.
Isosorbide dinitrate,The risk or severity of adverse effects can be increased when Streptokinase is combined with Isosorbide dinitrate.
Bumetanide,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bumetanide.
Remifentanil,The risk or severity of adverse effects can be increased when Streptokinase is combined with Remifentanil.
Etacrynic acid,The risk or severity of adverse effects can be increased when Streptokinase is combined with Etacrynic acid.
Levosimendan,The risk or severity of adverse effects can be increased when Streptokinase is combined with Levosimendan.
Levobupivacaine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Levobupivacaine.
Isosorbide mononitrate,The risk or severity of adverse effects can be increased when Streptokinase is combined with Isosorbide mononitrate.
Thalidomide,The risk or severity of adverse effects can be increased when Streptokinase is combined with Thalidomide.
Papaverine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Papaverine.
Amiodarone,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amiodarone.
Amifostine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amifostine.
Diclofenamide,The risk or severity of adverse effects can be increased when Streptokinase is combined with Diclofenamide.
Halothane,The risk or severity of adverse effects can be increased when Streptokinase is combined with Halothane.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Streptokinase is combined with Arsenic trioxide.
Desflurane,The risk or severity of adverse effects can be increased when Streptokinase is combined with Desflurane.
Bromocriptine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bromocriptine.
Quetiapine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Quetiapine.
Paclitaxel,The risk or severity of adverse effects can be increased when Streptokinase is combined with Paclitaxel.
Clomipramine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Clomipramine.
Carbetocin,The risk or severity of adverse effects can be increased when Streptokinase is combined with Carbetocin.
Amyl Nitrite,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amyl Nitrite.
Nesiritide,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nesiritide.
Clevidipine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Clevidipine.
Rotigotine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Rotigotine.
Dapagliflozin,The risk or severity of adverse effects can be increased when Streptokinase is combined with Dapagliflozin.
Canagliflozin,The risk or severity of adverse effects can be increased when Streptokinase is combined with Canagliflozin.
Isoxsuprine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Isoxsuprine.
Empagliflozin,The risk or severity of adverse effects can be increased when Streptokinase is combined with Empagliflozin.
Dinutuximab,The risk or severity of adverse effects can be increased when Streptokinase is combined with Dinutuximab.
Nitrous acid,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitrous acid.
Arotinolol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Arotinolol.
Barnidipine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Barnidipine.
Cilnidipine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Cilnidipine.
Fimasartan,The risk or severity of adverse effects can be increased when Streptokinase is combined with Fimasartan.
Pipamperone,The risk or severity of adverse effects can be increased when Streptokinase is combined with Pipamperone.
Esmolol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Esmolol.
Betaxolol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Betaxolol.
Reserpine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Reserpine.
Torasemide,The risk or severity of adverse effects can be increased when Streptokinase is combined with Torasemide.
Metoprolol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Metoprolol.
Isradipine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Isradipine.
Olmesartan,The risk or severity of adverse effects can be increased when Streptokinase is combined with Olmesartan.
Chlorthalidone,The risk or severity of adverse effects can be increased when Streptokinase is combined with Chlorthalidone.
Nitroprusside,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitroprusside.
Atenolol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Atenolol.
Diltiazem,The risk or severity of adverse effects can be increased when Streptokinase is combined with Diltiazem.
Minoxidil,The risk or severity of adverse effects can be increased when Streptokinase is combined with Minoxidil.
Timolol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Timolol.
Amlodipine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amlodipine.
Nimodipine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nimodipine.
Nisoldipine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nisoldipine.
Bendroflumethiazide,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bendroflumethiazide.
Prazosin,The risk or severity of adverse effects can be increased when Streptokinase is combined with Prazosin.
Metolazone,The risk or severity of adverse effects can be increased when Streptokinase is combined with Metolazone.
Lercanidipine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Lercanidipine.
Propranolol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Propranolol.
Clonidine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Clonidine.
Doxazosin,The risk or severity of adverse effects can be increased when Streptokinase is combined with Doxazosin.
Labetalol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Labetalol.
Bisoprolol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bisoprolol.
Nicardipine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nicardipine.
Mecamylamine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Mecamylamine.
Phentolamine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Phentolamine.
Eplerenone,The risk or severity of adverse effects can be increased when Streptokinase is combined with Eplerenone.
Nitroglycerin,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitroglycerin.
Hydroflumethiazide,The risk or severity of adverse effects can be increased when Streptokinase is combined with Hydroflumethiazide.
Candesartan cilexetil,The risk or severity of adverse effects can be increased when Streptokinase is combined with Candesartan cilexetil.
Tolazoline,The risk or severity of adverse effects can be increased when Streptokinase is combined with Tolazoline.
Fenoldopam,The risk or severity of adverse effects can be increased when Streptokinase is combined with Fenoldopam.
Indapamide,The risk or severity of adverse effects can be increased when Streptokinase is combined with Indapamide.
Chlorothiazide,The risk or severity of adverse effects can be increased when Streptokinase is combined with Chlorothiazide.
Phenoxybenzamine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Phenoxybenzamine.
Pindolol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Pindolol.
Methyldopa,The risk or severity of adverse effects can be increased when Streptokinase is combined with Methyldopa.
Hydrochlorothiazide,The risk or severity of adverse effects can be increased when Streptokinase is combined with Hydrochlorothiazide.
Guanfacine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Guanfacine.
Felodipine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Felodipine.
Irbesartan,The risk or severity of adverse effects can be increased when Streptokinase is combined with Irbesartan.
Nitrendipine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitrendipine.
Diazoxide,The risk or severity of adverse effects can be increased when Streptokinase is combined with Diazoxide.
Carvedilol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Carvedilol.
Bretylium,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bretylium.
Terazosin,The risk or severity of adverse effects can be increased when Streptokinase is combined with Terazosin.
Acebutolol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Acebutolol.
Nadolol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nadolol.
Bepridil,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bepridil.
Hydralazine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Hydralazine.
Penbutolol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Penbutolol.
Oxprenolol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Oxprenolol.
Nebivolol,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nebivolol.
Lofexidine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Lofexidine.
Nilvadipine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nilvadipine.
Riociguat,The risk or severity of adverse effects can be increased when Streptokinase is combined with Riociguat.
Indoramin,The risk or severity of adverse effects can be increased when Streptokinase is combined with Indoramin.
Aliskiren,The risk or severity of adverse effects can be increased when Streptokinase is combined with Aliskiren.
Efonidipine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Efonidipine.
Moxonidine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Moxonidine.
Nifedipine,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nifedipine.
Hemin,Hemin may increase the anticoagulant activities of Streptokinase.
Acemetacin,The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Streptokinase.
Lacidipine,Streptokinase may increase the hypotensive activities of Lacidipine.
Ethanol,Ethanol may increase the hypotensive activities of Streptokinase.
Testosterone,Testosterone may increase the anticoagulant activities of Streptokinase.
Testosterone propionate,Testosterone propionate may increase the anticoagulant activities of Streptokinase.
1-Testosterone,1-Testosterone may increase the anticoagulant activities of Streptokinase.
4-Hydroxytestosterone,4-Hydroxytestosterone may increase the anticoagulant activities of Streptokinase.
Dehydrochloromethyltestosterone,Dehydrochloromethyltestosterone may increase the anticoagulant activities of Streptokinase.
Boldenone,Boldenone may increase the anticoagulant activities of Streptokinase.
18-methyl-19-nortestosterone,18-methyl-19-nortestosterone may increase the anticoagulant activities of Streptokinase.
Calusterone,Calusterone may increase the anticoagulant activities of Streptokinase.
Formebolone,Formebolone may increase the anticoagulant activities of Streptokinase.
Methyl-1-testosterone,Methyl-1-testosterone may increase the anticoagulant activities of Streptokinase.
Stanolone,Stanolone may increase the anticoagulant activities of Streptokinase.
5beta-dihydrotestosterone,5beta-dihydrotestosterone may increase the anticoagulant activities of Streptokinase.
Testosterone succinate,Testosterone succinate may increase the anticoagulant activities of Streptokinase.
Mibolerone,Mibolerone may increase the anticoagulant activities of Streptokinase.
Testosterone cypionate,Testosterone cypionate may increase the anticoagulant activities of Streptokinase.
Testosterone enanthate,Testosterone enanthate may increase the anticoagulant activities of Streptokinase.
Testosterone undecanoate,Testosterone undecanoate may increase the anticoagulant activities of Streptokinase.
Testosterone enantate benzilic acid hydrazone,Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Streptokinase.
Stanolone acetate,Stanolone acetate may increase the anticoagulant activities of Streptokinase.
Trestolone acetate,Trestolone acetate may increase the anticoagulant activities of Streptokinase.
"(1,2,6,7-3H)Testosterone","(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Streptokinase."
Drostanolone propionate,Drostanolone propionate may increase the anticoagulant activities of Streptokinase.
Azficel-T,The risk or severity of adverse effects can be increased when Streptokinase is combined with Azficel-T.
Omega-3-carboxylic acids,The therapeutic efficacy of Streptokinase can be increased when used in combination with Omega-3-carboxylic acids.
Calcium acetate,The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Streptokinase.
Calcium chloride,The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Streptokinase.
Calcium,The therapeutic efficacy of Calcium can be decreased when used in combination with Streptokinase.
Calcium gluconate,The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Streptokinase.
Eftrenonacog alfa,The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Streptokinase.
Albutrepenonacog alfa,The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Streptokinase.
Emicizumab,The therapeutic efficacy of Emicizumab can be decreased when used in combination with Streptokinase.
Turoctocog alfa pegol,The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Streptokinase.
"Antihemophilic factor, human recombinant","The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Streptokinase."
Coagulation factor VIIa Recombinant Human,The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Streptokinase.
Coagulation Factor IX (Recombinant),The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Streptokinase.
Pantothenic acid,The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Streptokinase.
Formic acid,The therapeutic efficacy of Formic acid can be decreased when used in combination with Streptokinase.
Platelet Activating Factor,The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Streptokinase.
Calcium carbonate,The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Streptokinase.
Turoctocog alfa,The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Streptokinase.
Fibrinogen human,The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Streptokinase.
Catridecacog,The therapeutic efficacy of Catridecacog can be decreased when used in combination with Streptokinase.
"Antihemophilic Factor (Recombinant), PEGylated","The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Streptokinase."
Calcium citrate,The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Streptokinase.
Calcium threonate,The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Streptokinase.
Prothrombin,The therapeutic efficacy of Prothrombin can be decreased when used in combination with Streptokinase.
Factor IX Complex (Human),The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Streptokinase.
Calcium Phosphate,The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Streptokinase.
Susoctocog alfa,The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Streptokinase.
Rusalatide acetate,The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Streptokinase.
Vatreptacog alfa,The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Streptokinase.
Factor XIII (human),The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Streptokinase.
Von Willebrand Factor Human,The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Streptokinase.
Coagulation factor X human,The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Streptokinase.
Coagulation factor VII human,The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Streptokinase.
Anti-inhibitor coagulant complex,The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Streptokinase.
Coagulation Factor IX Human,The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Streptokinase.
Antihemophilic factor human,The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Streptokinase.
Kallidinogenase,The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Streptokinase.
Trenonacog alfa,The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Streptokinase.
Nonacog beta pegol,The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Streptokinase.
Moroctocog alfa,The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Streptokinase.
Beroctocog alfa,The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Streptokinase.
Andexanet alfa,The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Streptokinase.
Calcium cation,The therapeutic efficacy of Calcium cation can be decreased when used in combination with Streptokinase.
Damoctocog alfa pegol,The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Streptokinase.
Fluvoxamine,The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Streptokinase.
Citalopram,The risk or severity of hemorrhage can be increased when Citalopram is combined with Streptokinase.
Fluoxetine,The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Streptokinase.
Paroxetine,The risk or severity of hemorrhage can be increased when Paroxetine is combined with Streptokinase.
Nefazodone,The risk or severity of hemorrhage can be increased when Nefazodone is combined with Streptokinase.
Zimelidine,The risk or severity of hemorrhage can be increased when Zimelidine is combined with Streptokinase.
Dapoxetine,The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Streptokinase.
Seproxetine,The risk or severity of hemorrhage can be increased when Seproxetine is combined with Streptokinase.
Indalpine,The risk or severity of hemorrhage can be increased when Indalpine is combined with Streptokinase.
Ritanserin,The risk or severity of hemorrhage can be increased when Ritanserin is combined with Streptokinase.
Alaproclate,The risk or severity of hemorrhage can be increased when Alaproclate is combined with Streptokinase.
Sibutramine,The risk or severity of hemorrhage can be increased when Sibutramine is combined with Streptokinase.
Milnacipran,The risk or severity of hemorrhage can be increased when Milnacipran is combined with Streptokinase.
Desvenlafaxine,The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Streptokinase.
Levomilnacipran,The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Streptokinase.
Venlafaxine,Venlafaxine may increase the antiplatelet activities of Streptokinase.
Bivalirudin,The risk or severity of bleeding can be increased when Bivalirudin is combined with Streptokinase.
Dicoumarol,The risk or severity of bleeding can be increased when Dicoumarol is combined with Streptokinase.
Argatroban,The risk or severity of bleeding can be increased when Argatroban is combined with Streptokinase.
Phenindione,The risk or severity of bleeding can be increased when Phenindione is combined with Streptokinase.
Fondaparinux,The risk or severity of bleeding can be increased when Fondaparinux is combined with Streptokinase.
Warfarin,The risk or severity of bleeding can be increased when Warfarin is combined with Streptokinase.
Phenprocoumon,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Streptokinase.
Edetic acid,The risk or severity of bleeding can be increased when Edetic acid is combined with Streptokinase.
Acenocoumarol,The risk or severity of bleeding can be increased when Acenocoumarol is combined with Streptokinase.
Ximelagatran,The risk or severity of bleeding can be increased when Ximelagatran is combined with Streptokinase.
Ancrod,The risk or severity of bleeding can be increased when Ancrod is combined with Streptokinase.
Idraparinux,The risk or severity of bleeding can be increased when Idraparinux is combined with Streptokinase.
Otamixaban,The risk or severity of bleeding can be increased when Otamixaban is combined with Streptokinase.
Ferulic acid,The risk or severity of bleeding can be increased when Ferulic acid is combined with Streptokinase.
Ethyl biscoumacetate,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Streptokinase.
Dextran,The risk or severity of bleeding can be increased when Dextran is combined with Streptokinase.
Desirudin,The risk or severity of bleeding can be increased when Desirudin is combined with Streptokinase.
Protocatechualdehyde,The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Streptokinase.
Protein C,The risk or severity of bleeding can be increased when Protein C is combined with Streptokinase.
Antithrombin III human,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Streptokinase.
Letaxaban,The risk or severity of bleeding can be increased when Letaxaban is combined with Streptokinase.
Darexaban,The risk or severity of bleeding can be increased when Darexaban is combined with Streptokinase.
Nafamostat,The risk or severity of bleeding can be increased when Nafamostat is combined with Streptokinase.
Gabexate,The risk or severity of bleeding can be increased when Gabexate is combined with Streptokinase.
Troxerutin,The risk or severity of bleeding can be increased when Troxerutin is combined with Streptokinase.
Fluindione,The risk or severity of bleeding can be increased when Fluindione is combined with Streptokinase.
Protein S human,The risk or severity of bleeding can be increased when Protein S human is combined with Streptokinase.
Melagatran,The risk or severity of bleeding can be increased when Melagatran is combined with Streptokinase.
Potassium citrate,The risk or severity of bleeding can be increased when Potassium citrate is combined with Streptokinase.
Sodium citrate,The risk or severity of bleeding can be increased when Sodium citrate is combined with Streptokinase.
Tenecteplase,The risk or severity of bleeding can be increased when Tenecteplase is combined with Streptokinase.
Drotrecogin alfa,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Streptokinase.
Brinase,The risk or severity of bleeding can be increased when Brinase is combined with Streptokinase.
Saruplase,The risk or severity of bleeding can be increased when Saruplase is combined with Streptokinase.
Desmoteplase,The risk or severity of bleeding can be increased when Streptokinase is combined with Desmoteplase.
Fibrinolysin,The risk or severity of bleeding can be increased when Streptokinase is combined with Fibrinolysin.
Astaxanthin,The risk or severity of bleeding can be increased when Streptokinase is combined with Astaxanthin.
Ditazole,The risk or severity of bleeding can be increased when Streptokinase is combined with Ditazole.
Clorindione,The risk or severity of bleeding can be increased when Streptokinase is combined with Clorindione.
Diphenadione,The risk or severity of bleeding can be increased when Streptokinase is combined with Diphenadione.
Tioclomarol,The risk or severity of bleeding can be increased when Streptokinase is combined with Tioclomarol.
Lepirudin,The risk or severity of bleeding can be increased when Streptokinase is combined with Lepirudin.
Alteplase,The risk or severity of bleeding can be increased when Streptokinase is combined with Alteplase.
Reteplase,The risk or severity of bleeding can be increased when Streptokinase is combined with Reteplase.
Anistreplase,The risk or severity of bleeding can be increased when Streptokinase is combined with Anistreplase.
Tocopherylquinone,The risk or severity of bleeding can be increased when Streptokinase is combined with Tocopherylquinone.
Amediplase,The risk or severity of bleeding can be increased when Streptokinase is combined with Amediplase.
4-hydroxycoumarin,The risk or severity of bleeding can be increased when Streptokinase is combined with 4-hydroxycoumarin.
(R)-warfarin,The risk or severity of bleeding can be increased when Streptokinase is combined with (R)-warfarin.
(S)-Warfarin,The risk or severity of bleeding can be increased when Streptokinase is combined with (S)-Warfarin.
Betrixaban,The risk or severity of bleeding can be increased when Streptokinase is combined with Betrixaban.
Edetate calcium disodium anhydrous,The risk or severity of bleeding can be increased when Streptokinase is combined with Edetate calcium disodium anhydrous.
Zinc citrate,The risk or severity of bleeding can be increased when Streptokinase is combined with Zinc citrate.
Antithrombin Alfa,The risk or severity of bleeding can be increased when Streptokinase is combined with Antithrombin Alfa.
Coumarin,The risk or severity of bleeding can be increased when Streptokinase is combined with Coumarin.
Dabigatran,The risk or severity of bleeding can be increased when Streptokinase is combined with Dabigatran.
Monteplase,The risk or severity of bleeding can be increased when Streptokinase is combined with Monteplase.
Valsartan,The risk or severity of angioedema can be increased when Streptokinase is combined with Valsartan.
Ramipril,The risk or severity of angioedema can be increased when Streptokinase is combined with Ramipril.
Pregabalin,The risk or severity of angioedema can be increased when Streptokinase is combined with Pregabalin.
Fosinopril,The risk or severity of angioedema can be increased when Streptokinase is combined with Fosinopril.
Trandolapril,The risk or severity of angioedema can be increased when Streptokinase is combined with Trandolapril.
Benazepril,The risk or severity of angioedema can be increased when Streptokinase is combined with Benazepril.
Enalapril,The risk or severity of angioedema can be increased when Streptokinase is combined with Enalapril.
Losartan,The risk or severity of angioedema can be increased when Streptokinase is combined with Losartan.
Moexipril,The risk or severity of angioedema can be increased when Streptokinase is combined with Moexipril.
Lisinopril,The risk or severity of angioedema can be increased when Streptokinase is combined with Lisinopril.
Perindopril,The risk or severity of angioedema can be increased when Streptokinase is combined with Perindopril.
Eprosartan,The risk or severity of angioedema can be increased when Streptokinase is combined with Eprosartan.
Sirolimus,The risk or severity of angioedema can be increased when Streptokinase is combined with Sirolimus.
Quinapril,The risk or severity of angioedema can be increased when Streptokinase is combined with Quinapril.
Omapatrilat,The risk or severity of angioedema can be increased when Streptokinase is combined with Omapatrilat.
Telmisartan,The risk or severity of angioedema can be increased when Streptokinase is combined with Telmisartan.
Ibuprofen,The risk or severity of angioedema can be increased when Streptokinase is combined with Ibuprofen.
Rescinnamine,The risk or severity of angioedema can be increased when Streptokinase is combined with Rescinnamine.
Captopril,The risk or severity of angioedema can be increased when Streptokinase is combined with Captopril.
Sitagliptin,The risk or severity of angioedema can be increased when Streptokinase is combined with Sitagliptin.
Cilazapril,The risk or severity of angioedema can be increased when Streptokinase is combined with Cilazapril.
Forasartan,The risk or severity of angioedema can be increased when Streptokinase is combined with Forasartan.
Saprisartan,The risk or severity of angioedema can be increased when Streptokinase is combined with Saprisartan.
Spirapril,The risk or severity of angioedema can be increased when Streptokinase is combined with Spirapril.
Vildagliptin,The risk or severity of angioedema can be increased when Streptokinase is combined with Vildagliptin.
AMG-222,The risk or severity of angioedema can be increased when Streptokinase is combined with AMG-222.
Bisegliptin,The risk or severity of angioedema can be increased when Streptokinase is combined with Bisegliptin.
Icatibant,The risk or severity of angioedema can be increased when Streptokinase is combined with Icatibant.
Alogliptin,The risk or severity of angioedema can be increased when Streptokinase is combined with Alogliptin.
Lanoteplase,The risk or severity of angioedema can be increased when Streptokinase is combined with Lanoteplase.
Temsirolimus,The risk or severity of angioedema can be increased when Streptokinase is combined with Temsirolimus.
Saxagliptin,The risk or severity of angioedema can be increased when Streptokinase is combined with Saxagliptin.
Gosogliptin,The risk or severity of angioedema can be increased when Streptokinase is combined with Gosogliptin.
Azilsartan medoxomil,The risk or severity of angioedema can be increased when Streptokinase is combined with Azilsartan medoxomil.
Temocapril,The risk or severity of angioedema can be increased when Streptokinase is combined with Temocapril.
Linagliptin,The risk or severity of angioedema can be increased when Streptokinase is combined with Linagliptin.
Sacubitril,The risk or severity of angioedema can be increased when Streptokinase is combined with Sacubitril.
Enalaprilat,The risk or severity of angioedema can be increased when Streptokinase is combined with Enalaprilat.
Dutogliptin,The risk or severity of angioedema can be increased when Streptokinase is combined with Dutogliptin.
Imidapril,The risk or severity of angioedema can be increased when Streptokinase is combined with Imidapril.
Teneligliptin,The risk or severity of angioedema can be increased when Streptokinase is combined with Teneligliptin.
Omarigliptin,The risk or severity of angioedema can be increased when Streptokinase is combined with Omarigliptin.
Carmegliptin,The risk or severity of angioedema can be increased when Streptokinase is combined with Carmegliptin.
Gemigliptin,The risk or severity of angioedema can be increased when Streptokinase is combined with Gemigliptin.
Anagliptin,The risk or severity of angioedema can be increased when Streptokinase is combined with Anagliptin.
Evogliptin,The risk or severity of angioedema can be increased when Streptokinase is combined with Evogliptin.
Zofenopril,The risk or severity of angioedema can be increased when Streptokinase is combined with Zofenopril.
Delapril,The risk or severity of angioedema can be increased when Streptokinase is combined with Delapril.
Benazeprilat,The risk or severity of angioedema can be increased when Streptokinase is combined with Benazeprilat.
Fosinoprilat,The risk or severity of angioedema can be increased when Streptokinase is combined with Fosinoprilat.
Ramiprilat,The risk or severity of angioedema can be increased when Streptokinase is combined with Ramiprilat.
Trandolaprilat,The risk or severity of angioedema can be increased when Streptokinase is combined with Trandolaprilat.
Moexiprilat,The risk or severity of angioedema can be increased when Streptokinase is combined with Moexiprilat.
Perindoprilat,The risk or severity of angioedema can be increased when Streptokinase is combined with Perindoprilat.
Quinaprilat,The risk or severity of angioedema can be increased when Streptokinase is combined with Quinaprilat.
Quinoline Yellow WS,The risk or severity of angioedema can be increased when Streptokinase is combined with Quinoline Yellow WS.
Sildenafil,The risk or severity of hemorrhage can be increased when Streptokinase is combined with Sildenafil.
Peginterferon alfa-2a,The risk or severity of bleeding can be increased when Streptokinase is combined with Peginterferon alfa-2a.
Interferon alfa-n1,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-n1.
Interferon alfa-n3,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-n3.
Peginterferon alfa-2b,The risk or severity of bleeding can be increased when Streptokinase is combined with Peginterferon alfa-2b.
Interferon gamma-1b,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon gamma-1b.
"Interferon alfa-2a, Recombinant","The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-2a, Recombinant."
Gemtuzumab ozogamicin,The risk or severity of bleeding can be increased when Streptokinase is combined with Gemtuzumab ozogamicin.
Interferon beta-1b,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon beta-1b.
Interferon alfacon-1,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfacon-1.
Rituximab,The risk or severity of bleeding can be increased when Streptokinase is combined with Rituximab.
Ibritumomab tiuxetan,The risk or severity of bleeding can be increased when Streptokinase is combined with Ibritumomab tiuxetan.
Alemtuzumab,The risk or severity of bleeding can be increased when Streptokinase is combined with Alemtuzumab.
Interferon alfa-2b,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-2b.
Phenylalanine,The risk or severity of bleeding can be increased when Streptokinase is combined with Phenylalanine.
Cladribine,The risk or severity of bleeding can be increased when Streptokinase is combined with Cladribine.
Carmustine,The risk or severity of bleeding can be increased when Streptokinase is combined with Carmustine.
Amsacrine,The risk or severity of bleeding can be increased when Streptokinase is combined with Amsacrine.
Chlorambucil,The risk or severity of bleeding can be increased when Streptokinase is combined with Chlorambucil.
Raltitrexed,The risk or severity of bleeding can be increased when Streptokinase is combined with Raltitrexed.
Mitomycin,The risk or severity of bleeding can be increased when Streptokinase is combined with Mitomycin.
Bexarotene,The risk or severity of bleeding can be increased when Streptokinase is combined with Bexarotene.
Vindesine,The risk or severity of bleeding can be increased when Streptokinase is combined with Vindesine.
Floxuridine,The risk or severity of bleeding can be increased when Streptokinase is combined with Floxuridine.
Tioguanine,The risk or severity of bleeding can be increased when Streptokinase is combined with Tioguanine.
Vinorelbine,The risk or severity of bleeding can be increased when Streptokinase is combined with Vinorelbine.
Dexrazoxane,The risk or severity of bleeding can be increased when Streptokinase is combined with Dexrazoxane.
Sorafenib,The risk or severity of bleeding can be increased when Streptokinase is combined with Sorafenib.
Streptozocin,The risk or severity of bleeding can be increased when Streptokinase is combined with Streptozocin.
Gemcitabine,The risk or severity of bleeding can be increased when Streptokinase is combined with Gemcitabine.
Teniposide,The risk or severity of bleeding can be increased when Streptokinase is combined with Teniposide.
Epirubicin,The risk or severity of bleeding can be increased when Streptokinase is combined with Epirubicin.
Chloramphenicol,The risk or severity of bleeding can be increased when Streptokinase is combined with Chloramphenicol.
Lenalidomide,The risk or severity of bleeding can be increased when Streptokinase is combined with Lenalidomide.
Altretamine,The risk or severity of bleeding can be increased when Streptokinase is combined with Altretamine.
Zidovudine,The risk or severity of bleeding can be increased when Streptokinase is combined with Zidovudine.
Cisplatin,The risk or severity of bleeding can be increased when Streptokinase is combined with Cisplatin.
Oxaliplatin,The risk or severity of bleeding can be increased when Streptokinase is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of bleeding can be increased when Streptokinase is combined with Cyclophosphamide.
Fluorouracil,The risk or severity of bleeding can be increased when Streptokinase is combined with Fluorouracil.
Pentostatin,The risk or severity of bleeding can be increased when Streptokinase is combined with Pentostatin.
Methotrexate,The risk or severity of bleeding can be increased when Streptokinase is combined with Methotrexate.
Carbamazepine,The risk or severity of bleeding can be increased when Streptokinase is combined with Carbamazepine.
Vinblastine,The risk or severity of bleeding can be increased when Streptokinase is combined with Vinblastine.
Imatinib,The risk or severity of bleeding can be increased when Streptokinase is combined with Imatinib.
Pemetrexed,The risk or severity of bleeding can be increased when Streptokinase is combined with Pemetrexed.
Daunorubicin,The risk or severity of bleeding can be increased when Streptokinase is combined with Daunorubicin.
Irinotecan,The risk or severity of bleeding can be increased when Streptokinase is combined with Irinotecan.
Etoposide,The risk or severity of bleeding can be increased when Streptokinase is combined with Etoposide.
Dacarbazine,The risk or severity of bleeding can be increased when Streptokinase is combined with Dacarbazine.
Temozolomide,The risk or severity of bleeding can be increased when Streptokinase is combined with Temozolomide.
Penicillamine,The risk or severity of bleeding can be increased when Streptokinase is combined with Penicillamine.
Tacrolimus,The risk or severity of bleeding can be increased when Streptokinase is combined with Tacrolimus.
Mechlorethamine,The risk or severity of bleeding can be increased when Streptokinase is combined with Mechlorethamine.
Azacitidine,The risk or severity of bleeding can be increased when Streptokinase is combined with Azacitidine.
Carboplatin,The risk or severity of bleeding can be increased when Streptokinase is combined with Carboplatin.
Dactinomycin,The risk or severity of bleeding can be increased when Streptokinase is combined with Dactinomycin.
Cytarabine,The risk or severity of bleeding can be increased when Streptokinase is combined with Cytarabine.
Doxorubicin,The risk or severity of bleeding can be increased when Streptokinase is combined with Doxorubicin.
Hydroxyurea,The risk or severity of bleeding can be increased when Streptokinase is combined with Hydroxyurea.
Busulfan,The risk or severity of bleeding can be increased when Streptokinase is combined with Busulfan.
Topotecan,The risk or severity of bleeding can be increased when Streptokinase is combined with Topotecan.
Mercaptopurine,The risk or severity of bleeding can be increased when Streptokinase is combined with Mercaptopurine.
Melphalan,The risk or severity of bleeding can be increased when Streptokinase is combined with Melphalan.
Fludarabine,The risk or severity of bleeding can be increased when Streptokinase is combined with Fludarabine.
Flucytosine,The risk or severity of bleeding can be increased when Streptokinase is combined with Flucytosine.
Capecitabine,The risk or severity of bleeding can be increased when Streptokinase is combined with Capecitabine.
Idarubicin,The risk or severity of bleeding can be increased when Streptokinase is combined with Idarubicin.
Mitoxantrone,The risk or severity of bleeding can be increased when Streptokinase is combined with Mitoxantrone.
Lomustine,The risk or severity of bleeding can be increased when Streptokinase is combined with Lomustine.
Docetaxel,The risk or severity of bleeding can be increased when Streptokinase is combined with Docetaxel.
Decitabine,The risk or severity of bleeding can be increased when Streptokinase is combined with Decitabine.
Nelarabine,The risk or severity of bleeding can be increased when Streptokinase is combined with Nelarabine.
Everolimus,The risk or severity of bleeding can be increased when Streptokinase is combined with Everolimus.
Vorinostat,The risk or severity of bleeding can be increased when Streptokinase is combined with Vorinostat.
Thiotepa,The risk or severity of bleeding can be increased when Streptokinase is combined with Thiotepa.
Ixabepilone,The risk or severity of bleeding can be increased when Streptokinase is combined with Ixabepilone.
Nilotinib,The risk or severity of bleeding can be increased when Streptokinase is combined with Nilotinib.
Belinostat,The risk or severity of bleeding can be increased when Streptokinase is combined with Belinostat.
Trabectedin,The risk or severity of bleeding can be increased when Streptokinase is combined with Trabectedin.
Interferon alfa,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa.
omega interferon,The risk or severity of bleeding can be increased when Streptokinase is combined with omega interferon.
Trastuzumab emtansine,The risk or severity of bleeding can be increased when Streptokinase is combined with Trastuzumab emtansine.
Bosutinib,The risk or severity of bleeding can be increased when Streptokinase is combined with Bosutinib.
Bendamustine,The risk or severity of bleeding can be increased when Streptokinase is combined with Bendamustine.
Cabazitaxel,The risk or severity of bleeding can be increased when Streptokinase is combined with Cabazitaxel.
Eribulin,The risk or severity of bleeding can be increased when Streptokinase is combined with Eribulin.
Ruxolitinib,The risk or severity of bleeding can be increased when Streptokinase is combined with Ruxolitinib.
Carfilzomib,The risk or severity of bleeding can be increased when Streptokinase is combined with Carfilzomib.
Tofacitinib,The risk or severity of bleeding can be increased when Streptokinase is combined with Tofacitinib.
Ponatinib,The risk or severity of bleeding can be increased when Streptokinase is combined with Ponatinib.
Pomalidomide,The risk or severity of bleeding can be increased when Streptokinase is combined with Pomalidomide.
Tedizolid phosphate,The risk or severity of bleeding can be increased when Streptokinase is combined with Tedizolid phosphate.
Blinatumomab,The risk or severity of bleeding can be increased when Streptokinase is combined with Blinatumomab.
Palbociclib,The risk or severity of bleeding can be increased when Streptokinase is combined with Palbociclib.
Olaparib,The risk or severity of bleeding can be increased when Streptokinase is combined with Olaparib.
Peginterferon beta-1a,The risk or severity of bleeding can be increased when Streptokinase is combined with Peginterferon beta-1a.
Cepeginterferon alfa-2B,The risk or severity of bleeding can be increased when Streptokinase is combined with Cepeginterferon alfa-2B.
Bortezomib,The risk or severity of bleeding can be increased when Streptokinase is combined with Bortezomib.
Cefotiam,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefotiam.
Cefmenoxime,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefmenoxime.
Cefmetazole,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefmetazole.
Cefpiramide,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefpiramide.
Ceftazidime,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftazidime.
Loracarbef,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Loracarbef.
Cefalotin,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefalotin.
Cefotaxime,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefotaxime.
Cefdinir,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefdinir.
Cephalexin,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cephalexin.
Cefixime,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefixime.
Cephaloglycin,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cephaloglycin.
Cefaclor,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefaclor.
Ceforanide,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceforanide.
Cefditoren,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefditoren.
Cefuroxime,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefuroxime.
Cefapirin,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefapirin.
Cefadroxil,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefadroxil.
Cefprozil,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefprozil.
Ceftriaxone,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftriaxone.
Cefamandole,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefamandole.
Cefazolin,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefazolin.
Cefonicid,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefonicid.
Cefoperazone,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefoperazone.
Cefotetan,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefotetan.
Cefoxitin,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefoxitin.
Ceftizoxime,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftizoxime.
Cefradine,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefradine.
Cefepime,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefepime.
Cefacetrile,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefacetrile.
Ceftibuten,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftibuten.
Cefpodoxime,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefpodoxime.
Latamoxef,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Latamoxef.
Ceftobiprole,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftobiprole.
Ceftaroline fosamil,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftaroline fosamil.
Cefaloridine,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefaloridine.
Ceftolozane,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftolozane.
Cefminox,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefminox.
Cefroxadine,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefroxadine.
Flomoxef,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Flomoxef.
Cefatrizine,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefatrizine.
Cefcapene,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefcapene.
Cefodizime,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefodizime.
Cefsulodin,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefsulodin.
Cefetamet,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefetamet.
Cefbuperazone,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefbuperazone.
Cefozopran,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefozopran.
Cefpirome,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefpirome.
Cefazedone,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefazedone.
Ceftezole,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftezole.
Cefamandole nafate,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefamandole nafate.
Doxycycline,The risk or severity of bleeding can be increased when Doxycycline is combined with Streptokinase.
Azithromycin,The risk or severity of adverse effects can be increased when Azithromycin is combined with Streptokinase.
Omega-3-acid ethyl esters,The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Streptokinase.
Remikiren,Streptokinase may increase the hypotensive activities of Remikiren.
Bethanidine,Streptokinase may increase the hypotensive activities of Bethanidine.
Guanadrel,Streptokinase may increase the hypotensive activities of Guanadrel.
Bosentan,Streptokinase may increase the hypotensive activities of Bosentan.
Cyclothiazide,Streptokinase may increase the hypotensive activities of Cyclothiazide.
Candoxatril,Streptokinase may increase the hypotensive activities of Candoxatril.
Guanabenz,Streptokinase may increase the hypotensive activities of Guanabenz.
Metyrosine,Streptokinase may increase the hypotensive activities of Metyrosine.
Cryptenamine,Streptokinase may increase the hypotensive activities of Cryptenamine.
Tadalafil,Streptokinase may increase the hypotensive activities of Tadalafil.
Alprenolol,Streptokinase may increase the hypotensive activities of Alprenolol.
Trichlormethiazide,Streptokinase may increase the hypotensive activities of Trichlormethiazide.
Deserpidine,Streptokinase may increase the hypotensive activities of Deserpidine.
Pentolinium,Streptokinase may increase the hypotensive activities of Pentolinium.
Trimethaphan,Streptokinase may increase the hypotensive activities of Trimethaphan.
Guanethidine,Streptokinase may increase the hypotensive activities of Guanethidine.
Bevantolol,Streptokinase may increase the hypotensive activities of Bevantolol.
Practolol,Streptokinase may increase the hypotensive activities of Practolol.
Polythiazide,Streptokinase may increase the hypotensive activities of Polythiazide.
Mibefradil,Streptokinase may increase the hypotensive activities of Mibefradil.
Dexpropranolol,Streptokinase may increase the hypotensive activities of Dexpropranolol.
Tienilic acid,Streptokinase may increase the hypotensive activities of Tienilic acid.
Debrisoquine,Streptokinase may increase the hypotensive activities of Debrisoquine.
Celiprolol,Streptokinase may increase the hypotensive activities of Celiprolol.
Sitaxentan,Streptokinase may increase the hypotensive activities of Sitaxentan.
Ambrisentan,Streptokinase may increase the hypotensive activities of Ambrisentan.
Diethylnorspermine,Streptokinase may increase the hypotensive activities of Diethylnorspermine.
Pinacidil,Streptokinase may increase the hypotensive activities of Pinacidil.
Bupranolol,Streptokinase may increase the hypotensive activities of Bupranolol.
Macitentan,Streptokinase may increase the hypotensive activities of Macitentan.
Indenolol,Streptokinase may increase the hypotensive activities of Indenolol.
Hexamethonium,Streptokinase may increase the hypotensive activities of Hexamethonium.
Trimazosin,Streptokinase may increase the hypotensive activities of Trimazosin.
Manidipine,Streptokinase may increase the hypotensive activities of Manidipine.
Niguldipine,Streptokinase may increase the hypotensive activities of Niguldipine.
Rauwolfia serpentina root,Streptokinase may increase the hypotensive activities of Rauwolfia serpentina root.
Selexipag,Streptokinase may increase the hypotensive activities of Selexipag.
Angiotensin 1-7,Streptokinase may increase the hypotensive activities of Angiotensin 1-7.
Rilmenidine,Streptokinase may increase the hypotensive activities of Rilmenidine.
Talinolol,Streptokinase may increase the hypotensive activities of Talinolol.
BQ-123,Streptokinase may increase the hypotensive activities of BQ-123.
Tetrahydropalmatine,Streptokinase may increase the hypotensive activities of Tetrahydropalmatine.
Landiolol,Streptokinase may increase the hypotensive activities of Landiolol.
Urapidil,Streptokinase may increase the hypotensive activities of Urapidil.
Cicletanine,Streptokinase may increase the hypotensive activities of Cicletanine.
Dihydralazine,Streptokinase may increase the hypotensive activities of Dihydralazine.
Guanoxan,Streptokinase may increase the hypotensive activities of Guanoxan.
Vincamine,Streptokinase may increase the hypotensive activities of Vincamine.
Guanoxabenz,Streptokinase may increase the hypotensive activities of Guanoxabenz.
Tolonidine,Streptokinase may increase the hypotensive activities of Tolonidine.
Endralazine,Streptokinase may increase the hypotensive activities of Endralazine.
Esatenolol,Streptokinase may increase the hypotensive activities of Esatenolol.
Cadralazine,Streptokinase may increase the hypotensive activities of Cadralazine.
Cloranolol,Streptokinase may increase the hypotensive activities of Cloranolol.
Cyclopenthiazide,Streptokinase may increase the hypotensive activities of Cyclopenthiazide.
Bietaserpine,Streptokinase may increase the hypotensive activities of Bietaserpine.
Guanazodine,Streptokinase may increase the hypotensive activities of Guanazodine.
Methoserpidine,Streptokinase may increase the hypotensive activities of Methoserpidine.
Epanolol,Streptokinase may increase the hypotensive activities of Epanolol.
Guanoclor,Streptokinase may increase the hypotensive activities of Guanoclor.
Muzolimine,Streptokinase may increase the hypotensive activities of Muzolimine.
Xipamide,Streptokinase may increase the hypotensive activities of Xipamide.
Candesartan,Streptokinase may increase the hypotensive activities of Candesartan.
Dexniguldipine,Streptokinase may increase the hypotensive activities of Dexniguldipine.
Acetylsalicylic acid,Acetylsalicylic acid may increase the anticoagulant activities of Streptokinase.
Tazobactam,The risk or severity of bleeding can be increased when Tazobactam is combined with Streptokinase.
Erythromycin,The risk or severity of bleeding can be increased when Erythromycin is combined with Streptokinase.
Trazodone,The risk or severity of bleeding can be increased when Trazodone is combined with Streptokinase.
Triamcinolone,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Triamcinolone.
Nintedanib,The risk or severity of bleeding can be increased when Streptokinase is combined with Nintedanib.
Escitalopram,The risk or severity of bleeding can be increased when Escitalopram is combined with Streptokinase.
Sertraline,The risk or severity of bleeding can be increased when Sertraline is combined with Streptokinase.
Benzthiazide,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Benzthiazide.
Mebutizide,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Mebutizide.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Alemtuzumab.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Alemtuzumab.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Alemtuzumab.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Alemtuzumab.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Alemtuzumab.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Alemtuzumab.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Alemtuzumab.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Alemtuzumab.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Alemtuzumab."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Alemtuzumab.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Alemtuzumab.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alemtuzumab.
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Alemtuzumab.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Alemtuzumab.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Alemtuzumab.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Alemtuzumab.
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Alemtuzumab.
Basiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Alemtuzumab.
Muromonab,The risk or severity of adverse effects can be increased when Muromonab is combined with Alemtuzumab.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alemtuzumab.
Tositumomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Alemtuzumab.
Alefacept,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Alefacept.
Efalizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Interferon alfa-2b.
Daclizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Beclomethasone dipropionate.
Sorafenib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sorafenib.
Streptozocin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Altretamine.
Zidovudine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zidovudine.
Cisplatin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pentostatin.
Methotrexate,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Methotrexate.
Carbamazepine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carbamazepine.
Vinblastine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Linezolid.
Imatinib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Imatinib.
Triamcinolone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Paclitaxel.
Dexamethasone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexamethasone.
Docetaxel,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Decitabine.
Sunitinib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sunitinib.
Nelarabine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nelarabine.
Abatacept,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abatacept.
Corticotropin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with omega interferon.
Apremilast,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Apremilast.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ponatinib.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Certolizumab pegol.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Blinatumomab.
Ibrutinib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ibrutinib.
Idelalisib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Idelalisib.
Palbociclib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Palbociclib.
Olaparib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olaparib.
Dinutuximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dinutuximab.
Vilanterol,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vilanterol.
Tixocortol,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Antilymphocyte immunoglobulin (horse).
Fluprednisolone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Meprednisone.
Tepoxalin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tepoxalin.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Melengestrol.
Ixekizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Peficitinib.
Clobetasol,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clobetasol.
Sarilumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sirukumab.
Baricitinib,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Baricitinib.
Guselkumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Guselkumab.
Deflazacort,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Deflazacort.
Triptolide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Triptolide.
Siponimod,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Siponimod.
Ozanimod,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Prednylidene,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Prednylidene.
Fluocortin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluclorolone.
Fluticasone,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluticasone.
Tetrandrine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tetrandrine.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Monomethyl fumarate.
Mometasone furoate,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mometasone furoate.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydrocortisone aceponate.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydrocortisone acetate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydrocortisone succinate.
Emapalumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bleselumab.
Natalizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alemtuzumab.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Alemtuzumab.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alemtuzumab.
Clozapine,The risk or severity of neutropenia can be increased when Alemtuzumab is combined with Clozapine.
Darbepoetin alfa,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alemtuzumab.
Erythropoietin,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Alemtuzumab.
Peginesatide,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Alemtuzumab.
Methoxy polyethylene glycol-epoetin beta,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alemtuzumab.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Alemtuzumab.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Alemtuzumab.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Alemtuzumab.
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Alemtuzumab.
Estrone,Estrone may increase the thrombogenic activities of Alemtuzumab.
Estradiol,Estradiol may increase the thrombogenic activities of Alemtuzumab.
Dienestrol,Dienestrol may increase the thrombogenic activities of Alemtuzumab.
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Alemtuzumab.
Mestranol,Mestranol may increase the thrombogenic activities of Alemtuzumab.
Estriol,Estriol may increase the thrombogenic activities of Alemtuzumab.
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Alemtuzumab.
Quinestrol,Quinestrol may increase the thrombogenic activities of Alemtuzumab.
Hexestrol,Hexestrol may increase the thrombogenic activities of Alemtuzumab.
Tibolone,Tibolone may increase the thrombogenic activities of Alemtuzumab.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Alemtuzumab."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Alemtuzumab."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Alemtuzumab.
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Alemtuzumab.
Zeranol,Zeranol may increase the thrombogenic activities of Alemtuzumab.
Equol,Equol may increase the thrombogenic activities of Alemtuzumab.
Promestriene,Promestriene may increase the thrombogenic activities of Alemtuzumab.
Methallenestril,Methallenestril may increase the thrombogenic activities of Alemtuzumab.
Epimestrol,Epimestrol may increase the thrombogenic activities of Alemtuzumab.
Moxestrol,Moxestrol may increase the thrombogenic activities of Alemtuzumab.
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Alemtuzumab.
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Alemtuzumab.
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Alemtuzumab.
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Alemtuzumab.
Biochanin A,Biochanin A may increase the thrombogenic activities of Alemtuzumab.
Formononetin,Formononetin may increase the thrombogenic activities of Alemtuzumab.
Leflunomide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Leflunomide.
Tofacitinib,Alemtuzumab may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Alemtuzumab.
Fingolimod,Alemtuzumab may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Alemtuzumab.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Alemtuzumab.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Alemtuzumab.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Alemtuzumab.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Alemtuzumab.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Alemtuzumab.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Alemtuzumab.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Alemtuzumab.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Alemtuzumab.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Alemtuzumab.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Alemtuzumab."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alemtuzumab.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Alemtuzumab.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alemtuzumab."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Alemtuzumab.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Alemtuzumab.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Alemtuzumab.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alemtuzumab.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Alemtuzumab.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Alemtuzumab.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Alemtuzumab.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Alemtuzumab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Alemtuzumab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Alemtuzumab.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Alemtuzumab.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Alemtuzumab.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Alemtuzumab.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Alemtuzumab.
Eptifibatide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Alemtuzumab.
Ticlopidine,The risk or severity of bleeding can be increased when Ticlopidine is combined with Alemtuzumab.
Anagrelide,The risk or severity of bleeding can be increased when Anagrelide is combined with Alemtuzumab.
Clopidogrel,The risk or severity of bleeding can be increased when Clopidogrel is combined with Alemtuzumab.
Tirofiban,The risk or severity of bleeding can be increased when Tirofiban is combined with Alemtuzumab.
Pentoxifylline,The risk or severity of bleeding can be increased when Pentoxifylline is combined with Alemtuzumab.
Acetylsalicylic acid,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Alemtuzumab.
Dipyridamole,The risk or severity of bleeding can be increased when Dipyridamole is combined with Alemtuzumab.
Iloprost,The risk or severity of bleeding can be increased when Iloprost is combined with Alemtuzumab.
Sulfinpyrazone,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Alemtuzumab.
Cilostazol,The risk or severity of bleeding can be increased when Cilostazol is combined with Alemtuzumab.
Ridogrel,The risk or severity of bleeding can be increased when Ridogrel is combined with Alemtuzumab.
Sevoflurane,The risk or severity of bleeding can be increased when Sevoflurane is combined with Alemtuzumab.
Epoprostenol,The risk or severity of bleeding can be increased when Epoprostenol is combined with Alemtuzumab.
Resveratrol,The risk or severity of bleeding can be increased when Resveratrol is combined with Alemtuzumab.
Nimesulide,The risk or severity of bleeding can be increased when Nimesulide is combined with Alemtuzumab.
Tesmilifene,The risk or severity of bleeding can be increased when Tesmilifene is combined with Alemtuzumab.
Defibrotide,The risk or severity of bleeding can be increased when Defibrotide is combined with Alemtuzumab.
Beraprost,The risk or severity of bleeding can be increased when Beraprost is combined with Alemtuzumab.
Ibudilast,The risk or severity of bleeding can be increased when Ibudilast is combined with Alemtuzumab.
Andrographolide,The risk or severity of bleeding can be increased when Andrographolide is combined with Alemtuzumab.
Prasugrel,The risk or severity of bleeding can be increased when Prasugrel is combined with Alemtuzumab.
Cangrelor,The risk or severity of bleeding can be increased when Cangrelor is combined with Alemtuzumab.
Tranilast,The risk or severity of bleeding can be increased when Tranilast is combined with Alemtuzumab.
Triflusal,The risk or severity of bleeding can be increased when Triflusal is combined with Alemtuzumab.
Ticagrelor,The risk or severity of bleeding can be increased when Ticagrelor is combined with Alemtuzumab.
Icosapent ethyl,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Alemtuzumab.
Vorapaxar,The risk or severity of bleeding can be increased when Vorapaxar is combined with Alemtuzumab.
Trapidil,The risk or severity of bleeding can be increased when Trapidil is combined with Alemtuzumab.
Naftopidil,The risk or severity of bleeding can be increased when Naftopidil is combined with Alemtuzumab.
Sarpogrelate,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Alemtuzumab.
Ifetroban,The risk or severity of bleeding can be increased when Ifetroban is combined with Alemtuzumab.
Nitroaspirin,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Alemtuzumab.
Ketanserin,The risk or severity of bleeding can be increased when Ketanserin is combined with Alemtuzumab.
Indobufen,The risk or severity of bleeding can be increased when Indobufen is combined with Alemtuzumab.
Butylphthalide,The risk or severity of bleeding can be increased when Butylphthalide is combined with Alemtuzumab.
Hydroxytyrosol,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Alemtuzumab.
Ramatroban,The risk or severity of bleeding can be increased when Ramatroban is combined with Alemtuzumab.
Picotamide,The risk or severity of bleeding can be increased when Picotamide is combined with Alemtuzumab.
Cloricromen,The risk or severity of bleeding can be increased when Cloricromen is combined with Alemtuzumab.
Linsidomine,The risk or severity of bleeding can be increased when Linsidomine is combined with Alemtuzumab.
Buflomedil,The risk or severity of bleeding can be increased when Buflomedil is combined with Alemtuzumab.
Relcovaptan,The risk or severity of bleeding can be increased when Relcovaptan is combined with Alemtuzumab.
Ocrelizumab,Ocrelizumab may increase the immunosuppressive activities of Alemtuzumab.
Lipegfilgrastim,Alemtuzumab may increase the myelosuppressive activities of Lipegfilgrastim.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Alemtuzumab.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Alemtuzumab.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alemtuzumab.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Alemtuzumab.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Alemtuzumab.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Alemtuzumab.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Alemtuzumab.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Alemtuzumab.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Alemtuzumab.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Alemtuzumab.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Alemtuzumab.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Alemtuzumab.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Alemtuzumab.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Alemtuzumab.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Alemtuzumab.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Alemtuzumab.
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Alemtuzumab.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Alemtuzumab.
Capromab pendetide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Capromab pendetide.
Palivizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Palivizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Technetium Tc-99m arcitumomab.
Panitumumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pexelizumab.
Epratuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with NAV 1800.
Otelixizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Veltuzumab.
PRO-542,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lumiliximab.
Ipilimumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clenoliximab.
BIIB015,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Catumaxomab.
Volociximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ofatumumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Raxibacumab.
Nivolumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nivolumab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dulaglutide.
Asfotase alfa,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Evolocumab.
Daratumumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Necitumumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Solanezumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tremelimumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lampalizumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Anifrolumab.
Benralizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Plozalizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Besilesomab.
Burosumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cemiplimab.
Camrelizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Refanezumab.
Bermekimab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nemolizumab.
Gedivumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Naratuximab emtansine.
Tildrakizumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tildrakizumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ustekinumab.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zenocutuzumab.
Palifermin,The therapeutic efficacy of Palifermin can be decreased when used in combination with Alemtuzumab.
Lepirudin,The risk or severity of bleeding can be increased when Lepirudin is combined with Alemtuzumab.
Bivalirudin,The risk or severity of bleeding can be increased when Bivalirudin is combined with Alemtuzumab.
Alteplase,The risk or severity of bleeding can be increased when Alteplase is combined with Alemtuzumab.
Urokinase,The risk or severity of bleeding can be increased when Urokinase is combined with Alemtuzumab.
Reteplase,The risk or severity of bleeding can be increased when Reteplase is combined with Alemtuzumab.
Anistreplase,The risk or severity of bleeding can be increased when Anistreplase is combined with Alemtuzumab.
Tenecteplase,The risk or severity of bleeding can be increased when Tenecteplase is combined with Alemtuzumab.
Drotrecogin alfa,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Alemtuzumab.
Streptokinase,The risk or severity of bleeding can be increased when Streptokinase is combined with Alemtuzumab.
Dicoumarol,The risk or severity of bleeding can be increased when Dicoumarol is combined with Alemtuzumab.
Argatroban,The risk or severity of bleeding can be increased when Argatroban is combined with Alemtuzumab.
Ardeparin,The risk or severity of bleeding can be increased when Ardeparin is combined with Alemtuzumab.
Phenindione,The risk or severity of bleeding can be increased when Phenindione is combined with Alemtuzumab.
Fondaparinux,The risk or severity of bleeding can be increased when Fondaparinux is combined with Alemtuzumab.
Warfarin,The risk or severity of bleeding can be increased when Warfarin is combined with Alemtuzumab.
Pentosan polysulfate,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Alemtuzumab.
Phenprocoumon,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Alemtuzumab.
Heparin,The risk or severity of bleeding can be increased when Heparin is combined with Alemtuzumab.
Enoxaparin,The risk or severity of bleeding can be increased when Enoxaparin is combined with Alemtuzumab.
Acenocoumarol,The risk or severity of bleeding can be increased when Acenocoumarol is combined with Alemtuzumab.
4-hydroxycoumarin,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Alemtuzumab.
Coumarin,The risk or severity of bleeding can be increased when Coumarin is combined with Alemtuzumab.
Ximelagatran,The risk or severity of bleeding can be increased when Ximelagatran is combined with Alemtuzumab.
Desmoteplase,The risk or severity of bleeding can be increased when Desmoteplase is combined with Alemtuzumab.
Ancrod,The risk or severity of bleeding can be increased when Ancrod is combined with Alemtuzumab.
Fibrinolysin,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Alemtuzumab.
Rivaroxaban,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Alemtuzumab.
Sulodexide,The risk or severity of bleeding can be increased when Sulodexide is combined with Alemtuzumab.
Semuloparin,The risk or severity of bleeding can be increased when Semuloparin is combined with Alemtuzumab.
Idraparinux,The risk or severity of bleeding can be increased when Idraparinux is combined with Alemtuzumab.
Astaxanthin,The risk or severity of bleeding can be increased when Astaxanthin is combined with Alemtuzumab.
Apixaban,The risk or severity of bleeding can be increased when Apixaban is combined with Alemtuzumab.
Otamixaban,The risk or severity of bleeding can be increased when Otamixaban is combined with Alemtuzumab.
Amediplase,The risk or severity of bleeding can be increased when Amediplase is combined with Alemtuzumab.
Dabigatran etexilate,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Alemtuzumab.
Danaparoid,The risk or severity of bleeding can be increased when Danaparoid is combined with Alemtuzumab.
Dalteparin,The risk or severity of bleeding can be increased when Dalteparin is combined with Alemtuzumab.
Tinzaparin,The risk or severity of bleeding can be increased when Tinzaparin is combined with Alemtuzumab.
Ferulic acid,The risk or severity of bleeding can be increased when Ferulic acid is combined with Alemtuzumab.
(R)-warfarin,The risk or severity of bleeding can be increased when (R)-warfarin is combined with Alemtuzumab.
Ethyl biscoumacetate,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Alemtuzumab.
Nadroparin,The risk or severity of bleeding can be increased when Nadroparin is combined with Alemtuzumab.
Ditazole,The risk or severity of bleeding can be increased when Ditazole is combined with Alemtuzumab.
Edoxaban,The risk or severity of bleeding can be increased when Edoxaban is combined with Alemtuzumab.
Potassium citrate,The risk or severity of bleeding can be increased when Potassium citrate is combined with Alemtuzumab.
Sodium citrate,The risk or severity of bleeding can be increased when Sodium citrate is combined with Alemtuzumab.
Dextran,The risk or severity of bleeding can be increased when Dextran is combined with Alemtuzumab.
Bemiparin,The risk or severity of bleeding can be increased when Bemiparin is combined with Alemtuzumab.
Reviparin,The risk or severity of bleeding can be increased when Reviparin is combined with Alemtuzumab.
Parnaparin,The risk or severity of bleeding can be increased when Parnaparin is combined with Alemtuzumab.
Certoparin,The risk or severity of bleeding can be increased when Certoparin is combined with Alemtuzumab.
Desirudin,The risk or severity of bleeding can be increased when Desirudin is combined with Alemtuzumab.
Zinc citrate,The risk or severity of bleeding can be increased when Zinc citrate is combined with Alemtuzumab.
Antithrombin Alfa,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Alemtuzumab.
Protein C,The risk or severity of bleeding can be increased when Protein C is combined with Alemtuzumab.
Antithrombin III human,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Alemtuzumab.
Letaxaban,The risk or severity of bleeding can be increased when Letaxaban is combined with Alemtuzumab.
Darexaban,The risk or severity of bleeding can be increased when Darexaban is combined with Alemtuzumab.
Betrixaban,The risk or severity of bleeding can be increased when Betrixaban is combined with Alemtuzumab.
Nafamostat,The risk or severity of bleeding can be increased when Nafamostat is combined with Alemtuzumab.
Monteplase,The risk or severity of bleeding can be increased when Monteplase is combined with Alemtuzumab.
Gabexate,The risk or severity of bleeding can be increased when Gabexate is combined with Alemtuzumab.
Fluindione,The risk or severity of bleeding can be increased when Fluindione is combined with Alemtuzumab.
Protein S human,The risk or severity of bleeding can be increased when Protein S human is combined with Alemtuzumab.
Brinase,The risk or severity of bleeding can be increased when Brinase is combined with Alemtuzumab.
Clorindione,The risk or severity of bleeding can be increased when Clorindione is combined with Alemtuzumab.
Diphenadione,The risk or severity of bleeding can be increased when Diphenadione is combined with Alemtuzumab.
Tioclomarol,The risk or severity of bleeding can be increased when Tioclomarol is combined with Alemtuzumab.
Melagatran,The risk or severity of bleeding can be increased when Melagatran is combined with Alemtuzumab.
Saruplase,The risk or severity of bleeding can be increased when Saruplase is combined with Alemtuzumab.
(S)-Warfarin,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Alemtuzumab.
Tocopherylquinone,The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Alemtuzumab.
Edetate calcium disodium anhydrous,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Alemtuzumab.
Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Alemtuzumab.
Methyclothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Alemtuzumab.
Bendroflumethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Alemtuzumab.
Benzthiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Alemtuzumab.
Cyclothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Alemtuzumab.
Hydroflumethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Alemtuzumab.
Chlorothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Alemtuzumab.
Hydrochlorothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Alemtuzumab.
Trichlormethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Alemtuzumab.
Polythiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Alemtuzumab.
Mebutizide,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Alemtuzumab.
Cyclopenthiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Alemtuzumab.
Tedizolid phosphate,The risk or severity of myelosuppression can be increased when Alemtuzumab is combined with Tedizolid phosphate.
Cyclosporine,Alemtuzumab may increase the immunosuppressive activities of Cyclosporine.
Cyanocobalamin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Alemtuzumab.
Allopurinol,The risk or severity of adverse effects can be increased when Allopurinol is combined with Alemtuzumab.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Alemtuzumab."
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Alemtuzumab.
Lopinavir,The serum concentration of Alemtuzumab can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Alemtuzumab is combined with Inebilizumab.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Capromab pendetide.
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Capromab pendetide.
Estrone,Estrone may increase the thrombogenic activities of Capromab pendetide.
Dienestrol,Dienestrol may increase the thrombogenic activities of Capromab pendetide.
Estriol,Estriol may increase the thrombogenic activities of Capromab pendetide.
Quinestrol,Quinestrol may increase the thrombogenic activities of Capromab pendetide.
Hexestrol,Hexestrol may increase the thrombogenic activities of Capromab pendetide.
Tibolone,Tibolone may increase the thrombogenic activities of Capromab pendetide.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Capromab pendetide."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Capromab pendetide."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Capromab pendetide.
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Capromab pendetide.
Zeranol,Zeranol may increase the thrombogenic activities of Capromab pendetide.
Equol,Equol may increase the thrombogenic activities of Capromab pendetide.
Promestriene,Promestriene may increase the thrombogenic activities of Capromab pendetide.
Methallenestril,Methallenestril may increase the thrombogenic activities of Capromab pendetide.
Epimestrol,Epimestrol may increase the thrombogenic activities of Capromab pendetide.
Moxestrol,Moxestrol may increase the thrombogenic activities of Capromab pendetide.
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Capromab pendetide.
Biochanin A,Biochanin A may increase the thrombogenic activities of Capromab pendetide.
Formononetin,Formononetin may increase the thrombogenic activities of Capromab pendetide.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Capromab pendetide.
Estradiol,Estradiol may increase the thrombogenic activities of Capromab pendetide.
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Capromab pendetide.
Mestranol,Mestranol may increase the thrombogenic activities of Capromab pendetide.
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Capromab pendetide.
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Capromab pendetide.
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Capromab pendetide.
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Capromab pendetide.
Leuprolide,Leuprolide may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Goserelin,Goserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Gonadorelin,Gonadorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Nafarelin,Nafarelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Buserelin,Buserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Histrelin,Histrelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Triptorelin,Triptorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Deslorelin,Deslorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Danazol,Danazol may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Elagolix,Elagolix may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Gestrinone,Gestrinone may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Flutamide,Flutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Nilutamide,Nilutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Bicalutamide,Bicalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Enzalutamide,Enzalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Apalutamide,Apalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Darolutamide,Darolutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Cyproterone acetate,Cyproterone acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Chlormadinone,Chlormadinone may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Capromab pendetide.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Capromab pendetide.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Capromab pendetide.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Capromab pendetide.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Capromab pendetide.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Capromab pendetide.
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Capromab pendetide.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Capromab pendetide.
Trastuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Capromab pendetide.
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Capromab pendetide.
Basiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Capromab pendetide.
Muromonab,The risk or severity of adverse effects can be increased when Muromonab is combined with Capromab pendetide.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Capromab pendetide.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Capromab pendetide.
Tositumomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Capromab pendetide.
Alemtuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Capromab pendetide.
Efalizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Antithymocyte immunoglobulin (rabbit).
Natalizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Natalizumab.
Palivizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Palivizumab.
Daclizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bevacizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Technetium Tc-99m arcitumomab.
Eculizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eculizumab.
Panitumumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pexelizumab.
Afelimomab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Afelimomab.
Epratuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with NAV 1800.
Briakinumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Briakinumab.
Otelixizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Veltuzumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ustekinumab.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Trastuzumab emtansine.
PRO-542,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lumiliximab.
Canakinumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Canakinumab.
Ipilimumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Clenoliximab.
Tocilizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tocilizumab.
BIIB015,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Catumaxomab.
Mepolizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Mepolizumab.
Denosumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Denosumab.
Volociximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ofatumumab.
Golimumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Golimumab.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Brentuximab vedotin.
Belimumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Belimumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Raxibacumab.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Certolizumab pegol.
Obinutuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Obinutuzumab.
Secukinumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vedolizumab.
Nivolumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Nivolumab.
Siltuximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Siltuximab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dulaglutide.
Blinatumomab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Blinatumomab.
Anthrax immune globulin human,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Anthrax immune globulin human.
Dinutuximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dinutuximab.
Asfotase alfa,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Evolocumab.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Antilymphocyte immunoglobulin (horse).
Daratumumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Necitumumab.
Ixekizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ravulizumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Solanezumab.
Sarilumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sarilumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tremelimumab.
Brodalumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sirukumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lampalizumab.
Guselkumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Guselkumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Anifrolumab.
Ocrelizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ocrelizumab.
Benralizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Plozalizumab.
Inebilizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Inebilizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Besilesomab.
Tildrakizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tildrakizumab.
Burosumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Cemiplimab.
Emapalumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Risankizumab.
Camrelizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Refanezumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rozanolixizumab.
Bermekimab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Nemolizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bleselumab.
Gedivumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Naratuximab emtansine.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Zenocutuzumab.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Capromab pendetide."
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclosporine.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Cyclosporine.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclosporine.
Acetazolamide,The serum concentration of Cyclosporine can be increased when it is combined with Acetazolamide.
Adalimumab,The serum concentration of Cyclosporine can be decreased when it is combined with Adalimumab.
Afatinib,The serum concentration of Cyclosporine can be increased when it is combined with Afatinib.
Aliskiren,The serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.
Ambrisentan,The serum concentration of Ambrisentan can be increased when it is combined with Cyclosporine.
Amiodarone,The serum concentration of Cyclosporine can be increased when it is combined with Amiodarone.
Amphotericin B,Amphotericin B may increase the nephrotoxic activities of Cyclosporine.
Ketoconazole,Ketoconazole may increase the nephrotoxic activities of Cyclosporine.
Atorvastatin,The excretion of Atorvastatin can be decreased when combined with Cyclosporine.
Boceprevir,The serum concentration of Cyclosporine can be increased when it is combined with Boceprevir.
Bosentan,The serum concentration of Bosentan can be increased when it is combined with Cyclosporine.
Bromocriptine,The serum concentration of Cyclosporine can be increased when it is combined with Bromocriptine.
Carbamazepine,The serum concentration of Cyclosporine can be decreased when it is combined with Carbamazepine.
Carvedilol,The serum concentration of Cyclosporine can be increased when it is combined with Carvedilol.
Caspofungin,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Caspofungin.
Chloramphenicol,The serum concentration of Cyclosporine can be increased when it is combined with Chloramphenicol.
Glycochenodeoxycholic Acid,Cyclosporine may decrease the excretion rate of Glycochenodeoxycholic Acid which could result in a higher serum level.
Prasterone sulfate,Prasterone sulfate may decrease the excretion rate of Cyclosporine which could result in a higher serum level.
Glimepiride,Cyclosporine may decrease the excretion rate of Glimepiride which could result in a higher serum level.
Atropine,Cyclosporine may decrease the excretion rate of Atropine which could result in a higher serum level.
Fluorescein,Cyclosporine may decrease the excretion rate of Fluorescein which could result in a higher serum level.
Nitrofurantoin,Cyclosporine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Cefaclor,Cyclosporine may decrease the excretion rate of Cefaclor which could result in a higher serum level.
Indocyanine green acid form,Cyclosporine may decrease the excretion rate of Indocyanine green acid form which could result in a higher serum level.
Benzbromarone,Cyclosporine may decrease the excretion rate of Benzbromarone which could result in a higher serum level.
Pilsicainide,Cyclosporine may decrease the excretion rate of Pilsicainide which could result in a higher serum level.
Glycyrrhizic acid,Cyclosporine may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.
Rosiglitazone,Cyclosporine may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.
Cholic Acid,Cyclosporine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.
Taurocholic acid,Cyclosporine may decrease the excretion rate of Taurocholic acid which could result in a higher serum level.
Loratadine,Cyclosporine may decrease the excretion rate of Loratadine which could result in a higher serum level.
Dipyridamole,Cyclosporine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.
Colesevelam,The serum concentration of Cyclosporine can be decreased when it is combined with Colesevelam.
Crizotinib,The serum concentration of Cyclosporine can be increased when it is combined with Crizotinib.
Cyclophosphamide,The serum concentration of Cyclosporine can be decreased when it is combined with Cyclophosphamide.
Digoxin,The serum concentration of Digoxin can be increased when it is combined with Cyclosporine.
Metildigoxin,The serum concentration of Metildigoxin can be increased when it is combined with Cyclosporine.
Acetyldigoxin,The serum concentration of Acetyldigoxin can be increased when it is combined with Cyclosporine.
Dronedarone,The serum concentration of Dronedarone can be increased when it is combined with Cyclosporine.
Edoxaban,The serum concentration of Cyclosporine can be increased when it is combined with Edoxaban.
Efavirenz,The serum concentration of Cyclosporine can be decreased when it is combined with Efavirenz.
Enzalutamide,The serum concentration of Cyclosporine can be decreased when it is combined with Enzalutamide.
Etoposide,The serum concentration of Etoposide can be increased when it is combined with Cyclosporine.
Everolimus,The serum concentration of Everolimus can be increased when it is combined with Cyclosporine.
Ezetimibe,The serum concentration of Cyclosporine can be increased when it is combined with Ezetimibe.
Fluconazole,The serum concentration of Cyclosporine can be increased when it is combined with Fluconazole.
Fluvastatin,The serum concentration of Fluvastatin can be increased when it is combined with Cyclosporine.
Foscarnet,Foscarnet may increase the nephrotoxic activities of Cyclosporine.
Phenytoin,The serum concentration of Cyclosporine can be decreased when it is combined with Phenytoin.
Fosphenytoin,The serum concentration of Cyclosporine can be decreased when it is combined with Fosphenytoin.
Glyburide,The therapeutic efficacy of Glyburide can be decreased when used in combination with Cyclosporine.
Griseofulvin,The serum concentration of Cyclosporine can be decreased when it is combined with Griseofulvin.
Imatinib,The serum concentration of Cyclosporine can be increased when it is combined with Imatinib.
Imipenem,Cyclosporine may increase the neurotoxic activities of Imipenem.
Ledipasvir,The serum concentration of Cyclosporine can be increased when it is combined with Ledipasvir.
Lovastatin,The serum concentration of Lovastatin can be increased when it is combined with Cyclosporine.
Melphalan,Melphalan may increase the nephrotoxic activities of Cyclosporine.
Methotrexate,The serum concentration of Methotrexate can be increased when it is combined with Cyclosporine.
Methylprednisolone,The serum concentration of Methylprednisolone can be increased when it is combined with Cyclosporine.
Metoclopramide,Metoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Mifepristone,The serum concentration of Cyclosporine can be increased when it is combined with Mifepristone.
Mitoxantrone,The serum concentration of Mitoxantrone can be increased when it is combined with Cyclosporine.
Armodafinil,The serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil.
Modafinil,The serum concentration of Cyclosporine can be decreased when it is combined with Modafinil.
Nafcillin,The metabolism of Cyclosporine can be increased when combined with Nafcillin.
Norfloxacin,The metabolism of Cyclosporine can be decreased when combined with Norfloxacin.
Omeprazole,The serum concentration of Cyclosporine can be increased when it is combined with Omeprazole.
Esomeprazole,The serum concentration of Cyclosporine can be increased when it is combined with Esomeprazole.
Orlistat,Orlistat can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pitavastatin,The serum concentration of Pitavastatin can be increased when it is combined with Cyclosporine.
Pravastatin,The serum concentration of Pravastatin can be increased when it is combined with Cyclosporine.
Prucalopride,The serum concentration of Prucalopride can be increased when it is combined with Cyclosporine.
Pyrazinamide,The serum concentration of Cyclosporine can be decreased when it is combined with Pyrazinamide.
Quinupristin,The serum concentration of Cyclosporine can be increased when it is combined with Quinupristin.
Ranolazine,The serum concentration of Cyclosporine can be increased when it is combined with Ranolazine.
Repaglinide,The serum concentration of Repaglinide can be increased when it is combined with Cyclosporine.
Rifaximin,The serum concentration of Rifaximin can be increased when it is combined with Cyclosporine.
Ritonavir,The serum concentration of Cyclosporine can be increased when it is combined with Ritonavir.
Rosuvastatin,The serum concentration of Rosuvastatin can be increased when it is combined with Cyclosporine.
Sevelamer,The serum concentration of Cyclosporine can be decreased when it is combined with Sevelamer.
Silodosin,The serum concentration of Cyclosporine can be increased when it is combined with Silodosin.
Simeprevir,The serum concentration of Cyclosporine can be increased when it is combined with Simeprevir.
Simvastatin,The serum concentration of Simvastatin can be increased when it is combined with Cyclosporine.
Sitaxentan,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Sitaxentan.
Sulfinpyrazone,The serum concentration of Cyclosporine can be decreased when it is combined with Sulfinpyrazone.
Telaprevir,The serum concentration of Cyclosporine can be increased when it is combined with Telaprevir.
Ticagrelor,The serum concentration of Ticagrelor can be increased when it is combined with Cyclosporine.
Vitamin E,The serum concentration of Cyclosporine can be decreased when it is combined with Vitamin E.
Remikiren,Cyclosporine may decrease the antihypertensive activities of Remikiren.
Guanadrel,Cyclosporine may decrease the antihypertensive activities of Guanadrel.
Candoxatril,Cyclosporine may decrease the antihypertensive activities of Candoxatril.
Nitroglycerin,Cyclosporine may decrease the antihypertensive activities of Nitroglycerin.
Metyrosine,Cyclosporine may decrease the antihypertensive activities of Metyrosine.
Cryptenamine,Cyclosporine may decrease the antihypertensive activities of Cryptenamine.
Deserpidine,Cyclosporine may decrease the antihypertensive activities of Deserpidine.
Bretylium,Cyclosporine may decrease the antihypertensive activities of Bretylium.
Dexpropranolol,Cyclosporine may decrease the antihypertensive activities of Dexpropranolol.
Tienilic acid,Cyclosporine may decrease the antihypertensive activities of Tienilic acid.
Diethylnorspermine,Cyclosporine may decrease the antihypertensive activities of Diethylnorspermine.
Ferulic acid,Cyclosporine may decrease the antihypertensive activities of Ferulic acid.
Trimazosin,Cyclosporine may decrease the antihypertensive activities of Trimazosin.
Rauwolfia serpentina root,Cyclosporine may decrease the antihypertensive activities of Rauwolfia serpentina root.
Angiotensin 1-7,Cyclosporine may decrease the antihypertensive activities of Angiotensin 1-7.
BQ-123,Cyclosporine may decrease the antihypertensive activities of BQ-123.
Ketanserin,Cyclosporine may decrease the antihypertensive activities of Ketanserin.
Cicletanine,Cyclosporine may decrease the antihypertensive activities of Cicletanine.
Dihydralazine,Cyclosporine may decrease the antihypertensive activities of Dihydralazine.
Guanoxan,Cyclosporine may decrease the antihypertensive activities of Guanoxan.
Vincamine,Cyclosporine may decrease the antihypertensive activities of Vincamine.
Linsidomine,Cyclosporine may decrease the antihypertensive activities of Linsidomine.
Guanoxabenz,Cyclosporine may decrease the antihypertensive activities of Guanoxabenz.
Tolonidine,Cyclosporine may decrease the antihypertensive activities of Tolonidine.
Endralazine,Cyclosporine may decrease the antihypertensive activities of Endralazine.
Cadralazine,Cyclosporine may decrease the antihypertensive activities of Cadralazine.
Bietaserpine,Cyclosporine may decrease the antihypertensive activities of Bietaserpine.
Guanazodine,Cyclosporine may decrease the antihypertensive activities of Guanazodine.
Methoserpidine,Cyclosporine may decrease the antihypertensive activities of Methoserpidine.
Guanoclor,Cyclosporine may decrease the antihypertensive activities of Guanoclor.
Muzolimine,Cyclosporine may decrease the antihypertensive activities of Muzolimine.
Tocopherylquinone,Cyclosporine may decrease the antihypertensive activities of Tocopherylquinone.
Pinacidil,Cyclosporine may decrease the antihypertensive activities of Pinacidil.
Treprostinil,Cyclosporine may decrease the antihypertensive activities of Treprostinil.
Nimodipine,Cyclosporine may decrease the antihypertensive activities of Nimodipine.
Terazosin,Cyclosporine may decrease the antihypertensive activities of Terazosin.
Cilazapril,Cyclosporine may decrease the antihypertensive activities of Cilazapril.
Amlodipine,Cyclosporine may decrease the antihypertensive activities of Amlodipine.
Brexpiprazole,The metabolism of Brexpiprazole can be decreased when combined with Cyclosporine.
Eliglustat,The metabolism of Eliglustat can be decreased when combined with Cyclosporine.
Flibanserin,The metabolism of Cyclosporine can be decreased when combined with Flibanserin.
Ivabradine,The metabolism of Cyclosporine can be decreased when combined with Ivabradine.
Ivacaftor,The metabolism of Cyclosporine can be decreased when combined with Ivacaftor.
Lurasidone,The metabolism of Lurasidone can be decreased when combined with Cyclosporine.
Naloxegol,The metabolism of Naloxegol can be decreased when combined with Cyclosporine.
Sonidegib,The metabolism of Cyclosporine can be decreased when combined with Sonidegib.
Avanafil,The metabolism of Avanafil can be decreased when combined with Cyclosporine.
Succinylcholine,The therapeutic efficacy of Succinylcholine can be increased when used in combination with Cyclosporine.
Metocurine iodide,The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Cyclosporine.
Gallamine triethiodide,The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Cyclosporine.
Cisatracurium,The therapeutic efficacy of Cisatracurium can be increased when used in combination with Cyclosporine.
Rocuronium,The therapeutic efficacy of Rocuronium can be increased when used in combination with Cyclosporine.
Atracurium besylate,The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Cyclosporine.
Doxacurium,The therapeutic efficacy of Doxacurium can be increased when used in combination with Cyclosporine.
Mivacurium,The therapeutic efficacy of Mivacurium can be increased when used in combination with Cyclosporine.
Decamethonium,The therapeutic efficacy of Decamethonium can be increased when used in combination with Cyclosporine.
Metocurine,The therapeutic efficacy of Metocurine can be increased when used in combination with Cyclosporine.
Pancuronium,The therapeutic efficacy of Pancuronium can be increased when used in combination with Cyclosporine.
Pipecuronium,The therapeutic efficacy of Pipecuronium can be increased when used in combination with Cyclosporine.
Vecuronium,The therapeutic efficacy of Vecuronium can be increased when used in combination with Cyclosporine.
Rapacuronium,The therapeutic efficacy of Rapacuronium can be increased when used in combination with Cyclosporine.
Pyrantel,The therapeutic efficacy of Pyrantel can be increased when used in combination with Cyclosporine.
Neosaxitoxin,The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Cyclosporine.
Atracurium,The therapeutic efficacy of Atracurium can be increased when used in combination with Cyclosporine.
Gallamine,The therapeutic efficacy of Gallamine can be increased when used in combination with Cyclosporine.
Alcuronium,The therapeutic efficacy of Alcuronium can be increased when used in combination with Cyclosporine.
Tubocurarine,The therapeutic efficacy of Tubocurarine can be increased when used in combination with Cyclosporine.
Midodrine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Midodrine.
Bethanidine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Bethanidine.
Isoetharine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoetharine.
Zolmitriptan,The risk or severity of hypertension can be increased when Cyclosporine is combined with Zolmitriptan.
Norepinephrine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Norepinephrine.
Phenylephrine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenylephrine.
Phenylpropanolamine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenylpropanolamine.
Doxapram,The risk or severity of hypertension can be increased when Cyclosporine is combined with Doxapram.
Metaraminol,The risk or severity of hypertension can be increased when Cyclosporine is combined with Metaraminol.
Furazolidone,The risk or severity of hypertension can be increased when Cyclosporine is combined with Furazolidone.
Guanabenz,The risk or severity of hypertension can be increased when Cyclosporine is combined with Guanabenz.
Methoxamine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Methoxamine.
Isoflurane,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoflurane.
Propiomazine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Propiomazine.
Tolazoline,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tolazoline.
Orciprenaline,The risk or severity of hypertension can be increased when Cyclosporine is combined with Orciprenaline.
Phenmetrazine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenmetrazine.
Pseudoephedrine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pseudoephedrine.
Ritodrine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ritodrine.
Remifentanil,The risk or severity of hypertension can be increased when Cyclosporine is combined with Remifentanil.
Bitolterol,The risk or severity of hypertension can be increased when Cyclosporine is combined with Bitolterol.
Phenoxybenzamine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenoxybenzamine.
Oxymetazoline,The risk or severity of hypertension can be increased when Cyclosporine is combined with Oxymetazoline.
Diethylpropion,The risk or severity of hypertension can be increased when Cyclosporine is combined with Diethylpropion.
Naratriptan,The risk or severity of hypertension can be increased when Cyclosporine is combined with Naratriptan.
Frovatriptan,The risk or severity of hypertension can be increased when Cyclosporine is combined with Frovatriptan.
Isoprenaline,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoprenaline.
Arbutamine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Arbutamine.
Desflurane,The risk or severity of hypertension can be increased when Cyclosporine is combined with Desflurane.
Isocarboxazid,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isocarboxazid.
Fenoterol,The risk or severity of hypertension can be increased when Cyclosporine is combined with Fenoterol.
Pirbuterol,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pirbuterol.
Ephedra sinica root,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ephedra sinica root.
Ephedrine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ephedrine.
Mephentermine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Mephentermine.
Procaterol,The risk or severity of hypertension can be increased when Cyclosporine is combined with Procaterol.
Clenbuterol,The risk or severity of hypertension can be increased when Cyclosporine is combined with Clenbuterol.
Bambuterol,The risk or severity of hypertension can be increased when Cyclosporine is combined with Bambuterol.
MMDA,The risk or severity of hypertension can be increased when Cyclosporine is combined with MMDA.
"2,5-Dimethoxy-4-ethylamphetamine","The risk or severity of hypertension can be increased when Cyclosporine is combined with 2,5-Dimethoxy-4-ethylamphetamine."
"4-Bromo-2,5-dimethoxyamphetamine","The risk or severity of hypertension can be increased when Cyclosporine is combined with 4-Bromo-2,5-dimethoxyamphetamine."
Tenamfetamine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tenamfetamine.
Chlorphentermine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Chlorphentermine.
Phendimetrazine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phendimetrazine.
Pargyline,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pargyline.
Epicaptopril,The risk or severity of hypertension can be increased when Cyclosporine is combined with Epicaptopril.
Clorgiline,The risk or severity of hypertension can be increased when Cyclosporine is combined with Clorgiline.
1-benzylimidazole,The risk or severity of hypertension can be increased when Cyclosporine is combined with 1-benzylimidazole.
Iproniazid,The risk or severity of hypertension can be increased when Cyclosporine is combined with Iproniazid.
Nialamide,The risk or severity of hypertension can be increased when Cyclosporine is combined with Nialamide.
Amibegron,The risk or severity of hypertension can be increased when Cyclosporine is combined with Amibegron.
Naluzotan,The risk or severity of hypertension can be increased when Cyclosporine is combined with Naluzotan.
Pizotifen,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pizotifen.
Solabegron,The risk or severity of hypertension can be increased when Cyclosporine is combined with Solabegron.
Nitrous oxide,The risk or severity of hypertension can be increased when Cyclosporine is combined with Nitrous oxide.
Xylometazoline,The risk or severity of hypertension can be increased when Cyclosporine is combined with Xylometazoline.
Dexmethylphenidate,The risk or severity of hypertension can be increased when Cyclosporine is combined with Dexmethylphenidate.
Isometheptene,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isometheptene.
Levonordefrin,The risk or severity of hypertension can be increased when Cyclosporine is combined with Levonordefrin.
Naphazoline,The risk or severity of hypertension can be increased when Cyclosporine is combined with Naphazoline.
Tetryzoline,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tetryzoline.
Cinitapride,The risk or severity of hypertension can be increased when Cyclosporine is combined with Cinitapride.
Tyramine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tyramine.
Adrafinil,The risk or severity of hypertension can be increased when Cyclosporine is combined with Adrafinil.
Isoxsuprine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoxsuprine.
Indoramin,The risk or severity of hypertension can be increased when Cyclosporine is combined with Indoramin.
Hexoprenaline,The risk or severity of hypertension can be increased when Cyclosporine is combined with Hexoprenaline.
Etilefrine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Etilefrine.
Cirazoline,The risk or severity of hypertension can be increased when Cyclosporine is combined with Cirazoline.
Synephrine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Synephrine.
Moxonidine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Moxonidine.
Hydracarbazine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Hydracarbazine.
Benmoxin,The risk or severity of hypertension can be increased when Cyclosporine is combined with Benmoxin.
Mebanazine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Mebanazine.
Octamoxin,The risk or severity of hypertension can be increased when Cyclosporine is combined with Octamoxin.
Pheniprazine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pheniprazine.
Phenoxypropazine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenoxypropazine.
Pivhydrazine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pivhydrazine.
Safrazine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Safrazine.
Caroxazone,The risk or severity of hypertension can be increased when Cyclosporine is combined with Caroxazone.
Doxofylline,The risk or severity of hypertension can be increased when Cyclosporine is combined with Doxofylline.
Iofetamine I-123,The risk or severity of hypertension can be increased when Cyclosporine is combined with Iofetamine I-123.
Racepinephrine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Racepinephrine.
Amitraz,The risk or severity of hypertension can be increased when Cyclosporine is combined with Amitraz.
Medetomidine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Medetomidine.
Xylazine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Xylazine.
Atipamezole,The risk or severity of hypertension can be increased when Cyclosporine is combined with Atipamezole.
Ractopamine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ractopamine.
Romifidine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Romifidine.
Detomidine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Detomidine.
Rilmenidine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Rilmenidine.
Tetrahydrocannabivarin,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tetrahydrocannabivarin.
PF-00610355,The risk or severity of hypertension can be increased when Cyclosporine is combined with PF-00610355.
Ritobegron,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ritobegron.
Abediterol,The risk or severity of hypertension can be increased when Cyclosporine is combined with Abediterol.
Tulobuterol,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tulobuterol.
Dopexamine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Dopexamine.
Piclozotan,The risk or severity of hypertension can be increased when Cyclosporine is combined with Piclozotan.
Idazoxan,The risk or severity of hypertension can be increased when Cyclosporine is combined with Idazoxan.
Urapidil,The risk or severity of hypertension can be increased when Cyclosporine is combined with Urapidil.
Higenamine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Higenamine.
Reproterol,The risk or severity of hypertension can be increased when Cyclosporine is combined with Reproterol.
Theodrenaline,The risk or severity of hypertension can be increased when Cyclosporine is combined with Theodrenaline.
Tramazoline,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tramazoline.
Mephedrone,The risk or severity of hypertension can be increased when Cyclosporine is combined with Mephedrone.
Octopamine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Octopamine.
Ibopamine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ibopamine.
Trichloroethylene,The risk or severity of hypertension can be increased when Cyclosporine is combined with Trichloroethylene.
Fenozolone,The risk or severity of hypertension can be increased when Cyclosporine is combined with Fenozolone.
Norfenefrine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Norfenefrine.
Oxyfedrine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Oxyfedrine.
Xenon,The risk or severity of hypertension can be increased when Cyclosporine is combined with Xenon.
Buflomedil,The risk or severity of hypertension can be increased when Cyclosporine is combined with Buflomedil.
Metergoline,The risk or severity of hypertension can be increased when Cyclosporine is combined with Metergoline.
Rimiterol,The risk or severity of hypertension can be increased when Cyclosporine is combined with Rimiterol.
Methoxyphenamine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Methoxyphenamine.
Tretoquinol,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tretoquinol.
Gepefrine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Gepefrine.
Prenalterol,The risk or severity of hypertension can be increased when Cyclosporine is combined with Prenalterol.
Xamoterol,The risk or severity of hypertension can be increased when Cyclosporine is combined with Xamoterol.
Mefenorex,The risk or severity of hypertension can be increased when Cyclosporine is combined with Mefenorex.
Harmaline,The risk or severity of hypertension can be increased when Cyclosporine is combined with Harmaline.
Deoxyepinephrine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Deoxyepinephrine.
"2,5-Dimethoxy-4-ethylthioamphetamine","The risk or severity of hypertension can be increased when Cyclosporine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine."
Quinoline Yellow WS,The risk or severity of hypertension can be increased when Cyclosporine is combined with Quinoline Yellow WS.
Sufentanil,The risk or severity of hypertension can be increased when Cyclosporine is combined with Sufentanil.
Benzphetamine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Benzphetamine.
Ergoloid mesylate,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ergoloid mesylate.
Sevoflurane,The risk or severity of hypertension can be increased when Cyclosporine is combined with Sevoflurane.
Asenapine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Asenapine.
Terguride,The risk or severity of hypertension can be increased when Cyclosporine is combined with Terguride.
Trifluoperazine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Trifluoperazine.
Flupentixol,The risk or severity of hypertension can be increased when Cyclosporine is combined with Flupentixol.
Halothane,The risk or severity of hypertension can be increased when Cyclosporine is combined with Halothane.
Ergometrine,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ergometrine.
Olodaterol,The risk or severity of hypertension can be increased when Cyclosporine is combined with Olodaterol.
Diethyl ether,The risk or severity of hypertension can be increased when Cyclosporine is combined with Diethyl ether.
Pergolide,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pergolide.
Selpercatinib,The risk or severity of hypertension can be increased when Cyclosporine is combined with Selpercatinib.
Cilostazol,The metabolism of Cilostazol can be decreased when combined with Cyclosporine.
Fentanyl,The metabolism of Cyclosporine can be decreased when combined with Fentanyl.
Iloperidone,The metabolism of Iloperidone can be decreased when combined with Cyclosporine.
Retapamulin,The metabolism of Retapamulin can be decreased when combined with Cyclosporine.
Vardenafil,The metabolism of Vardenafil can be decreased when combined with Cyclosporine.
Eszopiclone,The metabolism of Eszopiclone can be decreased when combined with Cyclosporine.
Zopiclone,The metabolism of Zopiclone can be decreased when combined with Cyclosporine.
Metreleptin,The metabolism of Cyclosporine can be increased when combined with Metreleptin.
Alfuzosin,The metabolism of Alfuzosin can be decreased when combined with Cyclosporine.
Alprazolam,The metabolism of Alprazolam can be decreased when combined with Cyclosporine.
Atomoxetine,The metabolism of Atomoxetine can be decreased when combined with Cyclosporine.
Mannitol,The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cyclosporine.
Tenofovir alafenamide,Tenofovir alafenamide may increase the nephrotoxic activities of Cyclosporine.
Tenofovir,Tenofovir may increase the nephrotoxic activities of Cyclosporine.
Tenofovir disoproxil,Cyclosporine may increase the nephrotoxic activities of Tenofovir disoproxil.
Warfarin,The serum concentration of Warfarin can be increased when it is combined with Cyclosporine.
Acenocoumarol,The serum concentration of Acenocoumarol can be increased when it is combined with Cyclosporine.
(R)-warfarin,The serum concentration of (R)-warfarin can be increased when it is combined with Cyclosporine.
"R,S-Warfarin alcohol","The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Cyclosporine."
"S,R-Warfarin alcohol","The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Cyclosporine."
(S)-Warfarin,The serum concentration of (S)-Warfarin can be increased when it is combined with Cyclosporine.
Midazolam,The serum concentration of Midazolam can be increased when it is combined with Cyclosporine.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cyclosporine.
Doxorubicin,The serum concentration of Doxorubicin can be increased when it is combined with Cyclosporine.
Eluxadoline,The serum concentration of Eluxadoline can be increased when it is combined with Cyclosporine.
Clofibrate,The risk or severity of renal failure can be increased when Cyclosporine is combined with Clofibrate.
Fenofibrate,The risk or severity of renal failure can be increased when Cyclosporine is combined with Fenofibrate.
Gemfibrozil,The risk or severity of renal failure can be increased when Cyclosporine is combined with Gemfibrozil.
Bezafibrate,The risk or severity of renal failure can be increased when Cyclosporine is combined with Bezafibrate.
Etofibrate,The risk or severity of renal failure can be increased when Cyclosporine is combined with Etofibrate.
Ciprofibrate,The risk or severity of renal failure can be increased when Cyclosporine is combined with Ciprofibrate.
Simfibrate,The risk or severity of renal failure can be increased when Cyclosporine is combined with Simfibrate.
Ronifibrate,The risk or severity of renal failure can be increased when Cyclosporine is combined with Ronifibrate.
Aluminium clofibrate,The risk or severity of renal failure can be increased when Cyclosporine is combined with Aluminium clofibrate.
Clofibride,The risk or severity of renal failure can be increased when Cyclosporine is combined with Clofibride.
Fenofibric acid,The risk or severity of renal failure can be increased when Cyclosporine is combined with Fenofibric acid.
Minoxidil,The risk or severity of Hypertrichosis can be increased when Cyclosporine is combined with Minoxidil.
Tacrolimus,Tacrolimus may increase the nephrotoxic activities of Cyclosporine.
Octreotide,The serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.
Vapreotide,The serum concentration of Cyclosporine can be decreased when it is combined with Vapreotide.
Pasireotide,The serum concentration of Cyclosporine can be decreased when it is combined with Pasireotide.
Lanreotide,The serum concentration of Cyclosporine can be decreased when it is combined with Lanreotide.
Somatostatin,The serum concentration of Cyclosporine can be decreased when it is combined with Somatostatin.
Ascorbic acid,The serum concentration of Cyclosporine can be decreased when it is combined with Ascorbic acid.
Valsartan,The risk or severity of hyperkalemia can be increased when Valsartan is combined with Cyclosporine.
Olmesartan,The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Cyclosporine.
Losartan,The risk or severity of hyperkalemia can be increased when Losartan is combined with Cyclosporine.
Candesartan cilexetil,The risk or severity of hyperkalemia can be increased when Candesartan cilexetil is combined with Cyclosporine.
Eprosartan,The risk or severity of hyperkalemia can be increased when Eprosartan is combined with Cyclosporine.
Telmisartan,The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Cyclosporine.
Irbesartan,The risk or severity of hyperkalemia can be increased when Irbesartan is combined with Cyclosporine.
Forasartan,The risk or severity of hyperkalemia can be increased when Forasartan is combined with Cyclosporine.
Saprisartan,The risk or severity of hyperkalemia can be increased when Saprisartan is combined with Cyclosporine.
Tasosartan,The risk or severity of hyperkalemia can be increased when Tasosartan is combined with Cyclosporine.
Saralasin,The risk or severity of hyperkalemia can be increased when Saralasin is combined with Cyclosporine.
Azilsartan medoxomil,The risk or severity of hyperkalemia can be increased when Azilsartan medoxomil is combined with Cyclosporine.
Fimasartan,The risk or severity of hyperkalemia can be increased when Fimasartan is combined with Cyclosporine.
Candesartan,The risk or severity of hyperkalemia can be increased when Candesartan is combined with Cyclosporine.
Erythromycin,The metabolism of Cyclosporine can be decreased when combined with Erythromycin.
Azithromycin,The metabolism of Cyclosporine can be decreased when combined with Azithromycin.
Dirithromycin,The metabolism of Cyclosporine can be decreased when combined with Dirithromycin.
Telithromycin,The metabolism of Cyclosporine can be decreased when combined with Telithromycin.
Candicidin,The metabolism of Cyclosporine can be decreased when combined with Candicidin.
Clarithromycin,The metabolism of Cyclosporine can be decreased when combined with Clarithromycin.
Josamycin,The metabolism of Cyclosporine can be decreased when combined with Josamycin.
Epothilone D,The metabolism of Cyclosporine can be decreased when combined with Epothilone D.
Patupilone,The metabolism of Cyclosporine can be decreased when combined with Patupilone.
6-Deoxyerythronolide B,The metabolism of Cyclosporine can be decreased when combined with 6-Deoxyerythronolide B.
KOS-1584,The metabolism of Cyclosporine can be decreased when combined with KOS-1584.
Ridaforolimus,The metabolism of Cyclosporine can be decreased when combined with Ridaforolimus.
AVE9633,The metabolism of Cyclosporine can be decreased when combined with AVE9633.
Coltuximab ravtansine,The metabolism of Cyclosporine can be decreased when combined with Coltuximab ravtansine.
Cethromycin,The metabolism of Cyclosporine can be decreased when combined with Cethromycin.
Mitemcinal,The metabolism of Cyclosporine can be decreased when combined with Mitemcinal.
Brefeldin A,The metabolism of Cyclosporine can be decreased when combined with Brefeldin A.
Solithromycin,The metabolism of Cyclosporine can be decreased when combined with Solithromycin.
Kitasamycin,The metabolism of Cyclosporine can be decreased when combined with Kitasamycin.
Carbomycin,The metabolism of Cyclosporine can be decreased when combined with Carbomycin.
Doramectin,The metabolism of Cyclosporine can be decreased when combined with Doramectin.
Eprinomectin,The metabolism of Cyclosporine can be decreased when combined with Eprinomectin.
Oleandomycin,The metabolism of Cyclosporine can be decreased when combined with Oleandomycin.
Selamectin,The metabolism of Cyclosporine can be decreased when combined with Selamectin.
Tildipirosin,The metabolism of Cyclosporine can be decreased when combined with Tildipirosin.
Tilmicosin,The metabolism of Cyclosporine can be decreased when combined with Tilmicosin.
Tylosin,The metabolism of Cyclosporine can be decreased when combined with Tylosin.
Tylvalosin,The metabolism of Cyclosporine can be decreased when combined with Tylvalosin.
Bryostatin 1,The metabolism of Cyclosporine can be decreased when combined with Bryostatin 1.
Lorvotuzumab mertansine,The metabolism of Cyclosporine can be decreased when combined with Lorvotuzumab mertansine.
Epofolate,The metabolism of Cyclosporine can be decreased when combined with Epofolate.
Sagopilone,The metabolism of Cyclosporine can be decreased when combined with Sagopilone.
Mirvetuximab Soravtansine,The metabolism of Cyclosporine can be decreased when combined with Mirvetuximab Soravtansine.
Troleandomycin,The metabolism of Cyclosporine can be decreased when combined with Troleandomycin.
Miocamycin,The metabolism of Cyclosporine can be decreased when combined with Miocamycin.
Flurithromycin,The metabolism of Cyclosporine can be decreased when combined with Flurithromycin.
Rokitamycin,The metabolism of Cyclosporine can be decreased when combined with Rokitamycin.
Midecamycin,The metabolism of Cyclosporine can be decreased when combined with Midecamycin.
Mepartricin,The metabolism of Cyclosporine can be decreased when combined with Mepartricin.
Etacrynic acid,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Etacrynic acid.
Butalbital,The metabolism of Cyclosporine can be increased when combined with Butalbital.
Pentobarbital,The metabolism of Cyclosporine can be increased when combined with Pentobarbital.
Secobarbital,The metabolism of Cyclosporine can be increased when combined with Secobarbital.
Methohexital,The metabolism of Cyclosporine can be increased when combined with Methohexital.
Thiopental,The metabolism of Cyclosporine can be increased when combined with Thiopental.
Primidone,The metabolism of Cyclosporine can be increased when combined with Primidone.
Methylphenobarbital,The metabolism of Cyclosporine can be increased when combined with Methylphenobarbital.
Thiamylal,The metabolism of Cyclosporine can be increased when combined with Thiamylal.
Phenobarbital,The metabolism of Cyclosporine can be increased when combined with Phenobarbital.
Amobarbital,The metabolism of Cyclosporine can be increased when combined with Amobarbital.
Hexobarbital,The metabolism of Cyclosporine can be increased when combined with Hexobarbital.
Barbital,The metabolism of Cyclosporine can be increased when combined with Barbital.
Barbexaclone,The metabolism of Cyclosporine can be increased when combined with Barbexaclone.
Butabarbital,The metabolism of Butabarbital can be increased when combined with Cyclosporine.
Lumacaftor,The serum concentration of Cyclosporine can be decreased when it is combined with Lumacaftor.
Torasemide,The risk or severity of renal failure can be increased when Cyclosporine is combined with Torasemide.
Bumetanide,The risk or severity of renal failure can be increased when Cyclosporine is combined with Bumetanide.
Piretanide,The risk or severity of renal failure can be increased when Cyclosporine is combined with Piretanide.
Azosemide,The risk or severity of renal failure can be increased when Cyclosporine is combined with Azosemide.
Sildenafil,The risk or severity of renal failure can be increased when Sildenafil is combined with Cyclosporine.
Methyclothiazide,The risk or severity of renal failure can be increased when Methyclothiazide is combined with Cyclosporine.
Sulfisoxazole,The risk or severity of renal failure can be increased when Sulfisoxazole is combined with Cyclosporine.
Chlorthalidone,The risk or severity of renal failure can be increased when Chlorthalidone is combined with Cyclosporine.
Ethoxzolamide,The risk or severity of renal failure can be increased when Ethoxzolamide is combined with Cyclosporine.
Sulfadiazine,The risk or severity of renal failure can be increased when Sulfadiazine is combined with Cyclosporine.
Bendroflumethiazide,The risk or severity of renal failure can be increased when Bendroflumethiazide is combined with Cyclosporine.
Metolazone,The risk or severity of renal failure can be increased when Metolazone is combined with Cyclosporine.
Benzthiazide,The risk or severity of renal failure can be increased when Benzthiazide is combined with Cyclosporine.
Sulfamethizole,The risk or severity of renal failure can be increased when Sulfamethizole is combined with Cyclosporine.
Cyclothiazide,The risk or severity of renal failure can be increased when Cyclothiazide is combined with Cyclosporine.
Sulfametopyrazine,The risk or severity of renal failure can be increased when Sulfametopyrazine is combined with Cyclosporine.
Sumatriptan,The risk or severity of renal failure can be increased when Sumatriptan is combined with Cyclosporine.
Tamsulosin,The risk or severity of renal failure can be increased when Tamsulosin is combined with Cyclosporine.
Hydroflumethiazide,The risk or severity of renal failure can be increased when Hydroflumethiazide is combined with Cyclosporine.
Indapamide,The risk or severity of renal failure can be increased when Indapamide is combined with Cyclosporine.
Chlorothiazide,The risk or severity of renal failure can be increased when Chlorothiazide is combined with Cyclosporine.
Sulfapyridine,The risk or severity of renal failure can be increased when Sulfapyridine is combined with Cyclosporine.
Zonisamide,The risk or severity of renal failure can be increased when Zonisamide is combined with Cyclosporine.
Hydrochlorothiazide,The risk or severity of renal failure can be increased when Hydrochlorothiazide is combined with Cyclosporine.
Trichlormethiazide,The risk or severity of renal failure can be increased when Trichlormethiazide is combined with Cyclosporine.
Probenecid,The risk or severity of renal failure can be increased when Probenecid is combined with Cyclosporine.
Diazoxide,The risk or severity of renal failure can be increased when Diazoxide is combined with Cyclosporine.
Diclofenamide,The risk or severity of renal failure can be increased when Diclofenamide is combined with Cyclosporine.
Sulfacytine,The risk or severity of renal failure can be increased when Sulfacytine is combined with Cyclosporine.
Sulfadoxine,The risk or severity of renal failure can be increased when Sulfadoxine is combined with Cyclosporine.
Polythiazide,The risk or severity of renal failure can be increased when Polythiazide is combined with Cyclosporine.
Quinethazone,The risk or severity of renal failure can be increased when Quinethazone is combined with Cyclosporine.
Glymidine,The risk or severity of renal failure can be increased when Glymidine is combined with Cyclosporine.
Sulfamerazine,The risk or severity of renal failure can be increased when Sulfamerazine is combined with Cyclosporine.
Sulfamethazine,The risk or severity of renal failure can be increased when Sulfamethazine is combined with Cyclosporine.
Hydroxyfasudil,The risk or severity of renal failure can be increased when Hydroxyfasudil is combined with Cyclosporine.
Sulfadimethoxine,The risk or severity of renal failure can be increased when Sulfadimethoxine is combined with Cyclosporine.
Sulfaphenazole,The risk or severity of renal failure can be increased when Sulfaphenazole is combined with Cyclosporine.
Sulfameter,The risk or severity of renal failure can be increased when Sulfameter is combined with Cyclosporine.
5-(2-methylpiperazine-1-sulfonyl)isoquinoline,The risk or severity of renal failure can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Cyclosporine.
Fasudil,The risk or severity of renal failure can be increased when Fasudil is combined with Cyclosporine.
Sulfamoxole,The risk or severity of renal failure can be increased when Sulfamoxole is combined with Cyclosporine.
Clorsulon,The risk or severity of renal failure can be increased when Clorsulon is combined with Cyclosporine.
Sulfachlorpyridazine,The risk or severity of renal failure can be increased when Sulfachlorpyridazine is combined with Cyclosporine.
Sulfaethoxypyridazine,The risk or severity of renal failure can be increased when Sulfaethoxypyridazine is combined with Cyclosporine.
Sulfanitran,The risk or severity of renal failure can be increased when Sulfanitran is combined with Cyclosporine.
Sulfaquinoxaline,The risk or severity of renal failure can be increased when Sulfaquinoxaline is combined with Cyclosporine.
Setrobuvir,The risk or severity of renal failure can be increased when Setrobuvir is combined with Cyclosporine.
Chlorsulfaquinoxaline,The risk or severity of renal failure can be increased when Chlorsulfaquinoxaline is combined with Cyclosporine.
Sulfadicramide,The risk or severity of renal failure can be increased when Sulfadicramide is combined with Cyclosporine.
Phthalylsulfathiazole,The risk or severity of renal failure can be increased when Phthalylsulfathiazole is combined with Cyclosporine.
Sulfaisodimidine,The risk or severity of renal failure can be increased when Sulfaisodimidine is combined with Cyclosporine.
Meticrane,The risk or severity of renal failure can be increased when Meticrane is combined with Cyclosporine.
Sulfaperin,The risk or severity of renal failure can be increased when Sulfaperin is combined with Cyclosporine.
Mefruside,The risk or severity of renal failure can be increased when Mefruside is combined with Cyclosporine.
Mebutizide,The risk or severity of renal failure can be increased when Mebutizide is combined with Cyclosporine.
Sulfametomidine,The risk or severity of renal failure can be increased when Sulfametomidine is combined with Cyclosporine.
Cyclopenthiazide,The risk or severity of renal failure can be increased when Cyclopenthiazide is combined with Cyclosporine.
Sulfatolamide,The risk or severity of renal failure can be increased when Sulfatolamide is combined with Cyclosporine.
Sulfamazone,The risk or severity of renal failure can be increased when Sulfamazone is combined with Cyclosporine.
Succinylsulfathiazole,The risk or severity of renal failure can be increased when Succinylsulfathiazole is combined with Cyclosporine.
Clorexolone,The risk or severity of renal failure can be increased when Clorexolone is combined with Cyclosporine.
Clofenamide,The risk or severity of renal failure can be increased when Clofenamide is combined with Cyclosporine.
Sulfathiourea,The risk or severity of renal failure can be increased when Sulfathiourea is combined with Cyclosporine.
Fenquizone,The risk or severity of renal failure can be increased when Fenquizone is combined with Cyclosporine.
Sulfaguanidine,The risk or severity of renal failure can be increased when Sulfaguanidine is combined with Cyclosporine.
Sulfamethoxypyridazine,The risk or severity of renal failure can be increased when Sulfamethoxypyridazine is combined with Cyclosporine.
Clopamide,The risk or severity of renal failure can be increased when Clopamide is combined with Cyclosporine.
Xipamide,The risk or severity of renal failure can be increased when Xipamide is combined with Cyclosporine.
Acetyl sulfisoxazole,The risk or severity of renal failure can be increased when Acetyl sulfisoxazole is combined with Cyclosporine.
Tosylchloramide,The risk or severity of renal failure can be increased when Tosylchloramide is combined with Cyclosporine.
Indisulam,The risk or severity of renal failure can be increased when Cyclosporine is combined with Indisulam.
Methazolamide,The risk or severity of renal failure can be increased when Methazolamide is combined with Cyclosporine.
Triamterene,The risk or severity of hyperkalemia can be increased when Triamterene is combined with Cyclosporine.
Spironolactone,The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cyclosporine.
Amiloride,The risk or severity of hyperkalemia can be increased when Amiloride is combined with Cyclosporine.
Eplerenone,The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Cyclosporine.
Canrenoic acid,The risk or severity of hyperkalemia can be increased when Canrenoic acid is combined with Cyclosporine.
Canrenone,The risk or severity of hyperkalemia can be increased when Canrenone is combined with Cyclosporine.
Cefotiam,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefotiam.
Cefmenoxime,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefmenoxime.
Cefmetazole,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefmetazole.
Cefpiramide,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefpiramide.
Loracarbef,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Loracarbef.
Cefalotin,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefalotin.
Cefotaxime,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefotaxime.
Bacitracin,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Bacitracin.
Cephaloglycin,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cephaloglycin.
Adefovir dipivoxil,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Adefovir dipivoxil.
Ceforanide,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceforanide.
Cefditoren,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefditoren.
Colistimethate,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Colistimethate.
Cefuroxime,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefuroxime.
Cefapirin,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefapirin.
Cefprozil,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefprozil.
Cefamandole,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefamandole.
Cefazolin,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefazolin.
Cefonicid,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefonicid.
Cefoxitin,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefoxitin.
Ceftizoxime,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftizoxime.
Cefepime,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefepime.
Cefacetrile,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefacetrile.
Cefpodoxime,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefpodoxime.
Hydrolyzed Cephalothin,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Hydrolyzed Cephalothin.
Cephalothin Group,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cephalothin Group.
Latamoxef,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Latamoxef.
Ceftobiprole,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftobiprole.
Ceftaroline fosamil,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftaroline fosamil.
Cefaloridine,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefaloridine.
Cefminox,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefminox.
Flomoxef,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Flomoxef.
Cefatrizine,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefatrizine.
Cefcapene,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefcapene.
Cefodizime,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefodizime.
Cefsulodin,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefsulodin.
Cefetamet,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefetamet.
Cefbuperazone,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefbuperazone.
Cefozopran,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefozopran.
Cefpirome,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefpirome.
Cefazedone,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefazedone.
Ceftezole,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftezole.
Adefovir,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Adefovir.
Inotersen,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Inotersen.
Phenazopyridine,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Phenazopyridine.
Givosiran,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Givosiran.
Cefoperazone,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefoperazone.
Lithium cation,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Lithium cation.
Lithium citrate,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Lithium citrate.
Oxandrolone,The risk or severity of liver damage can be increased when Oxandrolone is combined with Cyclosporine.
Testosterone,The risk or severity of liver damage can be increased when Testosterone is combined with Cyclosporine.
Nandrolone phenpropionate,The risk or severity of liver damage can be increased when Nandrolone phenpropionate is combined with Cyclosporine.
Fluoxymesterone,The risk or severity of liver damage can be increased when Fluoxymesterone is combined with Cyclosporine.
Danazol,The risk or severity of liver damage can be increased when Danazol is combined with Cyclosporine.
Testosterone propionate,The risk or severity of liver damage can be increased when Testosterone propionate is combined with Cyclosporine.
Stanolone,The risk or severity of liver damage can be increased when Stanolone is combined with Cyclosporine.
Oxymetholone,The risk or severity of liver damage can be increased when Oxymetholone is combined with Cyclosporine.
Methyltestosterone,The risk or severity of liver damage can be increased when Methyltestosterone is combined with Cyclosporine.
Stanozolol,The risk or severity of liver damage can be increased when Stanozolol is combined with Cyclosporine.
Nandrolone decanoate,The risk or severity of liver damage can be increased when Nandrolone decanoate is combined with Cyclosporine.
GLPG-0492,The risk or severity of liver damage can be increased when GLPG-0492 is combined with Cyclosporine.
Nandrolone,The risk or severity of liver damage can be increased when Nandrolone is combined with Cyclosporine.
Mesterolone,The risk or severity of liver damage can be increased when Mesterolone is combined with Cyclosporine.
Testosterone cypionate,The risk or severity of liver damage can be increased when Testosterone cypionate is combined with Cyclosporine.
Testosterone enanthate,The risk or severity of liver damage can be increased when Testosterone enanthate is combined with Cyclosporine.
"5-methoxy-N,N-dimethyltryptamine","The metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Cyclosporine."
Codeine,The metabolism of Codeine can be decreased when combined with Cyclosporine.
Meperidine,The metabolism of Meperidine can be decreased when combined with Cyclosporine.
Imipramine,The metabolism of Imipramine can be decreased when combined with Cyclosporine.
Quinidine,The metabolism of Quinidine can be decreased when combined with Cyclosporine.
Procainamide,The metabolism of Procainamide can be decreased when combined with Cyclosporine.
Desipramine,The metabolism of Desipramine can be decreased when combined with Cyclosporine.
Clomipramine,The metabolism of Clomipramine can be decreased when combined with Cyclosporine.
Nevirapine,The metabolism of Cyclosporine can be decreased when combined with Nevirapine.
Asunaprevir,The metabolism of Cyclosporine can be decreased when combined with Asunaprevir.
Oxycodone,The metabolism of Cyclosporine can be decreased when combined with Oxycodone.
Dextromethorphan,The metabolism of Cyclosporine can be decreased when combined with Dextromethorphan.
Nateglinide,The metabolism of Cyclosporine can be decreased when combined with Nateglinide.
Pentamidine,The metabolism of Cyclosporine can be decreased when combined with Pentamidine.
Ondansetron,The metabolism of Cyclosporine can be decreased when combined with Ondansetron.
Chlorpheniramine,The metabolism of Cyclosporine can be decreased when combined with Chlorpheniramine.
Domperidone,The metabolism of Cyclosporine can be decreased when combined with Domperidone.
Vortioxetine,The metabolism of Cyclosporine can be decreased when combined with Vortioxetine.
Valbenazine,The metabolism of Cyclosporine can be decreased when combined with Valbenazine.
Deutetrabenazine,The metabolism of Cyclosporine can be decreased when combined with Deutetrabenazine.
Fluvoxamine,The metabolism of Cyclosporine can be decreased when combined with Fluvoxamine.
Lidocaine,The metabolism of Cyclosporine can be decreased when combined with Lidocaine.
Venlafaxine,The metabolism of Cyclosporine can be decreased when combined with Venlafaxine.
Acetaminophen,The metabolism of Cyclosporine can be decreased when combined with Acetaminophen.
Gefitinib,The metabolism of Cyclosporine can be decreased when combined with Gefitinib.
Methadone,The metabolism of Cyclosporine can be decreased when combined with Methadone.
Terfenadine,The metabolism of Cyclosporine can be decreased when combined with Terfenadine.
Diltiazem,The metabolism of Cyclosporine can be decreased when combined with Diltiazem.
Protriptyline,The metabolism of Cyclosporine can be decreased when combined with Protriptyline.
Quinine,The metabolism of Cyclosporine can be decreased when combined with Quinine.
Fluoxetine,The metabolism of Cyclosporine can be decreased when combined with Fluoxetine.
Duloxetine,The metabolism of Cyclosporine can be decreased when combined with Duloxetine.
Chlorpromazine,The metabolism of Cyclosporine can be decreased when combined with Chlorpromazine.
Buspirone,The metabolism of Cyclosporine can be decreased when combined with Buspirone.
Amoxapine,The metabolism of Cyclosporine can be decreased when combined with Amoxapine.
Doxazosin,The metabolism of Cyclosporine can be decreased when combined with Doxazosin.
Astemizole,The metabolism of Cyclosporine can be decreased when combined with Astemizole.
Paroxetine,The metabolism of Cyclosporine can be decreased when combined with Paroxetine.
Loperamide,The metabolism of Cyclosporine can be decreased when combined with Loperamide.
Buprenorphine,The metabolism of Cyclosporine can be decreased when combined with Buprenorphine.
Tipranavir,The metabolism of Cyclosporine can be decreased when combined with Tipranavir.
Azelastine,The metabolism of Cyclosporine can be decreased when combined with Azelastine.
Selegiline,The metabolism of Cyclosporine can be decreased when combined with Selegiline.
Promethazine,The metabolism of Cyclosporine can be decreased when combined with Promethazine.
Pimozide,The metabolism of Cyclosporine can be decreased when combined with Pimozide.
Sertraline,The metabolism of Cyclosporine can be decreased when combined with Sertraline.
Propafenone,The metabolism of Cyclosporine can be decreased when combined with Propafenone.
Bepridil,The metabolism of Cyclosporine can be decreased when combined with Bepridil.
Yohimbine,The metabolism of Cyclosporine can be decreased when combined with Yohimbine.
Benzyl alcohol,The metabolism of Cyclosporine can be decreased when combined with Benzyl alcohol.
Mirabegron,The metabolism of Cyclosporine can be decreased when combined with Mirabegron.
Netupitant,The metabolism of Cyclosporine can be decreased when combined with Netupitant.
Dacomitinib,The metabolism of Cyclosporine can be decreased when combined with Dacomitinib.
Letermovir,The metabolism of Cyclosporine can be decreased when combined with Letermovir.
Rucaparib,The metabolism of Cyclosporine can be decreased when combined with Rucaparib.
Enasidenib,The metabolism of Cyclosporine can be decreased when combined with Enasidenib.
Eletriptan,The metabolism of Eletriptan can be decreased when combined with Cyclosporine.
Theophylline,The metabolism of Theophylline can be decreased when combined with Cyclosporine.
Darifenacin,The metabolism of Darifenacin can be decreased when combined with Cyclosporine.
Nortriptyline,The metabolism of Nortriptyline can be decreased when combined with Cyclosporine.
Clonidine,The metabolism of Clonidine can be decreased when combined with Cyclosporine.
Trimipramine,The metabolism of Trimipramine can be decreased when combined with Cyclosporine.
Doxepin,The metabolism of Doxepin can be decreased when combined with Cyclosporine.
Quetiapine,The metabolism of Quetiapine can be decreased when combined with Cyclosporine.
Clozapine,The metabolism of Cyclosporine can be decreased when combined with Clozapine.
Progesterone,The metabolism of Cyclosporine can be decreased when combined with Progesterone.
Tamoxifen,The metabolism of Cyclosporine can be decreased when combined with Tamoxifen.
Nifedipine,The metabolism of Cyclosporine can be decreased when combined with Nifedipine.
Tesmilifene,The metabolism of Cyclosporine can be decreased when combined with Tesmilifene.
Clevidipine,The metabolism of Cyclosporine can be decreased when combined with Clevidipine.
Nefazodone,The metabolism of Cyclosporine can be decreased when combined with Nefazodone.
Delavirdine,The metabolism of Cyclosporine can be decreased when combined with Delavirdine.
Citalopram,The metabolism of Citalopram can be decreased when combined with Cyclosporine.
Atenolol,The metabolism of Atenolol can be decreased when combined with Cyclosporine.
Acebutolol,The metabolism of Acebutolol can be decreased when combined with Cyclosporine.
Nadolol,The metabolism of Nadolol can be decreased when combined with Cyclosporine.
Debrisoquine,The metabolism of Debrisoquine can be decreased when combined with Cyclosporine.
Celiprolol,The metabolism of Celiprolol can be decreased when combined with Cyclosporine.
Umeclidinium,The metabolism of Umeclidinium can be decreased when combined with Cyclosporine.
Talinolol,The metabolism of Talinolol can be decreased when combined with Cyclosporine.
Elagolix,The metabolism of Elagolix can be decreased when combined with Cyclosporine.
Amphetamine,The metabolism of Amphetamine can be decreased when combined with Cyclosporine.
Benzatropine,The metabolism of Benzatropine can be decreased when combined with Cyclosporine.
Labetalol,The metabolism of Labetalol can be decreased when combined with Cyclosporine.
Maprotiline,The metabolism of Maprotiline can be decreased when combined with Cyclosporine.
Pindolol,The metabolism of Pindolol can be decreased when combined with Cyclosporine.
Arformoterol,The metabolism of Arformoterol can be decreased when combined with Cyclosporine.
Penbutolol,The metabolism of Penbutolol can be decreased when combined with Cyclosporine.
Metamfetamine,The metabolism of Metamfetamine can be decreased when combined with Cyclosporine.
Lofexidine,The metabolism of Lofexidine can be decreased when combined with Cyclosporine.
Arotinolol,The metabolism of Arotinolol can be decreased when combined with Cyclosporine.
Mephenytoin,The metabolism of Mephenytoin can be decreased when combined with Cyclosporine.
Formoterol,The metabolism of Formoterol can be decreased when combined with Cyclosporine.
Diphenhydramine,The metabolism of Diphenhydramine can be decreased when combined with Cyclosporine.
Moclobemide,The metabolism of Moclobemide can be decreased when combined with Cyclosporine.
Tapentadol,The metabolism of Tapentadol can be decreased when combined with Cyclosporine.
Erlotinib,The metabolism of Erlotinib can be decreased when combined with Cyclosporine.
Esmolol,The metabolism of Esmolol can be decreased when combined with Cyclosporine.
Betaxolol,The metabolism of Betaxolol can be decreased when combined with Cyclosporine.
Olanzapine,The metabolism of Olanzapine can be decreased when combined with Cyclosporine.
Remoxipride,The metabolism of Remoxipride can be decreased when combined with Cyclosporine.
Sotalol,The metabolism of Sotalol can be decreased when combined with Cyclosporine.
Piperazine,The metabolism of Piperazine can be decreased when combined with Cyclosporine.
Thioridazine,The metabolism of Thioridazine can be decreased when combined with Cyclosporine.
Nicergoline,The metabolism of Nicergoline can be decreased when combined with Cyclosporine.
Meclizine,The metabolism of Meclizine can be decreased when combined with Cyclosporine.
Minaprine,The metabolism of Minaprine can be decreased when combined with Cyclosporine.
Alprenolol,The metabolism of Alprenolol can be decreased when combined with Cyclosporine.
Phenformin,The metabolism of Phenformin can be decreased when combined with Cyclosporine.
Mesoridazine,The metabolism of Mesoridazine can be decreased when combined with Cyclosporine.
Mequitazine,The metabolism of Mequitazine can be decreased when combined with Cyclosporine.
Tegaserod,The metabolism of Tegaserod can be decreased when combined with Cyclosporine.
Dexfenfluramine,The metabolism of Dexfenfluramine can be decreased when combined with Cyclosporine.
Flecainide,The metabolism of Flecainide can be decreased when combined with Cyclosporine.
Encainide,The metabolism of Encainide can be decreased when combined with Cyclosporine.
Lisdexamfetamine,The metabolism of Lisdexamfetamine can be decreased when combined with Cyclosporine.
Bevantolol,The metabolism of Bevantolol can be decreased when combined with Cyclosporine.
Practolol,The metabolism of Practolol can be decreased when combined with Cyclosporine.
Methotrimeprazine,The metabolism of Methotrimeprazine can be decreased when combined with Cyclosporine.
Aprindine,The metabolism of Aprindine can be decreased when combined with Cyclosporine.
Midomafetamine,The metabolism of Midomafetamine can be decreased when combined with Cyclosporine.
4-Methoxyamphetamine,The metabolism of 4-Methoxyamphetamine can be decreased when combined with Cyclosporine.
Dextroamphetamine,The metabolism of Dextroamphetamine can be decreased when combined with Cyclosporine.
Oxprenolol,The metabolism of Oxprenolol can be decreased when combined with Cyclosporine.
Tetrabenazine,The metabolism of Tetrabenazine can be decreased when combined with Cyclosporine.
Vernakalant,The metabolism of Vernakalant can be decreased when combined with Cyclosporine.
Repinotan,The metabolism of Repinotan can be decreased when combined with Cyclosporine.
Tafenoquine,The metabolism of Tafenoquine can be decreased when combined with Cyclosporine.
Esmirtazapine,The metabolism of Esmirtazapine can be decreased when combined with Cyclosporine.
Bufuralol,The metabolism of Bufuralol can be decreased when combined with Cyclosporine.
Sparteine,The metabolism of Sparteine can be decreased when combined with Cyclosporine.
Enclomiphene,The metabolism of Enclomiphene can be decreased when combined with Cyclosporine.
Bopindolol,The metabolism of Bopindolol can be decreased when combined with Cyclosporine.
Bupranolol,The metabolism of Bupranolol can be decreased when combined with Cyclosporine.
Indenolol,The metabolism of Indenolol can be decreased when combined with Cyclosporine.
Befunolol,The metabolism of Befunolol can be decreased when combined with Cyclosporine.
Dosulepin,The metabolism of Dosulepin can be decreased when combined with Cyclosporine.
Levobetaxolol,The metabolism of Levobetaxolol can be decreased when combined with Cyclosporine.
Anisodamine,The metabolism of Anisodamine can be decreased when combined with Cyclosporine.
Landiolol,The metabolism of Landiolol can be decreased when combined with Cyclosporine.
Bucindolol,The metabolism of Bucindolol can be decreased when combined with Cyclosporine.
Opipramol,The metabolism of Opipramol can be decreased when combined with Cyclosporine.
Esatenolol,The metabolism of Esatenolol can be decreased when combined with Cyclosporine.
Cloranolol,The metabolism of Cloranolol can be decreased when combined with Cyclosporine.
Mepindolol,The metabolism of Mepindolol can be decreased when combined with Cyclosporine.
Dexchlorpheniramine,The metabolism of Dexchlorpheniramine can be decreased when combined with Cyclosporine.
Epanolol,The metabolism of Epanolol can be decreased when combined with Cyclosporine.
Tertatolol,The metabolism of Tertatolol can be decreased when combined with Cyclosporine.
Levomilnacipran,The metabolism of Levomilnacipran can be decreased when combined with Cyclosporine.
Nicotine,The metabolism of Cyclosporine can be decreased when combined with Nicotine.
Cevimeline,The metabolism of Cyclosporine can be decreased when combined with Cevimeline.
Ticlopidine,The metabolism of Cyclosporine can be decreased when combined with Ticlopidine.
Metoprolol,The metabolism of Cyclosporine can be decreased when combined with Metoprolol.
Bupivacaine,The metabolism of Cyclosporine can be decreased when combined with Bupivacaine.
Chlorzoxazone,The metabolism of Cyclosporine can be decreased when combined with Chlorzoxazone.
Mirtazapine,The metabolism of Cyclosporine can be decreased when combined with Mirtazapine.
Palonosetron,The metabolism of Cyclosporine can be decreased when combined with Palonosetron.
Mexiletine,The metabolism of Cyclosporine can be decreased when combined with Mexiletine.
Promazine,The metabolism of Cyclosporine can be decreased when combined with Promazine.
Prochlorperazine,The metabolism of Cyclosporine can be decreased when combined with Prochlorperazine.
Cinnarizine,The metabolism of Cyclosporine can be decreased when combined with Cinnarizine.
Lisuride,The metabolism of Cyclosporine can be decreased when combined with Lisuride.
Dextropropoxyphene,The metabolism of Cyclosporine can be decreased when combined with Dextropropoxyphene.
Trazodone,The metabolism of Cyclosporine can be decreased when combined with Trazodone.
Galantamine,The metabolism of Cyclosporine can be decreased when combined with Galantamine.
Amprenavir,The metabolism of Cyclosporine can be decreased when combined with Amprenavir.
Risperidone,The metabolism of Cyclosporine can be decreased when combined with Risperidone.
Dolasetron,The metabolism of Cyclosporine can be decreased when combined with Dolasetron.
Donepezil,The metabolism of Cyclosporine can be decreased when combined with Donepezil.
Perphenazine,The metabolism of Cyclosporine can be decreased when combined with Perphenazine.
Almotriptan,The metabolism of Cyclosporine can be decreased when combined with Almotriptan.
Methoxyflurane,The metabolism of Cyclosporine can be decreased when combined with Methoxyflurane.
Tolterodine,The metabolism of Cyclosporine can be decreased when combined with Tolterodine.
Perhexiline,The metabolism of Cyclosporine can be decreased when combined with Perhexiline.
Escitalopram,The metabolism of Cyclosporine can be decreased when combined with Escitalopram.
Oxymorphone,The metabolism of Cyclosporine can be decreased when combined with Oxymorphone.
Tiotropium,The metabolism of Cyclosporine can be decreased when combined with Tiotropium.
Ethylmorphine,The metabolism of Cyclosporine can be decreased when combined with Ethylmorphine.
Dihydrocodeine,The metabolism of Cyclosporine can be decreased when combined with Dihydrocodeine.
Solifenacin,The metabolism of Cyclosporine can be decreased when combined with Solifenacin.
Pipotiazine,The metabolism of Cyclosporine can be decreased when combined with Pipotiazine.
Zuclopenthixol,The metabolism of Cyclosporine can be decreased when combined with Zuclopenthixol.
Fusidic acid,The metabolism of Cyclosporine can be decreased when combined with Fusidic acid.
Phenacetin,The metabolism of Cyclosporine can be decreased when combined with Phenacetin.
Lysergic acid diethylamide,The metabolism of Cyclosporine can be decreased when combined with Lysergic acid diethylamide.
Flunarizine,The metabolism of Cyclosporine can be decreased when combined with Flunarizine.
Nebivolol,The metabolism of Cyclosporine can be decreased when combined with Nebivolol.
Lorcaserin,The metabolism of Cyclosporine can be decreased when combined with Lorcaserin.
Dapoxetine,The metabolism of Cyclosporine can be decreased when combined with Dapoxetine.
Rotigotine,The metabolism of Cyclosporine can be decreased when combined with Rotigotine.
Cariprazine,The metabolism of Cyclosporine can be decreased when combined with Cariprazine.
Sertindole,The metabolism of Cyclosporine can be decreased when combined with Sertindole.
Mianserin,The metabolism of Cyclosporine can be decreased when combined with Mianserin.
Alogliptin,The metabolism of Cyclosporine can be decreased when combined with Alogliptin.
Dapagliflozin,The metabolism of Cyclosporine can be decreased when combined with Dapagliflozin.
Vilazodone,The metabolism of Cyclosporine can be decreased when combined with Vilazodone.
Fesoterodine,The metabolism of Cyclosporine can be decreased when combined with Fesoterodine.
Perospirone,The metabolism of Cyclosporine can be decreased when combined with Perospirone.
Dasabuvir,The metabolism of Cyclosporine can be decreased when combined with Dasabuvir.
Lorpiprazole,The metabolism of Cyclosporine can be decreased when combined with Lorpiprazole.
Dexchlorpheniramine maleate,The metabolism of Cyclosporine can be decreased when combined with Dexchlorpheniramine maleate.
Opium,The metabolism of Cyclosporine can be decreased when combined with Opium.
Rupatadine,The metabolism of Cyclosporine can be decreased when combined with Rupatadine.
Encorafenib,The metabolism of Cyclosporine can be decreased when combined with Encorafenib.
Triclabendazole,The metabolism of Cyclosporine can be decreased when combined with Triclabendazole.
Ipecac,The metabolism of Cyclosporine can be decreased when combined with Ipecac.
Butyrfentanyl,The metabolism of Butyrfentanyl can be decreased when combined with Cyclosporine.
Istradefylline,The metabolism of Istradefylline can be decreased when combined with Cyclosporine.
Bicifadine,The metabolism of Bicifadine can be decreased when combined with Cyclosporine.
Paliperidone,The metabolism of Cyclosporine can be decreased when combined with Paliperidone.
Propranolol,The metabolism of Cyclosporine can be decreased when combined with Propranolol.
Zolpidem,The metabolism of Zolpidem can be decreased when combined with Cyclosporine.
Hydrocodone,The metabolism of Hydrocodone can be decreased when combined with Cyclosporine.
Ramipril,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Ramipril.
Ardeparin,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Ardeparin.
Trandolapril,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Trandolapril.
Benazepril,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Benazepril.
Moexipril,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Moexipril.
Quinapril,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Quinapril.
Omapatrilat,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Omapatrilat.
Heparin,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Heparin.
Rescinnamine,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Rescinnamine.
Enoxaparin,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Enoxaparin.
Spirapril,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Spirapril.
Penicillin G Acyl-Serine,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Penicillin G Acyl-Serine.
Sulodexide,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Sulodexide.
Danaparoid,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Danaparoid.
Dalteparin,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Dalteparin.
Tinzaparin,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Tinzaparin.
Nadroparin,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Nadroparin.
Temocapril,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Temocapril.
Bemiparin,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Bemiparin.
Reviparin,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Reviparin.
Parnaparin,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Parnaparin.
Certoparin,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Certoparin.
Imidapril,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Imidapril.
Mannitol busulfan,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Mannitol busulfan.
Zofenopril,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Zofenopril.
Delapril,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Delapril.
Benazeprilat,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Benazeprilat.
Fosinoprilat,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Fosinoprilat.
Ramiprilat,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Ramiprilat.
Perindoprilat,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Perindoprilat.
Quinaprilat,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Quinaprilat.
Dantrolene,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Dantrolene.
Lacidipine,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Lacidipine.
Naftopidil,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Naftopidil.
Tetrahydropalmatine,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Tetrahydropalmatine.
Levomenthol,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Levomenthol.
Prenylamine,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Prenylamine.
Cyclandelate,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Cyclandelate.
Fluspirilene,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Fluspirilene.
Seletracetam,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Seletracetam.
Nylidrin,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Nylidrin.
Dotarizine,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Dotarizine.
Agmatine,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Agmatine.
Fendiline,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Fendiline.
Eperisone,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Eperisone.
Pinaverium,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Pinaverium.
Aranidipine,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Aranidipine.
Azelnidipine,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Azelnidipine.
Cilnidipine,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Cilnidipine.
Darodipine,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Darodipine.
Niludipine,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Niludipine.
Carboxyamidotriazole,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Carboxyamidotriazole.
Bencyclane,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Bencyclane.
Otilonium,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Otilonium.
Terodiline,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Terodiline.
Lidoflazine,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Lidoflazine.
Penfluridol,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Penfluridol.
Caroverine,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Caroverine.
Fish oil,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Fish oil.
Tranilast,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Tranilast.
Gallopamil,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Gallopamil.
Dexverapamil,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Dexverapamil.
Emopamil,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Emopamil.
Lomerizine,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Lomerizine.
Cobimetinib,The metabolism of Cyclosporine can be decreased when combined with Cobimetinib.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Cyclosporine.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Cyclosporine.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Cyclosporine.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Cyclosporine.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Cyclosporine.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cyclosporine.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Cyclosporine.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Cyclosporine.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Cyclosporine.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Cyclosporine."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Cyclosporine.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Cyclosporine.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cyclosporine."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Cyclosporine.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Cyclosporine.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cyclosporine.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Cyclosporine.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cyclosporine.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cyclosporine.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Cyclosporine.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Cyclosporine.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Cyclosporine.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Cyclosporine.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Cyclosporine.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Cyclosporine.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Cyclosporine.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Cyclosporine.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Cyclosporine."
Betrixaban,The serum concentration of Cyclosporine can be increased when it is combined with Betrixaban.
Vemurafenib,The serum concentration of Cyclosporine can be increased when it is combined with Vemurafenib.
Icosapent,The risk or severity of renal failure and hypertension can be increased when Icosapent is combined with Cyclosporine.
Mesalazine,The risk or severity of renal failure and hypertension can be increased when Mesalazine is combined with Cyclosporine.
Nabumetone,The risk or severity of renal failure and hypertension can be increased when Nabumetone is combined with Cyclosporine.
Ketorolac,The risk or severity of renal failure and hypertension can be increased when Ketorolac is combined with Cyclosporine.
Tenoxicam,The risk or severity of renal failure and hypertension can be increased when Tenoxicam is combined with Cyclosporine.
Celecoxib,The risk or severity of renal failure and hypertension can be increased when Celecoxib is combined with Cyclosporine.
Tolmetin,The risk or severity of renal failure and hypertension can be increased when Tolmetin is combined with Cyclosporine.
Rofecoxib,The risk or severity of renal failure and hypertension can be increased when Rofecoxib is combined with Cyclosporine.
Piroxicam,The risk or severity of renal failure and hypertension can be increased when Piroxicam is combined with Cyclosporine.
Fenoprofen,The risk or severity of renal failure and hypertension can be increased when Fenoprofen is combined with Cyclosporine.
Valdecoxib,The risk or severity of renal failure and hypertension can be increased when Valdecoxib is combined with Cyclosporine.
Sulindac,The risk or severity of renal failure and hypertension can be increased when Sulindac is combined with Cyclosporine.
Flurbiprofen,The risk or severity of renal failure and hypertension can be increased when Flurbiprofen is combined with Cyclosporine.
Etodolac,The risk or severity of renal failure and hypertension can be increased when Etodolac is combined with Cyclosporine.
Mefenamic acid,The risk or severity of renal failure and hypertension can be increased when Mefenamic acid is combined with Cyclosporine.
Naproxen,The risk or severity of renal failure and hypertension can be increased when Naproxen is combined with Cyclosporine.
Phenylbutazone,The risk or severity of renal failure and hypertension can be increased when Phenylbutazone is combined with Cyclosporine.
Meloxicam,The risk or severity of renal failure and hypertension can be increased when Meloxicam is combined with Cyclosporine.
Carprofen,The risk or severity of renal failure and hypertension can be increased when Carprofen is combined with Cyclosporine.
Diflunisal,The risk or severity of renal failure and hypertension can be increased when Diflunisal is combined with Cyclosporine.
Salicylic acid,The risk or severity of renal failure and hypertension can be increased when Salicylic acid is combined with Cyclosporine.
Meclofenamic acid,The risk or severity of renal failure and hypertension can be increased when Meclofenamic acid is combined with Cyclosporine.
Acetylsalicylic acid,The risk or severity of renal failure and hypertension can be increased when Acetylsalicylic acid is combined with Cyclosporine.
Oxaprozin,The risk or severity of renal failure and hypertension can be increased when Oxaprozin is combined with Cyclosporine.
Ketoprofen,The risk or severity of renal failure and hypertension can be increased when Ketoprofen is combined with Cyclosporine.
Balsalazide,The risk or severity of renal failure and hypertension can be increased when Balsalazide is combined with Cyclosporine.
Ibuprofen,The risk or severity of renal failure and hypertension can be increased when Ibuprofen is combined with Cyclosporine.
Olsalazine,The risk or severity of renal failure and hypertension can be increased when Olsalazine is combined with Cyclosporine.
Lumiracoxib,The risk or severity of renal failure and hypertension can be increased when Lumiracoxib is combined with Cyclosporine.
Magnesium salicylate,The risk or severity of renal failure and hypertension can be increased when Magnesium salicylate is combined with Cyclosporine.
Salsalate,The risk or severity of renal failure and hypertension can be increased when Salsalate is combined with Cyclosporine.
Choline magnesium trisalicylate,The risk or severity of renal failure and hypertension can be increased when Choline magnesium trisalicylate is combined with Cyclosporine.
Antrafenine,The risk or severity of renal failure and hypertension can be increased when Antrafenine is combined with Cyclosporine.
Aminophenazone,The risk or severity of renal failure and hypertension can be increased when Aminophenazone is combined with Cyclosporine.
Antipyrine,The risk or severity of renal failure and hypertension can be increased when Antipyrine is combined with Cyclosporine.
Tiaprofenic acid,The risk or severity of renal failure and hypertension can be increased when Tiaprofenic acid is combined with Cyclosporine.
Etoricoxib,The risk or severity of renal failure and hypertension can be increased when Etoricoxib is combined with Cyclosporine.
Taxifolin,The risk or severity of renal failure and hypertension can be increased when Taxifolin is combined with Cyclosporine.
Oxyphenbutazone,The risk or severity of renal failure and hypertension can be increased when Oxyphenbutazone is combined with Cyclosporine.
Niflumic acid,The risk or severity of renal failure and hypertension can be increased when Niflumic acid is combined with Cyclosporine.
Licofelone,The risk or severity of renal failure and hypertension can be increased when Licofelone is combined with Cyclosporine.
Nimesulide,The risk or severity of renal failure and hypertension can be increased when Nimesulide is combined with Cyclosporine.
Benoxaprofen,The risk or severity of renal failure and hypertension can be increased when Benoxaprofen is combined with Cyclosporine.
Metamizole,The risk or severity of renal failure and hypertension can be increased when Metamizole is combined with Cyclosporine.
Zomepirac,The risk or severity of renal failure and hypertension can be increased when Zomepirac is combined with Cyclosporine.
Cimicoxib,The risk or severity of renal failure and hypertension can be increased when Cimicoxib is combined with Cyclosporine.
Lornoxicam,The risk or severity of renal failure and hypertension can be increased when Lornoxicam is combined with Cyclosporine.
Aceclofenac,The risk or severity of renal failure and hypertension can be increased when Aceclofenac is combined with Cyclosporine.
Zaltoprofen,The risk or severity of renal failure and hypertension can be increased when Zaltoprofen is combined with Cyclosporine.
Azapropazone,The risk or severity of renal failure and hypertension can be increased when Azapropazone is combined with Cyclosporine.
Felbinac,The risk or severity of renal failure and hypertension can be increased when Felbinac is combined with Cyclosporine.
Parecoxib,The risk or severity of renal failure and hypertension can be increased when Parecoxib is combined with Cyclosporine.
Salicylamide,The risk or severity of renal failure and hypertension can be increased when Salicylamide is combined with Cyclosporine.
Kebuzone,The risk or severity of renal failure and hypertension can be increased when Kebuzone is combined with Cyclosporine.
Isoxicam,The risk or severity of renal failure and hypertension can be increased when Isoxicam is combined with Cyclosporine.
Indoprofen,The risk or severity of renal failure and hypertension can be increased when Indoprofen is combined with Cyclosporine.
Ibuproxam,The risk or severity of renal failure and hypertension can be increased when Ibuproxam is combined with Cyclosporine.
Floctafenine,The risk or severity of renal failure and hypertension can be increased when Floctafenine is combined with Cyclosporine.
Fenbufen,The risk or severity of renal failure and hypertension can be increased when Fenbufen is combined with Cyclosporine.
Etofenamate,The risk or severity of renal failure and hypertension can be increased when Etofenamate is combined with Cyclosporine.
Epirizole,The risk or severity of renal failure and hypertension can be increased when Epirizole is combined with Cyclosporine.
Benzydamine,The risk or severity of renal failure and hypertension can be increased when Benzydamine is combined with Cyclosporine.
Loxoprofen,The risk or severity of renal failure and hypertension can be increased when Loxoprofen is combined with Cyclosporine.
Dexibuprofen,The risk or severity of renal failure and hypertension can be increased when Dexibuprofen is combined with Cyclosporine.
Dexketoprofen,The risk or severity of renal failure and hypertension can be increased when Dexketoprofen is combined with Cyclosporine.
Droxicam,The risk or severity of renal failure and hypertension can be increased when Droxicam is combined with Cyclosporine.
Tolfenamic acid,The risk or severity of renal failure and hypertension can be increased when Tolfenamic acid is combined with Cyclosporine.
Firocoxib,The risk or severity of renal failure and hypertension can be increased when Firocoxib is combined with Cyclosporine.
Clonixin,The risk or severity of renal failure and hypertension can be increased when Clonixin is combined with Cyclosporine.
Morniflumate,The risk or severity of renal failure and hypertension can be increased when Morniflumate is combined with Cyclosporine.
Propacetamol,The risk or severity of renal failure and hypertension can be increased when Propacetamol is combined with Cyclosporine.
Talniflumate,The risk or severity of renal failure and hypertension can be increased when Talniflumate is combined with Cyclosporine.
Robenacoxib,The risk or severity of renal failure and hypertension can be increased when Robenacoxib is combined with Cyclosporine.
Flunixin,The risk or severity of renal failure and hypertension can be increased when Flunixin is combined with Cyclosporine.
Polmacoxib,The risk or severity of renal failure and hypertension can be increased when Polmacoxib is combined with Cyclosporine.
Nitroaspirin,The risk or severity of renal failure and hypertension can be increased when Nitroaspirin is combined with Cyclosporine.
Betulinic Acid,The risk or severity of renal failure and hypertension can be increased when Betulinic Acid is combined with Cyclosporine.
Indobufen,The risk or severity of renal failure and hypertension can be increased when Indobufen is combined with Cyclosporine.
Ebselen,The risk or severity of renal failure and hypertension can be increased when Ebselen is combined with Cyclosporine.
Tinoridine,The risk or severity of renal failure and hypertension can be increased when Tinoridine is combined with Cyclosporine.
Alclofenac,The risk or severity of renal failure and hypertension can be increased when Alclofenac is combined with Cyclosporine.
Fentiazac,The risk or severity of renal failure and hypertension can be increased when Fentiazac is combined with Cyclosporine.
Suxibuzone,The risk or severity of renal failure and hypertension can be increased when Suxibuzone is combined with Cyclosporine.
Bumadizone,The risk or severity of renal failure and hypertension can be increased when Bumadizone is combined with Cyclosporine.
Alminoprofen,The risk or severity of renal failure and hypertension can be increased when Alminoprofen is combined with Cyclosporine.
Flunoxaprofen,The risk or severity of renal failure and hypertension can be increased when Flunoxaprofen is combined with Cyclosporine.
Feprazone,The risk or severity of renal failure and hypertension can be increased when Feprazone is combined with Cyclosporine.
Difenpiramide,The risk or severity of renal failure and hypertension can be increased when Difenpiramide is combined with Cyclosporine.
Nifenazone,The risk or severity of renal failure and hypertension can be increased when Nifenazone is combined with Cyclosporine.
Lonazolac,The risk or severity of renal failure and hypertension can be increased when Lonazolac is combined with Cyclosporine.
Tenidap,The risk or severity of renal failure and hypertension can be increased when Tenidap is combined with Cyclosporine.
Bendazac,The risk or severity of renal failure and hypertension can be increased when Bendazac is combined with Cyclosporine.
Pranoprofen,The risk or severity of renal failure and hypertension can be increased when Pranoprofen is combined with Cyclosporine.
Propyphenazone,The risk or severity of renal failure and hypertension can be increased when Propyphenazone is combined with Cyclosporine.
Proglumetacin,The risk or severity of renal failure and hypertension can be increased when Proglumetacin is combined with Cyclosporine.
Guacetisal,The risk or severity of renal failure and hypertension can be increased when Guacetisal is combined with Cyclosporine.
Ethenzamide,The risk or severity of renal failure and hypertension can be increased when Ethenzamide is combined with Cyclosporine.
Carbaspirin calcium,The risk or severity of renal failure and hypertension can be increased when Carbaspirin calcium is combined with Cyclosporine.
Mofebutazone,The risk or severity of renal failure and hypertension can be increased when Mofebutazone is combined with Cyclosporine.
Proquazone,The risk or severity of renal failure and hypertension can be increased when Proquazone is combined with Cyclosporine.
Benorilate,The risk or severity of renal failure and hypertension can be increased when Benorilate is combined with Cyclosporine.
Pirprofen,The risk or severity of renal failure and hypertension can be increased when Pirprofen is combined with Cyclosporine.
Acemetacin,The risk or severity of renal failure and hypertension can be increased when Acemetacin is combined with Cyclosporine.
Imidazole salicylate,The risk or severity of renal failure and hypertension can be increased when Imidazole salicylate is combined with Cyclosporine.
SC-236,The risk or severity of renal failure and hypertension can be increased when SC-236 is combined with Cyclosporine.
NS-398,The risk or severity of renal failure and hypertension can be increased when NS-398 is combined with Cyclosporine.
Flurbiprofen axetil,The risk or severity of renal failure and hypertension can be increased when Flurbiprofen axetil is combined with Cyclosporine.
Barnidipine,The serum concentration of Barnidipine can be increased when it is combined with Cyclosporine.
Mifamurtide,The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Cyclosporine.
Apalutamide,The serum concentration of Cyclosporine can be decreased when it is combined with Apalutamide.
Pitolisant,The serum concentration of Cyclosporine can be decreased when it is combined with Pitolisant.
Isavuconazole,The serum concentration of Cyclosporine can be increased when it is combined with Isavuconazole.
Isavuconazonium,The serum concentration of Cyclosporine can be increased when it is combined with Isavuconazonium.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Cyclosporine.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Cyclosporine.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Cyclosporine.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Cyclosporine.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Cyclosporine.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Cyclosporine.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Cyclosporine.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Cyclosporine.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Cyclosporine.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Cyclosporine.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Cyclosporine.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Cyclosporine.
Folic acid,Cyclosporine may decrease the excretion rate of Folic acid which could result in a higher serum level.
Riluzole,Cyclosporine may decrease the excretion rate of Riluzole which could result in a higher serum level.
Alvocidib,Cyclosporine may decrease the excretion rate of Alvocidib which could result in a higher serum level.
Riociguat,Cyclosporine may decrease the excretion rate of Riociguat which could result in a higher serum level.
Darolutamide,Cyclosporine may decrease the excretion rate of Darolutamide which could result in a higher serum level.
Conjugated estrogens,Cyclosporine may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
Prazosin,Cyclosporine may decrease the excretion rate of Prazosin which could result in a higher serum level.
Lamivudine,Cyclosporine may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Camptothecin,Cyclosporine may decrease the excretion rate of Camptothecin which could result in a higher serum level.
Abemaciclib,Cyclosporine may decrease the excretion rate of Abemaciclib which could result in a higher serum level.
Lusutrombopag,Cyclosporine may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.
Bisoprolol,The serum concentration of Bisoprolol can be increased when it is combined with Cyclosporine.
Aripiprazole,The metabolism of Aripiprazole can be decreased when combined with Cyclosporine.
Aripiprazole lauroxil,The metabolism of Aripiprazole lauroxil can be decreased when combined with Cyclosporine.
Lymecycline,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Lymecycline.
Clomocycline,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Clomocycline.
Tigecycline,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Tigecycline.
Oxytetracycline,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Oxytetracycline.
Demeclocycline,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Demeclocycline.
Metacycline,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Metacycline.
Rolitetracycline,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Rolitetracycline.
Magnesium oxide,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium oxide.
Magnesium cation,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium cation.
Lincomycin,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Lincomycin.
Viomycin,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Viomycin.
Magnesium acetate tetrahydrate,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium acetate tetrahydrate.
Magnesium citrate,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium citrate.
Magnesium glycinate,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium glycinate.
Magnesium Aluminum Silicate,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium Aluminum Silicate.
Magnesium silicate,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium silicate.
Penimepicycline,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Penimepicycline.
Magnesium aspartate,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium aspartate.
Magnesium gluconate,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium gluconate.
Magnesium orotate,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium orotate.
Magnesium phosphate,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium phosphate.
Magnesium acetate,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium acetate.
Botulinum Toxin Type B,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Botulinum Toxin Type B.
Botulinum toxin type A,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Botulinum toxin type A.
Mecamylamine,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Mecamylamine.
Pentolinium,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Pentolinium.
Trimethaphan,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Trimethaphan.
Tetraethylammonium,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Tetraethylammonium.
Hexamethonium,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Hexamethonium.
Cyclopentamine,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Cyclopentamine.
Pamidronic acid,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Pamidronic acid.
Zoledronic acid,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Zoledronic acid.
Alendronic acid,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Alendronic acid.
Ibandronate,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Ibandronate.
Clodronic acid,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Clodronic acid.
Risedronic acid,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Risedronic acid.
Etidronic acid,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Etidronic acid.
Tiludronic acid,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Tiludronic acid.
Incadronic acid,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Incadronic acid.
Dabigatran etexilate,The serum concentration of Dabigatran etexilate can be increased when it is combined with Cyclosporine.
Dinoprostone,The excretion of Dinoprostone can be decreased when combined with Cyclosporine.
Benzylpenicillin,The excretion of Benzylpenicillin can be decreased when combined with Cyclosporine.
Ouabain,The excretion of Ouabain can be decreased when combined with Cyclosporine.
Atrasentan,The excretion of Atrasentan can be decreased when combined with Cyclosporine.
Gimatecan,The excretion of Gimatecan can be decreased when combined with Cyclosporine.
Cholecystokinin,The excretion of Cholecystokinin can be decreased when combined with Cyclosporine.
Gadoxetic acid,The excretion of Gadoxetic acid can be decreased when combined with Cyclosporine.
Liotrix,The excretion of Liotrix can be decreased when combined with Cyclosporine.
Ursodeoxycholic acid,The risk or severity of liver damage can be increased when Cyclosporine is combined with Ursodeoxycholic acid.
Valinomycin,The risk or severity of liver damage can be increased when Cyclosporine is combined with Valinomycin.
Lamotrigine,Cyclosporine may decrease the excretion rate of Lamotrigine which could result in a higher serum level.
Goserelin,Cyclosporine may decrease the excretion rate of Goserelin which could result in a higher serum level.
Salmon calcitonin,Cyclosporine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
Desmopressin,Cyclosporine may decrease the excretion rate of Desmopressin which could result in a higher serum level.
Daptomycin,Cyclosporine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cyanocobalamin,Cyclosporine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Pyridoxine,Cyclosporine may decrease the excretion rate of Pyridoxine which could result in a higher serum level.
Carbidopa,Cyclosporine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
Oseltamivir,Cyclosporine may decrease the excretion rate of Oseltamivir which could result in a higher serum level.
Hydroxocobalamin,Cyclosporine may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.
Gadodiamide,Cyclosporine may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
Milrinone,Cyclosporine may decrease the excretion rate of Milrinone which could result in a higher serum level.
Diatrizoate,Cyclosporine may decrease the excretion rate of Diatrizoate which could result in a higher serum level.
Acarbose,Cyclosporine may decrease the excretion rate of Acarbose which could result in a higher serum level.
Etomidate,Cyclosporine may decrease the excretion rate of Etomidate which could result in a higher serum level.
Ertapenem,Cyclosporine may decrease the excretion rate of Ertapenem which could result in a higher serum level.
Ibutilide,Cyclosporine may decrease the excretion rate of Ibutilide which could result in a higher serum level.
Piperacillin,Cyclosporine may decrease the excretion rate of Piperacillin which could result in a higher serum level.
Tolcapone,Cyclosporine may decrease the excretion rate of Tolcapone which could result in a higher serum level.
Nitroprusside,Cyclosporine may decrease the excretion rate of Nitroprusside which could result in a higher serum level.
Ethambutol,Cyclosporine may decrease the excretion rate of Ethambutol which could result in a higher serum level.
Metformin,Cyclosporine may decrease the excretion rate of Metformin which could result in a higher serum level.
Aztreonam,Cyclosporine may decrease the excretion rate of Aztreonam which could result in a higher serum level.
Sucralfate,Cyclosporine may decrease the excretion rate of Sucralfate which could result in a higher serum level.
Cidofovir,Cyclosporine may decrease the excretion rate of Cidofovir which could result in a higher serum level.
Thiethylperazine,Cyclosporine may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.
Pramipexole,Cyclosporine may decrease the excretion rate of Pramipexole which could result in a higher serum level.
Ampicillin,Cyclosporine may decrease the excretion rate of Ampicillin which could result in a higher serum level.
Methylphenidate,Cyclosporine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Ceftazidime,Cyclosporine may decrease the excretion rate of Ceftazidime which could result in a higher serum level.
Fosinopril,Cyclosporine may decrease the excretion rate of Fosinopril which could result in a higher serum level.
Cefdinir,Cyclosporine may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Azelaic acid,Cyclosporine may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
Methoxsalen,Cyclosporine may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
Zanamivir,Cyclosporine may decrease the excretion rate of Zanamivir which could result in a higher serum level.
Fondaparinux,Cyclosporine may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Valaciclovir,Cyclosporine may decrease the excretion rate of Valaciclovir which could result in a higher serum level.
Levocarnitine,Cyclosporine may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
Gadoteridol,Cyclosporine may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
Dexmedetomidine,Cyclosporine may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
Dyphylline,Cyclosporine may decrease the excretion rate of Dyphylline which could result in a higher serum level.
Metaxalone,Cyclosporine may decrease the excretion rate of Metaxalone which could result in a higher serum level.
Nilutamide,Cyclosporine may decrease the excretion rate of Nilutamide which could result in a higher serum level.
Chlorpropamide,Cyclosporine may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
Phentolamine,Cyclosporine may decrease the excretion rate of Phentolamine which could result in a higher serum level.
Oxacillin,Cyclosporine may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Nedocromil,Cyclosporine may decrease the excretion rate of Nedocromil which could result in a higher serum level.
Lisinopril,Cyclosporine may decrease the excretion rate of Lisinopril which could result in a higher serum level.
Thiabendazole,Cyclosporine may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
Pralidoxime,Cyclosporine may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
Gadobenic acid,Cyclosporine may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
Meropenem,Cyclosporine may decrease the excretion rate of Meropenem which could result in a higher serum level.
Potassium chloride,Cyclosporine may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
Tirofiban,Cyclosporine may decrease the excretion rate of Tirofiban which could result in a higher serum level.
Propantheline,Cyclosporine may decrease the excretion rate of Propantheline which could result in a higher serum level.
Acyclovir,Cyclosporine may decrease the excretion rate of Acyclovir which could result in a higher serum level.
Gadopentetic acid,Cyclosporine may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
Perindopril,Cyclosporine may decrease the excretion rate of Perindopril which could result in a higher serum level.
Fenoldopam,Cyclosporine may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
Dicyclomine,Cyclosporine may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Pentoxifylline,Cyclosporine may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.
Ribavirin,Cyclosporine may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Fosfomycin,Cyclosporine may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Tolazamide,Cyclosporine may decrease the excretion rate of Tolazamide which could result in a higher serum level.
Dobutamine,Cyclosporine may decrease the excretion rate of Dobutamine which could result in a higher serum level.
Terbutaline,Cyclosporine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Testolactone,Cyclosporine may decrease the excretion rate of Testolactone which could result in a higher serum level.
Didanosine,Cyclosporine may decrease the excretion rate of Didanosine which could result in a higher serum level.
Amantadine,Cyclosporine may decrease the excretion rate of Amantadine which could result in a higher serum level.
Rizatriptan,Cyclosporine may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
Mepivacaine,Cyclosporine may decrease the excretion rate of Mepivacaine which could result in a higher serum level.
Methyldopa,Cyclosporine may decrease the excretion rate of Methyldopa which could result in a higher serum level.
Dopamine,Cyclosporine may decrease the excretion rate of Dopamine which could result in a higher serum level.
Auranofin,Cyclosporine may decrease the excretion rate of Auranofin which could result in a higher serum level.
Ganciclovir,Cyclosporine may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
Edrophonium,Cyclosporine may decrease the excretion rate of Edrophonium which could result in a higher serum level.
Phylloquinone,Cyclosporine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Memantine,Cyclosporine may decrease the excretion rate of Memantine which could result in a higher serum level.
Lubiprostone,Cyclosporine may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Abacavir,Cyclosporine may decrease the excretion rate of Abacavir which could result in a higher serum level.
Amoxicillin,Cyclosporine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Tolbutamide,Cyclosporine may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
Cefadroxil,Cyclosporine may decrease the excretion rate of Cefadroxil which could result in a higher serum level.
Flavoxate,Cyclosporine may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Trimetrexate,Cyclosporine may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
Flumazenil,Cyclosporine may decrease the excretion rate of Flumazenil which could result in a higher serum level.
Fomepizole,Cyclosporine may decrease the excretion rate of Fomepizole which could result in a higher serum level.
Epoprostenol,Cyclosporine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.
Iodixanol,Cyclosporine may decrease the excretion rate of Iodixanol which could result in a higher serum level.
Varenicline,Cyclosporine may decrease the excretion rate of Varenicline which could result in a higher serum level.
Cefotetan,Cyclosporine may decrease the excretion rate of Cefotetan which could result in a higher serum level.
Rasagiline,Cyclosporine may decrease the excretion rate of Rasagiline which could result in a higher serum level.
Ceftibuten,Cyclosporine may decrease the excretion rate of Ceftibuten which could result in a higher serum level.
Amrinone,Cyclosporine may decrease the excretion rate of Amrinone which could result in a higher serum level.
Oxybenzone,Cyclosporine may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
Fenproporex,Cyclosporine may decrease the excretion rate of Fenproporex which could result in a higher serum level.
Chloral hydrate,Cyclosporine may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
Valganciclovir,Cyclosporine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Sorbitol,Cyclosporine may decrease the excretion rate of Sorbitol which could result in a higher serum level.
Pegaptanib,Cyclosporine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Ezogabine,Cyclosporine may decrease the excretion rate of Ezogabine which could result in a higher serum level.
Migalastat,Cyclosporine may decrease the excretion rate of Migalastat which could result in a higher serum level.
Pentaerythritol tetranitrate,Cyclosporine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
Ipilimumab,Cyclosporine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Icatibant,Cyclosporine may decrease the excretion rate of Icatibant which could result in a higher serum level.
Prasugrel,Cyclosporine may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Doripenem,Cyclosporine may decrease the excretion rate of Doripenem which could result in a higher serum level.
Nalmefene,Cyclosporine may decrease the excretion rate of Nalmefene which could result in a higher serum level.
Droxidopa,Cyclosporine may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Telavancin,Cyclosporine may decrease the excretion rate of Telavancin which could result in a higher serum level.
Flupirtine,Cyclosporine may decrease the excretion rate of Flupirtine which could result in a higher serum level.
Gadofosveset trisodium,Cyclosporine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Ammonium chloride,Cyclosporine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
Dimercaprol,Cyclosporine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
Mangafodipir,Cyclosporine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
Methylnaltrexone,Cyclosporine may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Plerixafor,Cyclosporine may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Tiopronin,Cyclosporine may decrease the excretion rate of Tiopronin which could result in a higher serum level.
Triethylenetetramine,Cyclosporine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Ioflupane I-123,Cyclosporine may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
Deferiprone,Cyclosporine may decrease the excretion rate of Deferiprone which could result in a higher serum level.
N-methylnicotinamide,Cyclosporine may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.
Gabapentin enacarbil,Cyclosporine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
Peginesatide,Cyclosporine may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Aclidinium,Cyclosporine may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Teduglutide,Cyclosporine may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Gemeprost,Cyclosporine may decrease the excretion rate of Gemeprost which could result in a higher serum level.
Ceftolozane,Cyclosporine may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Corifollitropin alfa,Cyclosporine may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
Idebenone,Cyclosporine may decrease the excretion rate of Idebenone which could result in a higher serum level.
Ancestim,Cyclosporine may decrease the excretion rate of Ancestim which could result in a higher serum level.
Magnesium hydroxide,Cyclosporine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Hydroxyethyl Starch,Cyclosporine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Pentastarch,Cyclosporine may decrease the excretion rate of Pentastarch which could result in a higher serum level.
Aurothioglucose,Cyclosporine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
Chromic chloride,Cyclosporine may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Gadoteric acid,Cyclosporine may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Iothalamic acid,Cyclosporine may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Ioversol,Cyclosporine may decrease the excretion rate of Ioversol which could result in a higher serum level.
Ioxilan,Cyclosporine may decrease the excretion rate of Ioxilan which could result in a higher serum level.
Isosulfan blue,Cyclosporine may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Technetium Tc-99m mebrofenin,Cyclosporine may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
Technetium Tc-99m oxidronate,Cyclosporine may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
Florbetaben (18F),Cyclosporine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir (18F),Cyclosporine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Iopromide,Cyclosporine may decrease the excretion rate of Iopromide which could result in a higher serum level.
Technetium Tc-99m exametazime,Cyclosporine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
Technetium Tc-99m pyrophosphate,Cyclosporine may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Viloxazine,Cyclosporine may decrease the excretion rate of Viloxazine which could result in a higher serum level.
Etoperidone,Cyclosporine may decrease the excretion rate of Etoperidone which could result in a higher serum level.
Moxisylyte,Cyclosporine may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
Pholcodine,Cyclosporine may decrease the excretion rate of Pholcodine which could result in a higher serum level.
Piracetam,Cyclosporine may decrease the excretion rate of Piracetam which could result in a higher serum level.
Bisoxatin,Cyclosporine may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
Nicorandil,Cyclosporine may decrease the excretion rate of Nicorandil which could result in a higher serum level.
Melperone,Cyclosporine may decrease the excretion rate of Melperone which could result in a higher serum level.
Pirlindole,Cyclosporine may decrease the excretion rate of Pirlindole which could result in a higher serum level.
Toloxatone,Cyclosporine may decrease the excretion rate of Toloxatone which could result in a higher serum level.
Dextran,Cyclosporine may decrease the excretion rate of Dextran which could result in a higher serum level.
Gimeracil,Cyclosporine may decrease the excretion rate of Gimeracil which could result in a higher serum level.
Idarucizumab,Cyclosporine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Lixisenatide,Cyclosporine may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Picosulfuric acid,Cyclosporine may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Sodium aurothiomalate,Cyclosporine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
Choline C 11,Cyclosporine may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
Magnesium trisilicate,Cyclosporine may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Sacubitril,Cyclosporine may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Chondroitin sulfate,Cyclosporine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
Procaine benzylpenicillin,Cyclosporine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Sulbactam,Cyclosporine may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sodium fluoride,Cyclosporine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
"Antihemophilic Factor (Recombinant), PEGylated","Cyclosporine may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level."
Mersalyl,Cyclosporine may decrease the excretion rate of Mersalyl which could result in a higher serum level.
Invert sugar,Cyclosporine may decrease the excretion rate of Invert sugar which could result in a higher serum level.
Dexpanthenol,Cyclosporine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Phosphoric acid,Cyclosporine may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Sodium acetate,Cyclosporine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Magnesium chloride,Cyclosporine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Potassium perchlorate,Cyclosporine may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
Sodium sulfate,Cyclosporine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Enalaprilat,Cyclosporine may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
Magnesium carbonate,Cyclosporine may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
Acrivastine,Cyclosporine may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Octinoxate,Cyclosporine may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Fludeoxyglucose (18F),Cyclosporine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Iobenguane sulfate I-123,Cyclosporine may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Polyethylene glycol 400,Cyclosporine may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
Potassium nitrate,Cyclosporine may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium bicarbonate,Cyclosporine may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
N-acetyltyrosine,Cyclosporine may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Eucalyptus oil,Cyclosporine may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Selenious acid,Cyclosporine may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Selenium,Cyclosporine may decrease the excretion rate of Selenium which could result in a higher serum level.
Chromium,Cyclosporine may decrease the excretion rate of Chromium which could result in a higher serum level.
Oxyquinoline,Cyclosporine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Bicisate,Cyclosporine may decrease the excretion rate of Bicisate which could result in a higher serum level.
DL-Methylephedrine,Cyclosporine may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
Tetradecyl hydrogen sulfate (ester),Cyclosporine may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Clove oil,Cyclosporine may decrease the excretion rate of Clove oil which could result in a higher serum level.
Evening primrose oil,Cyclosporine may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
Pidotimod,Cyclosporine may decrease the excretion rate of Pidotimod which could result in a higher serum level.
Cefroxadine,Cyclosporine may decrease the excretion rate of Cefroxadine which could result in a higher serum level.
Indigotindisulfonic acid,Cyclosporine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Etafedrine,Cyclosporine may decrease the excretion rate of Etafedrine which could result in a higher serum level.
Antithrombin III human,Cyclosporine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Naldemedine,Cyclosporine may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Tropisetron,Cyclosporine may decrease the excretion rate of Tropisetron which could result in a higher serum level.
Benznidazole,Cyclosporine may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Isoflavone,Cyclosporine may decrease the excretion rate of Isoflavone which could result in a higher serum level.
Vaborbactam,Cyclosporine may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Brincidofovir,Cyclosporine may decrease the excretion rate of Brincidofovir which could result in a higher serum level.
Benserazide,Cyclosporine may decrease the excretion rate of Benserazide which could result in a higher serum level.
Tiapride,Cyclosporine may decrease the excretion rate of Tiapride which could result in a higher serum level.
Inosine pranobex,Cyclosporine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
Inositol,Cyclosporine may decrease the excretion rate of Inositol which could result in a higher serum level.
Oxabolone cipionate,Cyclosporine may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.
Phosphocreatine,Cyclosporine may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.
Dichlorobenzyl alcohol,Cyclosporine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
Almasilate,Cyclosporine may decrease the excretion rate of Almasilate which could result in a higher serum level.
Albutrepenonacog alfa,Cyclosporine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Bismuth subgallate,Cyclosporine may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Patent Blue,Cyclosporine may decrease the excretion rate of Patent Blue which could result in a higher serum level.
Choline salicylate,Cyclosporine may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
Pentetic acid,Cyclosporine may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Potassium acetate,Cyclosporine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium sulfate,Cyclosporine may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
Chromic citrate,Cyclosporine may decrease the excretion rate of Chromic citrate which could result in a higher serum level.
Chromic nitrate,Cyclosporine may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
Chromium gluconate,Cyclosporine may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
Chromium nicotinate,Cyclosporine may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Chromous sulfate,Cyclosporine may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
Pyrithione,Cyclosporine may decrease the excretion rate of Pyrithione which could result in a higher serum level.
Chloroxylenol,Cyclosporine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
Oxazepam,Cyclosporine may decrease the excretion rate of Oxazepam which could result in a higher serum level.
Isosorbide mononitrate,Cyclosporine may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
Glipizide,Cyclosporine may decrease the excretion rate of Glipizide which could result in a higher serum level.
Bromazepam,Cyclosporine may decrease the excretion rate of Bromazepam which could result in a higher serum level.
Temazepam,Cyclosporine may decrease the excretion rate of Temazepam which could result in a higher serum level.
Guanethidine,Cyclosporine may decrease the excretion rate of Guanethidine which could result in a higher serum level.
Resorcinol,Cyclosporine may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Levosalbutamol,Cyclosporine may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
Guanfacine,Cyclosporine may decrease the excretion rate of Guanfacine which could result in a higher serum level.
Macitentan,Cyclosporine may decrease the excretion rate of Macitentan which could result in a higher serum level.
Etonogestrel,Cyclosporine may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
Dienogest,Cyclosporine may decrease the excretion rate of Dienogest which could result in a higher serum level.
Leuprolide,Cyclosporine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Disopyramide,Cyclosporine may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Ropivacaine,Cyclosporine may decrease the excretion rate of Ropivacaine which could result in a higher serum level.
Clorazepic acid,Cyclosporine may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
Tinidazole,Cyclosporine may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Salbutamol,Cyclosporine may decrease the excretion rate of Salbutamol which could result in a higher serum level.
Levobupivacaine,Cyclosporine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.
Sibutramine,Cyclosporine may decrease the excretion rate of Sibutramine which could result in a higher serum level.
Estazolam,Cyclosporine may decrease the excretion rate of Estazolam which could result in a higher serum level.
Levocetirizine,Cyclosporine may decrease the excretion rate of Levocetirizine which could result in a higher serum level.
Trimebutine,Cyclosporine may decrease the excretion rate of Trimebutine which could result in a higher serum level.
Blonanserin,Cyclosporine may decrease the excretion rate of Blonanserin which could result in a higher serum level.
Imidafenacin,Cyclosporine may decrease the excretion rate of Imidafenacin which could result in a higher serum level.
"Synthetic Conjugated Estrogens, A","Cyclosporine may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level."
"Synthetic Conjugated Estrogens, B","Cyclosporine may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level."
Tocopherol,Cyclosporine may decrease the excretion rate of Tocopherol which could result in a higher serum level.
Propiverine,Cyclosporine may decrease the excretion rate of Propiverine which could result in a higher serum level.
Golodirsen,Cyclosporine may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Hydromorphone,Cyclosporine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.
Ramelteon,Cyclosporine may decrease the excretion rate of Ramelteon which could result in a higher serum level.
Estrone sulfate,Cyclosporine may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
Liothyronine,Cyclosporine may decrease the excretion rate of Liothyronine which could result in a higher serum level.
Ranitidine,Cyclosporine may decrease the excretion rate of Ranitidine which could result in a higher serum level.
Pantoprazole,Cyclosporine may decrease the excretion rate of Pantoprazole which could result in a higher serum level.
Cetirizine,Cyclosporine may decrease the excretion rate of Cetirizine which could result in a higher serum level.
Megestrol acetate,Cyclosporine may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.
Trimethoprim,Cyclosporine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
Flurazepam,Cyclosporine may decrease the excretion rate of Flurazepam which could result in a higher serum level.
Ceftriaxone,Cyclosporine may decrease the excretion rate of Ceftriaxone which could result in a higher serum level.
Dimetacrine,Cyclosporine may decrease the excretion rate of Dimetacrine which could result in a higher serum level.
Emtricitabine,Cyclosporine may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
Lithium hydroxide,Cyclosporine may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.
Framycetin,Cyclosporine may decrease the excretion rate of Framycetin which could result in a higher serum level.
Amikacin,Cyclosporine may decrease the excretion rate of Amikacin which could result in a higher serum level.
Tobramycin,Cyclosporine may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Gentamicin,Cyclosporine may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Netilmicin,Cyclosporine may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Streptomycin,Cyclosporine may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Kanamycin,Cyclosporine may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Paromomycin,Cyclosporine may decrease the excretion rate of Paromomycin which could result in a higher serum level.
Ribostamycin,Cyclosporine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.
Geneticin,Cyclosporine may decrease the excretion rate of Geneticin which could result in a higher serum level.
Apramycin,Cyclosporine may decrease the excretion rate of Apramycin which could result in a higher serum level.
Gentamicin C1a,Cyclosporine may decrease the excretion rate of Gentamicin C1a which could result in a higher serum level.
Neamine,Cyclosporine may decrease the excretion rate of Neamine which could result in a higher serum level.
Arbekacin,Cyclosporine may decrease the excretion rate of Arbekacin which could result in a higher serum level.
Puromycin,Cyclosporine may decrease the excretion rate of Puromycin which could result in a higher serum level.
Dihydrostreptomycin,Cyclosporine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.
Hygromycin B,Cyclosporine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.
Sisomicin,Cyclosporine may decrease the excretion rate of Sisomicin which could result in a higher serum level.
Dibekacin,Cyclosporine may decrease the excretion rate of Dibekacin which could result in a higher serum level.
Micronomicin,Cyclosporine may decrease the excretion rate of Micronomicin which could result in a higher serum level.
Isepamicin,Cyclosporine may decrease the excretion rate of Isepamicin which could result in a higher serum level.
Bekanamycin,Cyclosporine may decrease the excretion rate of Bekanamycin which could result in a higher serum level.
Capreomycin,Cyclosporine may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Vancomycin,Cyclosporine may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Isotretinoin,Cyclosporine may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
Plazomicin,Cyclosporine may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Lithium carbonate,Cyclosporine may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
Nedaplatin,Cyclosporine may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
Loxapine,The serum concentration of Cyclosporine can be increased when it is combined with Loxapine.
Toremifene,The serum concentration of Cyclosporine can be increased when it is combined with Toremifene.
Conivaptan,The serum concentration of Cyclosporine can be increased when it is combined with Conivaptan.
Itraconazole,The serum concentration of Cyclosporine can be increased when it is combined with Itraconazole.
Lapatinib,The serum concentration of Cyclosporine can be increased when it is combined with Lapatinib.
Mibefradil,The serum concentration of Cyclosporine can be increased when it is combined with Mibefradil.
Biricodar,The serum concentration of Cyclosporine can be increased when it is combined with Biricodar.
Elacridar,The serum concentration of Cyclosporine can be increased when it is combined with Elacridar.
Vandetanib,The serum concentration of Cyclosporine can be increased when it is combined with Vandetanib.
Zosuquidar,The serum concentration of Cyclosporine can be increased when it is combined with Zosuquidar.
Tariquidar,The serum concentration of Cyclosporine can be increased when it is combined with Tariquidar.
Regorafenib,The serum concentration of Cyclosporine can be increased when it is combined with Regorafenib.
Canagliflozin,The serum concentration of Cyclosporine can be increased when it is combined with Canagliflozin.
Vorapaxar,The serum concentration of Cyclosporine can be increased when it is combined with Vorapaxar.
Suvorexant,The serum concentration of Cyclosporine can be increased when it is combined with Suvorexant.
Cobicistat,The serum concentration of Cyclosporine can be increased when it is combined with Cobicistat.
Daclatasvir,The serum concentration of Cyclosporine can be increased when it is combined with Daclatasvir.
Niguldipine,The serum concentration of Cyclosporine can be increased when it is combined with Niguldipine.
Rolapitant,The serum concentration of Cyclosporine can be increased when it is combined with Rolapitant.
Venetoclax,The serum concentration of Cyclosporine can be increased when it is combined with Venetoclax.
Velpatasvir,The serum concentration of Cyclosporine can be increased when it is combined with Velpatasvir.
Neratinib,The serum concentration of Cyclosporine can be increased when it is combined with Neratinib.
Valspodar,The serum concentration of Cyclosporine can be increased when it is combined with Valspodar.
Glasdegib,The serum concentration of Cyclosporine can be increased when it is combined with Glasdegib.
Voxilaprevir,The serum concentration of Cyclosporine can be increased when it is combined with Voxilaprevir.
Sarecycline,The serum concentration of Cyclosporine can be increased when it is combined with Sarecycline.
Laniquidar,The serum concentration of Cyclosporine can be increased when it is combined with Laniquidar.
Pibrentasvir,The serum concentration of Cyclosporine can be increased when it is combined with Pibrentasvir.
Glecaprevir,The serum concentration of Cyclosporine can be increased when it is combined with Glecaprevir.
Dexniguldipine,The serum concentration of Cyclosporine can be increased when it is combined with Dexniguldipine.
ONT-093,The serum concentration of Cyclosporine can be increased when it is combined with ONT-093.
Ivosidenib,The serum concentration of Cyclosporine can be increased when it is combined with Ivosidenib.
Fedratinib,The serum concentration of Fedratinib can be increased when it is combined with Cyclosporine.
Lomitapide,The serum concentration of Lomitapide can be increased when it is combined with Cyclosporine.
Linagliptin,The serum concentration of Cyclosporine can be increased when it is combined with Linagliptin.
Talazoparib,The serum concentration of Cyclosporine can be increased when it is combined with Talazoparib.
Reserpine,The serum concentration of Cyclosporine can be increased when it is combined with Reserpine.
Favipiravir,The serum concentration of Cyclosporine can be increased when it is combined with Favipiravir.
Binimetinib,The serum concentration of Binimetinib can be increased when it is combined with Cyclosporine.
Ripretinib,The serum concentration of Ripretinib can be increased when it is combined with Cyclosporine.
Potassium citrate,Cyclosporine may increase the hyperkalemic activities of Potassium citrate.
Potassium Iodide,Potassium Iodide may increase the hyperkalemic activities of Cyclosporine.
Potassium alum,Potassium alum may increase the hyperkalemic activities of Cyclosporine.
Monopotassium phosphate,Monopotassium phosphate may increase the hyperkalemic activities of Cyclosporine.
Dipotassium phosphate,Dipotassium phosphate may increase the hyperkalemic activities of Cyclosporine.
"Sodium phosphate, monobasic","Sodium phosphate, monobasic may increase the hyperkalemic activities of Cyclosporine."
Potassium lactate,Potassium lactate may increase the hyperkalemic activities of Cyclosporine.
Potassium bitartrate,Potassium bitartrate may increase the hyperkalemic activities of Cyclosporine.
Potassium hydroxide,Potassium hydroxide may increase the hyperkalemic activities of Cyclosporine.
Potassium gluconate,Potassium gluconate may increase the hyperkalemic activities of Cyclosporine.
Potassium Guaiacolsulfonate,Potassium Guaiacolsulfonate may increase the hyperkalemic activities of Cyclosporine.
Potassium permanganate,Potassium permanganate may increase the hyperkalemic activities of Cyclosporine.
Potassium carbonate,Potassium carbonate may increase the hyperkalemic activities of Cyclosporine.
Potassium triiodide,Potassium triiodide may increase the hyperkalemic activities of Cyclosporine.
Potassium,Potassium may increase the hyperkalemic activities of Cyclosporine.
Citrulline,The excretion of Citrulline can be decreased when combined with Cyclosporine.
Aminohippuric acid,The excretion of Aminohippuric acid can be decreased when combined with Cyclosporine.
Alprostadil,The excretion of Alprostadil can be decreased when combined with Cyclosporine.
Zalcitabine,The excretion of Zalcitabine can be decreased when combined with Cyclosporine.
Tazobactam,The excretion of Tazobactam can be decreased when combined with Cyclosporine.
Cyclic adenosine monophosphate,The excretion of Cyclic adenosine monophosphate can be decreased when combined with Cyclosporine.
Glutaric Acid,The excretion of Glutaric Acid can be decreased when combined with Cyclosporine.
Ellagic acid,The excretion of Ellagic acid can be decreased when combined with Cyclosporine.
Silibinin,The excretion of Silibinin can be decreased when combined with Cyclosporine.
Edaravone,The excretion of Edaravone can be decreased when combined with Cyclosporine.
Somatotropin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Cyclosporine."
Carbimazole,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Carbimazole."
Stavudine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Stavudine."
Nafarelin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Nafarelin."
Naltrexone,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Naltrexone."
Minocycline,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Minocycline."
Iloprost,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Iloprost."
Mevastatin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Mevastatin."
Raltegravir,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Raltegravir."
Acipimox,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Acipimox."
Mebeverine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Mebeverine."
Emetine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Emetine."
Letrozole,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Letrozole."
Enalapril,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Enalapril."
Captopril,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Captopril."
Tacrine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Tacrine."
Montelukast,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Montelukast."
Nizatidine,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Nizatidine."
Ubidecarenone,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Ubidecarenone."
Rifampicin,The metabolism of Cyclosporine can be increased when combined with Rifampicin.
St. John's Wort,The metabolism of Cyclosporine can be increased when combined with St. John's Wort.
Midostaurin,The metabolism of Cyclosporine can be increased when combined with Midostaurin.
Rifamycin,The metabolism of Cyclosporine can be increased when combined with Rifamycin.
Mitotane,The metabolism of Cyclosporine can be increased when combined with Mitotane.
Etravirine,The metabolism of Cyclosporine can be increased when combined with Etravirine.
Avasimibe,The metabolism of Cyclosporine can be increased when combined with Avasimibe.
Dabrafenib,The metabolism of Cyclosporine can be increased when combined with Dabrafenib.
Echinacea,The metabolism of Cyclosporine can be increased when combined with Echinacea.
Topiramate,The metabolism of Cyclosporine can be increased when combined with Topiramate.
Rifabutin,The metabolism of Cyclosporine can be increased when combined with Rifabutin.
Felbamate,The metabolism of Cyclosporine can be increased when combined with Felbamate.
Oritavancin,The metabolism of Cyclosporine can be increased when combined with Oritavancin.
Rufinamide,The metabolism of Cyclosporine can be increased when combined with Rufinamide.
Glycerol phenylbutyrate,The metabolism of Cyclosporine can be increased when combined with Glycerol phenylbutyrate.
Lenvatinib,The metabolism of Cyclosporine can be increased when combined with Lenvatinib.
Eslicarbazepine acetate,The metabolism of Cyclosporine can be increased when combined with Eslicarbazepine acetate.
Lesinurad,The metabolism of Lesinurad can be increased when combined with Cyclosporine.
Genistein,The metabolism of Cyclosporine can be increased when combined with Genistein.
Clobazam,The metabolism of Cyclosporine can be increased when combined with Clobazam.
Pegvisomant,The metabolism of Cyclosporine can be increased when combined with Pegvisomant.
Fosaprepitant,The metabolism of Fosaprepitant can be increased when combined with Cyclosporine.
Calcitriol,The metabolism of Cyclosporine can be increased when combined with Calcitriol.
Troglitazone,The metabolism of Cyclosporine can be increased when combined with Troglitazone.
Flucloxacillin,The metabolism of Cyclosporine can be increased when combined with Flucloxacillin.
Aminoglutethimide,The metabolism of Cyclosporine can be increased when combined with Aminoglutethimide.
Cerivastatin,The metabolism of Cyclosporine can be increased when combined with Cerivastatin.
Dicloxacillin,The metabolism of Cyclosporine can be increased when combined with Dicloxacillin.
Medroxyprogesterone acetate,The metabolism of Cyclosporine can be increased when combined with Medroxyprogesterone acetate.
Ethotoin,The metabolism of Cyclosporine can be increased when combined with Ethotoin.
Hydrocortamate,The metabolism of Cyclosporine can be increased when combined with Hydrocortamate.
Terbinafine,The metabolism of Cyclosporine can be increased when combined with Terbinafine.
Ethanol,The metabolism of Cyclosporine can be increased when combined with Ethanol.
Norgestimate,The metabolism of Cyclosporine can be increased when combined with Norgestimate.
Metyrapone,The metabolism of Cyclosporine can be increased when combined with Metyrapone.
Rifapentine,The metabolism of Cyclosporine can be increased when combined with Rifapentine.
Ketamine,The metabolism of Cyclosporine can be increased when combined with Ketamine.
Cefradine,The metabolism of Cyclosporine can be increased when combined with Cefradine.
Aprobarbital,The metabolism of Cyclosporine can be increased when combined with Aprobarbital.
Deferasirox,The metabolism of Cyclosporine can be increased when combined with Deferasirox.
Lumefantrine,The metabolism of Cyclosporine can be increased when combined with Lumefantrine.
Seratrodast,The metabolism of Cyclosporine can be increased when combined with Seratrodast.
Formestane,The metabolism of Cyclosporine can be increased when combined with Formestane.
Trametinib,The metabolism of Cyclosporine can be increased when combined with Trametinib.
Osimertinib,The metabolism of Cyclosporine can be increased when combined with Osimertinib.
Brigatinib,The metabolism of Cyclosporine can be increased when combined with Brigatinib.
Estradiol acetate,The metabolism of Cyclosporine can be increased when combined with Estradiol acetate.
Estradiol benzoate,The metabolism of Cyclosporine can be increased when combined with Estradiol benzoate.
Estradiol cypionate,The metabolism of Cyclosporine can be increased when combined with Estradiol cypionate.
Estradiol dienanthate,The metabolism of Cyclosporine can be increased when combined with Estradiol dienanthate.
Estradiol valerate,The metabolism of Cyclosporine can be increased when combined with Estradiol valerate.
Perampanel,The metabolism of Perampanel can be increased when combined with Cyclosporine.
Oxcarbazepine,The metabolism of Cyclosporine can be increased when combined with Oxcarbazepine.
Eslicarbazepine,The metabolism of Cyclosporine can be increased when combined with Eslicarbazepine.
Lansoprazole,The metabolism of Cyclosporine can be increased when combined with Lansoprazole.
Ivermectin,The metabolism of Ivermectin can be increased when combined with Cyclosporine.
Naloxone,The metabolism of Cyclosporine can be decreased when combined with Naloxone.
Stiripentol,The metabolism of Cyclosporine can be decreased when combined with Stiripentol.
Danoprevir,The metabolism of Cyclosporine can be decreased when combined with Danoprevir.
Ribociclib,The metabolism of Cyclosporine can be decreased when combined with Ribociclib.
Elvitegravir,The metabolism of Cyclosporine can be decreased when combined with Elvitegravir.
Ergotamine,The metabolism of Cyclosporine can be decreased when combined with Ergotamine.
Posaconazole,The metabolism of Posaconazole can be decreased when combined with Cyclosporine.
Atazanavir,The metabolism of Atazanavir can be decreased when combined with Cyclosporine.
Tezacaftor,The metabolism of Cyclosporine can be decreased when combined with Tezacaftor.
Digitoxin,The metabolism of Digitoxin can be decreased when combined with Cyclosporine.
Isoniazid,The metabolism of Isoniazid can be decreased when combined with Cyclosporine.
Voriconazole,The metabolism of Cyclosporine can be decreased when combined with Voriconazole.
Milnacipran,The metabolism of Milnacipran can be decreased when combined with Cyclosporine.
Vinflunine,The metabolism of Cyclosporine can be decreased when combined with Vinflunine.
Nilvadipine,The metabolism of Nilvadipine can be decreased when combined with Cyclosporine.
Desvenlafaxine,The metabolism of Desvenlafaxine can be decreased when combined with Cyclosporine.
Indalpine,The metabolism of Cyclosporine can be decreased when combined with Indalpine.
Fosnetupitant,The metabolism of Cyclosporine can be decreased when combined with Fosnetupitant.
Dofetilide,The metabolism of Dofetilide can be decreased when combined with Cyclosporine.
Levothyroxine,The metabolism of Levothyroxine can be decreased when combined with Cyclosporine.
Phenprocoumon,The metabolism of Phenprocoumon can be decreased when combined with Cyclosporine.
Aminophylline,The metabolism of Aminophylline can be decreased when combined with Cyclosporine.
4-hydroxycoumarin,The metabolism of 4-hydroxycoumarin can be decreased when combined with Cyclosporine.
Tianeptine,The metabolism of Tianeptine can be decreased when combined with Cyclosporine.
Fluindione,The metabolism of Fluindione can be decreased when combined with Cyclosporine.
Clorindione,The metabolism of Clorindione can be decreased when combined with Cyclosporine.
Isradipine,The metabolism of Cyclosporine can be decreased when combined with Isradipine.
Nicardipine,The metabolism of Cyclosporine can be decreased when combined with Nicardipine.
Miconazole,The metabolism of Cyclosporine can be decreased when combined with Miconazole.
Primaquine,The metabolism of Cyclosporine can be decreased when combined with Primaquine.
Zimelidine,The metabolism of Cyclosporine can be decreased when combined with Zimelidine.
Abiraterone,The metabolism of Abiraterone can be decreased when combined with Cyclosporine.
Alectinib,The metabolism of Alectinib can be decreased when combined with Cyclosporine.
Ixazomib,The metabolism of Ixazomib can be decreased when combined with Cyclosporine.
Pexidartinib,The metabolism of Pexidartinib can be decreased when combined with Cyclosporine.
Cimetidine,The metabolism of Cyclosporine can be decreased when combined with Cimetidine.
Dalfopristin,The metabolism of Cyclosporine can be decreased when combined with Dalfopristin.
Bifonazole,The metabolism of Cyclosporine can be decreased when combined with Bifonazole.
Ceritinib,The metabolism of Cyclosporine can be decreased when combined with Ceritinib.
Piperaquine,The metabolism of Piperaquine can be decreased when combined with Cyclosporine.
Manidipine,The metabolism of Manidipine can be decreased when combined with Cyclosporine.
Cyproterone acetate,The metabolism of Cyproterone acetate can be decreased when combined with Cyclosporine.
Roxithromycin,The metabolism of Cyclosporine can be decreased when combined with Roxithromycin.
Orphenadrine,The metabolism of Cyclosporine can be decreased when combined with Orphenadrine.
Propofol,The metabolism of Cyclosporine can be decreased when combined with Propofol.
Bicalutamide,The metabolism of Cyclosporine can be decreased when combined with Bicalutamide.
Dovitinib,The metabolism of Cyclosporine can be decreased when combined with Dovitinib.
Osilodrostat,The metabolism of Cyclosporine can be decreased when combined with Osilodrostat.
Rilpivirine,The metabolism of Cyclosporine can be decreased when combined with Rilpivirine.
Drospirenone,The metabolism of Cyclosporine can be decreased when combined with Drospirenone.
Lorazepam,The metabolism of Cyclosporine can be decreased when combined with Lorazepam.
Phentermine,The metabolism of Cyclosporine can be decreased when combined with Phentermine.
Famciclovir,The metabolism of Cyclosporine can be decreased when combined with Famciclovir.
Cephalexin,The metabolism of Cyclosporine can be decreased when combined with Cephalexin.
Pranlukast,The metabolism of Cyclosporine can be decreased when combined with Pranlukast.
Allylestrenol,The metabolism of Cyclosporine can be decreased when combined with Allylestrenol.
Lacosamide,The metabolism of Cyclosporine can be decreased when combined with Lacosamide.
Tasimelteon,The metabolism of Cyclosporine can be decreased when combined with Tasimelteon.
Nintedanib,The metabolism of Cyclosporine can be decreased when combined with Nintedanib.
Vitamin D,The metabolism of Cyclosporine can be decreased when combined with Vitamin D.
Dihydroergocornine,The metabolism of Cyclosporine can be decreased when combined with Dihydroergocornine.
Duvelisib,The metabolism of Cyclosporine can be decreased when combined with Duvelisib.
Gilteritinib,The metabolism of Cyclosporine can be decreased when combined with Gilteritinib.
9-aminocamptothecin,The metabolism of Cyclosporine can be decreased when combined with 9-aminocamptothecin.
Methylprednisone,The metabolism of Cyclosporine can be decreased when combined with Methylprednisone.
Dihydroergocristine,The metabolism of Cyclosporine can be decreased when combined with Dihydroergocristine.
Dihydroergocryptine,The metabolism of Cyclosporine can be decreased when combined with Dihydroergocryptine.
Tazemetostat,The metabolism of Tazemetostat can be decreased when combined with Cyclosporine.
Albendazole,The metabolism of Cyclosporine can be decreased when combined with Albendazole.
Methysergide,The metabolism of Methysergide can be decreased when combined with Cyclosporine.
Ebastine,The metabolism of Ebastine can be decreased when combined with Cyclosporine.
Nelfinavir,The metabolism of Cyclosporine can be decreased when combined with Nelfinavir.
Aprepitant,The metabolism of Aprepitant can be decreased when combined with Cyclosporine.
Saquinavir,The metabolism of Saquinavir can be decreased when combined with Cyclosporine.
Phenelzine,The metabolism of Cyclosporine can be decreased when combined with Phenelzine.
Ditiocarb,The metabolism of Cyclosporine can be decreased when combined with Ditiocarb.
Seproxetine,The metabolism of Cyclosporine can be decreased when combined with Seproxetine.
Elbasvir,The metabolism of Cyclosporine can be decreased when combined with Elbasvir.
Methylene blue,The metabolism of Methylene blue can be decreased when combined with Cyclosporine.
Safinamide,The metabolism of Cyclosporine can be decreased when combined with Safinamide.
Gestodene,The metabolism of Cyclosporine can be decreased when combined with Gestodene.
Acalabrutinib,The metabolism of Cyclosporine can be decreased when combined with Acalabrutinib.
Indinavir,The metabolism of Cyclosporine can be decreased when combined with Indinavir.
Dapsone,The metabolism of Cyclosporine can be decreased when combined with Dapsone.
Flutamide,The metabolism of Cyclosporine can be decreased when combined with Flutamide.
Clopidogrel,The metabolism of Cyclosporine can be decreased when combined with Clopidogrel.
Disulfiram,The metabolism of Cyclosporine can be decreased when combined with Disulfiram.
Zaleplon,The metabolism of Cyclosporine can be decreased when combined with Zaleplon.
Praziquantel,The metabolism of Cyclosporine can be decreased when combined with Praziquantel.
Dutasteride,The metabolism of Cyclosporine can be decreased when combined with Dutasteride.
Finasteride,The metabolism of Cyclosporine can be decreased when combined with Finasteride.
Halofantrine,The metabolism of Cyclosporine can be decreased when combined with Halofantrine.
Levacetylmethadol,The metabolism of Cyclosporine can be decreased when combined with Levacetylmethadol.
Romidepsin,The metabolism of Cyclosporine can be decreased when combined with Romidepsin.
Udenafil,The metabolism of Cyclosporine can be decreased when combined with Udenafil.
Saxagliptin,The metabolism of Cyclosporine can be decreased when combined with Saxagliptin.
Apixaban,The metabolism of Cyclosporine can be decreased when combined with Apixaban.
Axitinib,The metabolism of Cyclosporine can be decreased when combined with Axitinib.
Vicriviroc,The metabolism of Cyclosporine can be decreased when combined with Vicriviroc.
Hydroxyprogesterone caproate,The metabolism of Cyclosporine can be decreased when combined with Hydroxyprogesterone caproate.
Tegafur,The metabolism of Cyclosporine can be decreased when combined with Tegafur.
Icotinib,The metabolism of Cyclosporine can be decreased when combined with Icotinib.
Lorlatinib,The metabolism of Cyclosporine can be decreased when combined with Lorlatinib.
Doravirine,The metabolism of Cyclosporine can be decreased when combined with Doravirine.
Copanlisib,The metabolism of Cyclosporine can be decreased when combined with Copanlisib.
Hydrocortisone phosphate,The metabolism of Cyclosporine can be decreased when combined with Hydrocortisone phosphate.
Cisapride,The metabolism of Cisapride can be decreased when combined with Cyclosporine.
Tadalafil,The metabolism of Tadalafil can be decreased when combined with Cyclosporine.
Triazolam,The metabolism of Triazolam can be decreased when combined with Cyclosporine.
Rivaroxaban,The metabolism of Rivaroxaban can be decreased when combined with Cyclosporine.
Estradiol,The metabolism of Cyclosporine can be decreased when combined with Estradiol.
Ziprasidone,The metabolism of Cyclosporine can be decreased when combined with Ziprasidone.
Norethisterone,The metabolism of Cyclosporine can be decreased when combined with Norethisterone.
Diazepam,The metabolism of Cyclosporine can be decreased when combined with Diazepam.
Ethinylestradiol,The metabolism of Cyclosporine can be decreased when combined with Ethinylestradiol.
Oxybutynin,The metabolism of Cyclosporine can be decreased when combined with Oxybutynin.
Artemether,The metabolism of Artemether can be decreased when combined with Cyclosporine.
Dexloxiglumide,The metabolism of Dexloxiglumide can be decreased when combined with Cyclosporine.
Azimilide,The metabolism of Azimilide can be decreased when combined with Cyclosporine.
Levonorgestrel,The metabolism of Levonorgestrel can be decreased when combined with Cyclosporine.
Lercanidipine,The metabolism of Lercanidipine can be decreased when combined with Cyclosporine.
Salmeterol,The metabolism of Salmeterol can be decreased when combined with Cyclosporine.
Cannabidiol,The metabolism of Cannabidiol can be decreased when combined with Cyclosporine.
Benidipine,The metabolism of Benidipine can be decreased when combined with Cyclosporine.
Nabiximols,The metabolism of Nabiximols can be decreased when combined with Cyclosporine.
Hydroxyzine,The metabolism of Hydroxyzine can be decreased when combined with Cyclosporine.
Lemborexant,The metabolism of Lemborexant can be decreased when combined with Cyclosporine.
Clindamycin,The metabolism of Clindamycin can be decreased when combined with Cyclosporine.
Nitrendipine,The metabolism of Cyclosporine can be decreased when combined with Nitrendipine.
Quinacrine,The metabolism of Cyclosporine can be decreased when combined with Quinacrine.
Paritaprevir,The metabolism of Paritaprevir can be decreased when combined with Cyclosporine.
Nisoldipine,The metabolism of Cyclosporine can be decreased when combined with Nisoldipine.
Alfentanil,The metabolism of Cyclosporine can be decreased when combined with Alfentanil.
Apomorphine,The metabolism of Apomorphine can be decreased when combined with Cyclosporine.
Cycloserine,Cyclosporine may increase the neurotoxic activities of Cycloserine.
Sulpiride,Cyclosporine may increase the neurotoxic activities of Sulpiride.
Droperidol,Cyclosporine may increase the neurotoxic activities of Droperidol.
Moricizine,Cyclosporine may increase the neurotoxic activities of Moricizine.
Acetophenazine,Cyclosporine may increase the neurotoxic activities of Acetophenazine.
Bismuth subsalicylate,Cyclosporine may increase the neurotoxic activities of Bismuth subsalicylate.
Periciazine,Cyclosporine may increase the neurotoxic activities of Periciazine.
Acepromazine,Cyclosporine may increase the neurotoxic activities of Acepromazine.
Aceprometazine,Cyclosporine may increase the neurotoxic activities of Aceprometazine.
Molindone,Cyclosporine may increase the neurotoxic activities of Molindone.
Thioproperazine,Cyclosporine may increase the neurotoxic activities of Thioproperazine.
Thiothixene,Cyclosporine may increase the neurotoxic activities of Thiothixene.
Amineptine,Cyclosporine may increase the neurotoxic activities of Amineptine.
Osanetant,Cyclosporine may increase the neurotoxic activities of Osanetant.
Bifeprunox,Cyclosporine may increase the neurotoxic activities of Bifeprunox.
Pimavanserin,Cyclosporine may increase the neurotoxic activities of Pimavanserin.
BL-1020,Cyclosporine may increase the neurotoxic activities of BL-1020.
Amisulpride,Cyclosporine may increase the neurotoxic activities of Amisulpride.
Amperozide,Cyclosporine may increase the neurotoxic activities of Amperozide.
Cyamemazine,Cyclosporine may increase the neurotoxic activities of Cyamemazine.
Butriptyline,Cyclosporine may increase the neurotoxic activities of Butriptyline.
Sodium citrate,Cyclosporine may increase the neurotoxic activities of Sodium citrate.
Brilaroxazine,Cyclosporine may increase the neurotoxic activities of Brilaroxazine.
Bismuth subcitrate potassium,Cyclosporine may increase the neurotoxic activities of Bismuth subcitrate potassium.
Pipamperone,Cyclosporine may increase the neurotoxic activities of Pipamperone.
Oxaprotiline,Cyclosporine may increase the neurotoxic activities of Oxaprotiline.
Bismuth subcarbonate,Cyclosporine may increase the neurotoxic activities of Bismuth subcarbonate.
Azaperone,Cyclosporine may increase the neurotoxic activities of Azaperone.
Pirlimycin,Cyclosporine may increase the neurotoxic activities of Pirlimycin.
Propiopromazine,Cyclosporine may increase the neurotoxic activities of Propiopromazine.
Ecopipam,Cyclosporine may increase the neurotoxic activities of Ecopipam.
Raclopride,Cyclosporine may increase the neurotoxic activities of Raclopride.
Ritanserin,Cyclosporine may increase the neurotoxic activities of Ritanserin.
Perazine,Cyclosporine may increase the neurotoxic activities of Perazine.
Benperidol,Cyclosporine may increase the neurotoxic activities of Benperidol.
Prothipendyl,Cyclosporine may increase the neurotoxic activities of Prothipendyl.
Amitriptylinoxide,Cyclosporine may increase the neurotoxic activities of Amitriptylinoxide.
Bismuth subnitrate,Cyclosporine may increase the neurotoxic activities of Bismuth subnitrate.
Butaperazine,Cyclosporine may increase the neurotoxic activities of Butaperazine.
Dibenzepin,Cyclosporine may increase the neurotoxic activities of Dibenzepin.
Quinupramine,Cyclosporine may increase the neurotoxic activities of Quinupramine.
Clothiapine,Cyclosporine may increase the neurotoxic activities of Clothiapine.
Sultopride,Cyclosporine may increase the neurotoxic activities of Sultopride.
Chlorproethazine,Cyclosporine may increase the neurotoxic activities of Chlorproethazine.
Melitracen,Cyclosporine may increase the neurotoxic activities of Melitracen.
Oxypertine,Cyclosporine may increase the neurotoxic activities of Oxypertine.
Lofepramine,Cyclosporine may increase the neurotoxic activities of Lofepramine.
Thiazinam,Cyclosporine may increase the neurotoxic activities of Thiazinam.
Iprindole,Cyclosporine may increase the neurotoxic activities of Iprindole.
Veralipride,Cyclosporine may increase the neurotoxic activities of Veralipride.
Trifluperidol,Cyclosporine may increase the neurotoxic activities of Trifluperidol.
Moperone,Cyclosporine may increase the neurotoxic activities of Moperone.
Thiopropazate,Cyclosporine may increase the neurotoxic activities of Thiopropazate.
Fluanisone,Cyclosporine may increase the neurotoxic activities of Fluanisone.
Mosapramine,Cyclosporine may increase the neurotoxic activities of Mosapramine.
Imipramine oxide,Cyclosporine may increase the neurotoxic activities of Imipramine oxide.
Dixyrazine,Cyclosporine may increase the neurotoxic activities of Dixyrazine.
Clopenthixol,Cyclosporine may increase the neurotoxic activities of Clopenthixol.
Valproate bismuth,Cyclosporine may increase the neurotoxic activities of Valproate bismuth.
Perphenazine enanthate,Cyclosporine may increase the neurotoxic activities of Perphenazine enanthate.
Alimemazine,Cyclosporine may increase the neurotoxic activities of Alimemazine.
Zotepine,Cyclosporine may increase the neurotoxic activities of Zotepine.
Triflupromazine,Cyclosporine may increase the neurotoxic activities of Triflupromazine.
Fluphenazine,Cyclosporine may increase the neurotoxic activities of Fluphenazine.
Chlorprothixene,Cyclosporine may increase the neurotoxic activities of Chlorprothixene.
Bromperidol,Cyclosporine may increase the neurotoxic activities of Bromperidol.
Cyclobenzaprine,Cyclosporine may increase the neurotoxic activities of Cyclobenzaprine.
Cilastatin,The excretion of Cyclosporine can be increased when combined with Cilastatin.
Magnesium sulfate,The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Cyclosporine.
Metharbital,The therapeutic efficacy of Metharbital can be decreased when used in combination with Cyclosporine.
Tizanidine,The therapeutic efficacy of Tizanidine can be decreased when used in combination with Cyclosporine.
Phensuximide,The therapeutic efficacy of Phensuximide can be decreased when used in combination with Cyclosporine.
Progabide,The therapeutic efficacy of Progabide can be decreased when used in combination with Cyclosporine.
Vigabatrin,The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Cyclosporine.
Phenacemide,The therapeutic efficacy of Phenacemide can be decreased when used in combination with Cyclosporine.
Delorazepam,The therapeutic efficacy of Delorazepam can be decreased when used in combination with Cyclosporine.
7-Nitroindazole,The therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Cyclosporine.
Valpromide,The therapeutic efficacy of Valpromide can be decreased when used in combination with Cyclosporine.
Deramciclane,The therapeutic efficacy of Deramciclane can be decreased when used in combination with Cyclosporine.
Tramiprosate,The therapeutic efficacy of Tramiprosate can be decreased when used in combination with Cyclosporine.
Gaboxadol,The therapeutic efficacy of Gaboxadol can be decreased when used in combination with Cyclosporine.
Sulthiame,The therapeutic efficacy of Sulthiame can be decreased when used in combination with Cyclosporine.
Ifenprodil,The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Cyclosporine.
Beclamide,The therapeutic efficacy of Beclamide can be decreased when used in combination with Cyclosporine.
Paraldehyde,The therapeutic efficacy of Paraldehyde can be decreased when used in combination with Cyclosporine.
Tiletamine,The therapeutic efficacy of Tiletamine can be decreased when used in combination with Cyclosporine.
Brexanolone,The therapeutic efficacy of Brexanolone can be decreased when used in combination with Cyclosporine.
Etiracetam,The therapeutic efficacy of Etiracetam can be decreased when used in combination with Cyclosporine.
Carisbamate,The therapeutic efficacy of Carisbamate can be decreased when used in combination with Cyclosporine.
Pheneturide,The therapeutic efficacy of Pheneturide can be decreased when used in combination with Cyclosporine.
Neocitrullamon,The therapeutic efficacy of Neocitrullamon can be decreased when used in combination with Cyclosporine.
Medazepam,The therapeutic efficacy of Medazepam can be decreased when used in combination with Cyclosporine.
Phenibut,The therapeutic efficacy of Phenibut can be decreased when used in combination with Cyclosporine.
Ethadione,The therapeutic efficacy of Ethadione can be decreased when used in combination with Cyclosporine.
Cannabidivarin,The therapeutic efficacy of Cannabidivarin can be decreased when used in combination with Cyclosporine.
JNJ-26489112,The therapeutic efficacy of JNJ-26489112 can be decreased when used in combination with Cyclosporine.
Pregabalin,The therapeutic efficacy of Cyclosporine can be decreased when used in combination with Pregabalin.
Clonazepam,The therapeutic efficacy of Clonazepam can be decreased when used in combination with Cyclosporine.
Gabapentin,The therapeutic efficacy of Gabapentin can be decreased when used in combination with Cyclosporine.
Tiagabine,The therapeutic efficacy of Tiagabine can be decreased when used in combination with Cyclosporine.
Nitrazepam,The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Cyclosporine.
Clomethiazole,The therapeutic efficacy of Clomethiazole can be decreased when used in combination with Cyclosporine.
Vinpocetine,The therapeutic efficacy of Vinpocetine can be decreased when used in combination with Cyclosporine.
Trimethadione,The therapeutic efficacy of Trimethadione can be decreased when used in combination with Cyclosporine.
Paramethadione,The therapeutic efficacy of Paramethadione can be decreased when used in combination with Cyclosporine.
Methsuximide,The therapeutic efficacy of Methsuximide can be decreased when used in combination with Cyclosporine.
Brivaracetam,The therapeutic efficacy of Brivaracetam can be decreased when used in combination with Cyclosporine.
Levetiracetam,The therapeutic efficacy of Levetiracetam can be decreased when used in combination with Cyclosporine.
Ethosuximide,The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Cyclosporine.
Amifampridine,The risk or severity of seizure can be increased when Cyclosporine is combined with Amifampridine.
Sincalide,The excretion of Sincalide can be decreased when combined with Cyclosporine.
Bempedoic acid,The excretion of Bempedoic acid can be decreased when combined with Cyclosporine.
Revefenacin,Cyclosporine may decrease the excretion rate of Revefenacin which could result in a higher serum level.
Moxifloxacin,The risk or severity of nephrotoxicity can be increased when Moxifloxacin is combined with Cyclosporine.
Grepafloxacin,The risk or severity of nephrotoxicity can be increased when Grepafloxacin is combined with Cyclosporine.
Enoxacin,The risk or severity of nephrotoxicity can be increased when Enoxacin is combined with Cyclosporine.
Pefloxacin,The risk or severity of nephrotoxicity can be increased when Pefloxacin is combined with Cyclosporine.
Trovafloxacin,The risk or severity of nephrotoxicity can be increased when Trovafloxacin is combined with Cyclosporine.
Nalidixic acid,The risk or severity of nephrotoxicity can be increased when Nalidixic acid is combined with Cyclosporine.
Rosoxacin,The risk or severity of nephrotoxicity can be increased when Rosoxacin is combined with Cyclosporine.
Cinoxacin,The risk or severity of nephrotoxicity can be increased when Cinoxacin is combined with Cyclosporine.
Lomefloxacin,The risk or severity of nephrotoxicity can be increased when Lomefloxacin is combined with Cyclosporine.
Gatifloxacin,The risk or severity of nephrotoxicity can be increased when Gatifloxacin is combined with Cyclosporine.
Gemifloxacin,The risk or severity of nephrotoxicity can be increased when Gemifloxacin is combined with Cyclosporine.
Ofloxacin,The risk or severity of nephrotoxicity can be increased when Ofloxacin is combined with Cyclosporine.
Sparfloxacin,The risk or severity of nephrotoxicity can be increased when Sparfloxacin is combined with Cyclosporine.
Temafloxacin,The risk or severity of nephrotoxicity can be increased when Temafloxacin is combined with Cyclosporine.
Fleroxacin,The risk or severity of nephrotoxicity can be increased when Fleroxacin is combined with Cyclosporine.
Technetium Tc-99m ciprofloxacin,The risk or severity of nephrotoxicity can be increased when Technetium Tc-99m ciprofloxacin is combined with Cyclosporine.
Garenoxacin,The risk or severity of nephrotoxicity can be increased when Garenoxacin is combined with Cyclosporine.
Nemonoxacin,The risk or severity of nephrotoxicity can be increased when Nemonoxacin is combined with Cyclosporine.
Flumequine,The risk or severity of nephrotoxicity can be increased when Flumequine is combined with Cyclosporine.
Enrofloxacin,The risk or severity of nephrotoxicity can be increased when Enrofloxacin is combined with Cyclosporine.
Orbifloxacin,The risk or severity of nephrotoxicity can be increased when Orbifloxacin is combined with Cyclosporine.
Sarafloxacin,The risk or severity of nephrotoxicity can be increased when Sarafloxacin is combined with Cyclosporine.
Difloxacin,The risk or severity of nephrotoxicity can be increased when Difloxacin is combined with Cyclosporine.
Pazufloxacin,The risk or severity of nephrotoxicity can be increased when Pazufloxacin is combined with Cyclosporine.
Prulifloxacin,The risk or severity of nephrotoxicity can be increased when Prulifloxacin is combined with Cyclosporine.
Delafloxacin,The risk or severity of nephrotoxicity can be increased when Delafloxacin is combined with Cyclosporine.
Sitafloxacin,The risk or severity of nephrotoxicity can be increased when Sitafloxacin is combined with Cyclosporine.
Oxolinic acid,The risk or severity of nephrotoxicity can be increased when Oxolinic acid is combined with Cyclosporine.
Rufloxacin,The risk or severity of nephrotoxicity can be increased when Rufloxacin is combined with Cyclosporine.
Pipemidic acid,The risk or severity of nephrotoxicity can be increased when Pipemidic acid is combined with Cyclosporine.
Clomifene,The serum concentration of Cyclosporine can be increased when it is combined with Clomifene.
Inotuzumab ozogamicin,The serum concentration of Cyclosporine can be increased when it is combined with Inotuzumab ozogamicin.
Dolutegravir,The serum concentration of Cyclosporine can be increased when it is combined with Dolutegravir.
Sofosbuvir,The serum concentration of Cyclosporine can be increased when it is combined with Sofosbuvir.
Technetium Tc-99m sestamibi,The serum concentration of Cyclosporine can be increased when it is combined with Technetium Tc-99m sestamibi.
Ombitasvir,The serum concentration of Cyclosporine can be increased when it is combined with Ombitasvir.
Ertugliflozin,The serum concentration of Cyclosporine can be increased when it is combined with Ertugliflozin.
Avatrombopag,The serum concentration of Cyclosporine can be increased when it is combined with Avatrombopag.
Omadacycline,The serum concentration of Cyclosporine can be increased when it is combined with Omadacycline.
Grapiprant,The serum concentration of Cyclosporine can be increased when it is combined with Grapiprant.
Enfortumab vedotin,The serum concentration of Cyclosporine can be increased when it is combined with Enfortumab vedotin.
Tolvaptan,The serum concentration of Cyclosporine can be increased when it is combined with Tolvaptan.
Fexofenadine,The serum concentration of Cyclosporine can be increased when it is combined with Fexofenadine.
Morphine,The serum concentration of Cyclosporine can be increased when it is combined with Morphine.
Sitagliptin,The serum concentration of Cyclosporine can be increased when it is combined with Sitagliptin.
Indacaterol,The serum concentration of Cyclosporine can be increased when it is combined with Indacaterol.
Odanacatib,The serum concentration of Cyclosporine can be increased when it is combined with Odanacatib.
Selexipag,The serum concentration of Cyclosporine can be increased when it is combined with Selexipag.
Grazoprevir,The serum concentration of Cyclosporine can be increased when it is combined with Grazoprevir.
Larotrectinib,The serum concentration of Cyclosporine can be increased when it is combined with Larotrectinib.
Diclofenac,The serum concentration of Diclofenac can be increased when it is combined with Cyclosporine.
Etanercept,Etanercept may increase the immunosuppressive activities of Cyclosporine.
Peginterferon alfa-2a,Peginterferon alfa-2a may increase the immunosuppressive activities of Cyclosporine.
Interferon alfa-n1,Interferon alfa-n1 may increase the immunosuppressive activities of Cyclosporine.
Interferon alfa-n3,Interferon alfa-n3 may increase the immunosuppressive activities of Cyclosporine.
Peginterferon alfa-2b,Peginterferon alfa-2b may increase the immunosuppressive activities of Cyclosporine.
Anakinra,Anakinra may increase the immunosuppressive activities of Cyclosporine.
Interferon gamma-1b,Interferon gamma-1b may increase the immunosuppressive activities of Cyclosporine.
"Interferon alfa-2a, Recombinant","Interferon alfa-2a, Recombinant may increase the immunosuppressive activities of Cyclosporine."
Aldesleukin,Aldesleukin may increase the immunosuppressive activities of Cyclosporine.
Gemtuzumab ozogamicin,Gemtuzumab ozogamicin may increase the immunosuppressive activities of Cyclosporine.
Pegaspargase,Pegaspargase may increase the immunosuppressive activities of Cyclosporine.
Infliximab,Infliximab may increase the immunosuppressive activities of Cyclosporine.
Interferon beta-1b,Interferon beta-1b may increase the immunosuppressive activities of Cyclosporine.
Interferon alfacon-1,Interferon alfacon-1 may increase the immunosuppressive activities of Cyclosporine.
Trastuzumab,Trastuzumab may increase the immunosuppressive activities of Cyclosporine.
Rituximab,Rituximab may increase the immunosuppressive activities of Cyclosporine.
Basiliximab,Basiliximab may increase the immunosuppressive activities of Cyclosporine.
Muromonab,Muromonab may increase the immunosuppressive activities of Cyclosporine.
Ibritumomab tiuxetan,Ibritumomab tiuxetan may increase the immunosuppressive activities of Cyclosporine.
Tositumomab,Tositumomab may increase the immunosuppressive activities of Cyclosporine.
Alemtuzumab,Alemtuzumab may increase the immunosuppressive activities of Cyclosporine.
Alefacept,Alefacept may increase the immunosuppressive activities of Cyclosporine.
Efalizumab,Efalizumab may increase the immunosuppressive activities of Cyclosporine.
Antithymocyte immunoglobulin (rabbit),Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Cyclosporine.
Interferon alfa-2b,Interferon alfa-2b may increase the immunosuppressive activities of Cyclosporine.
Natalizumab,Natalizumab may increase the immunosuppressive activities of Cyclosporine.
Daclizumab,Daclizumab may increase the immunosuppressive activities of Cyclosporine.
Bevacizumab,Bevacizumab may increase the immunosuppressive activities of Cyclosporine.
Phenylalanine,Phenylalanine may increase the immunosuppressive activities of Cyclosporine.
Flunisolide,Flunisolide may increase the immunosuppressive activities of Cyclosporine.
Bortezomib,Bortezomib may increase the immunosuppressive activities of Cyclosporine.
Cladribine,Cladribine may increase the immunosuppressive activities of Cyclosporine.
Carmustine,Carmustine may increase the immunosuppressive activities of Cyclosporine.
Amsacrine,Amsacrine may increase the immunosuppressive activities of Cyclosporine.
Bleomycin,Bleomycin may increase the immunosuppressive activities of Cyclosporine.
Chlorambucil,Chlorambucil may increase the immunosuppressive activities of Cyclosporine.
Raltitrexed,Raltitrexed may increase the immunosuppressive activities of Cyclosporine.
Mitomycin,Mitomycin may increase the immunosuppressive activities of Cyclosporine.
Bexarotene,Bexarotene may increase the immunosuppressive activities of Cyclosporine.
Vindesine,Vindesine may increase the immunosuppressive activities of Cyclosporine.
Floxuridine,Floxuridine may increase the immunosuppressive activities of Cyclosporine.
Indomethacin,Indomethacin may increase the immunosuppressive activities of Cyclosporine.
Tioguanine,Tioguanine may increase the immunosuppressive activities of Cyclosporine.
Vinorelbine,Vinorelbine may increase the immunosuppressive activities of Cyclosporine.
Dexrazoxane,Dexrazoxane may increase the immunosuppressive activities of Cyclosporine.
Beclomethasone dipropionate,Beclomethasone dipropionate may increase the immunosuppressive activities of Cyclosporine.
Sorafenib,Sorafenib may increase the immunosuppressive activities of Cyclosporine.
Streptozocin,Streptozocin may increase the immunosuppressive activities of Cyclosporine.
Trifluridine,Trifluridine may increase the immunosuppressive activities of Cyclosporine.
Gemcitabine,Gemcitabine may increase the immunosuppressive activities of Cyclosporine.
Betamethasone,Betamethasone may increase the immunosuppressive activities of Cyclosporine.
Teniposide,Teniposide may increase the immunosuppressive activities of Cyclosporine.
Epirubicin,Epirubicin may increase the immunosuppressive activities of Cyclosporine.
Lenalidomide,Lenalidomide may increase the immunosuppressive activities of Cyclosporine.
Altretamine,Altretamine may increase the immunosuppressive activities of Cyclosporine.
Zidovudine,Zidovudine may increase the immunosuppressive activities of Cyclosporine.
Cisplatin,Cisplatin may increase the immunosuppressive activities of Cyclosporine.
Oxaliplatin,Oxaliplatin may increase the immunosuppressive activities of Cyclosporine.
Vincristine,Vincristine may increase the immunosuppressive activities of Cyclosporine.
Fluorouracil,Fluorouracil may increase the immunosuppressive activities of Cyclosporine.
Propylthiouracil,Propylthiouracil may increase the immunosuppressive activities of Cyclosporine.
Pentostatin,Pentostatin may increase the immunosuppressive activities of Cyclosporine.
Vinblastine,Vinblastine may increase the immunosuppressive activities of Cyclosporine.
Fluticasone propionate,Fluticasone propionate may increase the immunosuppressive activities of Cyclosporine.
Fluocinolone acetonide,Fluocinolone acetonide may increase the immunosuppressive activities of Cyclosporine.
Linezolid,Linezolid may increase the immunosuppressive activities of Cyclosporine.
Triamcinolone,Triamcinolone may increase the immunosuppressive activities of Cyclosporine.
Clofarabine,Clofarabine may increase the immunosuppressive activities of Cyclosporine.
Prednisone,Prednisone may increase the immunosuppressive activities of Cyclosporine.
Pemetrexed,Pemetrexed may increase the immunosuppressive activities of Cyclosporine.
Fludrocortisone,Fludrocortisone may increase the immunosuppressive activities of Cyclosporine.
Mycophenolate mofetil,Mycophenolate mofetil may increase the immunosuppressive activities of Cyclosporine.
Daunorubicin,Daunorubicin may increase the immunosuppressive activities of Cyclosporine.
Hydrocortisone,Hydrocortisone may increase the immunosuppressive activities of Cyclosporine.
Tretinoin,Tretinoin may increase the immunosuppressive activities of Cyclosporine.
Irinotecan,Irinotecan may increase the immunosuppressive activities of Cyclosporine.
Methimazole,Methimazole may increase the immunosuppressive activities of Cyclosporine.
Mometasone,Mometasone may increase the immunosuppressive activities of Cyclosporine.
Sulfasalazine,Sulfasalazine may increase the immunosuppressive activities of Cyclosporine.
Dacarbazine,Dacarbazine may increase the immunosuppressive activities of Cyclosporine.
Temozolomide,Temozolomide may increase the immunosuppressive activities of Cyclosporine.
Penicillamine,Penicillamine may increase the immunosuppressive activities of Cyclosporine.
Prednisolone,Prednisolone may increase the immunosuppressive activities of Cyclosporine.
Sirolimus,Sirolimus may increase the immunosuppressive activities of Cyclosporine.
Mechlorethamine,Mechlorethamine may increase the immunosuppressive activities of Cyclosporine.
Azacitidine,Azacitidine may increase the immunosuppressive activities of Cyclosporine.
Carboplatin,Carboplatin may increase the immunosuppressive activities of Cyclosporine.
Dactinomycin,Dactinomycin may increase the immunosuppressive activities of Cyclosporine.
Cytarabine,Cytarabine may increase the immunosuppressive activities of Cyclosporine.
Azathioprine,Azathioprine may increase the immunosuppressive activities of Cyclosporine.
Hydroxyurea,Hydroxyurea may increase the immunosuppressive activities of Cyclosporine.
Busulfan,Busulfan may increase the immunosuppressive activities of Cyclosporine.
Mycophenolic acid,Mycophenolic acid may increase the immunosuppressive activities of Cyclosporine.
Topotecan,Topotecan may increase the immunosuppressive activities of Cyclosporine.
Mercaptopurine,Mercaptopurine may increase the immunosuppressive activities of Cyclosporine.
Thalidomide,Thalidomide may increase the immunosuppressive activities of Cyclosporine.
Fludarabine,Fludarabine may increase the immunosuppressive activities of Cyclosporine.
Leflunomide,Leflunomide may increase the immunosuppressive activities of Cyclosporine.
Flucytosine,Flucytosine may increase the immunosuppressive activities of Cyclosporine.
Capecitabine,Capecitabine may increase the immunosuppressive activities of Cyclosporine.
Trilostane,Trilostane may increase the immunosuppressive activities of Cyclosporine.
Procarbazine,Procarbazine may increase the immunosuppressive activities of Cyclosporine.
Arsenic trioxide,Arsenic trioxide may increase the immunosuppressive activities of Cyclosporine.
Idarubicin,Idarubicin may increase the immunosuppressive activities of Cyclosporine.
Ifosfamide,Ifosfamide may increase the immunosuppressive activities of Cyclosporine.
Estramustine,Estramustine may increase the immunosuppressive activities of Cyclosporine.
Lomustine,Lomustine may increase the immunosuppressive activities of Cyclosporine.
Budesonide,Budesonide may increase the immunosuppressive activities of Cyclosporine.
Paclitaxel,Paclitaxel may increase the immunosuppressive activities of Cyclosporine.
Dexamethasone,Dexamethasone may increase the immunosuppressive activities of Cyclosporine.
Docetaxel,Docetaxel may increase the immunosuppressive activities of Cyclosporine.
Dasatinib,Dasatinib may increase the immunosuppressive activities of Cyclosporine.
Eculizumab,Eculizumab may increase the immunosuppressive activities of Cyclosporine.
Decitabine,Decitabine may increase the immunosuppressive activities of Cyclosporine.
Sunitinib,Sunitinib may increase the immunosuppressive activities of Cyclosporine.
Nelarabine,Nelarabine may increase the immunosuppressive activities of Cyclosporine.
Abatacept,Abatacept may increase the immunosuppressive activities of Cyclosporine.
Corticotropin,Corticotropin may increase the immunosuppressive activities of Cyclosporine.
Cortisone acetate,Cortisone acetate may increase the immunosuppressive activities of Cyclosporine.
Paramethasone,Paramethasone may increase the immunosuppressive activities of Cyclosporine.
Colchicine,Colchicine may increase the immunosuppressive activities of Cyclosporine.
Ciclesonide,Ciclesonide may increase the immunosuppressive activities of Cyclosporine.
Stepronin,Stepronin may increase the immunosuppressive activities of Cyclosporine.
Hydroxychloroquine,Hydroxychloroquine may increase the immunosuppressive activities of Cyclosporine.
Castanospermine,Castanospermine may increase the immunosuppressive activities of Cyclosporine.
Vorinostat,Vorinostat may increase the immunosuppressive activities of Cyclosporine.
2-Methoxyethanol,2-Methoxyethanol may increase the immunosuppressive activities of Cyclosporine.
Brequinar,Brequinar may increase the immunosuppressive activities of Cyclosporine.
Thiotepa,Thiotepa may increase the immunosuppressive activities of Cyclosporine.
Aldosterone,Aldosterone may increase the immunosuppressive activities of Cyclosporine.
Ixabepilone,Ixabepilone may increase the immunosuppressive activities of Cyclosporine.
Nilotinib,Nilotinib may increase the immunosuppressive activities of Cyclosporine.
Pirfenidone,Pirfenidone may increase the immunosuppressive activities of Cyclosporine.
Afelimomab,Afelimomab may increase the immunosuppressive activities of Cyclosporine.
Belinostat,Belinostat may increase the immunosuppressive activities of Cyclosporine.
Trabectedin,Trabectedin may increase the immunosuppressive activities of Cyclosporine.
Interferon alfa,Interferon alfa may increase the immunosuppressive activities of Cyclosporine.
Glatiramer,Glatiramer may increase the immunosuppressive activities of Cyclosporine.
Gallium nitrate,Gallium nitrate may increase the immunosuppressive activities of Cyclosporine.
Briakinumab,Briakinumab may increase the immunosuppressive activities of Cyclosporine.
omega interferon,omega interferon may increase the immunosuppressive activities of Cyclosporine.
Apremilast,Apremilast may increase the immunosuppressive activities of Cyclosporine.
Trastuzumab emtansine,Trastuzumab emtansine may increase the immunosuppressive activities of Cyclosporine.
Canakinumab,Canakinumab may increase the immunosuppressive activities of Cyclosporine.
Tocilizumab,Tocilizumab may increase the immunosuppressive activities of Cyclosporine.
Temsirolimus,Temsirolimus may increase the immunosuppressive activities of Cyclosporine.
Rilonacept,Rilonacept may increase the immunosuppressive activities of Cyclosporine.
Pazopanib,Pazopanib may increase the immunosuppressive activities of Cyclosporine.
Panobinostat,Panobinostat may increase the immunosuppressive activities of Cyclosporine.
Mepolizumab,Mepolizumab may increase the immunosuppressive activities of Cyclosporine.
Bosutinib,Bosutinib may increase the immunosuppressive activities of Cyclosporine.
Denosumab,Denosumab may increase the immunosuppressive activities of Cyclosporine.
Abetimus,Abetimus may increase the immunosuppressive activities of Cyclosporine.
Golimumab,Golimumab may increase the immunosuppressive activities of Cyclosporine.
Belatacept,Belatacept may increase the immunosuppressive activities of Cyclosporine.
Bendamustine,Bendamustine may increase the immunosuppressive activities of Cyclosporine.
Cabazitaxel,Cabazitaxel may increase the immunosuppressive activities of Cyclosporine.
Pralatrexate,Pralatrexate may increase the immunosuppressive activities of Cyclosporine.
Wortmannin,Wortmannin may increase the immunosuppressive activities of Cyclosporine.
Fingolimod,Fingolimod may increase the immunosuppressive activities of Cyclosporine.
Brentuximab vedotin,Brentuximab vedotin may increase the immunosuppressive activities of Cyclosporine.
Eribulin,Eribulin may increase the immunosuppressive activities of Cyclosporine.
Ruxolitinib,Ruxolitinib may increase the immunosuppressive activities of Cyclosporine.
Belimumab,Belimumab may increase the immunosuppressive activities of Cyclosporine.
Teriflunomide,Teriflunomide may increase the immunosuppressive activities of Cyclosporine.
Carfilzomib,Carfilzomib may increase the immunosuppressive activities of Cyclosporine.
Tofacitinib,Tofacitinib may increase the immunosuppressive activities of Cyclosporine.
Ponatinib,Ponatinib may increase the immunosuppressive activities of Cyclosporine.
Certolizumab pegol,Certolizumab pegol may increase the immunosuppressive activities of Cyclosporine.
Fluticasone furoate,Fluticasone furoate may increase the immunosuppressive activities of Cyclosporine.
Dimethyl fumarate,Dimethyl fumarate may increase the immunosuppressive activities of Cyclosporine.
Pomalidomide,Pomalidomide may increase the immunosuppressive activities of Cyclosporine.
Obinutuzumab,Obinutuzumab may increase the immunosuppressive activities of Cyclosporine.
Fluprednidene,Fluprednidene may increase the immunosuppressive activities of Cyclosporine.
Fluocortolone,Fluocortolone may increase the immunosuppressive activities of Cyclosporine.
Secukinumab,Secukinumab may increase the immunosuppressive activities of Cyclosporine.
Vedolizumab,Vedolizumab may increase the immunosuppressive activities of Cyclosporine.
Siltuximab,Siltuximab may increase the immunosuppressive activities of Cyclosporine.
Blinatumomab,Blinatumomab may increase the immunosuppressive activities of Cyclosporine.
Ibrutinib,Ibrutinib may increase the immunosuppressive activities of Cyclosporine.
Idelalisib,Idelalisib may increase the immunosuppressive activities of Cyclosporine.
Palbociclib,Palbociclib may increase the immunosuppressive activities of Cyclosporine.
Olaparib,Olaparib may increase the immunosuppressive activities of Cyclosporine.
Dinutuximab,Dinutuximab may increase the immunosuppressive activities of Cyclosporine.
Vilanterol,Vilanterol may increase the immunosuppressive activities of Cyclosporine.
Tixocortol,Tixocortol may increase the immunosuppressive activities of Cyclosporine.
Peginterferon beta-1a,Peginterferon beta-1a may increase the immunosuppressive activities of Cyclosporine.
Antilymphocyte immunoglobulin (horse),Antilymphocyte immunoglobulin (horse) may increase the immunosuppressive activities of Cyclosporine.
Fluprednisolone,Fluprednisolone may increase the immunosuppressive activities of Cyclosporine.
Meprednisone,Meprednisone may increase the immunosuppressive activities of Cyclosporine.
Tepoxalin,Tepoxalin may increase the immunosuppressive activities of Cyclosporine.
Dexamethasone isonicotinate,Dexamethasone isonicotinate may increase the immunosuppressive activities of Cyclosporine.
Melengestrol,Melengestrol may increase the immunosuppressive activities of Cyclosporine.
Ixekizumab,Ixekizumab may increase the immunosuppressive activities of Cyclosporine.
Ravulizumab,Ravulizumab may increase the immunosuppressive activities of Cyclosporine.
Pirarubicin,Pirarubicin may increase the immunosuppressive activities of Cyclosporine.
Voclosporin,Voclosporin may increase the immunosuppressive activities of Cyclosporine.
Peficitinib,Peficitinib may increase the immunosuppressive activities of Cyclosporine.
Clobetasol,Clobetasol may increase the immunosuppressive activities of Cyclosporine.
Sarilumab,Sarilumab may increase the immunosuppressive activities of Cyclosporine.
Brodalumab,Brodalumab may increase the immunosuppressive activities of Cyclosporine.
Sirukumab,Sirukumab may increase the immunosuppressive activities of Cyclosporine.
Baricitinib,Baricitinib may increase the immunosuppressive activities of Cyclosporine.
Guselkumab,Guselkumab may increase the immunosuppressive activities of Cyclosporine.
Deflazacort,Deflazacort may increase the immunosuppressive activities of Cyclosporine.
Ocrelizumab,Ocrelizumab may increase the immunosuppressive activities of Cyclosporine.
Triptolide,Triptolide may increase the immunosuppressive activities of Cyclosporine.
Siponimod,Siponimod may increase the immunosuppressive activities of Cyclosporine.
Ozanimod,Ozanimod may increase the immunosuppressive activities of Cyclosporine.
Mizoribine,Mizoribine may increase the immunosuppressive activities of Cyclosporine.
Gusperimus,Gusperimus may increase the immunosuppressive activities of Cyclosporine.
Cepeginterferon alfa-2B,Cepeginterferon alfa-2B may increase the immunosuppressive activities of Cyclosporine.
Trofosfamide,Trofosfamide may increase the immunosuppressive activities of Cyclosporine.
Doxifluridine,Doxifluridine may increase the immunosuppressive activities of Cyclosporine.
Deoxyspergualin,Deoxyspergualin may increase the immunosuppressive activities of Cyclosporine.
Acteoside,Acteoside may increase the immunosuppressive activities of Cyclosporine.
Cortivazol,Cortivazol may increase the immunosuppressive activities of Cyclosporine.
Hypericin,Hypericin may increase the immunosuppressive activities of Cyclosporine.
9-(N-methyl-L-isoleucine)-cyclosporin A,9-(N-methyl-L-isoleucine)-cyclosporin A may increase the immunosuppressive activities of Cyclosporine.
Prednylidene,Prednylidene may increase the immunosuppressive activities of Cyclosporine.
Fluocortin,Fluocortin may increase the immunosuppressive activities of Cyclosporine.
Begelomab,Begelomab may increase the immunosuppressive activities of Cyclosporine.
Fluperolone,Fluperolone may increase the immunosuppressive activities of Cyclosporine.
Formocortal,Formocortal may increase the immunosuppressive activities of Cyclosporine.
Halometasone,Halometasone may increase the immunosuppressive activities of Cyclosporine.
Cloprednol,Cloprednol may increase the immunosuppressive activities of Cyclosporine.
Fluclorolone,Fluclorolone may increase the immunosuppressive activities of Cyclosporine.
Fluticasone,Fluticasone may increase the immunosuppressive activities of Cyclosporine.
Tetrandrine,Tetrandrine may increase the immunosuppressive activities of Cyclosporine.
Monomethyl fumarate,Monomethyl fumarate may increase the immunosuppressive activities of Cyclosporine.
Mometasone furoate,Mometasone furoate may increase the immunosuppressive activities of Cyclosporine.
Hydrocortisone aceponate,Hydrocortisone aceponate may increase the immunosuppressive activities of Cyclosporine.
Hydrocortisone acetate,Hydrocortisone acetate may increase the immunosuppressive activities of Cyclosporine.
Hydrocortisone succinate,Hydrocortisone succinate may increase the immunosuppressive activities of Cyclosporine.
Emapalumab,Emapalumab may increase the immunosuppressive activities of Cyclosporine.
Risankizumab,Risankizumab may increase the immunosuppressive activities of Cyclosporine.
Rozanolixizumab,Rozanolixizumab may increase the immunosuppressive activities of Cyclosporine.
Bleselumab,Bleselumab may increase the immunosuppressive activities of Cyclosporine.
Amitriptyline,The metabolism of Amitriptyline can be decreased when combined with Cyclosporine.
Esketamine,The risk or severity of hypertension can be increased when Esketamine is combined with Cyclosporine.
Allopurinol,The serum concentration of Cyclosporine can be increased when it is combined with Allopurinol.
Polymyxin B,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Polymyxin B.
Solriamfetol,The risk or severity of hypertension can be increased when Solriamfetol is combined with Cyclosporine.
Testosterone undecanoate,Testosterone undecanoate may increase the hypertensive activities of Cyclosporine.
Erdafitinib,The serum concentration of Cyclosporine can be increased when it is combined with Erdafitinib.
Baclofen,Cyclosporine may decrease the excretion rate of Baclofen which could result in a higher serum level.
Ciprofloxacin,Cyclosporine may increase the nephrotoxic activities of Ciprofloxacin.
Alpelisib,The serum concentration of Alpelisib can be increased when it is combined with Cyclosporine.
Timolol,The metabolism of Timolol can be decreased when combined with Cyclosporine.
Pretomanid,The serum concentration of Pretomanid can be increased when it is combined with Cyclosporine.
Entrectinib,The metabolism of Entrectinib can be decreased when combined with Cyclosporine.
Lefamulin,The serum concentration of Lefamulin can be increased when it is combined with Cyclosporine.
Dalfampridine,The risk or severity of seizure can be increased when Cyclosporine is combined with Dalfampridine.
Lasmiditan,The serum concentration of Cyclosporine can be increased when it is combined with Lasmiditan.
Elexacaftor,The serum concentration of Elexacaftor can be increased when it is combined with Cyclosporine.
Hydrocortisone cypionate,The risk or severity of adverse effects can be increased when Hydrocortisone cypionate is combined with Cyclosporine.
Prednisolone phosphate,The risk or severity of adverse effects can be increased when Prednisolone phosphate is combined with Cyclosporine.
Prednisolone hemisuccinate,The risk or severity of adverse effects can be increased when Prednisolone hemisuccinate is combined with Cyclosporine.
Fluprednidene acetate,The risk or severity of adverse effects can be increased when Fluprednidene acetate is combined with Cyclosporine.
Methylprednisolone hemisuccinate,The risk or severity of adverse effects can be increased when Methylprednisolone hemisuccinate is combined with Cyclosporine.
Prednisone acetate,The risk or severity of adverse effects can be increased when Prednisone acetate is combined with Cyclosporine.
Clocortolone acetate,The risk or severity of adverse effects can be increased when Clocortolone acetate is combined with Cyclosporine.
Melengestrol acetate,The risk or severity of adverse effects can be increased when Melengestrol acetate is combined with Cyclosporine.
Betamethasone phosphate,The risk or severity of adverse effects can be increased when Betamethasone phosphate is combined with Cyclosporine.
Cortisone,The risk or severity of adverse effects can be increased when Cortisone is combined with Cyclosporine.
Diflorasone,The risk or severity of adverse effects can be increased when Diflorasone is combined with Cyclosporine.
Alclometasone,The risk or severity of adverse effects can be increased when Alclometasone is combined with Cyclosporine.
Medrysone,The risk or severity of adverse effects can be increased when Medrysone is combined with Cyclosporine.
Amcinonide,The risk or severity of adverse effects can be increased when Amcinonide is combined with Cyclosporine.
Fluorometholone,The risk or severity of adverse effects can be increased when Fluorometholone is combined with Cyclosporine.
Desoximetasone,The risk or severity of adverse effects can be increased when Desoximetasone is combined with Cyclosporine.
Ulobetasol,The risk or severity of adverse effects can be increased when Ulobetasol is combined with Cyclosporine.
Flumethasone,The risk or severity of adverse effects can be increased when Flumethasone is combined with Cyclosporine.
Clocortolone,The risk or severity of adverse effects can be increased when Clocortolone is combined with Cyclosporine.
Flurandrenolide,The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Cyclosporine.
Loteprednol etabonate,The risk or severity of adverse effects can be increased when Loteprednol etabonate is combined with Cyclosporine.
Rimexolone,The risk or severity of adverse effects can be increased when Rimexolone is combined with Cyclosporine.
Clobetasol propionate,The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Cyclosporine.
Fluocinonide,The risk or severity of adverse effects can be increased when Fluocinonide is combined with Cyclosporine.
Prednicarbate,The risk or severity of adverse effects can be increased when Prednicarbate is combined with Cyclosporine.
Desonide,The risk or severity of adverse effects can be increased when Desonide is combined with Cyclosporine.
Difluprednate,The risk or severity of adverse effects can be increased when Difluprednate is combined with Cyclosporine.
Halcinonide,The risk or severity of adverse effects can be increased when Halcinonide is combined with Cyclosporine.
Difluocortolone,The risk or severity of adverse effects can be increased when Difluocortolone is combined with Cyclosporine.
Clobetasone,The risk or severity of adverse effects can be increased when Clobetasone is combined with Cyclosporine.
Hydrocortisone butyrate,The risk or severity of adverse effects can be increased when Hydrocortisone butyrate is combined with Cyclosporine.
Hydrocortisone probutate,The risk or severity of adverse effects can be increased when Hydrocortisone probutate is combined with Cyclosporine.
Hydrocortisone valerate,The risk or severity of adverse effects can be increased when Hydrocortisone valerate is combined with Cyclosporine.
Loteprednol,The risk or severity of adverse effects can be increased when Loteprednol is combined with Cyclosporine.
Methylprednisolone aceponate,The risk or severity of adverse effects can be increased when Methylprednisolone aceponate is combined with Cyclosporine.
Prednisolone acetate,The risk or severity of adverse effects can be increased when Prednisolone acetate is combined with Cyclosporine.
Zanubrutinib,The metabolism of Zanubrutinib can be decreased when combined with Cyclosporine.
Voxelotor,The serum concentration of Voxelotor can be increased when it is combined with Cyclosporine.
Bupropion,The risk or severity of seizure can be increased when Cyclosporine is combined with Bupropion.
Verapamil,The serum concentration of Cyclosporine can be increased when it is combined with Verapamil.
Cenobamate,The serum concentration of Cenobamate can be decreased when it is combined with Cyclosporine.
Nystatin,The serum concentration of Cyclosporine can be increased when it is combined with Nystatin.
Levamlodipine,The serum concentration of Cyclosporine can be increased when it is combined with Levamlodipine.
Lumateperone,The serum concentration of Lumateperone can be increased when it is combined with Cyclosporine.
Ubrogepant,The serum concentration of Ubrogepant can be increased when it is combined with Cyclosporine.
Furosemide,The risk or severity of gouty arthritis can be increased when Cyclosporine is combined with Furosemide.
Tramadol,The metabolism of Cyclosporine can be decreased when combined with Tramadol.
Levofloxacin,The serum concentration of Cyclosporine can be increased when it is combined with Levofloxacin.
Rimegepant,The serum concentration of Rimegepant can be increased when it is combined with Cyclosporine.
Neomycin,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Neomycin.
Darunavir,The serum concentration of Cyclosporine can be increased when it is combined with Darunavir.
Chloroquine,The serum concentration of Cyclosporine can be increased when it is combined with Chloroquine.
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Cyclosporine.
Lopinavir,The serum concentration of Cyclosporine can be increased when it is combined with Lopinavir.
Haloperidol,The serum concentration of Cyclosporine can be increased when it is combined with Haloperidol.
Obeticholic acid,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Obeticholic acid.
Selumetinib,The serum concentration of Selumetinib can be increased when it is combined with Cyclosporine.
Tucatinib,Cyclosporine may decrease the excretion rate of Tucatinib which could result in a higher serum level.
Pemigatinib,The metabolism of Pemigatinib can be decreased when combined with Cyclosporine.
Capmatinib,The serum concentration of Cyclosporine can be increased when it is combined with Capmatinib.
Inebilizumab,The risk or severity of infection can be increased when Cyclosporine is combined with Inebilizumab.
Lurbinectedin,The serum concentration of Lurbinectedin can be increased when it is combined with Cyclosporine.
Niacin,The metabolism of Cyclosporine can be decreased when combined with Niacin.
Raloxifene,The metabolism of Raloxifene can be decreased when combined with Cyclosporine.
Nitric Oxide,The metabolism of Nitric Oxide can be decreased when combined with Cyclosporine.
Hydralazine,The metabolism of Hydralazine can be decreased when combined with Cyclosporine.
Topiroxostat,The metabolism of Topiroxostat can be decreased when combined with Cyclosporine.
Valproic acid,The metabolism of Valproic acid can be decreased when combined with Cyclosporine.
Zafirlukast,The metabolism of Zafirlukast can be decreased when combined with Cyclosporine.
Epinephrine,The metabolism of Cyclosporine can be decreased when combined with Epinephrine.
Tranylcypromine,The metabolism of Cyclosporine can be decreased when combined with Tranylcypromine.
Pilocarpine,The metabolism of Cyclosporine can be decreased when combined with Pilocarpine.
Rutin,The metabolism of Cyclosporine can be decreased when combined with Rutin.
Resveratrol,The metabolism of Cyclosporine can be decreased when combined with Resveratrol.
GPI-1485,The metabolism of Cyclosporine can be decreased when combined with GPI-1485.
Noscapine,The metabolism of Cyclosporine can be decreased when combined with Noscapine.
Remacemide,The metabolism of Cyclosporine can be decreased when combined with Remacemide.
Lestaurtinib,The metabolism of Cyclosporine can be decreased when combined with Lestaurtinib.
Capsaicin,The metabolism of Cyclosporine can be decreased when combined with Capsaicin.
Tofisopam,The metabolism of Cyclosporine can be decreased when combined with Tofisopam.
Peppermint oil,The metabolism of Cyclosporine can be decreased when combined with Peppermint oil.
Saracatinib,The metabolism of Cyclosporine can be decreased when combined with Saracatinib.
Oxetacaine,The metabolism of Cyclosporine can be decreased when combined with Oxetacaine.
Black cohosh,The metabolism of Cyclosporine can be decreased when combined with Black cohosh.
Cabergoline,The metabolism of Cyclosporine can be decreased when combined with Cabergoline.
Doxycycline,The metabolism of Cyclosporine can be decreased when combined with Doxycycline.
Diethylstilbestrol,The metabolism of Cyclosporine can be decreased when combined with Diethylstilbestrol.
Methylergometrine,The metabolism of Cyclosporine can be decreased when combined with Methylergometrine.
Tetracycline,The metabolism of Cyclosporine can be decreased when combined with Tetracycline.
Rabeprazole,The metabolism of Cyclosporine can be decreased when combined with Rabeprazole.
Ketazolam,The metabolism of Cyclosporine can be decreased when combined with Ketazolam.
7-ethyl-10-hydroxycamptothecin,The metabolism of Cyclosporine can be decreased when combined with 7-ethyl-10-hydroxycamptothecin.
Efonidipine,The metabolism of Cyclosporine can be decreased when combined with Efonidipine.
Fostamatinib,The metabolism of Cyclosporine can be decreased when combined with Fostamatinib.
WIN 55212-2,The metabolism of Cyclosporine can be decreased when combined with WIN 55212-2.
Medical Cannabis,The metabolism of Cyclosporine can be decreased when combined with Medical Cannabis.
Dimethyl sulfoxide,The metabolism of Cyclosporine can be decreased when combined with Dimethyl sulfoxide.
Curcumin sulfate,The metabolism of Cyclosporine can be decreased when combined with Curcumin sulfate.
Mefloquine,The metabolism of Cyclosporine can be decreased when combined with Mefloquine.
Clofazimine,The metabolism of Cyclosporine can be decreased when combined with Clofazimine.
Metronidazole,The metabolism of Cyclosporine can be decreased when combined with Metronidazole.
Dihydroergotamine,The metabolism of Cyclosporine can be decreased when combined with Dihydroergotamine.
Felodipine,The metabolism of Cyclosporine can be decreased when combined with Felodipine.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Alefacept.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Alefacept.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Alefacept.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Alefacept.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Alefacept.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Alefacept.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Alefacept.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Alefacept.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Alefacept."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Alefacept.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Alefacept.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alefacept.
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Alefacept.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Alefacept.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Alefacept.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Alefacept.
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Alefacept.
Basiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Alefacept.
Muromonab,The risk or severity of adverse effects can be increased when Muromonab is combined with Alefacept.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alefacept.
Tositumomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Alefacept.
Alemtuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Alefacept.
Efalizumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Alefacept is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Alefacept is combined with Interferon alfa-2b.
Daclizumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Alefacept is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Alefacept is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Alefacept is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Alefacept is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Alefacept is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Alefacept is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Alefacept is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Alefacept is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Alefacept is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Alefacept is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Alefacept is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Alefacept is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Alefacept is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Alefacept is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Alefacept is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Alefacept is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Alefacept is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Alefacept is combined with Beclomethasone dipropionate.
Sorafenib,The risk or severity of adverse effects can be increased when Alefacept is combined with Sorafenib.
Streptozocin,The risk or severity of adverse effects can be increased when Alefacept is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Alefacept is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Alefacept is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Alefacept is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Alefacept is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Alefacept is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Alefacept is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Alefacept is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Alefacept is combined with Altretamine.
Zidovudine,The risk or severity of adverse effects can be increased when Alefacept is combined with Zidovudine.
Cisplatin,The risk or severity of adverse effects can be increased when Alefacept is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Alefacept is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Alefacept is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Alefacept is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Alefacept is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Alefacept is combined with Pentostatin.
Methotrexate,The risk or severity of adverse effects can be increased when Alefacept is combined with Methotrexate.
Carbamazepine,The risk or severity of adverse effects can be increased when Alefacept is combined with Carbamazepine.
Vinblastine,The risk or severity of adverse effects can be increased when Alefacept is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Alefacept is combined with Linezolid.
Imatinib,The risk or severity of adverse effects can be increased when Alefacept is combined with Imatinib.
Triamcinolone,The risk or severity of adverse effects can be increased when Alefacept is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Alefacept is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Alefacept is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Alefacept is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Alefacept is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Alefacept is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Alefacept is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Alefacept is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Alefacept is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Alefacept is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Alefacept is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Alefacept is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Alefacept is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Alefacept is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Alefacept is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Alefacept is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Alefacept is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Alefacept is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Alefacept is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Alefacept is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Alefacept is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Alefacept is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Alefacept is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Alefacept is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Alefacept is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Alefacept is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Alefacept is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Alefacept is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Alefacept is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Alefacept is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Alefacept is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Alefacept is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Alefacept is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Alefacept is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Alefacept is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Alefacept is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Alefacept is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Alefacept is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Alefacept is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Alefacept is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Alefacept is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Alefacept is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Alefacept is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Alefacept is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Alefacept is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Alefacept is combined with Paclitaxel.
Dexamethasone,The risk or severity of adverse effects can be increased when Alefacept is combined with Dexamethasone.
Docetaxel,The risk or severity of adverse effects can be increased when Alefacept is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Alefacept is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Alefacept is combined with Decitabine.
Sunitinib,The risk or severity of adverse effects can be increased when Alefacept is combined with Sunitinib.
Nelarabine,The risk or severity of adverse effects can be increased when Alefacept is combined with Nelarabine.
Abatacept,The risk or severity of adverse effects can be increased when Alefacept is combined with Abatacept.
Corticotropin,The risk or severity of adverse effects can be increased when Alefacept is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Alefacept is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Alefacept is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Alefacept is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Alefacept is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Alefacept is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Alefacept is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Alefacept is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Alefacept is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Alefacept is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Alefacept is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Alefacept is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Alefacept is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Alefacept is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Alefacept is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Alefacept is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Alefacept is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Alefacept is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Alefacept is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Alefacept is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Alefacept is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Alefacept is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Alefacept is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Alefacept is combined with omega interferon.
Apremilast,The risk or severity of adverse effects can be increased when Alefacept is combined with Apremilast.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Alefacept is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Alefacept is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Alefacept is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Alefacept is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Alefacept is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Alefacept is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Alefacept is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Alefacept is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Alefacept is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Alefacept is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Alefacept is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Alefacept is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Alefacept is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Alefacept is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Alefacept is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Alefacept is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Alefacept is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Alefacept is combined with Ponatinib.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Alefacept is combined with Certolizumab pegol.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Alefacept is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Alefacept is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Alefacept is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Alefacept is combined with Blinatumomab.
Ibrutinib,The risk or severity of adverse effects can be increased when Alefacept is combined with Ibrutinib.
Idelalisib,The risk or severity of adverse effects can be increased when Alefacept is combined with Idelalisib.
Palbociclib,The risk or severity of adverse effects can be increased when Alefacept is combined with Palbociclib.
Olaparib,The risk or severity of adverse effects can be increased when Alefacept is combined with Olaparib.
Dinutuximab,The risk or severity of adverse effects can be increased when Alefacept is combined with Dinutuximab.
Vilanterol,The risk or severity of adverse effects can be increased when Alefacept is combined with Vilanterol.
Tixocortol,The risk or severity of adverse effects can be increased when Alefacept is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Alefacept is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Alefacept is combined with Antilymphocyte immunoglobulin (horse).
Fluprednisolone,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Alefacept is combined with Meprednisone.
Tepoxalin,The risk or severity of adverse effects can be increased when Alefacept is combined with Tepoxalin.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Alefacept is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Alefacept is combined with Melengestrol.
Ixekizumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Alefacept is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Alefacept is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Alefacept is combined with Peficitinib.
Clobetasol,The risk or severity of adverse effects can be increased when Alefacept is combined with Clobetasol.
Sarilumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Sirukumab.
Baricitinib,The risk or severity of adverse effects can be increased when Alefacept is combined with Baricitinib.
Guselkumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Guselkumab.
Deflazacort,The risk or severity of adverse effects can be increased when Alefacept is combined with Deflazacort.
Ocrelizumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Ocrelizumab.
Triptolide,The risk or severity of adverse effects can be increased when Alefacept is combined with Triptolide.
Siponimod,The risk or severity of adverse effects can be increased when Alefacept is combined with Siponimod.
Ozanimod,The risk or severity of adverse effects can be increased when Alefacept is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Alefacept is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Alefacept is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Alefacept is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Alefacept is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Alefacept is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Alefacept is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Alefacept is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Alefacept is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Alefacept is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Alefacept is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Prednylidene,The risk or severity of adverse effects can be increased when Alefacept is combined with Prednylidene.
Fluocortin,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Alefacept is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Alefacept is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Alefacept is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Alefacept is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluclorolone.
Fluticasone,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluticasone.
Tetrandrine,The risk or severity of adverse effects can be increased when Alefacept is combined with Tetrandrine.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Alefacept is combined with Monomethyl fumarate.
Mometasone furoate,The risk or severity of adverse effects can be increased when Alefacept is combined with Mometasone furoate.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Alefacept is combined with Hydrocortisone aceponate.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Alefacept is combined with Hydrocortisone acetate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Alefacept is combined with Hydrocortisone succinate.
Emapalumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Bleselumab.
Natalizumab,The risk or severity of adverse effects can be increased when Alefacept is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alefacept.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Alefacept.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alefacept.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Alefacept.
Leflunomide,The risk or severity of adverse effects can be increased when Alefacept is combined with Leflunomide.
Tofacitinib,Alefacept may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Alefacept.
Fingolimod,Alefacept may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Alefacept.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Alefacept.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Alefacept.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Alefacept.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Alefacept.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Alefacept.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Alefacept.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Alefacept.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Alefacept.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Alefacept.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Alefacept."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alefacept.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Alefacept.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alefacept."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Alefacept.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Alefacept.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Alefacept.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alefacept.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Alefacept.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Alefacept.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Alefacept.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Alefacept.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Alefacept.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Alefacept.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Alefacept.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Alefacept.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Alefacept.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Alefacept.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Alefacept."
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Alefacept.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Alefacept.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alefacept.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Alefacept.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Alefacept.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Alefacept.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Alefacept.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Alefacept.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Alefacept.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Alefacept.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Alefacept.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Alefacept.
Cyclosporine,Alefacept may increase the immunosuppressive activities of Cyclosporine.
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Alefacept.
Lopinavir,The serum concentration of Alefacept can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Alefacept is combined with Inebilizumab.
Patent Blue,The risk or severity of hypotension can be increased when Patent Blue is combined with Felypressin.
Thyrotropin alfa,Thyrotropin alfa may increase the vasoconstricting activities of Felypressin.
Liothyronine,Liothyronine may increase the vasoconstricting activities of Felypressin.
Levothyroxine,Levothyroxine may increase the vasoconstricting activities of Felypressin.
Liotrix,Liotrix may increase the vasoconstricting activities of Felypressin.
Tiratricol,Tiratricol may increase the vasoconstricting activities of Felypressin.
"Thyroid, porcine","Thyroid, porcine may increase the vasoconstricting activities of Felypressin."
Lidocaine,The risk or severity of hypertension can be increased when Felypressin is combined with Lidocaine.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Efalizumab.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Efalizumab.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Efalizumab.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Efalizumab.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Efalizumab.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Efalizumab.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Efalizumab.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Efalizumab.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Efalizumab."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Efalizumab.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Efalizumab.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Efalizumab.
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Efalizumab.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Efalizumab.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Efalizumab.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Efalizumab.
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Efalizumab.
Basiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Efalizumab.
Muromonab,The risk or severity of adverse effects can be increased when Muromonab is combined with Efalizumab.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Efalizumab.
Tositumomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Efalizumab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Efalizumab.
Alefacept,The risk or severity of adverse effects can be increased when Alefacept is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Efalizumab is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Efalizumab is combined with Interferon alfa-2b.
Daclizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Efalizumab is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Efalizumab is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Efalizumab is combined with Beclomethasone dipropionate.
Sorafenib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sorafenib.
Streptozocin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Efalizumab is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Altretamine.
Zidovudine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Zidovudine.
Cisplatin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Efalizumab is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pentostatin.
Methotrexate,The risk or severity of adverse effects can be increased when Efalizumab is combined with Methotrexate.
Carbamazepine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carbamazepine.
Vinblastine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Efalizumab is combined with Linezolid.
Imatinib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Imatinib.
Triamcinolone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Efalizumab is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Efalizumab is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Efalizumab is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Efalizumab is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Efalizumab is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Efalizumab is combined with Paclitaxel.
Dexamethasone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dexamethasone.
Docetaxel,The risk or severity of adverse effects can be increased when Efalizumab is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Decitabine.
Sunitinib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sunitinib.
Nelarabine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nelarabine.
Abatacept,The risk or severity of adverse effects can be increased when Efalizumab is combined with Abatacept.
Corticotropin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Efalizumab is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Efalizumab is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Efalizumab is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Efalizumab is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Efalizumab is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Efalizumab is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Efalizumab is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Efalizumab is combined with omega interferon.
Apremilast,The risk or severity of adverse effects can be increased when Efalizumab is combined with Apremilast.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Efalizumab is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Efalizumab is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Efalizumab is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Efalizumab is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ponatinib.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Efalizumab is combined with Certolizumab pegol.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Blinatumomab.
Ibrutinib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ibrutinib.
Idelalisib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Idelalisib.
Palbociclib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Palbociclib.
Olaparib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Olaparib.
Dinutuximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dinutuximab.
Vilanterol,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vilanterol.
Tixocortol,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Efalizumab is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Efalizumab is combined with Antilymphocyte immunoglobulin (horse).
Fluprednisolone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Meprednisone.
Tepoxalin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tepoxalin.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Efalizumab is combined with Melengestrol.
Ixekizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Peficitinib.
Clobetasol,The risk or severity of adverse effects can be increased when Efalizumab is combined with Clobetasol.
Sarilumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sirukumab.
Baricitinib,The risk or severity of adverse effects can be increased when Efalizumab is combined with Baricitinib.
Guselkumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Guselkumab.
Deflazacort,The risk or severity of adverse effects can be increased when Efalizumab is combined with Deflazacort.
Ocrelizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ocrelizumab.
Triptolide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Triptolide.
Siponimod,The risk or severity of adverse effects can be increased when Efalizumab is combined with Siponimod.
Ozanimod,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Efalizumab is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Efalizumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Prednylidene,The risk or severity of adverse effects can be increased when Efalizumab is combined with Prednylidene.
Fluocortin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Efalizumab is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluclorolone.
Fluticasone,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluticasone.
Tetrandrine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tetrandrine.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Efalizumab is combined with Monomethyl fumarate.
Mometasone furoate,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mometasone furoate.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydrocortisone aceponate.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydrocortisone acetate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydrocortisone succinate.
Emapalumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bleselumab.
Natalizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Efalizumab.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Efalizumab.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Efalizumab.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Efalizumab.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Efalizumab.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Efalizumab.
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Efalizumab.
Estrone,Estrone may increase the thrombogenic activities of Efalizumab.
Estradiol,Estradiol may increase the thrombogenic activities of Efalizumab.
Dienestrol,Dienestrol may increase the thrombogenic activities of Efalizumab.
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Efalizumab.
Mestranol,Mestranol may increase the thrombogenic activities of Efalizumab.
Estriol,Estriol may increase the thrombogenic activities of Efalizumab.
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Efalizumab.
Quinestrol,Quinestrol may increase the thrombogenic activities of Efalizumab.
Hexestrol,Hexestrol may increase the thrombogenic activities of Efalizumab.
Tibolone,Tibolone may increase the thrombogenic activities of Efalizumab.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Efalizumab."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Efalizumab."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Efalizumab.
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Efalizumab.
Zeranol,Zeranol may increase the thrombogenic activities of Efalizumab.
Equol,Equol may increase the thrombogenic activities of Efalizumab.
Promestriene,Promestriene may increase the thrombogenic activities of Efalizumab.
Methallenestril,Methallenestril may increase the thrombogenic activities of Efalizumab.
Epimestrol,Epimestrol may increase the thrombogenic activities of Efalizumab.
Moxestrol,Moxestrol may increase the thrombogenic activities of Efalizumab.
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Efalizumab.
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Efalizumab.
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Efalizumab.
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Efalizumab.
Biochanin A,Biochanin A may increase the thrombogenic activities of Efalizumab.
Formononetin,Formononetin may increase the thrombogenic activities of Efalizumab.
Leflunomide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Leflunomide.
Tofacitinib,Efalizumab may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Efalizumab.
Fingolimod,Efalizumab may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Efalizumab.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Efalizumab.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Efalizumab.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Efalizumab.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Efalizumab.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Efalizumab.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Efalizumab.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Efalizumab.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Efalizumab.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Efalizumab.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Efalizumab."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Efalizumab.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Efalizumab.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Efalizumab."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Efalizumab.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Efalizumab.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Efalizumab.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Efalizumab.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Efalizumab.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Efalizumab.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Efalizumab.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Efalizumab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Efalizumab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Efalizumab.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Efalizumab.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Efalizumab.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Efalizumab.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Efalizumab.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Efalizumab.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Efalizumab.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Efalizumab.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Efalizumab.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Efalizumab.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Efalizumab.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Efalizumab.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Efalizumab.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Efalizumab.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Efalizumab.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Efalizumab.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Efalizumab.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Efalizumab.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Efalizumab.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Efalizumab.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Efalizumab.
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Efalizumab.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Efalizumab.
Capromab pendetide,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Efalizumab.
Palivizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Palivizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Technetium Tc-99m arcitumomab.
Panitumumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pexelizumab.
Epratuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Efalizumab is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Efalizumab is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Efalizumab is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Efalizumab is combined with NAV 1800.
Otelixizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Efalizumab is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Veltuzumab.
PRO-542,The risk or severity of adverse effects can be increased when Efalizumab is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Efalizumab is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Efalizumab is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Efalizumab is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Efalizumab is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Efalizumab is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Efalizumab is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Efalizumab is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lumiliximab.
Ipilimumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Clenoliximab.
BIIB015,The risk or severity of adverse effects can be increased when Efalizumab is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Efalizumab is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Efalizumab is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Catumaxomab.
Volociximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ofatumumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Raxibacumab.
Nivolumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nivolumab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dulaglutide.
Asfotase alfa,The risk or severity of adverse effects can be increased when Efalizumab is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Evolocumab.
Daratumumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Necitumumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Efalizumab is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Solanezumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tremelimumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lampalizumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Anifrolumab.
Benralizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Efalizumab is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Efalizumab is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Efalizumab is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Plozalizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Efalizumab is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Besilesomab.
Burosumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cemiplimab.
Camrelizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Refanezumab.
Bermekimab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Efalizumab is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nemolizumab.
Gedivumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Efalizumab is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Efalizumab is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Efalizumab is combined with Naratuximab emtansine.
Tildrakizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tildrakizumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ustekinumab.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Zenocutuzumab.
Cyclosporine,Efalizumab may increase the immunosuppressive activities of Cyclosporine.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Efalizumab."
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Efalizumab.
Lopinavir,The serum concentration of Efalizumab can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Efalizumab is combined with Inebilizumab.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Antithymocyte immunoglobulin (rabbit).
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Antithymocyte immunoglobulin (rabbit).
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Antithymocyte immunoglobulin (rabbit).
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Antithymocyte immunoglobulin (rabbit).
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Antithymocyte immunoglobulin (rabbit).
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Antithymocyte immunoglobulin (rabbit).
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Antithymocyte immunoglobulin (rabbit)."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Antithymocyte immunoglobulin (rabbit).
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Antithymocyte immunoglobulin (rabbit).
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antithymocyte immunoglobulin (rabbit).
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Antithymocyte immunoglobulin (rabbit).
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Antithymocyte immunoglobulin (rabbit).
Interferon beta-1b,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Antithymocyte immunoglobulin (rabbit).
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Antithymocyte immunoglobulin (rabbit).
Basiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Antithymocyte immunoglobulin (rabbit).
Muromonab,The risk or severity of adverse effects can be increased when Muromonab is combined with Antithymocyte immunoglobulin (rabbit).
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antithymocyte immunoglobulin (rabbit).
Tositumomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Antithymocyte immunoglobulin (rabbit).
Alemtuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Antithymocyte immunoglobulin (rabbit).
Alefacept,The risk or severity of adverse effects can be increased when Alefacept is combined with Antithymocyte immunoglobulin (rabbit).
Efalizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Interferon alfa-2b.
Daclizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Beclomethasone dipropionate.
Sorafenib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sorafenib.
Streptozocin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Altretamine.
Zidovudine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zidovudine.
Cisplatin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pentostatin.
Methotrexate,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Methotrexate.
Carbamazepine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carbamazepine.
Vinblastine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Linezolid.
Imatinib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Imatinib.
Triamcinolone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Paclitaxel.
Dexamethasone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexamethasone.
Docetaxel,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Decitabine.
Sunitinib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sunitinib.
Nelarabine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nelarabine.
Abatacept,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abatacept.
Corticotropin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with omega interferon.
Apremilast,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Apremilast.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ponatinib.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Certolizumab pegol.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Blinatumomab.
Ibrutinib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ibrutinib.
Idelalisib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Idelalisib.
Palbociclib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Palbociclib.
Olaparib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Olaparib.
Dinutuximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dinutuximab.
Vilanterol,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vilanterol.
Tixocortol,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Antilymphocyte immunoglobulin (horse).
Fluprednisolone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Meprednisone.
Tepoxalin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tepoxalin.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Melengestrol.
Ixekizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Peficitinib.
Clobetasol,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clobetasol.
Sarilumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sirukumab.
Baricitinib,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Baricitinib.
Guselkumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Guselkumab.
Deflazacort,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Deflazacort.
Triptolide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Triptolide.
Siponimod,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Siponimod.
Ozanimod,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Prednylidene,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Prednylidene.
Fluocortin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluclorolone.
Fluticasone,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluticasone.
Tetrandrine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tetrandrine.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Monomethyl fumarate.
Mometasone furoate,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mometasone furoate.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydrocortisone aceponate.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydrocortisone acetate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydrocortisone succinate.
Emapalumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bleselumab.
Natalizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Antithymocyte immunoglobulin (rabbit).
Roflumilast,Roflumilast may increase the immunosuppressive activities of Antithymocyte immunoglobulin (rabbit).
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Antithymocyte immunoglobulin (rabbit).
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Estrone,Estrone may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Estradiol,Estradiol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Dienestrol,Dienestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Mestranol,Mestranol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Estriol,Estriol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Quinestrol,Quinestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Hexestrol,Hexestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Tibolone,Tibolone may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit)."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit)."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Zeranol,Zeranol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Equol,Equol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Promestriene,Promestriene may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Methallenestril,Methallenestril may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Epimestrol,Epimestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Moxestrol,Moxestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Biochanin A,Biochanin A may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Formononetin,Formononetin may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Leflunomide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Leflunomide.
Tofacitinib,Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Antithymocyte immunoglobulin (rabbit).
Fingolimod,Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Antithymocyte immunoglobulin (rabbit).
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit)."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit)."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Ocrelizumab,Ocrelizumab may increase the immunosuppressive activities of Antithymocyte immunoglobulin (rabbit).
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Antithymocyte immunoglobulin (rabbit).
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Antithymocyte immunoglobulin (rabbit).
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Antithymocyte immunoglobulin (rabbit).
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Antithymocyte immunoglobulin (rabbit).
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Antithymocyte immunoglobulin (rabbit).
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Antithymocyte immunoglobulin (rabbit).
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Antithymocyte immunoglobulin (rabbit).
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Antithymocyte immunoglobulin (rabbit).
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Antithymocyte immunoglobulin (rabbit).
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Antithymocyte immunoglobulin (rabbit).
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Antithymocyte immunoglobulin (rabbit).
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Antithymocyte immunoglobulin (rabbit).
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Antithymocyte immunoglobulin (rabbit).
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Antithymocyte immunoglobulin (rabbit).
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Antithymocyte immunoglobulin (rabbit).
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Antithymocyte immunoglobulin (rabbit).
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Antithymocyte immunoglobulin (rabbit).
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Antithymocyte immunoglobulin (rabbit).
Capromab pendetide,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Antithymocyte immunoglobulin (rabbit).
Palivizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Palivizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Technetium Tc-99m arcitumomab.
Panitumumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pexelizumab.
Epratuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with NAV 1800.
Otelixizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Veltuzumab.
PRO-542,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lumiliximab.
Ipilimumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clenoliximab.
BIIB015,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Catumaxomab.
Volociximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ofatumumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Raxibacumab.
Nivolumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nivolumab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dulaglutide.
Asfotase alfa,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Evolocumab.
Daratumumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Necitumumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Solanezumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tremelimumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lampalizumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Anifrolumab.
Benralizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Plozalizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Besilesomab.
Burosumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cemiplimab.
Camrelizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Refanezumab.
Bermekimab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nemolizumab.
Gedivumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Naratuximab emtansine.
Tildrakizumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tildrakizumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ustekinumab.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zenocutuzumab.
Cyclosporine,Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Cyclosporine.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit)."
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Antithymocyte immunoglobulin (rabbit).
Lopinavir,The serum concentration of Antithymocyte immunoglobulin (rabbit) can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Inebilizumab.
Bleomycin,The risk or severity of pulmonary toxicity can be increased when Filgrastim is combined with Bleomycin.
Cyclophosphamide,The risk or severity of pulmonary toxicity can be increased when Filgrastim is combined with Cyclophosphamide.
Topotecan,The risk or severity of neutropenia can be increased when Filgrastim is combined with Topotecan.
Vindesine,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vindesine.
Vinorelbine,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vinorelbine.
Vincristine,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vincristine.
Vinblastine,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vinblastine.
Vintafolide,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vintafolide.
Vinflunine,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vinflunine.
Vincamine,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vincamine.
Aminocaproic acid,The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Coagulation Factor IX (Recombinant).
Alpha-1-proteinase inhibitor,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).
Menadione,Menadione may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).
Tranexamic acid,Tranexamic acid may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).
Aprotinin,Aprotinin may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).
Hydrogen peroxide,Hydrogen peroxide may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).
Aminomethylbenzoic acid,Aminomethylbenzoic acid may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).
Camostat,Camostat may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).
Monteplase,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Monteplase.
Lepirudin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Lepirudin.
Bivalirudin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Bivalirudin.
Alteplase,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Alteplase.
Urokinase,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Urokinase.
Reteplase,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Reteplase.
Anistreplase,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Anistreplase.
Tenecteplase,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Tenecteplase.
Abciximab,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Abciximab.
Drotrecogin alfa,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Drotrecogin alfa.
Streptokinase,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Streptokinase.
Dicoumarol,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dicoumarol.
Argatroban,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Argatroban.
Ardeparin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ardeparin.
Phenindione,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Phenindione.
Fondaparinux,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Fondaparinux.
Warfarin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Warfarin.
Pentosan polysulfate,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Pentosan polysulfate.
Acetylsalicylic acid,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Acetylsalicylic acid.
Phenprocoumon,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Phenprocoumon.
Dipyridamole,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dipyridamole.
Iloprost,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Iloprost.
Heparin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Heparin.
Enoxaparin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Enoxaparin.
Epoprostenol,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Epoprostenol.
Acenocoumarol,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Acenocoumarol.
4-hydroxycoumarin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with 4-hydroxycoumarin.
Coumarin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Coumarin.
Ximelagatran,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ximelagatran.
Desmoteplase,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Desmoteplase.
Defibrotide,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Defibrotide.
Ancrod,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ancrod.
Beraprost,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Beraprost.
Fibrinolysin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Fibrinolysin.
Prasugrel,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Prasugrel.
Rivaroxaban,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Rivaroxaban.
Sulodexide,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Sulodexide.
Idraparinux,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Idraparinux.
Cangrelor,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Cangrelor.
Astaxanthin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Astaxanthin.
Apixaban,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Apixaban.
Otamixaban,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Otamixaban.
Amediplase,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Amediplase.
Dabigatran etexilate,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dabigatran etexilate.
Danaparoid,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Danaparoid.
Dalteparin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dalteparin.
Tinzaparin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Tinzaparin.
Ferulic acid,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ferulic acid.
(R)-warfarin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with (R)-warfarin.
Ethyl biscoumacetate,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ethyl biscoumacetate.
Nadroparin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Nadroparin.
Triflusal,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Triflusal.
Ticagrelor,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ticagrelor.
Ditazole,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ditazole.
Vorapaxar,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Vorapaxar.
Edoxaban,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Edoxaban.
Potassium citrate,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Potassium citrate.
Sodium citrate,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Sodium citrate.
Dextran,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dextran.
Bemiparin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Bemiparin.
Reviparin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Reviparin.
Parnaparin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Parnaparin.
Certoparin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Certoparin.
Desirudin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Desirudin.
Zinc citrate,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Zinc citrate.
Antithrombin Alfa,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Antithrombin Alfa.
Protein C,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Protein C.
Antithrombin III human,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Antithrombin III human.
Letaxaban,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Letaxaban.
Darexaban,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Darexaban.
Betrixaban,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Betrixaban.
Nafamostat,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Nafamostat.
Gabexate,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Gabexate.
Fluindione,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Fluindione.
Protein S human,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Protein S human.
Brinase,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Brinase.
Clorindione,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Clorindione.
Diphenadione,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Diphenadione.
Tioclomarol,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Tioclomarol.
Melagatran,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Melagatran.
Saruplase,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Saruplase.
(S)-Warfarin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with (S)-Warfarin.
Tocopherylquinone,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Tocopherylquinone.
Edetate calcium disodium anhydrous,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Edetate calcium disodium anhydrous.
Dabigatran,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dabigatran.
Semuloparin,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Semuloparin.
Chloroquine,The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Chloroquine.
Gentamicin,The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Gentamicin.
Amiodarone,The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Amiodarone.
Darbepoetin alfa,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Octreotide.
Erythropoietin,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Octreotide.
Peginesatide,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Octreotide.
Methoxy polyethylene glycol-epoetin beta,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Octreotide.
Lomitapide,The metabolism of Octreotide can be decreased when combined with Lomitapide.
Bromocriptine,The serum concentration of Bromocriptine can be increased when it is combined with Octreotide.
Ceritinib,Octreotide may increase the bradycardic activities of Ceritinib.
Ivabradine,Octreotide may increase the bradycardic activities of Ivabradine.
Pegvisomant,The risk or severity of increased transaminases can be increased when Octreotide is combined with Pegvisomant.
Ruxolitinib,Ruxolitinib may increase the bradycardic activities of Octreotide.
Eliglustat,The metabolism of Eliglustat can be decreased when combined with Octreotide.
Ibrutinib,The metabolism of Ibrutinib can be decreased when combined with Octreotide.
Cilostazol,The metabolism of Cilostazol can be decreased when combined with Octreotide.
Colchicine,The metabolism of Colchicine can be decreased when combined with Octreotide.
Fentanyl,The metabolism of Fentanyl can be decreased when combined with Octreotide.
Iloperidone,The metabolism of Iloperidone can be decreased when combined with Octreotide.
Retapamulin,The metabolism of Retapamulin can be decreased when combined with Octreotide.
Tofacitinib,The metabolism of Tofacitinib can be decreased when combined with Octreotide.
Vardenafil,The metabolism of Vardenafil can be decreased when combined with Octreotide.
Eszopiclone,The metabolism of Eszopiclone can be decreased when combined with Octreotide.
Zopiclone,The metabolism of Zopiclone can be decreased when combined with Octreotide.
Lovastatin,The metabolism of Lovastatin can be decreased when combined with Octreotide.
Alfuzosin,The metabolism of Alfuzosin can be decreased when combined with Octreotide.
Alprazolam,The metabolism of Alprazolam can be decreased when combined with Octreotide.
Warfarin,The serum concentration of Warfarin can be increased when it is combined with Octreotide.
Acenocoumarol,The serum concentration of Acenocoumarol can be increased when it is combined with Octreotide.
(R)-warfarin,The serum concentration of (R)-warfarin can be increased when it is combined with Octreotide.
"R,S-Warfarin alcohol","The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Octreotide."
"S,R-Warfarin alcohol","The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Octreotide."
(S)-Warfarin,The serum concentration of (S)-Warfarin can be increased when it is combined with Octreotide.
Midazolam,The serum concentration of Midazolam can be increased when it is combined with Octreotide.
Tacrolimus,The serum concentration of Tacrolimus can be increased when it is combined with Octreotide.
Atorvastatin,The metabolism of Atorvastatin can be decreased when combined with Octreotide.
Cyclosporine,The serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.
Insulin human,The therapeutic efficacy of Insulin human can be decreased when used in combination with Octreotide.
Insulin lispro,The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Octreotide.
Insulin glargine,The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Octreotide.
Insulin pork,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Octreotide.
Troglitazone,The therapeutic efficacy of Troglitazone can be decreased when used in combination with Octreotide.
Glimepiride,The therapeutic efficacy of Glimepiride can be decreased when used in combination with Octreotide.
Acarbose,The therapeutic efficacy of Acarbose can be decreased when used in combination with Octreotide.
Sulfadiazine,The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Octreotide.
Rosiglitazone,The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Octreotide.
Acetohexamide,The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Octreotide.
Miglitol,The therapeutic efficacy of Miglitol can be decreased when used in combination with Octreotide.
Chlorpropamide,The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Octreotide.
Nateglinide,The therapeutic efficacy of Nateglinide can be decreased when used in combination with Octreotide.
Tolazamide,The therapeutic efficacy of Tolazamide can be decreased when used in combination with Octreotide.
Repaglinide,The therapeutic efficacy of Repaglinide can be decreased when used in combination with Octreotide.
Phenformin,The therapeutic efficacy of Phenformin can be decreased when used in combination with Octreotide.
Sulfamethoxazole,The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Octreotide.
Glipizide,The therapeutic efficacy of Glipizide can be decreased when used in combination with Octreotide.
Gliclazide,The therapeutic efficacy of Gliclazide can be decreased when used in combination with Octreotide.
Tolbutamide,The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Octreotide.
Pioglitazone,The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Octreotide.
Gliquidone,The therapeutic efficacy of Gliquidone can be decreased when used in combination with Octreotide.
Mitiglinide,The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Octreotide.
Sitagliptin,The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Octreotide.
Exenatide,The therapeutic efficacy of Exenatide can be decreased when used in combination with Octreotide.
Mecasermin,The therapeutic efficacy of Mecasermin can be decreased when used in combination with Octreotide.
Pramlintide,The therapeutic efficacy of Pramlintide can be decreased when used in combination with Octreotide.
Glisoxepide,The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Octreotide.
Insulin aspart,The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Octreotide.
Insulin detemir,The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Octreotide.
Insulin glulisine,The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Octreotide.
Glymidine,The therapeutic efficacy of Glymidine can be decreased when used in combination with Octreotide.
AICA ribonucleotide,The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Octreotide.
Buformin,The therapeutic efficacy of Buformin can be decreased when used in combination with Octreotide.
Vildagliptin,The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Octreotide.
Voglibose,The therapeutic efficacy of Voglibose can be decreased when used in combination with Octreotide.
NN344,The therapeutic efficacy of NN344 can be decreased when used in combination with Octreotide.
NBI-6024,The therapeutic efficacy of NBI-6024 can be decreased when used in combination with Octreotide.
AMG-222,The therapeutic efficacy of AMG-222 can be decreased when used in combination with Octreotide.
Bisegliptin,The therapeutic efficacy of Bisegliptin can be decreased when used in combination with Octreotide.
Alogliptin,The therapeutic efficacy of Alogliptin can be decreased when used in combination with Octreotide.
Dapagliflozin,The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Octreotide.
Saxagliptin,The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Octreotide.
Liraglutide,The therapeutic efficacy of Liraglutide can be decreased when used in combination with Octreotide.
Gosogliptin,The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Octreotide.
Glibornuride,The therapeutic efficacy of Glibornuride can be decreased when used in combination with Octreotide.
Benfluorex,The therapeutic efficacy of Benfluorex can be decreased when used in combination with Octreotide.
Empagliflozin,The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Octreotide.
Albiglutide,The therapeutic efficacy of Albiglutide can be decreased when used in combination with Octreotide.
Dulaglutide,The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Octreotide.
Lobeglitazone,The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Octreotide.
Netoglitazone,The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Octreotide.
Rivoglitazone,The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Octreotide.
Ciglitazone,The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Octreotide.
Lixisenatide,The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Octreotide.
Insulin beef,The therapeutic efficacy of Insulin beef can be decreased when used in combination with Octreotide.
Insulin degludec,The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Octreotide.
Insulin peglispro,The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Octreotide.
Insulin tregopil,The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Octreotide.
Ipragliflozin,The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Octreotide.
Dutogliptin,The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Octreotide.
Allicin,The therapeutic efficacy of Allicin can be decreased when used in combination with Octreotide.
Tofogliflozin,The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Octreotide.
"2,4-thiazolidinedione","The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Octreotide."
Teneligliptin,The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Octreotide.
Omarigliptin,The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Octreotide.
Carmegliptin,The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Octreotide.
Gemigliptin,The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Octreotide.
Anagliptin,The therapeutic efficacy of Anagliptin can be decreased when used in combination with Octreotide.
Evogliptin,The therapeutic efficacy of Evogliptin can be decreased when used in combination with Octreotide.
Sotagliflozin,The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Octreotide.
Balaglitazone,The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Octreotide.
Remogliflozin etabonate,The therapeutic efficacy of Remogliflozin etabonate can be decreased when used in combination with Octreotide.
Carbutamide,The therapeutic efficacy of Carbutamide can be decreased when used in combination with Octreotide.
Guar gum,The therapeutic efficacy of Guar gum can be decreased when used in combination with Octreotide.
Metahexamide,The therapeutic efficacy of Metahexamide can be decreased when used in combination with Octreotide.
Semaglutide,The therapeutic efficacy of Semaglutide can be decreased when used in combination with Octreotide.
Taspoglutide,The therapeutic efficacy of Taspoglutide can be decreased when used in combination with Octreotide.
Englitazone,The therapeutic efficacy of Englitazone can be decreased when used in combination with Octreotide.
Tirzepatide,The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Octreotide.
Gastric inhibitory polypeptide,The therapeutic efficacy of Gastric inhibitory polypeptide can be decreased when used in combination with Octreotide.
Linagliptin,The therapeutic efficacy of Linagliptin can be decreased when used in combination with Octreotide.
Glyburide,The therapeutic efficacy of Glyburide can be decreased when used in combination with Octreotide.
Canagliflozin,The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Octreotide.
Ertugliflozin,The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Octreotide.
Leuprolide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Leuprolide.
Goserelin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Goserelin.
Betaxolol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Betaxolol.
Moxifloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Moxifloxacin.
Sulfisoxazole,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sulfisoxazole.
Sulpiride,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sulpiride.
Promazine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Promazine.
Prochlorperazine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Prochlorperazine.
Droperidol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Droperidol.
Oxaliplatin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxaliplatin.
Ciprofloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ciprofloxacin.
Fluorouracil,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluorouracil.
Perflutren,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Perflutren.
Cinnarizine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cinnarizine.
Propranolol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Propranolol.
Atropine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Atropine.
Efavirenz,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Efavirenz.
Adenosine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Adenosine.
Pentamidine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pentamidine.
Gadobenic acid,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gadobenic acid.
Carbinoxamine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Carbinoxamine.
Dolasetron,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dolasetron.
Roxithromycin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Roxithromycin.
Nalidixic acid,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nalidixic acid.
Cinoxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cinoxacin.
Granisetron,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Granisetron.
Ondansetron,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ondansetron.
Levosimendan,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levosimendan.
Mesoridazine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mesoridazine.
Desloratadine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Desloratadine.
Telithromycin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Telithromycin.
Lomefloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lomefloxacin.
Dimenhydrinate,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dimenhydrinate.
Papaverine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Papaverine.
Chlorpheniramine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorpheniramine.
Nifedipine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nifedipine.
Gemifloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gemifloxacin.
Ofloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ofloxacin.
Acebutolol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Acebutolol.
Flecainide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Flecainide.
Oxprenolol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxprenolol.
Probucol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Probucol.
Aceprometazine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Aceprometazine.
Terlipressin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Terlipressin.
Prenylamine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Prenylamine.
Fluspirilene,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluspirilene.
Lofexidine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lofexidine.
Azimilide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Azimilide.
Pracinostat,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pracinostat.
Technetium Tc-99m ciprofloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Technetium Tc-99m ciprofloxacin.
Garenoxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Garenoxacin.
Tedisamil,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tedisamil.
Tucidinostat,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tucidinostat.
Telavancin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Telavancin.
Nemonoxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nemonoxacin.
Nilvadipine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nilvadipine.
Antazoline,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Antazoline.
Bedaquiline,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bedaquiline.
Indenolol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Indenolol.
Fendiline,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fendiline.
Eperisone,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Eperisone.
Butriptyline,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Butriptyline.
Lenvatinib,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lenvatinib.
Melperone,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Melperone.
Benidipine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Benidipine.
Dexchlorpheniramine maleate,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexchlorpheniramine maleate.
Amifampridine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amifampridine.
Mocetinostat,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mocetinostat.
Entinostat,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Entinostat.
Gilteritinib,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gilteritinib.
CUDC-101,The risk or severity of QTc prolongation can be increased when Octreotide is combined with CUDC-101.
Simendan,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Simendan.
Ricolinostat,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ricolinostat.
Mizolastine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mizolastine.
Abexinostat,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Abexinostat.
Oxatomide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxatomide.
Sitafloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sitafloxacin.
Sultopride,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sultopride.
Otilonium,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Otilonium.
Nizofenone,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nizofenone.
Bunaftine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bunaftine.
Lorcainide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lorcainide.
Dexchlorpheniramine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexchlorpheniramine.
Penfluridol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Penfluridol.
Azithromycin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Azithromycin.
Chlorpromazine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorpromazine.
Erythromycin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Erythromycin.
Ranolazine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ranolazine.
Amitriptyline,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amitriptyline.
Methadone,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Methadone.
Diltiazem,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Diltiazem.
Nimodipine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nimodipine.
Imipramine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Imipramine.
Chloroquine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chloroquine.
Loperamide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Loperamide.
Primaquine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Primaquine.
Levofloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levofloxacin.
Propafenone,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Propafenone.
Clarithromycin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Clarithromycin.
Quetiapine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Quetiapine.
Mibefradil,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mibefradil.
Dexverapamil,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexverapamil.
Levacetylmethadol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levacetylmethadol.
Saquinavir,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Saquinavir.
Clomipramine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Clomipramine.
Lipoic acid,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Lipoic acid.
Dapoxetine,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Dapoxetine.
Milnacipran,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Milnacipran.
Desvenlafaxine,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Desvenlafaxine.
Indalpine,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Indalpine.
Ritanserin,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Ritanserin.
Alaproclate,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Alaproclate.
Clinafloxacin,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Clinafloxacin.
Fluvoxamine,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Fluvoxamine.
Indomethacin,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Indomethacin.
Paroxetine,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Paroxetine.
Sertraline,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Sertraline.
Nefazodone,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Nefazodone.
Zimelidine,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Zimelidine.
Levomilnacipran,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Levomilnacipran.
Ubidecarenone,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Ubidecarenone.
Midodrine,Octreotide may increase the bradycardic activities of Midodrine.
Atenolol,Octreotide may increase the bradycardic activities of Atenolol.
Bendroflumethiazide,Octreotide may increase the bradycardic activities of Bendroflumethiazide.
Lercanidipine,Octreotide may increase the bradycardic activities of Lercanidipine.
Labetalol,Octreotide may increase the bradycardic activities of Labetalol.
Dexmedetomidine,Octreotide may increase the bradycardic activities of Dexmedetomidine.
Magnesium sulfate,Octreotide may increase the bradycardic activities of Magnesium sulfate.
Sufentanil,Octreotide may increase the bradycardic activities of Sufentanil.
Alprenolol,Octreotide may increase the bradycardic activities of Alprenolol.
Remifentanil,Octreotide may increase the bradycardic activities of Remifentanil.
Pindolol,Octreotide may increase the bradycardic activities of Pindolol.
Methyldopa,Octreotide may increase the bradycardic activities of Methyldopa.
Rivastigmine,Octreotide may increase the bradycardic activities of Rivastigmine.
Guanfacine,Octreotide may increase the bradycardic activities of Guanfacine.
Bevantolol,Octreotide may increase the bradycardic activities of Bevantolol.
Practolol,Octreotide may increase the bradycardic activities of Practolol.
Penbutolol,Octreotide may increase the bradycardic activities of Penbutolol.
Nimesulide,Octreotide may increase the bradycardic activities of Nimesulide.
Cyclandelate,Octreotide may increase the bradycardic activities of Cyclandelate.
Flunarizine,Octreotide may increase the bradycardic activities of Flunarizine.
Nebivolol,Octreotide may increase the bradycardic activities of Nebivolol.
Lucinactant,Octreotide may increase the bradycardic activities of Lucinactant.
Clevidipine,Octreotide may increase the bradycardic activities of Clevidipine.
Seletracetam,Octreotide may increase the bradycardic activities of Seletracetam.
Nylidrin,Octreotide may increase the bradycardic activities of Nylidrin.
Lacosamide,Octreotide may increase the bradycardic activities of Lacosamide.
Calfactant,Octreotide may increase the bradycardic activities of Calfactant.
Dotarizine,Octreotide may increase the bradycardic activities of Dotarizine.
Bufuralol,Octreotide may increase the bradycardic activities of Bufuralol.
Beractant,Octreotide may increase the bradycardic activities of Beractant.
Lanreotide,Octreotide may increase the bradycardic activities of Lanreotide.
Tranilast,Octreotide may increase the bradycardic activities of Tranilast.
Bopindolol,Octreotide may increase the bradycardic activities of Bopindolol.
Agmatine,Octreotide may increase the bradycardic activities of Agmatine.
Befunolol,Octreotide may increase the bradycardic activities of Befunolol.
Poractant alfa,Octreotide may increase the bradycardic activities of Poractant alfa.
Arotinolol,Octreotide may increase the bradycardic activities of Arotinolol.
Tolfenamic acid,Octreotide may increase the bradycardic activities of Tolfenamic acid.
Barnidipine,Octreotide may increase the bradycardic activities of Barnidipine.
Azelnidipine,Octreotide may increase the bradycardic activities of Azelnidipine.
Cilnidipine,Octreotide may increase the bradycardic activities of Cilnidipine.
Darodipine,Octreotide may increase the bradycardic activities of Darodipine.
Manidipine,Octreotide may increase the bradycardic activities of Manidipine.
Niludipine,Octreotide may increase the bradycardic activities of Niludipine.
Levobetaxolol,Octreotide may increase the bradycardic activities of Levobetaxolol.
Carboxyamidotriazole,Octreotide may increase the bradycardic activities of Carboxyamidotriazole.
Naftopidil,Octreotide may increase the bradycardic activities of Naftopidil.
Vinpocetine,Octreotide may increase the bradycardic activities of Vinpocetine.
Landiolol,Octreotide may increase the bradycardic activities of Landiolol.
Bucindolol,Octreotide may increase the bradycardic activities of Bucindolol.
Esatenolol,Octreotide may increase the bradycardic activities of Esatenolol.
Cloranolol,Octreotide may increase the bradycardic activities of Cloranolol.
Mepindolol,Octreotide may increase the bradycardic activities of Mepindolol.
Epanolol,Octreotide may increase the bradycardic activities of Epanolol.
Tertatolol,Octreotide may increase the bradycardic activities of Tertatolol.
Caroverine,Octreotide may increase the bradycardic activities of Caroverine.
WIN 55212-2,Octreotide may increase the bradycardic activities of WIN 55212-2.
Fish oil,Octreotide may increase the bradycardic activities of Fish oil.
Amlodipine,Octreotide may increase the bradycardic activities of Amlodipine.
Bisoprolol,Octreotide may increase the bradycardic activities of Bisoprolol.
Verapamil,Octreotide may increase the bradycardic activities of Verapamil.
Donepezil,Octreotide may increase the bradycardic activities of Donepezil.
Carvedilol,Octreotide may increase the bradycardic activities of Carvedilol.
Nadolol,Octreotide may increase the bradycardic activities of Nadolol.
Fingolimod,Octreotide may increase the bradycardic activities of Fingolimod.
Regorafenib,Octreotide may increase the bradycardic activities of Regorafenib.
Emopamil,Octreotide may increase the bradycardic activities of Emopamil.
Lomerizine,Octreotide may increase the bradycardic activities of Lomerizine.
Tetrandrine,Octreotide may increase the bradycardic activities of Tetrandrine.
Dexniguldipine,Octreotide may increase the bradycardic activities of Dexniguldipine.
Nisoldipine,Octreotide may increase the bradycardic activities of Nisoldipine.
Clonidine,Octreotide may increase the bradycardic activities of Clonidine.
Alfentanil,Octreotide may increase the bradycardic activities of Alfentanil.
Citalopram,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Citalopram.
Anagrelide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Anagrelide.
Disopyramide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Disopyramide.
Clemastine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Clemastine.
Ibutilide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ibutilide.
Valproic acid,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Valproic acid.
Grepafloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Grepafloxacin.
Quinine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Quinine.
Sotalol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sotalol.
Toremifene,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Toremifene.
Thioridazine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Thioridazine.
Trovafloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Trovafloxacin.
Mifepristone,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mifepristone.
Flupentixol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Flupentixol.
Cocaine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cocaine.
Procainamide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Procainamide.
Arsenic trioxide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Arsenic trioxide.
Escitalopram,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Escitalopram.
Domperidone,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Domperidone.
Sparfloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sparfloxacin.
Halofantrine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Halofantrine.
Bepridil,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bepridil.
Paliperidone,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Paliperidone.
Lithium cation,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lithium cation.
Temafloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Temafloxacin.
Zuclopenthixol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Zuclopenthixol.
Tetrabenazine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tetrabenazine.
Romidepsin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Romidepsin.
Asenapine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Asenapine.
Artemether,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Artemether.
Lumefantrine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lumefantrine.
Ribociclib,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ribociclib.
Glasdegib,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Glasdegib.
Deutetrabenazine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Deutetrabenazine.
Terodiline,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Terodiline.
Astemizole,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Astemizole.
Vemurafenib,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Vemurafenib.
Dotatate gallium Ga-68,Octreotide may decrease effectiveness of Dotatate gallium Ga-68 as a diagnostic agent.
Lutetium Lu 177 dotatate,The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Octreotide.
Delamanid,Octreotide may increase the QTc-prolonging activities of Delamanid.
Aripiprazole,The metabolism of Aripiprazole can be decreased when combined with Octreotide.
Aripiprazole lauroxil,The metabolism of Aripiprazole lauroxil can be decreased when combined with Octreotide.
Pregabalin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pregabalin.
Pasireotide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pasireotide.
Oxytocin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxytocin.
Esmolol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Esmolol.
Benzatropine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Benzatropine.
Atomoxetine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Atomoxetine.
Trimethadione,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Trimethadione.
Buclizine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Buclizine.
Doxylamine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Doxylamine.
Mirtazapine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mirtazapine.
Treprostinil,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Treprostinil.
Dexbrompheniramine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexbrompheniramine.
Hyoscyamine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hyoscyamine.
Triprolidine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Triprolidine.
Cyproheptadine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cyproheptadine.
Enoxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Enoxacin.
Pefloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pefloxacin.
Foscarnet,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Foscarnet.
Voriconazole,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Voriconazole.
Galantamine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Galantamine.
Moricizine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Moricizine.
Moexipril,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Moexipril.
Tizanidine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tizanidine.
Ibandronate,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ibandronate.
Apomorphine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Apomorphine.
Azatadine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Azatadine.
Isoflurane,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Isoflurane.
Indapamide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Indapamide.
Rosoxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Rosoxacin.
Disulfiram,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Disulfiram.
Levomenthol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levomenthol.
Brompheniramine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Brompheniramine.
Terbutaline,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Terbutaline.
Amantadine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amantadine.
Ketotifen,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ketotifen.
Famotidine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Famotidine.
Maprotiline,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Maprotiline.
Felbamate,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Felbamate.
Formoterol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Formoterol.
Hydrochlorothiazide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydrochlorothiazide.
Salbutamol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Salbutamol.
Tolterodine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tolterodine.
Gatifloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gatifloxacin.
Norfloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Norfloxacin.
Mequitazine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mequitazine.
Perhexiline,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Perhexiline.
Diphenhydramine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Diphenhydramine.
Levocabastine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levocabastine.
Bretylium,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bretylium.
Orphenadrine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Orphenadrine.
Cyclizine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cyclizine.
Desflurane,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Desflurane.
Encainide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Encainide.
Sevoflurane,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sevoflurane.
Alimemazine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Alimemazine.
Arformoterol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Arformoterol.
Methotrimeprazine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Methotrimeprazine.
Ajmaline,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ajmaline.
Solifenacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Solifenacin.
Pheniramine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pheniramine.
Thiothixene,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Thiothixene.
Vorinostat,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Vorinostat.
Fleroxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fleroxacin.
Farnesyl thiopyrophosphate,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Farnesyl thiopyrophosphate.
Ezogabine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ezogabine.
Methsuximide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Methsuximide.
Tandutinib,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tandutinib.
Vernakalant,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Vernakalant.
Levocetirizine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levocetirizine.
Amisulpride,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amisulpride.
Cariporide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cariporide.
Mepyramine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mepyramine.
Degarelix,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Degarelix.
Buserelin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Buserelin.
Histrelin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Histrelin.
Triptorelin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Triptorelin.
Farnesyl diphosphate,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Farnesyl diphosphate.
Geranylgeranyl diphosphate,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Geranylgeranyl diphosphate.
Bupranolol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bupranolol.
Eribulin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Eribulin.
Chlorcyclizine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorcyclizine.
Flumequine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Flumequine.
Olodaterol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Olodaterol.
Vilanterol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Vilanterol.
Trimebutine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Trimebutine.
Pinaverium,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pinaverium.
Dosulepin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dosulepin.
Aranidipine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Aranidipine.
Efonidipine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Efonidipine.
Lacidipine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lacidipine.
Acrivastine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Acrivastine.
Coumaphos,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Coumaphos.
Dichlorvos,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dichlorvos.
Famphur,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Famphur.
Fenthion,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fenthion.
Orbifloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Orbifloxacin.
Phosmet,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Phosmet.
Sarafloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sarafloxacin.
Difloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Difloxacin.
Bilastine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bilastine.
Rupatadine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Rupatadine.
Pazufloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pazufloxacin.
Anisodamine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Anisodamine.
CUDC-907,The risk or severity of QTc prolongation can be increased when Octreotide is combined with CUDC-907.
Prulifloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Prulifloxacin.
Delafloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Delafloxacin.
Tetrahydropalmatine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tetrahydropalmatine.
Temefos,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Temefos.
Triclabendazole,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Triclabendazole.
Givinostat,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Givinostat.
Pilsicainide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pilsicainide.
Cicletanine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cicletanine.
Cibenzoline,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cibenzoline.
Bencyclane,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bencyclane.
Prajmaline,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Prajmaline.
Oxolinic acid,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxolinic acid.
Lorajmine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lorajmine.
Acetyldigoxin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Acetyldigoxin.
Piromidic acid,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Piromidic acid.
Lidoflazine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lidoflazine.
Rufloxacin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Rufloxacin.
Pipemidic acid,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pipemidic acid.
Inotersen,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Inotersen.
Salmeterol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Salmeterol.
Atazanavir,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Atazanavir.
Desipramine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Desipramine.
Fluconazole,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluconazole.
Nelfinavir,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nelfinavir.
Isradipine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Isradipine.
Venlafaxine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Venlafaxine.
Olanzapine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Olanzapine.
Cetirizine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cetirizine.
Protriptyline,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Protriptyline.
Mefloquine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mefloquine.
Timolol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Timolol.
Digoxin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Digoxin.
Ritonavir,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ritonavir.
Amoxapine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amoxapine.
Lamotrigine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lamotrigine.
Amodiaquine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amodiaquine.
Nicardipine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nicardipine.
Losartan,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Losartan.
Trimipramine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Trimipramine.
Risperidone,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Risperidone.
Propofol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Propofol.
Zonisamide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Zonisamide.
Metronidazole,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Metronidazole.
Ketoconazole,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ketoconazole.
Nitrendipine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nitrendipine.
Promethazine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Promethazine.
Doxepin,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Doxepin.
Itraconazole,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Itraconazole.
Metoclopramide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Metoclopramide.
Chlorprothixene,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorprothixene.
Lapatinib,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lapatinib.
Posaconazole,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Posaconazole.
Lopinavir,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lopinavir.
Hydroxychloroquine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydroxychloroquine.
Celiprolol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Celiprolol.
Indacaterol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Indacaterol.
Mirabegron,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mirabegron.
Niguldipine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Niguldipine.
Talinolol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Talinolol.
Gallopamil,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gallopamil.
Ethosuximide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ethosuximide.
Felodipine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Felodipine.
Nortriptyline,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nortriptyline.
Lurasidone,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lurasidone.
Rilpivirine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Rilpivirine.
Ebastine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ebastine.
Clofazimine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Clofazimine.
Lorazepam,The metabolism of Lorazepam can be decreased when combined with Octreotide.
Phentermine,The metabolism of Phentermine can be decreased when combined with Octreotide.
Ticlopidine,The metabolism of Ticlopidine can be decreased when combined with Octreotide.
Famciclovir,The metabolism of Famciclovir can be decreased when combined with Octreotide.
Cephalexin,The metabolism of Cephalexin can be decreased when combined with Octreotide.
Norethisterone,The metabolism of Norethisterone can be decreased when combined with Octreotide.
St. John's Wort,The metabolism of St. John's Wort can be decreased when combined with Octreotide.
Drospirenone,The metabolism of Drospirenone can be decreased when combined with Octreotide.
Pranlukast,The metabolism of Pranlukast can be decreased when combined with Octreotide.
Allylestrenol,The metabolism of Allylestrenol can be decreased when combined with Octreotide.
Roflumilast,The metabolism of Roflumilast can be decreased when combined with Octreotide.
Rufinamide,The metabolism of Rufinamide can be decreased when combined with Octreotide.
Tasimelteon,The metabolism of Tasimelteon can be decreased when combined with Octreotide.
Vitamin D,The metabolism of Vitamin D can be decreased when combined with Octreotide.
Dihydroergocornine,The metabolism of Dihydroergocornine can be decreased when combined with Octreotide.
9-aminocamptothecin,The metabolism of 9-aminocamptothecin can be decreased when combined with Octreotide.
Methylprednisone,The metabolism of Methylprednisone can be decreased when combined with Octreotide.
Dihydroergocristine,The metabolism of Dihydroergocristine can be decreased when combined with Octreotide.
Dihydroergocryptine,The metabolism of Dihydroergocryptine can be decreased when combined with Octreotide.
Medical Cannabis,The metabolism of Medical Cannabis can be decreased when combined with Octreotide.
Rosuvastatin,The metabolism of Rosuvastatin can be decreased when combined with Octreotide.
Zafirlukast,The metabolism of Zafirlukast can be decreased when combined with Octreotide.
Elexacaftor,The metabolism of Elexacaftor can be decreased when combined with Octreotide.
Duloxetine,The metabolism of Duloxetine can be decreased when combined with Octreotide.
Albendazole,The metabolism of Albendazole can be decreased when combined with Octreotide.
Doxazosin,The metabolism of Doxazosin can be decreased when combined with Octreotide.
Fenofibrate,The metabolism of Fenofibrate can be decreased when combined with Octreotide.
Fosaprepitant,The metabolism of Fosaprepitant can be decreased when combined with Octreotide.
Vorapaxar,The metabolism of Vorapaxar can be decreased when combined with Octreotide.
Suvorexant,The metabolism of Suvorexant can be decreased when combined with Octreotide.
Netupitant,The metabolism of Netupitant can be decreased when combined with Octreotide.
Metoprolol,The metabolism of Metoprolol can be decreased when combined with Octreotide.
Nintedanib,The metabolism of Nintedanib can be decreased when combined with Octreotide.
Tenofovir alafenamide,The metabolism of Tenofovir alafenamide can be decreased when combined with Octreotide.
Osimertinib,The metabolism of Osimertinib can be decreased when combined with Octreotide.
Duvelisib,The metabolism of Duvelisib can be decreased when combined with Octreotide.
Tazemetostat,The metabolism of Tazemetostat can be decreased when combined with Octreotide.
Tenofovir,The metabolism of Tenofovir can be decreased when combined with Octreotide.
Methysergide,The metabolism of Methysergide can be decreased when combined with Octreotide.
Meperidine,The metabolism of Meperidine can be decreased when combined with Octreotide.
Siponimod,The metabolism of Siponimod can be decreased when combined with Octreotide.
Clozapine,The metabolism of Clozapine can be decreased when combined with Octreotide.
Pazopanib,The metabolism of Pazopanib can be decreased when combined with Octreotide.
Panobinostat,The metabolism of Panobinostat can be decreased when combined with Octreotide.
Erlotinib,The metabolism of Erlotinib can be decreased when combined with Octreotide.
Imatinib,The metabolism of Imatinib can be decreased when combined with Octreotide.
Nilotinib,The metabolism of Nilotinib can be decreased when combined with Octreotide.
Vandetanib,The metabolism of Vandetanib can be decreased when combined with Octreotide.
Bortezomib,The metabolism of Bortezomib can be decreased when combined with Octreotide.
Terfenadine,The metabolism of Octreotide can be decreased when combined with Terfenadine.
Sirolimus,The metabolism of Octreotide can be decreased when combined with Sirolimus.
Quinidine,The metabolism of Octreotide can be decreased when combined with Quinidine.
Pimozide,The metabolism of Octreotide can be decreased when combined with Pimozide.
Amiodarone,The metabolism of Octreotide can be decreased when combined with Amiodarone.
Paclitaxel,The metabolism of Octreotide can be decreased when combined with Paclitaxel.
Dasatinib,The metabolism of Octreotide can be decreased when combined with Dasatinib.
Everolimus,The metabolism of Octreotide can be decreased when combined with Everolimus.
Dronedarone,The metabolism of Octreotide can be decreased when combined with Dronedarone.
Temsirolimus,The metabolism of Octreotide can be decreased when combined with Temsirolimus.
Carbamazepine,The metabolism of Carbamazepine can be decreased when combined with Octreotide.
Digitoxin,The metabolism of Digitoxin can be decreased when combined with Octreotide.
Dofetilide,The metabolism of Dofetilide can be decreased when combined with Octreotide.
Theophylline,The metabolism of Theophylline can be decreased when combined with Octreotide.
Cisapride,The metabolism of Cisapride can be decreased when combined with Octreotide.
Phenprocoumon,The metabolism of Phenprocoumon can be decreased when combined with Octreotide.
Busulfan,The metabolism of Busulfan can be decreased when combined with Octreotide.
Aminophylline,The metabolism of Aminophylline can be decreased when combined with Octreotide.
Fosphenytoin,The metabolism of Fosphenytoin can be decreased when combined with Octreotide.
4-hydroxycoumarin,The metabolism of 4-hydroxycoumarin can be decreased when combined with Octreotide.
Tianeptine,The metabolism of Tianeptine can be decreased when combined with Octreotide.
Fluindione,The metabolism of Fluindione can be decreased when combined with Octreotide.
Clorindione,The metabolism of Clorindione can be decreased when combined with Octreotide.
Levothyroxine,The metabolism of Levothyroxine can be decreased when combined with Octreotide.
Idelalisib,The metabolism of Idelalisib can be decreased when combined with Octreotide.
Isavuconazole,The metabolism of Isavuconazole can be decreased when combined with Octreotide.
Dacomitinib,The metabolism of Dacomitinib can be decreased when combined with Octreotide.
Alpelisib,The metabolism of Alpelisib can be decreased when combined with Octreotide.
Cobimetinib,The metabolism of Cobimetinib can be decreased when combined with Octreotide.
Sunitinib,The metabolism of Sunitinib can be decreased when combined with Octreotide.
Crizotinib,The metabolism of Crizotinib can be decreased when combined with Octreotide.
Ivosidenib,The metabolism of Ivosidenib can be decreased when combined with Octreotide.
Sorafenib,The metabolism of Sorafenib can be decreased when combined with Octreotide.
Tamoxifen,The metabolism of Tamoxifen can be decreased when combined with Octreotide.
Dabrafenib,The metabolism of Dabrafenib can be decreased when combined with Octreotide.
Methotrexate,The metabolism of Methotrexate can be decreased when combined with Octreotide.
Vinorelbine,The metabolism of Vinorelbine can be decreased when combined with Octreotide.
Vincristine,The metabolism of Vincristine can be decreased when combined with Octreotide.
Vinblastine,The metabolism of Vinblastine can be decreased when combined with Octreotide.
Daunorubicin,The metabolism of Daunorubicin can be decreased when combined with Octreotide.
Cytarabine,The metabolism of Cytarabine can be decreased when combined with Octreotide.
Doxorubicin,The metabolism of Doxorubicin can be decreased when combined with Octreotide.
Trilostane,The metabolism of Trilostane can be decreased when combined with Octreotide.
Docetaxel,The metabolism of Docetaxel can be decreased when combined with Octreotide.
Thiotepa,The metabolism of Thiotepa can be decreased when combined with Octreotide.
Trabectedin,The metabolism of Trabectedin can be decreased when combined with Octreotide.
Abiraterone,The metabolism of Abiraterone can be decreased when combined with Octreotide.
Alectinib,The metabolism of Alectinib can be decreased when combined with Octreotide.
Venetoclax,The metabolism of Venetoclax can be decreased when combined with Octreotide.
Vinflunine,The metabolism of Vinflunine can be decreased when combined with Octreotide.
Acalabrutinib,The metabolism of Acalabrutinib can be decreased when combined with Octreotide.
Enasidenib,The metabolism of Enasidenib can be decreased when combined with Octreotide.
Zanubrutinib,The metabolism of Zanubrutinib can be decreased when combined with Octreotide.
Cabergoline,The metabolism of Cabergoline can be decreased when combined with Octreotide.
Vindesine,The metabolism of Vindesine can be decreased when combined with Octreotide.
Teniposide,The metabolism of Teniposide can be decreased when combined with Octreotide.
Etoposide,The metabolism of Etoposide can be decreased when combined with Octreotide.
Ifosfamide,The metabolism of Ifosfamide can be decreased when combined with Octreotide.
Ixabepilone,The metabolism of Ixabepilone can be decreased when combined with Octreotide.
Belinostat,The metabolism of Belinostat can be decreased when combined with Octreotide.
Midostaurin,The metabolism of Midostaurin can be decreased when combined with Octreotide.
Bosutinib,The metabolism of Bosutinib can be decreased when combined with Octreotide.
Axitinib,The metabolism of Axitinib can be decreased when combined with Octreotide.
Brentuximab vedotin,The metabolism of Brentuximab vedotin can be decreased when combined with Octreotide.
Ponatinib,The metabolism of Ponatinib can be decreased when combined with Octreotide.
Palbociclib,The metabolism of Palbociclib can be decreased when combined with Octreotide.
Sonidegib,The metabolism of Sonidegib can be decreased when combined with Octreotide.
Ixazomib,The metabolism of Ixazomib can be decreased when combined with Octreotide.
Encorafenib,The metabolism of Encorafenib can be decreased when combined with Octreotide.
Neratinib,The metabolism of Neratinib can be decreased when combined with Octreotide.
Erdafitinib,The metabolism of Erdafitinib can be decreased when combined with Octreotide.
Brigatinib,The metabolism of Brigatinib can be decreased when combined with Octreotide.
Copanlisib,The metabolism of Copanlisib can be decreased when combined with Octreotide.
Pexidartinib,The metabolism of Pexidartinib can be decreased when combined with Octreotide.
Prucalopride,The metabolism of Prucalopride can be decreased when combined with Octreotide.
Macimorelin,The therapeutic efficacy of Macimorelin can be decreased when used in combination with Octreotide.
Metformin,The therapeutic efficacy of Metformin can be decreased when used in combination with Octreotide.
Trazodone,The risk or severity of QTc prolongation can be increased when Trazodone is combined with Octreotide.
Entrectinib,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Entrectinib.
Pitolisant,Pitolisant may increase the QTc-prolonging activities of Octreotide.
Lefamulin,Lefamulin may increase the QTc-prolonging activities of Octreotide.
Edotreotide gallium Ga-68,Octreotide may decrease effectiveness of Edotreotide gallium Ga-68 as a diagnostic agent.
Lasmiditan,Lasmiditan may increase the bradycardic activities of Octreotide.
Voxelotor,The serum concentration of Voxelotor can be increased when it is combined with Octreotide.
Levamlodipine,The serum concentration of Levamlodipine can be increased when it is combined with Octreotide.
Ubrogepant,The serum concentration of Ubrogepant can be increased when it is combined with Octreotide.
Hydroxyzine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydroxyzine.
Tramadol,The metabolism of Tramadol can be decreased when combined with Octreotide.
Ziprasidone,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ziprasidone.
Haloperidol,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Haloperidol.
Fluoxetine,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluoxetine.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon alfa-2b.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa-2b.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfa-2b.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfa-2b.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon alfa-2b.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon alfa-2b.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfa-2b.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon alfa-2b.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Interferon alfa-2b."
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Interferon alfa-2b.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfa-2b.
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon alfa-2b.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon alfa-2b.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfa-2b.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Interferon alfa-2b.
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Interferon alfa-2b.
Basiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Interferon alfa-2b.
Muromonab,The risk or severity of adverse effects can be increased when Muromonab is combined with Interferon alfa-2b.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Interferon alfa-2b.
Tositumomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Interferon alfa-2b.
Alemtuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Interferon alfa-2b.
Alefacept,The risk or severity of adverse effects can be increased when Alefacept is combined with Interferon alfa-2b.
Efalizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Interferon alfa-2b.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Interferon alfa-2b.
Daclizumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Beclomethasone dipropionate.
Sorafenib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sorafenib.
Streptozocin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Altretamine.
Cisplatin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pentostatin.
Methotrexate,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Methotrexate.
Vinblastine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Linezolid.
Imatinib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Imatinib.
Triamcinolone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Paclitaxel.
Dexamethasone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dexamethasone.
Docetaxel,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Decitabine.
Sunitinib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sunitinib.
Nelarabine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Nelarabine.
Abatacept,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Abatacept.
Corticotropin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with omega interferon.
Apremilast,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Apremilast.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ponatinib.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Certolizumab pegol.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Blinatumomab.
Ibrutinib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ibrutinib.
Idelalisib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Idelalisib.
Palbociclib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Palbociclib.
Olaparib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Olaparib.
Dinutuximab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dinutuximab.
Vilanterol,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vilanterol.
Tixocortol,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Antilymphocyte immunoglobulin (horse).
Fluprednisolone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Meprednisone.
Tepoxalin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tepoxalin.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Melengestrol.
Ixekizumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Peficitinib.
Clobetasol,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Clobetasol.
Sarilumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sirukumab.
Baricitinib,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Baricitinib.
Guselkumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Guselkumab.
Deflazacort,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Deflazacort.
Triptolide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Triptolide.
Siponimod,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Siponimod.
Ozanimod,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Prednylidene,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Prednylidene.
Fluocortin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluclorolone.
Fluticasone,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluticasone.
Tetrandrine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tetrandrine.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Monomethyl fumarate.
Mometasone furoate,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mometasone furoate.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydrocortisone aceponate.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydrocortisone acetate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydrocortisone succinate.
Emapalumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bleselumab.
Natalizumab,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon alfa-2b.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Interferon alfa-2b.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Interferon alfa-2b.
Aldesleukin,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Aldesleukin.
Clozapine,The risk or severity of neutropenia can be increased when Interferon alfa-2b is combined with Clozapine.
Methadone,The serum concentration of Methadone can be increased when it is combined with Interferon alfa-2b.
Ribavirin,The risk or severity of anemia can be increased when Interferon alfa-2b is combined with Ribavirin.
Zidovudine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Zidovudine.
Darbepoetin alfa,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Interferon alfa-2b.
Erythropoietin,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Interferon alfa-2b.
Peginesatide,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Interferon alfa-2b.
Methoxy polyethylene glycol-epoetin beta,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Interferon alfa-2b.
Zolmitriptan,The metabolism of Zolmitriptan can be decreased when combined with Interferon alfa-2b.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon alfa-2b.
Metamizole,The risk or severity of myelosuppression can be increased when Metamizole is combined with Interferon alfa-2b.
Telbivudine,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Telbivudine.
Leflunomide,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Leflunomide.
Tofacitinib,Interferon alfa-2b may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Interferon alfa-2b.
Fingolimod,Interferon alfa-2b may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Interferon alfa-2b.
Caffeine,The metabolism of Caffeine can be decreased when combined with Interferon alfa-2b.
Dyphylline,The metabolism of Dyphylline can be decreased when combined with Interferon alfa-2b.
Pentoxifylline,The metabolism of Pentoxifylline can be decreased when combined with Interferon alfa-2b.
Oxtriphylline,The metabolism of Oxtriphylline can be decreased when combined with Interferon alfa-2b.
Theobromine,The metabolism of Theobromine can be decreased when combined with Interferon alfa-2b.
Fenethylline,The metabolism of Fenethylline can be decreased when combined with Interferon alfa-2b.
8-azaguanine,The metabolism of 8-azaguanine can be decreased when combined with Interferon alfa-2b.
"7,9-Dimethylguanine","The metabolism of 7,9-Dimethylguanine can be decreased when combined with Interferon alfa-2b."
Xanthine,The metabolism of Xanthine can be decreased when combined with Interferon alfa-2b.
7-Deazaguanine,The metabolism of 7-Deazaguanine can be decreased when combined with Interferon alfa-2b.
Guanine,The metabolism of Guanine can be decreased when combined with Interferon alfa-2b.
9-Methylguanine,The metabolism of 9-Methylguanine can be decreased when combined with Interferon alfa-2b.
Peldesine,The metabolism of Peldesine can be decreased when combined with Interferon alfa-2b.
Hypoxanthine,The metabolism of Hypoxanthine can be decreased when combined with Interferon alfa-2b.
9-Deazaguanine,The metabolism of 9-Deazaguanine can be decreased when combined with Interferon alfa-2b.
Propentofylline,The metabolism of Propentofylline can be decreased when combined with Interferon alfa-2b.
Valomaciclovir,The metabolism of Valomaciclovir can be decreased when combined with Interferon alfa-2b.
3-isobutyl-1-methyl-7H-xanthine,The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Interferon alfa-2b.
Uric acid,The metabolism of Uric acid can be decreased when combined with Interferon alfa-2b.
Doxofylline,The metabolism of Doxofylline can be decreased when combined with Interferon alfa-2b.
6-O-benzylguanine,The metabolism of 6-O-benzylguanine can be decreased when combined with Interferon alfa-2b.
Lisofylline,The metabolism of Lisofylline can be decreased when combined with Interferon alfa-2b.
Lobucavir,The metabolism of Lobucavir can be decreased when combined with Interferon alfa-2b.
Cafedrine,The metabolism of Cafedrine can be decreased when combined with Interferon alfa-2b.
Theodrenaline,The metabolism of Theodrenaline can be decreased when combined with Interferon alfa-2b.
Bamifylline,The metabolism of Bamifylline can be decreased when combined with Interferon alfa-2b.
Proxyphylline,The metabolism of Proxyphylline can be decreased when combined with Interferon alfa-2b.
Acefylline,The metabolism of Acefylline can be decreased when combined with Interferon alfa-2b.
Etamiphylline,The metabolism of Etamiphylline can be decreased when combined with Interferon alfa-2b.
Pentifylline,The metabolism of Pentifylline can be decreased when combined with Interferon alfa-2b.
Bufylline,The metabolism of Bufylline can be decreased when combined with Interferon alfa-2b.
Bromotheophylline,The metabolism of Bromotheophylline can be decreased when combined with Interferon alfa-2b.
Furafylline,The metabolism of Furafylline can be decreased when combined with Interferon alfa-2b.
8-chlorotheophylline,The metabolism of 8-chlorotheophylline can be decreased when combined with Interferon alfa-2b.
PCS-499,The metabolism of PCS-499 can be decreased when combined with Interferon alfa-2b.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Interferon alfa-2b.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Interferon alfa-2b.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Interferon alfa-2b.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Interferon alfa-2b.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Interferon alfa-2b.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon alfa-2b.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Interferon alfa-2b.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Interferon alfa-2b.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon alfa-2b.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Interferon alfa-2b."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfa-2b.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Interferon alfa-2b.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Interferon alfa-2b."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Interferon alfa-2b.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Interferon alfa-2b.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfa-2b.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfa-2b.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon alfa-2b.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Interferon alfa-2b.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Interferon alfa-2b.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Interferon alfa-2b.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Interferon alfa-2b.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Interferon alfa-2b.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Interferon alfa-2b.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Interferon alfa-2b.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Interferon alfa-2b.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Interferon alfa-2b.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Interferon alfa-2b."
Abciximab,The risk or severity of bleeding can be increased when Abciximab is combined with Interferon alfa-2b.
Eptifibatide,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-2b.
Ticlopidine,The risk or severity of bleeding can be increased when Ticlopidine is combined with Interferon alfa-2b.
Tirofiban,The risk or severity of bleeding can be increased when Tirofiban is combined with Interferon alfa-2b.
Acetylsalicylic acid,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon alfa-2b.
Dipyridamole,The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon alfa-2b.
Iloprost,The risk or severity of bleeding can be increased when Iloprost is combined with Interferon alfa-2b.
Sulfinpyrazone,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon alfa-2b.
Ridogrel,The risk or severity of bleeding can be increased when Ridogrel is combined with Interferon alfa-2b.
Sevoflurane,The risk or severity of bleeding can be increased when Sevoflurane is combined with Interferon alfa-2b.
Epoprostenol,The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon alfa-2b.
Nimesulide,The risk or severity of bleeding can be increased when Nimesulide is combined with Interferon alfa-2b.
Tesmilifene,The risk or severity of bleeding can be increased when Tesmilifene is combined with Interferon alfa-2b.
Defibrotide,The risk or severity of bleeding can be increased when Defibrotide is combined with Interferon alfa-2b.
Beraprost,The risk or severity of bleeding can be increased when Beraprost is combined with Interferon alfa-2b.
Ibudilast,The risk or severity of bleeding can be increased when Ibudilast is combined with Interferon alfa-2b.
Andrographolide,The risk or severity of bleeding can be increased when Andrographolide is combined with Interferon alfa-2b.
Caplacizumab,The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfa-2b.
Prasugrel,The risk or severity of bleeding can be increased when Prasugrel is combined with Interferon alfa-2b.
Cangrelor,The risk or severity of bleeding can be increased when Cangrelor is combined with Interferon alfa-2b.
Tranilast,The risk or severity of bleeding can be increased when Tranilast is combined with Interferon alfa-2b.
Triflusal,The risk or severity of bleeding can be increased when Triflusal is combined with Interferon alfa-2b.
Ticagrelor,The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon alfa-2b.
Icosapent ethyl,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Interferon alfa-2b.
Vorapaxar,The risk or severity of bleeding can be increased when Vorapaxar is combined with Interferon alfa-2b.
Trapidil,The risk or severity of bleeding can be increased when Trapidil is combined with Interferon alfa-2b.
Naftopidil,The risk or severity of bleeding can be increased when Naftopidil is combined with Interferon alfa-2b.
Sarpogrelate,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Interferon alfa-2b.
Ifetroban,The risk or severity of bleeding can be increased when Ifetroban is combined with Interferon alfa-2b.
Nitroaspirin,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Interferon alfa-2b.
Ketanserin,The risk or severity of bleeding can be increased when Ketanserin is combined with Interferon alfa-2b.
Indobufen,The risk or severity of bleeding can be increased when Indobufen is combined with Interferon alfa-2b.
Butylphthalide,The risk or severity of bleeding can be increased when Butylphthalide is combined with Interferon alfa-2b.
Hydroxytyrosol,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Interferon alfa-2b.
Ramatroban,The risk or severity of bleeding can be increased when Ramatroban is combined with Interferon alfa-2b.
Picotamide,The risk or severity of bleeding can be increased when Picotamide is combined with Interferon alfa-2b.
Cloricromen,The risk or severity of bleeding can be increased when Cloricromen is combined with Interferon alfa-2b.
Linsidomine,The risk or severity of bleeding can be increased when Linsidomine is combined with Interferon alfa-2b.
Buflomedil,The risk or severity of bleeding can be increased when Buflomedil is combined with Interferon alfa-2b.
Relcovaptan,The risk or severity of bleeding can be increased when Relcovaptan is combined with Interferon alfa-2b.
Ocrelizumab,Ocrelizumab may increase the immunosuppressive activities of Interferon alfa-2b.
Lipegfilgrastim,Interferon alfa-2b may increase the myelosuppressive activities of Lipegfilgrastim.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon alfa-2b.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Interferon alfa-2b.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Interferon alfa-2b.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Interferon alfa-2b.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Interferon alfa-2b.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Interferon alfa-2b.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Interferon alfa-2b.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Interferon alfa-2b.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Interferon alfa-2b.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Interferon alfa-2b.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Interferon alfa-2b.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Interferon alfa-2b.
Palifermin,The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfa-2b.
Fluvoxamine,The metabolism of Fluvoxamine can be decreased when combined with Interferon alfa-2b.
Nicotine,The metabolism of Nicotine can be decreased when combined with Interferon alfa-2b.
Betaxolol,The metabolism of Betaxolol can be decreased when combined with Interferon alfa-2b.
Anagrelide,The metabolism of Anagrelide can be decreased when combined with Interferon alfa-2b.
Disopyramide,The metabolism of Disopyramide can be decreased when combined with Interferon alfa-2b.
Lidocaine,The metabolism of Lidocaine can be decreased when combined with Interferon alfa-2b.
Conjugated estrogens,The metabolism of Conjugated estrogens can be decreased when combined with Interferon alfa-2b.
Ropivacaine,The metabolism of Ropivacaine can be decreased when combined with Interferon alfa-2b.
Acetaminophen,The metabolism of Acetaminophen can be decreased when combined with Interferon alfa-2b.
Olanzapine,The metabolism of Olanzapine can be decreased when combined with Interferon alfa-2b.
Chlorzoxazone,The metabolism of Chlorzoxazone can be decreased when combined with Interferon alfa-2b.
Grepafloxacin,The metabolism of Grepafloxacin can be decreased when combined with Interferon alfa-2b.
Mirtazapine,The metabolism of Mirtazapine can be decreased when combined with Interferon alfa-2b.
Mexiletine,The metabolism of Mexiletine can be decreased when combined with Interferon alfa-2b.
Tacrine,The metabolism of Tacrine can be decreased when combined with Interferon alfa-2b.
Triamterene,The metabolism of Triamterene can be decreased when combined with Interferon alfa-2b.
Promazine,The metabolism of Promazine can be decreased when combined with Interferon alfa-2b.
Zolpidem,The metabolism of Zolpidem can be decreased when combined with Interferon alfa-2b.
Entecavir,The metabolism of Entecavir can be decreased when combined with Interferon alfa-2b.
Nabumetone,The metabolism of Nabumetone can be decreased when combined with Interferon alfa-2b.
Quinine,The metabolism of Quinine can be decreased when combined with Interferon alfa-2b.
Fluoxetine,The metabolism of Fluoxetine can be decreased when combined with Interferon alfa-2b.
Duloxetine,The metabolism of Duloxetine can be decreased when combined with Interferon alfa-2b.
Chlorpromazine,The metabolism of Chlorpromazine can be decreased when combined with Interferon alfa-2b.
Flutamide,The metabolism of Flutamide can be decreased when combined with Interferon alfa-2b.
Haloperidol,The metabolism of Haloperidol can be decreased when combined with Interferon alfa-2b.
Albendazole,The metabolism of Albendazole can be decreased when combined with Interferon alfa-2b.
Rofecoxib,The metabolism of Rofecoxib can be decreased when combined with Interferon alfa-2b.
Cinnarizine,The metabolism of Cinnarizine can be decreased when combined with Interferon alfa-2b.
Propranolol,The metabolism of Propranolol can be decreased when combined with Interferon alfa-2b.
Diclofenac,The metabolism of Diclofenac can be decreased when combined with Interferon alfa-2b.
Guanabenz,The metabolism of Guanabenz can be decreased when combined with Interferon alfa-2b.
Verapamil,The metabolism of Verapamil can be decreased when combined with Interferon alfa-2b.
Paroxetine,The metabolism of Paroxetine can be decreased when combined with Interferon alfa-2b.
Thiabendazole,The metabolism of Thiabendazole can be decreased when combined with Interferon alfa-2b.
Riluzole,The metabolism of Riluzole can be decreased when combined with Interferon alfa-2b.
Zileuton,The metabolism of Zileuton can be decreased when combined with Interferon alfa-2b.
Clopidogrel,The metabolism of Clopidogrel can be decreased when combined with Interferon alfa-2b.
Estradiol,The metabolism of Estradiol can be decreased when combined with Interferon alfa-2b.
Acyclovir,The metabolism of Acyclovir can be decreased when combined with Interferon alfa-2b.
Naproxen,The metabolism of Naproxen can be decreased when combined with Interferon alfa-2b.
Trifluoperazine,The metabolism of Trifluoperazine can be decreased when combined with Interferon alfa-2b.
Perphenazine,The metabolism of Perphenazine can be decreased when combined with Interferon alfa-2b.
Terbinafine,The metabolism of Terbinafine can be decreased when combined with Interferon alfa-2b.
Ranitidine,The metabolism of Ranitidine can be decreased when combined with Interferon alfa-2b.
Ethanol,The metabolism of Ethanol can be decreased when combined with Interferon alfa-2b.
Maprotiline,The metabolism of Maprotiline can be decreased when combined with Interferon alfa-2b.
Alosetron,The metabolism of Alosetron can be decreased when combined with Interferon alfa-2b.
Lomefloxacin,The metabolism of Lomefloxacin can be decreased when combined with Interferon alfa-2b.
Ramelteon,The metabolism of Ramelteon can be decreased when combined with Interferon alfa-2b.
Frovatriptan,The metabolism of Frovatriptan can be decreased when combined with Interferon alfa-2b.
Levobupivacaine,The metabolism of Levobupivacaine can be decreased when combined with Interferon alfa-2b.
Cinacalcet,The metabolism of Cinacalcet can be decreased when combined with Interferon alfa-2b.
Selegiline,The metabolism of Selegiline can be decreased when combined with Interferon alfa-2b.
Tocainide,The metabolism of Tocainide can be decreased when combined with Interferon alfa-2b.
Praziquantel,The metabolism of Praziquantel can be decreased when combined with Interferon alfa-2b.
Melatonin,The metabolism of Melatonin can be decreased when combined with Interferon alfa-2b.
Primaquine,The metabolism of Primaquine can be decreased when combined with Interferon alfa-2b.
Hesperetin,The metabolism of Hesperetin can be decreased when combined with Interferon alfa-2b.
Nifedipine,The metabolism of Nifedipine can be decreased when combined with Interferon alfa-2b.
Carvedilol,The metabolism of Carvedilol can be decreased when combined with Interferon alfa-2b.
Cilostazol,The metabolism of Cilostazol can be decreased when combined with Interferon alfa-2b.
Propafenone,The metabolism of Propafenone can be decreased when combined with Interferon alfa-2b.
Domperidone,The metabolism of Domperidone can be decreased when combined with Interferon alfa-2b.
Dexfenfluramine,The metabolism of Dexfenfluramine can be decreased when combined with Interferon alfa-2b.
Rasagiline,The metabolism of Rasagiline can be decreased when combined with Interferon alfa-2b.
Temafloxacin,The metabolism of Temafloxacin can be decreased when combined with Interferon alfa-2b.
Aminophenazone,The metabolism of Aminophenazone can be decreased when combined with Interferon alfa-2b.
Antipyrine,The metabolism of Antipyrine can be decreased when combined with Interferon alfa-2b.
Bromazepam,The metabolism of Bromazepam can be decreased when combined with Interferon alfa-2b.
Thiothixene,The metabolism of Thiothixene can be decreased when combined with Interferon alfa-2b.
Etoricoxib,The metabolism of Etoricoxib can be decreased when combined with Interferon alfa-2b.
Genistein,The metabolism of Genistein can be decreased when combined with Interferon alfa-2b.
Resveratrol,The metabolism of Resveratrol can be decreased when combined with Interferon alfa-2b.
Phenacetin,The metabolism of Phenacetin can be decreased when combined with Interferon alfa-2b.
Estrone sulfate,The metabolism of Estrone sulfate can be decreased when combined with Interferon alfa-2b.
Flunarizine,The metabolism of Flunarizine can be decreased when combined with Interferon alfa-2b.
Lorcaserin,The metabolism of Lorcaserin can be decreased when combined with Interferon alfa-2b.
Lofexidine,The metabolism of Lofexidine can be decreased when combined with Interferon alfa-2b.
Mianserin,The metabolism of Mianserin can be decreased when combined with Interferon alfa-2b.
Eltrombopag,The metabolism of Eltrombopag can be decreased when combined with Interferon alfa-2b.
Asenapine,The metabolism of Asenapine can be decreased when combined with Interferon alfa-2b.
Vadimezan,The metabolism of Vadimezan can be decreased when combined with Interferon alfa-2b.
Dapagliflozin,The metabolism of Dapagliflozin can be decreased when combined with Interferon alfa-2b.
Agomelatine,The metabolism of Agomelatine can be decreased when combined with Interferon alfa-2b.
Axitinib,The metabolism of Axitinib can be decreased when combined with Interferon alfa-2b.
Benzyl alcohol,The metabolism of Benzyl alcohol can be decreased when combined with Interferon alfa-2b.
Capsaicin,The metabolism of Capsaicin can be decreased when combined with Interferon alfa-2b.
(R)-warfarin,The metabolism of (R)-warfarin can be decreased when combined with Interferon alfa-2b.
Perampanel,The metabolism of Perampanel can be decreased when combined with Interferon alfa-2b.
Tasimelteon,The metabolism of Tasimelteon can be decreased when combined with Interferon alfa-2b.
Stiripentol,The metabolism of Stiripentol can be decreased when combined with Interferon alfa-2b.
Zotepine,The metabolism of Zotepine can be decreased when combined with Interferon alfa-2b.
Propacetamol,The metabolism of Propacetamol can be decreased when combined with Interferon alfa-2b.
Ramosetron,The metabolism of Ramosetron can be decreased when combined with Interferon alfa-2b.
Binimetinib,The metabolism of Binimetinib can be decreased when combined with Interferon alfa-2b.
Voxilaprevir,The metabolism of Voxilaprevir can be decreased when combined with Interferon alfa-2b.
Triclabendazole,The metabolism of Triclabendazole can be decreased when combined with Interferon alfa-2b.
Rucaparib,The metabolism of Rucaparib can be decreased when combined with Interferon alfa-2b.
Dihydralazine,The metabolism of Dihydralazine can be decreased when combined with Interferon alfa-2b.
Estradiol acetate,The metabolism of Estradiol acetate can be decreased when combined with Interferon alfa-2b.
Estradiol benzoate,The metabolism of Estradiol benzoate can be decreased when combined with Interferon alfa-2b.
Estradiol cypionate,The metabolism of Estradiol cypionate can be decreased when combined with Interferon alfa-2b.
Estradiol dienanthate,The metabolism of Estradiol dienanthate can be decreased when combined with Interferon alfa-2b.
Estradiol valerate,The metabolism of Estradiol valerate can be decreased when combined with Interferon alfa-2b.
Istradefylline,The metabolism of Istradefylline can be decreased when combined with Interferon alfa-2b.
Azelastine,The metabolism of Azelastine can be decreased when combined with Interferon alfa-2b.
Efavirenz,The metabolism of Efavirenz can be decreased when combined with Interferon alfa-2b.
Metoclopramide,The metabolism of Metoclopramide can be decreased when combined with Interferon alfa-2b.
Bicifadine,The metabolism of Bicifadine can be decreased when combined with Interferon alfa-2b.
GTS-21,The metabolism of GTS-21 can be decreased when combined with Interferon alfa-2b.
Flecainide,The metabolism of Flecainide can be decreased when combined with Interferon alfa-2b.
Ethinylestradiol,The metabolism of Ethinylestradiol can be decreased when combined with Interferon alfa-2b.
Amitriptyline,The metabolism of Amitriptyline can be decreased when combined with Interferon alfa-2b.
Imipramine,The metabolism of Imipramine can be decreased when combined with Interferon alfa-2b.
Doxepin,The metabolism of Doxepin can be decreased when combined with Interferon alfa-2b.
Mephenytoin,The metabolism of Mephenytoin can be decreased when combined with Interferon alfa-2b.
Nortriptyline,The metabolism of Nortriptyline can be decreased when combined with Interferon alfa-2b.
Clonidine,The metabolism of Clonidine can be decreased when combined with Interferon alfa-2b.
Cyclobenzaprine,The metabolism of Cyclobenzaprine can be decreased when combined with Interferon alfa-2b.
Desipramine,The metabolism of Desipramine can be decreased when combined with Interferon alfa-2b.
Clomipramine,The metabolism of Clomipramine can be decreased when combined with Interferon alfa-2b.
Selumetinib,The metabolism of Selumetinib can be decreased when combined with Interferon alfa-2b.
Theophylline,The metabolism of Theophylline can be decreased when combined with Interferon alfa-2b.
Carbamazepine,The metabolism of Carbamazepine can be decreased when combined with Interferon alfa-2b.
Warfarin,The metabolism of Warfarin can be decreased when combined with Interferon alfa-2b.
Tizanidine,The metabolism of Tizanidine can be decreased when combined with Interferon alfa-2b.
Pimozide,The metabolism of Pimozide can be decreased when combined with Interferon alfa-2b.
Aminophylline,The metabolism of Aminophylline can be decreased when combined with Interferon alfa-2b.
Acenocoumarol,The metabolism of Acenocoumarol can be decreased when combined with Interferon alfa-2b.
Erlotinib,The metabolism of Erlotinib can be decreased when combined with Interferon alfa-2b.
Tegafur,The metabolism of Tegafur can be decreased when combined with Interferon alfa-2b.
Enasidenib,The metabolism of Enasidenib can be decreased when combined with Interferon alfa-2b.
Tamoxifen,The metabolism of Tamoxifen can be decreased when combined with Interferon alfa-2b.
Lepirudin,The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-2b.
Bivalirudin,The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon alfa-2b.
Alteplase,The risk or severity of bleeding can be increased when Alteplase is combined with Interferon alfa-2b.
Urokinase,The risk or severity of bleeding can be increased when Urokinase is combined with Interferon alfa-2b.
Reteplase,The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-2b.
Anistreplase,The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon alfa-2b.
Tenecteplase,The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon alfa-2b.
Drotrecogin alfa,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-2b.
Streptokinase,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-2b.
Dicoumarol,The risk or severity of bleeding can be increased when Dicoumarol is combined with Interferon alfa-2b.
Argatroban,The risk or severity of bleeding can be increased when Argatroban is combined with Interferon alfa-2b.
Ardeparin,The risk or severity of bleeding can be increased when Ardeparin is combined with Interferon alfa-2b.
Phenindione,The risk or severity of bleeding can be increased when Phenindione is combined with Interferon alfa-2b.
Fondaparinux,The risk or severity of bleeding can be increased when Fondaparinux is combined with Interferon alfa-2b.
Pentosan polysulfate,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Interferon alfa-2b.
Phenprocoumon,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Interferon alfa-2b.
Heparin,The risk or severity of bleeding can be increased when Heparin is combined with Interferon alfa-2b.
Enoxaparin,The risk or severity of bleeding can be increased when Enoxaparin is combined with Interferon alfa-2b.
4-hydroxycoumarin,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Interferon alfa-2b.
Coumarin,The risk or severity of bleeding can be increased when Coumarin is combined with Interferon alfa-2b.
Ximelagatran,The risk or severity of bleeding can be increased when Ximelagatran is combined with Interferon alfa-2b.
Desmoteplase,The risk or severity of bleeding can be increased when Desmoteplase is combined with Interferon alfa-2b.
Ancrod,The risk or severity of bleeding can be increased when Ancrod is combined with Interferon alfa-2b.
Fibrinolysin,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Interferon alfa-2b.
Rivaroxaban,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Interferon alfa-2b.
Sulodexide,The risk or severity of bleeding can be increased when Sulodexide is combined with Interferon alfa-2b.
Semuloparin,The risk or severity of bleeding can be increased when Semuloparin is combined with Interferon alfa-2b.
Idraparinux,The risk or severity of bleeding can be increased when Idraparinux is combined with Interferon alfa-2b.
Astaxanthin,The risk or severity of bleeding can be increased when Astaxanthin is combined with Interferon alfa-2b.
Apixaban,The risk or severity of bleeding can be increased when Apixaban is combined with Interferon alfa-2b.
Otamixaban,The risk or severity of bleeding can be increased when Otamixaban is combined with Interferon alfa-2b.
Amediplase,The risk or severity of bleeding can be increased when Amediplase is combined with Interferon alfa-2b.
Dabigatran etexilate,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon alfa-2b.
Danaparoid,The risk or severity of bleeding can be increased when Danaparoid is combined with Interferon alfa-2b.
Dalteparin,The risk or severity of bleeding can be increased when Dalteparin is combined with Interferon alfa-2b.
Tinzaparin,The risk or severity of bleeding can be increased when Tinzaparin is combined with Interferon alfa-2b.
Ferulic acid,The risk or severity of bleeding can be increased when Ferulic acid is combined with Interferon alfa-2b.
Ethyl biscoumacetate,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Interferon alfa-2b.
Nadroparin,The risk or severity of bleeding can be increased when Nadroparin is combined with Interferon alfa-2b.
Ditazole,The risk or severity of bleeding can be increased when Ditazole is combined with Interferon alfa-2b.
Edoxaban,The risk or severity of bleeding can be increased when Edoxaban is combined with Interferon alfa-2b.
Potassium citrate,The risk or severity of bleeding can be increased when Potassium citrate is combined with Interferon alfa-2b.
Sodium citrate,The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon alfa-2b.
Dextran,The risk or severity of bleeding can be increased when Dextran is combined with Interferon alfa-2b.
Bemiparin,The risk or severity of bleeding can be increased when Bemiparin is combined with Interferon alfa-2b.
Reviparin,The risk or severity of bleeding can be increased when Reviparin is combined with Interferon alfa-2b.
Parnaparin,The risk or severity of bleeding can be increased when Parnaparin is combined with Interferon alfa-2b.
Certoparin,The risk or severity of bleeding can be increased when Certoparin is combined with Interferon alfa-2b.
Desirudin,The risk or severity of bleeding can be increased when Desirudin is combined with Interferon alfa-2b.
Zinc citrate,The risk or severity of bleeding can be increased when Zinc citrate is combined with Interferon alfa-2b.
Antithrombin Alfa,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon alfa-2b.
Protein C,The risk or severity of bleeding can be increased when Protein C is combined with Interferon alfa-2b.
Antithrombin III human,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon alfa-2b.
Letaxaban,The risk or severity of bleeding can be increased when Letaxaban is combined with Interferon alfa-2b.
Darexaban,The risk or severity of bleeding can be increased when Darexaban is combined with Interferon alfa-2b.
Betrixaban,The risk or severity of bleeding can be increased when Betrixaban is combined with Interferon alfa-2b.
Nafamostat,The risk or severity of bleeding can be increased when Nafamostat is combined with Interferon alfa-2b.
Monteplase,The risk or severity of bleeding can be increased when Monteplase is combined with Interferon alfa-2b.
Gabexate,The risk or severity of bleeding can be increased when Gabexate is combined with Interferon alfa-2b.
Fluindione,The risk or severity of bleeding can be increased when Fluindione is combined with Interferon alfa-2b.
Protein S human,The risk or severity of bleeding can be increased when Protein S human is combined with Interferon alfa-2b.
Brinase,The risk or severity of bleeding can be increased when Brinase is combined with Interferon alfa-2b.
Clorindione,The risk or severity of bleeding can be increased when Clorindione is combined with Interferon alfa-2b.
Diphenadione,The risk or severity of bleeding can be increased when Diphenadione is combined with Interferon alfa-2b.
Tioclomarol,The risk or severity of bleeding can be increased when Tioclomarol is combined with Interferon alfa-2b.
Melagatran,The risk or severity of bleeding can be increased when Melagatran is combined with Interferon alfa-2b.
Saruplase,The risk or severity of bleeding can be increased when Saruplase is combined with Interferon alfa-2b.
(S)-Warfarin,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Interferon alfa-2b.
Tocopherylquinone,The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Interferon alfa-2b.
Edetate calcium disodium anhydrous,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Interferon alfa-2b.
Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon alfa-2b.
Methyclothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon alfa-2b.
Bendroflumethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon alfa-2b.
Benzthiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Interferon alfa-2b.
Cyclothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Interferon alfa-2b.
Hydroflumethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Interferon alfa-2b.
Chlorothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Interferon alfa-2b.
Hydrochlorothiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Interferon alfa-2b.
Trichlormethiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Interferon alfa-2b.
Polythiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Interferon alfa-2b.
Mebutizide,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Interferon alfa-2b.
Cyclopenthiazide,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Interferon alfa-2b.
Tedizolid phosphate,The risk or severity of myelosuppression can be increased when Interferon alfa-2b is combined with Tedizolid phosphate.
Cyclosporine,Interferon alfa-2b may increase the immunosuppressive activities of Cyclosporine.
Ropinirole,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ropinirole.
Cyanocobalamin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-2b.
Allopurinol,The risk or severity of adverse effects can be increased when Allopurinol is combined with Interferon alfa-2b.
Pexidartinib,Interferon alfa-2b may increase the hepatotoxic activities of Pexidartinib.
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Interferon alfa-2b.
Lopinavir,The serum concentration of Interferon alfa-2b can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Interferon alfa-2b is combined with Inebilizumab.
Carboprost tromethamine,Carboprost tromethamine may increase the uterotonic activities of Oxytocin.
Dinoprostone,The risk or severity of adverse effects can be increased when Dinoprostone is combined with Oxytocin.
Misoprostol,The risk or severity of adverse effects can be increased when Misoprostol is combined with Oxytocin.
Leuprolide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Leuprolide.
Goserelin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Goserelin.
Betaxolol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Betaxolol.
Erythromycin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Erythromycin.
Azithromycin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Azithromycin.
Moxifloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Moxifloxacin.
Ranolazine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ranolazine.
Sulfisoxazole,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sulfisoxazole.
Amitriptyline,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amitriptyline.
Methadone,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methadone.
Diltiazem,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Diltiazem.
Clozapine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clozapine.
Sulpiride,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sulpiride.
Nimodipine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nimodipine.
Promazine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Promazine.
Prochlorperazine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prochlorperazine.
Droperidol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Droperidol.
Imipramine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Imipramine.
Chlorpromazine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorpromazine.
Oxaliplatin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxaliplatin.
Ciprofloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ciprofloxacin.
Fluorouracil,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluorouracil.
Perflutren,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Perflutren.
Cinnarizine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cinnarizine.
Propranolol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Propranolol.
Atropine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Atropine.
Chloroquine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chloroquine.
Efavirenz,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Efavirenz.
Adenosine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Adenosine.
Pentamidine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pentamidine.
Gadobenic acid,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gadobenic acid.
Carbinoxamine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Carbinoxamine.
Dolasetron,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dolasetron.
Roxithromycin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Roxithromycin.
Nalidixic acid,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nalidixic acid.
Cinoxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cinoxacin.
Loperamide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Loperamide.
Granisetron,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Granisetron.
Ondansetron,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ondansetron.
Levosimendan,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levosimendan.
Mesoridazine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mesoridazine.
Desloratadine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Desloratadine.
Telithromycin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Telithromycin.
Lomefloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lomefloxacin.
Dimenhydrinate,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dimenhydrinate.
Primaquine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Primaquine.
Papaverine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Papaverine.
Chlorpheniramine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorpheniramine.
Nifedipine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nifedipine.
Levofloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levofloxacin.
Gemifloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gemifloxacin.
Ofloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ofloxacin.
Propafenone,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Propafenone.
Acebutolol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Acebutolol.
Flecainide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Flecainide.
Clarithromycin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clarithromycin.
Levacetylmethadol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levacetylmethadol.
Saquinavir,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Saquinavir.
Clomipramine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clomipramine.
Mibefradil,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mibefradil.
Oxprenolol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxprenolol.
Probucol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Probucol.
Aceprometazine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aceprometazine.
Terlipressin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terlipressin.
Prenylamine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prenylamine.
Fluspirilene,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluspirilene.
Lofexidine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lofexidine.
Azimilide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Azimilide.
Pracinostat,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pracinostat.
Technetium Tc-99m ciprofloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Technetium Tc-99m ciprofloxacin.
Garenoxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Garenoxacin.
Tedisamil,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tedisamil.
Tucidinostat,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tucidinostat.
Telavancin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Telavancin.
Pazopanib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pazopanib.
Nemonoxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nemonoxacin.
Panobinostat,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Panobinostat.
Nilvadipine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nilvadipine.
Antazoline,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Antazoline.
Crizotinib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Crizotinib.
Bedaquiline,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bedaquiline.
Indenolol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Indenolol.
Fendiline,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fendiline.
Eperisone,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Eperisone.
Butriptyline,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Butriptyline.
Ceritinib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ceritinib.
Lenvatinib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lenvatinib.
Melperone,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Melperone.
Benidipine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Benidipine.
Dexchlorpheniramine maleate,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexchlorpheniramine maleate.
Amifampridine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amifampridine.
Mocetinostat,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mocetinostat.
Entinostat,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Entinostat.
Gilteritinib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gilteritinib.
CUDC-101,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with CUDC-101.
Simendan,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Simendan.
Ricolinostat,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ricolinostat.
Mizolastine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mizolastine.
Abexinostat,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Abexinostat.
Oxatomide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxatomide.
Sitafloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sitafloxacin.
Sultopride,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sultopride.
Otilonium,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Otilonium.
Nizofenone,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nizofenone.
Bunaftine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bunaftine.
Lorcainide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lorcainide.
Dexchlorpheniramine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexchlorpheniramine.
Penfluridol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Penfluridol.
Dexverapamil,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexverapamil.
Ivosidenib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ivosidenib.
Quetiapine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Quetiapine.
Encorafenib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Encorafenib.
Dofetilide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dofetilide.
Citalopram,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Citalopram.
Anagrelide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Anagrelide.
Disopyramide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Disopyramide.
Clemastine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clemastine.
Ibutilide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ibutilide.
Valproic acid,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Valproic acid.
Terfenadine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terfenadine.
Grepafloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Grepafloxacin.
Quinine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Quinine.
Sotalol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sotalol.
Erlotinib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Erlotinib.
Toremifene,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Toremifene.
Cisapride,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cisapride.
Imatinib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Imatinib.
Astemizole,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Astemizole.
Thioridazine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Thioridazine.
Trovafloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trovafloxacin.
Mifepristone,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mifepristone.
Flupentixol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Flupentixol.
Cocaine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cocaine.
Quinidine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Quinidine.
Procainamide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Procainamide.
Pimozide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pimozide.
Amiodarone,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amiodarone.
Arsenic trioxide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Arsenic trioxide.
Escitalopram,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Escitalopram.
Domperidone,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Domperidone.
Sparfloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sparfloxacin.
Halofantrine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Halofantrine.
Bepridil,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bepridil.
Paliperidone,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Paliperidone.
Lithium cation,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lithium cation.
Temafloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Temafloxacin.
Zuclopenthixol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Zuclopenthixol.
Tetrabenazine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tetrabenazine.
Dronedarone,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dronedarone.
Nilotinib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nilotinib.
Iloperidone,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Iloperidone.
Vandetanib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vandetanib.
Romidepsin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Romidepsin.
Asenapine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Asenapine.
Artemether,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Artemether.
Lumefantrine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lumefantrine.
Eliglustat,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Eliglustat.
Ivabradine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ivabradine.
Ribociclib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ribociclib.
Glasdegib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Glasdegib.
Deutetrabenazine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Deutetrabenazine.
Macimorelin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Macimorelin.
Terodiline,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terodiline.
Vemurafenib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vemurafenib.
Delamanid,Oxytocin may increase the QTc-prolonging activities of Delamanid.
Octreotide,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxytocin.
Esmolol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Esmolol.
Bortezomib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bortezomib.
Fluconazole,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluconazole.
Nelfinavir,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nelfinavir.
Pregabalin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pregabalin.
Benzatropine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Benzatropine.
Isradipine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Isradipine.
Venlafaxine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Venlafaxine.
Atomoxetine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Atomoxetine.
Olanzapine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Olanzapine.
Cetirizine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cetirizine.
Protriptyline,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Protriptyline.
Alfuzosin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Alfuzosin.
Trimethadione,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trimethadione.
Buclizine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Buclizine.
Mefloquine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mefloquine.
Doxylamine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Doxylamine.
Mirtazapine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mirtazapine.
Timolol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Timolol.
Treprostinil,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Treprostinil.
Digoxin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Digoxin.
Sorafenib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sorafenib.
Dexbrompheniramine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexbrompheniramine.
Hyoscyamine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hyoscyamine.
Triprolidine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Triprolidine.
Cyproheptadine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cyproheptadine.
Enoxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Enoxacin.
Pefloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pefloxacin.
Ritonavir,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ritonavir.
Foscarnet,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Foscarnet.
Nortriptyline,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nortriptyline.
Amoxapine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amoxapine.
Lamotrigine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lamotrigine.
Voriconazole,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Voriconazole.
Ethosuximide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ethosuximide.
Amodiaquine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amodiaquine.
Nicardipine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nicardipine.
Galantamine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Galantamine.
Tamoxifen,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tamoxifen.
Losartan,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Losartan.
Moricizine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Moricizine.
Moexipril,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Moexipril.
Tizanidine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tizanidine.
Ibandronate,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ibandronate.
Apomorphine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Apomorphine.
Azatadine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Azatadine.
Trimipramine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trimipramine.
Risperidone,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Risperidone.
Isoflurane,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Isoflurane.
Indapamide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Indapamide.
Rosoxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Rosoxacin.
Propofol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Propofol.
Disulfiram,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Disulfiram.
Levomenthol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levomenthol.
Brompheniramine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Brompheniramine.
Vardenafil,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vardenafil.
Tacrolimus,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tacrolimus.
Terbutaline,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terbutaline.
Zonisamide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Zonisamide.
Amantadine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amantadine.
Metronidazole,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Metronidazole.
Ketotifen,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ketotifen.
Famotidine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Famotidine.
Maprotiline,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Maprotiline.
Salmeterol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Salmeterol.
Felbamate,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Felbamate.
Formoterol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Formoterol.
Hydrochlorothiazide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hydrochlorothiazide.
Salbutamol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Salbutamol.
Sulfamethoxazole,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sulfamethoxazole.
Felodipine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Felodipine.
Ketoconazole,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ketoconazole.
Tolterodine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tolterodine.
Gatifloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gatifloxacin.
Nitrendipine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nitrendipine.
Norfloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Norfloxacin.
Promethazine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Promethazine.
Mequitazine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mequitazine.
Atazanavir,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Atazanavir.
Perhexiline,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Perhexiline.
Diphenhydramine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Diphenhydramine.
Levocabastine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levocabastine.
Doxepin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Doxepin.
Desipramine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Desipramine.
Bretylium,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bretylium.
Cilostazol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cilostazol.
Itraconazole,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Itraconazole.
Orphenadrine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Orphenadrine.
Cyclizine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cyclizine.
Desflurane,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Desflurane.
Encainide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Encainide.
Metoclopramide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Metoclopramide.
Sevoflurane,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sevoflurane.
Aripiprazole,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aripiprazole.
Chlorprothixene,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorprothixene.
Alimemazine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Alimemazine.
Dasatinib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dasatinib.
Lapatinib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lapatinib.
Posaconazole,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Posaconazole.
Sunitinib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sunitinib.
Arformoterol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Arformoterol.
Digitoxin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Digitoxin.
Methotrimeprazine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methotrimeprazine.
Ajmaline,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ajmaline.
Solifenacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Solifenacin.
Hydroxychloroquine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hydroxychloroquine.
Pheniramine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pheniramine.
Thiothixene,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Thiothixene.
Vorinostat,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vorinostat.
Fleroxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fleroxacin.
Farnesyl thiopyrophosphate,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Farnesyl thiopyrophosphate.
Celiprolol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Celiprolol.
Ezogabine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ezogabine.
Indacaterol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Indacaterol.
Methsuximide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methsuximide.
Tandutinib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tandutinib.
Vernakalant,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vernakalant.
Levocetirizine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levocetirizine.
Amisulpride,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amisulpride.
Cariporide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cariporide.
Pasireotide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pasireotide.
Mepyramine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mepyramine.
Degarelix,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Degarelix.
Buserelin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Buserelin.
Histrelin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Histrelin.
Triptorelin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Triptorelin.
Farnesyl diphosphate,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Farnesyl diphosphate.
Geranylgeranyl diphosphate,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Geranylgeranyl diphosphate.
Bupranolol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bupranolol.
Lurasidone,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lurasidone.
Rilpivirine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Rilpivirine.
Eribulin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Eribulin.
Mirabegron,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mirabegron.
Dabrafenib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dabrafenib.
Chlorcyclizine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorcyclizine.
Flumequine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Flumequine.
Olodaterol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Olodaterol.
Vilanterol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vilanterol.
Trimebutine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trimebutine.
Pinaverium,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pinaverium.
Dosulepin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dosulepin.
Aranidipine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aranidipine.
Efonidipine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Efonidipine.
Lacidipine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lacidipine.
Niguldipine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Niguldipine.
Acrivastine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Acrivastine.
Coumaphos,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Coumaphos.
Dichlorvos,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dichlorvos.
Famphur,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Famphur.
Fenthion,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fenthion.
Orbifloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Orbifloxacin.
Phosmet,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Phosmet.
Sarafloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sarafloxacin.
Difloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Difloxacin.
Bilastine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bilastine.
Rupatadine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Rupatadine.
Ebastine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ebastine.
Talinolol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Talinolol.
Pazufloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pazufloxacin.
Anisodamine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Anisodamine.
CUDC-907,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with CUDC-907.
Prulifloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prulifloxacin.
Delafloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Delafloxacin.
Tetrahydropalmatine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tetrahydropalmatine.
Temefos,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Temefos.
Triclabendazole,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Triclabendazole.
Givinostat,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Givinostat.
Pilsicainide,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pilsicainide.
Cicletanine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cicletanine.
Gallopamil,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gallopamil.
Cibenzoline,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cibenzoline.
Bencyclane,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bencyclane.
Prajmaline,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prajmaline.
Oxolinic acid,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxolinic acid.
Lorajmine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lorajmine.
Acetyldigoxin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Acetyldigoxin.
Piromidic acid,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Piromidic acid.
Lidoflazine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lidoflazine.
Rufloxacin,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Rufloxacin.
Pipemidic acid,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pipemidic acid.
Aripiprazole lauroxil,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aripiprazole lauroxil.
Inotersen,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Inotersen.
Lopinavir,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lopinavir.
Clofazimine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clofazimine.
Trazodone,The risk or severity of QTc prolongation can be increased when Trazodone is combined with Oxytocin.
Entrectinib,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Entrectinib.
Pitolisant,Oxytocin may increase the QTc-prolonging activities of Pitolisant.
Lefamulin,Lefamulin may increase the QTc-prolonging activities of Oxytocin.
Phenylephrine,The risk or severity of hypertension can be increased when Oxytocin is combined with Phenylephrine.
Hydroxyzine,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hydroxyzine.
Ziprasidone,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ziprasidone.
Haloperidol,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Haloperidol.
Ephedrine,The risk or severity of hypertension can be increased when Oxytocin is combined with Ephedrine.
Fluoxetine,The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Oxytocin.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Natalizumab.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Natalizumab.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Natalizumab.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Natalizumab.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Natalizumab.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Natalizumab.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Natalizumab.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Natalizumab.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Natalizumab."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Natalizumab.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Natalizumab.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Natalizumab.
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Natalizumab.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Natalizumab.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Natalizumab.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Natalizumab.
Trastuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Natalizumab.
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Natalizumab.
Basiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Natalizumab.
Muromonab,The risk or severity of adverse effects can be increased when Muromonab is combined with Natalizumab.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Natalizumab.
Tositumomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Natalizumab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Natalizumab.
Alefacept,The risk or severity of adverse effects can be increased when Alefacept is combined with Natalizumab.
Efalizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Natalizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Natalizumab.
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Natalizumab.
Daclizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Natalizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Natalizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Natalizumab.
Flunisolide,The risk or severity of adverse effects can be increased when Flunisolide is combined with Natalizumab.
Bortezomib,The risk or severity of adverse effects can be increased when Bortezomib is combined with Natalizumab.
Cladribine,The risk or severity of adverse effects can be increased when Cladribine is combined with Natalizumab.
Carmustine,The risk or severity of adverse effects can be increased when Carmustine is combined with Natalizumab.
Amsacrine,The risk or severity of adverse effects can be increased when Amsacrine is combined with Natalizumab.
Bleomycin,The risk or severity of adverse effects can be increased when Bleomycin is combined with Natalizumab.
Chlorambucil,The risk or severity of adverse effects can be increased when Chlorambucil is combined with Natalizumab.
Raltitrexed,The risk or severity of adverse effects can be increased when Raltitrexed is combined with Natalizumab.
Mitomycin,The risk or severity of adverse effects can be increased when Mitomycin is combined with Natalizumab.
Bexarotene,The risk or severity of adverse effects can be increased when Bexarotene is combined with Natalizumab.
Vindesine,The risk or severity of adverse effects can be increased when Vindesine is combined with Natalizumab.
Floxuridine,The risk or severity of adverse effects can be increased when Floxuridine is combined with Natalizumab.
Indomethacin,The risk or severity of adverse effects can be increased when Indomethacin is combined with Natalizumab.
Tioguanine,The risk or severity of adverse effects can be increased when Tioguanine is combined with Natalizumab.
Vinorelbine,The risk or severity of adverse effects can be increased when Vinorelbine is combined with Natalizumab.
Dexrazoxane,The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Natalizumab.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Natalizumab.
Sorafenib,The risk or severity of adverse effects can be increased when Sorafenib is combined with Natalizumab.
Streptozocin,The risk or severity of adverse effects can be increased when Streptozocin is combined with Natalizumab.
Trifluridine,The risk or severity of adverse effects can be increased when Trifluridine is combined with Natalizumab.
Gemcitabine,The risk or severity of adverse effects can be increased when Gemcitabine is combined with Natalizumab.
Betamethasone,The risk or severity of adverse effects can be increased when Betamethasone is combined with Natalizumab.
Teniposide,The risk or severity of adverse effects can be increased when Teniposide is combined with Natalizumab.
Epirubicin,The risk or severity of adverse effects can be increased when Epirubicin is combined with Natalizumab.
Chloramphenicol,The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Natalizumab.
Lenalidomide,The risk or severity of adverse effects can be increased when Lenalidomide is combined with Natalizumab.
Altretamine,The risk or severity of adverse effects can be increased when Altretamine is combined with Natalizumab.
Zidovudine,The risk or severity of adverse effects can be increased when Zidovudine is combined with Natalizumab.
Cisplatin,The risk or severity of adverse effects can be increased when Cisplatin is combined with Natalizumab.
Oxaliplatin,The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Natalizumab.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Natalizumab.
Vincristine,The risk or severity of adverse effects can be increased when Vincristine is combined with Natalizumab.
Fluorouracil,The risk or severity of adverse effects can be increased when Fluorouracil is combined with Natalizumab.
Propylthiouracil,The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Natalizumab.
Pentostatin,The risk or severity of adverse effects can be increased when Pentostatin is combined with Natalizumab.
Methotrexate,The risk or severity of adverse effects can be increased when Methotrexate is combined with Natalizumab.
Carbamazepine,The risk or severity of adverse effects can be increased when Carbamazepine is combined with Natalizumab.
Vinblastine,The risk or severity of adverse effects can be increased when Vinblastine is combined with Natalizumab.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Natalizumab.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Natalizumab.
Linezolid,The risk or severity of adverse effects can be increased when Linezolid is combined with Natalizumab.
Imatinib,The risk or severity of adverse effects can be increased when Imatinib is combined with Natalizumab.
Triamcinolone,The risk or severity of adverse effects can be increased when Triamcinolone is combined with Natalizumab.
Clofarabine,The risk or severity of adverse effects can be increased when Clofarabine is combined with Natalizumab.
Prednisone,The risk or severity of adverse effects can be increased when Prednisone is combined with Natalizumab.
Pemetrexed,The risk or severity of adverse effects can be increased when Pemetrexed is combined with Natalizumab.
Fludrocortisone,The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Natalizumab.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Natalizumab.
Daunorubicin,The risk or severity of adverse effects can be increased when Daunorubicin is combined with Natalizumab.
Hydrocortisone,The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Natalizumab.
Tretinoin,The risk or severity of adverse effects can be increased when Tretinoin is combined with Natalizumab.
Irinotecan,The risk or severity of adverse effects can be increased when Irinotecan is combined with Natalizumab.
Methimazole,The risk or severity of adverse effects can be increased when Methimazole is combined with Natalizumab.
Mometasone,The risk or severity of adverse effects can be increased when Mometasone is combined with Natalizumab.
Etoposide,The risk or severity of adverse effects can be increased when Etoposide is combined with Natalizumab.
Sulfasalazine,The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Natalizumab.
Dacarbazine,The risk or severity of adverse effects can be increased when Dacarbazine is combined with Natalizumab.
Temozolomide,The risk or severity of adverse effects can be increased when Temozolomide is combined with Natalizumab.
Penicillamine,The risk or severity of adverse effects can be increased when Penicillamine is combined with Natalizumab.
Prednisolone,The risk or severity of adverse effects can be increased when Prednisolone is combined with Natalizumab.
Tacrolimus,The risk or severity of adverse effects can be increased when Tacrolimus is combined with Natalizumab.
Sirolimus,The risk or severity of adverse effects can be increased when Sirolimus is combined with Natalizumab.
Mechlorethamine,The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Natalizumab.
Azacitidine,The risk or severity of adverse effects can be increased when Azacitidine is combined with Natalizumab.
Carboplatin,The risk or severity of adverse effects can be increased when Carboplatin is combined with Natalizumab.
Methylprednisolone,The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Natalizumab.
Dactinomycin,The risk or severity of adverse effects can be increased when Dactinomycin is combined with Natalizumab.
Cytarabine,The risk or severity of adverse effects can be increased when Cytarabine is combined with Natalizumab.
Azathioprine,The risk or severity of adverse effects can be increased when Azathioprine is combined with Natalizumab.
Doxorubicin,The risk or severity of adverse effects can be increased when Doxorubicin is combined with Natalizumab.
Hydroxyurea,The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Natalizumab.
Busulfan,The risk or severity of adverse effects can be increased when Busulfan is combined with Natalizumab.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Natalizumab.
Topotecan,The risk or severity of adverse effects can be increased when Topotecan is combined with Natalizumab.
Mercaptopurine,The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Natalizumab.
Thalidomide,The risk or severity of adverse effects can be increased when Thalidomide is combined with Natalizumab.
Melphalan,The risk or severity of adverse effects can be increased when Melphalan is combined with Natalizumab.
Fludarabine,The risk or severity of adverse effects can be increased when Fludarabine is combined with Natalizumab.
Leflunomide,The risk or severity of adverse effects can be increased when Leflunomide is combined with Natalizumab.
Flucytosine,The risk or severity of adverse effects can be increased when Flucytosine is combined with Natalizumab.
Capecitabine,The risk or severity of adverse effects can be increased when Capecitabine is combined with Natalizumab.
Trilostane,The risk or severity of adverse effects can be increased when Trilostane is combined with Natalizumab.
Procarbazine,The risk or severity of adverse effects can be increased when Procarbazine is combined with Natalizumab.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Natalizumab.
Idarubicin,The risk or severity of adverse effects can be increased when Idarubicin is combined with Natalizumab.
Ifosfamide,The risk or severity of adverse effects can be increased when Ifosfamide is combined with Natalizumab.
Estramustine,The risk or severity of adverse effects can be increased when Estramustine is combined with Natalizumab.
Mitoxantrone,The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Natalizumab.
Lomustine,The risk or severity of adverse effects can be increased when Lomustine is combined with Natalizumab.
Budesonide,The risk or severity of adverse effects can be increased when Budesonide is combined with Natalizumab.
Paclitaxel,The risk or severity of adverse effects can be increased when Paclitaxel is combined with Natalizumab.
Dexamethasone,The risk or severity of adverse effects can be increased when Dexamethasone is combined with Natalizumab.
Docetaxel,The risk or severity of adverse effects can be increased when Docetaxel is combined with Natalizumab.
Dasatinib,The risk or severity of adverse effects can be increased when Dasatinib is combined with Natalizumab.
Eculizumab,The risk or severity of adverse effects can be increased when Eculizumab is combined with Natalizumab.
Decitabine,The risk or severity of adverse effects can be increased when Decitabine is combined with Natalizumab.
Sunitinib,The risk or severity of adverse effects can be increased when Sunitinib is combined with Natalizumab.
Nelarabine,The risk or severity of adverse effects can be increased when Nelarabine is combined with Natalizumab.
Abatacept,The risk or severity of adverse effects can be increased when Abatacept is combined with Natalizumab.
Corticotropin,The risk or severity of adverse effects can be increased when Corticotropin is combined with Natalizumab.
Cortisone acetate,The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Natalizumab.
Paramethasone,The risk or severity of adverse effects can be increased when Paramethasone is combined with Natalizumab.
Colchicine,The risk or severity of adverse effects can be increased when Colchicine is combined with Natalizumab.
Ciclesonide,The risk or severity of adverse effects can be increased when Ciclesonide is combined with Natalizumab.
Stepronin,The risk or severity of adverse effects can be increased when Stepronin is combined with Natalizumab.
Everolimus,The risk or severity of adverse effects can be increased when Everolimus is combined with Natalizumab.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Natalizumab.
Castanospermine,The risk or severity of adverse effects can be increased when Castanospermine is combined with Natalizumab.
Vorinostat,The risk or severity of adverse effects can be increased when Vorinostat is combined with Natalizumab.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Natalizumab.
Brequinar,The risk or severity of adverse effects can be increased when Brequinar is combined with Natalizumab.
Thiotepa,The risk or severity of adverse effects can be increased when Thiotepa is combined with Natalizumab.
Aldosterone,The risk or severity of adverse effects can be increased when Aldosterone is combined with Natalizumab.
Ixabepilone,The risk or severity of adverse effects can be increased when Ixabepilone is combined with Natalizumab.
Nilotinib,The risk or severity of adverse effects can be increased when Nilotinib is combined with Natalizumab.
Pirfenidone,The risk or severity of adverse effects can be increased when Pirfenidone is combined with Natalizumab.
Afelimomab,The risk or severity of adverse effects can be increased when Afelimomab is combined with Natalizumab.
Belinostat,The risk or severity of adverse effects can be increased when Belinostat is combined with Natalizumab.
Trabectedin,The risk or severity of adverse effects can be increased when Trabectedin is combined with Natalizumab.
Interferon alfa,The risk or severity of adverse effects can be increased when Interferon alfa is combined with Natalizumab.
Glatiramer,The risk or severity of adverse effects can be increased when Glatiramer is combined with Natalizumab.
Gallium nitrate,The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Natalizumab.
Briakinumab,The risk or severity of adverse effects can be increased when Briakinumab is combined with Natalizumab.
omega interferon,The risk or severity of adverse effects can be increased when omega interferon is combined with Natalizumab.
Apremilast,The risk or severity of adverse effects can be increased when Apremilast is combined with Natalizumab.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Natalizumab.
Canakinumab,The risk or severity of adverse effects can be increased when Canakinumab is combined with Natalizumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Tocilizumab is combined with Natalizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Temsirolimus is combined with Natalizumab.
Rilonacept,The risk or severity of adverse effects can be increased when Rilonacept is combined with Natalizumab.
Pazopanib,The risk or severity of adverse effects can be increased when Pazopanib is combined with Natalizumab.
Panobinostat,The risk or severity of adverse effects can be increased when Panobinostat is combined with Natalizumab.
Mepolizumab,The risk or severity of adverse effects can be increased when Mepolizumab is combined with Natalizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Bosutinib is combined with Natalizumab.
Abetimus,The risk or severity of adverse effects can be increased when Abetimus is combined with Natalizumab.
Golimumab,The risk or severity of adverse effects can be increased when Golimumab is combined with Natalizumab.
Belatacept,The risk or severity of adverse effects can be increased when Belatacept is combined with Natalizumab.
Bendamustine,The risk or severity of adverse effects can be increased when Bendamustine is combined with Natalizumab.
Cabazitaxel,The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Natalizumab.
Pralatrexate,The risk or severity of adverse effects can be increased when Pralatrexate is combined with Natalizumab.
Wortmannin,The risk or severity of adverse effects can be increased when Wortmannin is combined with Natalizumab.
Fingolimod,The risk or severity of adverse effects can be increased when Fingolimod is combined with Natalizumab.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Natalizumab.
Eribulin,The risk or severity of adverse effects can be increased when Eribulin is combined with Natalizumab.
Ruxolitinib,The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Natalizumab.
Belimumab,The risk or severity of adverse effects can be increased when Belimumab is combined with Natalizumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Teriflunomide is combined with Natalizumab.
Carfilzomib,The risk or severity of adverse effects can be increased when Carfilzomib is combined with Natalizumab.
Tofacitinib,The risk or severity of adverse effects can be increased when Tofacitinib is combined with Natalizumab.
Ponatinib,The risk or severity of adverse effects can be increased when Ponatinib is combined with Natalizumab.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Natalizumab.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Natalizumab.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Natalizumab.
Pomalidomide,The risk or severity of adverse effects can be increased when Pomalidomide is combined with Natalizumab.
Obinutuzumab,The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Natalizumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Fluprednidene is combined with Natalizumab.
Fluocortolone,The risk or severity of adverse effects can be increased when Fluocortolone is combined with Natalizumab.
Secukinumab,The risk or severity of adverse effects can be increased when Secukinumab is combined with Natalizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Siltuximab is combined with Natalizumab.
Blinatumomab,The risk or severity of adverse effects can be increased when Blinatumomab is combined with Natalizumab.
Ibrutinib,The risk or severity of adverse effects can be increased when Ibrutinib is combined with Natalizumab.
Idelalisib,The risk or severity of adverse effects can be increased when Idelalisib is combined with Natalizumab.
Palbociclib,The risk or severity of adverse effects can be increased when Palbociclib is combined with Natalizumab.
Olaparib,The risk or severity of adverse effects can be increased when Olaparib is combined with Natalizumab.
Dinutuximab,The risk or severity of adverse effects can be increased when Dinutuximab is combined with Natalizumab.
Vilanterol,The risk or severity of adverse effects can be increased when Vilanterol is combined with Natalizumab.
Tixocortol,The risk or severity of adverse effects can be increased when Tixocortol is combined with Natalizumab.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Peginterferon beta-1a is combined with Natalizumab.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Natalizumab.
Fluprednisolone,The risk or severity of adverse effects can be increased when Fluprednisolone is combined with Natalizumab.
Meprednisone,The risk or severity of adverse effects can be increased when Meprednisone is combined with Natalizumab.
Tepoxalin,The risk or severity of adverse effects can be increased when Tepoxalin is combined with Natalizumab.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Natalizumab.
Melengestrol,The risk or severity of adverse effects can be increased when Melengestrol is combined with Natalizumab.
Ixekizumab,The risk or severity of adverse effects can be increased when Ixekizumab is combined with Natalizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Ravulizumab is combined with Natalizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Pirarubicin is combined with Natalizumab.
Voclosporin,The risk or severity of adverse effects can be increased when Voclosporin is combined with Natalizumab.
Peficitinib,The risk or severity of adverse effects can be increased when Peficitinib is combined with Natalizumab.
Clobetasol,The risk or severity of adverse effects can be increased when Clobetasol is combined with Natalizumab.
Sarilumab,The risk or severity of adverse effects can be increased when Sarilumab is combined with Natalizumab.
Brodalumab,The risk or severity of adverse effects can be increased when Brodalumab is combined with Natalizumab.
Sirukumab,The risk or severity of adverse effects can be increased when Sirukumab is combined with Natalizumab.
Baricitinib,The risk or severity of adverse effects can be increased when Baricitinib is combined with Natalizumab.
Guselkumab,The risk or severity of adverse effects can be increased when Guselkumab is combined with Natalizumab.
Deflazacort,The risk or severity of adverse effects can be increased when Deflazacort is combined with Natalizumab.
Triptolide,The risk or severity of adverse effects can be increased when Triptolide is combined with Natalizumab.
Siponimod,The risk or severity of adverse effects can be increased when Siponimod is combined with Natalizumab.
Ozanimod,The risk or severity of adverse effects can be increased when Ozanimod is combined with Natalizumab.
Mizoribine,The risk or severity of adverse effects can be increased when Mizoribine is combined with Natalizumab.
Gusperimus,The risk or severity of adverse effects can be increased when Gusperimus is combined with Natalizumab.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Cepeginterferon alfa-2B is combined with Natalizumab.
Trofosfamide,The risk or severity of adverse effects can be increased when Trofosfamide is combined with Natalizumab.
Doxifluridine,The risk or severity of adverse effects can be increased when Doxifluridine is combined with Natalizumab.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Deoxyspergualin is combined with Natalizumab.
Acteoside,The risk or severity of adverse effects can be increased when Acteoside is combined with Natalizumab.
Cortivazol,The risk or severity of adverse effects can be increased when Cortivazol is combined with Natalizumab.
Hypericin,The risk or severity of adverse effects can be increased when Hypericin is combined with Natalizumab.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when 9-(N-methyl-L-isoleucine)-cyclosporin A is combined with Natalizumab.
Prednylidene,The risk or severity of adverse effects can be increased when Prednylidene is combined with Natalizumab.
Fluocortin,The risk or severity of adverse effects can be increased when Fluocortin is combined with Natalizumab.
Begelomab,The risk or severity of adverse effects can be increased when Begelomab is combined with Natalizumab.
Fluperolone,The risk or severity of adverse effects can be increased when Fluperolone is combined with Natalizumab.
Formocortal,The risk or severity of adverse effects can be increased when Formocortal is combined with Natalizumab.
Halometasone,The risk or severity of adverse effects can be increased when Halometasone is combined with Natalizumab.
Cloprednol,The risk or severity of adverse effects can be increased when Cloprednol is combined with Natalizumab.
Fluclorolone,The risk or severity of adverse effects can be increased when Fluclorolone is combined with Natalizumab.
Fluticasone,The risk or severity of adverse effects can be increased when Fluticasone is combined with Natalizumab.
Tetrandrine,The risk or severity of adverse effects can be increased when Tetrandrine is combined with Natalizumab.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Monomethyl fumarate is combined with Natalizumab.
Mometasone furoate,The risk or severity of adverse effects can be increased when Mometasone furoate is combined with Natalizumab.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Hydrocortisone aceponate is combined with Natalizumab.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Hydrocortisone acetate is combined with Natalizumab.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Hydrocortisone succinate is combined with Natalizumab.
Emapalumab,The risk or severity of adverse effects can be increased when Emapalumab is combined with Natalizumab.
Risankizumab,The risk or severity of adverse effects can be increased when Risankizumab is combined with Natalizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Rozanolixizumab is combined with Natalizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Bleselumab is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Natalizumab.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Natalizumab.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Natalizumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Vedolizumab is combined with Natalizumab.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Natalizumab.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Natalizumab.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Natalizumab.
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Natalizumab.
Estrone,Estrone may increase the thrombogenic activities of Natalizumab.
Estradiol,Estradiol may increase the thrombogenic activities of Natalizumab.
Dienestrol,Dienestrol may increase the thrombogenic activities of Natalizumab.
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Natalizumab.
Mestranol,Mestranol may increase the thrombogenic activities of Natalizumab.
Estriol,Estriol may increase the thrombogenic activities of Natalizumab.
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Natalizumab.
Quinestrol,Quinestrol may increase the thrombogenic activities of Natalizumab.
Hexestrol,Hexestrol may increase the thrombogenic activities of Natalizumab.
Tibolone,Tibolone may increase the thrombogenic activities of Natalizumab.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Natalizumab."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Natalizumab."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Natalizumab.
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Natalizumab.
Zeranol,Zeranol may increase the thrombogenic activities of Natalizumab.
Equol,Equol may increase the thrombogenic activities of Natalizumab.
Promestriene,Promestriene may increase the thrombogenic activities of Natalizumab.
Methallenestril,Methallenestril may increase the thrombogenic activities of Natalizumab.
Epimestrol,Epimestrol may increase the thrombogenic activities of Natalizumab.
Moxestrol,Moxestrol may increase the thrombogenic activities of Natalizumab.
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Natalizumab.
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Natalizumab.
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Natalizumab.
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Natalizumab.
Biochanin A,Biochanin A may increase the thrombogenic activities of Natalizumab.
Formononetin,Formononetin may increase the thrombogenic activities of Natalizumab.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Natalizumab.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Natalizumab.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Natalizumab.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Natalizumab.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Natalizumab.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Natalizumab.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Natalizumab.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Natalizumab.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Natalizumab.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Natalizumab."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Natalizumab.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Natalizumab.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Natalizumab."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Natalizumab.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Natalizumab.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Natalizumab.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Natalizumab.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Natalizumab.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Natalizumab.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Natalizumab.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Natalizumab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Natalizumab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Natalizumab.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Natalizumab.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Natalizumab.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Natalizumab.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Natalizumab.
Ocrelizumab,Ocrelizumab may increase the immunosuppressive activities of Natalizumab.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Natalizumab.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Natalizumab.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Natalizumab.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Natalizumab.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Natalizumab.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Natalizumab.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Natalizumab.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Natalizumab.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Natalizumab.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Natalizumab.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Natalizumab.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Natalizumab.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Natalizumab.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Natalizumab.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Natalizumab.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Natalizumab.
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Natalizumab.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Natalizumab.
Capromab pendetide,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Natalizumab.
Palivizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Palivizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Technetium Tc-99m arcitumomab.
Panitumumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pexelizumab.
Epratuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Natalizumab is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Natalizumab is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Natalizumab is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Natalizumab is combined with NAV 1800.
Otelixizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Natalizumab is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Veltuzumab.
PRO-542,The risk or severity of adverse effects can be increased when Natalizumab is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Natalizumab is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Natalizumab is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Natalizumab is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Natalizumab is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Natalizumab is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Natalizumab is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Natalizumab is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Natalizumab is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Natalizumab is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lumiliximab.
Ipilimumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Clenoliximab.
BIIB015,The risk or severity of adverse effects can be increased when Natalizumab is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Natalizumab is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Natalizumab is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Natalizumab is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Catumaxomab.
Volociximab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ofatumumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Raxibacumab.
Nivolumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Nivolumab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dulaglutide.
Asfotase alfa,The risk or severity of adverse effects can be increased when Natalizumab is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Evolocumab.
Daratumumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Necitumumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Natalizumab is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Natalizumab is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Natalizumab is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Solanezumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tremelimumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lampalizumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Natalizumab is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Anifrolumab.
Benralizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Natalizumab is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Natalizumab is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Natalizumab is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Natalizumab is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Natalizumab is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Natalizumab is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Plozalizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Natalizumab is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Natalizumab is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Natalizumab is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Besilesomab.
Burosumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Cemiplimab.
Camrelizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Natalizumab is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Refanezumab.
Bermekimab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Natalizumab is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Natalizumab is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Natalizumab is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Nemolizumab.
Gedivumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Natalizumab is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Natalizumab is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Natalizumab is combined with Naratuximab emtansine.
Tildrakizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tildrakizumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ustekinumab.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Zenocutuzumab.
Cyclosporine,Natalizumab may increase the immunosuppressive activities of Cyclosporine.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Natalizumab."
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Natalizumab.
Lopinavir,The serum concentration of Natalizumab can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Natalizumab is combined with Inebilizumab.
Ritonavir,The serum concentration of Enfuvirtide can be increased when it is combined with Ritonavir.
Rubella virus vaccine,The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Enfuvirtide.
Bacillus calmette-guerin substrain tice live antigen,The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Enfuvirtide.
Bacillus calmette-guerin substrain connaught live antigen,The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Enfuvirtide.
Yellow Fever Vaccine,The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Enfuvirtide.
Anthrax vaccine,The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Enfuvirtide.
Typhoid Vaccine Live,The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Enfuvirtide.
Bacillus calmette-guerin substrain danish 1331 live antigen,The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Enfuvirtide.
BCG vaccine,The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Enfuvirtide.
Human adenovirus e serotype 4 strain cl-68578 antigen,The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Enfuvirtide.
Vibrio cholerae CVD 103-HgR strain live antigen,The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Enfuvirtide.
Adenovirus type 7 vaccine live,The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Enfuvirtide.
Varicella Zoster Vaccine (Live/attenuated),The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Enfuvirtide.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Palivizumab.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Palivizumab.
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Palivizumab.
Estrone,Estrone may increase the thrombogenic activities of Palivizumab.
Estradiol,Estradiol may increase the thrombogenic activities of Palivizumab.
Dienestrol,Dienestrol may increase the thrombogenic activities of Palivizumab.
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Palivizumab.
Mestranol,Mestranol may increase the thrombogenic activities of Palivizumab.
Estriol,Estriol may increase the thrombogenic activities of Palivizumab.
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Palivizumab.
Quinestrol,Quinestrol may increase the thrombogenic activities of Palivizumab.
Hexestrol,Hexestrol may increase the thrombogenic activities of Palivizumab.
Tibolone,Tibolone may increase the thrombogenic activities of Palivizumab.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Palivizumab."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Palivizumab."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Palivizumab.
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Palivizumab.
Zeranol,Zeranol may increase the thrombogenic activities of Palivizumab.
Equol,Equol may increase the thrombogenic activities of Palivizumab.
Promestriene,Promestriene may increase the thrombogenic activities of Palivizumab.
Methallenestril,Methallenestril may increase the thrombogenic activities of Palivizumab.
Epimestrol,Epimestrol may increase the thrombogenic activities of Palivizumab.
Moxestrol,Moxestrol may increase the thrombogenic activities of Palivizumab.
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Palivizumab.
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Palivizumab.
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Palivizumab.
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Palivizumab.
Biochanin A,Biochanin A may increase the thrombogenic activities of Palivizumab.
Formononetin,Formononetin may increase the thrombogenic activities of Palivizumab.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Palivizumab.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Palivizumab.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Palivizumab.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Palivizumab.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Palivizumab.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Palivizumab.
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Palivizumab.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Palivizumab.
Trastuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Palivizumab.
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Palivizumab.
Basiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Palivizumab.
Muromonab,The risk or severity of adverse effects can be increased when Muromonab is combined with Palivizumab.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Palivizumab.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Palivizumab.
Tositumomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Palivizumab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Palivizumab.
Capromab pendetide,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Palivizumab.
Efalizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Palivizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Palivizumab.
Natalizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Palivizumab.
Daclizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bevacizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Technetium Tc-99m arcitumomab.
Eculizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Eculizumab.
Panitumumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pexelizumab.
Afelimomab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Afelimomab.
Epratuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Palivizumab is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Palivizumab is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Palivizumab is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Palivizumab is combined with NAV 1800.
Briakinumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Briakinumab.
Otelixizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Palivizumab is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Veltuzumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ustekinumab.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Palivizumab is combined with Trastuzumab emtansine.
PRO-542,The risk or severity of adverse effects can be increased when Palivizumab is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Palivizumab is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Palivizumab is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Palivizumab is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Palivizumab is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Palivizumab is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Palivizumab is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Palivizumab is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Palivizumab is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Palivizumab is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lumiliximab.
Canakinumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Canakinumab.
Ipilimumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Clenoliximab.
Tocilizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tocilizumab.
BIIB015,The risk or severity of adverse effects can be increased when Palivizumab is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Palivizumab is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Palivizumab is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Palivizumab is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Catumaxomab.
Mepolizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Mepolizumab.
Denosumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Denosumab.
Volociximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ofatumumab.
Golimumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Golimumab.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Palivizumab is combined with Brentuximab vedotin.
Belimumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Belimumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Raxibacumab.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Palivizumab is combined with Certolizumab pegol.
Obinutuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Obinutuzumab.
Secukinumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Vedolizumab.
Nivolumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Nivolumab.
Siltuximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Siltuximab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dulaglutide.
Blinatumomab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Blinatumomab.
Anthrax immune globulin human,The risk or severity of adverse effects can be increased when Palivizumab is combined with Anthrax immune globulin human.
Dinutuximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dinutuximab.
Asfotase alfa,The risk or severity of adverse effects can be increased when Palivizumab is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Evolocumab.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Palivizumab is combined with Antilymphocyte immunoglobulin (horse).
Daratumumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Necitumumab.
Ixekizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ravulizumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Palivizumab is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Palivizumab is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Palivizumab is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Solanezumab.
Sarilumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sarilumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tremelimumab.
Brodalumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sirukumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lampalizumab.
Guselkumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Guselkumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Palivizumab is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Anifrolumab.
Ocrelizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ocrelizumab.
Benralizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Palivizumab is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Palivizumab is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Palivizumab is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Palivizumab is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Palivizumab is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Palivizumab is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Plozalizumab.
Inebilizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Inebilizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Palivizumab is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Palivizumab is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Palivizumab is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Besilesomab.
Tildrakizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tildrakizumab.
Burosumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Cemiplimab.
Emapalumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Risankizumab.
Camrelizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Palivizumab is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Refanezumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Rozanolixizumab.
Bermekimab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Palivizumab is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Palivizumab is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Palivizumab is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Nemolizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bleselumab.
Gedivumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Palivizumab is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Palivizumab is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Palivizumab is combined with Naratuximab emtansine.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Zenocutuzumab.
Rubella virus vaccine,The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Palivizumab.
Bacillus calmette-guerin substrain tice live antigen,The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Palivizumab.
Bacillus calmette-guerin substrain connaught live antigen,The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Palivizumab.
Yellow Fever Vaccine,The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Palivizumab.
Anthrax vaccine,The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Palivizumab.
Typhoid Vaccine Live,The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Palivizumab.
Bacillus calmette-guerin substrain danish 1331 live antigen,The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Palivizumab.
BCG vaccine,The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Palivizumab.
Human adenovirus e serotype 4 strain cl-68578 antigen,The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Palivizumab.
Vibrio cholerae CVD 103-HgR strain live antigen,The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Palivizumab.
Adenovirus type 7 vaccine live,The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Palivizumab.
Varicella Zoster Vaccine (Live/attenuated),The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Palivizumab.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Palivizumab."
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Daclizumab.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Daclizumab.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Daclizumab.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Daclizumab.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Daclizumab.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Daclizumab.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Daclizumab.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Daclizumab.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Daclizumab."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Daclizumab.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Daclizumab.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daclizumab.
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Daclizumab.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Daclizumab.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daclizumab.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daclizumab.
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Daclizumab.
Basiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Daclizumab.
Muromonab,The risk or severity of adverse effects can be increased when Muromonab is combined with Daclizumab.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daclizumab.
Tositumomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Daclizumab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daclizumab.
Alefacept,The risk or severity of adverse effects can be increased when Alefacept is combined with Daclizumab.
Efalizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Daclizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daclizumab.
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Daclizumab.
Bevacizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Daclizumab is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Daclizumab is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Daclizumab is combined with Beclomethasone dipropionate.
Sorafenib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sorafenib.
Streptozocin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Daclizumab is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Altretamine.
Zidovudine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Zidovudine.
Cisplatin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Daclizumab is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pentostatin.
Methotrexate,The risk or severity of adverse effects can be increased when Daclizumab is combined with Methotrexate.
Carbamazepine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carbamazepine.
Vinblastine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Daclizumab is combined with Linezolid.
Imatinib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Imatinib.
Triamcinolone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Daclizumab is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Daclizumab is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Daclizumab is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Daclizumab is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Daclizumab is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Daclizumab is combined with Paclitaxel.
Dexamethasone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dexamethasone.
Docetaxel,The risk or severity of adverse effects can be increased when Daclizumab is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Decitabine.
Sunitinib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sunitinib.
Nelarabine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nelarabine.
Abatacept,The risk or severity of adverse effects can be increased when Daclizumab is combined with Abatacept.
Corticotropin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Daclizumab is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Daclizumab is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Daclizumab is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Daclizumab is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Daclizumab is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Daclizumab is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Daclizumab is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Daclizumab is combined with omega interferon.
Apremilast,The risk or severity of adverse effects can be increased when Daclizumab is combined with Apremilast.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Daclizumab is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Daclizumab is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Daclizumab is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Daclizumab is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ponatinib.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Daclizumab is combined with Certolizumab pegol.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Blinatumomab.
Ibrutinib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ibrutinib.
Idelalisib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Idelalisib.
Palbociclib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Palbociclib.
Olaparib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Olaparib.
Dinutuximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dinutuximab.
Vilanterol,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vilanterol.
Tixocortol,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Daclizumab is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Daclizumab is combined with Antilymphocyte immunoglobulin (horse).
Fluprednisolone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Meprednisone.
Tepoxalin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tepoxalin.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Daclizumab is combined with Melengestrol.
Ixekizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Peficitinib.
Clobetasol,The risk or severity of adverse effects can be increased when Daclizumab is combined with Clobetasol.
Sarilumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sirukumab.
Baricitinib,The risk or severity of adverse effects can be increased when Daclizumab is combined with Baricitinib.
Guselkumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Guselkumab.
Deflazacort,The risk or severity of adverse effects can be increased when Daclizumab is combined with Deflazacort.
Triptolide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Triptolide.
Siponimod,The risk or severity of adverse effects can be increased when Daclizumab is combined with Siponimod.
Ozanimod,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Daclizumab is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Daclizumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Prednylidene,The risk or severity of adverse effects can be increased when Daclizumab is combined with Prednylidene.
Fluocortin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Daclizumab is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluclorolone.
Fluticasone,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluticasone.
Tetrandrine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tetrandrine.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Daclizumab is combined with Monomethyl fumarate.
Mometasone furoate,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mometasone furoate.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydrocortisone aceponate.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydrocortisone acetate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydrocortisone succinate.
Emapalumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bleselumab.
Natalizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daclizumab.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Daclizumab.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Daclizumab.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Daclizumab.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Daclizumab.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Daclizumab.
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Daclizumab.
Estrone,Estrone may increase the thrombogenic activities of Daclizumab.
Estradiol,Estradiol may increase the thrombogenic activities of Daclizumab.
Dienestrol,Dienestrol may increase the thrombogenic activities of Daclizumab.
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Daclizumab.
Mestranol,Mestranol may increase the thrombogenic activities of Daclizumab.
Estriol,Estriol may increase the thrombogenic activities of Daclizumab.
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Daclizumab.
Quinestrol,Quinestrol may increase the thrombogenic activities of Daclizumab.
Hexestrol,Hexestrol may increase the thrombogenic activities of Daclizumab.
Tibolone,Tibolone may increase the thrombogenic activities of Daclizumab.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Daclizumab."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Daclizumab."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Daclizumab.
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Daclizumab.
Zeranol,Zeranol may increase the thrombogenic activities of Daclizumab.
Equol,Equol may increase the thrombogenic activities of Daclizumab.
Promestriene,Promestriene may increase the thrombogenic activities of Daclizumab.
Methallenestril,Methallenestril may increase the thrombogenic activities of Daclizumab.
Epimestrol,Epimestrol may increase the thrombogenic activities of Daclizumab.
Moxestrol,Moxestrol may increase the thrombogenic activities of Daclizumab.
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Daclizumab.
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Daclizumab.
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Daclizumab.
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Daclizumab.
Biochanin A,Biochanin A may increase the thrombogenic activities of Daclizumab.
Formononetin,Formononetin may increase the thrombogenic activities of Daclizumab.
Leflunomide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Leflunomide.
Tofacitinib,Daclizumab may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Daclizumab.
Fingolimod,Daclizumab may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Daclizumab.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Daclizumab.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Daclizumab.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Daclizumab.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Daclizumab.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Daclizumab.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Daclizumab.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Daclizumab.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Daclizumab.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Daclizumab.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Daclizumab."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Daclizumab.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Daclizumab.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Daclizumab."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Daclizumab.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Daclizumab.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Daclizumab.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Daclizumab.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Daclizumab.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Daclizumab.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Daclizumab.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Daclizumab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Daclizumab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Daclizumab.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Daclizumab.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Daclizumab.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Daclizumab.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Daclizumab.
Ocrelizumab,Ocrelizumab may increase the immunosuppressive activities of Daclizumab.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Daclizumab.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Daclizumab.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Daclizumab.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Daclizumab.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Daclizumab.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Daclizumab.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Daclizumab.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Daclizumab.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Daclizumab.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Daclizumab.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Daclizumab.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Daclizumab.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Daclizumab.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Daclizumab.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Daclizumab.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Daclizumab.
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Daclizumab.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Daclizumab.
Capromab pendetide,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Daclizumab.
Palivizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Daclizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Technetium Tc-99m arcitumomab.
Panitumumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pexelizumab.
Epratuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Daclizumab is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Daclizumab is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Daclizumab is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Daclizumab is combined with NAV 1800.
Otelixizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Daclizumab is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Veltuzumab.
PRO-542,The risk or severity of adverse effects can be increased when Daclizumab is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Daclizumab is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Daclizumab is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Daclizumab is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Daclizumab is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Daclizumab is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Daclizumab is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Daclizumab is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lumiliximab.
Ipilimumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Clenoliximab.
BIIB015,The risk or severity of adverse effects can be increased when Daclizumab is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Daclizumab is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Daclizumab is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Catumaxomab.
Volociximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ofatumumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Raxibacumab.
Nivolumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nivolumab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dulaglutide.
Asfotase alfa,The risk or severity of adverse effects can be increased when Daclizumab is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Evolocumab.
Daratumumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Necitumumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Daclizumab is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Solanezumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tremelimumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lampalizumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Anifrolumab.
Benralizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Daclizumab is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Daclizumab is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Daclizumab is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Plozalizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Daclizumab is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Besilesomab.
Burosumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cemiplimab.
Camrelizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Refanezumab.
Bermekimab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Daclizumab is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nemolizumab.
Gedivumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Daclizumab is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Daclizumab is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Daclizumab is combined with Naratuximab emtansine.
Tildrakizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tildrakizumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ustekinumab.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Zenocutuzumab.
Cyclosporine,Daclizumab may increase the immunosuppressive activities of Cyclosporine.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Daclizumab."
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Daclizumab.
Lopinavir,The serum concentration of Daclizumab can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Daclizumab is combined with Inebilizumab.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Bevacizumab.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Bevacizumab.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bevacizumab.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bevacizumab.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Bevacizumab.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bevacizumab.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Bevacizumab.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Bevacizumab.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Bevacizumab."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bevacizumab.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Bevacizumab.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bevacizumab.
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bevacizumab.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Bevacizumab.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bevacizumab.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bevacizumab.
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Bevacizumab.
Basiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bevacizumab.
Muromonab,The risk or severity of adverse effects can be increased when Muromonab is combined with Bevacizumab.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bevacizumab.
Tositumomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bevacizumab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bevacizumab.
Alefacept,The risk or severity of adverse effects can be increased when Alefacept is combined with Bevacizumab.
Efalizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bevacizumab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bevacizumab.
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bevacizumab.
Daclizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bevacizumab.
Phenylalanine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Beclomethasone dipropionate.
Streptozocin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Altretamine.
Zidovudine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Zidovudine.
Cisplatin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pentostatin.
Methotrexate,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Methotrexate.
Carbamazepine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carbamazepine.
Vinblastine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Linezolid.
Imatinib,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Imatinib.
Triamcinolone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Paclitaxel.
Dexamethasone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dexamethasone.
Docetaxel,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Decitabine.
Nelarabine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nelarabine.
Abatacept,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Abatacept.
Corticotropin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Bevacizumab is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Bevacizumab is combined with omega interferon.
Apremilast,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Apremilast.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ponatinib.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Certolizumab pegol.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Blinatumomab.
Ibrutinib,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ibrutinib.
Idelalisib,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Idelalisib.
Palbociclib,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Palbociclib.
Olaparib,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Olaparib.
Dinutuximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dinutuximab.
Vilanterol,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vilanterol.
Tixocortol,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tixocortol.
Peginterferon beta-1a,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Bevacizumab is combined with Antilymphocyte immunoglobulin (horse).
Fluprednisolone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluprednisolone.
Meprednisone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Meprednisone.
Tepoxalin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tepoxalin.
Dexamethasone isonicotinate,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dexamethasone isonicotinate.
Melengestrol,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Melengestrol.
Ixekizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ravulizumab.
Pirarubicin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pirarubicin.
Voclosporin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Voclosporin.
Peficitinib,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Peficitinib.
Clobetasol,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Clobetasol.
Sarilumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sarilumab.
Brodalumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sirukumab.
Baricitinib,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Baricitinib.
Guselkumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Guselkumab.
Deflazacort,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Deflazacort.
Triptolide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Triptolide.
Siponimod,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Siponimod.
Ozanimod,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ozanimod.
Mizoribine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mizoribine.
Gusperimus,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gusperimus.
Cepeginterferon alfa-2B,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cepeginterferon alfa-2B.
Trofosfamide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trofosfamide.
Doxifluridine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Doxifluridine.
Deoxyspergualin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Deoxyspergualin.
Acteoside,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Acteoside.
Cortivazol,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cortivazol.
Hypericin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hypericin.
9-(N-methyl-L-isoleucine)-cyclosporin A,The risk or severity of adverse effects can be increased when Bevacizumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Prednylidene,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Prednylidene.
Fluocortin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluocortin.
Begelomab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Begelomab.
Fluperolone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluperolone.
Formocortal,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Formocortal.
Halometasone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Halometasone.
Cloprednol,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cloprednol.
Fluclorolone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluclorolone.
Fluticasone,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluticasone.
Tetrandrine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tetrandrine.
Monomethyl fumarate,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Monomethyl fumarate.
Mometasone furoate,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mometasone furoate.
Hydrocortisone aceponate,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hydrocortisone aceponate.
Hydrocortisone acetate,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hydrocortisone acetate.
Hydrocortisone succinate,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hydrocortisone succinate.
Emapalumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Risankizumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rozanolixizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bleselumab.
Natalizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Natalizumab.
Pimecrolimus,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bevacizumab.
Roflumilast,Roflumilast may increase the immunosuppressive activities of Bevacizumab.
Sipuleucel-T,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Bevacizumab.
Darbepoetin alfa,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bevacizumab.
Erythropoietin,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bevacizumab.
Peginesatide,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Bevacizumab.
Methoxy polyethylene glycol-epoetin beta,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bevacizumab.
Sorafenib,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sorafenib.
Sunitinib,The risk or severity of adverse effects can be increased when Sunitinib is combined with Bevacizumab.
Sulfamethoxazole,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Bevacizumab.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Bevacizumab.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Bevacizumab.
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Bevacizumab.
Estrone,Estrone may increase the thrombogenic activities of Bevacizumab.
Estradiol,Estradiol may increase the thrombogenic activities of Bevacizumab.
Dienestrol,Dienestrol may increase the thrombogenic activities of Bevacizumab.
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Bevacizumab.
Mestranol,Mestranol may increase the thrombogenic activities of Bevacizumab.
Estriol,Estriol may increase the thrombogenic activities of Bevacizumab.
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Bevacizumab.
Quinestrol,Quinestrol may increase the thrombogenic activities of Bevacizumab.
Hexestrol,Hexestrol may increase the thrombogenic activities of Bevacizumab.
Tibolone,Tibolone may increase the thrombogenic activities of Bevacizumab.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Bevacizumab."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bevacizumab."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Bevacizumab.
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Bevacizumab.
Zeranol,Zeranol may increase the thrombogenic activities of Bevacizumab.
Equol,Equol may increase the thrombogenic activities of Bevacizumab.
Promestriene,Promestriene may increase the thrombogenic activities of Bevacizumab.
Methallenestril,Methallenestril may increase the thrombogenic activities of Bevacizumab.
Epimestrol,Epimestrol may increase the thrombogenic activities of Bevacizumab.
Moxestrol,Moxestrol may increase the thrombogenic activities of Bevacizumab.
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Bevacizumab.
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Bevacizumab.
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Bevacizumab.
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Bevacizumab.
Biochanin A,Biochanin A may increase the thrombogenic activities of Bevacizumab.
Formononetin,Formononetin may increase the thrombogenic activities of Bevacizumab.
Leflunomide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Leflunomide.
Tofacitinib,Bevacizumab may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab,Trastuzumab may increase the neutropenic activities of Bevacizumab.
Fingolimod,Bevacizumab may increase the immunosuppressive activities of Fingolimod.
Tacrolimus,Tacrolimus may increase the immunosuppressive activities of Bevacizumab.
Pamidronic acid,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Pamidronic acid.
Zoledronic acid,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Zoledronic acid.
Alendronic acid,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Alendronic acid.
Ibandronate,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Ibandronate.
Clodronic acid,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Clodronic acid.
Risedronic acid,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Risedronic acid.
Etidronic acid,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Etidronic acid.
Tiludronic acid,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Tiludronic acid.
Incadronic acid,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Incadronic acid.
Digoxin,Digoxin may decrease the cardiotoxic activities of Bevacizumab.
Acetyldigitoxin,Acetyldigitoxin may decrease the cardiotoxic activities of Bevacizumab.
Deslanoside,Deslanoside may decrease the cardiotoxic activities of Bevacizumab.
Ouabain,Ouabain may decrease the cardiotoxic activities of Bevacizumab.
Digitoxin,Digitoxin may decrease the cardiotoxic activities of Bevacizumab.
Oleandrin,Oleandrin may decrease the cardiotoxic activities of Bevacizumab.
Cymarin,Cymarin may decrease the cardiotoxic activities of Bevacizumab.
Proscillaridin,Proscillaridin may decrease the cardiotoxic activities of Bevacizumab.
Metildigoxin,Metildigoxin may decrease the cardiotoxic activities of Bevacizumab.
Lanatoside C,Lanatoside C may decrease the cardiotoxic activities of Bevacizumab.
Gitoformate,Gitoformate may decrease the cardiotoxic activities of Bevacizumab.
Acetyldigoxin,Acetyldigoxin may decrease the cardiotoxic activities of Bevacizumab.
Peruvoside,Peruvoside may decrease the cardiotoxic activities of Bevacizumab.
Tamoxifen,The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Tamoxifen.
Anastrozole,The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Anastrozole.
Aldoxorubicin,The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Aldoxorubicin.
Paclitaxel trevatide,The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel trevatide.
Paclitaxel poliglumex,The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel poliglumex.
G17DT,The therapeutic efficacy of G17DT can be decreased when used in combination with Bevacizumab.
PEV3A,The therapeutic efficacy of PEV3A can be decreased when used in combination with Bevacizumab.
INGN 225,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Bevacizumab.
Rindopepimut,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Bevacizumab.
SRP 299,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Bevacizumab.
GI-5005,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Bevacizumab.
Vitespen,The therapeutic efficacy of Vitespen can be decreased when used in combination with Bevacizumab.
TG4010,The therapeutic efficacy of TG4010 can be decreased when used in combination with Bevacizumab.
Anthrax immune globulin human,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bevacizumab.
"Rabies virus inactivated antigen, B","The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Bevacizumab."
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Bevacizumab.
Rotavirus vaccine,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Bevacizumab.
"Rabies virus inactivated antigen, A","The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bevacizumab."
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Bevacizumab.
Clostridium tetani toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.
Typhoid Vi polysaccharide vaccine,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Bevacizumab.
Hepatitis A Vaccine,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bevacizumab.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Bevacizumab.
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.
Human rabies virus immune globulin,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bevacizumab.
Hepatitis B Vaccine (Recombinant),The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bevacizumab.
Tecemotide,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Bevacizumab.
Typhoid vaccine,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Bevacizumab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Bevacizumab.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Bevacizumab.
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.
Vaccinia virus strain new york city board of health live antigen,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Bevacizumab.
Pertussis vaccine,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Bevacizumab.
Yersinia pestis 195/p antigen (formaldehyde inactivated),The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.
Varicella Zoster Vaccine (Recombinant),The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Bevacizumab.
Modified vaccinia ankara,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Bevacizumab.
Ocrelizumab,Ocrelizumab may increase the immunosuppressive activities of Bevacizumab.
Rubella virus vaccine,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Bevacizumab.
Varicella Zoster Vaccine (Live/attenuated),The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Bevacizumab.
Bacillus calmette-guerin substrain tice live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Bevacizumab.
Bacillus calmette-guerin substrain connaught live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Bevacizumab.
Yellow Fever Vaccine,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Bevacizumab.
Anthrax vaccine,The risk or severity of infection can be increased when Anthrax vaccine is combined with Bevacizumab.
Typhoid Vaccine Live,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Bevacizumab.
Bacillus calmette-guerin substrain danish 1331 live antigen,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Bevacizumab.
BCG vaccine,The risk or severity of infection can be increased when BCG vaccine is combined with Bevacizumab.
Human adenovirus e serotype 4 strain cl-68578 antigen,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Bevacizumab.
Vibrio cholerae CVD 103-HgR strain live antigen,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Bevacizumab.
Adenovirus type 7 vaccine live,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Bevacizumab.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Bevacizumab.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bevacizumab.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Bevacizumab.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Bevacizumab.
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bevacizumab.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bevacizumab.
Capromab pendetide,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bevacizumab.
Palivizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bevacizumab.
Technetium Tc-99m arcitumomab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Technetium Tc-99m arcitumomab.
Panitumumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pexelizumab.
Epratuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Bevacizumab is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Bevacizumab is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Bevacizumab is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Bevacizumab is combined with NAV 1800.
Otelixizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Bevacizumab is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Veltuzumab.
PRO-542,The risk or severity of adverse effects can be increased when Bevacizumab is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Bevacizumab is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Bevacizumab is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Bevacizumab is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Bevacizumab is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Bevacizumab is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Bevacizumab is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Bevacizumab is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lumiliximab.
Ipilimumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Clenoliximab.
BIIB015,The risk or severity of adverse effects can be increased when Bevacizumab is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Bevacizumab is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Bevacizumab is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Catumaxomab.
Volociximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ofatumumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Raxibacumab.
Nivolumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nivolumab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dulaglutide.
Asfotase alfa,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Evolocumab.
Daratumumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Necitumumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Solanezumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tremelimumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lampalizumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Anifrolumab.
Benralizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Bevacizumab is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Plozalizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Besilesomab.
Burosumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cemiplimab.
Camrelizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Refanezumab.
Bermekimab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nemolizumab.
Gedivumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Bevacizumab is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Naratuximab emtansine.
Tildrakizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tildrakizumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ustekinumab.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Zenocutuzumab.
Cyclosporine,Bevacizumab may increase the immunosuppressive activities of Cyclosporine.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Bevacizumab."
Magnesium,The serum concentration of Magnesium can be decreased when it is combined with Bevacizumab.
Lopinavir,The serum concentration of Bevacizumab can be increased when it is combined with Lopinavir.
Inebilizumab,The risk or severity of infection can be increased when Bevacizumab is combined with Inebilizumab.
Diethylstilbestrol,Diethylstilbestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Chlorotrianisene,Chlorotrianisene may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Conjugated estrogens,Conjugated estrogens may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Estrone,Estrone may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Estradiol,Estradiol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Dienestrol,Dienestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Ethinylestradiol,Ethinylestradiol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Mestranol,Mestranol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Estriol,Estriol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Estrone sulfate,Estrone sulfate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Quinestrol,Quinestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Hexestrol,Hexestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Tibolone,Tibolone may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
"Synthetic Conjugated Estrogens, A","Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Technetium Tc-99m arcitumomab."
"Synthetic Conjugated Estrogens, B","Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Technetium Tc-99m arcitumomab."
Polyestradiol phosphate,Polyestradiol phosphate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Esterified estrogens,Esterified estrogens may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Zeranol,Zeranol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Equol,Equol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Promestriene,Promestriene may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Methallenestril,Methallenestril may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Epimestrol,Epimestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Moxestrol,Moxestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Estradiol acetate,Estradiol acetate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Estradiol benzoate,Estradiol benzoate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Estradiol cypionate,Estradiol cypionate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Estradiol valerate,Estradiol valerate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Biochanin A,Biochanin A may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Formononetin,Formononetin may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Cetuximab,The risk or severity of adverse effects can be increased when Cetuximab is combined with Technetium Tc-99m arcitumomab.
Human immunoglobulin G,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Technetium Tc-99m arcitumomab.
Omalizumab,The risk or severity of adverse effects can be increased when Omalizumab is combined with Technetium Tc-99m arcitumomab.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Technetium Tc-99m arcitumomab.
Abciximab,The risk or severity of adverse effects can be increased when Abciximab is combined with Technetium Tc-99m arcitumomab.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Technetium Tc-99m arcitumomab.
Indium In-111 satumomab pendetide,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Technetium Tc-99m arcitumomab.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Technetium Tc-99m arcitumomab.
Trastuzumab,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Technetium Tc-99m arcitumomab.
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Technetium Tc-99m arcitumomab.
Basiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Technetium Tc-99m arcitumomab.
Muromonab,The risk or severity of adverse effects can be increased when Muromonab is combined with Technetium Tc-99m arcitumomab.
Digoxin Immune Fab (Ovine),The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Technetium Tc-99m arcitumomab.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Technetium Tc-99m arcitumomab.
Tositumomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Technetium Tc-99m arcitumomab.
Alemtuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Technetium Tc-99m arcitumomab.
Capromab pendetide,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Technetium Tc-99m arcitumomab.
Efalizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Technetium Tc-99m arcitumomab.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Technetium Tc-99m arcitumomab.
Natalizumab,The risk or severity of adverse effects can be increased when Natalizumab is combined with Technetium Tc-99m arcitumomab.
Palivizumab,The risk or severity of adverse effects can be increased when Palivizumab is combined with Technetium Tc-99m arcitumomab.
Daclizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Technetium Tc-99m arcitumomab.
Bevacizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Technetium Tc-99m arcitumomab.
Eculizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eculizumab.
Panitumumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Panitumumab.
Ranibizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ranibizumab.
Galiximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Galiximab.
Pexelizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pexelizumab.
Afelimomab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Afelimomab.
Epratuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Epratuzumab.
Bectumomab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bectumomab.
Oregovomab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Oregovomab.
IGN311,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with IGN311.
Adecatumumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Adecatumumab.
Labetuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Labetuzumab.
Matuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Matuzumab.
Fontolizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fontolizumab.
Bavituximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bavituximab.
CR002,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with CR002.
Rozrolimupab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rozrolimupab.
Girentuximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Girentuximab.
Obiltoxaximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Obiltoxaximab.
XTL-001,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with XTL-001.
NAV 1800,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with NAV 1800.
Briakinumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Briakinumab.
Otelixizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Otelixizumab.
AMG 108,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with AMG 108.
Iratumumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Iratumumab.
Enokizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Enokizumab.
Ramucirumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ramucirumab.
Farletuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Farletuzumab.
Veltuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Veltuzumab.
Ustekinumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ustekinumab.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Trastuzumab emtansine.
PRO-542,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with PRO-542.
TNX-901,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with TNX-901.
Inotuzumab ozogamicin,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Inotuzumab ozogamicin.
RI 624,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with RI 624.
MYO-029,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with MYO-029.
CT-011,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with CT-011.
Leronlimab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Leronlimab.
Glembatumumab vedotin,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Glembatumumab vedotin.
Olaratumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Olaratumab.
IPH 2101,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with IPH 2101.
TB-402,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with TB-402.
Caplacizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Caplacizumab.
IMC-1C11,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with IMC-1C11.
Eldelumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eldelumab.
Lumiliximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lumiliximab.
Canakinumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Canakinumab.
Ipilimumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ipilimumab.
Nimotuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Nimotuzumab.
Clenoliximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Clenoliximab.
Tocilizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tocilizumab.
BIIB015,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with BIIB015.
Sonepcizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sonepcizumab.
Motavizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Motavizumab.
Elotuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Elotuzumab.
AVE9633,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with AVE9633.
Carotuximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Carotuximab.
XmAb 2513,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with XmAb 2513.
Coltuximab ravtansine,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Coltuximab ravtansine.
Teprotumumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Teprotumumab.
Lucatumumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lucatumumab.
Pertuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pertuzumab.
Siplizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Siplizumab.
Apolizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Apolizumab.
Sibrotuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sibrotuzumab.
Bivatuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bivatuzumab.
Lerdelimumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lerdelimumab.
Lexatumumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lexatumumab.
Reslizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Reslizumab.
Teplizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Teplizumab.
Catumaxomab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Catumaxomab.
Mepolizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Mepolizumab.
Denosumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Denosumab.
Volociximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Volociximab.
Ofatumumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ofatumumab.
Golimumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Golimumab.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Brentuximab vedotin.
Belimumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Belimumab.
Raxibacumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Raxibacumab.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Certolizumab pegol.
Obinutuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Obinutuzumab.
Secukinumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vedolizumab.
Nivolumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Nivolumab.
Siltuximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Siltuximab.
Pembrolizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pembrolizumab.
Dulaglutide,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dulaglutide.
Blinatumomab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Blinatumomab.
Anthrax immune globulin human,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Anthrax immune globulin human.
Dinutuximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dinutuximab.
Asfotase alfa,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Asfotase alfa.
Idarucizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Idarucizumab.
Alirocumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Alirocumab.
Evolocumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Evolocumab.
Antilymphocyte immunoglobulin (horse),The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Antilymphocyte immunoglobulin (horse).
Daratumumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Daratumumab.
Necitumumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Necitumumab.
Ixekizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ixekizumab.
Ravulizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ravulizumab.
Atezolizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Atezolizumab.
Tetanus Immune Globulin,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tetanus Immune Globulin.
Eftrenonacog alfa,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eftrenonacog alfa.
Human Varicella-Zoster Immune Globulin,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Human Varicella-Zoster Immune Globulin.
Conatumumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Conatumumab.
Tabalumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tabalumab.
Ficlatuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ficlatuzumab.
Figitumumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Figitumumab.
Durvalumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Durvalumab.
Bapineuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bapineuzumab.
Depatuxizumab mafodotin,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Depatuxizumab mafodotin.
Onartuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Onartuzumab.
Solanezumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Solanezumab.
Sarilumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sarilumab.
Tremelimumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tremelimumab.
Brodalumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Brodalumab.
Sirukumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sirukumab.
Lampalizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lampalizumab.
Guselkumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Guselkumab.
Dalotuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dalotuzumab.
Emibetuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Emibetuzumab.
Ublituximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ublituximab.
Ligelizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ligelizumab.
Seribantumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Seribantumab.
Landogrozumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Landogrozumab.
Romosozumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Romosozumab.
Vadastuximab Talirine,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vadastuximab Talirine.
Lebrikizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lebrikizumab.
Varlilumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Varlilumab.
Avelumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Avelumab.
Crenezumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Crenezumab.
Rilotumumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rilotumumab.
Anifrolumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Anifrolumab.
Ocrelizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ocrelizumab.
Benralizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Benralizumab.
Gantenerumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gantenerumab.
Visilizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Visilizumab.
Urelumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Urelumab.
Lorvotuzumab mertansine,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lorvotuzumab mertansine.
Patritumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Patritumab.
Fulranumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fulranumab.
Tarextumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tarextumab.
Sotatercept,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sotatercept.
Gevokizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gevokizumab.
Duligotuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Duligotuzumab.
Simtuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Simtuzumab.
Fasinumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fasinumab.
Dupilumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dupilumab.
Tralokinumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tralokinumab.
Etrolizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Etrolizumab.
Zalutumumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Zalutumumab.
Ganitumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ganitumab.
Etaracizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Etaracizumab.
Polatuzumab vedotin,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Polatuzumab vedotin.
Inclacumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Inclacumab.
Cixutumumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Cixutumumab.
Ascrinvacumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ascrinvacumab.
Aducanumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Aducanumab.
Luspatercept,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Luspatercept.
GS-5745,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with GS-5745.
Vanucizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vanucizumab.
Labetuzumab govitecan,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Labetuzumab govitecan.
Tanezumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tanezumab.
Ensituximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ensituximab.
Fezakinumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fezakinumab.
Dusigitumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dusigitumab.
Fresolimumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fresolimumab.
Indusatumab vedotin,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Indusatumab vedotin.
Bococizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bococizumab.
Mirvetuximab Soravtansine,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Mirvetuximab Soravtansine.
Mogamulizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Mogamulizumab.
Plozalizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Plozalizumab.
Inebilizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Inebilizumab.
Mavrilimumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Mavrilimumab.
Blosozumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Blosozumab.
Bimagrumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bimagrumab.
Dacetuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dacetuzumab.
Tovetumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tovetumab.
Lumretuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lumretuzumab.
Ibalizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ibalizumab.
Intetumumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Intetumumab.
Carlumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Carlumab.
Demcizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Demcizumab.
Sifalimumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sifalimumab.
Abituzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Abituzumab.
Ecromeximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ecromeximab.
Naptumomab Estafenatox,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Naptumomab Estafenatox.
Crotedumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Crotedumab.
Concizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Concizumab.
Depatuxizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Depatuxizumab.
Rontalizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rontalizumab.
Amatuximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Amatuximab.
Clazakizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Clazakizumab.
Ozanezumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ozanezumab.
Sacituzumab govitecan,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sacituzumab govitecan.
Bimekizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bimekizumab.
Milatuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Milatuzumab.
Robatumumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Robatumumab.
Rovalpituzumab Tesirine,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rovalpituzumab Tesirine.
Namilumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Namilumab.
Racotumomab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Racotumomab.
Tregalizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tregalizumab.
Olokizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Olokizumab.
Bezlotoxumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bezlotoxumab.
Edrecolomab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Edrecolomab.
Nebacumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Nebacumab.
Human cytomegalovirus immune globulin,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Human cytomegalovirus immune globulin.
Emicizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Emicizumab.
Sulesomab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sulesomab.
Besilesomab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Besilesomab.
Tildrakizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tildrakizumab.
Burosumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Burosumab.
Erenumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Erenumab.
Eptinezumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eptinezumab.
Fremanezumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fremanezumab.
Galcanezumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Galcanezumab.
Fanolesomab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fanolesomab.
Lecanemab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lecanemab.
Lanadelumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lanadelumab.
Cemiplimab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Cemiplimab.
Emapalumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Emapalumab.
Risankizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Risankizumab.
Camrelizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Camrelizumab.
Setrusumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Setrusumab.
Gancotamab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gancotamab.
Anetumab ravtansine,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Anetumab ravtansine.
Isatuximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Isatuximab.
Icrucumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Icrucumab.
Codrituzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Codrituzumab.
Brolucizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Brolucizumab.
Xentuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Xentuzumab.
Lintuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lintuzumab.
Vobarilizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vobarilizumab.
Parsatuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Parsatuzumab.
Emactuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Emactuzumab.
Bevacizumab zirconium Zr-89,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bevacizumab zirconium Zr-89.
Refanezumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Refanezumab.
Rozanolixizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rozanolixizumab.
Bermekimab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bermekimab.
Pamrevlumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pamrevlumab.
Opicinumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Opicinumab.
Trastuzumab deruxtecan,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Trastuzumab deruxtecan.
Margetuximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Margetuximab.
Dalantercept,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dalantercept.
Pateclizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pateclizumab.
Gremubamab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gremubamab.
Apomab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Apomab.
Tafasitamab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tafasitamab.
Ipafricept,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ipafricept.
Abrilumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Abrilumab.
Frovocimab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Frovocimab.
Tezepelumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tezepelumab.
Tigatuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tigatuzumab.
Telisotuzumab vedotin,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Telisotuzumab vedotin.
Utomilumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Utomilumab.
Zolbetuximab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Zolbetuximab.
Ponezumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ponezumab.
Asunercept,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Asunercept.
Suvratoxumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Suvratoxumab.
Mitazalimab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Mitazalimab.
Nemolizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Nemolizumab.
Bleselumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bleselumab.
Gedivumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gedivumab.
Valanafusp alfa,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Valanafusp alfa.
Sofituzumab vedotin,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sofituzumab vedotin.
Evinacumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Evinacumab.
Istiratumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Istiratumab.
Pidilizumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pidilizumab.
GMA-161,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with GMA-161.
Ladiratuzumab vedotin,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ladiratuzumab vedotin.
Tomaralimab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tomaralimab.
Vesencumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vesencumab.
Pinatuzumab vedotin,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pinatuzumab vedotin.
Lulizumab pegol,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lulizumab pegol.
Lorukafusp alfa,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lorukafusp alfa.
Naratuximab emtansine,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Naratuximab emtansine.
Zenocutuzumab,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Zenocutuzumab.
"Ebola Zaire vaccine (live, attenuated)","The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Technetium Tc-99m arcitumomab."
Chloramphenicol,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Chloramphenicol.
Colchicine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Colchicine.
Cyclosporine,Cyclosporine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefotiam,Cefotiam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Mesalazine,Mesalazine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefmenoxime,Cefmenoxime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefmetazole,Cefmetazole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Pamidronic acid,Pamidronic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Tenofovir disoproxil,Tenofovir disoproxil may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cidofovir,Cidofovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Triamterene,Triamterene may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefpiramide,Cefpiramide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Ceftazidime,Ceftazidime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Loracarbef,Loracarbef may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefalotin,Cefalotin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Nabumetone,Nabumetone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Ketorolac,Ketorolac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Tenoxicam,Tenoxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Celecoxib,Celecoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefotaxime,Cefotaxime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Tolmetin,Tolmetin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Foscarnet,Foscarnet may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Rofecoxib,Rofecoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Piroxicam,Piroxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cephalexin,Cephalexin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Fenoprofen,Fenoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Valaciclovir,Valaciclovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Valdecoxib,Valdecoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Diclofenac,Diclofenac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Sulindac,Sulindac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Bacitracin,Bacitracin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Amphotericin B,Amphotericin B may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cephaloglycin,Cephaloglycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Flurbiprofen,Flurbiprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Adefovir dipivoxil,Adefovir dipivoxil may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Pentamidine,Pentamidine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Mannitol,Mannitol may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Etodolac,Etodolac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Mefenamic acid,Mefenamic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Acyclovir,Acyclovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Naproxen,Naproxen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Sulfasalazine,Sulfasalazine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Phenylbutazone,Phenylbutazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Meloxicam,Meloxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Carprofen,Carprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefaclor,Cefaclor may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Diflunisal,Diflunisal may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Etacrynic acid,Etacrynic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Ceforanide,Ceforanide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Salicylic acid,Salicylic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Meclofenamic acid,Meclofenamic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Acetylsalicylic acid,Acetylsalicylic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Oxaprozin,Oxaprozin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Hydrochlorothiazide,Hydrochlorothiazide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Ketoprofen,Ketoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Balsalazide,Balsalazide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Ibuprofen,Ibuprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefditoren,Cefditoren may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Atazanavir,Atazanavir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Colistimethate,Colistimethate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefuroxime,Cefuroxime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefapirin,Cefapirin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefadroxil,Cefadroxil may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefprozil,Cefprozil may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Ceftriaxone,Ceftriaxone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Olsalazine,Olsalazine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Lumiracoxib,Lumiracoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefamandole,Cefamandole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefazolin,Cefazolin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefonicid,Cefonicid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefoperazone,Cefoperazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefotetan,Cefotetan may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefoxitin,Cefoxitin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Ceftizoxime,Ceftizoxime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefradine,Cefradine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Magnesium salicylate,Magnesium salicylate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Salsalate,Salsalate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Choline magnesium trisalicylate,Choline magnesium trisalicylate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefepime,Cefepime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefacetrile,Cefacetrile may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Ceftibuten,Ceftibuten may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefpodoxime,Cefpodoxime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Antrafenine,Antrafenine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Aminophenazone,Aminophenazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Antipyrine,Antipyrine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Tiaprofenic acid,Tiaprofenic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Lopinavir,Lopinavir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Etoricoxib,Etoricoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Hydrolyzed Cephalothin,Hydrolyzed Cephalothin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cephalothin Group,Cephalothin Group may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Oxyphenbutazone,Oxyphenbutazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Niflumic acid,Niflumic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Latamoxef,Latamoxef may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Nimesulide,Nimesulide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Benoxaprofen,Benoxaprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Metamizole,Metamizole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Zomepirac,Zomepirac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Ceftobiprole,Ceftobiprole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cimicoxib,Cimicoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Ceftaroline fosamil,Ceftaroline fosamil may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Lornoxicam,Lornoxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Aceclofenac,Aceclofenac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Zaltoprofen,Zaltoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Azapropazone,Azapropazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Felbinac,Felbinac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Parecoxib,Parecoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Salicylamide,Salicylamide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Kebuzone,Kebuzone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Isoxicam,Isoxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Indoprofen,Indoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Ibuproxam,Ibuproxam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Floctafenine,Floctafenine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Fenbufen,Fenbufen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Etofenamate,Etofenamate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Epirizole,Epirizole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefaloridine,Cefaloridine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefminox,Cefminox may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Benzydamine,Benzydamine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Loxoprofen,Loxoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Dexibuprofen,Dexibuprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Dexketoprofen,Dexketoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Droxicam,Droxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Tolfenamic acid,Tolfenamic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Firocoxib,Firocoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Clonixin,Clonixin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Morniflumate,Morniflumate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Propacetamol,Propacetamol may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Talniflumate,Talniflumate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Tenofovir alafenamide,Tenofovir alafenamide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefroxadine,Cefroxadine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Robenacoxib,Robenacoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Tepoxalin,Tepoxalin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Flunixin,Flunixin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Flomoxef,Flomoxef may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Brincidofovir,Brincidofovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Nitroaspirin,Nitroaspirin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Indobufen,Indobufen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Tinoridine,Tinoridine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Alclofenac,Alclofenac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Fentiazac,Fentiazac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Suxibuzone,Suxibuzone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefatrizine,Cefatrizine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Bumadizone,Bumadizone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Alminoprofen,Alminoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Flunoxaprofen,Flunoxaprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Feprazone,Feprazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Difenpiramide,Difenpiramide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Nifenazone,Nifenazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Lonazolac,Lonazolac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefcapene,Cefcapene may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefodizime,Cefodizime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Tenidap,Tenidap may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefsulodin,Cefsulodin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Bendazac,Bendazac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefetamet,Cefetamet may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Pranoprofen,Pranoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Propyphenazone,Propyphenazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Proglumetacin,Proglumetacin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Guacetisal,Guacetisal may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Ethenzamide,Ethenzamide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Carbaspirin calcium,Carbaspirin calcium may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Mofebutazone,Mofebutazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefbuperazone,Cefbuperazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Proquazone,Proquazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Benorilate,Benorilate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefozopran,Cefozopran may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefpirome,Cefpirome may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Pirprofen,Pirprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cefazedone,Cefazedone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Acemetacin,Acemetacin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Ceftezole,Ceftezole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Imidazole salicylate,Imidazole salicylate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Adefovir,Adefovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
SC-236,SC-236 may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
NS-398,NS-398 may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Tenofovir,Tenofovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Inotersen,Inotersen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Phenazopyridine,Phenazopyridine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Givosiran,Givosiran may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Lithium cation,Lithium cation may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Lithium citrate,Lithium citrate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cimetidine,Cimetidine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Leuprolide,Leuprolide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Goserelin,Goserelin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Salmon calcitonin,Salmon calcitonin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Desmopressin,Desmopressin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Daptomycin,Daptomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Fluvoxamine,Cyanocobalamin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.
Baclofen,Cyanocobalamin may decrease the excretion rate of Baclofen which could result in a higher serum level.
Amphetamine,Cyanocobalamin may decrease the excretion rate of Amphetamine which could result in a higher serum level.
Cevimeline,Cyanocobalamin may decrease the excretion rate of Cevimeline which could result in a higher serum level.
Lorazepam,Cyanocobalamin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
Carbidopa,Cyanocobalamin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
Tramadol,Cyanocobalamin may decrease the excretion rate of Tramadol which could result in a higher serum level.
Fluconazole,Cyanocobalamin may decrease the excretion rate of Fluconazole which could result in a higher serum level.
Oseltamivir,Cyanocobalamin may decrease the excretion rate of Oseltamivir which could result in a higher serum level.
Hydroxocobalamin,Cyanocobalamin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.
Reserpine,Cyanocobalamin may decrease the excretion rate of Reserpine which could result in a higher serum level.
Ticlopidine,Cyanocobalamin may decrease the excretion rate of Ticlopidine which could result in a higher serum level.
Pantoprazole,Cyanocobalamin may decrease the excretion rate of Pantoprazole which could result in a higher serum level.
Gadodiamide,Cyanocobalamin may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
Pregabalin,Cyanocobalamin may decrease the excretion rate of Pregabalin which could result in a higher serum level.
Temazepam,Cyanocobalamin may decrease the excretion rate of Temazepam which could result in a higher serum level.
Milrinone,Cyanocobalamin may decrease the excretion rate of Milrinone which could result in a higher serum level.
Butabarbital,Cyanocobalamin may decrease the excretion rate of Butabarbital which could result in a higher serum level.
Ranolazine,Cyanocobalamin may decrease the excretion rate of Ranolazine which could result in a higher serum level.
Benzatropine,Cyanocobalamin may decrease the excretion rate of Benzatropine which could result in a higher serum level.
Doxycycline,Cyanocobalamin may decrease the excretion rate of Doxycycline which could result in a higher serum level.
Metoprolol,Cyanocobalamin may decrease the excretion rate of Metoprolol which could result in a higher serum level.
Isradipine,Cyanocobalamin may decrease the excretion rate of Isradipine which could result in a higher serum level.
Diatrizoate,Cyanocobalamin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.
Topiramate,Cyanocobalamin may decrease the excretion rate of Topiramate which could result in a higher serum level.
Liothyronine,Cyanocobalamin may decrease the excretion rate of Liothyronine which could result in a higher serum level.
Disopyramide,Cyanocobalamin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Acarbose,Cyanocobalamin may decrease the excretion rate of Acarbose which could result in a higher serum level.
Venlafaxine,Cyanocobalamin may decrease the excretion rate of Venlafaxine which could result in a higher serum level.
Conjugated estrogens,Cyanocobalamin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
Atomoxetine,Cyanocobalamin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.
Bleomycin,Cyanocobalamin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Etomidate,Cyanocobalamin may decrease the excretion rate of Etomidate which could result in a higher serum level.
Etonogestrel,Cyanocobalamin may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
Ropivacaine,Cyanocobalamin may decrease the excretion rate of Ropivacaine which could result in a higher serum level.
Ertapenem,Cyanocobalamin may decrease the excretion rate of Ertapenem which could result in a higher serum level.
Ibutilide,Cyanocobalamin may decrease the excretion rate of Ibutilide which could result in a higher serum level.
Pentobarbital,Cyanocobalamin may decrease the excretion rate of Pentobarbital which could result in a higher serum level.
Acetaminophen,Cyanocobalamin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Piperacillin,Cyanocobalamin may decrease the excretion rate of Piperacillin which could result in a higher serum level.
Tolcapone,Cyanocobalamin may decrease the excretion rate of Tolcapone which could result in a higher serum level.
Nitroprusside,Cyanocobalamin may decrease the excretion rate of Nitroprusside which could result in a higher serum level.
Hydromorphone,Cyanocobalamin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.
Ethambutol,Cyanocobalamin may decrease the excretion rate of Ethambutol which could result in a higher serum level.
Metformin,Cyanocobalamin may decrease the excretion rate of Metformin which could result in a higher serum level.
Methadone,Cyanocobalamin may decrease the excretion rate of Methadone which could result in a higher serum level.
Pyrazinamide,Cyanocobalamin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
Cetirizine,Cyanocobalamin may decrease the excretion rate of Cetirizine which could result in a higher serum level.
Clobazam,Cyanocobalamin may decrease the excretion rate of Clobazam which could result in a higher serum level.
Megestrol acetate,Cyanocobalamin may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.
Aztreonam,Cyanocobalamin may decrease the excretion rate of Aztreonam which could result in a higher serum level.
Chlorzoxazone,Cyanocobalamin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.
Sulfadiazine,Cyanocobalamin may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.
Clozapine,Cyanocobalamin may decrease the excretion rate of Clozapine which could result in a higher serum level.
Sucralfate,Cyanocobalamin may decrease the excretion rate of Sucralfate which could result in a higher serum level.
Thiethylperazine,Cyanocobalamin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.
Timolol,Cyanocobalamin may decrease the excretion rate of Timolol which could result in a higher serum level.
Palonosetron,Cyanocobalamin may decrease the excretion rate of Palonosetron which could result in a higher serum level.
Nisoldipine,Cyanocobalamin may decrease the excretion rate of Nisoldipine which could result in a higher serum level.
Eszopiclone,Cyanocobalamin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.
Alprazolam,Cyanocobalamin may decrease the excretion rate of Alprazolam which could result in a higher serum level.
Rosiglitazone,Cyanocobalamin may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.
Pramipexole,Cyanocobalamin may decrease the excretion rate of Pramipexole which could result in a higher serum level.
Ampicillin,Cyanocobalamin may decrease the excretion rate of Ampicillin which could result in a higher serum level.
Secobarbital,Cyanocobalamin may decrease the excretion rate of Secobarbital which could result in a higher serum level.
Methylphenidate,Cyanocobalamin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Trifluridine,Cyanocobalamin may decrease the excretion rate of Trifluridine which could result in a higher serum level.
Nitric Oxide,Cyanocobalamin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
Allopurinol,Cyanocobalamin may decrease the excretion rate of Allopurinol which could result in a higher serum level.
Trimethoprim,Cyanocobalamin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
Duloxetine,Cyanocobalamin may decrease the excretion rate of Duloxetine which could result in a higher serum level.
Chlorpromazine,Cyanocobalamin may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.
Buspirone,Cyanocobalamin may decrease the excretion rate of Buspirone which could result in a higher serum level.
Fosinopril,Cyanocobalamin may decrease the excretion rate of Fosinopril which could result in a higher serum level.
Flutamide,Cyanocobalamin may decrease the excretion rate of Flutamide which could result in a higher serum level.
Haloperidol,Cyanocobalamin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cefdinir,Cyanocobalamin may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Ciprofloxacin,Cyanocobalamin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.
Azelaic acid,Cyanocobalamin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
Methoxsalen,Cyanocobalamin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
Lamotrigine,Cyanocobalamin may decrease the excretion rate of Lamotrigine which could result in a higher serum level.
Zanamivir,Cyanocobalamin may decrease the excretion rate of Zanamivir which could result in a higher serum level.
Fondaparinux,Cyanocobalamin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Propranolol,Cyanocobalamin may decrease the excretion rate of Propranolol which could result in a higher serum level.
Levocarnitine,Cyanocobalamin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
Fluocinolone acetonide,Cyanocobalamin may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.
Gadoteridol,Cyanocobalamin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
Labetalol,Cyanocobalamin may decrease the excretion rate of Labetalol which could result in a higher serum level.
Medroxyprogesterone acetate,Cyanocobalamin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.
Chloroquine,Cyanocobalamin may decrease the excretion rate of Chloroquine which could result in a higher serum level.
Bisoprolol,Cyanocobalamin may decrease the excretion rate of Bisoprolol which could result in a higher serum level.
Testosterone,Cyanocobalamin may decrease the excretion rate of Testosterone which could result in a higher serum level.
Clorazepic acid,Cyanocobalamin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
Dexmedetomidine,Cyanocobalamin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
Prednisone,Cyanocobalamin may decrease the excretion rate of Prednisone which could result in a higher serum level.
Dyphylline,Cyanocobalamin may decrease the excretion rate of Dyphylline which could result in a higher serum level.
Mecamylamine,Cyanocobalamin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
Metaxalone,Cyanocobalamin may decrease the excretion rate of Metaxalone which could result in a higher serum level.
Verapamil,Cyanocobalamin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Nilutamide,Cyanocobalamin may decrease the excretion rate of Nilutamide which could result in a higher serum level.
Sumatriptan,Cyanocobalamin may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
Chlorpropamide,Cyanocobalamin may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
Midazolam,Cyanocobalamin may decrease the excretion rate of Midazolam which could result in a higher serum level.
Mycophenolate mofetil,Cyanocobalamin may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.
Flurazepam,Cyanocobalamin may decrease the excretion rate of Flurazepam which could result in a higher serum level.
Phentolamine,Cyanocobalamin may decrease the excretion rate of Phentolamine which could result in a higher serum level.
Nitrofurantoin,Cyanocobalamin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Tamsulosin,Cyanocobalamin may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
Lamivudine,Cyanocobalamin may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Oxacillin,Cyanocobalamin may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Nedocromil,Cyanocobalamin may decrease the excretion rate of Nedocromil which could result in a higher serum level.
Lisinopril,Cyanocobalamin may decrease the excretion rate of Lisinopril which could result in a higher serum level.
Thiabendazole,Cyanocobalamin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
Nateglinide,Cyanocobalamin may decrease the excretion rate of Nateglinide which could result in a higher serum level.
Pralidoxime,Cyanocobalamin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
Gadobenic acid,Cyanocobalamin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
Tetracycline,Cyanocobalamin may decrease the excretion rate of Tetracycline which could result in a higher serum level.
Meropenem,Cyanocobalamin may decrease the excretion rate of Meropenem which could result in a higher serum level.
Tirofiban,Cyanocobalamin may decrease the excretion rate of Tirofiban which could result in a higher serum level.
Phenelzine,Cyanocobalamin may decrease the excretion rate of Phenelzine which could result in a higher serum level.
Propantheline,Cyanocobalamin may decrease the excretion rate of Propantheline which could result in a higher serum level.
Estradiol,Cyanocobalamin may decrease the excretion rate of Estradiol which could result in a higher serum level.
Gadopentetic acid,Cyanocobalamin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
Perindopril,Cyanocobalamin may decrease the excretion rate of Perindopril which could result in a higher serum level.
Fenoldopam,Cyanocobalamin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
Dicyclomine,Cyanocobalamin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Pentoxifylline,Cyanocobalamin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.
Ribavirin,Cyanocobalamin may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Tadalafil,Cyanocobalamin may decrease the excretion rate of Tadalafil which could result in a higher serum level.
Fosfomycin,Cyanocobalamin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Diazepam,Cyanocobalamin may decrease the excretion rate of Diazepam which could result in a higher serum level.
Tolazamide,Cyanocobalamin may decrease the excretion rate of Tolazamide which could result in a higher serum level.
Dobutamine,Cyanocobalamin may decrease the excretion rate of Dobutamine which could result in a higher serum level.
Oxazepam,Cyanocobalamin may decrease the excretion rate of Oxazepam which could result in a higher serum level.
Ranitidine,Cyanocobalamin may decrease the excretion rate of Ranitidine which could result in a higher serum level.
Terbutaline,Cyanocobalamin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Testolactone,Cyanocobalamin may decrease the excretion rate of Testolactone which could result in a higher serum level.
Triazolam,Cyanocobalamin may decrease the excretion rate of Triazolam which could result in a higher serum level.
Didanosine,Cyanocobalamin may decrease the excretion rate of Didanosine which could result in a higher serum level.
Tinidazole,Cyanocobalamin may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Amantadine,Cyanocobalamin may decrease the excretion rate of Amantadine which could result in a higher serum level.
Almotriptan,Cyanocobalamin may decrease the excretion rate of Almotriptan which could result in a higher serum level.
Maprotiline,Cyanocobalamin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Isoniazid,Cyanocobalamin may decrease the excretion rate of Isoniazid which could result in a higher serum level.
Rizatriptan,Cyanocobalamin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
Pindolol,Cyanocobalamin may decrease the excretion rate of Pindolol which could result in a higher serum level.
Mepivacaine,Cyanocobalamin may decrease the excretion rate of Mepivacaine which could result in a higher serum level.
Zaleplon,Cyanocobalamin may decrease the excretion rate of Zaleplon which could result in a higher serum level.
Methyldopa,Cyanocobalamin may decrease the excretion rate of Methyldopa which could result in a higher serum level.
Ramelteon,Cyanocobalamin may decrease the excretion rate of Ramelteon which could result in a higher serum level.
Dopamine,Cyanocobalamin may decrease the excretion rate of Dopamine which could result in a higher serum level.
Azathioprine,Cyanocobalamin may decrease the excretion rate of Azathioprine which could result in a higher serum level.
Auranofin,Cyanocobalamin may decrease the excretion rate of Auranofin which could result in a higher serum level.
Salbutamol,Cyanocobalamin may decrease the excretion rate of Salbutamol which could result in a higher serum level.
Levobupivacaine,Cyanocobalamin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.
Ganciclovir,Cyanocobalamin may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
Edrophonium,Cyanocobalamin may decrease the excretion rate of Edrophonium which could result in a higher serum level.
Metyrapone,Cyanocobalamin may decrease the excretion rate of Metyrapone which could result in a higher serum level.
Sulfamethoxazole,Cyanocobalamin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.
Guanfacine,Cyanocobalamin may decrease the excretion rate of Guanfacine which could result in a higher serum level.
Isosorbide mononitrate,Cyanocobalamin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
Mycophenolic acid,Cyanocobalamin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
Probenecid,Cyanocobalamin may decrease the excretion rate of Probenecid which could result in a higher serum level.
Tolterodine,Cyanocobalamin may decrease the excretion rate of Tolterodine which could result in a higher serum level.
Fenofibrate,Cyanocobalamin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Memantine,Cyanocobalamin may decrease the excretion rate of Memantine which could result in a higher serum level.
Lubiprostone,Cyanocobalamin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Abacavir,Cyanocobalamin may decrease the excretion rate of Abacavir which could result in a higher serum level.
Amoxicillin,Cyanocobalamin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Glipizide,Cyanocobalamin may decrease the excretion rate of Glipizide which could result in a higher serum level.
Clonazepam,Cyanocobalamin may decrease the excretion rate of Clonazepam which could result in a higher serum level.
Promethazine,Cyanocobalamin may decrease the excretion rate of Promethazine which could result in a higher serum level.
Dimethyl sulfoxide,Cyanocobalamin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
Sibutramine,Cyanocobalamin may decrease the excretion rate of Sibutramine which could result in a higher serum level.
Nifedipine,Cyanocobalamin may decrease the excretion rate of Nifedipine which could result in a higher serum level.
Tolbutamide,Cyanocobalamin may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
Rabeprazole,Cyanocobalamin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
Tiludronic acid,Cyanocobalamin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
Doxacurium,Cyanocobalamin may decrease the excretion rate of Doxacurium which could result in a higher serum level.
Levofloxacin,Cyanocobalamin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.
Flavoxate,Cyanocobalamin may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Nefazodone,Cyanocobalamin may decrease the excretion rate of Nefazodone which could result in a higher serum level.
Bupropion,Cyanocobalamin may decrease the excretion rate of Bupropion which could result in a higher serum level.
Trimetrexate,Cyanocobalamin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
Cilostazol,Cyanocobalamin may decrease the excretion rate of Cilostazol which could result in a higher serum level.
Guanethidine,Cyanocobalamin may decrease the excretion rate of Guanethidine which could result in a higher serum level.
Naloxone,Cyanocobalamin may decrease the excretion rate of Naloxone which could result in a higher serum level.
Nadolol,Cyanocobalamin may decrease the excretion rate of Nadolol which could result in a higher serum level.
Flumazenil,Cyanocobalamin may decrease the excretion rate of Flumazenil which could result in a higher serum level.
Fomepizole,Cyanocobalamin may decrease the excretion rate of Fomepizole which could result in a higher serum level.
Estazolam,Cyanocobalamin may decrease the excretion rate of Estazolam which could result in a higher serum level.
Ketamine,Cyanocobalamin may decrease the excretion rate of Ketamine which could result in a higher serum level.
Budesonide,Cyanocobalamin may decrease the excretion rate of Budesonide which could result in a higher serum level.
Quetiapine,Cyanocobalamin may decrease the excretion rate of Quetiapine which could result in a higher serum level.
Metoclopramide,Cyanocobalamin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Epoprostenol,Cyanocobalamin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.
Gemfibrozil,Cyanocobalamin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.
Iodixanol,Cyanocobalamin may decrease the excretion rate of Iodixanol which could result in a higher serum level.
Sitagliptin,Cyanocobalamin may decrease the excretion rate of Sitagliptin which could result in a higher serum level.
Paliperidone,Cyanocobalamin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Varenicline,Cyanocobalamin may decrease the excretion rate of Varenicline which could result in a higher serum level.
Arformoterol,Cyanocobalamin may decrease the excretion rate of Arformoterol which could result in a higher serum level.
Hydralazine,Cyanocobalamin may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Penbutolol,Cyanocobalamin may decrease the excretion rate of Penbutolol which could result in a higher serum level.
Rasagiline,Cyanocobalamin may decrease the excretion rate of Rasagiline which could result in a higher serum level.
Tiotropium,Cyanocobalamin may decrease the excretion rate of Tiotropium which could result in a higher serum level.
Testosterone propionate,Cyanocobalamin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.
Amrinone,Cyanocobalamin may decrease the excretion rate of Amrinone which could result in a higher serum level.
Oxybenzone,Cyanocobalamin may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
Allylestrenol,Cyanocobalamin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
Fenproporex,Cyanocobalamin may decrease the excretion rate of Fenproporex which could result in a higher serum level.
Bromazepam,Cyanocobalamin may decrease the excretion rate of Bromazepam which could result in a higher serum level.
Chloral hydrate,Cyanocobalamin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
Metamfetamine,Cyanocobalamin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ketazolam,Cyanocobalamin may decrease the excretion rate of Ketazolam which could result in a higher serum level.
Valganciclovir,Cyanocobalamin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Sorbitol,Cyanocobalamin may decrease the excretion rate of Sorbitol which could result in a higher serum level.
Roflumilast,Cyanocobalamin may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Topiroxostat,Cyanocobalamin may decrease the excretion rate of Topiroxostat which could result in a higher serum level.
Estrone sulfate,Cyanocobalamin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
Lorcaserin,Cyanocobalamin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.
Pegaptanib,Cyanocobalamin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Milnacipran,Cyanocobalamin may decrease the excretion rate of Milnacipran which could result in a higher serum level.
Clevidipine,Cyanocobalamin may decrease the excretion rate of Clevidipine which could result in a higher serum level.
Lofexidine,Cyanocobalamin may decrease the excretion rate of Lofexidine which could result in a higher serum level.
Ezogabine,Cyanocobalamin may decrease the excretion rate of Ezogabine which could result in a higher serum level.
Migalastat,Cyanocobalamin may decrease the excretion rate of Migalastat which could result in a higher serum level.
Brivaracetam,Cyanocobalamin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
Apremilast,Cyanocobalamin may decrease the excretion rate of Apremilast which could result in a higher serum level.
Pentaerythritol tetranitrate,Cyanocobalamin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
Ipilimumab,Cyanocobalamin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Icatibant,Cyanocobalamin may decrease the excretion rate of Icatibant which could result in a higher serum level.
Alogliptin,Cyanocobalamin may decrease the excretion rate of Alogliptin which could result in a higher serum level.
Prasugrel,Cyanocobalamin may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Doripenem,Cyanocobalamin may decrease the excretion rate of Doripenem which could result in a higher serum level.
Rivaroxaban,Cyanocobalamin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Nalmefene,Cyanocobalamin may decrease the excretion rate of Nalmefene which could result in a higher serum level.
Droxidopa,Cyanocobalamin may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Levocetirizine,Cyanocobalamin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.
Saxagliptin,Cyanocobalamin may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
Telavancin,Cyanocobalamin may decrease the excretion rate of Telavancin which could result in a higher serum level.
Prucalopride,Cyanocobalamin may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Flupirtine,Cyanocobalamin may decrease the excretion rate of Flupirtine which could result in a higher serum level.
Dalfampridine,Cyanocobalamin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
Dabigatran etexilate,Cyanocobalamin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
Desvenlafaxine,Cyanocobalamin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.
Fesoterodine,Cyanocobalamin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Gadofosveset trisodium,Cyanocobalamin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Methyltestosterone,Cyanocobalamin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
Ammonium chloride,Cyanocobalamin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
Dimercaprol,Cyanocobalamin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
Mangafodipir,Cyanocobalamin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
Methylnaltrexone,Cyanocobalamin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Plerixafor,Cyanocobalamin may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Pralatrexate,Cyanocobalamin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tiopronin,Cyanocobalamin may decrease the excretion rate of Tiopronin which could result in a higher serum level.
Triethylenetetramine,Cyanocobalamin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Ioflupane I-123,Cyanocobalamin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
Deferiprone,Cyanocobalamin may decrease the excretion rate of Deferiprone which could result in a higher serum level.
N-methylnicotinamide,Cyanocobalamin may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.
Gabapentin enacarbil,Cyanocobalamin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
Mirabegron,Cyanocobalamin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Peginesatide,Cyanocobalamin may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Aclidinium,Cyanocobalamin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Enzalutamide,Cyanocobalamin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Teduglutide,Cyanocobalamin may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Certolizumab pegol,Cyanocobalamin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.
Formestane,Cyanocobalamin may decrease the excretion rate of Formestane which could result in a higher serum level.
Glycerol phenylbutyrate,Cyanocobalamin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
Trametinib,Cyanocobalamin may decrease the excretion rate of Trametinib which could result in a higher serum level.
Levomilnacipran,Cyanocobalamin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Macitentan,Cyanocobalamin may decrease the excretion rate of Macitentan which could result in a higher serum level.
Sofosbuvir,Cyanocobalamin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Gemeprost,Cyanocobalamin may decrease the excretion rate of Gemeprost which could result in a higher serum level.
Ledipasvir,Cyanocobalamin may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
Ceftolozane,Cyanocobalamin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Corifollitropin alfa,Cyanocobalamin may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
Vortioxetine,Cyanocobalamin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
Tasimelteon,Cyanocobalamin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
Edoxaban,Cyanocobalamin may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Idebenone,Cyanocobalamin may decrease the excretion rate of Idebenone which could result in a higher serum level.
Vilanterol,Cyanocobalamin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Trimebutine,Cyanocobalamin may decrease the excretion rate of Trimebutine which could result in a higher serum level.
Tixocortol,Cyanocobalamin may decrease the excretion rate of Tixocortol which could result in a higher serum level.
Ancestim,Cyanocobalamin may decrease the excretion rate of Ancestim which could result in a higher serum level.
Magnesium hydroxide,Cyanocobalamin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Hydroxyethyl Starch,Cyanocobalamin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Pentastarch,Cyanocobalamin may decrease the excretion rate of Pentastarch which could result in a higher serum level.
Stiripentol,Cyanocobalamin may decrease the excretion rate of Stiripentol which could result in a higher serum level.
Aurothioglucose,Cyanocobalamin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
Dienogest,Cyanocobalamin may decrease the excretion rate of Dienogest which could result in a higher serum level.
Gadoteric acid,Cyanocobalamin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Iothalamic acid,Cyanocobalamin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Ioversol,Cyanocobalamin may decrease the excretion rate of Ioversol which could result in a higher serum level.
Ioxilan,Cyanocobalamin may decrease the excretion rate of Ioxilan which could result in a higher serum level.
Isosulfan blue,Cyanocobalamin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Technetium Tc-99m mebrofenin,Cyanocobalamin may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
Technetium Tc-99m oxidronate,Cyanocobalamin may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
Florbetaben (18F),Cyanocobalamin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir (18F),Cyanocobalamin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Iopromide,Cyanocobalamin may decrease the excretion rate of Iopromide which could result in a higher serum level.
Technetium Tc-99m exametazime,Cyanocobalamin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
Technetium Tc-99m pyrophosphate,Cyanocobalamin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Viloxazine,Cyanocobalamin may decrease the excretion rate of Viloxazine which could result in a higher serum level.
Etoperidone,Cyanocobalamin may decrease the excretion rate of Etoperidone which could result in a higher serum level.
Lorpiprazole,Cyanocobalamin may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
Arotinolol,Cyanocobalamin may decrease the excretion rate of Arotinolol which could result in a higher serum level.
Moxisylyte,Cyanocobalamin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
Pholcodine,Cyanocobalamin may decrease the excretion rate of Pholcodine which could result in a higher serum level.
Piracetam,Cyanocobalamin may decrease the excretion rate of Piracetam which could result in a higher serum level.
Bisoxatin,Cyanocobalamin may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
Nicorandil,Cyanocobalamin may decrease the excretion rate of Nicorandil which could result in a higher serum level.
Blonanserin,Cyanocobalamin may decrease the excretion rate of Blonanserin which could result in a higher serum level.
Melperone,Cyanocobalamin may decrease the excretion rate of Melperone which could result in a higher serum level.
Methylene blue,Cyanocobalamin may decrease the excretion rate of Methylene blue which could result in a higher serum level.
Pirlindole,Cyanocobalamin may decrease the excretion rate of Pirlindole which could result in a higher serum level.
Toloxatone,Cyanocobalamin may decrease the excretion rate of Toloxatone which could result in a higher serum level.
Dextran,Cyanocobalamin may decrease the excretion rate of Dextran which could result in a higher serum level.
Tegafur,Cyanocobalamin may decrease the excretion rate of Tegafur which could result in a higher serum level.
Gimeracil,Cyanocobalamin may decrease the excretion rate of Gimeracil which could result in a higher serum level.
Imidafenacin,Cyanocobalamin may decrease the excretion rate of Imidafenacin which could result in a higher serum level.
Idarucizumab,Cyanocobalamin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Lixisenatide,Cyanocobalamin may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Picosulfuric acid,Cyanocobalamin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Sodium aurothiomalate,Cyanocobalamin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
Choline C 11,Cyanocobalamin may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
Magnesium trisilicate,Cyanocobalamin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Sacubitril,Cyanocobalamin may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Chondroitin sulfate,Cyanocobalamin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
"Synthetic Conjugated Estrogens, A","Cyanocobalamin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level."
"Synthetic Conjugated Estrogens, B","Cyanocobalamin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level."
Procaine benzylpenicillin,Cyanocobalamin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Sulbactam,Cyanocobalamin may decrease the excretion rate of Sulbactam which could result in a higher serum level.
"Antihemophilic Factor (Recombinant), PEGylated","Cyanocobalamin may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level."
Invert sugar,Cyanocobalamin may decrease the excretion rate of Invert sugar which could result in a higher serum level.
Phosphoric acid,Cyanocobalamin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Sodium acetate,Cyanocobalamin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Magnesium chloride,Cyanocobalamin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Potassium perchlorate,Cyanocobalamin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
Sodium sulfate,Cyanocobalamin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Enalaprilat,Cyanocobalamin may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
Acrivastine,Cyanocobalamin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Octinoxate,Cyanocobalamin may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Fludeoxyglucose (18F),Cyanocobalamin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Iobenguane sulfate I-123,Cyanocobalamin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Ixazomib,Cyanocobalamin may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Polyethylene glycol 400,Cyanocobalamin may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
Potassium nitrate,Cyanocobalamin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium bicarbonate,Cyanocobalamin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
N-acetyltyrosine,Cyanocobalamin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Eucalyptus oil,Cyanocobalamin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Opium,Cyanocobalamin may decrease the excretion rate of Opium which could result in a higher serum level.
Oxyquinoline,Cyanocobalamin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Pyrantel,Cyanocobalamin may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Bicisate,Cyanocobalamin may decrease the excretion rate of Bicisate which could result in a higher serum level.
DL-Methylephedrine,Cyanocobalamin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
Tetradecyl hydrogen sulfate (ester),Cyanocobalamin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Clove oil,Cyanocobalamin may decrease the excretion rate of Clove oil which could result in a higher serum level.
Evening primrose oil,Cyanocobalamin may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
Pidotimod,Cyanocobalamin may decrease the excretion rate of Pidotimod which could result in a higher serum level.
Lesinurad,Cyanocobalamin may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Indigotindisulfonic acid,Cyanocobalamin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Etafedrine,Cyanocobalamin may decrease the excretion rate of Etafedrine which could result in a higher serum level.
Antithrombin III human,Cyanocobalamin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Pitolisant,Cyanocobalamin may decrease the excretion rate of Pitolisant which could result in a higher serum level.
Naldemedine,Cyanocobalamin may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Tropisetron,Cyanocobalamin may decrease the excretion rate of Tropisetron which could result in a higher serum level.
Baricitinib,Cyanocobalamin may decrease the excretion rate of Baricitinib which could result in a higher serum level.
Apalutamide,Cyanocobalamin may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Valbenazine,Cyanocobalamin may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Delafloxacin,Cyanocobalamin may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
Benznidazole,Cyanocobalamin may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Isoflavone,Cyanocobalamin may decrease the excretion rate of Isoflavone which could result in a higher serum level.
Vaborbactam,Cyanocobalamin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Deutetrabenazine,Cyanocobalamin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Propiverine,Cyanocobalamin may decrease the excretion rate of Propiverine which could result in a higher serum level.
Benserazide,Cyanocobalamin may decrease the excretion rate of Benserazide which could result in a higher serum level.
Tiapride,Cyanocobalamin may decrease the excretion rate of Tiapride which could result in a higher serum level.
Levosalbutamol,Cyanocobalamin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
Inosine pranobex,Cyanocobalamin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
Oxabolone cipionate,Cyanocobalamin may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.
Phosphocreatine,Cyanocobalamin may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.
Dichlorobenzyl alcohol,Cyanocobalamin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
Ipecac,Cyanocobalamin may decrease the excretion rate of Ipecac which could result in a higher serum level.
Almasilate,Cyanocobalamin may decrease the excretion rate of Almasilate which could result in a higher serum level.
Fenofibric acid,Cyanocobalamin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
Albutrepenonacog alfa,Cyanocobalamin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Bismuth subgallate,Cyanocobalamin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Testosterone cypionate,Cyanocobalamin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
Testosterone enanthate,Cyanocobalamin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
Testosterone undecanoate,Cyanocobalamin may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
Estradiol acetate,Cyanocobalamin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
Estradiol cypionate,Cyanocobalamin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
Estradiol dienanthate,Cyanocobalamin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.
Estradiol valerate,Cyanocobalamin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
Patent Blue,Cyanocobalamin may decrease the excretion rate of Patent Blue which could result in a higher serum level.
Choline salicylate,Cyanocobalamin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
Pentetic acid,Cyanocobalamin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Potassium acetate,Cyanocobalamin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium sulfate,Cyanocobalamin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
Chromic citrate,Cyanocobalamin may decrease the excretion rate of Chromic citrate which could result in a higher serum level.
Chromic nitrate,Cyanocobalamin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
Chromium gluconate,Cyanocobalamin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
Chromium nicotinate,Cyanocobalamin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Chromous sulfate,Cyanocobalamin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
Solriamfetol,Cyanocobalamin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
Pyrithione,Cyanocobalamin may decrease the excretion rate of Pyrithione which could result in a higher serum level.
Chloroxylenol,Cyanocobalamin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
Resorcinol,Cyanocobalamin may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Golodirsen,Cyanocobalamin may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Amitriptyline,Cyanocobalamin may decrease the excretion rate of Amitriptyline which could result in a higher serum level.
Imipramine,Cyanocobalamin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Doxepin,Cyanocobalamin may decrease the excretion rate of Doxepin which could result in a higher serum level.
Codeine,Cyanocobalamin may decrease the excretion rate of Codeine which could result in a higher serum level.
Meperidine,Cyanocobalamin may decrease the excretion rate of Meperidine which could result in a higher serum level.
Fentanyl,Cyanocobalamin may decrease the excretion rate of Fentanyl which could result in a higher serum level.
Emtricitabine,Cyanocobalamin may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
Desipramine,Cyanocobalamin may decrease the excretion rate of Desipramine which could result in a higher serum level.
Clomipramine,Cyanocobalamin may decrease the excretion rate of Clomipramine which could result in a higher serum level.
Dimetacrine,Cyanocobalamin may decrease the excretion rate of Dimetacrine which could result in a higher serum level.
Lithium hydroxide,Cyanocobalamin may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.
Framycetin,Framycetin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Amikacin,Amikacin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Tobramycin,Tobramycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Gentamicin,Gentamicin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Netilmicin,Netilmicin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Streptomycin,Streptomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Kanamycin,Kanamycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Paromomycin,Paromomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Ribostamycin,Ribostamycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Geneticin,Geneticin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Apramycin,Apramycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Gentamicin C1a,Gentamicin C1a may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Neamine,Neamine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Arbekacin,Arbekacin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Puromycin,Puromycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Dihydrostreptomycin,Dihydrostreptomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Hygromycin B,Hygromycin B may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Sisomicin,Sisomicin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Dibekacin,Dibekacin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Micronomicin,Micronomicin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Isepamicin,Isepamicin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Bekanamycin,Bekanamycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Nedaplatin,Cyanocobalamin may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
Capreomycin,Cyanocobalamin may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Digoxin,Cyanocobalamin may decrease the excretion rate of Digoxin which could result in a higher serum level.
Vancomycin,Cyanocobalamin may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Warfarin,Cyanocobalamin may decrease the excretion rate of Warfarin which could result in a higher serum level.
Quinidine,Cyanocobalamin may decrease the excretion rate of Quinidine which could result in a higher serum level.
Isotretinoin,Cyanocobalamin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
Procainamide,Cyanocobalamin may decrease the excretion rate of Procainamide which could result in a higher serum level.
Plazomicin,Cyanocobalamin may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Lithium carbonate,Cyanocobalamin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
Metolazone,Cyanocobalamin may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.
Furosemide,Cyanocobalamin may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.
Indapamide,Cyanocobalamin may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.
Bumetanide,Cyanocobalamin may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.
Zonisamide,Cyanocobalamin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Canagliflozin,Cyanocobalamin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Mersalyl,Cyanocobalamin may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.
Torasemide,Torasemide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Methyclothiazide,Methyclothiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone,Chlorthalidone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Ethoxzolamide,Ethoxzolamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Spironolactone,Spironolactone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Bendroflumethiazide,Bendroflumethiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Benzthiazide,Benzthiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Amiloride,Amiloride may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Cyclothiazide,Cyclothiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Eplerenone,Eplerenone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Methazolamide,Methazolamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Hydroflumethiazide,Hydroflumethiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Acetazolamide,Acetazolamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Conivaptan,Conivaptan may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Chlorothiazide,Chlorothiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Trichlormethiazide,Trichlormethiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Diazoxide,Diazoxide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Diclofenamide,Diclofenamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Polythiazide,Polythiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Quinethazone,Quinethazone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Drospirenone,Drospirenone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Theobromine,Theobromine may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Piretanide,Piretanide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Tienilic acid,Tienilic acid may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Ularitide,Ularitide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Tolvaptan,Tolvaptan may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Dapagliflozin,Dapagliflozin may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Indisulam,Indisulam may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Azosemide,Azosemide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Canrenoic acid,Canrenoic acid may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Potassium citrate,Potassium citrate may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Efonidipine,Efonidipine may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide,Isosorbide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Ertugliflozin,Ertugliflozin may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Canrenone,Canrenone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Rolofylline,Rolofylline may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Spiradoline,Spiradoline may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Cicletanine,Cicletanine may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Meticrane,Meticrane may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Ibopamine,Ibopamine may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Mefruside,Mefruside may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Mebutizide,Mebutizide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Cyclopenthiazide,Cyclopenthiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Clorexolone,Clorexolone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Clofenamide,Clofenamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Fenquizone,Fenquizone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Clopamide,Clopamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Muzolimine,Muzolimine may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Xipamide,Xipamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Epitizide,Epitizide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Bromotheophylline,Bromotheophylline may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
Peginterferon alfa-2a,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Peginterferon alfa-2a.
Interferon alfa-n1,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-n1.
Interferon alfa-n3,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-n3.
Peginterferon alfa-2b,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Peginterferon alfa-2b.
Interferon gamma-1b,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon gamma-1b.
"Interferon alfa-2a, Recombinant","The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-2a, Recombinant."
Aldesleukin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Aldesleukin.
Gemtuzumab ozogamicin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Gemtuzumab ozogamicin.
Interferon beta-1b,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon beta-1b.
Interferon alfacon-1,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfacon-1.
Rituximab,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Rituximab.
Ibritumomab tiuxetan,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ibritumomab tiuxetan.
Tositumomab,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tositumomab.
Alemtuzumab,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Alemtuzumab.
Interferon alfa-2b,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-2b.
Phenylalanine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Phenylalanine.
Bortezomib,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bortezomib.
Cladribine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cladribine.
Carmustine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Carmustine.
Amsacrine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Amsacrine.
Chlorambucil,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Chlorambucil.
Raltitrexed,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Raltitrexed.
Mitomycin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Mitomycin.
Bexarotene,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bexarotene.
Vindesine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Vindesine.
Floxuridine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Floxuridine.
Indomethacin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Indomethacin.
Tioguanine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tioguanine.
Vinorelbine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Vinorelbine.
Dexrazoxane,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dexrazoxane.
Sorafenib,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Sorafenib.
Streptozocin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Streptozocin.
Gemcitabine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Gemcitabine.
Teniposide,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Teniposide.
Epirubicin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Epirubicin.
Lenalidomide,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Lenalidomide.
Altretamine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Altretamine.
Zidovudine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Zidovudine.
Cisplatin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cisplatin.
Oxaliplatin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Oxaliplatin.
Cyclophosphamide,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cyclophosphamide.
Fluorouracil,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Fluorouracil.
Propylthiouracil,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Propylthiouracil.
Pentostatin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Pentostatin.
Methotrexate,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Methotrexate.
Carbamazepine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Carbamazepine.
Vinblastine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Vinblastine.
Linezolid,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Linezolid.
Imatinib,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Imatinib.
Clofarabine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Clofarabine.
Pemetrexed,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Pemetrexed.
Daunorubicin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Daunorubicin.
Irinotecan,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Irinotecan.
Methimazole,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Methimazole.
Etoposide,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Etoposide.
Dacarbazine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dacarbazine.
Temozolomide,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Temozolomide.
Penicillamine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Penicillamine.
Tacrolimus,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tacrolimus.
Sirolimus,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Sirolimus.
Mechlorethamine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Mechlorethamine.
Azacitidine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Azacitidine.
Carboplatin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Carboplatin.
Dactinomycin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dactinomycin.
Cytarabine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cytarabine.
Doxorubicin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Doxorubicin.
Hydroxyurea,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Hydroxyurea.
Busulfan,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Busulfan.
Topotecan,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Topotecan.
Mercaptopurine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Mercaptopurine.
Thalidomide,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Thalidomide.
Melphalan,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Melphalan.
Fludarabine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Fludarabine.
Flucytosine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Flucytosine.
Capecitabine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Capecitabine.
Procarbazine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Procarbazine.
Arsenic trioxide,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Arsenic trioxide.
Idarubicin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Idarubicin.
Ifosfamide,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ifosfamide.
Mitoxantrone,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Mitoxantrone.
Lomustine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Lomustine.
Paclitaxel,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Paclitaxel.
Docetaxel,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Docetaxel.
Dasatinib,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dasatinib.
Decitabine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Decitabine.
Nelarabine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Nelarabine.
Everolimus,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Everolimus.
Vorinostat,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Vorinostat.
Thiotepa,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Thiotepa.
Ixabepilone,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ixabepilone.
Nilotinib,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Nilotinib.
Belinostat,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Belinostat.
Trabectedin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Trabectedin.
Interferon alfa,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa.
omega interferon,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with omega interferon.
Trastuzumab emtansine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Trastuzumab emtansine.
Temsirolimus,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Temsirolimus.
Bosutinib,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bosutinib.
Bendamustine,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bendamustine.
Cabazitaxel,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cabazitaxel.
Eribulin,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Eribulin.
Ruxolitinib,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ruxolitinib.
Carfilzomib,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Carfilzomib.
Tofacitinib,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tofacitinib.
Ponatinib,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ponatinib.
Pomalidomide,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Pomalidomide.
Obinutuzumab,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Obinutuzumab.
Tedizolid phosphate,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tedizolid phosphate.
Blinatumomab,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Blinatumomab.
Ibrutinib,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ibrutinib.
Palbociclib,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Palbociclib.
Olaparib,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Olaparib.
Dinutuximab,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dinutuximab.
Peginterferon beta-1a,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Peginterferon beta-1a.
Cepeginterferon alfa-2B,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cepeginterferon alfa-2B.
Neomycin,Neomycin can cause a decrease in the absorption of Cyanocobalamin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fosphenytoin,The serum concentration of Fosphenytoin can be decreased when it is combined with Tetrahydrofolic acid.
Raltitrexed,The therapeutic efficacy of Raltitrexed can be decreased when used in combination with Tetrahydrofolic acid.
Sulfasalazine,The serum concentration of Tetrahydrofolic acid can be decreased when it is combined with Sulfasalazine.
Phenytoin,The serum concentration of Phenytoin can be decreased when it is combined with Tetrahydrofolic acid.
Glucarpidase,The serum concentration of the active metabolites of Tetrahydrofolic acid can be reduced when Tetrahydrofolic acid is used in combination with Glucarpidase resulting in a loss in efficacy.
Phenobarbital,The serum concentration of Phenobarbital can be decreased when it is combined with Tetrahydrofolic acid.
Primidone,The serum concentration of Primidone can be decreased when it is combined with Tetrahydrofolic acid.
Pyrimethamine,The therapeutic efficacy of Pyrimethamine can be decreased when used in combination with Tetrahydrofolic acid.
Dapsone,The therapeutic efficacy of Dapsone can be decreased when used in combination with Tetrahydrofolic acid.
Trimethoprim,The therapeutic efficacy of Trimethoprim can be decreased when used in combination with Tetrahydrofolic acid.
Methotrexate,The therapeutic efficacy of Methotrexate can be decreased when used in combination with Tetrahydrofolic acid.
Pemetrexed,The therapeutic efficacy of Pemetrexed can be decreased when used in combination with Tetrahydrofolic acid.
Proguanil,The therapeutic efficacy of Proguanil can be decreased when used in combination with Tetrahydrofolic acid.
Trimetrexate,The therapeutic efficacy of Trimetrexate can be decreased when used in combination with Tetrahydrofolic acid.
Piritrexim,The therapeutic efficacy of Piritrexim can be decreased when used in combination with Tetrahydrofolic acid.
Metoprine,The therapeutic efficacy of Metoprine can be decreased when used in combination with Tetrahydrofolic acid.
Iclaprim,The therapeutic efficacy of Iclaprim can be decreased when used in combination with Tetrahydrofolic acid.
Pralatrexate,The therapeutic efficacy of Pralatrexate can be decreased when used in combination with Tetrahydrofolic acid.
Aminopterin,The therapeutic efficacy of Aminopterin can be decreased when used in combination with Tetrahydrofolic acid.
Lometrexol,The therapeutic efficacy of Lometrexol can be decreased when used in combination with Tetrahydrofolic acid.
Nolatrexed,The therapeutic efficacy of Nolatrexed can be decreased when used in combination with Tetrahydrofolic acid.
Brodimoprim,The therapeutic efficacy of Brodimoprim can be decreased when used in combination with Tetrahydrofolic acid.
Cycloguanil,The therapeutic efficacy of Cycloguanil can be decreased when used in combination with Tetrahydrofolic acid.
Valproic acid,The serum concentration of Tetrahydrofolic acid can be decreased when it is combined with Valproic acid.
Colestipol,The serum concentration of Tetrahydrofolic acid can be decreased when it is combined with Colestipol.
Carbamazepine,The serum concentration of Carbamazepine can be decreased when it is combined with Tetrahydrofolic acid.
Fluorouracil,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Fluorouracil.
Flucytosine,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Capecitabine.
5-fluorouridine,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with 5-fluorouridine.
Uracil,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Uracil.
Tegafur,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Tegafur.
Doxifluridine,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Doxifluridine.
Enflurane,The metabolism of Enflurane can be decreased when combined with Ademetionine.
Trimethadione,The metabolism of Trimethadione can be decreased when combined with Ademetionine.
Chlorzoxazone,The metabolism of Chlorzoxazone can be decreased when combined with Ademetionine.
Isoflurane,The metabolism of Isoflurane can be decreased when combined with Ademetionine.
Ethanol,The metabolism of Ethanol can be decreased when combined with Ademetionine.
Methoxyflurane,The metabolism of Methoxyflurane can be decreased when combined with Ademetionine.
Halothane,The metabolism of Halothane can be decreased when combined with Ademetionine.
Sevoflurane,The metabolism of Sevoflurane can be decreased when combined with Ademetionine.
Nilvadipine,The metabolism of Nilvadipine can be decreased when combined with Ademetionine.
Aniline,The metabolism of Aniline can be decreased when combined with Ademetionine.
Benzyl alcohol,The metabolism of Benzyl alcohol can be decreased when combined with Ademetionine.
Felbamate,The metabolism of Felbamate can be decreased when combined with Ademetionine.
Cenobamate,The metabolism of Cenobamate can be decreased when combined with Ademetionine.
Carvedilol,The metabolism of Carvedilol can be decreased when combined with Ademetionine.
Phenytoin,The metabolism of Phenytoin can be decreased when combined with Ademetionine.
Fingolimod,The metabolism of Fingolimod can be decreased when combined with Ademetionine.
Ethosuximide,The metabolism of Ethosuximide can be decreased when combined with Ademetionine.
Selumetinib,The metabolism of Selumetinib can be decreased when combined with Ademetionine.
Quinidine,The metabolism of Quinidine can be decreased when combined with Ademetionine.
Tamoxifen,The metabolism of Tamoxifen can be decreased when combined with Ademetionine.
Trabectedin,The metabolism of Trabectedin can be decreased when combined with Ademetionine.
Acetaminophen,Ademetionine may increase the hepatotoxic activities of Acetaminophen.
Propacetamol,Ademetionine may increase the hepatotoxic activities of Propacetamol.
Denosumab,The risk or severity of adverse effects can be increased when Denosumab is combined with Phenylalanine.
Etanercept,The risk or severity of adverse effects can be increased when Etanercept is combined with Phenylalanine.
Peginterferon alfa-2a,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Phenylalanine.
Interferon alfa-n1,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Phenylalanine.
Interferon alfa-n3,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Phenylalanine.
Peginterferon alfa-2b,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Phenylalanine.
Anakinra,The risk or severity of adverse effects can be increased when Anakinra is combined with Phenylalanine.
Interferon gamma-1b,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Phenylalanine.
"Interferon alfa-2a, Recombinant","The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Phenylalanine."
Aldesleukin,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Phenylalanine.
Adalimumab,The risk or severity of adverse effects can be increased when Adalimumab is combined with Phenylalanine.
Gemtuzumab ozogamicin,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Phenylalanine.
Pegaspargase,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Phenylalanine.
Infliximab,The risk or severity of adverse effects can be increased when Infliximab is combined with Phenylalanine.
Interferon beta-1b,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Phenylalanine.
Interferon alfacon-1,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Phenylalanine.
Rituximab,The risk or severity of adverse effects can be increased when Rituximab is combined with Phenylalanine.
Basiliximab,The risk or severity of adverse effects can be increased when Basiliximab is combined with Phenylalanine.
Muromonab,The risk or severity of adverse effects can be increased when Muromonab is combined with Phenylalanine.
Ibritumomab tiuxetan,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Phenylalanine.
Tositumomab,The risk or severity of adverse effects can be increased when Tositumomab is combined with Phenylalanine.
Alemtuzumab,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Phenylalanine.
Alefacept,The risk or severity of adverse effects can be increased when Alefacept is combined with Phenylalanine.
Efalizumab,The risk or severity of adverse effects can be increased when Efalizumab is combined with Phenylalanine.
Antithymocyte immunoglobulin (rabbit),The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Phenylalanine.
Interferon alfa-2b,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Phenylalanine.
Daclizumab,The risk or severity of adverse effects can be increased when Daclizumab is combined with Phenylalanine.
Bevacizumab,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Phenylalanine.
Flunisolide,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Flunisolide.
Bortezomib,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bortezomib.
Cladribine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cladribine.
Carmustine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carmustine.
Amsacrine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Amsacrine.
Bleomycin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bleomycin.
Chlorambucil,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Chlorambucil.
Raltitrexed,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Raltitrexed.
Mitomycin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mitomycin.
Bexarotene,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bexarotene.
Vindesine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vindesine.
Floxuridine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Floxuridine.
Indomethacin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Indomethacin.
Tioguanine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Tioguanine.
Vinorelbine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vinorelbine.
Dexrazoxane,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dexrazoxane.
Beclomethasone dipropionate,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Beclomethasone dipropionate.
Sorafenib,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Sorafenib.
Streptozocin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Streptozocin.
Trifluridine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trifluridine.
Gemcitabine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Gemcitabine.
Betamethasone,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Betamethasone.
Teniposide,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Teniposide.
Epirubicin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Epirubicin.
Chloramphenicol,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Chloramphenicol.
Lenalidomide,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Lenalidomide.
Altretamine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Altretamine.
Zidovudine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Zidovudine.
Cisplatin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cisplatin.
Oxaliplatin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Oxaliplatin.
Cyclophosphamide,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cyclophosphamide.
Vincristine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vincristine.
Fluorouracil,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluorouracil.
Propylthiouracil,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Propylthiouracil.
Pentostatin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pentostatin.
Methotrexate,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Methotrexate.
Carbamazepine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carbamazepine.
Vinblastine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vinblastine.
Fluticasone propionate,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluticasone propionate.
Fluocinolone acetonide,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluocinolone acetonide.
Linezolid,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Linezolid.
Imatinib,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Imatinib.
Triamcinolone,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Triamcinolone.
Clofarabine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Clofarabine.
Prednisone,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Prednisone.
Pemetrexed,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pemetrexed.
Fludrocortisone,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fludrocortisone.
Mycophenolate mofetil,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mycophenolate mofetil.
Daunorubicin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Daunorubicin.
Tretinoin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Tretinoin.
Irinotecan,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Irinotecan.
Methimazole,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Methimazole.
Mometasone,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mometasone.
Etoposide,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Etoposide.
Sulfasalazine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Sulfasalazine.
Dacarbazine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dacarbazine.
Temozolomide,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Temozolomide.
Penicillamine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Penicillamine.
Prednisolone,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Prednisolone.
Sirolimus,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Sirolimus.
Mechlorethamine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mechlorethamine.
Azacitidine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Azacitidine.
Carboplatin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carboplatin.
Methylprednisolone,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Methylprednisolone.
Dactinomycin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dactinomycin.
Cytarabine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cytarabine.
Azathioprine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Azathioprine.
Doxorubicin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Doxorubicin.
Hydroxyurea,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Hydroxyurea.
Busulfan,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Busulfan.
Mycophenolic acid,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mycophenolic acid.
Topotecan,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Topotecan.
Mercaptopurine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mercaptopurine.
Thalidomide,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Thalidomide.
Melphalan,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Melphalan.
Fludarabine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fludarabine.
Flucytosine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Flucytosine.
Capecitabine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Capecitabine.
Trilostane,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trilostane.
Procarbazine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Procarbazine.
Arsenic trioxide,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Arsenic trioxide.
Idarubicin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Idarubicin.
Ifosfamide,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ifosfamide.
Estramustine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Estramustine.
Mitoxantrone,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mitoxantrone.
Lomustine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Lomustine.
Budesonide,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Budesonide.
Paclitaxel,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Paclitaxel.
Dexamethasone,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dexamethasone.
Docetaxel,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Docetaxel.
Dasatinib,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dasatinib.
Eculizumab,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Eculizumab.
Decitabine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Decitabine.
Sunitinib,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Sunitinib.
Nelarabine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Nelarabine.
Abatacept,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Abatacept.
Corticotropin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Corticotropin.
Cortisone acetate,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cortisone acetate.
Paramethasone,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Paramethasone.
Colchicine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Colchicine.
Ciclesonide,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ciclesonide.
Stepronin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Stepronin.
Everolimus,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Everolimus.
Hydroxychloroquine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Hydroxychloroquine.
Castanospermine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Castanospermine.
Vorinostat,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vorinostat.
2-Methoxyethanol,The risk or severity of adverse effects can be increased when Phenylalanine is combined with 2-Methoxyethanol.
Brequinar,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Brequinar.
Thiotepa,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Thiotepa.
Aldosterone,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Aldosterone.
Ixabepilone,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ixabepilone.
Nilotinib,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Nilotinib.
Pirfenidone,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pirfenidone.
Afelimomab,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Afelimomab.
Belinostat,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Belinostat.
Trabectedin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trabectedin.
Interferon alfa,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Interferon alfa.
Glatiramer,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Glatiramer.
Gallium nitrate,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Gallium nitrate.
Briakinumab,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Briakinumab.
omega interferon,The risk or severity of adverse effects can be increased when Phenylalanine is combined with omega interferon.
Apremilast,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Apremilast.
Trastuzumab emtansine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trastuzumab emtansine.
Canakinumab,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Canakinumab.
Tocilizumab,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Tocilizumab.
Temsirolimus,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Temsirolimus.
Rilonacept,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Rilonacept.
Pazopanib,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pazopanib.
Panobinostat,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Panobinostat.
Mepolizumab,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mepolizumab.
Bosutinib,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bosutinib.
Abetimus,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Abetimus.
Golimumab,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Golimumab.
Belatacept,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Belatacept.
Bendamustine,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bendamustine.
Cabazitaxel,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cabazitaxel.
Pralatrexate,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pralatrexate.
Wortmannin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Wortmannin.
Brentuximab vedotin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Brentuximab vedotin.
Eribulin,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Eribulin.
Ruxolitinib,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ruxolitinib.
Belimumab,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Belimumab.
Teriflunomide,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Teriflunomide.
Carfilzomib,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carfilzomib.
Ponatinib,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ponatinib.
Certolizumab pegol,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Certolizumab pegol.
Fluticasone furoate,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluticasone furoate.
Dimethyl fumarate,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dimethyl fumarate.
Pomalidomide,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pomalidomide.
Obinutuzumab,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Obinutuzumab.
Fluprednidene,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluprednidene.
Fluocortolone,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluocortolone.
Secukinumab,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Secukinumab.
Vedolizumab,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vedolizumab.
Siltuximab,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Siltuximab.
Blinatumomab,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Blinatumomab.
